PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MONNING, U; SANDBRINK, R; WEIDEMANN, A; BANATI, RB; MASTERS, CL; BEYREUTHER, K				MONNING, U; SANDBRINK, R; WEIDEMANN, A; BANATI, RB; MASTERS, CL; BEYREUTHER, K			EXTRACELLULAR-MATRIX INFLUENCES THE BIOGENESIS OF AMYLOID PRECURSOR PROTEIN IN MICROGLIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; MESSENGER-RNA; NEXIN-II; NERVOUS-SYSTEM; EXPRESSION; DOMAIN; BRAIN; LOCALIZATION; DERIVATIVES	During axotomy studies, we discovered that the beta A4-amyloid precursor protein (APP) participates in immune responses of the central nervous system. Since microglia constitute the main immune effector cell population of this response, we used the murine microglial cell line BV-2 to analyze immune response-related APP expression. We show that interaction of microglia with the extracellular environment, particularly components of the extracellular matrix, affects APP secretion as well as intracellular APP biogenesis and catabolism. Fibronectin enhanced APP secretion and decreased the level of cellular mature transmembrane APP, whereas laminin and collagen caused a decrease in secretion and an accumulation of cellular mature APP and APP fragments. Our results demonstrate that APP plays a fundamental role in the regulation of microglial mobility, i.e. migration, initial target recognition, and binding. The decrease in APP secretion and the concomitant increase in cellular mature APP were accompanied by an accumulation of C-terminal APP fragments. Enrichment of APP and APP fragments is assumedly based on inhibition of catabolic processes that is caused by a disorganization of the actin microfilament network. These observations provide evidence that microglia, which are closely associated with certain amyloid deposits in the brain of Alzheimer patients, can play a key role in initial events of amyloidogenesis by initiating accumulation of APP and also of amyloidogenic APP fragments in response to physiological changes upon brain injury.	UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,D-82452 PLANEGG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; Max Planck Society; University of Melbourne								BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BREEN KC, 1992, MOL CHEM NEUROPATHOL, V16, P109, DOI 10.1007/BF03159964; BUSH AI, 1990, J BIOL CHEM, V265, P15977; CHAMAK B, 1991, NEUROSCIENCE, V45, P513, DOI 10.1016/0306-4522(91)90267-R; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Del Rio P., 1932, CYTOLOGY CELLULAR PA, P481; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GEHRMANN J, 1992, LAB INVEST, V67, P100; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Graeber MB, 1990, BRAIN PATHOL, V1, P2, DOI 10.1111/j.1750-3639.1990.tb00630.x; GUILIAN D, 1988, J NEUROSCI, V8, P4707; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; HILBICH C, 1991, EUR J BIOCHEM, V201, P61, DOI 10.1111/j.1432-1033.1991.tb16256.x; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KONIG G, 1992, J BIOL CHEM, V267, P10804; LEFCORT F, 1992, DEVELOPMENT, V116, P767; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MONNING U, 1994, FEBS LETT, V342, P267, DOI 10.1016/0014-5793(94)80514-8; MONNING U, 1982, J BIOL CHEM, V267, P23950; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MULTHAUP G, 1992, J PROTEIN CHEM, V11, P298; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; REFOLO LM, 1991, J NEUROSCI, V11, P3888; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIGEMATSU K, 1992, BRAIN RES, V593, P117, DOI 10.1016/0006-8993(92)91272-G; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887	65	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7104	7110		10.1074/jbc.270.13.7104	http://dx.doi.org/10.1074/jbc.270.13.7104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706247	hybrid			2022-12-25	WOS:A1995QQ43100017
J	MEDCALF, EA; MILNER, J				MEDCALF, EA; MILNER, J			TARGETING AND DEGRADATION OF P53 BY E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 IS PREFERENTIAL FOR THE 1620+ P53 CONFORMATION	ONCOGENE			English	Note							MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; WILD-TYPE; MUTANT CONFORMATION; SUPPRESSOR; PROTEIN; EXPRESSION; TRANSFORMATION; MUTATIONS; DISTINCT	E6-mediated degradation of p53 is believed to play a role in the transformation of cells by high-risk types of human papillomavirus. In order to explore the structural requirements for targeting of p53 we have compared E6-mediated degradation of variant p53 forms expressed in vitro. Complete degradation was observed in samples containing monomers, dimers and higher molecular weight structures of wild-type p53, indicating that E6 targets all quaternary forms of wild-type p53. Wild-type human and murine p53s reactive with PAb 1620 (which recognizes a conformation-dependent epitope) were degraded when incubated with E6. Mutant p53 proteins were variably resistant to E6-mediated degradation, and this correlated with PAb 1620 reactivity. Thus, mutants hp53Val-154, hp53Val-266 and hp53Pro-273 (1620-degrees) were completely resistant to degradation, whereas hp53Ile-247 and hp53Trp-248 (1620+) were degraded. Mutants hp53Leu-273 and mp53Val-135, which are temperature sensitive for conformation, were completely degraded in the 1620+ form but degradation resistant in the 1620-degrees form. Although the PAb 1620+ conformation appeared important for recognition of p53 by E6, the epitope itself is unlikely to be the actual recognition target since the PAb 1620 monoclonal antibody failed to protect against E6-mediated degradation.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge								ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUSEN HZ, 1987, PAPOVAVIRIDAE, V2, P245; HUIGBREGTSE J, 1991, EMBO J, V10, P4129; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1993, ONCOGENE, V8, P2001; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	33	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2847	2851						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690928				2022-12-25	WOS:A1993LX34300028
J	GELFAND, CA; WANG, Q; RANDALL, S; JENTOFT, JE				GELFAND, CA; WANG, Q; RANDALL, S; JENTOFT, JE			INTERACTIONS OF AVIAN-MYELOBLASTOSIS VIRUS NUCLEOCAPSID PROTEIN WITH NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; REPRESSOR-OPERATOR INTERACTION; PRIMER TRANSFER-RNA; GENE 32 PROTEIN; VIRAL-RNA; ESCHERICHIA-COLI; LEUKEMIA-VIRUS; BINDING; DNA; RETROVIRUSES	The retroviral nucleocapsid protein (NC) associates, histone-like, with genomic RNA within the viral capsid. NC, an essential component of replication competent retroviruses, is also associated with events leading both to virus assembly and to reverse transcription. The nucleic acid binding properties of NC are key to understanding these properties, yet only a minimal biochemical description of NC-nucleic acid interactions is available. We have used the anisotropy of the intrinsic fluorescence of NC from avian myeloblastosis virus to quantify its binding to a variety of nucleic acids. Using salt back-titrations, the intrinsic equilibrium association constant per nucleic acid site, K(obs), was determined for NC binding to single- and double-stranded RNAs and DNAs. In 0.125 M NaCl, 40 mm HEPES at pH 7.0 and 27-degrees-C, the log K(obs) ranged from 3.3 to 4.0 (average 3.7) for these nucleic acids. From the salt dependence of K(obs), it was estimated that, on balance, 1 ion was displaced upon formation of each complex; it is likely that cation displacement from nucleic acid is offset by anion binding by protein during complex formation. The logarithm of the mean intrinsic affinity in the absence of polyelectrolyte effects, log K(T), was 3.1, corresponding to a DELTAG of -4.2 kcal/mol. K(obs), K(T), and the number of displaced ions were independent of pH between pH 5.6 and 8.9, indicating that NC residues that titrate in this pH range are not contributing to binding. K(obs) and K(T) increase with temperature, in the range 15 to 47-degrees-C. From van't Hoff analysis, entropy was found to be the driving force for formation of the NC-poly(rA) complex, even in the absence of the polyelectrolyte effect. The general nature of NC interactions with nucleic acids is shown by the similarity of the K(obs) values for RNAs and DNAs in both single-stranded and double-stranded structures. This ability of NC to interact with all types of nucleic acids may provide it with the necessary versatility to function like a histone in facilitating the packaging of viral RNA and yet function early in infection, where it has been ascribed a role in facilitating reverse transcription.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University					NIAMS NIH HHS [AR 20168] Funding Source: Medline; NIGMS NIH HHS [GM 36948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036948] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P454; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; DAVIS J, 1976, J VIROL, V18, P709, DOI 10.1128/JVI.18.2.709-718.1976; DAVIS NL, 1972, J VIROL, V10, P1010, DOI 10.1128/JVI.10.5.1010-1020.1972; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P477; FLEISSNER E, 1971, J VIROL, V8, P778, DOI 10.1128/JVI.8.5.778-785.1971; FU XD, 1985, J BIOL CHEM, V260, P9941; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; JOHNSON SP, 1983, J VIROL, V45, P876, DOI 10.1128/JVI.45.2.876-881.1983; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATZ RA, 1989, BIOESSAYS, V11, P176, DOI 10.1002/bies.950110605; KATZ RA, 1986, GENE, V50, P361, DOI 10.1016/0378-1119(86)90340-9; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LEIS J, 1983, J VIROL, V48, P361, DOI 10.1128/JVI.48.2.361-369.1983; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LEIS JP, 1978, VIROLOGY, V84, P87, DOI 10.1016/0042-6822(78)90220-9; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PAL BK, 1977, VIROLOGY, V83, P423, DOI 10.1016/0042-6822(77)90188-X; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SECNIK J, 1992, BIOCHEMISTRY-US, V31, P2982, DOI 10.1021/bi00126a020; SECNIK J, 1990, BIOCHEMISTRY-US, V29, P7991, DOI 10.1021/bi00486a030; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; STEEG CM, 1990, J VIROL, V64, P847, DOI 10.1128/JVI.64.2.847-855.1990; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; TAKAHASHI M, 1990, BIOCHEMISTRY-US, V29, P3431, DOI 10.1021/bi00466a002	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18450	18456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689554				2022-12-25	WOS:A1993LV65900014
J	GERSHONI, JM; DENISOVA, G; RAVIV, D; SMORODINSKY, NI; BUYANER, D				GERSHONI, JM; DENISOVA, G; RAVIV, D; SMORODINSKY, NI; BUYANER, D			HIV BINDING TO ITS RECEPTOR CREATES SPECIFIC EPITOPES FOR THE CD4/GP120 COMPLEX	FASEB JOURNAL			English	Article						AIDS; HIV; RECEPTOR LIGAND INTERACTIONS; VACCINE	AIDS PATHOGENESIS; VIRUS BINDING; FUSION; CD4; ENVELOPE; IDENTIFICATION; RECOGNIZES; ANTIBODIES; INFECTION; CELLS	Effective vaccines against the human immunodeficiency virus (HIV) must cope with the genetic variation of the viral envelope (gp120) to combat or prevent acquired immunodeficiency syndrome (AIDS). Here we describe novel epitopes that are accentuated when gp120 complexes with its receptor (CD4). The presentation of these epitopes results through conformational rearrangements in the CD4/gp120 complex. Monoclonal antibodies directed to these epitopes inhibit syncytium formation, thus indicating the potential use of these epitopes as subunit vaccines.			GERSHONI, JM (corresponding author), TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL.							ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649, DOI 10.1146/annurev.iy.09.040191.003245; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; GERSHONI JM, 1988, P NATL ACAD SCI USA, V85, P4087, DOI 10.1073/pnas.85.11.4087; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HILLMAN K, 1990, J IMMUNOL, V144, P2131; OHNO T, 1991, P NATL ACAD SCI USA, V88, P10726, DOI 10.1073/pnas.88.23.10726; PROFY AT, 1990, J IMMUNOL, V144, P4641; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0	14	62	75	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1993	7	12					1185	1187		10.1096/fasebj.7.12.7690724	http://dx.doi.org/10.1096/fasebj.7.12.7690724			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LW817	7690724				2022-12-25	WOS:A1993LW81700014
J	SZUMILO, T; DRAKE, RR; YORK, JL; ELBEIN, AD				SZUMILO, T; DRAKE, RR; YORK, JL; ELBEIN, AD			GDP-MANNOSE PYROPHOSPHORYLASE - PURIFICATION TO HOMOGENEITY, PROPERTIES, AND UTILIZATION TO PREPARE PHOTOAFFINITY ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS	Pig liver GDP-mannose pyrophosphorylase was purified 5,000-fold to apparent homogeneity using standard techniques. The native enzyme showed a single band on gels of about 450 kDa and two subunits of 43 and 37 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The 37-kDa (beta-) subunit had only methionine at its amino terminus and a surprisingly hydrophobic sequence: Met-Lys-Ala-Leu-Ile-Leu-Val Gly-Gly-Tyr-Gly-Thr-Arg-Leu-Arg-Pro-Leu-Thr Leu-Ser-Ile-Pro-Lys. The 43-kDa (alpha-) subunit was blocked at the amino terminus, but a 29-kDa CNBr fragment had the following sequence: Leu-Asp-Ala-His-Arg-His-Arg-Pro-His-Pro-Phe-Leu-Leu-. Substrate specificity studies done in the direction of formation of nucleoside triphosphate and sugar-1-P indicated that the enzyme was most effective with GDP-glucose as substrate (100%) followed by IDP-mannose (72%) and then GDP-mannose (61%). That GDP-mannose and GDP-glucose activities were indeed catalyzed by the same enzyme was indicated by the following. (i) Various studies indicated that the enzyme was homogeneous. (ii) A staining procedure for production of GTP stained the same single band on native gels when either GDP-mannose or GDP-glucose was the substrate. (iii). GDP-mannose inhibited the utilization of GDP-glucose by the enzyme, and vice versa. When 8-azido-[P-32]GTP was incubated with native enzyme and exposed to UV light, both the 43-kDa and the 37-kDa subunits became labeled, although the 37-kDa subunit reacted more strongly. On the other hand, 8-azido-GDP-[P-32]mannose only photolabeled the 43-kDa band. Most importantly, the purified enzyme can be utilized to produce 8-azido-[P-32]GDP mannose or 8-azido-[P-32]GDP glucose.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,1301 W MARKHAM,MS 516,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GINSBURG V, 1964, ADV ENZYMOL REL S BI, V26, P35; GROVES WE, 1968, ANAL BIOCHEM, V22, P195, DOI 10.1016/0003-2697(68)90307-2; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUNCHPETERSEN A, 1956, ACTA CHEM SCAND, V10, P928, DOI 10.3891/acta.chem.scand.10-0928; PASTUSZAK I, 1990, Glycobiology, V1, P71, DOI 10.1093/glycob/1.1.71; PREISS J, 1964, J BIOL CHEM, V239, P3119; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; SMOOT JW, 1985, EUR J BIOCHEM, V148, P83, DOI 10.1111/j.1432-1033.1985.tb08810.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERACHTERT H, 1966, J BIOL CHEM, V241, P2007	17	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17943	17950						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688733				2022-12-25	WOS:A1993LT74300048
J	ZALATAN, F; GALLOWAYSALVO, J; PLATT, T				ZALATAN, F; GALLOWAYSALVO, J; PLATT, T			DELETION ANALYSIS OF THE ESCHERICHIA-COLI RHO-DEPENDENT TRANSCRIPTION TERMINATOR TRP-T'	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRO MESSENGER-RNA; ATPASE ACTIVITY; GENE-EXPRESSION; 3' END; REQUIREMENT; LAMBDA-TR1; SEQUENCE; UPSTREAM; DOMAINS; PROTEIN	We have analyzed with deletion mutations the Escherichia coli rho-dependent transcription terminator trp t'. This site, 211 nucleotides in length, contains multiple sequence elements that are recognized by rho. Among these multiple elements are two that together appear to be important for full transcription termination efficiency in vitro and are similar to the rutA and rutB sequence elements in the lambdatR1 rho-dependent terminator previously described by Chen and Richardson (1987). The results suggest for the first time that common functionally important elements are shared among rho-dependent terminators. Other regions of trp t' also appear to contribute to its functional efficiency, consistent with the idea that rho-dependent terminators contain dispersed and redundant recognition segments.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNION COLL,DEPT BIOL,SCHENECTADY,NY 12308	University of Rochester; University of Rochester; Union College					NIGMS NIH HHS [GM22830] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFANO P, 1991, CELL, V64, P553; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; GALLOWAY J, 1987, THESIS YALE U; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLOWAY JL, 1986, REGULATION GENE EXPR, P155; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; LAU LF, 1985, J BIOL CHEM, V260, P574; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERYGOLDHAMME.C, 1974, P NATL ACAD SCI USA, V71, P1162; MCKENNY K, 1982, GENE AMPLIFICATION A, V2, P383; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; NEHRKE KW, 1993, IN PRESS GENE EXPRES; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; RICHARDSON LV, 1992, NUCLEIC ACIDS RES, V20, P5383, DOI 10.1093/nar/20.20.5383; SCHNEIDER D, 1993, FASEB J, V7, P201, DOI 10.1096/fasebj.7.1.7678562; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; WU AM, 1980, CELL, V19, P829, DOI 10.1016/0092-8674(80)90073-2; ZALATAN F, 1992, J BIOL CHEM, V267, P19082	32	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17051	17056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688721				2022-12-25	WOS:A1993LQ98800028
J	HANADA, K; IZAWA, K; NISHIJIMA, M; AKAMATSU, Y				HANADA, K; IZAWA, K; NISHIJIMA, M; AKAMATSU, Y			SPHINGOLIPID DEFICIENCY INDUCES HYPERSENSITIVITY OF CD14, A GLYCOSYL PHOSPHATIDYLINOSITOL-ANCHORED PROTEIN, TO PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING; BIOSYNTHESIS; MEMBRANE; SPHINGOMYELIN; METABOLISM; RECEPTOR; MUTANT; CELLS	Strain SPB-1 is a temperature-sensitive Chinese hamster ovary cell mutant defective in sphingoid base biosynthesis. To examine the effects of sphingolipid deficiency on a glycosyl phosphatidylinositol-anchored protein, we constructed transfectants expressing mouse CD14 from the SPB-1 and the wild type cells. When the cells were precultured in a sphingolipid-deficient medium at 39-degrees-C, CD14 expressed in the SPB-1 cells was hypersensitive to phosphatidylinositol-specific phospholipase C (PI-PLC), compared with that in the wild type cells. Moreover, after exposure of the cells to fumonisin B1, an inhibitor of ceramide synthase, CD14, even in the wild type cells, became hypersensitive to PI-PLC. The PI-PLC hypersensitivity in the SPB-1 cells was almost completely suppressed when the cells were cultured in the presence of exogenous sphingosine or sphingomyelin. On the other hand, the hypersensitivity induced by fumonisin B1 was suppressed by exogenous sphingomyelin but not by sphingosine. The suppression by exogenous glucosylceramide was partial under both conditions. Likewise, CD14 molecules in membranes prepared from the sphingolipid-deficient cells were more sensitive to PI-PLC than those from the control cells. These results indicated that a deficiency in cellular complex sphingolipids caused the PI-PLC hypersensitivity of CD14, suggesting the interaction of CD14 with sphingolipids in membranes.	NATL INST HLTH,DEPT BIOCHEM & CELL BIOL,SHINJUKU KU,TOKYO 162,JAPAN					Hanada, Kentaro/0000-0003-1383-2781				BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1990, J BIOL CHEM, V265, P22137; HARAKUGE S, 1990, J BIOL CHEM, V265, P6606; HAZIOT A, 1988, J IMMUNOL, V141, P547; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1989, NUCLEIC ACIDS RES, V17, P2132, DOI 10.1093/nar/17.5.2132; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3260, DOI 10.1021/bi00257a002; NASU N, 1991, INT IMMUNOL, V3, P205, DOI 10.1093/intimm/3.2.205; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHUTT C, 1988, IMMUNOL LETT, V19, P321, DOI 10.1016/0165-2478(88)90162-9; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG E, 1991, J BIOL CHEM, V266, P14486; White D.A., 1973, FORM FUNCTION PHOSPH; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	30	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13820	13823						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686144				2022-12-25	WOS:A1993LJ82500011
J	MOY, P; LOBB, R; TIZARD, R; OLSON, D; HESSION, C				MOY, P; LOBB, R; TIZARD, R; OLSON, D; HESSION, C			CLONING OF AN INFLAMMATION-SPECIFIC PHOSPHATIDYL INOSITOL-LINKED FORM OF MURINE VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL; LEUKOCYTE ADHESION; INTEGRIN VLA-4; ENDOTHELIAL-CELLS; PROTEINS; VCAM-1; LYMPHOCYTES; EXPRESSION; BIOSYNTHESIS; PRECURSORS	Vascular cell adhesion molecule-1 (VCAM1) is a member of the immunoglobulin (Ig) superfamily which interacts with the integrin very late antigen-4 (VLA4). The VCAM1/VLA4 interaction mediates both adhesion and signal transduction and is thought to play an important role in inflammatory and immune responses in vivo. VCAM1 cDNAs cloned from mouse, rat, rabbit, and human libraries contain six, seven, or eight extracellular Ig-like domains generated by alternate splicing, but to date shorter forms have not been found. We have cloned a novel cDNA encoding only the three N-terminal domains of murine VCAM1 followed by a unique C-terminal tail generated by alternate splicing of a previously undescribed exon. This truncated form of murine VCAM1 (3D-VCAM1) is expressed in COS cells as a functional adhesion molecule which is lost from the cell surface following treatment with phosphatidylinositol-specific phospholipase C. 3D-VCAM1 is found only in endotoxin-treated but not control murine and rat tissues. Thus in rodents alternate splicing of the VCAM1 gene generates a unique truncated inflammation-specific phosphatidylinositol-linked form of VCAM1.	BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142	Biogen								BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHISHOLM PL, 1993, IN PRESS EUR J IMMUN; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GRABER N, 1990, J IMMUNOL, V145, P819; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HESSION C, 1991, J BIOL CHEM, V266, P6682; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JOSEPH J, 1992, FASEB J, V6, P1200; LOBB RR, 1991, J IMMUNOL, V147, P124; LOBB RR, 1991, CELLULAR MOL MECHANI, V2, P151; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MARLOR CW, 1992, AM J PATHOL, V140, P1055; MCEVOY LM, 1992, FASEB J, V6, P5506; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; OBRIEN K, 1993, IN PRESS CIRCULATION; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; POLTE T, 1991, DNA CELL BIOL, V10, P349, DOI 10.1089/dna.1991.10.349; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WEG VB, 1993, IN PRESS J EXP MED; WINN R, 1992, FASEB J, V6, P4359; WUTHRICH RP, 1992, KIDNEY INT, V42, P903, DOI 10.1038/ki.1992.367; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	51	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8835	8841						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682556				2022-12-25	WOS:A1993KX81100068
J	THEVENIN, C; LUCAS, BP; KOZLOW, EJ; KEHRL, JH				THEVENIN, C; LUCAS, BP; KOZLOW, EJ; KEHRL, JH			CELL TYPE-SPECIFIC AND STAGE-SPECIFIC EXPRESSION OF THE CD20/B1 ANTIGEN CORRELATES WITH THE ACTIVITY OF A DIVERGED OCTAMER DNA MOTIF PRESENT IN ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PROMOTER; TRANSCRIPTION FACTOR; STIMULATES TRANSCRIPTION; IMMUNOGLOBULIN GENES; BINDING PROTEINS; LYMPHOCYTES-B; HELA-CELLS; ACTIVATION; DOMAINS; REQUIREMENT	The CD20(B1) gene encodes a B cell-specific protein involved in the regulation of human B cell proliferation and differentiation. Studies with 5' deletion CD20 promoter-CAT constructs have previously revealed two regions of the promoter between bases -186 and -280 and between bases -280 and -454 which contained positive regulatory elements. In this study we identified a sequence element present in the most proximal region located between bases -214 and -201, TTCTTCTAATTAA, which is important in the high constitutive expression of CD20 in mature B cells and the induction of CD20 in pre-B cells. This sequence element was referred to as the BAT box and its deletion significantly reduced the activity of a CD20 promoter-CAT construct in B cells. Mobility shift assays with various mutant probes and B cell nuclear extracts demonstrated that the core sequence TAAT was essential for binding to this site. Cross competition experiments with an octamer sequence from the Ig heavy chain promoter, the BAT box, and a TA-rich sequence present in the CD21 promoter revealed that all three sequences bound the same nuclear proteins suggesting that the BAT box binding proteins were Oct-1 and Oct-2. Southwestern blotting and UV cross-linking studies confirmed that the BAT box binding proteins were Oct-1 and Oct-2. The affinity of the BAT box binding proteins for the BAT box was approximately 25-fold less than for the octamer sequence and the BAT box binding proteins dissociated from the BAT box 10-fold more rapidly than from the octamer sequence. Despite this lower affinity, a trimer of the BAT box sequence was as efficiently transactivated by an Oct-2 expression vector as was a trimer of the octamer sequence in HeLa cells. The BAT box and Oct-2 were also implicated in the induction of CD20 in the pre-B cell line, PB-697, via phorbol esters. The induction of CD20 mRNA was temporally associated with induction of Oct-2 mRNA and a BAT box-deleted CD20-CAT construct, in contrast to the wild type, was poorly induced by phorbol esters. Together these results suggest that the BAT box binding proteins are important in the B cell specific expression of CD20 and perhaps CD21.	NIAID, IMMUNOREGULAT LAB, BLDG 10, RM 11B-13, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel FM, 1991, CURRENT PROTOCOLS MO; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK EA, 1989, ADV CANCER RES, V52, P81; COOPER MD, 1987, NEW ENGL J MED, V317, P1452, DOI 10.1056/NEJM198712033172306; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LOKEN MR, 1987, BLOOD, V70, P1316; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NADLER LM, 1982, J CLIN INVEST, V70, P433, DOI 10.1172/JCI110633; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; RAYHEL EJ, 1991, J IMMUNOL, V146, P2021; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STASHENKO P, 1981, P NATL ACAD SCI-BIOL, V78, P3848, DOI 10.1073/pnas.78.6.3848; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STIMAC E, 1988, MOL CELL BIOL, V8, P3734, DOI 10.1128/MCB.8.9.3734; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YOZA BK, 1990, MOL CELL BIOL, V10, P2145, DOI 10.1128/MCB.10.5.2145	32	55	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5949	5956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680653				2022-12-25	WOS:A1993KR82200088
J	KANOFSKY, JR; SIMA, PD				KANOFSKY, JR; SIMA, PD			SINGLET OXYGEN GENERATION FROM THE REACTION OF OZONE WITH PLANT-LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; BIOMOLECULES; DEPOSITION; CELLS	Aqueous extracts of the intercellular fluid from Sedum album L. leaves generated singlet oxygen chemiluminescence at 1270 nm when exposed to a nitrogen gas stream containing ozone at 21 +/- 2 ppm. The concentration of ascorbic acid in the intercellular fluid extracts was 310 +/- 40 mu M. The intensity of the singlet oxygen chemiluminescence from the intercellular fluid extracts was comparable with the chemiluminescence from a control solution containing 300 mu M ascorbic acid. The intensity of the singlet oxygen emission from intercellular fluid treated with ascorbate oxidase was 0.19 +/- 0.07 of the intensity of the singlet oxygen chemiluminescence from untreated samples of intercellular fluid extract. The simplest explanation for the effect of ascorbate oxidase is that ascorbic acid is the major ozone target generating singlet oxygen. Much weaker singlet oxygen chemiluminescence was detected at 1270 nm when intact S. album L. plant tips were exposed to a nitrogen gas stream containing ozone at 22 +/- 5 ppm. Various explanations for the relatively low intensity of the singlet oxygen chemiluminescence from intact S. album L. plant tips are discussed.	US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,RES SERV,HINES,IL 60141; LOYOLA UNIV,STRITCH SCH MED,DEPT MED,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,DEPT MOLEC & CELLULAR BIOCHEM,MAYWOOD,IL 60153	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Loyola University Chicago	KANOFSKY, JR (corresponding author), US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,MED SERV,BOX 278,HINES,IL 60141, USA.							BADER H, 1981, WATER RES, V15, P449, DOI 10.1016/0043-1354(81)90054-3; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; CASTILLO FJ, 1988, ENVIRON EXP BOT, V28, P231, DOI 10.1016/0098-8472(88)90033-0; CHAMEIDES WL, 1989, ENVIRON SCI TECHNOL, V23, P595, DOI 10.1021/es00063a013; GIAMALVA D, 1985, BIOCHEM BIOPH RES CO, V133, P773, DOI 10.1016/0006-291X(85)90971-4; KANGASJARVI J, 1994, PLANT CELL ENVIRON, V17, P783, DOI 10.1111/j.1365-3040.1994.tb00173.x; KANOFSKY JR, 1993, PHOTOCHEM PHOTOBIOL, V58, P335, DOI 10.1111/j.1751-1097.1993.tb09570.x; KANOFSKY JR, 1991, J BIOL CHEM, V266, P9039; KANOFSKY JR, 1989, CHEM-BIOL INTERACT, V70, P1, DOI 10.1016/0009-2797(89)90059-8; KANOFSKY JR, 1994, ARCH BIOCHEM BIOPHYS, V312, P244, DOI 10.1006/abbi.1994.1306; KANOFSKY JR, 1983, J BIOL CHEM, V258, P5991; KANOFSKY JR, 1995, ARCH BIOCHEM BIOPHYS, V316, P52, DOI 10.1006/abbi.1995.1009; KANOFSKY JR, 1988, J BIOL CHEM, V263, P14171; KERSTIENS G, 1989, NEW PHYTOL, V112, P13, DOI 10.1111/j.1469-8137.1989.tb00303.x; KRASNOVSKII AA, 1988, MOL MEKHANIZMY BIOL, P23; LAISK A, 1989, PLANT PHYSIOL, V90, P1163, DOI 10.1104/pp.90.3.1163; LEE EH, 1984, ENVIRON EXP BOT, V24, P331, DOI 10.1016/0098-8472(84)90030-3; LUWE MWF, 1993, PLANT PHYSIOL, V101, P969, DOI 10.1104/pp.101.3.969; MATHESON IBC, 1975, PHOTOCHEM PHOTOBIOL, V21, P165, DOI 10.1111/j.1751-1097.1975.tb06647.x; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; ROUGEE M, 1986, CR ACAD SCI II, V302, P1223; SALTZMAN BE, 1959, ANAL CHEM, V31, P1914, DOI 10.1021/ac60155a078; WAYNE RP, 1985, SINGLET MOL OXYGEN, P00081	23	62	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7850	7852		10.1074/jbc.270.14.7850	http://dx.doi.org/10.1074/jbc.270.14.7850			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713876	hybrid			2022-12-25	WOS:A1995QR52600012
J	ZHANG, P; FRUGULHETTI, I; JIANG, YQ; HOLT, GL; CONDIT, RC; LEE, MYWT				ZHANG, P; FRUGULHETTI, I; JIANG, YQ; HOLT, GL; CONDIT, RC; LEE, MYWT			EXPRESSION OF THE CATALYTIC SUBUNIT OF HUMAN DNA-POLYMERASE-DELTA IN MAMMALIAN-CELLS USING A VACCINIA VIRUS VECTOR SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' EXONUCLEASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE; REPLICATION; PURIFICATION; PROTEIN	The catalytic polypeptide of human DNA polymerase delta was overexpressed in BSC-40 cells (African green monkey kidney cell line) using the vaccinia virus/pTM1 system. The recombinant human DNA polymerase delta was purified to homogeneity in two steps using an immunoaffinity column and a single-stranded DNA-cellulose column. Levels of expression were about 1% of soluble cytosolic protein. The recombinant catalytic subunit was fully active and exhibited enzymatic properties similar to that of the native two-subunit enzyme including the possession of an associated 3' to 5' exonuclease activity. Recombinant pol delta was stimulated by proliferating cell nuclear antigen (PCNA); however, the degree of stimulation was lower than that of the native human enzyme. Analysis of a double mutant of the catalytic subunit, H142R/F144S, showed that it had a greatly reduced sensitivity to PCNA, suggesting that the PCNA binding site of pol delta may be located in this region of the N terminus.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV FLORIDA,DEPT MICROBIOL & IMMUNOL,GAINESVILLE,FL 32610	University of Miami; State University System of Florida; University of Florida			Paixão, Izabel/S-7490-2019; Paixão, Izabel/AAM-1668-2020		NIGMS NIH HHS [GM31973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1993, J BIOL CHEM, V268, P982; BROWN WC, 1993, J BIOL CHEM, V268, P32176; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; DOTTO GP, 1981, VIROLOGY, V114, P463, DOI 10.1016/0042-6822(81)90226-9; DOTTO GP, 1984, J MOL BIOL, V172, P507, DOI 10.1016/S0022-2836(84)80020-0; DOTTO GP, 1983, VIROLOGY, V30, P252; FEHER Z, 1994, BBA-GENE STRUCT EXPR, V1218, P35, DOI 10.1016/0167-4781(94)90098-1; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LU CD, 1992, BIOCHEMISTRY-US, V31, P12403, DOI 10.1021/bi00164a015; MILLER LK, 1988, AN REV MICROBIOL, V42, P8177; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAKANO R, 1991, GENE, V105, P173, DOI 10.1016/0378-1119(91)90148-5; PIGNEDE G, 1991, J MOL BIOL, V222, P209, DOI 10.1016/0022-2836(91)90207-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988	32	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7993	7998		10.1074/jbc.270.14.7993	http://dx.doi.org/10.1074/jbc.270.14.7993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713899	hybrid			2022-12-25	WOS:A1995QR52600035
J	STEINERT, PM; MAREKOV, LN; PARRY, DAD				STEINERT, PM; MAREKOV, LN; PARRY, DAD			DIVERSITY OF INTERMEDIATE FILAMENT STRUCTURE - EVIDENCE THAT THE ALIGNMENT OF COILED-COIL MOLECULES IN VIMENTIN IS DIFFERENT FROM THAT IN KERATIN INTERMEDIATE FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFILAMENT-L PROTEIN; INVITRO; CELLS; ARCHITECTURE; HETERODIMER; EXPRESSION; COMPLEXES; REGISTER; SUBUNITS	Although vimentin intermediate filaments (IF) are morphologically similar to all other IF types, cells have evolved different ways of manipulating vimentin and keratin IF. The structural basis for such differences is unknown. We have explored this by use of cross-linking experiments on vimentin oligomers, polymers, and intact IF to determine the axial length of vimentin molecules and the degrees to which neighboring molecules are aligned in IF. Our data reveal that the homodimer vimentin molecule (43.9 nm) is clearly shorter than a keratin heterodimer molecule (46.2 nm). Vimentin assemblies contain three modes of antiparallel molecular alignments: A11 and A22 in two-molecule or larger oligomeric assemblies, in which the two molecules are staggered so as to bring their 1B and 2B rod domain segments, respectively, into register; and A12 in higher order molecular assemblies in which the two neighboring molecules are largely overlapped. Since the repeat axial length of the vimentin assemblies (42.6 nm) is less than the molecular length, this means there is an overlap (designated as alignment A(CN)) of about 1 nm (5-10 residues) between the end of the 2B and beginning of the IA rod domain segments of similarly directed molecules in the IF. Interestingly, these four modes of nearest neighbor molecular alignments also occur in keratin IF. However, the degree of stagger of alignments in the A11 and A22 modes is different (staggers of -19.5 for vimentin versus -16.6 nm for keratin, and 23.3 and 28.6 nm, respectively). Two-dimensional surface lattice maps of the two IF types are very similar, except for differences in molecule alignments and different axial repeats of 21.4 nm in vimentin and 22.6 nm in keratin IF. Although vimentin-keratin hybrid molecules can be induced to form in vitro, they do not assemble into higher order structures. The data suggest that vimentin and keratin are incapable of assembly into IF in vitro or in vivo simply because their molecules are of different axial lengths and because the exact axial alignments of neighboring molecules are different.	MASSEY UNIV,DEPT PHYS & BIOPHYS,PALMERSTON NORTH,NEW ZEALAND	Massey University	STEINERT, PM (corresponding author), NIAMSD,SKIN BIOL BRANCH,BLDG 6,RM 425,BETHESDA,MD 20892, USA.							BRAGG PD, 1980, EUR J BIOCHEM, V106, P493; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; DESSEV G, 1988, DEV BIOL, V130, P543, DOI 10.1016/0012-1606(88)90349-1; Fraser R.D.B., 1990, CELLULAR MOL BIOL IN, P205; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRASER RDB, 1985, BIOSCIENCE REP, V5, P573, DOI 10.1007/BF01117070; GEISLER N, 1993, FEBS LETT, V323, P63, DOI 10.1016/0014-5793(93)81449-A; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GOLDMAN RD, 1990, CELLULAR MOL BIOL IN; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HENDERSON D, 1982, J MOL BIOL, V155, P173, DOI 10.1016/0022-2836(82)90444-2; HERRLING J, 1991, INT J BIOL MACROMOL, V13, P115, DOI 10.1016/0141-8130(91)90059-4; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HISANAGA S, 1990, J MOL BIOL, V211, P857, DOI 10.1016/0022-2836(90)90079-2; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MILAM L, 1982, J CELL BIOL, V94, P592, DOI 10.1083/jcb.94.3.592; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; POTSCHKA M, 1990, EUR J CEL LBIOL, V190, P505; QUAX W, 1983, CELL, V35, P215, DOI 10.1016/0092-8674(83)90224-6; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; SKALLI O, 1992, Trends in Cell Biology, V2, P308, DOI 10.1016/0962-8924(92)90121-3; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1993, J BIOL CHEM, V268, P2878; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; STEINERT PM, 1993, IN PRESS BIOCHEMISTR; STEINERT PM, 1982, COLD SPRING HARB SYM, V46, P465; STEVEN AC, 1990, CELLULAR MOL BIOL IN, P533; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; ZACKROFF RV, 1979, P NATL ACAD SCI USA, V76, P6226, DOI 10.1073/pnas.76.12.6226	45	143	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24916	24925						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693709				2022-12-25	WOS:A1993MG67300061
J	CUTLER, RL; LIU, L; DAMEN, JE; KRYSTAL, G				CUTLER, RL; LIU, L; DAMEN, JE; KRYSTAL, G			MULTIPLE CYTOKINES INDUCE THE TYROSINE PHOSPHORYLATION OF SHC AND ITS ASSOCIATION WITH GRB2 IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; INTERLEUKIN-3; RECEPTOR; KINASE; RAS; CLONING; PRODUCT; DOMAIN	The identification and characterization of proteins that become tyrosine-phosphorylated in response to growth factor stimulation is critical to furthering our understanding of the signal transduction pathways involved in regulating cell proliferation and differentiation. In this report we demonstrate that interleukin-3, erythropoietin, and steel factor all induce the tyrosine phosphorylation of the SH2 containing protein, p52shc. These studies were carried out with various human and murine cell lines to document that this is a common event in hemopoietic cells. We also show that upon tyrosine phosphorylation, p52shc becomes associated with the adaptor protein, Grb2. The formation of this complex may directly link tyrosine phosphorylation events to Ras activation in hemopoietic progenitors and may be a critical step in stimulating these cells to transit through G1 into S phase.	BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER V5Z 1L3,BC,CANADA	British Columbia Cancer Agency				Krystal, Gerald/0000-0002-1961-6281				ALAI M, 1992, J BIOL CHEM, V267, P18021; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KRYSTAL G, 1991, HEMATOL PATHOL, V5, P141; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MURTHY SC, 1989, BLOOD, V73, P1180; OKUDA K, 1992, BLOOD, V79, P2880; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMIESON S, 1993, J BIOL CHEM, V268, P7310; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SORENSEN PHB, 1989, BLOOD, V73, P406; TORTI M, 1992, J BIOL CHEM, V267, P8293	34	234	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21463	21465						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691810				2022-12-25	WOS:A1993MC80900003
J	XU, M; AKABAS, MH				XU, M; AKABAS, MH			AMINO-ACIDS LINING THE CHANNEL OF THE GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR IDENTIFIED BY CYSTEINE SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GATED ION CHANNELS; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-BIOLOGY; BRAIN; PERMEATION; SUBUNITS	The binding of gamma-aminobutyric acid (GABA) to gamma-aminobutyric acid type A (GABA(A)) receptors triggers the opening of an anion-selective channel. To identify amino acid residues that line the channel, we combined cysteine mutagenesis and covalent chemical modification. We mutated, one at a time, four consecutive residues (268-271) in the M2 membrane-spanning segment of the rat GABA(A) receptor alpha1 subunit to cysteine and expressed the mutant alpha1 subunits, together with either the beta1 subunit or the beta1 and gamma2 subunits, in Xenopus oocytes. We probed the susceptibility of the cysteine substitution mutants to covalent modification by charged, sulfhydryl reagents added extracellularly. We assumed that among the residues in membrane-spanning segments, only those lining the channel would be susceptible to modification by polar reagents and that such modification would irreversibly alter conduction. We infer that the residues Thr-268 and Ile-271 are exposed in the channel in both the open and closed states but that Leu-269 and Ser-270 are not exposed. The susceptibility of Thr-268 and Ile-271 in the closed state implies that the gate must be closer to the cytoplasmic end of the channel than Thr-268.	COLUMBIA UNIV COLL PHYS & SURG,CTR MOLEC RECOGNIT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University				Akabas, Myles/0000-0001-8781-7846	NINDS NIH HHS [NS07065] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ERICKSSON AE, 1992, SCIENCE, V255, P178; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Kenyon G L, 1977, Methods Enzymol, V47, P407; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NISHIMURA C, 1982, NEUROCHEM INT, V4, P413, DOI 10.1016/0197-0186(82)90084-5; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	24	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21505	21508						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691812				2022-12-25	WOS:A1993MC80900014
J	SARTOR, O; ROBBINS, KC				SARTOR, O; ROBBINS, KC			SUBSTRATE-SPECIFICITY FOR NORMAL BUT NOT MUTATIONALLY ACTIVATED VARIANTS OF SRC FAMILY KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SH3 DOMAINS; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; STABLE ASSOCIATION; CATALYTIC DOMAINS; PP60SRC SUBSTRATE; CELLULAR PROTEINS; CELLS; GENE	Although structural features and expression patterns of the src family of tyrosine kinases have been extensively analyzed, there are no direct comparative studies of the putative protein substrates that are tyrosine-phosphorylated by the normal cellular versions of these enzymes. In this report, we have expressed normal and enzymatically activated versions of the fyn, fgr, and src translational products by transfection of appropriate cDNAs into mouse fibroblasts. Because the same parental cell line was used for all transfections, each enzyme was expressed in a similar milieu of potential in vivo substrates. After verification of appropriate expression from each transfected cDNA and assessment of relative transforming potency, a series of putative protein substrates was specifically assayed for expression and tyrosine phosphorylation. Our data indicate that the normal src family kinases display some degree of substrate specificity but that specificity is diminished when these enzymes are constitutively activated. In the course of these studies, tyrosine-phosphorylated proteins were noted to coimmunoprecipitate with some of these putative in vivo substrates. Some of these coimmunoprecipitating proteins have been reported previously, whereas others, such as the presence of p59fyn in anti-p80/85 immunoprecipitates, are heretofore undescribed.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	SARTOR, O (corresponding author), NCI,CLIN PHARMACOL BRANCH,RM 12N226,BLDG 10,BETHESDA,MD 20892, USA.							CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1989, ONCOGENE RES, V1, P185; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SARTOR O, 1992, J BIOL CHEM, V267, P21044; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SUDOL M, 1993, IN PRESS MOL BASIS H; VEILLETTE A, 1992, ONCOGENE, V7, P971; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21014	21020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691803				2022-12-25	WOS:A1993MA28800059
J	TILLY, BC; VANDENBERGHE, N; TERTOOLEN, LGJ; EDIXHOVEN, MJ; DEJONGE, HR				TILLY, BC; VANDENBERGHE, N; TERTOOLEN, LGJ; EDIXHOVEN, MJ; DEJONGE, HR			PROTEIN-TYROSINE PHOSPHORYLATION IS INVOLVED IN OSMOREGULATION OF IONIC CONDUCTANCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN EPITHELIAL-CELLS; RESISTANCE P-GLYCOPROTEIN; VOLUME REGULATION; CHANNELS; INTEGRINS; PATHWAYS; ADHESION; LINE	Using the human Intestine 407 cell line as a model, we investigated a possible role for tyrosine kinase(s) in regulating the ion efflux pathways induced by hyposmotic stimulation (regulatory volume decrease, RVD). Pretreatment of I-125-- and Rb-86+-loaded cells with the phosphotyrosine phosphatase inhibitor sodium orthovanadate (200 muM) potentiated isotope efflux triggered by mild hypotonicity (10-20%) but did not further increase the efflux in response to more vigorous osmotic stimulation (30% hypotonicity). The tyrosine kinase inhibitors herbimycin A and genistein largely reduced the osmoshock-induced efflux in both control and vanadate-pretreated cells, while not affecting calcium-activated Rb-86+ efflux. Potentiation of the RVD response by vanadate was confirmed by direct measurements of hypotonicity-induced changes in cell volume. Hypotonic shock alone triggered a rapid and transient increase in tyrosine phosphorylation of several proteins as well as phosphorylation of mitogen-activated protein kinase. Furthermore, the potentiating effects of vanadate on hypotonicity-induced ion efflux and mitogen-activated protein (MAP) kinase phosphorylation were mimicked by epidermal growth factor. Neither vanadate nor epidermal growth factor provoked a RVD-like ionic response under isotonic conditions. These results indicate that tyrosine phosphorylation is an essential step in the RVD response and suggest a novel role of growth factors in the cellular defense against osmotic stress.	UNIV HOSP LEIDEN,DEPT ENDOCRINOL,2300 RC LEIDEN,NETHERLANDS; NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	TILLY, BC (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAUSSINGER D, 1990, HEPATOLOGY, V11, P243, DOI 10.1002/hep.1840110214; HAZAMA A, 1988, J PHYSIOL-LONDON, V402, P687, DOI 10.1113/jphysiol.1988.sp017229; HENLE G, 1957, J IMMUNOL, V79, P54; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JILL E, 1987, AM J PHYSIOL, V252, pF1; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; OKADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P201, DOI 10.1016/0005-2736(92)90348-P; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SWARUP G, 1982, J BIOL CHEM, V257, P7298; UEHARA Y, 1989, CANCER RES, V49, P780; VAANDRAGER AB, 1991, AM J PHYSIOL, V261, pG958, DOI 10.1152/ajpgi.1991.261.6.G958; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	23	197	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19919	19922						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690749				2022-12-25	WOS:A1993LY01900002
J	SANO, M; HAYAKAWA, K; KATO, I				SANO, M; HAYAKAWA, K; KATO, I			PURIFICATION AND CHARACTERIZATION OF AN ENZYME RELEASING LACTO-N-BIOSE FROM OLIGOSACCHARIDES WITH TYPE-1 CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID RESIDUES; ALPHA-L-FUCOSIDASE; LINKED OLIGOSACCHARIDES; SUGAR CHAINS; ANTIGEN; GLYCOSPHINGOLIPIDS; ADHESION; LIGAND; FETUIN; ALMOND	An enzyme specific for oligosaccharides with type 1 chain was purified 7,000-fold from the culture broth of Streptomyces sp. 142. The enzyme, lacto-N-biosidase, was induced and secreted into culture medium when the strain was cultured in the presence of porcine stomach mucin. The enzyme was purified by anion-exchange chromatography on Q Sepharose, cation-exchange chromatography on S Sepharose, fast protein liquid chromatography on a Mono S column, and gel filtration chromatography on TSK gel HW55S. To remove contaminating alpha-1,3/4-fucosidase and beta-N-acetylglucosaminidase, final purification was done by fast protein liquid chromatography on a Mono S column and affinity chromatography on N-acetylglucosamine agarose. The purified enzyme gave only one major protein band with an apparent M(r) of 60,000 on sodium dodesyl sulfate-polyacrylamide gel electrophoresis. The enzyme had maximum activity at pH 5.5 and was stable at the pH range of 4.0-10.0. Substrate specificity studies with oligosaccharides labeled with 2-aminopyridine showed that the enzyme specifically hydrolyzed lacto-N-tetraose and the N-acetyllactosamine type of triantennary sugar chain with the type 1 chain, but did not hydrolyze type 2 chain oligosaccharides or the type 1 chain oligosaccharides with fucose or sialic acid including lacto-N-fucopentaose I and II and alpha-2,3-sialyl lacto-N-tetraose. The enzyme released lacto-N-biose from asialofetuin, and almost all oligosaccharides in asialofetuin were found to have only type 2 chains. Sequential digestion of extended type 1 chain oligosaccharides with alpha-1,3/4-fucosidase and lacto-N-biosidase was possible.			SANO, M (corresponding author), TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,3-4-1 SETA,OTSU,SHIGA 52021,JAPAN.							BERG EL, 1991, J BIOL CHEM, V266, P14869; EGGENS I, 1989, J BIOL CHEM, V264, P9476; GOELZ SE, 1992, TRENDS GLYCOSCI GLYC, V4, P14; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HOYER LL, 1991, J BIOCHEM-TOKYO, V110, P462, DOI 10.1093/oxfordjournals.jbchem.a123603; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OGATAARAKAWA M, 1977, ARCH BIOCHEM BIOPHYS, V181, P353, DOI 10.1016/0003-9861(77)90514-8; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; SANO M, 1992, P NATL ACAD SCI USA, V89, P8512, DOI 10.1073/pnas.89.18.8512; SANO M, 1992, J BIOL CHEM, V267, P1522; SCUDDER P, 1990, J BIOL CHEM, V265, P16472; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROUD MR, 1992, EUR J BIOCHEM, V203, P577, DOI 10.1111/j.1432-1033.1992.tb16586.x; STROUD MR, 1991, J BIOL CHEM, V266, P8439; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5709, DOI 10.1021/bi00367a054; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372	20	17	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18560	18566						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689556				2022-12-25	WOS:A1993LV65900031
J	OLSON, DC; MARECHAL, V; MOMAND, J; CHEN, JD; ROMOCKI, C; LEVINE, AJ				OLSON, DC; MARECHAL, V; MOMAND, J; CHEN, JD; ROMOCKI, C; LEVINE, AJ			IDENTIFICATION AND CHARACTERIZATION OF MULTIPLE MDM-2 PROTEINS AND MDM-2-P53 PROTEIN COMPLEXES	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; P53 PROTEIN; WILD-TYPE; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; GENE-EXPRESSION; T-ANTIGEN; SV40; PRODUCT	A protein product of the mdm-2 oncogene (p90) has been recently shown to associate with the protein encoded by the tumor-suppressor gene p53. The mdm-2 gene was originally identified as a gene amplified in a spontaneously transformed Balb/c 3T3 cell line (3T3DM). This report describes the characterization of mdm-2 gene products and their interactions with the p53 protein. Polyclonal and monoclonal antibodies were generated against murine and human mdm-2 protein. These antibodies detected the mdm-2 p90 protein and at least four additional polypeptides (p85, p76, p74, p58-p57) in cultured cells. These additional proteins may arise from different spliced mRNA forms of the mdm-2 gene or post-translational modifications of the mdm-2 protein. The monoclonal antibodies distinguished at least three sets of mdm-2 proteins with distinct combinations of epitopes (p90 and p85; p76 and p74; p58-57). One or two of these proteins forms a complex with the p53 protein (p90, p58). These mdm-2 proteins were found to be overexpressed in 3T3DM cells and a subset of these proteins were complexed with p53. In 3T3DM cells, p90, like p53, had a short half-life of approximately 20 min and was localized to the cell nucleus. In resting cells stimulated with serum p90 levels and p90/p53 complex levels increased in the late G1 phase of the cell cycle. The p90 mdm-2 protein could regulate p53 activity in the late G1 phase of the cell cycle.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University			Momand, Jamil/F-8154-2012; marechal, vincent/P-7719-2017		NCI NIH HHS [CA09258-07, P01 CA41086, 5 F32 CA08771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008771, P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JH, 1993, UNPUB; CORDONCARDO C, 1993, UNPUB; ELDEIRY WS, 1992, NAT GENET, V1, P44; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WU X, 1993, UNPUB; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	33	231	235	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2353	2360						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689721				2022-12-25	WOS:A1993LT36800005
J	KANAI, F; NISHIOKA, Y; HAYASHI, H; KAMOHARA, S; TODAKA, M; EBINA, Y				KANAI, F; NISHIOKA, Y; HAYASHI, H; KAMOHARA, S; TODAKA, M; EBINA, Y			DIRECT DEMONSTRATION OF INSULIN-INDUCED GLUT4 TRANSLOCATION TO THE SURFACE OF INTACT-CELLS BY INSERTION OF A C-MYC EPITOPE INTO AN EXOFACIAL GLUT4 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; RAT ADIPOSE CELL; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; ALPHA-TOXIN; RECEPTOR; EXPRESSION; PROTEIN; CDNA; SYSTEMS	Stimulation of glucose transport is the main physiological effect of insulin in target tissues. This effect is linked to translocation of the GLUT4 glucose transporter from an intracellular pool to the cell surface. To elucidate the molecular mechanisms involved in this effect, we developed a simple direct sensitive method to detect GLUT4 immunologically on the cell surface. cDNA containing GLUT4 inserted by a c-myc epitope in the first ectodomain (GLUT4myc) was constructed without disrupting the functions of GLUT4 and was expressed in 3T3-L1 and Chinese hamster ovary fibroblast cells. In response to insulin, the GLUT4myc expressed in 3T3-L1 adipocytes was translocated to the cell surface from the intracellular pool, as shown by assays of exofacial antibody binding against the myc epitope and of the uptake of 2-deoxyglucose. Insulin, guanosine 5'-O-(3-thiotriphosphate), guanylyl imidodiphosphate, NaF, and phorbol 12-myristate 13-acetate also induced the translocation of GLUT4myc in Chinese hamster ovary cells coexpressing the human insulin receptor.	UNIV TOKUSHIMA, INST ENZYME RES, DEPT ENZYME GENET, 3-18-15 KURAMOTO CHO, TOKUSHIMA 770, JAPAN	Tokushima University				Kamohara, Seika/0000-0002-2482-6611; Hayashi, Hideki/0000-0003-4585-6542				AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOULD GW, 1989, J BIOL CHEM, V264, P2180; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SALTIS J, 1991, J BIOL CHEM, V266, P261; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VOGT B, 1991, BIOCHEM J, V275, P597, DOI 10.1042/bj2750597	28	140	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14523	14526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686158				2022-12-25	WOS:A1993LJ82500104
J	NAG, B; DESHPANDE, SV; SHARMA, SD; CLARK, BR				NAG, B; DESHPANDE, SV; SHARMA, SD; CLARK, BR			CLONED T-CELLS INTERNALIZE PEPTIDE FROM BOUND COMPLEXES OF PEPTIDE AND PURIFIED CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IA MOLECULES; RECEPTOR; STIMULATION; INHIBITION; BINDING; MHC; RECOGNITION; AFFINITY	Antigen presentation to helper T cells involves the formation of a trimolecular complex consisting of a class II major histocompatibility complex (MHC) antigen combined with an antigenic peptide on the surface of an antigen-presenting cell and a T cell receptor (TCR) on the T cell. The fate of the MHC class II, peptide, or TCR moieties of the ternary complex following antigen presentation is unknown. Using radio-labeled complexes of affinity-purified murine MHC class II molecules and peptides corresponding to T cell epitopes of myelin basic protein (MBP), this report presents evidence that the binding of preformed relevant MHC class II-peptide complexes to cloned T cells in vitro results in internalization of the peptide moiety. Neither the restricting MHC class II molecule nor the TCR moiety of the trimolecular complex was internalized by T cells. The specificity of peptide internalization was demonstrated using complexes of syngeneic MHC class II with an irrelevant MBP peptide analog and by cloned T cells restricted for a different epitope of the same MBP antigen. Furthermore, the peptide translocation mediated by MHC class II and TCR was demonstrated by antibody-blocking experiments using anti-class II and anti-TCR monoclonal antibodies. The peptide internalization by T cells was markedly reduced when binding was performed at 4-degrees-C as compared with 37-degrees-C. In addition, a significant inhibition of peptide translocation was observed in the presence of a metabolic inhibitor (sodium azide) but not in the presence of cytochalasin B. These results together demonstrate that the in vitro interaction of soluble MHC II-peptide complexes with cloned T cells is an active process associated with uptake of the antigenic peptide.			NAG, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSS S, 1987, IMMUNOL REV, V98, P115; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; DAVIS CB, 1989, J IMMUNOL, V143, P2083; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JENKINS MK, 1990, J IMMUNOL, V144, P16; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUMAR V, 1989, ANNU REV IMMUNOL, V7, P657, DOI 10.1146/annurev.iy.07.040189.003301; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; NAG B, 1993, P NATL ACAD SCI USA, V90, P1604, DOI 10.1073/pnas.90.4.1604; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; NAG B, 1992, J BIOL CHEM, V267, P22624; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; QUILL H, 1987, J IMMUNOL, V138, P3704; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SU XM, 1992, CELL IMMUNOL, V141, P485, DOI 10.1016/0008-8749(92)90165-L; YOSHINAGA M, 1972, P NATL ACAD SCI USA, V69, P3251, DOI 10.1073/pnas.69.11.3251	29	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14360	14366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686154				2022-12-25	WOS:A1993LJ82500083
J	ROEBROEK, AJM; VANDEVELDE, HJK; VANBOKHOVEN, A; BROERS, JLV; RAMAEKERS, FCS; VANDEVEN, WJM				ROEBROEK, AJM; VANDEVELDE, HJK; VANBOKHOVEN, A; BROERS, JLV; RAMAEKERS, FCS; VANDEVEN, WJM			CLONING AND EXPRESSION OF ALTERNATIVE TRANSCRIPTS OF A NOVEL NEUROENDOCRINE-SPECIFIC GENE AND IDENTIFICATION OF ITS 135-KDA TRANSLATIONAL PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LUNG-CANCER; GROWTH-PROPERTIES; LINES; PROTEINS; ESTABLISHMENT; SEQUENCES	Monoclonal antibodies RNL-2 and RNL-3 were previously shown to react with four 35-45-kDa proteins, expressed only in small cell lung carcinoma NCI-H82 cells, but to stain a subset of neuroendocrine tissues and neoplasms (Broers, J. L. V., Mijnheere, E. P., Klein Rot, M., Schaart, G., Sijlmans, A., Boerman, 0. C., and Ramaekers, F. C. S. (1991) Cancer 67, 619-633). We used RNL-2 and RNL-3 to isolate cDNA sequences that code for proteins containing the two corresponding epitopes and utilized such cDNAs to develop second generation antibodies. Using these antibodies, we identified a novel 135-kDa protein. The corresponding cDNAs were found to belong to a previously unknown gene with a neuroendocrine-specific expression pattern, tentatively designated NSP gene. NSP transcription appeared to result in mRNAs of 3.4 and 1.8 kilobases (kb). In the NCI-H82 cells only, an apparently aberrant transcript of 2.3 kb was found. cDNAs containing coding sequences of the 3.4-, 2.3-, and 1.8-kb transcripts were isolated, and nucleotide sequence analysis revealed extensive sequence overlap and open reading frames for proteins of 776, 356, and 208 amino acids, respectively. The three deduced proteins all have a common carboxyl-terminal part with two large hydrophobic regions. Transfection of the complete coding sequences of the 3.4-kb transcript resulted in the production of a protein with an apparent molecular mass of 135 kDa. This protein is predicted to be highly negatively charged (calculated pI of 4.35), to be rich in proline and serine, and to contain multiple potential phosphorylation sites.	UNIV LIMBURG, DEPT MOLEC CELL BIOL & GENET, 6229 ER MAASTRICHT, NETHERLANDS	Hasselt University	ROEBROEK, AJM (corresponding author), CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, MOLEC ONCOL LAB, HEREST 49, B-3000 LOUVAIN, BELGIUM.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; [Anonymous], 1982, Am J Clin Pathol, V77, P123; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEPLER G, 1987, J CANCER RES CLIN, V113, P31, DOI 10.1007/BF00389964; BEVERLY PCL, 1990, BR J CANCER S14, V63, P1; BROERS JLV, 1991, CANCER-AM CANCER SOC, V67, P619, DOI 10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y; CARNEY DN, 1985, CANCER RES, V45, P2913; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELEIJ L, 1985, CANCER RES, V45, P6024; GAZDAR AF, 1985, CANCER RES, V45, P2924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MINNA JD, 1985, CANCER PRINCIPLES PR, P505; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J, 1989, MOL CLONING LABORATO; TEMPLETON D, 1984, MOL CELL BIOL, V4, P817, DOI 10.1128/MCB.4.5.817; VANDEVEN WJM, 1978, J VIROL, V27, P595, DOI 10.1128/JVI.27.3.595-603.1978; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; WARREN WH, 1989, J THORAC CARDIOV SUR, V98, P321; WIEDENMANN B, 1989, VIRCHOWS ARCH B, V58, P95, DOI 10.1007/BF02890062; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	26	82	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13439	13447						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685762				2022-12-25	WOS:A1993LH55300061
J	SECKL, M; ROZENGURT, E				SECKL, M; ROZENGURT, E			TYRPHOSTIN INHIBITS BOMBESIN STIMULATION OF TYROSINE PHOSPHORYLATION, C-FOS EXPRESSION, AND DNA-SYNTHESIS IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AFFINITY CROSS-LINKING; GROWTH-FACTOR; RAPIDLY STIMULATE; PHOSPHOLIPASE-C; PHORBOL ESTERS; EARLY EVENTS; SIGNAL TRANSDUCTION; BETA-1 ISOZYME; GQ CLASS	Treatment of quiescent Swiss 3T3 cells with 20 muM {[(3,4,5-trihydroxyphenyl)methylene]propanedinitrile} (tyrphostin) caused a 76% r eduction in the tyrosine phosphorylation of the M(r) 110,000-130,000 band induced by bombesin. This was accompanied by a 48% reduction in the tyrosine phosphorylation of the cytosolic tyrosine kinase p125 focal adhesion kinase. Preincubation with 20 muM tyrphostin did not inhibit either protein kinase A activation by forskolin or protein kinase C (PKC) activation by phorbol 12,13-dibutyrate in intact Swiss 3T3 cells. Similarly, 20 muM tyrphostin neither interfered with binding of bombesin to its receptor nor prevented bombesin-stimulated Ca2+ mobilization or PKC activation. Thus tyrphostin selectively inhibits tyrosine phosphorylation induced by bombesin in intact Swiss 3T3 cells. Consequently, we examined the contribution of this tyrosine phosphorylation pathway to the subsequent induction of c-fos and stimulation of mitogenesis by bombesin. Tyrphostin prevented both c-fos mRNA expression and DNA synthesis induced by bombesin. The incorporation of [H-3] thymidine was inhibited by tyrphostin in a dose-dependent manner (IC50 = 20 muM), and this effect was not reversed even at high concentrations of bombesin. These results provide evidence that tyrosine phosphorylation is a mitogenic signal for bombesin.	IMPERIAL CANC RES FUND, POB 123, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ANAFI M, 1992, J BIOL CHEM, V267, P4518; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BILDER GE, 1991, AM J PHYSIOL, V260, pC721, DOI 10.1152/ajpcell.1991.260.4.C721; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MEHMET H, 1990, EXP CELL RES, V190, P265, DOI 10.1016/0014-4827(90)90195-G; MEHMET H, 1989, ONCOGENE RES, V4, P215; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETHI T, 1992, CANCER RES, V52, pS2737; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STADDON JM, 1991, J BIOL CHEM, V266, P4840; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	54	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9548	9554						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683655				2022-12-25	WOS:A1993LA68900062
J	CHANG, JH; WILSON, LK; MOYERS, JS; ZHANG, K; PARSONS, SJ				CHANG, JH; WILSON, LK; MOYERS, JS; ZHANG, K; PARSONS, SJ			INCREASED LEVELS OF P21RAS-GTP AND ENHANCED DNA-SYNTHESIS ACCOMPANY ELEVATED TYROSYL PHOSPHORYLATION OF GAP-ASSOCIATED PROTEINS, P190 AND P62, IN C-SRC OVEREXPRESSORS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; EPIDERMAL GROWTH-FACTOR; RAS P21 GTPASE; SIGNAL TRANSDUCTION; MITOGENIC RESPONSIVENESS; CELLULAR PROTEINS; KINASE; TRANSFORMATION; RECEPTOR; CELLS	While examining the role of pp60c-src in cellular proliferation, we found that overexpression of c-src in C3H10T1/2 murine fibroblasts results in an augmented mitogenic response to epidermal growth factor (EGF) [Luttrell, D.K., Luttrell, L.M. & Parsons, S.J. (1988). Mol. Cell. Biol., 8, 497-501; Wilson, L.K., Luttrell, D.K., Parsons, S.J. (1989). Mol. Cell. Biol., 9, 1536-1544] and enhanced tyrosyl phosphorylation of specific cellular proteins [Wilson, L.K. & Parsons, S.J. (1990). 5, 1471-14801. Here we identify two of these proteins as the GAP (GTPase-activating protein of p21ras)associated proteins, p190 and p62. Evidence is presented to support the notion that, in 10T1/2 fibroblasts, p190 is a preferred substrate of pp6Oc-src, while p62 is preferentially phosphorylated by the EGF receptor. First, the phosphotyrosine content of p190 in quiescent cells is three- to fivefold higher in c-src overexpressors than in control cells and is not altered by growth factor treatment. In contrast, tyrosyl phosphorylation of p62 is undetectable in quiescent cells and transiently observable upon EGF addition. Second, the phosphotyrosine content of p190 in cells overexpressing defective pp60c-src is reduced in comparison with wild-type (wt) c-src overexpressors, while that of p62 is significantly less affected. Further studies revealed that tyrosyl phosphorylation of p190 and p62 is not required for GAP complex formation, as equal amounts of p190 and p62 proteins could be detected in GAP complexes from wt and variant c-src overexpressors both before and after EGF stimulation. However, analysis of GTP-bound p21ras revealed higher basal and EGF-stimulated levels in c-src overexpressors than in control cells. Taken together, these results suggest that one mechanism by which pp60c-src may contribute to early events in the EGF-induced mitogenic pathway in 10T1/2 fibroblasts is by increasing the level of GAP-associated p190 and p62 tyrosyl phosphorylation, which in turn results in higher levels of p21ras-GTP.	UNIV VIRGINIA,HLTH SCI CTR,CTR CANC,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,INST MOLEC BIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HEIDARAN MA, 1992, ONCOGENE, V7, P147; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1990, CELL, V56, P5; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PARSONS JT, 1990, TRENDS GENET, V6, P169; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	39	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					959	967						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681161				2022-12-25	WOS:A1993KT22000018
J	MARTINIS, SA; SCHIMMEL, P				MARTINIS, SA; SCHIMMEL, P			MICROHELIX AMINOACYLATION BY A CLASS-I TRANSFER-RNA SYNTHETASE - NONCONSERVED BASE-PAIRS REQUIRED FOR SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUPPRESSOR TRANSFER-RNAS; ESCHERICHIA-COLI; ENZYMATIC AMINOACYLATION; CHEMICAL SYNTHESIS; ACCEPTOR STEM; ANTICODON; RECOGNITION; IDENTITY; SEQUENCE; NUCLEOTIDES	Nucleotides in tRNAs that are conserved among isoacceptors are typically considered as candidates for tRNA synthetase recognition, with less importance attached to non-conserved nucleotides. Although the anticodon is an important contributor to the identity of methionine tRNAs, the class I methionine tRNA synthetase aminoacylates microhelices with high specificity. The microhelix substrates are comprised of as few as the 1st 4 base pairs of the acceptor stems of the elongator and initiator methionine tRNAs. For these two tRNAs, only the central 2:71 and 3:70 base pairs are common to the 1st 4 acceptor stem base pairs. We show here that, although the flanking 4:69 base pair is not conserved, a particular substitution at this position substantially reduces the gel electrophoresis-detected aminoacylation of an acceptor stem substrate that has the conserved 2:71 and 3:70 base pairs. Although the two methionine tRNAs have either U:A or G:C at position 4:69, substitution with C:G reduces charging of 9- or 4-base pair substrates that recreate part or all of the acceptor stem of a methionine tRNA. This effect is sufficient for methionine tRNA synthetase to discriminate between the closely related methionine and isoleucine tRNA acceptor stems. The ability to distinguish G:C and U:A from C:G is contrary to a simple scheme for recognition of atoms in the RNA minor groove.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Martinis, Susan/0000-0001-5730-8346	NIGMS NIH HHS [GM 15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRANCKLYN C, 1992, EUR J BIOCHEM, V206, P315, DOI 10.1111/j.1432-1033.1992.tb16929.x; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; HARADA F, 1974, BIOCHEMISTRY-US, V13, P300, DOI 10.1021/bi00699a011; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; Schimmel P, 1991, CURR OPIN STRUC BIOL, V1, P811, DOI 10.1016/0959-440X(91)90183-T; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	47	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6069	6072						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681057				2022-12-25	WOS:A1993KT36800002
J	TRIAS, JQ; BENZ, R				TRIAS, JQ; BENZ, R			CHARACTERIZATION OF THE CHANNEL FORMED BY THE MYCOBACTERIAL PORIN IN LIPID BILAYER-MEMBRANES - DEMONSTRATION OF VOLTAGE GATING AND OF NEGATIVE POINT CHARGES AT THE CHANNEL MOUTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA OUTER-MEMBRANE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; HYDROPHILIC SOLUTES; BACTERIAL PORINS; INTACT-CELLS; BINDING-SITE; PERMEABILITY; PROTEIN; IDENTIFICATION	We studied the channel formed by the mycobacterial porin from the cell wall of Mycobacterium chelonae (Trias, J., Jarlier, V., and Benz, R. (1992) Science 258, 1479-1481) by reconstituting the mycobacterial porin and cell wall extracts in lipid bilayer membranes. The channel exhibited two different states in lipid bilayer membranes at 10 mV of applied voltage. One was characterized by a steplike appearance while the other showed a fast, voltage-dependent, flickering behavior between a closed and an open state. The channel was voltage-gated, and starting at 40 mV of applied voltage the mycobacterial porin channel switched to a closed configuration in an asymmetric fashion. The channel was cation-selective and had 2.5-point negative charges at both sides of the channel. Identical channels were observed when membranes were reconstituted with cell wall extracts, suggesting that there is only one porin species in the mycobacterial cell wall.	UNIV PARIS 06,BACTERIOL VIROL LAB,F-75634 PARIS 13,FRANCE; UNIV WURZBURG,BIOZENTRUM,LEHRSTUHL BIOTECHNOL,W-8700 WURZBURG,GERMANY	UDICE-French Research Universities; Sorbonne Universite; University of Wurzburg				Benz, Roland/0000-0002-9510-9265				BENZ R, 1987, J GEN PHYSIOL, V89, P275, DOI 10.1085/jgp.89.2.275; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BENZ R, 1987, J MEMBRANE BIOL, V100, P12; BRUNEN M, 1991, J BACTERIOL, V173, P4182, DOI 10.1128/jb.173.13.4182-4187.1991; DRAPER P, 1982, BIOL MYCOBACTERIA, P9; HELLIO R, 1988, CURR MICROBIOL, V17, P235, DOI 10.1007/BF01589458; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; MAIER C, 1988, J BIOL CHEM, V263, P2493; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; NELSON AP, 1975, J THEOR BIOL, V55, P13, DOI 10.1016/S0022-5193(75)80106-8; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; NIKAIDO H, 1986, METHOD ENZYMOL, V125, P265; RASTOGI N, 1986, CURR MICROBIOL, V13, P237, DOI 10.1007/BF01568645; RATLEDGE CR, 1982, BIOL MYCOBACTERIA, P53; SCHMID A, 1991, J BACTERIOL, V173, P4909, DOI 10.1128/jb.173.16.4909-4913.1991; SEN K, 1988, J BIOL CHEM, V263, P1182; STOCK JB, 1977, J BIOL CHEM, V252, P7850; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; YOSHIMURA F, 1982, J BACTERIOL, V152, P636	27	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6234	6240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681063				2022-12-25	WOS:A1993KT36800027
J	LIU, HZ; XIONG, SH; SHI, YW; SAMUEL, SJ; LACHAAL, M; JUNG, CY				LIU, HZ; XIONG, SH; SHI, YW; SAMUEL, SJ; LACHAAL, M; JUNG, CY			ATP-SENSITIVE BINDING OF A 70-KDA CYTOSOLIC PROTEIN TO THE GLUCOSE-TRANSPORTER IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR SEQUESTRATION; ADIPOSE-CELLS; INSULIN; GLUT4; PHOSPHORYLATION; IDENTIFICATION; TRANSLOCATION; ISOFORMS; MEMBRANE; TERMINUS	We have identified a 70-kDa cytosolic protein (GTBP70) in rat adipocytes that binds to glutathione S-transferase fusion proteins corresponding to the cytoplasmic domains of the facilitative glucose transporter isoforms Glut1, Glut2, and Glut4. GTBP70 did not bind to irrelevant fusion proteins, indicating that the binding is specific to the glucose transporter. GTBP70 binding to the glucose transporter showed little isoform specificity but was significantly subdomain-specific; it bound to the C-terminal domain and the central loop, but not to the N-terminal domain of Glut4. The GTBP70 binding to Glut4 was not affected by the presence of 2 mM EDTA, 2.4 mM Ca2+, or 150 mm K+. The binding was inhibited by ATP in a dose-dependent manner, with 50% inhibition at 10 mM ATP. This inhibition was specific to ATP, as ADP and AMP-PCP (adenosine 5'-(beta,gamma-methylenetriphosphate)) were without effect. GTBP70 did not react with antibodies against phosphotyrosine, phosphothreonine, or phosphoserine, suggesting that it is not a phosphoprotein. The binding of GTBP70 to Glut4 was not affected by the pretreatment of adipocytes with insulin. When these experiments were repeated using rat hepatocyte cytosols, no ATP-sensitive 70-kDa protein binding to the glucose transporter fusion proteins was evident, suggesting that either GTBP70 expression or its function is cell-specific. These findings strongly suggest the possibility that GTBP70 may play a key role in glucose transporter regulation in insulin target cells such as adipocytes.	VET ADM MED CTR,BIOPHYS LAB,BUFFALO,NY 14215; SUNY BUFFALO,DEPT BIOPHYS SCI,BUFFALO,NY 14215	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13376] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BELL GI, 1993, J BIOL CHEM, V268, P1916; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1993, J CELL BIOL, V122, P127; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KONO T, 1981, J BIOL CHEM, V256, P6400; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LIN JL, 1992, BIOCHEM BIOPH RES CO, V184, P865, DOI 10.1016/0006-291X(92)90670-G; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MORGAN A, 1993, BIOCHEM SOC T, V21, P401, DOI 10.1042/bst0210401; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	29	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7869	7875		10.1074/jbc.270.14.7869	http://dx.doi.org/10.1074/jbc.270.14.7869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713880	hybrid			2022-12-25	WOS:A1995QR52600016
J	OKAMOTO, K; NISHINO, T				OKAMOTO, K; NISHINO, T			MECHANISM OF INHIBITION OF XANTHINE-OXIDASE WITH A NEW TIGHT-BINDING INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DEHYDROGENASE; PURIFICATION; SPECTROSCOPY; MOLYBDENUM; FORMS; EXAFS; INACTIVATION; ALLOPURINOL; RADICALS	The mechanism of inhibition of milk xanthine oxidase and xanthine dehydrogenase by the tight binding inhibitor, sodium-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-alpha]-1,3,5-triazine-4-olate monohydrate (BOF-4272), was studied after separation of the two isomers. The steady state kinetics showed that the inhibition by these compounds was a mixed type. One of the isomers had a K-i value of 1.2 x 10(-9) M and a K-i' value of 9 x 10(-9) M, while the other isomer had a K-i value of 3 x 10(-7) M and a K-i' value of 9 x 10(-6) M. Spectral changes were not observed by mixing either the oxidized or reduced form of the enzyme with BOF-4272 on various substrates showed that BOF-4272 bound to the xanthine binding site of the enzyme. K-d values of the enzyme and one of the isomers, which has a higher affinity for the enzyme, were also found to be 2 x 10(-9) M for the desulfo-form using fluorometric titration, and the binding has stoichiometry of 1:1. The inhibitor could not bind to the enzyme when the enzyme was previously treated with oxipurinol.	NIPPON MED COLL, DEPT BIOCHEM & MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN	Nippon Medical School								Ball EG, 1939, J BIOL CHEM, V128, P51; BORDAS J, 1980, BIOCHEM J, V191, P499, DOI 10.1042/bj1910499; Bray R. C., 1975, ENZYMES, P300; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; Eger BT, 1994, FLAVINS AND FLAVOPROTEINS 1993, P727; ELION GB, 1963, BIOCHEM PHARMACOL, V12, P85, DOI 10.1016/0006-2952(63)90012-1; GEORGE GN, 1988, BIOCHEMISTRY-US, V27, P3603, DOI 10.1021/bi00410a011; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; HILLE R, 1981, PHARMACOL THERAPEUT, V14, P249, DOI 10.1016/0163-7258(81)90063-2; HUNT J, 1992, J BIOL CHEM, V267, P21479; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MOORHOUSE PC, 1987, FEBS LETT, V213, P23, DOI 10.1016/0014-5793(87)81458-8; NAKAMURA M, 1992, J BIOCHEM-TOKYO, V92, P1279; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1986, J BIOL CHEM, V261, P1242; OLSON JS, 1974, J BIOL CHEM, V249, P4350; PARKS DA, 1983, AM J PHYSIOL, V245, pG285, DOI 10.1152/ajpgi.1983.245.2.G285; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SAITO T, 1989, J BIOL CHEM, V264, P10015; SATO S, 1991, ADV EXP MED BIOL, V309, P135; SHLAFER M, 1982, CIRCULATION, V66, P85; SPECTOR T, 1968, BIOCHEM BIOPH RES CO, V32, P1039, DOI 10.1016/0006-291X(68)90134-4; SPECTOR T, 1970, J BIOL CHEM, V245, P5079; STIRPE F, 1969, J BIOL CHEM, V244, P3855; SUZUKI H, 1994, J CLIN INVEST, V93, P155, DOI 10.1172/JCI116939; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4	34	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7816	7821		10.1074/jbc.270.14.7816	http://dx.doi.org/10.1074/jbc.270.14.7816			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713871	hybrid			2022-12-25	WOS:A1995QR52600007
J	PIAN, MS; DOBBS, LG				PIAN, MS; DOBBS, LG			EVIDENCE FOR G-BETA-GAMMA-MEDIATED CROSS-TALK IN PRIMARY CULTURES OF LUNG ALVEOLAR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL CYCLASE; SURFACTANT SECRETION; II CELLS; RAT LUNG; CLONING; EXPRESSION; INHIBITION; PHOSPHATIDYLCHOLINE; SEQUENCE; STIMULATION	In the presence of activated G(s alpha) the beta gamma complex of heterotrimeric G proteins (beta gamma) stimulates adenylyl cyclase (AC) in membranes prepared from cells expressing recombinant AC II or AC IV, Conditional stimulation of AC by beta gamma has been hypothesized to integrate cross-talk between G(s)- and non-G(s)-coupled regulation of cellular cAMP (Tang, W. J., and Gilman, A. G. (1991) Science 254, 1500-1503). Although observations in cells expressing recombinant receptors, G(alpha)s, and AC support this hypothesis (Federman, A. D., Conklin, B. R., Schrader, K. A., Reed, R. R,, and Bourne, H. R. (1992) Nature 356, 159-161), this mechanism has not been investigated in differentiated cells. Expression of AC II has been reported only in lung, olfactory, and brain tissue. We found that rat lung alveolar type II cells express AC II and IV. Therefore, we hypothesized that beta gamma conditionally stimulates AC in type II cells. Consistent with this hypothesis, we found that the alpha(2)-adrenergic agonist UK14304 did not affect basal cAMP in type II cells but potentiated terbutaline stimulated cAMP accumulation. Treatment of cells with pertussis toxin partially inhibited terbutaline stimulated cAMP accumulation and completely inhibited the effects of UK14304. In type II cell membranes, purified beta gamma tripled the terbutaline-stimulated increase in AC activity. In contrast, beta gamma inhibited AC activity in the absence of terbutaline. The addition of purified G(o alpha) blocked beta gamma induced effects. In summary, type II cells expressing endogenous AC II and TV regulate cAMP accumulation and AC activity in a manner consistent with conditional stimulation by beta gamma. These observations support the overall hypothesis that conditional stimulation of AC by beta gamma integrates cross-talk between signal transduction systems in differentiated cells,	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	PIAN, MS (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-02157, HL-24075] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024075, K08HL002157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BROWN LAS, 1981, J BIOL CHEM, V256, P66; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHANDER A, 1990, AM J PHYSIOL, V258, pL241, DOI 10.1152/ajplung.1990.258.6.L241; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CORBET A, 1983, AM REV RESPIR DIS, V128, P695; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; FANESTIL DD, 1965, J GERONTOL, V20, P462; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILFILLAN AM, 1987, J PHARMACOL EXP THER, V241, P907; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GOBRAN LI, 1990, AM J PHYSIOL, V258, pL45, DOI 10.1152/ajplung.1990.258.2.L45; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MESCHER EJ, 1983, EXP LUNG RES, V5, P173, DOI 10.3109/01902148309061512; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PIAN MS, 1994, AM J PHYSIOL, V266, pL375, DOI 10.1152/ajplung.1994.266.4.L375; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RICE WR, 1984, BIOCHIM BIOPHYS ACTA, V805, P261, DOI 10.1016/0167-4889(84)90081-8; RYBIN VO, 1991, AM J PHYSIOL, V260, pL539, DOI 10.1152/ajplung.1991.260.6.L539; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TSILIBARY EC, 1983, J HISTOCHEM CYTOCHEM, V31, P1289, DOI 10.1177/31.11.6684669; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7427	7430		10.1074/jbc.270.13.7427	http://dx.doi.org/10.1074/jbc.270.13.7427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706288	hybrid			2022-12-25	WOS:A1995QQ43100062
J	KOIDE, M; KAWAHARA, Y; NAKAYAMA, I; TSUDA, T; YOKOYAMA, M				KOIDE, M; KAWAHARA, Y; NAKAYAMA, I; TSUDA, T; YOKOYAMA, M			CYCLIC AMP-ELEVATING AGENTS INDUCE AN INDUCIBLE TYPE OF NITRIC-OXIDE SYNTHASE IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS - SYNERGISM WITH THE INDUCTION ELICITED BY INFLAMMATORY CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOUSE MACROPHAGES; INTERFERON-GAMMA; INTERLEUKIN-1; NITRATE; LIPOPOLYSACCHARIDE; BIOSYNTHESIS; EXPRESSION; PROTEINS; CLONING	In cultured vascular smooth muscle cells, interferon gamma (IFN-gamma) induced the accumulation of nitrite, a stable metabolite of nitric oxide, in a dose- and time-dependent manner. In parallel with this reaction, this cytokine increased the mRNA and protein levels of an inducible macrophage-type of nitric oxide synthase (iNOS). Forskolin, a direct activator of adenylate cyclase, or dibutyryl cAMP alone caused small increases in nitrite accumulation and iNOS mRNA and protein levels and synergistically enhanced the IFN-gamma-stimulated reactions. 8-Bromo-cGMP neither increased by itself nor synergized with IFN-gamma to increase the same reactions. Prostaglandin E1 and beraprost, a stable analogue of prostaglandin I2, which by themselves showed only marginal effects on these reactions, also synergized with IFN-gamma to stimulate the reactions. Interleukin 1beta or tumor necrosis factor alpha stimulated the same reactions which were similarly enhanced by forskolin. These results indicate that an elevation of intracellular cAMP, particularly in combination with inflammatory cytokines, positively regulates nitric oxide production at the level of iNOS mRNA expression in vascular smooth muscle cells.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN	Kobe University								AKIBA T, 1986, BRIT J PHARMACOL, V89, P703, DOI 10.1111/j.1476-5381.1986.tb11174.x; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; JOLY GA, 1992, CIRC RES, V71, P331, DOI 10.1161/01.RES.71.2.331; JONASSON L, 1988, LAB INVEST, V58, P310; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1991, LAB INVEST, V64, P5; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER SJC, 1989, J IMMUNOL, V142, P100; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	31	191	194	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24959	24966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693710				2022-12-25	WOS:A1993MG67300066
J	PANETTI, TS; MCKEOWNLONGO, PJ				PANETTI, TS; MCKEOWNLONGO, PJ			RECEPTOR-MEDIATED ENDOCYTOSIS OF VITRONECTIN IS REGULATED BY ITS CONFORMATIONAL STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; ARG-GLY-ASP; THROMBIN-ANTITHROMBIN-III; HUMAN S-PROTEIN; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; HUMAN-PLASMA; VONWILLEBRAND-FACTOR; ADHESIVE PROTEINS; SPREADING FACTOR	Vitronectin is a structurally labile molecule with a native, non-heparin binding form and a conformationally altered, heparin binding form. To understand the physiological significance of the two conformers of vitronectin, we examined the metabolism of both conformers by cultured human skin fibroblasts. Both native and altered vitronectin bound to confluent fibroblast monolayers. Both conformers of vitronectin competed equally well for the binding of altered vitronectin to the cell layer, suggesting that both conformers bound to the same site in the cell layer. In contrast, I-125-altered vitronectin, but not I-125-native vitronectin, was degraded to trichloroacetic acid-soluble radioactivity by the fibroblast monolayer. Degradation of vitronectin was saturable, sensitive to chloroquine, and occurred intracellularly, suggesting that vitronectin was degraded through a lysosomal pathway. Heparin and thrombospondin inhibited the degradation of altered vitronectin. The degradation of native vitronectin was induced by addition of gamma-thrombin which exposes vitronectin's cryptic heparin-binding domain. These studies suggest that the heparin-binding domain in vitronectin is required for the clearance of vitronectin from the matrix. In addition, these data demonstrate that the conformation of vitronectin regulates its half-life in the matrix. These studies provide the first evidence for a distinct function for the conformers of vitronectin.	ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208	Albany Medical College					NATIONAL CANCER INSTITUTE [R01CA037785] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37785] Funding Source: Medline; NHLBI NIH HHS [HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BARNES DW, 1985, J CELL PHYSIOL, V125, P207, DOI 10.1002/jcp.1041250206; BLYSTONE SD, 1991, BLOOD, V78, P2900; BODARY SC, 1990, J BIOL CHEM, V265, P5938; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; GEBB C, 1986, J BIOL CHEM, V261, P6698; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; ILL CR, 1985, J BIOL CHEM, V260, P5610; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; PODACK ER, 1978, J IMMUNOL, V120, P1841; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7671; UNDERWOOD PA, 1989, J CELL SCI, V93, P641; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	45	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11988	11993						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685028				2022-12-25	WOS:A1993LF28400080
J	MORGAN, WT; MUSTER, P; TATUM, F; KAO, SM; ALAM, J; SMITH, A				MORGAN, WT; MUSTER, P; TATUM, F; KAO, SM; ALAM, J; SMITH, A			IDENTIFICATION OF THE HISTIDINE-RESIDUES OF HEMOPEXIN THAT COORDINATE WITH HEME-IRON AND OF A RECEPTOR-BINDING REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; RABBIT HEMOPEXIN; GENE-EXPRESSION; MEDIATED TRANSPORT; SEQUENCE; RAT; PROTEINS; SERUM; DETERMINANTS; COMPLEXES	Rabbit hemopexin cDNA was cloned from a rabbit liver lambdagt11 cDNA expression library using a mixture of five monoclonal antibodies raised against rabbit hemopexin, and the entire rabbit hemopexin sequence was determined. The heme-binding domain I of rabbit hemopexin (Smith, A., and Morgan, W. T. (1984) J. Biol. Chem. 259, 12049-12053) contains only 4 histidine residues which are conserved in rabbit, human, rat, and mouse hemopexin. The 2 axial heme-iron coordinating histidine residues, identified by Edman microsequencing and amino acid analyses of chemically modified domain I and isolated fragments of domain I, are the conserved histidine residues at positions 56 and 127 of the mature rabbit protein. The epitope recognized by JEN-14 (a monoclonal antibody which specifically reacts with domain I and blocks the hemopexin-receptor interaction (Morgan, W. T., Muster, P., Tatum, F. M., McConnell, J., Conway, T. P., Hensley, P., and Smith, A. (1988) J. Biol. Chem. 263, 8220-8225) was shown to lie between residues 122 and 142 by Western blotting of protease-digested domain I and transposon-insertion mutants of domain I expressed in a plasmid vector system. The location of this epitope near the heme-binding histidine residue 127 is compatible with a transport mechanism in which the release of heme from hemopexin is accompanied by a concomitant transfer of heme to the hemopexin receptor or the membrane heme-binding protein (Smith, A., and Morgan, W. T. (1985) J. Biol. Chem. 260, 8325-8329).			MORGAN, WT (corresponding author), UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, 5100 ROCKHILL RD, KANSAS CITY, MO 64110 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-27237] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027237] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALTRUDA F, 1985, NUCLEIC ACIDS RES, V13, P3841, DOI 10.1093/nar/13.11.3841; BEARDEN AJ, 1974, BIOCHEM BIOPH RES CO, V61, P265, DOI 10.1016/0006-291X(74)90562-2; BERG DE, 1983, BIO-TECHNOL, V1, P417, DOI 10.1038/nbt0783-417; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROWN SB, 1969, BIOCHEM J, V115, P279, DOI 10.1042/bj1150279; CONWAY TP, 1975, J BIOL CHEM, V250, P3067; DAVIES DM, 1979, BIOCHEM BIOPH RES CO, V91, P1504, DOI 10.1016/0006-291X(79)91235-X; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HANSON MS, 1992, P NATL ACAD SCI USA, V89, P1973, DOI 10.1073/pnas.89.5.1973; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miles E W, 1977, Methods Enzymol, V47, P431; MILLAND J, 1990, AM J PHYSIOL, V259, pG340, DOI 10.1152/ajpgi.1990.259.3.G340; MORGAN WT, 1988, J BIOL CHEM, V263, P8226; MORGAN WT, 1976, BIOCHIM BIOPHYS ACTA, V434, P311, DOI 10.1016/0005-2795(76)90223-3; MORGAN WT, 1988, J BIOL CHEM, V263, P8220; MORGAN WT, 1984, J BIOL CHEM, V259, P2001; MORGAN WT, 1976, ARCH BIOCHEM BIOPHYS, V176, P431, DOI 10.1016/0003-9861(76)90185-5; MORGAN WT, 1974, ENZYME, V17, P108, DOI 10.1159/000459315; MORGAN WT, 1972, J BIOL CHEM, V247, P7181; MORGAN WT, 1978, J BIOL CHEM, V253, P2940; MORGAN WT, 1976, ANN CLIN RES, V8, P223; MORRIS JP, 1981, BIOCHEMISTRY-US, V20, P4811, DOI 10.1021/bi00520a001; MULLEREBERHARD U, 1970, J LAB CLIN MED, V76, P426; MUSTER P, 1991, J PROTEIN CHEM, V10, P123, DOI 10.1007/BF01024662; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SEERY VL, 1972, ARCH BIOCHEM BIOPHYS, V150, P269, DOI 10.1016/0003-9861(72)90035-5; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; SMITH A, 1985, J BIOL CHEM, V260, P8325; SMITH A, 1985, BIOCHEM J, V231, P663, DOI 10.1042/bj2310663; SMITH A, 1988, J BIOL CHEM, V263, P5224; SMITH A, 1990, EUR J CELL BIOL, V53, P234; SMITH A, 1978, BIOCHEM BIOPH RES CO, V84, P151, DOI 10.1016/0006-291X(78)90276-0; SMITH A, 1981, J BIOL CHEM, V256, P902; SMITH A, 1984, J BIOL CHEM, V259, P2049; Smith A., 1990, BIOSYNTHESIS HEME CH, P435; STRUHL K, 1985, Biotechniques, V3, P452; SUTTNAR J, 1986, INT J BIOCHEM, V18, P283, DOI 10.1016/0020-711X(86)90120-5; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P2021, DOI 10.1073/pnas.81.7.2021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	49	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6256	6262						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681064				2022-12-25	WOS:A1993KT36800030
J	GILON, P; BIRD, GSJ; BIAN, XP; YAKEL, JL; PUTNEY, JW				GILON, P; BIRD, GSJ; BIAN, XP; YAKEL, JL; PUTNEY, JW			THE CA2+-MOBILIZING ACTIONS OF A JURKAT CELL EXTRACT ON MAMMALIAN-CELLS XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL TRISPHOSPHATE; INFLUX; THAPSIGARGIN; STORES; CA2+; OSCILLATIONS; INHIBITION; MESSENGER; PROTEIN	Randriamampita and Tsien (Randriamampita, C., and Tsien, R. Y, (1993) Nature 364, 809-814) suggested that an acid-extracted fraction from a Jurkat cell line contains a messenger responsible for the coupling of calcium entry to the depletion of intracellular stores, i.e. capacitative calcium entry, We found that the extract, prepared as described by Randriamampita and Tsien, caused Ca2+ entry in 1321N1 astrocytoma cells which was not blocked by the D-myo-1,4,5-trisphosphate-receptor antagonist, heparin. In contrast to astrocytoma cells, when applied to mouse lacrimal acinar cells and rat hepatocytes the Jurkat extract always caused the release of intracellular Ca2+, followed by Ca2+ entry across the plasma membrane, This activity of the extract on lacrimal cells was blocked by either intracellular injection of heparin or extracellular atropine, Similarly prepared lacrimal cell extracts gave Ca2+ responses when applied to astrocytoma cells or lacrimal cells which were similar to Obese for Jurkat-derived extract, However, extracts from hepatocytes had no effect, In most Xenopus oocytes, the Jurkat extract had no effect, while in a few oocytes, the extract gave a [Ca2+](i) response similar to that seen in lacrimal cells, that is, release of Ca2+ followed by Ca2+ entry. We conclude that the actions of the Jurkat cell extract are not consistent with its containing the long sought messenger for capacitative calcium entry, It is Likely that this fraction contains a number of factors that mediate Ca2+ response in different cell types, possibly through receptor-mediated mechanisms.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; Yakel, Jerrel/0000-0001-5463-674X				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WHITE MM, 1990, MOL PHARMACOL, V37, P720	19	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8050	8055		10.1074/jbc.270.14.8050	http://dx.doi.org/10.1074/jbc.270.14.8050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713906	hybrid			2022-12-25	WOS:A1995QR52600043
J	WEI, L; HUBBARD, SR; HENDRICKSON, WA; ELLIS, L				WEI, L; HUBBARD, SR; HENDRICKSON, WA; ELLIS, L			EXPRESSION, CHARACTERIZATION, AND CRYSTALLIZATION OF THE CATALYTIC CORE OF THE HUMAN INSULIN-RECEPTOR PROTEIN-TYROSINE KINASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED AMINO-ACIDS; BETA-SUBUNIT; CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; AUTOPHOSPHORYLATION SITES; CRYSTAL-STRUCTURE; INTACT-CELLS; PHOSPHORYLATION; REPLACEMENT; RESIDUES	The deduced primary sequence of the cytoplasmic protein-tyrosine kinase domain of the insulin receptor contains a conserved kinase homology region (receptor residues 1002-1257) flanked by a juxtamembrane region and a C-terminal tail. A soluble 48-kDa derivative (residues 959-1355) containing these regions but lacking the first six residues of the juxtamembrane region had earlier been synthesized in Sf9 cells using a baculovirus expression system. The catalytic core of the kinase domain was studied first by proteolytic analysis of the 48-kDa kinase and then by expressing a series of truncated kinase domains in transiently transfected COS cells. Based on these studies, two core kinases of 34 (residues 985-1283) and 35 (residues 978-1283) kDa, respectively, were overexpressed in Sf9 cells. Biochemical characterization of the 35-kDa kinase revealed that the core kinase conserved the major functional properties of the native receptor kinase domain. Activity of the 35-kDa kinase toward a synthetic peptide increased more than 200-fold upon autophosphorylation, which occurred exclusively at Tyr-1158, Tyr-1162, and Tyr-1163; the largest increase was observed between bis- and trisphosphorylation of the kinase. The activated 35- and 48-kDa kinases were similar with respect to specific activity and ATP ang Mg2+ requirements for peptide phosphorylation. Moreover, autophosphorylation appeared to initiate predominantly at Tyr-1162, immediately followed by phosphorylation at Tyr-1158 and then at Tyr-1163. The rate of autophosphorylation was dependent on enzyme concentration, consistent with a trans-phosphorylation mechanism. Finally, the 35-kDa kinase was crystallized, making possible elucidation of its three-dimensional structure by x-ray crystallography.	TEXAS A&M UNIV,INST BIOSCI & TECHNOL,WM KECK CTR GENOME INFORMAT,HOUSTON,TX 77030; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Texas A&M University System; Columbia University; Columbia University; Howard Hughes Medical Institute								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; GRUPPUSO PA, 1992, BIOCHEM BIOPH RES CO, V189, P1457, DOI 10.1016/0006-291X(92)90238-G; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LEVINE BA, 1991, J BIOL CHEM, V266, P13405; LEVINE BA, 1991, J BIOL CHEM, V266, P12369; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; NEMENOFF RA, 1984, J BIOL CHEM, V259, P5058; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; Summers MD, 1987, TEXAS AGR EXPT STATI; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1992, BIOCHEM BIOPH RES CO, V188, P86, DOI 10.1016/0006-291X(92)92353-Y; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEI L, 1994, CURR OPIN STRUC BIOL, V4, P450, DOI 10.1016/S0959-440X(94)90115-5; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	42	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8122	8130		10.1074/jbc.270.14.8122	http://dx.doi.org/10.1074/jbc.270.14.8122			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713916	hybrid			2022-12-25	WOS:A1995QR52600054
J	TSAIMORRIS, CH; GENG, Y; BUCZKO, E; DUFAU, ML				TSAIMORRIS, CH; GENG, Y; BUCZKO, E; DUFAU, ML			CHARACTERIZATION OF DIVERSE FUNCTIONAL ELEMENTS IN THE UPSTREAM SP1 DOMAIN OF THE RAT LUTEINIZING-HORMONE RECEPTOR GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; DNA; BOX; RECOGNITION; ACTIVATION; SEQUENCE; PROTEINS; CLONING; BINDS; SITES	Transcription of the luteinizing hormone receptor gene is dependent on Sp1-induced promoter activation from two Sp1 binding domains (Sp1(2) and Sp1(4)) within the 173-base pair promoter. Of the two Sp1 binding domains, the canonical GC box (GGGCGG) was determined by mutation to be the binding element for only the Sp1(2) domain. The Sp1 binding element within the Sp1(4) domain was identified by mutation and immunological/competition studies as the 5'-GGG GTG GGG that conforms to a Zif-268 like three zinc finger binding domain, rather than the canonical 3' Sp1(4) GC box (GGGCGG). The guanines in the third trinucleotide (GGG GTG GGG) were not required for Sp1 binding, although they increased binding affinity, Non-Sp1 protein(s) bind the 3' Sp1(4), GC box, and by themselves exhibit transcriptional activity, Tissue specific differences were localized to this non-Sp1 binding domain, which functionally substituted for the downstream activating M1 regulatory domain in non expressing but not in expressing cells, Mutations of both non-Sp1 and M1 domains were required for inhibition of promoter activity in constructs that retained the Sp1 binding elements in non expressing cells, indicating that together these domains may play a role in regulation of luteinizing hormone receptor gene expression.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,MOLEC ENDOCRINOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Tsai Morris, Chon Hwa/0000-0002-8113-0979				ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERG JM, 1992, P NATL ACAD SCI USA, V51, P1109; BLAKE MC, 1990, MOL CELL BIOL, V10, P6635; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SHIN SI, 1967, ENDOCRINOLOGY, V81, P440, DOI 10.1210/endo-81-3-440; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TSAIMORRIS CH, 1994, J BIOL CHEM, V269, P15868; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; WORRAD DM, 1994, DEVELOPMENT, V120, P2347; YASUMURA Y, 1966, CANCER RES, V26, P529	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7487	7494		10.1074/jbc.270.13.7487	http://dx.doi.org/10.1074/jbc.270.13.7487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706295	hybrid			2022-12-25	WOS:A1995QQ43100070
J	ZIMONJIC, DB; ALIMANDI, M; MIKI, T; POPESCU, NC; KRAUS, MH				ZIMONJIC, DB; ALIMANDI, M; MIKI, T; POPESCU, NC; KRAUS, MH			LOCALIZATION OF THE HUMAN HER4/ERBB-4 GENE TO CHROMOSOME-2	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE; ERBB FAMILY; GENE MAPPING; FISH	FACTOR RECEPTOR FAMILY; FRAGILE SITES; TRANSLOCATION (2-13)(Q37-Q14); ALVEOLAR RHABDOMYOSARCOMA; NERVOUS-SYSTEM; ONCOGENE; MEMBER; HER4/P180(ERBB4); EXPRESSION; HEREGULIN	The HER4/erbB-4 gene has been isolated as the fourth member of the human EGFR subfamily of tyrosine kinases and has been reported to encode a receptor for NDF/heregulin. In the present study we determined the chromosomal location of the HER4/erbB-4 gene within the human genome. Using human cDNA probes in fluorescence in situ hybridization (FISH), we mapped the HER4/erbB-4 gene to human chromosome 2q33.3-34. This finding established that also the HER4/erbB-4 gene is located in close vicinity of homeobox and collagen gene loci, as is the case for the related EGFR, erbB-2/neu and erbB-3. Aberrations of this chromosomal region associated with T cell leukemias and lymphomas as well as alveolar rhabdomyosarcomas raise the possibility that HER4/erbB-4 might be activated in these tumour types.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zimonjic, Drazen/AAX-7513-2020	Alimandi, Maurizio/0000-0002-1409-6803				CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRAIGHOLMES AP, 1987, HUM GENET, V76, P134, DOI 10.1007/BF00284909; DANIEL A, 1984, AM J MED GENET, V18, P483, DOI 10.1002/ajmg.1320180318; Di Fiore P P, 1992, Cancer Treat Res, V61, P139; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAI JL, 1987, CANCER GENET CYTOGEN, V25, P371, DOI 10.1016/0165-4608(87)90201-9; LIZARDNACOL S, 1987, CANCER GENET CYTOGEN, V25, P373, DOI 10.1016/0165-4608(87)90202-0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCKUSICK VA, 1993, J MED GENET, V30, P1, DOI 10.1136/jmg.30.1.1; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; RABIN M, 1986, P NATL ACAD SCI USA, V83, P9104, DOI 10.1073/pnas.83.23.9104; RETIEF E, 1985, HUM GENET, V69, P304, DOI 10.1007/BF00291646; SEIDAL T, 1982, ACTA PATH MICRO IM A, V90, P345; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; TILLER GE, 1994, GENOMICS, V20, P275, DOI 10.1006/geno.1994.1164; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang-Wuu S, 1988, Cancer Res, V48, P983; WEIL D, 1988, AM J HUM GENET, V42, P435; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XU J, 1994, CANCER GENET CYTOGEN, V74, P1, DOI 10.1016/0165-4608(94)90020-5; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	31	27	31	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1235	1237						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700649				2022-12-25	WOS:A1995QN35300026
J	DU, XP; GU, MY; WEISEL, JW; NAGASWAMI, C; BENNETT, JS; BOWDITCH, R; GINSBERG, MH				DU, XP; GU, MY; WEISEL, JW; NAGASWAMI, C; BENNETT, JS; BOWDITCH, R; GINSBERG, MH			LONG-RANGE PROPAGATION OF CONFORMATIONAL-CHANGES IN INTEGRIN-ALPHA(IIB)BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIB; PLATELET GPIIB-IIIA; ELECTRON-MICROSCOPY; SYNTHETIC PEPTIDES; FIBRINOGEN BINDING; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR; RECOGNITION SITE; DISULFIDE BONDS; LIGAND-BINDING	Integrin adhesion receptors participate in two-way transfer of information across the plasma membrane. For example, cytoplasmic events, such as activation of protein kinase C, cause an increase in the fibrinogen (Fg) binding affinity of the extracellular domain of integrin alpha(IIb)beta3 (''inside-out signaling''). Conversely, ligand binding to alpha(IIb)beta3 results in the generation of intracellular signals. We used anti-LIBS2, an anti-beta3 monoclonal antibody, to understand potential mechanisms of this bidirectional signaling. Anti-LIBS2 bound to alpha(IIb)beta3 with low affinity (K(d) = 7.4 muM), and mimicked inside-out signaling by promoting Fg binding. The affinity of anti-LIBS2 binding was increased 20-fold (K(d) = 326 nm) by addition of an Fg-mimetic synthetic peptide, RGDS. Thus, anti-LIBS2 and ligands (Fg and Fg-mimetic peptides) bind cooperatively to integrin alpha(IIb)beta3, indicating a functional linkage between the ligand-binding site and the antibody-binding site. The anti-LIBS2-binding site was mapped by its binding to proteolytic and recombinant fragments of the beta3 subunit. The epitope was located within an 89-residue region immediately adjacent to the transmembrane domain and 400 residues carboxyl-terminal to the known ligand-binding site(s). Electron microscope images of rotary shadowed ternary complexes of Fg, anti-LIBS2, and alpha(IIb)beta3 revealed that the ligand-binding site and anti-LIBS2 epitope are separated by about 16 nm. This indicates that propagated long distance conformational changes can occur in alpha(IIb)beta3. Such changes are likely to be involved in the bidirectional signaling function of this integral membrane protein.	UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	DU, XP (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-28235, HL-30954] Funding Source: Medline; NIAMS NIH HHS [AR-27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028235, R01HL030954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAJT ML, 1992, J BIOL CHEM, V267, P3789; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DONNER DB, 1983, J BIOL CHEM, V258, P9413; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU X, 1991, CELL, V65, P49; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1980, BLOOD, V55, P661; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; METZGER H, 1983, CONTEMP TOP MOLEC IM, V9, P115; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PILCH PF, 1980, SCIENCE, V210, P1152, DOI 10.1126/science.7003712; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PONCZ M, 1987, J BIOL CHEM, V262, P8476; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	54	185	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23087	23092						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693683				2022-12-25	WOS:A1993MF51500022
J	GRONBORG, M; WULFF, BS; RASMUSSEN, JS; KJELDSEN, T; GAMMELTOFT, S				GRONBORG, M; WULFF, BS; RASMUSSEN, JS; KJELDSEN, T; GAMMELTOFT, S			STRUCTURE-FUNCTION RELATIONSHIP OF THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; DOMAIN AUTOPHOSPHORYLATION; CELLS; PROTEIN; PHOSPHORYLATION; SPECIFICITY; MITOGENESIS; REPLACEMENT; BINDING; TRANSMISSION	Insulin-like growth factor I (IGF-1) and insulin receptors are structurally similar with ligand-stimulated tyrosine kinase activity in their cytoplasmic domains. The function of the insulin receptor tyrosine kinase in signal transduction has been studied extensively in contrast to the IGF-I receptor tyrosine kinase. In the present study we have analyzed the regulatory function of the IGF-I receptor tyrosine kinase and carboxyl-terminal domains in mitogenic signaling by overexpression of mutant IGF-I receptors in mouse NIH-3T3 fibroblasts. A mutant IGF-I receptor, in which 3 tyrosines (Tyr1131, Tyr1135, and Tyr1136) analogous to the three major autophosphorylation sites in the insulin receptor kinase were replaced by phenylalanines, was devoid of kinase activity in vivo and in vitro and inactive with respect to IGF-I internalization and stimulation of thymidine incorporation. Another mutant IGF-I receptor, which lacks the 49 carboxyl-terminal amino acids (residues 1289-1337) of the beta-subunit, was fully active. Our data suggest that the structure-function relationship of the IGF-I receptor tyrosine kinase activation and signal transduction is similar to that of the insulin receptor.	BISPEBJERG HOSP,DEPT CLIN CHEM,BISPEBJERG BAKKE 23,DK-2400 COPENHAGEN,DENMARK; NOVO NORDISK IND,DK-2880 BAGSVAERD,DENMARK	University of Copenhagen; Bispebjerg Hospital; Novo Nordisk				Kjeldsen, Thomas/0000-0003-0094-9286				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDO A, 1992, J BIOL CHEM, V267, P12788; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DREJER K, 1991, DIABETES, V40, P1488, DOI 10.2337/diabetes.40.11.1488; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GAMMELTOFT S, 1990, PEPTIDE HORMONE ACTI, V7, P1; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P812; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V264, P12820; THORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VERLAND S, 1989, MOL CELL ENDOCRINOL, V67, P207, DOI 10.1016/0303-7207(89)90211-6; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; ZHANG B, 1991, J BIOL CHEM, V266, P990	38	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23435	23440						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693688				2022-12-25	WOS:A1993MF51500074
J	PAN, JL; MCEVER, RP				PAN, JL; MCEVER, RP			CHARACTERIZATION OF THE PROMOTER FOR THE HUMAN P-SELECTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NF-KAPPA-B; TISSUE-SPECIFIC EXPRESSION; GRANULE MEMBRANE-PROTEIN; DNA-BINDING PROTEIN; PLATELET FACTOR-IV; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; FUNCTIONAL-ANALYSIS; ENDOTHELIAL-CELLS	P-selectin, an adhesion receptor for leukocytes, is synthesized selectively by megakaryocytes and endothelial cells. We have cloned the 5'-flanking region of the human P-selectin gene and conducted a preliminary analysis of its features. As determined by primer extension, RNase protection, and anchored polymerase chain reaction cloning, there were multiple transcriptional initiation sites from -95 to -25 nucleotides relative to the start of protein-coding sequence. Transfection of bovine aortic endothelial cells with serially truncated segments of the 5'-flanking region linked to luciferase indicated that the sequence from -249 to -13 was sufficient to promote high level gene expression. Deletions to -197, -147, and -128 gradually reduced expression to basal levels, and further deletion to -100 abolished expression. The sequence from -309 to -13 supported only basal luciferase expression in COS-7, 293, or HeLa cells. Putative regulatory elements in the short 5'-flanking sequence included a CACCC sequence, two inverted repeats similar to binding sites for the ETS and NF-kappaB/rel families, a GATA motif, and a sequence related to the GT-IIC element of the SV40 enhancer. The GATA element was functional, as it bound recombinant GATA-2, and mutations in the core sequence impaired both nuclear protein binding and gene expression. These data suggest that the P-selectin gene is regulated by a combination of cis elements and their cognate transcription factors.	UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,WK WARREN MED RES INST,DEPT MED,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,WK WARREN MED RES INST,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation								ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V153, P1159, DOI 10.1016/S0006-291X(88)81349-4; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COX LH, 1991, BLOOD, V77, P286; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EISMAN R, 1990, BLOOD, V76, P336; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P135; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NOMURA N, 1991, J BIOL CHEM, V266, P8590; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SANDERS WE, 1992, BLOOD, V80, P795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UZAN G, 1991, J BIOL CHEM, V266, P8932; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WELLER A, 1992, J BIOL CHEM, V267, P15176; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WITTE DP, 1986, CANCER-AM CANCER SOC, V58, P238, DOI 10.1002/1097-0142(19860715)58:2<238::AID-CNCR2820580207>3.0.CO;2-#; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	61	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22600	22608						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693674				2022-12-25	WOS:A1993MD34800063
J	WARSHAWSKY, I; BU, GJ; SCHWARTZ, AL				WARSHAWSKY, I; BU, GJ; SCHWARTZ, AL			IDENTIFICATION OF DOMAINS ON THE 39-KDA PROTEIN THAT INHIBIT THE BINDING OF LIGANDS TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; HIGH-AFFINITY; COMPLEXES; CLONING; TYPE-1; LIVER; GP330	The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR) binds and internalizes several plasma proteins including tissue-type plasminogen activator (t-PA) and alpha2-macroglobulin-protease complexes (alpha2M*). A 39-kDa protein that copurifies with LRP/alpha2MR inhibits the binding and uptake of ligands by LRP/alpha2MR, including t-PA and alpha2M*. To define domains on the 39-kDa protein which are essential for inhibition of t-PA and alpha2M* binding to LRP/alpha2MR, we have generated bacterial expression constructs encoding discrete regions of the 39-kDa protein as fusion proteins with glutathione S-transferase. Inhibition of t-PA and alpha2M* binding to LRP/alpha2MR on rat hepatoma MH1C1 cells are shown to require amino acid residues 18-24 and 100-107 on the 39-kDa protein. Inhibition of t-PA but not alpha2M* binding to LRP/alpha2MR is also mediated by residues 200-225 and 311-319. The same 39-kDa protein constructs that inhibit alpha2M* and t-PA binding to MH1C1 cells are able to bind directly to purified LRP/alpha2MR immobilized on nitrocellulose. Thus, our studies demonstrate several specific regions on the 39-kDa protein which are required for the inhibition of t-PA and alpha2M* binding to LRP/alpha2MR.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	WARSHAWSKY, I (corresponding author), WASHINGTON UNIV,CHILDRENS HOSP,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63130, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646, T32HL007275] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07275, HL17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; Landon, 1977, Methods Enzymol, V47, P145; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	27	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22046	22054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691821				2022-12-25	WOS:A1993MC80900091
J	SHI, YB; BROWN, DD				SHI, YB; BROWN, DD			THE EARLIEST CHANGES IN GENE-EXPRESSION IN TADPOLE INTESTINE INDUCED BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR BETA GENES; XENOPUS-LAEVIS; AMPHIBIAN METAMORPHOSIS; LARVAL	Genes induced by thyroid hormone (TH) to change their expression in the Xenopus laevis gastrointestinal (GI) tract have been isolated using a subtractive hybridization method. An exhaustive search for down-regulated genes identified a single gene. Thirty-two different cDNA fragments derived from the up-regulated mRNA of tadpole intestine 18 h after addition of TH were cloned. They map to no more than 22 distinct genes. The isolation of multiple cDNA fragments derived from a single mRNA indicates that the complexity of up-regulated genes is limited. Both ubiquitous and intestine-specific up-regulated genes were found in this screen. The majority of these genes respond directly to TH induction as judged by the resistance of up-regulation to inhibitors of protein synthesis. The biological significance of these genes is supported by their dramatic regulation in the GI tract during spontaneous metamorphosis.	CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science	SHI, YB (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.			Shi, Yun-Bo/0000-0002-6330-0639				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN PP, 1978, HORMONAL PROTEINS PE, P273; DAUCA M, 1978, BIOL CELLULAIRE, V31, P277; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Foulkes, 1991, HORMONAL CONTROL REG, P257; Fox H., 1981, P327; Galton VA, 1983, MOL BASIS THYROID HO, P445; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; ISHIZUYAOKA A, 1987, ANAT ANZEIGER, V164, P81; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; Janes RG, 1934, J EXP ZOOL, V67, P73, DOI 10.1002/jez.1400670103; KANAMORI A, 1993, P NATL ACAD SCI USA, V90, P6013, DOI 10.1073/pnas.90.13.6013; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KORDYLEWSKI L, 1983, Z MIKROSK ANAT FORSC, V97, P719; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Maniatis T., 1982, MOL CLONING; MARSHALL JA, 1978, J ANAT, V126, P133; MCAVOY JW, 1977, J EXP ZOOL, V202, P129, DOI 10.1002/jez.1402020115; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V259, P144, DOI 10.1016/0003-9861(87)90479-6; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Nunez EA, 1989, CURR OPIN CELL BIOL, V1, P177, DOI 10.1016/0955-0674(89)90083-5; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHI YB, 1992, J BIOL CHEM, V267, P733; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WANG Z, 1993, J BIOL CHEM, V268, P16270; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; White B.A., 1981, P363; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	37	165	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20312	20317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690754				2022-12-25	WOS:A1993LY01900060
J	OKADA, M; HOWELL, BW; BROOME, MA; COOPER, JA				OKADA, M; HOWELL, BW; BROOME, MA; COOPER, JA			DELETION OF THE SH3 DOMAIN OF SRC INTERFERES WITH REGULATION BY THE PHOSPHORYLATED CARBOXYL-TERMINAL TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; STABLE ASSOCIATION; BINDING SITE; PROTEIN; KINASE; P60C-SRC; PP60C-SRC; MUTATIONS; AUTOPHOSPHORYLATION; PHOSPHOTYROSINE	A current model for the regulation of the Src protein-tyrosine kinase proposes that the COOH-terminal phosphotyrosine, Tyr-527, binds to the Src homology 2 (SH2) region in an intramolecular interaction that represses the kinase domain. This model is consistent with the activation of Src by mutations in the SH2 domain or COOH terminus. Mutations in the SH3 domain also activate Src, although this region is not thought to bind phosphotyrosine. Seidel-Dugan et al. (Seidel-Dugan, C., Meyer, B. E., Thomas, S. M., and Brugge, J. S. (1992) Mol. Cell. Biol. 12, 1835-1845) have shown that Src mutants with deletions in the SH2 or SH3 domain transform chicken embryo fibroblasts and have increased kinase activity. These mutant proteins are underphosphorylated at Tyr-527, a change that could in itself activate the mutants. Therefore, it is not possible to distinguish whether the SH2 and SH3 domains are needed for phosphorylation of Tyr-527 or for Src to adopt or maintain the repressed state. We have artificially increased the level of Tyr-527 phosphorylation of SH2 and SH3 deletion mutants by coexpressing them with the Tyr-527 kinase, Csk, in yeast cells. We find that both the SH2 and SH3 domains are needed for inhibition of Src by Csk. The SH2 domain is needed for efficient phosphorylation by Csk, both in yeast cells and in vitro. The SH3 domain is needed for Src to be inhibited when Tyr-527 is phosphorylated by Csk. This suggests that the SH3 domain cooperates with the SH2 domain and phosphorylated Tyr-527 to inhibit the kinase domain. Dephosphorylation of SH3 domain mutants at Tyr-527 in fibroblasts could be a consequence of a failure of the proposed SH2/phosphotyrosine interaction.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; SALK INST BIOL STUDIES, SAN DIEGO, CA 92138 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Fred Hutchinson Cancer Center; Salk Institute; University of California System; University of California San Diego				Howell, Brian/0000-0002-0204-0773	NCI NIH HHS [CA-41072, CA-39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; DHANG S, 1991, CELL PHYSIOL BIOCHEM, V1, P24; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1990, New Biologist, V2, P828; MACAULEY A, 1993, ONCOGENE, V8, P117; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	43	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18070	18075						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688738				2022-12-25	WOS:A1993LT74300064
J	BACOLLA, A; SHIH, CK; ROSE, JM; PIRAS, G; WARREN, TC; GRYGON, CA; INGRAHAM, RH; COUSINS, RC; GREENWOOD, DJ; RICHMAN, D; CHENG, YC; GRIFFIN, JA				BACOLLA, A; SHIH, CK; ROSE, JM; PIRAS, G; WARREN, TC; GRYGON, CA; INGRAHAM, RH; COUSINS, RC; GREENWOOD, DJ; RICHMAN, D; CHENG, YC; GRIFFIN, JA			AMINO-ACID SUBSTITUTIONS IN HIV-1 REVERSE-TRANSCRIPTASE WITH CORRESPONDING RESIDUES FROM HIV-2 - EFFECT ON KINETIC CONSTANTS AND INHIBITION BY NONNUCLEOSIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONNUCLEOSIDE INHIBITORS; BINDING-SITE; TYPE-1; MUTAGENESIS; RESISTANCE; BI-RG-587; SELECTION	Nevirapine is a highly potent and specific inhibitor of human immunodeficiency virus type 1 (HIV-1) polymerase, but is inactive against HIV-2 and other polymerases. Previous studies demonstrated that residues 176-190 of HIV-1 reverse transcriptase (RT) can confer nevirapine sensitivity to HIV-2 RT. To better characterize the role of this sequence in HIV-1 RT, we have progressively substituted residues 176-190 of HIV-2 RT for those of HIV-1 RT and monitored the impact on the kinetic properties; inhibitory activity of nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[2,3-b:2',3'-e][1,4]diazepin-6-one), E-BPU (5-ethyl-1-benzyloxymethyl-6-(phenylthio)-uracil), and TIBO-R82150 ((+)-S-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-thione); and inhibitor-induced fluorescence changes of the mutant enzymes. The study revealed that in addition to Tyr-181 and Tyr- 188, a new amino acid residue (Gly-190) plays an important role in determining susceptibility to nevirapine and E-BPU, but not to TIBO-R82150. These data argue that these non-nucleoside inhibitors fit differently, even though they share a common binding pocket. Nevirapine was seen to exert inhibitory activity by altering the interaction of the enzyme with the template-primer. Kinetic parameters were modulated by the template (DNA versus RNA) as well as by some of the mutations.	BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT MOLEC BIOL, R&D, 900 RIDGEBURY RD, POB 368, RIDGEFIELD, CT 06877 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL & MED, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, DEPT PATHOL MED, SAN DIEGO, CA 92093 USA	Boehringer Ingelheim; Yale University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423; Piras, Giovanna/0000-0003-4550-6606	NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1986, PICO TAG AMINO ACID; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; CHENG YC, 1987, J BIOL CHEM, V262, P2187; COHEN KA, 1991, J BIOL CHEM, V266, P14670; CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045; HIZI A, 1991, J BIOL CHEM, V266, P6230; KLUNDER JM, 1992, J MED CHEM, V35, P1887, DOI 10.1021/jm00088a027; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Le Pecq J B, 1971, Methods Biochem Anal, V20, P41, DOI 10.1002/9780470110393.ch2; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1992, J ENZYM INHIB, V6, P1, DOI 10.3109/14756369209041352; MULLER B, 1989, J BIOL CHEM, V264, P13975; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; Sambrook J, 1989, MOL CLONING LABORATO; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; TONG L, 1993, BIOORG MED CHEM LETT, V3, P721, DOI 10.1016/S0960-894X(01)81262-2; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WARREN TC, 1992, PROTEIN EXPRES PURIF, V3, P479, DOI 10.1016/1046-5928(92)90065-5; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	28	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16571	16577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688367				2022-12-25	WOS:A1993LQ33600071
J	BENARTZI, H; ZEELON, E; AMIT, B; WORTZEL, A; GORECKI, M; PANET, A				BENARTZI, H; ZEELON, E; AMIT, B; WORTZEL, A; GORECKI, M; PANET, A			RNASE H ACTIVITY OF REVERSE TRANSCRIPTASES ON SUBSTRATES DERIVED FROM THE 5' END OF RETROVIRAL GENOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT DNA POLYMERASE; PLUS-STRAND DNA; RIBONUCLEASE-H; SARCOMA VIRUS; HTLV-III; HIV-1; ENDONUCLEASE; HYDROLYSIS; VIRIONS	RNA/DNA substrates derived from the 5' ends of human immunodeficiency virus (HIV) and Moloney murine leukemia virus (MMuLV) genomes were used to study the specificity of the RNase H activities of HIV, AMV (avian myeloblastosis virus), and MMuLV reverse transcriptases. These substrates were selected because they represent the site for the first template switch during proviral DNA synthesis. Variability of cleavage was observed depending on the origin of the enzyme as well as the sequence of the RNA/DNA substrate. The minimal size of hybrid recognized by the RNase H activity of reverse transcriptase was also affected by the same parameters, namely, the enzyme and the substrate origin. Moreover, the size of the residual 5'-undigested RNA after completion of the RNase H reaction depended on the position of the DNA annealed to the genomic RNA. When the hybrid was located at the 5' R region of the viral genome, stable hybrids with RNAs of 13-18 nucleotides remained following digestion by HIV reverse transcriptase, and 21-24 nucleotides following digestion by AMV reverse transcriptase and MMuLV reverse transcriptase. On the other hand, with all three enzymes, smaller sized hybrids remained when the DNA was hybridized to internal U5 or R sequences. The reason for this variance in size appears to be the inability of RNase H to efficiently digest at the 5' end of hybrid structures. Surprisingly, hybridization to the RNA template, of a DNA oligomer that extended 15 nucleotides beyond the 5' end of the RNA R region sequences, resulted in further digestion of the RNA. This unexpected mode of action of RNase H at the 5' end of the genomic RNA should be taken in consideration in studies of the first template switch.			BENARTZI, H (corresponding author), BIOTECHNOL GEN LTD,KIRYAT WEIZMANN,IL-76326 REHOVOT,ISRAEL.				NIAID NIH HHS [R1AI33353A] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033353] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FISCHER M, 1992, PROTEIN EXPRES PURIF, V3, P301, DOI 10.1016/1046-5928(92)90005-H; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; MOLLING K, 1971, NATURE, V234, P241; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEISS R, 1985, RNA TUMOUR VIRUSES, P369	25	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16465	16471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688365				2022-12-25	WOS:A1993LQ33600057
J	NORGARD, KE; MOORE, KL; DIAZ, S; STULTS, NL; USHIYAMA, S; MCEVER, RP; CUMMINGS, RD; VARKI, A				NORGARD, KE; MOORE, KL; DIAZ, S; STULTS, NL; USHIYAMA, S; MCEVER, RP; CUMMINGS, RD; VARKI, A			CHARACTERIZATION OF A SPECIFIC LIGAND FOR P-SELECTIN ON MYELOID CELLS - A MINOR GLYCOPROTEIN WITH SIALYLATED O-LINKED OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN AFFINITY-CHROMATOGRAPHY; ADHESION MOLECULE-1 ELAM-1; ACID-DEPENDENT EPITOPE; SIALIC-ACID; CARBOHYDRATE LIGAND; MONOCLONAL-ANTIBODY; LYSOSOMAL-ENZYME; STRUCTURAL DETERMINANTS; LIQUID-CHROMATOGRAPHY; IGA1 IMMUNOGLOBULIN	Lectin-carbohydrate recognition between the selectins and their ligands are among the earliest events in leukocyte recirculation, leukocyte recruitment into inflamed areas, and abnormal egress of leukocytes in diseases. Previously, we have described a dimeric sialoglycoprotein from myeloid cells with subunits of molecular mass = 120 kDa, which is selectively recognized by P-selectin (Moore, K. L., Stults, N. L., Diaz, S., Smith, D. F., Cummings, R. D., Varki, A., and McEver, R. P. (1992) J. Cell Biol. 188, 445-456). Here, we demonstrate that this P-selectin ligand carries alpha2-3-linked sialic acids and the sialyl-Lewis(x) (SLe(x)) tetrasaccharide motif. This glycoprotein contains < 1 % of the total membrane-bound sialic acids and a very small fraction of the total SLe(x) on neutrophil membranes. In spite of a relative resistance to sialidase digestion, the predominant form of sialic acid on the ligand is N-acetylneuraminic acid. Selective periodate oxidation of the side chain of sialic acids does not affect P-selectin binding and allows the introduction of tritium label into the truncated sialic acids. Beta-elimination with alkaline borohydride releases labeled O-linked oligosaccharides both from the labeled neutrophil ligand and from the ligand purified from HL-60 cells metabolically labeled with [H-3]glucosamine. The ligand from both neutrophils and HL-60 cells is also susceptible to cleavage by the enzyme O-sialoglycoprotease from Pasteurella hemolytica. Analysis of the specificity of this enzyme suggests that the P-selectin ligand carries large numbers of closely spaced sialylated O-linked oligosaccharides. O-Sialoglycoprotease abolishes both direct binding of P-selectin to HL-60 cells and the adhesion of HL-60 cells to immobilized P-selectin, without significantly decreasing overall cell surface SLe(x) expression. This indicates that the 120-kDa ligand may be the major determinant of P-selectin: myeloid cell interaction in vivo. Finally, based on the current and previous data, we hypothesize that the high affinity recognition site(s) of this P-selectin ligand may be derived from a ''clustered saccharide patch'' of sialylated fucosylated O-linked oligosaccharide sequences.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; OKLAHOMA MED RES FDN, CARDIOL BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA HLTH SCI CTR, WK WARREN MED RES INST, DEPT MED, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA HLTH SCI CTR, WK WARREN MED RES INST, DEPT BIOCHEM, OKLAHOMA CITY, OK 73190 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Georgia; University of Georgia; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL CANCER INSTITUTE [R01CA038701, R01CA037626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R37HL034363] Funding Source: NIH RePORTER; NCI NIH HHS [CA37626, CA38701] Funding Source: Medline; NHLBI NIH HHS [HL 34363] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ALEXANDER LJ, 1988, EUR J BIOCHEM, V178, P395, DOI 10.1111/j.1432-1033.1988.tb14463.x; ALSINET E, 1990, EUR J IMMUNOL, V20, P2801, DOI 10.1002/eji.1830201240; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARA J, 1992, J IMMUNOL METHODS, V149, P105, DOI 10.1016/S0022-1759(12)80054-8; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BAZIL V, 1989, IMMUNOGENETICS, V29, P202, DOI 10.1007/BF00373646; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARVER JP, 1989, CIBA F SYMP, V145, P6; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; DEVINE PL, 1991, BIOL CHEM H-S, V372, P935, DOI 10.1515/bchm3.1991.372.2.935; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DO SI, 1992, GLYCOBIOLOGY, V2, P345, DOI 10.1093/glycob/2.4.345; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; FURTHMAYR H, 1977, J SUPRAMOL STR CELL, V7, P121, DOI 10.1002/jss.400070111; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAMBURGER SA, 1990, BLOOD, V75, P550; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HANISCH FG, 1992, CANCER RES, V52, P3138; HANISCH FG, 1988, CARBOHYD RES, V178, P29, DOI 10.1016/0008-6215(88)80100-9; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; HORTIN GL, 1990, ANAL BIOCHEM, V191, P262, DOI 10.1016/0003-2697(90)90217-W; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KITAGAWA H, 1988, J BIOCHEM-TOKYO, V104, P817, DOI 10.1093/oxfordjournals.jbchem.a122555; LAI R, 1991, LAB INVEST, V64, P844; LARKIN M, 1991, CLIN EXP IMMUNOL, V85, P536; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MARSH JCW, 1992, LEUKEMIA, V6, P926; MARTI T, 1988, EUR J BIOCHEM, V173, P57, DOI 10.1111/j.1432-1033.1988.tb13966.x; MATROSOVICH MN, 1991, VIROLOGY, V182, P879, DOI 10.1016/0042-6822(91)90634-N; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; MEHMET H, 1990, CLIN EXP IMMUNOL, V81, P489; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POPPEMA S, 1991, J IMMUNOL, V147, P218; POWELLLD, 1993, J BIOL CHEM, V268, P7019; PUTNAM FW, 1979, J BIOL CHEM, V254, P2865; REMOLDODONNELL E, 1990, J IMMUNOL, V145, P3372; REUTER G, 1989, GLYCOCONJUGATE J, V6, P35, DOI 10.1007/BF01047888; RICE KG, 1991, BIOCHEMISTRY-US, V30, P6646, DOI 10.1021/bi00241a003; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SGROI D, 1993, J BIOL CHEM, V268, P7011; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; STAHLI C, 1988, CANCER RES, V48, P6799; STOLL M, 1989, LEUKOCYTE TYPING 4, P604; STOOLMAN LM, 1992, CELL SURFACE CARBOHY, P71; SUTHERLAND DR, 1992, EXP HEMATOL, V20, P590; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1983, J BIOL CHEM, V258, P2465; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	113	248	256	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12764	12774						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685350				2022-12-25	WOS:A1993LG65800080
J	LIU, XQ; BRODEUR, SR; GISH, G; SONGYANG, Z; CANTLEY, LC; LAUDANO, AP; PAWSON, T				LIU, XQ; BRODEUR, SR; GISH, G; SONGYANG, Z; CANTLEY, LC; LAUDANO, AP; PAWSON, T			REGULATION OF C-SRC TYROSINE KINASE-ACTIVITY BY THE SRC SH2 DOMAIN	ONCOGENE			English	Article							PHOSPHORYLATED CELLULAR PROTEINS; GROWTH-FACTOR RECEPTORS; MIDDLE-T-ANTIGEN; CARBOXY TERMINUS; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; PP60C-SRC; ACTIVATION; P60C-SRC; BINDING	The protein-tyrosine kinase activity of pp60c-src (c-Src) is inhibited by phosphorylation of tyr527, within the c-Src c-terminal tail. Genetic and biochemical data have suggested that this negative regulation requires an intact Src homology 2 (SH2) domain. Since SH2 domains recognize phosphotyrosine, it is possible that these two noncatalytic domains associate, and thereby repress c-Src kinase activity. Consistent with this model, an isolated Src SH2 domain expressed in bacteria as a GST fusion protein bound in vitro to a synthetic phosphotyrosine-containing peptide modeled on the C-terminal 13 residues of the c-Src tail. Binding was absolutely dependent on phosphorylation of tyr527 in the tail peptide, and was modified by both the length and sequence of the peptide. Competition experiments indicated only a moderate binding affinity between the Src SH2 domain and the phosphorylated tail. A distinct phosphotyrosine-containing peptide previously identified as binding the Src SH2 domain with high affinity stimulated c-Src tyrosine kinase activity in vitro, possibly by competing with the endogenous tail phosphorylation site for binding to the SH2 domain. Indeed, this activation was competitively inhibited by purified bacterial Src SH2 domain. These data provide direct evidence that the c-Src tail has an intrinsic affinity for the Src SH2 domain, and suggest that such an interaction in the intact molecule contributes to maintaining c-Src in an inactive form.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03825; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University System Of New Hampshire; University of New Hampshire; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Toronto			Gish, Gerald D/C-7228-2017; Cantley, Lewis C/D-1800-2014; Pawson, Tony J/E-4578-2013	Cantley, Lewis C/0000-0002-1298-7653; Liu, X. Johne/0000-0003-3381-5030				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CH, 1987, CELL, V40, P83; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HU P, 1992, MOL CELL BIOL, V981, P990; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MACAULEY A, 1990, New Biologist, V2, P828; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1987, ONCOGENE, V1, P181; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VEILLETTE A, 1992, ONCOGENE, V7, P971; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	42	199	208	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1119	1126						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683128				2022-12-25	WOS:A1993KY32800002
J	LIN, LH; CHEN, LTL; HARRIS, RA				LIN, LH; CHEN, LTL; HARRIS, RA			ENFLURANE INHIBITS NMDA, AMPA, AND KAINATE-INDUCED CURRENTS IN XENOPUS OOCYTES EXPRESSING MOUSE AND HUMAN BRAIN MESSENGER-RNA	FASEB JOURNAL			English	Article						ENFLURANE; INHALATIONAL ANESTHETIC; NMDA; AMPA; KAINATE; XENOPUS OOCYTES; MOUSE CORTICAL MESSENGER RNA; HUMAN CORTICAL MESSENGER RNA	METHYL-D-ASPARTATE; VOLTAGE-OPERATED CHANNELS; RAT-BRAIN; AMINO-ACIDS; RECEPTORS; ANTAGONISTS; ETHANOL; CALCIUM; SUBUNIT; PHENCYCLIDINE	Effects of enflurane, an inhalational anesthetic, on NMDA, AMPA, and kainate-gated currents were examined in Xenopus laevis oocytes expressing mouse or human brain mRNA. In oocytes expressing mouse mRNA, enflurane at an anesthetic concentration (1.8 mM) inhibited the NMDA-, AMPA-, and kainate-induced currents by 29-40%, 30-33%, and 20-27%, respectively, suggesting that all three glutamate ionotropic receptors are susceptible to suppression by inhalational anesthetics. Furthermore, inhibition by enflurane was independent of the concentrations of the agonists (NMDA, AMPA, and kainate) or the NMDA-coagonist (glycine). This suggests that enflurane inhibition does not result from a competitive interaction at glutamate or glycine binding sites. Enflurane also suppressed the oscillation and apparent desensitization of NMDA currents, suggesting an inhibition of Ca2+ influx through the NMDA channel. In oocytes expressing human brain mRNA, only kainate produced observable currents. Kainate currents of human channels were smaller in size than those of the mouse; however, the kainate concentration-response curve and percent inhibition (27-29%) by enflurane were similar for mice and humans. The results suggest that human and mouse kainate receptors have similar pharmacological characteristics.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,BOX C-236,4200 E 9TH AVE,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06399] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLOTT PR, 1973, BRIT J ANAESTH, V45, P294, DOI 10.1093/bja/45.3.294; BALSTER R L, 1978, National Institute on Drug Abuse Research Monograph, P53; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLLINS GGS, 1987, NEUROPHARMACOLOGY, V26, P167, DOI 10.1016/0028-3908(87)90205-X; DANIELL LC, 1991, PHARMACOL BIOCHEM BE, V40, P767, DOI 10.1016/0091-3057(91)90083-E; DANIELL LC, 1990, PHARMACOL BIOCHEM BE, V36, P111, DOI 10.1016/0091-3057(90)90134-4; DILDYMAYFIELD JE, 1992, J PHARMACOL EXP THER, V262, P487; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GUNDERSEN CB, 1984, NATURE, V308, P421, DOI 10.1038/308421a0; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOEK W, 1988, SIGMA PHENCYCLIDINE, P493; KUSHNER L, 1988, P NATL ACAD SCI USA, V85, P3250, DOI 10.1073/pnas.85.9.3250; LEONARD JP, 1990, NEURON, V2, P53; LEONARD S, 1991, SOC NEUR ABSTR, V21, P798; LIN LH, 1992, IN PRESS J PHARM EXP; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MARSHALL BE, 1990, PHARMACOL BASIS THER, P285; MARTIN D, 1985, NEUROPHARMACOLOGY, V24, P999, DOI 10.1016/0028-3908(85)90128-5; MAZZE RI, 1985, ANESTHESIOLOGY, V62, P339, DOI 10.1097/00000542-198503000-00021; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; PUIL E, 1990, BRIT J PHARMACOL, V101, P61, DOI 10.1111/j.1476-5381.1990.tb12089.x; PUIL E, 1986, MOL CELLULAR MECHANI, P82; RAGSDALE DS, 1991, P NATL ACAD SCI USA, V88, P1854, DOI 10.1073/pnas.88.5.1854; RENZI R, 1977, ANESTHESIOLOGY, V47, P62; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; UMBACH JA, 1989, MOL PHARMACOL, V36, P582; VERDOORN TA, 1987, SCIENCE, V238, P1114, DOI 10.1126/science.2825347; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8	35	41	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					479	485		10.1096/fasebj.7.5.7681790	http://dx.doi.org/10.1096/fasebj.7.5.7681790			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	7681790				2022-12-25	WOS:A1993KV35100013
J	HATTORI, M; HORIUCHI, R; HOSAKA, K; HAYASHI, H; KOJIMA, I				HATTORI, M; HORIUCHI, R; HOSAKA, K; HAYASHI, H; KOJIMA, I			SIALYLLACTOSE-MEDIATED CELL-INTERACTION DURING GRANULOSA-CELL DIFFERENTIATION - IDENTIFICATION OF ITS BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; EMBRYONAL CARCINOMA-CELLS; PHOSPHATIDYLCHOLINE BILAYERS; CARBOHYDRATE-RECOGNITION; GANGLIOSIDE GM3; MELANOMA-CELLS; NERVOUS-SYSTEM; SIALYL-LEX; RECEPTOR; GLYCOLIPIDS	The present study was designed to prove the carbohydrate-binding proteins interacting with cell surface sialyllactosylceramide (G(M3), NeuAc alpha 2-->3Gal beta-4Glc beta--> 1'Cer), which is highly expressed during differentiation of rat ovarian granulosa cells. As a specific ligand for the sialyllactose (SL)-binding proteins on granulosa cells, we used a radioiodinated multivalent SL-linked albumin (Alb-(SL)(17)). The specific association of the ligand to the putative proteins on the intact cells was competitively inhibited by G(M3) more effectively than other gangliosides, sialyllactotetraosylceramide, sialylneolactotetraosylceramide, and several glycoproteins with N-linked oligosaccharides. However, the proteins had no specificity for the side chain (N-acetyl or N-glycolyl forms) of sialic acid in G(M3). Scatchard analysis of Alb(SL)(17) binding showed high (K-b = 6.4 x 10(-10) M) and low (K-d = 3.1 x 10(-8) M) affinity population of binding sites. By direct binding of I-125-Alb-(SL)(17) to SL-binding proteins on Western blots, the putative proteins with molecular masses of 35, 18, and 14 kDa were detected. The interaction of the multivalent derivative with these binding proteins was differently modulated by Ca2+ and Mn2+. The SL-binding proteins occurred in immature granulosa cells and progressively decreased during differentiation, whereas their endogenous ligand G(M3) increased. These results indicate that relatively low molecular weight SL-binding proteins exist on the surface of immature granulosa cells and that they may serve as receptor sites for newly synthesized G(M3) during differentiation.	GUNMA UNIV, INST MOLEC & CELLULAR REGULAT, DEPT CELL BIOL, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, INST MOLEC & CELLULAR REGULAT, DEPT MOLEC MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT BIOCHEM, MAEBASHI, GUMMA 371, JAPAN	Gunma University; Gunma University; Gunma University								AHMED H, 1989, J BIOL CHEM, V264, P18673; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FRAZIER W, 1979, ANNU REV BIOCHEM, V48, P491, DOI 10.1146/annurev.bi.48.070179.002423; GABIUS HJ, 1986, ANTICANCER RES, V6, P573; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HATTORI M, 1994, BBA-MOL CELL RES, V1221, P47, DOI 10.1016/0167-4889(94)90214-3; HATTORI M, 1992, MOL CELL ENDOCRINOL, V88, P47, DOI 10.1016/0303-7207(92)90008-T; HATTORI M, 1991, MOL CELL ENDOCRINOL, V81, P69, DOI 10.1016/0303-7207(91)90205-7; HATTORI M, 1988, MOL CELL ENDOCRINOL, V57, P17; HATTORI MA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P101, DOI 10.1016/0167-4889(92)90106-L; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; Ito M, 1994, Seikagaku, V66, P99; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; NAKAISHI H, 1988, BIOCHEM BIOPH RES CO, V150, P766, DOI 10.1016/0006-291X(88)90457-3; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; ROSEN SD, 1989, J IMMUNOL, V142, P1895; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHARON N, 1984, BIOL CELL, V51, P239, DOI 10.1111/j.1768-322X.1984.tb00304.x; SHUR BD, 1982, J BIOL CHEM, V257, P6871; TIEMEYER M, 1990, J BIOL CHEM, V265, P11990; TIEMEYER M, 1989, J BIOL CHEM, V264, P1671; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YAMADA KM, 1981, J CELL PHYSIOL, V109, P343, DOI 10.1002/jcp.1041090218; YAMADA KM, 1983, EXP CELL RES, V143, P295, DOI 10.1016/0014-4827(83)90054-X; YOHE HC, 1983, J NEUROSCI RES, V9, P401, DOI 10.1002/jnr.490090406	43	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7858	7863		10.1074/jbc.270.14.7858	http://dx.doi.org/10.1074/jbc.270.14.7858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713878	hybrid			2022-12-25	WOS:A1995QR52600014
J	LUNDSTROMLJUNG, J; HOLMGREN, A				LUNDSTROMLJUNG, J; HOLMGREN, A			GLUTAREDOXIN ACCELERATES GLUTATHIONE-DEPENDENT FOLDING OF REDUCED RIBONUCLEASE-A TOGETHER WITH PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM PROTEIN; ESCHERICHIA-COLI GLUTAREDOXIN; BOND FORMATION INVIVO; THIOREDOXIN REDUCTASE; ACTIVE-SITE; ALKALINE-PHOSPHATASE; PHOSPHOLIPASE-C; MIXED DISULFIDE; REGENERATION; CATALYSIS	Glutaredoxin (Grx) contains a redox-active disulfide and catalyzed thiol-disulfide interchange reactions with specificity for GSH. The dithiol form of Grx reduces mixed disulfides involving GSH or protein disulfides. During oxidative refolding of 8 mu M reduced and denatured ribonuclease RNase-(SH)(8) in a redox buffer of 1 mM GSH and 0.2 mM GSSG to yield native RNase-(S-2)(4), a large number of GSH-mixed disulfide species are formed. A lag phase that precedes formation of folded active RNase at a steady-state rate was shortened or eliminated by the presence of a catalytic concentration (0.5 mu M) of Escherichia coli Grx together with protein disulfide-isomerase (PDI), its procaryotic equivalent E. coli DsbA, or the PDI analogue the E. coli thioredoxin mutant protein P34H. A mutant Grx in which one of the active site cysteine residues (Cys-11 and Cys-14) had been replaced by serine, C14S Grx, had similar effect compared with its wild-type counterpart. This demonstrated that Grx acted by a monothiol mechanism involving only Cys-11 and that RNase-S-SG-mixed disulfides were the substrates. Grx displayed synergistic activity together with PDI only in GSH/GSSG redox buffers with sufficiently low redox potential (E'(0) of -208 or -181 mV) to allow reduction of the active site of Grx. In refolding systems that do not depend on glutathione, like cystamine/cysteamine or in the presence of selenite (SeO32-), no synergistic activity of Grx was observed with PDI. We conclude that Grx acts by reducing mixed disulfides between GSH and RNase that are rate-limiting in enzyme-catalyzed refolding.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST BIOCHEM,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet								AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; BUSHWELLER JH, 1993, EUR J BIOCHEM, V327, P327; CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FULLEKRUG I, 1994, J CELL SCI, V107, P2719; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4741, DOI 10.1021/bi00262a034; KONISHI Y, 1981, BIOCHEMISTRY-US, V20, P3945, DOI 10.1021/bi00517a001; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4734, DOI 10.1021/bi00262a033; KONISHI Y, 1982, P NATL ACAD SCI USA, V79, P5734, DOI 10.1073/pnas.79.18.5734; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2690, DOI 10.1021/bi00061a029; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2680, DOI 10.1021/bi00061a028; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2697; RUPP K, 1994, J BIOL CHEM, V269, P2501; SCHERAGA HA, 1987, P NATL ACAD SCI USA, V84, P5740, DOI 10.1073/pnas.84.16.5740; SCOTT EM, 1963, J BIOL CHEM, V238, P3928; SHAFFER SW, 1975, J BIOL CHEM, V250, P8483; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; SODANO P, 1991, J MOL BIOL, V221, P1311; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; XIA TH, 1992, PROTEIN SCI, V1, P310	59	50	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7822	7828		10.1074/jbc.270.14.7822	http://dx.doi.org/10.1074/jbc.270.14.7822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713872	hybrid			2022-12-25	WOS:A1995QR52600008
J	PEYRET, P; PEREZ, P; ALRIC, M				PEYRET, P; PEREZ, P; ALRIC, M			STRUCTURE, GENOMIC ORGANIZATION, AND EXPRESSION OF THE ARABIDOPSIS-THALIANA ACONITASE GENE - PLANT ACONITASE SHOW SIGNIFICANT HOMOLOGY WITH MAMMALIAN IRON-RESPONSIVE ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; PIG-HEART ACONITASE; MESSENGER-RNA; CYTOSOLIC ACONITASE; REGULATORY FACTOR; AGROBACTERIUM-TUMEFACIENS; MITOCHONDRIAL ACONITASE; FERRITIN; CLUSTER; PURIFICATION	We report the purification of the unstable aconitase enzyme from melon needs and the NH2-terminal amino acid sequence determination. Antibodies raised against this protein enabled the first isolation and characterization of cDNA encoding aconitase in plants. A full-length cDNA clone of 3210 base pairs was isolated from a library of cDNA clones derived from immature pods of Arabidopsis thaliana. The amino acid sequence deduced from the open reading frame includes the sequence obtained by direct sequencing of the NH2 terminus of the purified enzyme. Genomic clones of the aconitase gene were isolated, and comparison of the cDNA ang genomic sequences reveals that the coding sequence is divided among 20 exons. There are five putative sites for transcription initiation. The aconitase gene is constitutively expressed, but at a low level, during most developmental stages, with a dramatic increase during seed and pollen maturation and during germination. Surprisingly, plant aconitases have reasonably high homology to binding proteins for iron-responsive elements from mammalian species, opening the possibility that a similar type of translational regulation occurs in plants.	LAB BIOCEM GRP LIMAGRAIN, F-63170 CLERMONT FERRAND, FRANCE					PEYRET, Pierre/0000-0003-3114-0586				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BROUQUISSE R, 1987, PLANT PHYSIOL, V84, P1402, DOI 10.1104/pp.84.4.1402; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHATTON B, 1988, J BIOL CHEM, V263, P52; COURTOISVERNIQUET F, 1993, BIOCHEM J, V294, P103, DOI 10.1042/bj2940103; DALE PJ, 1989, PLANT SCI, V63, P237, DOI 10.1016/0168-9452(89)90249-5; DEBELLIS L, 1993, PHYSIOL PLANTARUM, V88, P485, DOI 10.1111/j.1399-3054.1993.tb01363.x; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EANES RZ, 1971, BIOCHIM BIOPHYS ACTA, V227, P204, DOI 10.1016/0005-2744(71)90181-1; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; GLUSKER JP, 1971, ENZYMES, V5, P413; Goodall GJ, 1991, OXFORD SURVEYS PLANT, V7, P255; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; JEFFERSON RA, 1987, EMBO J, V6, P3901; JORDANOV J, 1992, J BIOL CHEM, V267, P16775; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY C, 1972, BIOCHEM BIOPH RES CO, V47, P740; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONECKI DS, 1992, BIOCHEMISTRY-US, V31, P8363, DOI 10.1021/bi00150a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LOBREAUX S, 1991, BIOCHEM J, V274, P601, DOI 10.1042/bj2740601; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; POVEY S, 1976, ANN HUM GENET, V39, P413, DOI 10.1111/j.1469-1809.1976.tb00145.x; QUATTROCCHIO F, 1990, PLANT MOL BIOL, V15, P81, DOI 10.1007/BF00017726; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; RUZICKA FJ, 1978, J BIOL CHEM, V253, P2514; Sambrook J, 1989, MOL CLONING LABORATO; SELIGMAN PA, 1987, MOL BASIS BLOOD DISE, P219; SLAUGHTER CA, 1978, CYTOGENET CELL GENET, V22, P223, DOI 10.1159/000130941; SPENCE MJ, 1991, PLANT MOL BIOL, V17, P499, DOI 10.1007/BF00040644; TELSER J, 1986, J BIOL CHEM, V261, P4840; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANTUNEN AJ, 1990, PLANT CELL, V2, P393, DOI 10.1105/tpc.2.5.393; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; WU M, 1987, J BIOL CHEM, V262, P12275; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG L, 1992, J BIOL CHEM, V267, P7895	65	53	61	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8131	8137		10.1074/jbc.270.14.8131	http://dx.doi.org/10.1074/jbc.270.14.8131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713917	hybrid			2022-12-25	WOS:A1995QR52600055
J	SONG, LX; FRICKER, LD				SONG, LX; FRICKER, LD			CALCIUM-DEPENDENT AND PH-DEPENDENT AGGREGATION OF CARBOXYPEPTIDASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SECRETOGRANIN-I; CHROMAFFIN GRANULES; SECRETORY PROTEINS; ENKEPHALIN CONVERTASE; ENDOPROTEASE FAMILY; CHROMOGRANIN-A; IDENTIFICATION; KEX2; GLYCOPROTEINS; PURIFICATION	Carboxypeptides E (CPE) is involved with the biosynthesis of numerous peptide hormones and neurotransmitters. Several forms of CPE have been previously detected in neuroendocrine cells, including a form which is soluble at pH 5.5 (S-CPE), a form which can be extracted from membranes with 1 M NaCl at pH 5.5 (M1-CPE), and a form which requires both 1% Triton X-100 and 1 M NaCl for extraction from membranes at pH 5.5 (M2-CPE). Like other peptide processing enzymes, CPE is known to be sorted into peptide-containing secretory vesicles of the regulated pathway. One mechanism that has been proposed to be important for sorting of regulated pathway proteins is Ca2+ and pH-induced aggregation. CPE purified from bovine pituitary membranes aggregates at pH 5.5 when the concentration of CPE is 0.3 mu g/mu l or higher, but not when the concentration is 0.01 mu g/mu l. Aggregation of CPE is pH-dependent, with very little aggregation occurring at pH 6 or above. At pH 5.0-5.5, the M2 form of CPE shows a greater tendency to aggregate than the other two forms. At pH 6, Ca2+ concentrations from 1-30 mM increase the aggregation of M1- and M2-CPE, but not S-CPE. The aggregation of M2-CPE does not explain the apparent membrane binding of this protein since the aggregate is solubilized by 1% Triton X-100 at pH 5.5 or by pH 6.0, whereas M2-CPE is not extracted from membranes under these conditions. Taken together, these results are consistent with a model in which the decreasing pH and increasing Ca2+ levels in the trans Golgi network induce the aggregation of CPE, which contributes to the sorting of this protein into regulated pathway secretory vesicles.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [K02 DA-00194, R01 DA-04494] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AGUILARDIOSDADO M, 1994, DIABETES, V43, P418, DOI 10.2337/diabetes.43.3.418; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1994, IN PRESS NEUROPROTOC, V5; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GORR SU, 1992, J BIOL CHEM, V267, P21595; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LASLOP A, 1986, NEUROSCI LETT, V72, P300, DOI 10.1016/0304-3940(86)90530-6; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MITRA A, 1994, J BIOL CHEM, V269, P19876; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NALAMACHU SR, 1994, J BIOL CHEM, V269, P11192; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PALMER DJ, 1992, J BIOL CHEM, V267, P19806; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; ROOS N, 1988, SCANNING MICROSCOPY, V2, P33; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1641; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; SUPATTAPONE S, 1984, J NEUROCHEM, V42, P1017, DOI 10.1111/j.1471-4159.1984.tb12705.x; YOO SH, 1990, J BIOL CHEM, V265, P14414; [No title captured]	41	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7963	7967		10.1074/jbc.270.14.7963	http://dx.doi.org/10.1074/jbc.270.14.7963			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713894	hybrid			2022-12-25	WOS:A1995QR52600030
J	ZHANG, SJ; ZENG, XR; ZHANG, P; TOOMEY, NL; CHUANG, RY; CHANG, LS; LEE, MYWT				ZHANG, SJ; ZENG, XR; ZHANG, P; TOOMEY, NL; CHUANG, RY; CHANG, LS; LEE, MYWT			A CONSERVED REGION IN THE AMINO-TERMINUS OF DNA-POLYMERASE-DELTA IS INVOLVED IN PROLIFERATING CELL NUCLEAR ANTIGEN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' EXONUCLEASE ACTIVITY; REPLICATION INVITRO; CATALYTIC SUBUNIT; AUXILIARY PROTEIN; CALF THYMUS; KINASES; CYCLIN; ORIGIN; MOTIF; SITE	Synthetic peptides to selected sequences in human DNA polymerase delta (pol delta) were used to identify the region involved in the interaction of pol delta to proliferating cell nuclear antigen. Peptides corresponding to sequences in five regions in the amino terminus of human pol delta and three in the carboxyl terminus, which are conserved with the yeast homologs of pol delta, were tested. These studies showed that the peptide corresponding to the N2 region (residues 129-149) selectively and specifically inhibited the PCNA stimulation of pol delta. This inhibition was relieved by titration with excess PCNA. The identification of the N-2 region as being involved in PCNA binding was supported by studies that demonstrated that the N2 peptide could bind PCNA. Deletion mutants of pol delta expressed in Sf9 cells provided evidence that the binding region for PCNA was located in the first 182 residues of the amino terminus. These studies provide reasonable evidence that residues within the region 129-149 of pol delta are involved in the binding site for PCNA.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; CHILDRENS HOSP,DEPT PEDIAT,COLUMBUS,OH 43205	University of Miami; University System of Ohio; Ohio State University; Nationwide Childrens Hospital			Chang, Long-sheng/E-2871-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BROTT DA, 1993, J CELL BIOCHEM, V52, P362, DOI 10.1002/jcb.240520312; BROWN WC, 1993, J BIOL CHEM, V268, P21706; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; DONG Q, 1993, MOL CELL BIOL, V13, P8090; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HAO H, 1992, CHROMOSOMA, V102, P121; HRUBY VJ, 1992, SYNTHETIC PEPTIDES U, P259; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027	35	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7988	7992		10.1074/jbc.270.14.7988	http://dx.doi.org/10.1074/jbc.270.14.7988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713898	hybrid			2022-12-25	WOS:A1995QR52600034
J	BAI, G; KUSIAK, JW				BAI, G; KUSIAK, JW			FUNCTIONAL-ANALYSIS OF THE PROXIMAL 5'-FLANKING REGION OF THE N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT GENE, NMDAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MESSENGER-RNA; BINDING PROTEIN; NERVOUS-SYSTEM; GABA-A; PROMOTER; RAT; EXPRESSION; CELLS; CLONING	The NMDAR1 receptor subunit is a common subunit of N-methyl-D-aspartate receptors. We have previously characterized 3 kilobases (kb) of 5'-flanking sequence of the NMDAR1 gene and now report on the ability of this region to direct transcription of a reporter gene and on its interaction with nuclear proteins, The sequence 356 base pairs (bp) 5' of the first nucleotide of codon 1 was sufficient to express a luciferase reporter gene in rat PC12 pheochromocytoma cells, Additional sequences upstream of nucleotide -356 influenced the activity approximately 2-fold. A labeled 112-bp fragment (position -356 to -245) formed six complexes (C1A and -B, C2A and -B, and C3A and -B), grouped as three double bands, with nuclear extracts from PC12 cells, Competition with Sp1 oligonucleotides abolished formation of C2A and -B and C3A and -B complexes. Sp1 antibody recognized the C3A complex in supershift experiments, Prior immunoprecipitation of nuclear extracts with Spl antibody abolished formation of C2A and -B and C3A and -B complexes. Purified Sp1 protein alone did not form a C3A complex but potentiated its formation when PC12 nuclear extract was added, A CC-rich sequence in this fragment was protected from DNase I digestion by nuclear extract, These results suggest that a 356-bp sequence comprises the NMDAR1 basal promoter, and that NMDAR1 gene expression may be regulated by Sp1-like nuclear factors.			BAI, G (corresponding author), NIA, GERONTOL RES CTR, MOLEC NEUROBIOL UNIT, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA.							ABMAYR SM, 1990, CURRENT PROTOCOLS MO; Awobuluyi M., 1994, Society for Neuroscience Abstracts, V20, P237; BAI G, 1993, MOL CELL BIOL, V13, P993, DOI 10.1128/MCB.13.2.993; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BRANN DW, 1993, NEUROENDOCRINOLOGY, V58, P666, DOI 10.1159/000126607; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROSE N, 1993, J BIOL CHEM, V268, P22663; Casado M., 1994, Society for Neuroscience Abstracts, V20, P495; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DAY ML, 1990, J BIOL CHEM, V265, P15253; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRANKLIN SO, 1993, MOL BRAIN RES, V19, P93, DOI 10.1016/0169-328X(93)90153-G; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; IKEDA K, 1993, EUR J BIOCHEM, V218, P195, DOI 10.1111/j.1432-1033.1993.tb18365.x; ISHIDA N, 1994, NEUROSCI LETT, V166, P211, DOI 10.1016/0304-3940(94)90488-X; ISHII T, 1993, J BIOL CHEM, V268, P2836; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LESCH KP, 1992, EUR J PHARM-MOLEC PH, V227, P109, DOI 10.1016/0922-4106(92)90151-K; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PRATT GD, 1993, NEUROSCIENCE, V57, P307, DOI 10.1016/0306-4522(93)90064-M; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; Sambrook J, 1989, MOL CLONING LABORATO; Schatten L. J., 1994, Society for Neuroscience Abstracts, V20, P495; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SUBRAMANIAM S, 1991, J PHARMACOL EXP THER, V256, P811; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; WENK GL, 1991, NEUROBIOL AGING, V12, P93, DOI 10.1016/0197-4580(91)90047-N; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	55	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7737	7744		10.1074/jbc.270.13.7737	http://dx.doi.org/10.1074/jbc.270.13.7737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706322	hybrid			2022-12-25	WOS:A1995QQ43100102
J	BUGGY, JJ; LIVINGSTON, JN; RABIN, DU; YOOWARREN, H				BUGGY, JJ; LIVINGSTON, JN; RABIN, DU; YOOWARREN, H			GLUCAGON-CENTER-DOT-GLUCAGON-LIKE PEPTIDE-I RECEPTOR CHIMERAS REVEAL DOMAINS THAT DETERMINE SPECIFICITY OF GLUCAGON BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; IDENTIFICATION; EXPRESSION; CLONING	The binding of glucagon to its hepatic receptor triggers a G-protein-mediated signal that ultimately leads to an increase in hepatic glucose production (gluconeogenesis) and glycogen breakdown (glycogenolysis). In order to elucidate the structural domain(s) of the human glucagon receptor (hGR) involved in the selective binding of glucagon, a series of chimeras was constructed in which various domains of the hGR were replaced by homologous regions from the receptor for the glucoin-cretin hormone, glucagon-like peptide I (GLP-IR), hGR and GLP-IR are quite similar (47% amino acid identity) yet have readily distinguishable ligand binding characteristics; glucagon binds to the recombinant hGR expressed in COS-7 cells with a K-d that is 1000-fold lower than the K-d for glucagon binding to GLP-IR, In the present study, chimeric receptors were transiently expressed in COS-7 cells and analyzed for glucagon binding, Expression of each receptor chimera was confirmed by immunofluorescence staining using a hGR-specific monoclonal antibody, This report identifies several noncontiguous domains of the hGR that are important for high affinity glucagon binding, Mast notable are the membrane-proximal half of the amino-terminal extension, the first extracellular loop, and the third, fourth, and sixth transmembrane domains.	MILES INC,INST METAB DISORDERS,SIGNAL TRANSDUCT GRP,W HAVEN,CT 06516									CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; DILLON JS, 1993, ENDOCRINOLOGY, V133, P1907, DOI 10.1210/en.133.4.1907; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUPRE J, 1991, ENDOCRINE PANCREAS, P253; EBERT R, 1987, Diabetes Metabolism Reviews, V3, P1; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; IYENGAR R, 1984, J BIOL CHEM, V259, P5222; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Sambrook J, 1989, MOL CLONING LABORATO; SMITH RJ, 1989, ENDOCRINOLOGY, P1333; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THORENS B, 1992, IABETES, V42, P1678; UNGER RH, 1992, WILLIAMS TXB ENDOCRI, P1255; UNGER RH, 1990, DIABETES MELLITUS TH; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454	22	65	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7474	7478		10.1074/jbc.270.13.7474	http://dx.doi.org/10.1074/jbc.270.13.7474			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706293	hybrid			2022-12-25	WOS:A1995QQ43100068
J	CHAIKOF, EL; CABAN, R; YAN, CN; RAO, GN; RUNGE, MS				CHAIKOF, EL; CABAN, R; YAN, CN; RAO, GN; RUNGE, MS			GROWTH-RELATED RESPONSES IN ARTERIAL SMOOTH-MUSCLE CELLS ARE ARRESTED BY THROMBIN RECEPTOR ANTISENSE SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; BALLOON ANGIOPLASTY; ANTITHROMBIN-III; PHOSPHOLIPASE-C; G-PROTEIN; DESENSITIZATION; RESTENOSIS; EXPRESSION; ACTIVATION; INDUCTION	The capacity of antisense sequences to the thrombin receptor to selectively inhibit thrombin receptor expression and limit mitogenic responses in vascular wall cells was investigated in vitro, Eight phosphorothioate oligodeoxynucleotides based on the sequences of the rat thrombin receptor (including sense, antisense, scrambled, and missense controls) were synthesized, characterized, and purified by high performance liquid chromatography, The antisense oligodeoxynucleotide (ODN 4) inhibitory effect was sequence-specific and both time-and concentration-dependent. A reduction in serum or alpha-thrombin-induced smooth muscle cell (SMC) proliferation was noted as early as 3 days at 30 mu M (82%; 6.17 +/- 1.01 versus 34.08 +/- 3.89 x 10(4) cells/well; p < 0.05) and at a dose as low as 15 mu M after 4 days in culture (19%; p < 0.05), Nonspecific effects were enhanced after prolonged exposure of SMC to the antisense oligodeoxynucleotide (greater than or equal to 6 days), A reduction of inositol phosphate generation greater than 50% (p < 0.05) was detected after exposure of SMC to antisense but not to sense or scrambled nucleotide sequences, This was observed after stimulation with both thrombin and SFFLRN (thrombin receptor peptide agonist), Northern blot analysis and enzyme-linked immunosorbent assays revealed 50 and 22% decreases, respectively, in thrombin receptor mRNA and protein (cell surface) levels in antisense oligonucleotide-treated (72 h) SMC as compared to untreated cells, suggesting that thrombin receptor down-regulation occurred at the pretranslational level, Thus, thrombin receptor-specific antisense sequences inhibit growth-related effects both of serum and thrombin on smooth muscle cells, potentially providing a new strategy for selective inhibition of receptor-mediated arterial injury responses.	EMORY UNIV,SCH MED,DEPT SURG,DIV VASC,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,ATLANTA,GA 30322; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV CARDIOL,GALVESTON,TX 77555	Emory University; Emory University; University of Texas System; University of Texas Medical Branch Galveston					NHLBI NIH HHS [HL-48667, HL-02414] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002414, P01HL048667] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1992, AM J RESP CELL MOL, V6, P123, DOI 10.1165/ajrcmb/6.2.123; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1988, J BIOL CHEM, V263, P5348; CARNEY DH, 1992, J CLIN INVEST, V89, P1469, DOI 10.1172/JCI115737; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DAVIDSON A, 1991, FEBS LETT, V284, P252, DOI 10.1016/0014-5793(91)80697-2; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DETWILER TC, 1992, SEMIN THROMB HEMOST, V18, P600; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; GIBBONS GH, 1993, CLIN RES, V41, P143; GIMPLE LW, 1992, CIRCULATION, V86, P1536, DOI 10.1161/01.CIR.86.5.1536; GOROG PG, 1993, THROMB HAEMOSTASIS, V69, P804; GRAHAM DJ, 1990, J VASC SURG, V11, P307, DOI 10.1067/mva.1990.17098; HATTON MWC, 1989, AM J PATHOL, V135, P499; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; JOSEPHSILVERSTE.J, 1987, SEMIN THROMB HEMOST, V13, P504; KNOLLER S, 1991, EUR J BIOCHEM, V195, P801, DOI 10.1111/j.1432-1033.1991.tb15769.x; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LIBBY P, 1989, TRANSPLANT P, V21, P3677; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MELZIG M, 1986, BIOMED BIOCHIM ACTA, V45, P1199; MINTER AJ, 1992, THROMB HAEMOSTASIS, V67, P718; MORONI MC, 1992, J BIOL CHEM, V267, P2714; OKAZAKI H, 1992, CIRC RES, V71, P1285, DOI 10.1161/01.RES.71.6.1285; PARIS S, 1987, J BIOL CHEM, V262, P1970; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHWARTZ SM, 1993, J CARDIOVASC PHARM S, V1, pS31; SOFF GA, 1991, BLOOD, V77, P515; TRAVO P, 1980, BLOOD VESSELS, V17, P110; WEISS RH, 1991, BIOCHEM BIOPH RES CO, V181, P617, DOI 10.1016/0006-291X(91)91235-5; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WEST AP, 1991, MOL CELL ENDOCRINOL, V79, pR9, DOI 10.1016/0303-7207(91)90111-5; WILCOX JN, 1991, CIRCULATION, V84, P432, DOI 10.1161/01.CIR.84.1.432; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975; ZWAGINGA JJ, 1990, ARTERIOSCLEROSIS, V10, P437, DOI 10.1161/01.ATV.10.3.437	39	34	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7431	7436		10.1074/jbc.270.13.7431	http://dx.doi.org/10.1074/jbc.270.13.7431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706289	hybrid			2022-12-25	WOS:A1995QQ43100063
J	LARSEN, LK; KRISTIANSEN, K				LARSEN, LK; KRISTIANSEN, K			TRANSCRIPTION IN-VITRO OF TETRAHYMENA CLASS-II AND CLASS-III GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-FREE TRANSCRIPTION; INVITRO TRANSCRIPTION; ACCURATE TRANSCRIPTION; PROMOTER ELEMENTS; SEQUENCE ELEMENTS; NUCLEAR-PROTEIN; REDUCTASE GENE; THERMOPHILA; BINDING	A method for preparation of transcriptionally active nuclear extracts from the ciliated protozoan Tetrahymena thermophila is described. Cells were lysed in the presence of gum arabic, and nuclei were further purified in the presence of Ficoll 400. Highly concentrated nuclear extracts were prepared by ultracentrifugation of nuclei in a buffer containing potassium glutamate and spermidine. These extracts supported accurate transcription initiation of T. thermophila class II and III genes. Using the histone HS-II gene as a template, we demonstrated that physiologically induced changes in transcriptional activity in vivo were reflected in the transcriptional activity of the nuclear extract in vitro. By electrophoretic mobility shift assays, five conserved sequence elements in the upstream region of the histone H3-II gene were shown specifically to bind proteins in extracts from exponentially growing as well as from starved cells, and by UV cross-linking we further characterized the specific binding of two proteins to an oligonucleotide containing a conserved CCAAT box motif. Transcription competition experiments showed that addition of this oligonucleotide decreased transcription significantly. Competition with oligonucleotides corresponding to the two proximal conserved sequence elements almost completely abolished transcription of the H3-II gene suggesting that binding of transacting factors to these elements is crucial for initiation of transcription.	ODENSE UNIV, DEPT MOLEC BIOL, DK-5230 ODENSE, DENMARK	University of Southern Denmark			Kristiansen, Karsten/J-5148-2014	Kristiansen, Karsten/0000-0002-6024-0917				BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1991, GENE, V100, P173, DOI 10.1016/0378-1119(91)90363-G; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DEMCZUK S, 1991, NUCLEIC ACIDS RES, V19, P677, DOI 10.1093/nar/19.3.677; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EICHLER W, 1989, BIOL CHEM H-S, V370, P451, DOI 10.1515/bchm3.1989.370.1.451; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANSEN TS, 1991, GENE, V105, P143, DOI 10.1016/0378-1119(91)90144-Z; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KUMAZAKI T, 1982, NUCLEIC ACIDS RES, V10, P4409, DOI 10.1093/nar/10.14.4409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; LUEHRSEN KR, 1980, CURR MICROBIOL, V4, P123, DOI 10.1007/BF02602905; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUURA T, 1986, GENE, V49, P225; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; NIELSEN H, 1986, EMBO J, V86, P2711; NIELSEN JN, 1993, NUCLEIC ACIDS RES, V21, P3631, DOI 10.1093/nar/21.16.3631; NILSSON B, 1983, NUCLEIC ACIDS RES, V11, P8019, DOI 10.1093/nar/11.22.8019; NORGAARD P, 1992, EUR J BIOCHEM, V210, P621; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PEDERSON DS, 1984, NUCLEIC ACIDS RES, V12, P3003, DOI 10.1093/nar/12.6.3003; PEDERSON DS, 1986, MOL CELL BIOL, V6, P3014, DOI 10.1128/MCB.6.8.3014; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; ROSENDAHL G, 1991, GENE, V98, P161, DOI 10.1016/0378-1119(91)90169-C; SAKUNJO S, 1980, CELL, V19, P13; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; SUTIPHONG J, 1984, BIOCHEMISTRY-US, V23, P6319, DOI 10.1021/bi00321a005; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; TURKEWITZ AP, 1991, EMBO J, V10, P1979, DOI 10.1002/j.1460-2075.1991.tb07727.x; TYLER BM, 1985, P NATL ACAD SCI USA, V82, P5450, DOI 10.1073/pnas.82.16.5450; TYLER BM, 1987, J MOL BIOL, V196, P801, DOI 10.1016/0022-2836(87)90406-2; VACCARO M, 1990, P NATL ACAD SCI USA, V87, P3047, DOI 10.1073/pnas.87.8.3047; VANWIJNEN AJ, 1987, NUCLEIC ACIDS RES, V15, P1679, DOI 10.1093/nar/15.4.1679; VERDIER JM, 1990, NUCLEIC ACIDS RES, V18, P7033, DOI 10.1093/nar/18.23.7033; Warburg O, 1942, BIOCHEM Z, V310, P384; WARNER JR, 1993, TRANSLATIONAL APPARATUS, P109; YAO MC, 1991, P NATL ACAD SCI USA, V88, P9493, DOI 10.1073/pnas.88.21.9493; YOGANATHAN T, 1992, BIOCHEM J, V285, P721, DOI 10.1042/bj2850721; ZAHRADKA P, 1988, EUR J BIOCHEM, V171, P37, DOI 10.1111/j.1432-1033.1988.tb13755.x; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	61	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7601	7608		10.1074/jbc.270.13.7601	http://dx.doi.org/10.1074/jbc.270.13.7601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706308	hybrid			2022-12-25	WOS:A1995QQ43100085
J	ONEILL, FJ; FRISQUE, RJ; XU, XL; HU, YX; CARNEY, H				ONEILL, FJ; FRISQUE, RJ; XU, XL; HU, YX; CARNEY, H			IMMORTALIZATION OF HUMAN-CELLS BY MUTANT AND CHIMERIC PRIMATE POLYOMAVIRUS T-ANTIGEN GENES	ONCOGENE			English	Article						TRANSFORMATION; IMMORTALIZATION; POLYOMAVIRUSES; T-ANTIGEN; SV40; JCV; BKV	SV40-TRANSFORMED HUMAN-FIBROBLASTS; PAPILLOMAVIRUS TYPE-16 DNA; MOUSE EMBRYO FIBROBLASTS; VIRUS 40 GENE; SIMIAN VIRUS-40; JC-VIRUS; MALIGNANT TRANSFORMATION; CELLULAR SENESCENCE; VIRAL-DNA; 3' END	Human fibroblasts were morphologically transformed with wild type and mutant SV40 T-antigens (T-Ags) and with SV40/JCV and SV40/BKV chimeric T-Ags. The transformants were then assayed for the attainment of immortal cell growth. Several observations relating T-Ag and T-Ag domains to immortalization were made. Approximately 10% of SV40-transformants became immortal. Transformants generated by transfection or infection of cells with C-terminal T-Ag deletion mutants of SV40 did not immortalize. SV40/JCV and SV40/BKV chimeric T-Ags, containing C-terminal sequences from JCV or BKV, immortalized cells more efficiently than did the intact SV40 T-Ag, suggesting that the C-termini of the JCV and BKV T-Ags contain an enhanced immortalization function. However, chimeras in which the N-terminal or proximal-central portions of T-Ag were composed of JCV sequences failed to immortalize but did induce transformation, Constructs in which the JCV T-Ag Rb binding domain was replaced with SV40 sequences transformed human cells, but again the cells failed to immortalize. Transformants and immortalized cell lines produced by some SV40/JCV chimeras, contained p53 which was unbound by T-Ag. This occurred under conditions where p53 from SV40 and SV40/BKV transformants was bound to T-Ag. This may reflect the reduced stability of the SV40/JCV T-Ags.	UNIV UTAH,DEPT CELLULAR VIRAL & MOLEC BIOL,DEPT PATHOL,SALT LAKE CITY,UT 84132; PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	ONEILL, FJ (corresponding author), VET AFFAIRS MED CTR,RES SERV,SALT LAKE CITY,UT 84148, USA.				NATIONAL CANCER INSTITUTE [R01CA044970] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE CN, 1979, J VIROL, V30, P683, DOI 10.1128/JVI.30.3.683-691.1979; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; CRISTOFALO VJ, 1985, GERONTOLOGIST, V25, P577, DOI 10.1093/geront/25.6.577; DEFENDI V, 1982, J CELL PHYSL S, V2, P131; DEPPERT W, 1989, VECTORS TOOLS STUDY, P399; DURST M, 1987, ONCOGENE, V1, P251; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIRARDI AJ, 1965, J CELL COMP PHYSL, V165, P69; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GROSSI MP, 1982, J GEN VIROL, V63, P393, DOI 10.1099/0022-1317-63-2-393; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KAO CH, 1993, J VIROL, V67, P1987, DOI 10.1128/JVI.67.4.1987-1995.1993; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUHAR SG, 1991, ONCOGENE, V6, P1499; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MANIATIS T, 1982, MOL CLONING LAB MANU; MARTIN RG, 1975, J VIROL, V15, P599, DOI 10.1128/JVI.15.3.599-612.1975; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MICHAELMICHALOV.D, 1991, J VIROL, V65, P4160; MONIER R, 1986, PAPOVAVIRIDAE; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; ONEILL FJ, 1980, J VIROL, V35, P233, DOI 10.1128/JVI.35.1.233-245.1980; ONEILL FJ, 1990, INTERVIROLOGY, V31, P175, DOI 10.1159/000150152; ONEILL FJ, 1988, VIRUS RES, V11, P109, DOI 10.1016/0168-1702(88)90037-8; ONEILL FJ, 1986, VIROLOGY, V154, P344, DOI 10.1016/0042-6822(86)90460-5; ONEILL FJ, 1993, VIRUS RES, V30, P171, DOI 10.1016/0168-1702(93)90005-8; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1994, VIRUS RES, V34, P237, DOI 10.1016/0168-1702(94)90126-0; ONEILL FJ, 1982, J VIROL, V43, P18, DOI 10.1128/JVI.43.1.18-25.1982; ONEILL FJ, 1981, VIROLOGY, V112, P800, DOI 10.1016/0042-6822(81)90330-5; PATER A, 1980, J VIROL, V36, P480, DOI 10.1128/JVI.36.2.480-487.1980; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPAS JM, 1983, MOL CELL BIOL, V3, P201; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMA.L, 1991, J VIROL, V65, P2843; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1990, CANCER CELL-MON REV, V2, P360; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; TOOZE J, 1981, COLD SPRING HARBOR L; TROWBRIDGE PW, 1993, VIROLOGY, V196, P458, DOI 10.1006/viro.1993.1502; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; VANHEUVERSWYN H, 1979, J VIROL, V67, P1817; WALKER DL, 1986, POLYOMAVIRUSES; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	66	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1131	1139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700639				2022-12-25	WOS:A1995QN35300014
J	GUIMOND, S; MACCARANA, M; OLWIN, BB; LINDAHL, U; RAPRAEGER, AC				GUIMOND, S; MACCARANA, M; OLWIN, BB; LINDAHL, U; RAPRAEGER, AC			ACTIVATING AND INHIBITORY HEPARIN SEQUENCES FOR FGF-2 (BASIC FGF) - DISTINCT REQUIREMENTS FOR FGF-1, FGF-2, AND FGF-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MYOGENIC DIFFERENTIATION; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; BINDING SEQUENCE; SULFATE; IDENTIFICATION; PROTEINS; RELEASE; SURFACE	Chlorate-treated Swiss 3T3 fibroblasts, with impaired synthesis of heparan sulfate proteoglycan, were used as target cells in assessing the ability of exogenous heparin-derived saccharides to promote the mitogenic activity of basic fibroblast growth factor 2 (FGF-2). Full-size native heparin (carrying iduronosyl 2-O-sulfate and glucosaminyl 6-O-sulfate groups), as well as a dodecasaccharide fraction isolated after limited deaminative cleavage of heparin, were efficient promoters, whereas the corresponding decasaccharides, or smaller oligosaccharides, were inactive. Neither selectively 2-O-desulfated nor preferentially 6-O-desulfated heparin were active. However, the latter derivative competed with native heparin for binding to FGF-2 and thus blocked the ability of native heparin to promote the mitogenic activity of FGF-2. The 6-O-desulfated heparin also prevented the ability of FGF-2 to suppress myogenic differentiation in MM14 mouse myoblasts. The binding region for FGF-2 has been identified as a pentasaccharide sequence containing a single essential O-sulfate group, at C2 of iduronic acid (1). It is proposed that the dodecasaccharide sequence required to promote receptor signaling by FGF-2 encompasses this pentasaccharide region, which binds the growth factor, and a site interacting with the receptor that contains essential 2-O- and 6-O-sulfate groups. Similar studies involving the related growth factors, FGF-1 and FGF-4, revealed differential effects of saccharides. The mitogenic effect induced by FGF-1 thus was not blocked by either the 2-O- or the 6-O-desulfated heparins. However, both of these derivatives, at high concentrations, promote mitogenic activity of FGF-4. It is concluded that specific saccharide sequences within heparan sulfate glycosaminoglycan chains favor the signaling by distinct members of the FGF family.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Uppsala University			maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921	NICHD NIH HHS [HD21881] Funding Source: Medline; NIGMS NIH HHS [GM48850] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD021881, R01HD021881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048850] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hauschka SD, 1979, MUSCLE REGENERATION, P311; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U., 1989, HEPARIN, P159; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PEJLER G, 1988, J BIOL CHEM, V263, P5197; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	512	519	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23906	23914						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693696				2022-12-25	WOS:A1993MF29400033
J	SKALSKI, V; CHANG, CN; DUTSCHMAN, G; CHENG, YC				SKALSKI, V; CHANG, CN; DUTSCHMAN, G; CHENG, YC			THE BIOCHEMICAL BASIS FOR THE DIFFERENTIAL ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITY OF 2 CIS ENANTIOMERS OF 2',3'-DIDEOXY-3'-THIACYTIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-ALPHA; REVERSE-TRANSCRIPTASE; REPLICATION; 3'-AZIDO-3'-DEOXYTHYMIDINE; INHIBITION; INVITRO; 2'-DEOXY-3'-THIACYTIDINE; 2',3'-DIDEOXYCYTIDINE; 5'-TRIPHOSPHATE; TRIPHOSPHATE	Two cis stereoisomers of 2',3'-dideoxy-3'-thiacytidine (SddC) were investigated for their activity against human immunodeficiency virus type 1 (HIV-1) in human acute lymphoblastic leukemia H-9 cells. (-)-SddC is six times more potent against HIV-1 and at Least 1.7-fold less cytotoxic than (+)-SddC. Metabolism studies showed that the intracellular accumulation of the active triphosphate form of (-)-SddC is more than 2-fold greater than that of (+)-SddCTP in H-9 cells. In contrast, (+)SddCTP is approximately 1.5 times more potent than (-)-SddCTP as an inhibitor of HIV-1 reverse transcriptase using a RRNA template (K(i) = 0.22 and 0.0.34 muM, respectively) and gapped DNA (K(i) = 0.53 and 1.02 muM, respectively). The enantiomers are comparable as substrates for incorporation into DNA by the RNA-dependent HIV-1 reverse transcriptase; however, neither analog is incorporated as readily as dCTP. The above observations do not explain the difference in the anti-HIV potency between the enantiomers. A novel 3'-5' exonuclease was partially purified from the cytosol of H-9 cells and assayed for the removal of (+)- and (-)-SddCMP-terminated DNA. Removal of (+)-SddCMP was approximately two to three times faster from 3'-terminals of single-stranded and double-stranded DNA, whereas on DNA/RNA substrates, the exonucleolytic cleavage of (+)-SddCMP proceeded approximately six times faster than that of (-)-SddCMP. This result correlates with the observed difference in the anti-HIV effect between the two compounds and suggests that this novel enzyme may be an important determinant of their antiviral activities.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University					NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NCI NIH HHS [CA44358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACH JW, 1992, J ORG CHEM, V57, P2217, DOI 10.1021/jo00034a006; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CAMMACK N, 1992, BIOCHEM PHARMACOL, V43, P2059, DOI 10.1016/0006-2952(92)90162-C; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CHENG YC, 1991, ANN NY ACAD SCI, V616, P217; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAO Z, 1988, MOL PHARMACOL, V34, P431; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HUANG P, 1992, J BIOL CHEM, V267, P2817; MELLORS JW, 1993, MOL PHARMACOL, V43, P11; PARKER WB, 1991, J BIOL CHEM, V266, P1754; SEGEL IH, 1990, ENZYME KINETICS BEHA, P104; SHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672; STARNES MC, 1987, VIRUS GENES, V23, P241; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76	24	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23234	23238						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693686				2022-12-25	WOS:A1993MF51500047
J	LUKACS, GL; CHANG, XB; BEAR, C; KARTNER, N; MOHAMED, A; RIORDAN, JR; GRINSTEIN, S				LUKACS, GL; CHANG, XB; BEAR, C; KARTNER, N; MOHAMED, A; RIORDAN, JR; GRINSTEIN, S			THE DELTA-F508 MUTATION DECREASES THE STABILITY OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN THE PLASMA-MEMBRANE - DETERMINATION OF FUNCTIONAL HALF-LIVES ON TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; BREFELDIN-A; CHLORIDE CONDUCTANCE; CL CHANNEL; GENE; CFTR; IDENTIFICATION; LOCALIZATION; TRANSPORT; EXPRESSION	Deletion of the phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR) is the most prevalent mutation in cystic fibrosis (CF). This mutation (DELTAF508CFTR) leads to a reduced cAMP-sensitive Cl- conductance in epithelial cells. While the mutant protein can function as a Cl- channel, it seems to be misprocessed and unable to accumulate at normal levels in the plasma membrane. Under conditions where the biosynthetic block of DELTAF508CFTR is not complete, the residence time of DELTAF508CFTR in the plasma membrane is a critical determinant of the cAMP-sensitive Cl- conductance. To assess the stability of the mutant and wild-type CFTR, we compared their functional half-lives at the plasma membrane of transfected Chinese hamster ovary cells. The plasma membrane Cl- conductance was assessed by patch-clamp recordings and/or by fluorimetric determinations of the membrane potential. Accumulation of DELTAF508CFTR in the plasma membrane was promoted by growing the transfected cells at reduced temperature (24-28-degrees-C), and was verified by immunoblotting and by detecting the appearance of a plasmalemmal cAMP-activated Cl- conductance. Subsequently increasing the temperature to 37-degrees-C inhibited further delivery of newly synthesized DELTAF508CFTR to the surface membrane. By studying the time dependence of the disappearance of the Cl- conductance, the functional half-life of the mutant protein at the plasma membrane was determined to be <4 h, which is considerably shorter than the half-life of wild-type CFTR (>24 h). The latter was estimated by terminating protein synthesis or secretion with cycloheximide or brefeldin A, respectively. Inhibition of protein synthesis did not alter the rate of disappearance of DELTAF508CFTR at 37-degrees-C, validating the difference in turnover between mutant and wild-type CFTR. These results indicate that the structural abnormality of DELTAF508CFTR affects not only the delivery of the protein to the plasma membrane, but also its stability therein. Moreover, they suggest that overcoming the processing block at the endoplasmic reticulum may not suffice to restore normal Cl- conductance in CF.			LUKACS, GL (corresponding author), HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.			Lukacs, Gergely/0000-0003-0900-0675				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CANHUI L, 1993, NAT GENET, V3, P311; CHENG SH, 1990, CELL, V65, P1; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MATUSLEIBOVITCH N, 1992, BIOCHEM J, V285, P753, DOI 10.1042/bj2850753; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K	37	325	332	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21592	21598						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691813				2022-12-25	WOS:A1993MC80900027
J	STUTTS, MJ; GABRIEL, SE; OLSEN, JC; GATZY, JT; OCONNELL, TL; PRICE, EM; BOUCHER, RC				STUTTS, MJ; GABRIEL, SE; OLSEN, JC; GATZY, JT; OCONNELL, TL; PRICE, EM; BOUCHER, RC			FUNCTIONAL CONSEQUENCES OF HETEROLOGOUS EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CHLORIDE CHANNEL; GROWTH-FACTOR; CL CHANNEL; GENE; PHOSPHORYLATION; CFTR	We studied the consequences of cystic fibrosis transmembrane conductance regulator (CFTR) expression in NIH-3T3 fibroblasts as a model for the effects of virally transduced CFTR expression in non-epithelial cells. Fibroblasts were infected with a retrovirus vector that contained the human CFTR and neo(r) cDNAs. We selected and expanded G418-resistant clones that encompassed a range of CFTR expression. CFTR-mediated Cl- conductance function was measured as whole cell current, and CFTR protein was quantitated by immunoblot analysis. Overall, there was a good relationship between CFTR protein levels and CFTR-mediated Cl- conductance. Some clones had consistently high basal levels of CFTR-mediated Cl- conductance. This variation in function was partially explained by CFTR protein levels and was not due to clonal variation in cAMP metabolism. High levels of CFTR expression were associated with depolarization of fibroblast membrane potential. The CFTR-expressing clones with the largest basally active CFTR Cl- conductances and the most depolarized membrane potentials also exhibited slower growth rates. These results suggest that potential side effects of gene replacement therapy for cystic fibrosis include functional consequences of CFTR expression in non-epithelial cells.	UNIV N CAROLINA,LINEBERGER CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	STUTTS, MJ (corresponding author), UNIV N CAROLINA,CTR CYST FIBROSIS RES,CB 7020,CHAPEL HILL,NC 27599, USA.							BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; ESTACION M, 1991, J PHYSIOL-LONDON, V436, P579, DOI 10.1113/jphysiol.1991.sp018568; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; MAGNI M, 1991, J BIOL CHEM, V266, P6329; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9	18	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20653	20658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690761				2022-12-25	WOS:A1993LY01900104
J	WALKER, F; DEBLAQUIERE, J; BURGESS, AW				WALKER, F; DEBLAQUIERE, J; BURGESS, AW			TRANSLOCATION OF PP60(C-SRC) FROM THE PLASMA-MEMBRANE TO THE CYTOSOL AFTER STIMULATION BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-KINASE-C; MORPHOLOGICAL TRANSFORMATION; PHASE-SEPARATION; TYROSINE KINASE; FACTOR RECEPTOR; TRITON X-114; SRC PROTEIN; PHOSPHORYLATION; ASSOCIATION	The src family of protein-tyrosine kinases has long been implicated in signal transduction by growth factor receptors. In particular, pp60c-src, the product of the protooncogene c-src, has been shown to associate with the activated platelet-derived growth factor (PDGF) receptor. We demonstrate that, following stimulation of quiescent cells with PDGF, pp60c-src, is translocated from the plasma membrane to the cytosol. This phenomenon was better defined utilizing an isolated plasma membrane system. The release of pp60c-src from the membrane in response to PDGF is accompanied by a 4-fold activation of its kinase activity and by phosphorylation at the amino terminus on serine/threonine residues as well as tyrosine residues. This amino-terminal phosphorylation appears to be responsible for a change in hydrophobicity of the pp60c-src, molecule and hence for its release from the membrane. The kinase responsible for the serine/threonine phosphorylation and the concomitant release of pp60c-src has been identified as the cAMP-dependent protein kinase. Thus, PDGF stimulation activates at least two membrane-associated kinases (pp60c-src and cAMP-dependent protein kinase) very early in its signal transduction pathway.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital								ALCARAZ G, 1984, J BIOL CHEM, V259, P4922; BAGRODIA S, 1991, NATURE, V349, P1722; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURGESS AW, 1983, EMBO J, V2, P2065, DOI 10.1002/j.1460-2075.1983.tb01701.x; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER JA, 1989, PEPTIDES PROTEIN PHO; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; FEDER D, 1989, J BIOL CHEM, V264, P8205; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TAMURA T, 1984, FEBS LETT, V177, P151, DOI 10.1016/0014-5793(84)81001-7; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; WALKER F, 1991, J BIOL CHEM, V266, P2746; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	31	75	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19552	19558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690037				2022-12-25	WOS:A1993LW81900063
J	GUO, HL; PRICE, DH				GUO, HL; PRICE, DH			MECHANISM OF DMS-II-MEDIATED PAUSE SUPPRESSION BY DROSOPHILA RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTOR; FACTOR-S-II; ASCITES TUMOR-CELLS; FACTOR-SII; STIMULATORY FACTORS; INITIATION-FACTOR; MESSENGER-RNA; GENE; PURIFICATION; COMPLEX	Transcription elongation factor S-II mediates nascent transcript cleavage by RNA Polymerase II (Reines, D. (1992) J. Biol. Chem. 267, 3795-3800). We have examined the mechanism of action of the Drosophila S-II analog, DmS-II, in a defined transcription system. Our results show that DmS-II is necessary and sufficient to activate nascent transcript cleavage by RNA polymerase II during transcription of a dC-tailed template. The pattern of transcripts resulting from prolonged action by DmS-II indicates that there are kinetic barriers to transcript shortening. During the cleavage reaction, the polymerase remains in register with the template strand and generates mainly nucleotide dimers. The ability of DmS-II to mediate transcript shortening resides in the carboxyl-terminal half of the protein. Our results support a model for pause suppression in which DmS-II binds to the paused polymerase, causes one cleavage event and is then released from the complex. Elongation by the polymerase then allows a second encounter with the pause site and a second chance of passing the site. Complete pause suppression may require multiple transcript shortening events for some polymerase molecules.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; FLORES O, 1989, J BIOL CHEM, V264, P8913; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAUSKOPF A, 1991, MOL CELL BIOL, V11, P3515, DOI 10.1128/MCB.11.7.3515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1984, CELL, V38, P423, DOI 10.1016/0092-8674(84)90497-5; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1979, EXP CELL RES, V124, P63, DOI 10.1016/0014-4827(79)90257-X; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	47	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18762	18770						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689559				2022-12-25	WOS:A1993LV65900062
J	KOMADA, M; KITAMURA, N				KOMADA, M; KITAMURA, N			THE CELL-DISSOCIATION AND MOTILITY TRIGGERED BY SCATTER FACTOR HEPATOCYTE GROWTH-FACTOR ARE MEDIATED THROUGH THE CYTOPLASMIC DOMAIN OF THE C-MET RECEPTOR	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; TYROSINE KINASE-ACTIVITY; HUMAN-FIBROBLASTS; EPITHELIAL-CELLS; PROTO-ONCOGENE; SIGNAL TRANSDUCTION; CHIMERIC RECEPTOR; MOLECULAR-CLONING; RAT HEPATOCYTES; HEPATOPOIETIN-A	Scatter factor (SF), which dissociates epithelial cell colonies into individual cells and stimulates the migration of epithelial cells, is identical to hepatocyte growth factor (HGF), a mitogen for melanocytes, endothelial cells and epithelial cells, including hepatocytes. It was previously shown by cDNA transfection that the mitogenic effect of SF/HGF is mediated by activation of the tyrosine phosphorylation of the c-Met receptor (the c-met protooncogene product). In this study, we constructed a cDNA encoding a chimeric receptor composed of the extracellular domain of the epidermal growth factor (EGF) receptor and the transmembrane and cytoplasmic domains of the c-Met receptor. We transfected the cDNA into the B16-F1 mouse melanoma cell line to investigate whether the cell dissociation and motility were mediated through this chimeric receptor following ligand stimulation. The chimeric receptor cDNA was expressed in the transfected cells and the protein product was transported to the cell surface in the correct transmembrane orientation. EGF treatment of the chimeric receptor-expressing cells markedly enhanced tyrosine phosphorylation of the chimeric receptor and led to scattered morphology and enhanced motility. This scattered morphology was inhibited by a tyrosine kinase inhibitor. Based on these results, we concluded that the cell dissociation and motility triggered by SF/HGF were mediated through the cytoplasmic domain of the c-Met receptor by activation of its tyrosine kinase. Thus, it is likely that the different biological effects of SF/HGF are mediated by different intracellular signal cascades.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARAKAKI N, 1992, J BIOL CHEM, V267, P7101; BARDELLI A, 1992, ONCOGENE, V7, P1973; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHAN AML, 1988, ONCOGENE, V2, P593; DAS M, 1978, P NATL ACAD SCI USA, V75, P2644, DOI 10.1073/pnas.75.6.2644; DEMOUZON SH, 1992, J CELL PHYSL, V150, P180; FIDLER IJ, 1975, CANCER RES, V35, P218; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KING AC, 1982, J BIOL CHEM, V257, P3053; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZARNEGAR R, 1989, CANCER RES, V49, P3314	65	57	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2381	2390						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689722				2022-12-25	WOS:A1993LT36800008
J	BURNS, LA; KARNITZ, LM; SUTOR, SL; ABRAHAM, RT				BURNS, LA; KARNITZ, LM; SUTOR, SL; ABRAHAM, RT			INTERLEUKIN-2-INDUCED TYROSINE PHOSPHORYLATION OF P52(SHC) IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL LINE; ACTIVATION; RECEPTOR; SHC; ASSOCIATION; P56LCK; DOMAIN	Stimulation of activated T cells with interleukin-2 (IL-2) results in the tyrosine phosphorylation of several intracellular proteins. The present studies demonstrate that IL-2 stimulation induces phosphorylation of the src homology 2 domain-containing protein, p52shc, on both tyrosine and serine residues. The level of p52shc phosphorylation was maximal within 5 min after growth factor addition and declined gradually thereafter. In addition, anti-Shc immunoprecipitates from IL-2-stimulated T cells contained a co-precipitating protein tyrosine kinase (PTK) activity that phosphorylated p52shc on tyrosine residues in immune complex kinase assays. These results demonstrate that p52shc is an early substrate for IL-2 receptor-coupled PTK activity(s) and suggest that this protein may be involved in the transduction of PTK-dependent regulatory signals in IL-2-stimulated T cells.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,RM 342B,GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047286] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09127] Funding Source: Medline; NIGMS NIH HHS [GM47286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227	23	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17659	17661						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688728				2022-12-25	WOS:A1993LT74300003
J	MARSDEN, PA; HENG, HHQ; SCHERER, SW; STEWART, RJ; HALL, AV; SHI, XM; TSUI, LC; SCHAPPERT, KT				MARSDEN, PA; HENG, HHQ; SCHERER, SW; STEWART, RJ; HALL, AV; SHI, XM; TSUI, LC; SCHAPPERT, KT			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN CONSTITUTIVE ENDOTHELIAL NITRIC-OXIDE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; MOLECULAR-CLONING; BINDING PROTEIN; RECEPTOR GENE; HUMAN DNA; CYTOCHROME-P-450 REDUCTASE; TRANSCRIPTIONAL REGULATION; PREPROENDOTHELIN-1 GENE; SYNERGISTIC ACTIVATION; NUCLEOTIDE-SEQUENCE	Endothelial nitric oxide (NO) synthase is a unique NO synthase isoform that is expressed constitutively by vascular endothelium both in vivo and in vitro and is believed essential to local vascular homeostasis. This calcium/calmodulin-dependent isoform is distinct from neuronal NO synthase. Genomic clones encoding the human endothelial NO synthase were isolated and the structural organization of the gene was determined. The gene contains 26 exons spanning almost-equal-to 21 kilobases of genomic DNA, encodes a messenger RNA of 4052 nucleotides, and is present as a single copy in the haploid human genome. Characterization of 5'-flanking genomic regions indicates that the endothelial NO synthase promoter is ''TATA-less'' and exhibits proximal promoter elements consistent with a constitutively expressed gene that is found in endothelial cells, namely Sp1 and GATA motifs. The 5'-flanking region contains putative AP-1, AP-2, NF-1, heavy metal, acute-phase response shear stress, and sterol-regulatory cis-elements. The human endothelial NO synthase gene was assigned to the 7q35 --> 7q36 region of chromosome 7 by Southern blot hybridization of human-rodent somatic cell hybrid lines and fluorescence in situ hybridization, whereas human neuronal NO synthase localized to the 12q24.2 region of chromosome 12.	UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	MARSDEN, PA (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,DIV RENAL,TORONTO M5S 1A8,ONTARIO,CANADA.		Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010; Marsden, Philip A/B-1441-2012	Scherer, Stephen W./0000-0002-8326-1999; 				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARAKI E, 1991, J BIOL CHEM, V266, P3944; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE A, 1989, J BIOL CHEM, V264, P14954; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JONES KA, 1985, CELL, V42, P5559; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO J, 1992, GENOMICS, V14, P802, DOI 10.1016/S0888-7543(05)80192-2; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE ME, 1991, J BIOL CHEM, V266, P16188; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PENNY LA, 1991, GENOMICS, V11, P974, DOI 10.1016/0888-7543(91)90022-7; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHERER SW, 1991, CYTOGENET CELL GENET, V56, P176, DOI 10.1159/000133081; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHARP S, 1981, P NATL ACAD SCI-BIOL, V78, P6657, DOI 10.1073/pnas.78.11.6657; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEPHARD EA, 1989, ANN HUM GENET, V53, P291, DOI 10.1111/j.1469-1809.1989.tb01798.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TSAI S, 1989, NATURE, V339, P448; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UPHOLT WB, 1986, P NATL ACAD SCI USA, V83, P2325, DOI 10.1073/pnas.83.8.2325; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZULIANI G, 1990, AM J HUM GENET, V46, P963	88	761	804	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17478	17488						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688726				2022-12-25	WOS:A1993LQ98800087
J	CROVELLO, CS; FURIE, BC; FURIE, B				CROVELLO, CS; FURIE, BC; FURIE, B			RAPID PHOSPHORYLATION AND SELECTIVE DEPHOSPHORYLATION OF P-SELECTIN ACCOMPANIES PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GRANULE MEMBRANE-PROTEIN; LYMPHOCYTE HOMING RECEPTOR; WEIBEL-PALADE BODIES; CELL-CYCLE; ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIIA; PLASMA-MEMBRANE; ADHESION; THROMBIN; GMP-140	P-selectin, a receptor for neutrophils and monocytes, is an adhesion molecule on the surface of activated platelets that resides in the alpha granule membrane of unstimulated platelets. To determine whether phosphorylation of P-selectin might accompany platelet activation, P-selectin in resting and thrombin-stimulated platelets labeled with o-[P-32]phosphate was immunoprecipitated with the monoclonal antibody AC1.2 directed against P-selectin. SDS-gel electrophoresis of the immunoprecipitates indicated about 10-20-fold higher levels of P-32 incorporated into P-selectin from thrombin-activated platelets than in resting platelets, although both sets of platelets contained equivalent amounts of P-selectin. The lower limits of the molar ratio of phosphate to P-selectin in activated platelets is about 0.52 +/- 0.08. Other platelet agonists, including the thrombin receptor peptide (SFLLR), epinephrine, ADP, and collagen, similarly stimulated phosphorylation of P-selectin. The kinetics of P-selectin phosphorylation following thrombin stimulation was rapid, with maximum phosphorylation observed at 15-30 s. Phosphoamino acid analysis of the phosphorylated P-selectin revealed the rapid synthesis of phosphoserine, phosphothreonine, and phosphotyrosine, but 80-90% of the phosphotyrosine and phosphothreonine disappeared within 5 min of platelet activation while the maximal level of phosphoserine remained stable. The rapid phosphorylation and selective dephosphorylation of specific amino acids in P-selectin following platelet activation may be important for P-selectin function and signal transduction within platelets.	TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University; Tufts University	CROVELLO, CS (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.				NHLBI NIH HHS [HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; Brass L F, 1991, Prog Hemost Thromb, V10, P127; BRYCKAERT MC, 1989, J BIOL CHEM, V264, P4336; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CARTY DJ, 1986, BLOOD, V67, P1738; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DIDIER M, 1992, MOL BIOL CELL, V3, P309; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KROLL MH, 1989, BLOOD, V74, P1181; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PARISE LV, 1990, BLOOD, V75, P2363; SCOTT PC, 1991, IMMUNOGENETICS, V34, P69; SHAI SY, 1990, BIOCHEM BIOPH RES CO, V167, P1128, DOI 10.1016/0006-291X(90)90640-9; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILSON DB, 1985, J BIOL CHEM, V260, P1046	41	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14590	14593						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686899				2022-12-25	WOS:A1993LL75900011
J	MOLMENTI, EP; ZIAMBARAS, T; PERLMUTTER, DH				MOLMENTI, EP; ZIAMBARAS, T; PERLMUTTER, DH			EVIDENCE FOR AN ACUTE-PHASE RESPONSE IN HUMAN INTESTINAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; SERUM AMYLOID-A; HUMAN INTERLEUKIN-6; GENE-EXPRESSION; MESSENGER-RNA; FACTOR-B; PROTEIN; FIBROBLASTS; ALPHA-1-ANTITRYPSIN; COMBINATIONS	During the host response to inflammation/tissue in jury there are many changes in intermediary metabolism including a dramatic change in the concentration of many 'acute phase'' plasma proteins. Although many of these acute phase proteins are predominantly derived from the liver and the response can be elicited from liver cells incubated in tissue culture with cytokines such as interleukin-6 (IL-6), interleukin-I (IL-1), tumor necrosis factor-alpha, interferon-gamma, leukemia inhibitory factor, interleukin-11 (IL-11), and oncostatin M, there is now evidence that the response can also be elicited in extrahepatic tissues and cell types. In this study, we show that many of the acute phase plasma proteins are expressed in human intestinal epithelial cell lines Caco2 and T84 and that their expression is induced or regulated by cytokines IL-6, IL-1, interferon, and tumor necrosis factor in a manner characteristic of the acute phase response. In fact, effects of IL-1 and IL-6 which are additive, synergistic, and antagonistic in liver cell lines are also observed in these intestinal epithelial cell lines. Responses to IL-6 and IL-1 are seen at all stages of differentiation of Caco2 cells from crypt-like enterocytes to villus-like enterocytes. Caco2 cells express binding sites for IL-6 at both poles, for IL-I at the basolateral pole and, to a lesser extent, at the apical pole. T84 cells have IL-1 and IL-6 receptor binding sites only at the basolateral pole. IL-6 and IL-1 also regulate the expression of enterocyte-specific integral membrane proteins as exemplified by down-regulation of sucrase-isomaltase gene expression in response to IL-6. These data raise the possibility that enterocytes are involved in a local response to injury/inflammation at the epithelial surface and establish a model system for examining coordination of the acute phase response in a bipolar cell.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [DK45085] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045085] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENSTEDT O, 1990, NEW ENGL J MED, V322, P1345, DOI 10.1056/NEJM199005103221903; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CROSS HS, 1991, AM J PHYSIOL, V261, pC1173; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; FALUS A, 1987, J IMMUNOL, V138, P856; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GITLIN JD, 1987, LYMPHOKINES, V14, P123; HAFEEZ W, 1992, J CLIN INVEST, V89, P1214, DOI 10.1172/JCI115705; HUBI M, 1990, CELL, V63, P1149; KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605; KULICS J, 1990, J CLIN INVEST, V85, P943, DOI 10.1172/JCI114523; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MAY LT, 1988, J BIOL CHEM, V263, P7760; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MIURA N, 1987, J BIOL CHEM, V262, P7298; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PERLMUTTER DH, 1984, J BIOL CHEM, V259, P380; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P9485; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133; PERLMUTTER DH, 1986, SCIENCE, V232, P850, DOI 10.1126/science.3010455; PERLMUTTER DH, 1989, ANN NY ACAD SCI, V557, P337; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RAMADORI G, 1985, J IMMUNOL, V135, P3645; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; VALENTINE JF, 1992, GASTROENTEROLOGY, V103, P905, DOI 10.1016/0016-5085(92)90024-S; WU GD, 1992, J BIOL CHEM, V267, P7863; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YU S, 1984, J BIOL CHEM, V259, P574	40	213	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14116	14124						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686149				2022-12-25	WOS:A1993LJ82500051
J	SALLES, JP; GAYRALTAMINH, M; FAUVEL, J; DELOBBE, I; MIGNONCONTE, M; CONTE, JJ; CHAP, H				SALLES, JP; GAYRALTAMINH, M; FAUVEL, J; DELOBBE, I; MIGNONCONTE, M; CONTE, JJ; CHAP, H			SUSTAINED EFFECT OF ANGIOTENSIN-II ON TYROSINE PHOSPHORYLATION OF ANNEXIN-I IN GLOMERULAR MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHOSPHOLIPID BINDING-PROTEINS; SWISS 3T3 CELLS; GROWTH-FACTOR; LIPOCORTIN-I; CALPACTIN-I; BILAYER-MEMBRANES; RECEPTOR KINASE; A-431 CELLS; CALCIUM	By means of selective extraction in a Ca2+-chelating medium and immunoblotting, four annexins (I, II, V, and VI) were identified in both isolated rat renal glomeruli and rat glomerular mesangial cells. Upon P-32 labeling of these cells in culture, annexin I was immunoprecipitated using a specific polyclonal antibody and was found to incorporate radioactivity in a constitutive manner. However, as with epidermal growth factor (200 ng/ml), addition of angiotensin II (10(-7) M), arginine-vasopressin (10(-7) M), or endothelin I (10(-7) M) resulted in a 2-3-fold stimulation of annexin I phosphorylation. The basal phosphorylation as well as the stimulating effect of angiotensin II were also detected by immunoblotting annexin extracts using an anti-phosphotyrosine antibody. In addition, among various phosphotyrosyl proteins isolated from EGTA extracts by adsorption onto an anti-phosphotyrosine antibody, annexin I was specifically recognized by Western blotting using a monoclonal anti-annexin I antibody, and displayed the same increase upon cell stimulation with angiotensin II. Moreover, thin layer chromatographic analysis of phosphoamino acids present in immunoprecipitated [P-32]annexin I showed an exclusive labeling of phosphotyrosine residue(s). Finally, the effect of angiotensin II was detectable after 10 min, maximal at 6 h, and present until 12 h of incubation. Using 12-h stimulation, tyrosine phosphorylation of annexin I displayed a maximum at 10(-7) to 10(-6) M angiotensin II. These data report for the first time the stimulation of annexin I tyrosine phosphorylation by biologically active peptides acting via receptors belonging to the superfamily of seven hydrophobic domain, G-protein-linked receptors, which lack an intrinsic protein tyrosine kinase. This suggests a possible role of annexin I in the mitogenic effect of angiotensin II, arginine-vasopressin, and endothelin I, which was previously observed on rat glomerular mesangial cells as well as on other cells.	HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; HOP PURPAN,NEPHROL LAB,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse			SALLES, Jean Pierre/K-2998-2014					AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; BIENKOWSKI MJ, 1989, J BIOL CHEM, V264, P6536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3398; CHAP H, 1988, BIOCHEM BIOPH RES CO, V150, P972, DOI 10.1016/0006-291X(88)90724-3; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; CIRINO G, 1987, NATURE, V328, P270, DOI 10.1038/328270a0; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FAUVEL J, 1987, FEBS LETT, V216, P45, DOI 10.1016/0014-5793(87)80754-8; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FORCE T, 1991, J BIOL CHEM, V266, P6650; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; GASSAMADIAGNE A, 1990, J BIOL CHEM, V265, P4309; GEISOW MJ, 1987, BIOSCIENCE REP, V7, P289, DOI 10.1007/BF01121450; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HULLIN F, 1989, J BIOL CHEM, V264, P3506; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KUMBLE KD, 1991, J CELL SCI, V99, P751; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; NORTHUP JK, 1988, J CLIN INVEST, V82, P1347, DOI 10.1172/JCI113737; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; RAY PE, 1991, KIDNEY INT, V40, P764, DOI 10.1038/ki.1991.273; RAYNAL P, 1992, BIOCHEM BIOPH RES CO, V186, P432, DOI 10.1016/S0006-291X(05)80826-5; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1992, J BIOL CHEM, V267, P9529; STRIKER GE, 1985, LAB INVEST, V53, P122; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOWLE CA, 1992, J BIOL CHEM, V267, P5416; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WOLTHUIS A, 1992, KIDNEY INT, V41, P124, DOI 10.1038/ki.1992.16; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	61	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12805	12811						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685351				2022-12-25	WOS:A1993LG65800085
J	CIFUENTES, ME; HONKANEN, L; REBECCHI, MJ				CIFUENTES, ME; HONKANEN, L; REBECCHI, MJ			PROTEOLYTIC FRAGMENTS OF PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA-1 - CATALYTIC AND MEMBRANE-BINDING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; KINETIC-ANALYSIS; MIXED MICELLES; POLYACRYLAMIDE GELS; BOVINE BRAIN; C-GAMMA; PURIFICATION; PROTEINS; SEQUENCE; FORMS	Active proteolytic fragments of phosphoinositide-specific phospholipase C-delta1 (PLC-delta1) were generated by trypsin digestion of the native protein. Brief proteolysis produced a 77-kDa fragment that contained the highly conserved X and Y regions but lacked the amino-terminal domain (amino acids 1-60). Prolonged digestion of PLC-delta1 produced two fragments, one of 45 kDa that contained the entire X region and another of 32 kDa that consisted of the entire Y region and COOH-terminal domain. The 45- and 32-kDa fragments were isolated as an active heterodimeric complex. The 77-kDa fragment and the complex catalyzed calcium-dependent hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in detergent/phospholipid mixed micelles. When compared with the native enzyme, both the 77-kDa fragment and the complex exhibited a reduced capacity to processively hydrolyze PIP2; increasing the mole fraction of PIP2 in the mixed micelle surface greatly increased the rate of PIP2 hydrolysis catalyzed by the native enzyme but not the fragments. Both fragments also exhibited a reduced affinity for substrate; the native enzyme bound to bilayer vesicles consisting of phosphatidylcholine and PIP2 with high affinity (K(a) is similar to 10(6) M-1), whereas the fragments bound weakly (K(a) < 10(4) M-1). These results demonstrate that the X, Y, and COOH-terminal regions form a calcium-dependent catalytic core that is resistant to proteolysis. The amino-terminal domain appears to be essential for high affinity binding to PIP2 but not catalysis. These observations are consistent with the idea that the amino-terminal domain forms part of a PIP2 binding site, which anchors PLC-delta1 to the membrane surface during processive hydrolysis of its substrate.	SUNY, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College				Cifuentes-Pagano, Eugenia/0000-0002-2482-080X	NIGMS NIH HHS [GM-43422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043422, R01GM043422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUKUI T, 1988, J BIOL CHEM, V263, P17730; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; HARDEN TK, 1991, BIOCHEM SOC T, V19, P342, DOI 10.1042/bst0190342; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; Hurn B A, 1980, Methods Enzymol, V70, P104; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KATAN M, 1988, COLD SPRING HARB SYM, V53, P921, DOI 10.1101/SQB.1988.053.01.106; KIM JW, 1990, J BIOL CHEM, V265, P3940; KRIZ R, 1990, CIBA F SYMP, V150, P112; Low M. G, 1990, METHODS INOSITIDE RE, P145; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONALD LJ, 1989, BIOCHEMISTRY-US, V28, P9926, DOI 10.1021/bi00452a008; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P3925, DOI 10.1021/bi00411a006; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Segel I.H., 1975, ENZYME KINETICS; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WILSON DB, 1984, J BIOL CHEM, V259, P1718	43	159	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11586	11593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685017				2022-12-25	WOS:A1993LF28400023
J	GODSON, C; BELL, KS; INSEL, PA				GODSON, C; BELL, KS; INSEL, PA			INHIBITION OF EXPRESSION OF PROTEIN KINASE-C-ALPHA BY ANTISENSE CDNA INHIBITS PHORBOL ESTER-MEDIATED ARACHIDONATE RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; CANINE KIDNEY-CELLS; RAT FIBROBLASTS; DOWN-REGULATION; ACTIVATION; ISOZYMES; RECEPTOR; CLONING; CA-2+; FORMS	A major unresolved issue in the area of signal transduction relates to the role of particular isoforms of protein kinase C (PKC) in mediating cellular responses subsequent to activation of that enzyme. We have addressed this issue by the use of antisense technology. We have stably transfected Madin-Darby canine kidney cells with antisense PKCalpha, PKCbeta, or both PKCalpha and -beta cDNAs. The transfected cDNA was integrated and expressed. We have isolated cells in which expression of PKCalpha is inhibited. In cells transfected with antisense PKCalpha or both PKCalpha and -beta, phorbol ester-stimulated release of arachidonate and its metabolites was inhibited, whereas in cells transfected with antisense PKCbeta cDNA alone, phorbol ester-stimulated arachidonate release was not significantly different from control cells. We thus demonstrate the use of a novel technique to inhibit PKC isoform expression. We show that inhibition of expression of PKCalpha causes a loss in phospholipase A2-mediated arachidonate release. Antisense-inhibited expression of PKC isoforms may provide a useful approach to define additional functions of particular PKC isoforms.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Godson, Catherine/0000-0003-0655-1041	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35018] Funding Source: Medline; NIGMS NIH HHS [GM 31987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOVENTRE JV, 1990, J BIOL CHEM, V266, P4934; BRICKGHANNAM C, 1991, J BIOL CHEM, V266, P24169; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; GODSON C, 1990, J BIOL CHEM, V265, P8369; GODSON C, 1991, FASEB J, V5, pA834; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; MASLIAH E, 1990, J NEUROSCI, V10, P2113; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; TOQUI L, 1986, NATURE, V321, P177; WEISS BA, 1991, J BIOL CHEM, V266, P2126; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	36	66	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11946	11950						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685027				2022-12-25	WOS:A1993LF28400073
J	CHANG, XB; TABCHARANI, JA; HOU, YX; JENSEN, TJ; KARTNER, N; ALON, N; HANRAHAN, JW; RIORDAN, JR				CHANG, XB; TABCHARANI, JA; HOU, YX; JENSEN, TJ; KARTNER, N; ALON, N; HANRAHAN, JW; RIORDAN, JR			PROTEIN KINASE-A (PKA) STILL ACTIVATES CFTR CHLORIDE CHANNEL AFTER MUTAGENESIS OF ALL 10 PKA CONSENSUS PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS GENE; R-DOMAIN; CONDUCTANCE; IDENTIFICATION; EXPRESSION; CAMP	The cystic fibrosis transmembrane conductance regulator (CFTR) plays a central role in transepithelial ion transport by acting as a tightly regulated apical chloride channel. Regulation is achieved by the concerted action of ATP at conserved nucleotide binding folds and serine phosphorylation at multiple sites by protein kinases A (PKA) and C (PKC). A previous investigation concluded that activation by PKA is critically dependent on phosphorylation at four of the nine predicted PKA sites in the R domain (S660A, S737A, S795A, S813A), because a ''Quad'' mutant lacking these sites could not be activated. We show in the present work that not only can this mutant be phosphorylated and activated, but a mutant in which all 10 predicted PKA sites have been altered still retains significant PKA-activated function. Potentiation of the PKA response by PKC is also preserved in this mutant. Thus CFTR may be regulated by cryptic PKA sites which also mediate interactions between different kinases. Such hierarchical phosphorylation of CFTR by obvious and cryptic PKA sites could provide a metered response to secretagogues.	HOSP SICK CHILDREN,RES INST,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Toronto; University of Toronto			Hanrahan, John/AGG-1926-2022; Alon, Noga/GOV-5970-2022	Hanrahan, John/0000-0001-9080-2039; Alon, Noga/0000-0003-1332-4883				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K	23	268	271	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11304	11311						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684377				2022-12-25	WOS:A1993LD46600086
J	KING, MP; ATTARDI, G				KING, MP; ATTARDI, G			POSTTRANSCRIPTIONAL REGULATION OF THE STEADY-STATE LEVELS OF MITOCHONDRIAL TRANSFER-RNAS IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON-CHOICE PATTERNS; ESCHERICHIA-COLI; RIBOSOMAL-RNA; HEAVY-STRAND; SACCHAROMYCES-CEREVISIAE; RESPECTIVE CODONS; RIBONUCLEIC-ACID; PROTEIN GENES; DNA; YEAST	In human mitochondrial DNA (mtDNA), the tRNA genes are located in three different transcription units that are transcribed at three different rates. To analyze the regulation of tRNA formation by the three transcription units, we have examined the steady-state levels and metabolic properties of the tRNAs of HeLa cell mitochondria. DNA excess hybridization experiments utilizing separated strands of mtDNA and purified tRNA samples from exponential cells long term labeled with [P-32]orthophosphate have revealed a steady-state level of 6 x 10(5) tRNA molecules/cell, with three-fourths being encoded in the H-strand and one-fourth in the L-strand. Hybridization of the tRNAs with a panel of M13 clones of human mtDNA containing, in most cases, single tRNA genes and a quantitation of two-dimensional electrophoretic fractionations of the tRNAs have shown that the steady-state levels of tRNA(Phe) and tRNA(Val) are two to three times higher than the average level of the other H-strand-encoded tRNAs and three to four times higher than the average level of the L-strand-encoded tRNAs. Similar experiments carried out with tRNAs isolated from cells labeled with very short pulses of [5-H-3]uridine have indicated that the rates of formation of the individual tRNA species are proportional to their steady-state amounts. Therefore, the approximately 25-fold higher rate of transcription of the tRNA(Phe) and tRNA(Val) genes relative to the other H-strand tRNA genes and the 10-16-fold higher rate of transcription of the L-strand tRNA genes relative to the H-strand tRNA genes are not reflected in the steady-state levels or the rates of formation of the corresponding tRNAs. A comparison of the steady-state levels of the individual tRNAs with the corresponding codon usage for protein synthesis, as determined from the DNA sequence and the rates of synthesis of the various polypeptides, has not revealed any significant correlation between the two parameters.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM11726, GM07616] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONI Y, 1971, P NATL ACAD SCI USA, V68, P1757, DOI 10.1073/pnas.68.8.1757; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATKINS JF, 1979, CELL, V18, P1119, DOI 10.1016/0092-8674(79)90225-3; ATTARDI B, 1971, J MOL BIOL, V55, P231, DOI 10.1016/0022-2836(71)90194-X; ATTARDI B, 1969, J MOL BIOL, V44, P47, DOI 10.1016/0022-2836(69)90404-5; ATTARDI G, 1983, METHOD ENZYMOL, V97, P435; ATTARDI G, 1990, BIOCHEM SOC T, V18, P509, DOI 10.1042/bst0180509; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; BOGENHAGEN DF, 1984, CELL, V36, P1105, DOI 10.1016/0092-8674(84)90061-8; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHIA LLSY, 1976, BIOCHIM BIOPHYS ACTA, V425, P49, DOI 10.1016/0005-2787(76)90215-X; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHOMYN A, 1987, CYTOCHROME SYSTEMS M, P145; CHOMYN A, 1992, BECHANISMS BIOENERGE, P483; CREWS S, 1980, CELL, V19, P775, DOI 10.1016/S0092-8674(80)80053-5; DARNELL JE, 1968, BACTERIOL REV, V32, P262, DOI 10.1128/MMBR.32.3.262-290.1968; DEBRUIJN MHL, 1980, NUCLEIC ACIDS RES, V8, P5213, DOI 10.1093/nar/8.22.5213; DENNIS PP, 1974, J BACTERIOL, V119, P270, DOI 10.1128/JB.119.1.270-281.1974; DUBIN DT, 1974, BIOCHIM BIOPHYS ACTA, V340, P269, DOI 10.1016/0005-2787(74)90272-X; DUBIN DT, 1982, J MOL BIOL, V157, P1, DOI 10.1016/0022-2836(82)90510-1; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GILLESPIE D, 1973, BIOCHEM GENET, V10, P175, DOI 10.1007/BF00485764; GOUY M, 1980, FEBS LETT, V115, P151, DOI 10.1016/0014-5793(80)81155-0; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; IKEMURA T, 1973, J BIOL CHEM, V248, P5033; JEANTEUR P, 1968, MOL CELL BIOL, V33, P757; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KNIGHT E, 1969, BIOCHEMISTRY-US, V8, P5089, DOI 10.1021/bi00840a062; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; LABBE D, 1990, J BIOL CHEM, V265, P2988; LIN JP, 1986, GENE, V49, P383, DOI 10.1016/0378-1119(86)90375-6; LYNCH DC, 1976, J MOL BIOL, V102, P125, DOI 10.1016/0022-2836(76)90077-2; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; MORAES CT, 1991, CURRENT NEUROLOGY, V11, P83; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; MURPHY WI, 1977, BIOCHEM BIOPH RES CO, V74, P291, DOI 10.1016/0006-291X(77)91407-3; NEIDHARDT FC, 1977, J BACTERIOL, V129, P378, DOI 10.1128/JB.129.1.378-387.1977; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; PURE GA, 1985, J MOL BIOL, V183, P31, DOI 10.1016/0022-2836(85)90278-5; Roe B. A., 1981, RECOMBINANT DNA, P167; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; SPANJAARD RA, 1990, NUCLEIC ACIDS RES, V18, P5031, DOI 10.1093/nar/18.17.5031; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; ULRICH AK, 1991, BIOCHIM BIOPHYS ACTA, V1089, P362, DOI 10.1016/0167-4781(91)90177-N; WALACE DC, 1992, ANN REV BIOCH, V61, P1175; WEISS WA, 1986, J MOL BIOL, V192, P725, DOI 10.1016/0022-2836(86)90024-0; YAMAO F, 1991, NUCLEIC ACIDS RES, V19, P6119, DOI 10.1093/nar/19.22.6119; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOZA BK, 1984, J BIOL CHEM, V259, P3909; ZYLBER E, 1969, J MOL BIOL, V46, P201, DOI 10.1016/0022-2836(69)90067-9	60	97	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10228	10237						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683672				2022-12-25	WOS:A1993LB80000043
J	SCHWALB, DM; HAN, HM; MARINO, M; WARREN, R; PORTER, A; GOH, C; FAIR, WR; DONNER, DB				SCHWALB, DM; HAN, HM; MARINO, M; WARREN, R; PORTER, A; GOH, C; FAIR, WR; DONNER, DB			IDENTIFICATION OF A NEW RECEPTOR SUBTYPE FOR TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-ENDOTHELIAL CELLS; PHASE-I TRIAL; FACTOR-BETA; MOLECULAR-CLONING; FACTOR TNF; LYMPHOTOXIN; EXPRESSION; PURIFICATION; MALIGNANCY; PROTEINS	Two distinct receptors, which bind both tumor necrosis factor-alpha and tumor necrosis factor-beta (TNF-alpha and TNF-beta), have been previously identified and cloned from transformed cells. The present study identifies a novel receptor subtype in normal human liver which binds TNF-alpha but not TNF-beta. TNF-alpha but not TNF-beta competes for I-125-TNF-alpha binding and incorporation into affinity-labeled complexes in human liver plasma membranes (HLPM). Antisera to the cloned receptors competed for I-125-TNF-alpha binding to plasma membranes isolated from various transformed cell lines but not to HLPM. However, mRNAs corresponding in size to both known TNF receptors were detected in liver RNA, making it likely that post-transcriptional modifications account for the TNF-alpha specificity of HLPM. These observations suggest that the effects of TNF-alpha and TNF-beta on some normal tissues may be more distinct than previously realized.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,SLOAN KETTERING DIV,NEW YORK,NY 10021; MEM HOSP CANC & ALLIED DIS,UROL SERV,NEW YORK,NY 10021; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore					NATIONAL CANCER INSTITUTE [R01CA044747] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44747] Funding Source: Medline; NIADDK NIH HHS [AM07313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS JS, 1990, J IMMUNOL, V144, P2582; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUDY VC, 1987, J IMMUNOL, V138, P4298; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; GAMM H, 1991, EUR J CANCER, V27, P856, DOI 10.1016/0277-5379(91)90134-Y; HAN HM, 1990, J BIOL CHEM, V265, P18590; HAYAKAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P323, DOI 10.1016/0003-9861(91)90047-M; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MEAGER A, 1989, J IMMUNOL METHODS, V116, P1, DOI 10.1016/0022-1759(89)90306-2; MIKI T, 1992, P NATL ACAD SCI USA, V89, P2246; OSTER W, 1987, BLOOD, V70, P1700; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PORTER A G, 1990, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V64, P193, DOI 10.1016/0378-1097(90)90609-T; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEOW HF, 1989, BIO-TECHNOL, V7, P363, DOI 10.1038/nbt0489-363; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STARNES HF, 1987, J CLIN INVEST, V80, P1384, DOI 10.1172/JCI113216; STAUBER GB, 1988, J BIOL CHEM, V263, P19098; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; VILCEK J, 1991, J BIOL CHEM, V266, P7313	22	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9949	9954						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683686				2022-12-25	WOS:A1993LB80000004
J	CAMPAGNONI, AT; PRIBYL, TM; CAMPAGNONI, CW; KAMPF, K; AMURUMARJEE, S; LANDRY, CF; HANDLEY, VW; NEWMAN, SL; GARBAY, B; KITAMURA, K				CAMPAGNONI, AT; PRIBYL, TM; CAMPAGNONI, CW; KAMPF, K; AMURUMARJEE, S; LANDRY, CF; HANDLEY, VW; NEWMAN, SL; GARBAY, B; KITAMURA, K			STRUCTURE AND DEVELOPMENTAL REGULATION OF GOLLI-MBP, A 105-KILOBASE GENE THAT ENCOMPASSES THE MYELIN BASIC-PROTEIN GENE AND IS EXPRESSED IN CELLS IN THE OLIGODENROCYTE LINEAGE IN THE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; TRANSGENIC SHIVERER MICE; CENTRAL-NERVOUS-SYSTEM; MOUSE-BRAIN; INSITU HYBRIDIZATION; MESSENGER-RNAS; IDENTIFICATION; TRANSCRIPTION; CULTURES; PROMOTER	We have identified a novel transcription unit of 105 kilobases (called the Golli-mbp gene) that encompasses the mouse myelin basic protein (MBP) gene. Three unique exons within this gene are alternatively spliced into MBP exons and introns to produce a family of MBP gene-related mRNAs that are under individual developmental regulation. These mRNAs are temporally expressed within cells of the oligodendrocyte lineage at progressive stages of differentiation. Thus, the MBP gene is a part of a more complex gene structure, the products of which may play a role in oligodendrocyte differentiation prior to myelination. One Golli-mbp mRNA that encodes a protein antigenically related to MBP is also expressed in the spleen and other non-neural tissues.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA; CNRS, INST BIOCHEM CELLULAIRE & NEUROCHEM, F-33077 BORDEAUX, FRANCE; SAITAMA MED SCH, DEPT PHYSIOL, MOROYAMA, SAITAMA 35004, JAPAN	Virginia Commonwealth University; Centre National de la Recherche Scientifique (CNRS); Saitama Medical University	CAMPAGNONI, AT (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, MENTAL RETARDAT RES CTR, LOS ANGELES, CA 90024 USA.			GARBAY, Bertrand/0000-0001-5756-2627	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023322, R01NS023022] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25831] Funding Source: Medline; NINDS NIH HHS [NS23022, NS23322] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMURUMARJEE SG, 1990, DEV NEUROSCI-BASEL, V12, P263, DOI 10.1159/000111855; AMURUMARJEE SG, 1990, DEV NEUROSCI-BASEL, V12, P251, DOI 10.1159/000111854; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; ARUGA J, 1991, J NEUROCHEM, V56, P1222, DOI 10.1111/j.1471-4159.1991.tb11414.x; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BANSAL G, 1987, J NEUROIMMUNOL, V15, P279, DOI 10.1016/0165-5728(87)90122-6; BARBARESE E, 1981, P NATL ACAD SCI-BIOL, V78, P1953, DOI 10.1073/pnas.78.3.1953; BARBARESE E, 1983, J NEUROCHEM, V40, P1680, DOI 10.1111/j.1471-4159.1983.tb08142.x; Bell R B, 1991, Semin Immunol, V3, P237; CAMERON RS, 1991, GLIA, V4, P124, DOI 10.1002/glia.440040204; CAMPAGNONI AT, 1974, J NEUROCHEM, V23, P887, DOI 10.1111/j.1471-4159.1974.tb04422.x; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DIVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HRUBY S, 1987, MOL IMMUNOL, V24, P1359, DOI 10.1016/0161-5890(87)90132-5; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KIMURA M, 1989, P NATL ACAD SCI USA, V86, P5661, DOI 10.1073/pnas.86.14.5661; KITAMURA K, 1990, J NEUROCHEM, V54, P2032, DOI 10.1111/j.1471-4159.1990.tb04908.x; KNAPP PE, 1991, J NEUROSCI RES, V30, P336, DOI 10.1002/jnr.490300209; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDRY CF, 1989, MOL BRAIN RES, V6, P251, DOI 10.1016/0169-328X(89)90071-5; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MISKIMINS R, 1992, DEV BRAIN RES, V65, P217, DOI 10.1016/0165-3806(92)90182-V; MIURA M, 1989, GENE, V75, P31; MOLINEAUX SM, 1986, P NATL ACAD SCI USA, V83, P7542, DOI 10.1073/pnas.83.19.7542; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; READHEAD C, 1990, ANN NY ACAD SCI, V605, P280; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; SUZUMURA A, 1984, BRAIN RES, V324, P379, DOI 10.1016/0006-8993(84)90054-4; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; VERDI JM, 1990, J BIOL CHEM, V265, P20314; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	41	212	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4930	4938						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680345				2022-12-25	WOS:A1993KP88400057
J	AMLER, LC; CORVI, R; PRAML, C; SAVELYEVA, L; LEPASLIER, D; SCHWAB, M				AMLER, LC; CORVI, R; PRAML, C; SAVELYEVA, L; LEPASLIER, D; SCHWAB, M			A RECIPROCAL TRANSLOCATION (1-15) (36.2-Q24) IN A NEUROBLASTOMA CELL-LINE IS ACCOMPANIED BY DNA DUPLICATION AND MAY SIGNAL THE SITE OF A PUTATIVE TUMOR SUPPRESSOR-GENE	ONCOGENE			English	Article						D1S1160/D1S244; PEDIATRIC YEAST ARTIFICIAL CHROMOSOME (YAC); FLUORESCENCE IN SITU HYBRIDIZATION (FISH)	HUMAN NEURO-BLASTOMA; YEAST ARTIFICIAL CHROMOSOMES; N-MYC AMPLIFICATION; HUMAN GENOME; SHORT ARM; INSITU HYBRIDIZATION; LINKAGE MAP; HETEROZYGOSITY; ABNORMALITIES; DEFINITION	Cytogenetic analyses and molecular deletion studies of human neuroblastomas have indicated the chromosomal bands 1p36.1-1p36.2 as a location of genetic information which may be involved in tumorigenesis. To define this putative neuroblastoma locus in more detail we have analysed cell lines with alterations of distal Ip, Here we show, by fluorescence in situ hybridization (FISH), that cell line NGP has a reciprocal 1;15 translocation. Loci D1S214/D1S96 could be shown to map telomeric/distal, D1S228 centromeric/proximal to the break, We have identified yeast artificial chromosomes (YACs) that cover the break and map to D1S160 and D1S244. This chromosomal position is within the smallest region of overlap (SRO) found in neuroblastoma tumors (Weith et al., 1989; Caron et al., 1993; Schleiermacher ct al., 1994) and within the region of a constitutional interstitial deletion of a neuroblastoma patient (Biegel et al., 1993). Mapping studies with FISH revealed that the translocation is associated with duplication of DNA. It appears, as if the subchromosomal region we describe here is a good candidate for harboring the postulated neuroblastoma suppressor-gene.	CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE		AMLER, LC (corresponding author), GERMAN CANC RES CTR,DEPT CYTOGENET,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.			Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BARILLOT E, 1992, NUCLEIC ACIDS RES, V19, P6241; BARKER PE, 1993, ONCOGENE, V8, P3353; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; CARON H, 1994, AM J HUM GENET, V55, P341; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DONTI E, 1988, CANCER GENET CYTOGEN, V30, P225, DOI 10.1016/0165-4608(88)90188-4; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GILBERT F, 1984, CANCER RES, V44, P5444; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUNT JD, 1990, GENE CHROMOSOME CANC, V2, P137, DOI 10.1002/gcc.2870020210; LAHTI MJ, 1994, NAT GENET, V7, P370; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LAUREYS G, IN PRESS ONCOGENE; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; PIETSCH T, 1988, ANTICANCER RES, V8, P1329; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; Sambrook J, 1989, J SAMBROOK MOL CLONI; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHAFER BW, 1993, GENOMICS, V17, P249, DOI 10.1006/geno.1993.1315; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1982, J IMMUNOL, V128, P983; SEEGER RC, 1977, CANCER RES, V37, P1364; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WADA RK, 1988, ADV NEUROBLASTOMA RE, V2, P57; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WELCH HM, 1989, GENOMICS, V5, P423, DOI 10.1016/0888-7543(89)90005-0	45	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1095	1101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700634				2022-12-25	WOS:A1995QN35300009
J	CAI, H; BLOOM, LB; ERITJA, R; GOODMAN, MF				CAI, H; BLOOM, LB; ERITJA, R; GOODMAN, MF			KINETICS OF DEOXYRIBONUCLEOTIDE INSERTION AND EXTENSION AT ABASIC TEMPLATE LESIONS IN DIFFERENT SEQUENCE CONTEXTS USING HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC-APYRIMIDINIC SITES; DNA POLYMERASE-ALPHA; ESCHERICHIA-COLI; REPAIR ENZYMES; BASE PAIR; MUTAGENESIS; OPPOSITE; FIDELITY; SPECIFICITY; MECHANISM	Deoxyribonucleotide insertion efficiencies were measured opposite site-directed abasic template lesions using human immunodeficiency virus 1 reverse transcriptase (HIV-1RT), and the efficiencies to continue primer synthesis beyond the lesion, by addition of the ''next correct'' deoxynucleotide, were measured as a function of sequence context. Insertion of purines was favored over pyrimidines, A > G > T is similar to C. Primer extension past the lesion occurred by two distinct mechanisms, either by direct or by misalignment extension. An ''A-rule'' appeared to hold for the case of direct extension, where the abasic template moiety is intrahelical, aligned opposite the primer 3'-terminus. In misalignment extension, the primer terminus is realigned from a site directly opposite the lesion to a new position opposite a neighboring template base 5' to the lesion. Direct extension efficiencies were measured in 16 different configurations, by varying 4 bases at the primer 3'-termini and 4 at the 5'-side (downstream) of the lesion. The predominant order of direct extension was A > G > T is similar to C, similar to that observed for insertion. Reduced primer extension rates were not caused by a reduction in HIV-1 RT-DNA binding. Primers terminating in C showed inefficient direct extension, but were readily extended via misaligned configurations. The ratios of direct-to-misalignment extension efficiencies were 27:1, 2.5:1, and 1:25 for A, G, and C opposite the lesion, respectively. For the case of primers terminating in T, misalignment extension was not observed. A striking result was that while primers were extended past an abasic lesion by HIV-1 RT in both direct and misalignment modes, avian myeloblastosis virus RT failed to catalyze significant extension by either mode.	CTR RES & DEV, DEPT MOLEC GENET, E-08034 BARCELONA, SPAIN		CAI, H (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA.		Bloom, Linda B/F-3684-2014; Eritja, Ramon/B-5613-2008	Eritja, Ramon/0000-0001-5383-9334	NIA NIH HHS [AG11398] Funding Source: Medline; NIGMS NIH HHS [GM21422, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422, R01GM042554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; ERITJA R, 1987, NUCLEOS NUCLEOT, V6, P803, DOI 10.1080/15257778708073426; GENTIL A, 1990, BIOCHEM BIOPH RES CO, V173, P704, DOI 10.1016/S0006-291X(05)80092-0; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KLINEDINST DK, 1992, MOL CARCINOGEN, V6, P32, DOI 10.1002/mc.2940060107; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; NG L, 1989, J BIOL CHEM, V264, P13018; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888	36	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23567	23572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693691				2022-12-25	WOS:A1993MF51500093
J	SOWERS, KR; THAI, TT; GUNSALUS, RP				SOWERS, KR; THAI, TT; GUNSALUS, RP			TRANSCRIPTIONAL REGULATION OF THE CARBON-MONOXIDE DEHYDROGENASE GENE (CDHA) IN METHANOSARCINA-THERMOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL COENZYME-M; RNA-POLYMERASE-BINDING; METHANOCOCCUS-VANNIELII; ENZYME COMPLEX; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOTHRIX-SOEHNGENII; NUCLEOTIDE-SEQUENCE; PLASMID DNA; M REDUCTASE; ACETYL-COA	The mechanisms of gene regulation in the phylogenetic domain Archaea are not yet understood. To examine the expression of a gene encoding a highly regulated catabolic enzyme from the methanogenic archaea, a Methanosarcina thermophila lambdagt11 chromosomal library was probed with antiserum prepared against the 89-kDa subunit of carbon monoxide dehydrogenase, an enzyme which is required for growth and methanogenesis from acetate. A 2.3-kilobase DNA fragment was isolated that encoded 300 bases of the 5'-end of cdhA, the gene which encodes the 89-kDa subunit, and 2 kilobases upstream of cdhA that included an upstream open reading frame (ORF1). Primer extension analyses determined that cdhA and ORF1 each had a single transcriptional initiation site located 370 and 9 nucleotides, respectively, 5' of the putative translation initiation codons for cdhA and ORF1. Each promoter element had sequence similarity to a consensus archaeal promoter sequence. Three discrete mRNA cdhA transcripts of 9.5, 5.6, and 4.8 kilobases and one mRNA ORF1 transcript of <2 kilobases were identified. All four transcripts were optimally expressed in cells grown with acetate, while growth with the more energetically favorable substrates methanol and trimethylamine caused a significant reduction in levels of the cdhA and ORF1 mRNA's. The half-lives of the 5' ends of the three cdhA transcripts and entire ORF1 mRNA transcript were approximately 2 min upon addition of methanol to cells growing exponentially in medium that contained acetate. Results of this study demonstrate that transcription of both cdhA and ORF1 is highly regulated in response to substrate by this methanogenic archaeon.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALLMANSBERGER R, 1988, NUCLEIC ACIDS RES, V16, P7419, DOI 10.1093/nar/16.15.7419; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOKRANZ M, 1988, J BACTERIOL, V170, P568, DOI 10.1128/jb.170.2.568-577.1988; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; BROWN JW, 1988, NUCLEIC ACIDS RES, V16, P135, DOI 10.1093/nar/16.1.135; BROWN JW, 1989, FEMS MICROBIOL LETT, V60, P131, DOI 10.1111/j.1574-6968.1989.tb03432.x; CLEMENTS AP, 1992, J BACTERIOL, V174, P5244, DOI 10.1128/JB.174.16.5244-5250.1992; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER R, 1988, FEBS LETT, V228, P249, DOI 10.1016/0014-5793(88)80009-7; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; HANNAHAN D, 1983, J MOL BIOL, V166, P557; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JETTEN MSM, 1989, EUR J BIOCHEM, V181, P437, DOI 10.1111/j.1432-1033.1989.tb14744.x; KRZYCKI JA, 1985, J BACTERIOL, V163, P1000, DOI 10.1128/JB.163.3.1000-1006.1985; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDIE LL, 1989, J BIOL CHEM, V264, P18392; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MURAKAWA GJ, 1991, J BACTERIOL, V173, P28, DOI 10.1128/jb.173.1.28-36.1991; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; NELSON MJK, 1984, J BACTERIOL, V160, P526, DOI 10.1128/JB.160.2.526-532.1984; OSHIMA T, 1986, THERMOPHILES GENERAL, P137; PATEL PS, 1988, J BACTERIOL, V170, P3390, DOI 10.1128/jb.170.8.3390-3395.1988; REEVE JN, 1992, ANNU REV MICROBIOL, V46, P165; Sambrook J, 1989, MOL CLONING LABORATO; SMITH MR, 1978, APPL ENVIRON MICROB, V36, P870, DOI 10.1128/AEM.36.6.870-879.1978; SOWERS KR, 1988, J BACTERIOL, V170, P998, DOI 10.1128/jb.170.2.998-1002.1988; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; THOMM M, 1988, J BACTERIOL, V170, P1958, DOI 10.1128/jb.170.4.1958-1961.1988; WEIL CF, 1988, J BACTERIOL, V170, P4718, DOI 10.1128/jb.170.10.4718-4726.1988; WHITE WB, 1992, J BACTERIOL, V174, P4997, DOI 10.1128/JB.174.15.4997-5004.1992; WICH G, 1986, NUCLEIC ACIDS RES, V14, P2459, DOI 10.1093/nar/14.6.2459; WIDDEL F, 1989, ARCH MICROBIOL, V152, P322, DOI 10.1007/BF00425168; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZINDER SH, 1985, J BACTERIOL, V163, P317, DOI 10.1128/JB.163.1.317-323.1985	47	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23172	23178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693685				2022-12-25	WOS:A1993MF51500036
J	TIMERMAN, AP; OGUNBUMNI, E; FREUND, E; WIEDERRECHT, G; MARKS, AR; FLEISCHER, S				TIMERMAN, AP; OGUNBUMNI, E; FREUND, E; WIEDERRECHT, G; MARKS, AR; FLEISCHER, S			THE CALCIUM-RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM IS MODULATED BY FK-506-BINDING PROTEIN - DISSOCIATION AND RECONSTITUTION OF FKBP-12 TO THE CALCIUM-RELEASE CHANNEL OF SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-BINDING-PROTEIN; JUNCTIONAL TERMINAL CISTERNAE; RYANODINE RECEPTOR; CYCLOSPORINE-A; CA-2+ RELEASE; CYCLOPHILIN; FK-506; FK506; PURIFICATION; RAPAMYCIN	The ryanodine receptor/calcium release channel (CRC) of rabbit skeletal muscle terminal cisternae (TC) of sarcoplasmic reticulum (SR) has been found to be tightly associated with FK-506 binding protein (FKBP-12), the cytosolic receptor (immunophilin) for the immunosuppressant drug FK-506 (Jayaraman, T., Brillantes, A. M., Timerman, A. P., Fleischer, S., Erdjument-Bromage, H., Tempst, P., and Marks, A. (1992) J. Biol. Chem. 267, 9474-9477). In this study, a procedure is described to dissociate FKBP from TC and reconstitute human recombinant FKBP-12 back to the ryanodine receptor so that the role of the immunophilin on CRC activity can be assessed. Titration of TC vesicles with FK-506 dissociates FKBP from the ryanodine receptor. Sedimentation of FK-506-treated vesicles effectively separates the TC from the soluble FKBP-FK506 complex which remains in the supernatant. The FKBP-deficient TC vesicles have altered functional characteristics: 1) the ATP-stimulated calcium uptake rate of TC vesicles is reduced 2-fold; and 2) the threshold concentration of caffeine required to induce calcium release from TC vesicles is decreased. These changes appear to reflect modification of the calcium release channel since: 1) severalfold higher concentrations of FK-506 do not alter the calcium uptake rate of either longitudinal tubules of SR, or TC vesicles in the presence of ruthenium red; 2) human recombinant FKBP reassociates with FKBP-deficient TC but not with control TC or longitudinal tubules of SR; and 3) the reduced Ca2+ uptake rate in FKBP-deficient TC is restored to control values in the FKBP-reconstituted TC. These studies demonstrate that FKBP-12 modulates the CRC of rabbit skeletal muscle sarcoplasmic reticulum.	VANDERBILT UNIV,DEPT MOLEC BIOL,NASHVILLE,TN 37235; MERCK RES LABS,RAHWAY,NJ 07065; MERCK RES LABS,RAHWAY,NJ 07065; MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL & MOLEC MED,NEW YORK,NY 10021	Vanderbilt University; Merck & Company; Merck & Company; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHU A, 1987, ARCH BIOCHEM BIOPHYS, V248, P13; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1983, J MUSCLE RES CELL M, V4, P233, DOI 10.1007/BF00712033; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; PALADE P, 1987, J BIOL CHEM, V262, P6135; SAITO A, 1989, Biophysical Journal, V55, p206A; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1991, TRANSPLANT P, V23, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH KA, 1988, INTERLEUKIN, V2, P1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	332	337	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22992	22999						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693682				2022-12-25	WOS:A1993MF51500009
J	SIDOLI, A; TAMBORINI, E; GIUNTINI, I; LEVI, S; VOLONTE, G; PAINI, C; DELALLA, C; SICCARDI, AG; BARALLE, FE; GALLIANI, S; AROSIO, P				SIDOLI, A; TAMBORINI, E; GIUNTINI, I; LEVI, S; VOLONTE, G; PAINI, C; DELALLA, C; SICCARDI, AG; BARALLE, FE; GALLIANI, S; AROSIO, P			CLONING, EXPRESSION, AND IMMUNOLOGICAL CHARACTERIZATION OF RECOMBINANT LOLIUM-PERENNE ALLERGEN LOL P-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRASS POLLEN ALLERGEN; AMINO-ACID-SEQUENCE; DUST MITE ALLERGEN; FERRITIN-H-CHAIN; ESCHERICHIA-COLI; MAJOR ALLERGEN; CDNA CLONING; SKIN-TEST; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS	The molecular cloning of the cDNA encoding for an isoallergenic form of Lol p II, a major rye grass (Lolium perenne) pollen allergen, was performed by polymerase chain reaction amplification on mRNA extracted from pollen. The amino acid sequence derived from the cDNA was truncated by 4 and 5 residues at the NH2- and COOH-terminal ends, respectively, and differed only in one position from that previously reported. This cDNA was expressed in Escherichia coli by fusion to the carboxyl terminus of the human ferritin H-chain. The molecule was produced in high yields as a soluble protein and was easily purified. The protein retains the multimeric quaternary structure of ferritin, and it exposes on the surface the allergenic moiety, which can be recognized in Western blotting and in enzyme-linked immunosorbent assay experiments by specific IgE from allergic patients. The recombinant allergen was used to analyze the sera of 26 patients allergic to L. perenne compared with control sera. The results were in good agreement with the values obtained with the radioallergosorbent test assay. In addition, histamine release experiments in whole blood from an allergic patient and skin prick tests showed that the recombinant allergen retains some of the biological properties of the natural compound. These findings indicate that the availability of homogeneous recombinant allergens may be useful for the development of more specific diagnostic and therapeutic procedures. Moreover, this expression system may be of more general interest for producing large amounts of soluble protein domains in E. coli.	BYK GULDEN ITALIA SPA,I-20100 MILAN,ITALY; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; PRIMM SRL,I-20134 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO SCI & TECNOL BIOMED,I-20122 MILAN,ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan	SIDOLI, A (corresponding author), IST SCI H SAN RAFFAELE,DIPARTIMENTO RIC BIOL & TECNOL,VIA OLGETTINA 58,I-20132 MILAN,ITALY.		arosio, paolo/E-6817-2010; Tamborini, Elena/C-3307-2017; levi, sonia/A-3161-2015	Tamborini, Elena/0000-0002-3819-8687; levi, sonia/0000-0002-5092-0847; Baralle, Francisco/0000-0002-4645-2809; arosio, paolo/0000-0002-5343-8992				ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; ANSARI AA, 1989, J BIOL CHEM, V264, P11181; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BALDO BA, 1988, ALLERGY, V43, P81; BASKAR S, 1992, J IMMUNOL, V148, P2378; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1987, GENE, V51, P269, DOI 10.1016/0378-1119(87)90315-5; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LUZZAGO A, 1989, EMBO J, V8, P569, DOI 10.1002/j.1460-2075.1989.tb03411.x; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MOSER M, 1992, J IMMUNOL, V149, P454; NELSON HS, 1983, ANN ALLERGY, V51, P411; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; RAFNAR T, 1992, J BIOL CHEM, V267, P2119; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANTAMBROGIO P, 1992, J BIOL CHEM, V2672, P14077; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHEN HD, 1991, CLIN EXP ALLERGY, V21, P675, DOI 10.1111/j.1365-2222.1991.tb03195.x; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH DJ, 1989, INT ARCH ALLER A IMM, V90, P78, DOI 10.1159/000235004; 1989, ALLERGY CPH, V44, P369	40	32	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21819	21825						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691817				2022-12-25	WOS:A1993MC80900060
J	MENG, QH; CALABRESI, L; FRUCHART, JC; MARCEL, YL				MENG, QH; CALABRESI, L; FRUCHART, JC; MARCEL, YL			APOLIPOPROTEIN-A-I DOMAINS INVOLVED IN THE ACTIVATION OF LECITHIN - CHOLESTEROL ACYLTRANSFERASE - IMPORTANCE OF THE CENTRAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; GRADIENT GEL-ELECTROPHORESIS; MICELLAR COMPLEXES; PHOSPHATIDYLCHOLINE; EPITOPES	The reaction of highly purified lecithin:cholesterol acyltransferase (LCAT) with defined reconstituted discoidal apoA-I-containing lipoproteins (LpA-I) with 2, 3, or 4 apoA-I molecules/particle (Lp2, 3, or 4A-I) has been studied in the presence of a number of specific anti apoA-I antibodies. Among nine anti-apoA-I monoclonal antibodies (mAbs) reacting with epitopes distributed over 80% of the sequence, three significantly inhibit the LCAT reaction with all particles. The position of their epitopes located in the middle to COOH-terminal region between residues 96-121 (3G10), 135-148 (A03), and 149-186 (A44) is compatible with an inhibition by steric hindrance over a central domain. Antibody 4H1 binding to the NH2 terminus (residues 2-8) profoundly increases (5-fold) the LCAT reaction with Lp2A-I (7.8 nm), but not with other particles. Other mAbs, A11 and 5F6, binding to epitopes (residues 99-139 and 118-141) enhance LCAT reactivity with the small Lp2A-I (7.8 nm) and Lp3A-I (10.8 nm) but not with their larger counterparts. Most mAbs have similar effects on LCAT reaction with native high density lipoprotein3 as with LpA-I. The inhibitory or enhancing effects of these mAbs are also observed with Fab fragments and not related to their binding affinity for apoA-I containing reconstituted lipoprotein particles. The intercalation of epitopes for mAbs that inhibit or enhance LCAT reaction with small LpA-I is compatible not with steric hindrance but with conformational modifications of apoA-I and indirectly of the lipids in small particles. We propose that enhancing mAbs act by stabilization of an apoA-I conformation which is not favored in small LpA-I, i.e. by increasing binding of amphipathic helices to lipids or by interfering with the mobility of a hinged domain. The epitopes for the inhibitory mAbs can be shown to overlap on several LpA-I models, indicating that steric hindrance over a single site is a possible mechanism of inhibition.	UNIV OTTAWA,OTTAWA HEART INST,LIPOPROT & ATHEROSCLEROSIS GRP,1053 CARLING AVE,OTTAWA K1Y 4E9,ONTARIO,CANADA; INST PASTEUR,SERV ETUD & RECH LIPIDES & ATHEROSCLEROSE,F-59019 LILLE,FRANCE	University of Ottawa; University of Ottawa Heart Institute; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Calabresi, Laura/0000-0001-5042-9532				BANKA CL, 1991, J BIOL CHEM, V266, P23886; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CALABRESI L, 1993, IN PRESS BIOCHEMISTR; CHEN CH, 1982, J LIPID RES, V23, P680; CHEUNG MC, 1987, J LIPID RES, V28, P913; COLLET X, 1991, J BIOL CHEM, V266, P9145; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; GLOMSET JA, 1972, BLOOD LIPIDS LIPOPRO, P745; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILNE R, 1987, MOL IMMUNOL, V24, P127, DOI 10.1016/0161-5890(87)90084-8; MILTHORP P, 1986, HUMAN APOLIPOPROTEIN, P103; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; PETIT E, 1987, BIOCHIM BIOPHYS ACTA, V919, P287, DOI 10.1016/0005-2760(87)90268-2; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; WALD JH, 1990, J BIOL CHEM, V265, P20037; WILLIAMS PT, 1990, J LIPID RES, V31, P1131	28	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16966	16973						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688720				2022-12-25	WOS:A1993LQ98800016
J	ENDEMANN, G; STANTON, LW; MADDEN, KS; BRYANT, CM; WHITE, RT; PROTTER, AA				ENDEMANN, G; STANTON, LW; MADDEN, KS; BRYANT, CM; WHITE, RT; PROTTER, AA			CD36 IS A RECEPTOR FOR OXIDIZED LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; ENHANCED MACROPHAGE DEGRADATION; MONOCLONAL-ANTIBODY; SCAVENGER RECEPTOR; HUMAN-MONOCYTES; INFECTED ERYTHROCYTES; PLATELET ACTIVATION; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS	The oxidation of low density lipoprotein (LDL) in the arterial wall is thought to contribute to human atherosclerotic lesion formation, in part by the high affinity uptake of oxidized LDL (OxLDL) by macrophages, resulting in foam cell formation. We have utilized cloning by expression to identify CD36 as a macrophage receptor for OxLDL. Transfection of a CD36 clone into 293 cells results in the specific and high affinity binding of OxLDL, followed by its internalization and degradation. An anti-CD36 antibody blocks 50% of the binding of OxLDL to platelets and to human macrophage-like THP cells. Furthermore, like mouse macrophages, 293 cells expressing CD36 recognize LDL which has been oxidized only 4 h, whereas more extensive oxidation of the LDL is required for recognition by the other known OxLDL receptors, the acetylated LDL (AcLDL) receptor and FcgammaRII-B2. CD36 may play a role in scavenging LDL modified by oxidation and may mediate effects of OxLDL on monocytes and platelets in atherosclerotic lesions.			ENDEMANN, G (corresponding author), SCIOS NOVA INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043, USA.				NHLBI NIH HHS [1R43 HL47220-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL047220] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN ML, 1990, BLOOD, V76, P2501; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; FONG LG, 1987, J LIPID RES, V28, P1466; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORSEWOOD P, 1991, BLOOD, V78, P1019; KAMPS JAAM, 1992, ARTERIOSCLER THROMB, V12, P1079, DOI 10.1161/01.ATV.12.9.1079; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P178, DOI 10.1161/01.ATV.10.2.178; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VALONE FH, 1979, IMMUNOLOGY, V37, P841; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; YAMAMOTO N, 1990, THROMB HAEMOSTASIS, V63, P97; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	45	1065	1096	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11811	11816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685021				2022-12-25	WOS:A1993LF28400054
J	LUTZ, MP; SUTOR, SL; ABRAHAM, RT; MILLER, LJ				LUTZ, MP; SUTOR, SL; ABRAHAM, RT; MILLER, LJ			A ROLE FOR CHOLECYSTOKININ-STIMULATED PROTEIN-TYROSINE PHOSPHORYLATION IN REGULATED SECRETION BY THE PANCREATIC ACINAR CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; KINASE-C; ENZYME-SECRETION; AMYLASE SECRETION; GROWTH-FACTOR; INTACT-CELLS; RECEPTOR; STAUROSPORINE; BOMBESIN; CALCIUM	Cholecystokinin (CCK) is a gastrointestinal hormone that acts through a G protein-coupled receptor to stimulate pancreatic enzyme secretion. In this work, we demonstrate that CCK stimulation of dispersed pancreatic acini results in increased tyrosine phosphorylation of several cellular proteins. This is mediated via a calcium-dependent pathway, also activated by a phenethyl ester analogue of CCK and calcium ionophores, and by a protein kinase C-dependent cascade, also activated by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. All demonstrable stimulated tyrosine phosphorylation events were inhibited by genistein, with different subsets of proteins affected by staurosporine and H-7. The importance of tyrosine phosphorylation events in agonist-stimulated amylase secretion was studied using genistein and staurosporine as protein kinase inhibitors. Genistein inhibited the secretory response to CCK, its phenethyl ester analogue, and calcium ionophores, all known to stimulate secretion in a calcium-dependent fashion. In contrast, genistein had no effect on the secretory response to 12-O-tetradecanoylphorbol-13-acetate, suggesting that the protein kinase C-dependent tyrosine phosphorylation events were not involved in the secretory mechanism. Furthermore, CCK-induced secretion was not affected by relatively specific protein kinase C inhibition by H-7, but was decreased by staurosporine, an inhibitor of both protein kinase C and tyrosine kinase activities in these cells. These results provide evidence that acinar cell tyrosine phosphorylation is stimulated by agonists acting via calcium-dependent and protein kinase C-dependent pathways, with only the calcium-dependent tyrosine phosphorylation cascade involved in triggering hormone-induced amylase release.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,GUGGENHEIM 17,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic				Lutz, Manfred/0000-0003-1989-4553	PHS HHS [D32878] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; EDERVEEN AGH, 1990, EUR J BIOCHEM, V193, P291, DOI 10.1111/j.1432-1033.1990.tb19335.x; FREEDMAN SD, 1982, J CELL BIOL, V95, P903, DOI 10.1083/jcb.95.3.903; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JENA BP, 1991, J BIOL CHEM, V266, P17744; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KUSUI T, 1991, BIOCHIM BIOPHYS ACTA, V1094, P231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LOGSDON CD, 1986, AM J PHYSIOL, V251, pG487, DOI 10.1152/ajpgi.1986.251.4.G487; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; PANDOL SJ, 1986, J BIOL CHEM, V261, P4438; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SCHULTZ GS, 1980, EXP CELL RES, V130, P49, DOI 10.1016/0014-4827(80)90041-5; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VERME TB, 1989, AM J PHYSIOL, V257, pG548, DOI 10.1152/ajpgi.1989.257.4.G548; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WILLIAMS JA, 1980, AM J PHYSIOL, V238, pG269, DOI 10.1152/ajpgi.1980.238.4.G269; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	29	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11119	11124						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684371				2022-12-25	WOS:A1993LD46600061
J	CONRAD, KP; JOFFE, GM; KRUSZYNA, H; KRUSZYNA, R; ROCHELLE, LG; SMITH, RP; CHAVEZ, JE; MOSHER, MD				CONRAD, KP; JOFFE, GM; KRUSZYNA, H; KRUSZYNA, R; ROCHELLE, LG; SMITH, RP; CHAVEZ, JE; MOSHER, MD			IDENTIFICATION OF INCREASED NITRIC-OXIDE BIOSYNTHESIS DURING PREGNANCY IN RATS	FASEB JOURNAL			English	Note						PSEUDOPREGNANCY; NITRATE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE; NITRIC OXIDE HEMOGLOBIN; ELECTRON PARAMAGNETIC RESONANCE SPECTROSCOPY	CYCLIC GUANOSINE-MONOPHOSPHATE; L-ARGININE; URINARY-EXCRETION; NITRATE BIOSYNTHESIS; BIOLOGICAL-ACTIVITY; CONSCIOUS RATS; PLASMA; CELLS; HYPERTENSION; MACROPHAGES	We reported previously that plasma levels. urinary excretion, and metabolic production of cyclic guanosine 3',5'-monophosphate (cGMP) are increased in gravid rats, and postulated that endogenous nitric oxide (NO), a potent vasodilator and immune modulator, may mediate this change. Four lines of evidence are now presented demonstrating increased biosynthesis of NO during pregnancy in rats: 1) Urinary excretion and plasma levels of the stable NO metabolite, nitrate, are elevated in pregnant rats; urinary excretion of nitrate is increased in pseudopregnant rats. 2) The urinary excretion of cGMP also increases during pregnancy and pseudopregnancy, paralleling the rise in urinary nitrate excretion. 3) Chronic treatment with the NO synthase inhibitor, N(G)-nitroarginine methyl ester (NAME), inhibits the increase in urinary nitrate excretion. 4) Nitric oxide hemoglobin is detected by electron paramagnetic resonance spectroscopy in the blood of pregnant, but not in nonpregnant, rats. The results show endogenous NO production is increased in gravid rats. This finding raises the possibility that NO may contribute to maternal vasodilation and uterine immune suppression of normal pregnancy.	UNIV NEW MEXICO,SCH MED,DEPT PHYSIOL & OBSTET & GYNECOL,ALBUQUERQUE,NM 87131; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756	University of New Mexico; Dartmouth College					NHLBI NIH HHS [HL14127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBINA JE, 1991, J IMMUNOL, V147, P144; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; ATHERTON JC, 1982, J PHYSIOL-LONDON, V330, P81, DOI 10.1113/jphysiol.1982.sp014330; BAYLIS C, 1987, AM J PHYSIOL, V253, pF158, DOI 10.1152/ajprenal.1987.253.1.F158; BAYLIS C, 1982, AM J PHYSIOL, V234, pF300; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CHESLEY LC, 1971, OBSTET GYNECOL, V38, P1; CONRAD KP, 1987, AM J PHYSIOL, V253, pF1197, DOI 10.1152/ajprenal.1987.253.6.F1197; CONRAD KP, 1984, KIDNEY INT, V26, P24, DOI 10.1038/ki.1984.129; CONRAD KP, 1989, AM J PHYSIOL, V257, pR847, DOI 10.1152/ajpregu.1989.257.4.R847; CONRAD KP, 1991, J CLIN INVEST, V87, P1700, DOI 10.1172/JCI115187; CONRAD KP, 1986, J CLIN INVEST, V77, P236, DOI 10.1172/JCI112282; CONRAD KP, 1992, UROL ANN, V6, P313; DAVIDGE ST, 1992, AM J OBSTET GYNECOL, V167, P1691, DOI 10.1016/0002-9378(92)91763-Z; FEINBERG BB, 1991, CLIN OBSTET GYNECOL, V34, P3, DOI 10.1097/00003081-199103000-00005; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; GARNER GB, 1956, ANAL CHEM, V28, P1589, DOI 10.1021/ac60118a026; GERBER JG, 1981, J CLIN INVEST, V67, P632, DOI 10.1172/JCI110077; GERZER R, 1985, J CLIN ENDOCR METAB, V61, P1217, DOI 10.1210/jcem-61-6-1217; GILSON GJ, 1992, AM J PHYSIOL, V263, pH1911, DOI 10.1152/ajpheart.1992.263.6.H1911; GOODMAN RP, 1982, AM J OBSTET GYNECOL, V142, P817, DOI 10.1016/S0002-9378(16)32525-X; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; GROENENDIJK R, 1984, AM J OBSTET GYNECOL, V150, P232, DOI 10.1016/S0002-9378(84)90357-0; HARRISON GL, 1989, AM J OBSTET GYNECOL, V160, P258, DOI 10.1016/0002-9378(89)90132-4; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; HUNT JS, 1992, IMMUNOLOGICAL OBSTET, P73; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; JANSAKUL C, 1989, J ENDOCRINOL, V120, P113, DOI 10.1677/joe.0.1200113; KOPP L, 1977, J CLIN ENDOCR METAB, V44, P590, DOI 10.1210/jcem-44-3-590; KRUSZYNA H, 1987, TOXICOL APPL PHARM, V91, P429, DOI 10.1016/0041-008X(87)90064-0; LEAF CD, 1989, BIOCHEM BIOPH RES CO, V163, P1032, DOI 10.1016/0006-291X(89)92325-5; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MILLS CD, 1991, J IMMUNOL, V146, P2719; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NADEN RP, 1985, AM J OBSTET GYNECOL, V151, P484, DOI 10.1016/0002-9378(85)90275-3; NISELL H, 1985, CLIN PHYSIOL, V5, P479, DOI 10.1111/j.1475-097X.1985.tb00779.x; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REDMAN CWG, 1990, FETAL MED REV, V2, P21; ROBSON SC, 1989, AM J PHYSIOL, V256, pH1060, DOI 10.1152/ajpheart.1989.256.4.H1060; SABAI BM, 1991, CLIN OBSTET GYNECOL, V34, P27; WAGNER DA, 1983, CANCER RES, V43, P1921; WILCOX DE, 1990, CHEM RES TOXICOL, V3, P71, DOI 10.1021/tx00013a012	50	400	416	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					566	571		10.1096/fasebj.7.6.7682524	http://dx.doi.org/10.1096/fasebj.7.6.7682524			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	7682524				2022-12-25	WOS:A1993KY00900010
J	BLANCHOIN, L; FIEVEZ, S; TRAVERS, F; CARLIER, MF; PANTALONI, D				BLANCHOIN, L; FIEVEZ, S; TRAVERS, F; CARLIER, MF; PANTALONI, D			KINETICS OF THE INTERACTION OF MYOSIN SUBFRAGMENT-L WITH G-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; DEOXYRIBONUCLEASE-I; DNASE-I; TROPONIN-TROPOMYOSIN; ACTOMYOSIN ATPASE; BINDING-SITES; COMPLEX; POLYMERIZATION; CONTRACTION	The kinetics of interaction of monomeric pyrenyl-labeled G-actin with myosin subfragment-1 (S-1 (A(1)) and S-1(A(2)) isomers) has been examined in the stopped-flow at low ionic strength, The data confirm the previously reported existence of binary GS and ternary G(2)S complexes, The increase in pyrenyl-actin fluorescence which monitors the G-actin-S1 interactions is linked to the isomerization of these complexes following rapid equilibrium binding steps, The rates of isomerization are similar to 200 s(-1) for GS and similar to 50 s(-1) for G(2)S at 4 degrees C and in the absence of ATP, DNaseI and S-1 bind G-actin essentially in a mutually exclusive fashion, Both GS and G(2)S are dissociated by MgATP and MgADP, The kinetics and mechanism of ATP-induced dissociation of G(2)S are quantitatively close to the ATP-induced dissociation of F-actin-S-1, which indicates the G(2)S is a good model for the F-actin-S-1 interface, GS and G(2)S display different kinetic behaviors in response to nucleotides, GS being less efficiently dissociated than G(2)S by MgATP, This result suggests that different mechanical properties of the crossbridge might correlate with different orientations of the myosin head and different actin/myosin binding ratios.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ANDREEV OA, 1993, BIOCHEMISTRY-US, V32, P12046, DOI 10.1021/bi00096a015; ARATA T, 1991, J BIOCHEM-TOKYO, V109, P335; BARDEN JA, 1990, BIOCHEMISTRY-US, V29, P1348, DOI 10.1021/bi00457a034; BETTACHE N, 1990, BIOCHEMISTRY-US, V29, P9085, DOI 10.1021/bi00490a028; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; CHEN T, 1992, BIOCHEMISTRY-US, V31, P2941, DOI 10.1021/bi00126a014; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; COMBEAU C, 1992, BIOCHEMISTRY-US, V31, P300, DOI 10.1021/bi00116a041; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FIEVEZ S, 1993, FEBS LETT, V316, P186, DOI 10.1016/0014-5793(93)81212-I; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HOWARD J, 1994, NATURE, V368, P98, DOI 10.1038/368098a0; JIANG MY, 1994, BIOESSAYS, V16, P531, DOI 10.1002/bies.950160803; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LABBE JP, 1990, BIOCHEM J, V271, P407, DOI 10.1042/bj2710407; LHEUREUX K, 1993, BIOCHEMISTRY-US, V32, P10005, DOI 10.1021/bi00089a016; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; MANNHERZ HG, 1975, FEBS LETT, V60, P34, DOI 10.1016/0014-5793(75)80412-1; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MIKI M, 1987, EUR J BIOCHEM, V165, P125, DOI 10.1111/j.1432-1033.1987.tb11202.x; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V19, P5358; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; PINDER JC, 1982, BIOCHEMISTRY-US, V21, P4886, DOI 10.1021/bi00263a009; PRICE PA, 1969, J BIOL CHEM, V244, P917; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TESI C, 1990, BIOCHEMISTRY-US, V29, P1846, DOI 10.1021/bi00459a026; VALENTINRANC C, 1992, J BIOL CHEM, V267, P21543; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	48	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7125	7133		10.1074/jbc.270.13.7125	http://dx.doi.org/10.1074/jbc.270.13.7125			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706249	hybrid			2022-12-25	WOS:A1995QQ43100020
J	FIERER, DS; CHALLBERG, MD				FIERER, DS; CHALLBERG, MD			THE STOICHIOMETRY OF BINDING OF THE HERPES-SIMPLEX VIRUS TYPE-1 ORIGIN-BINDING PROTEIN, UL9, TO ORI(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA REPLICATION; ESCHERICHIA-COLI; GEL RETARDATION; LAC PROMOTER; DOMAIN; ORIS; SEQUENCE; HELICASE; GENE; PURIFICATION	A number of studies have demonstrated that the herpes simplex virus type 1 (HSV-1) UL9 protein, which is a homodimer in solution, binds to two high affinity binding sites in each origin of replication. Interaction between the proteins bound at the two sites leads to the formation of a complex nucleoprotein structure. The simplest models for this binding interaction predict two possible binding stoichiometries: 1) one UL9 dimer is bound at each site; or 2) one UL9 monomer is bound at each site so that one UL9 dimer occupies both sites, Two recent papers have addressed this issue by using indirect methods to measure the binding stoichiometry, Martin et al. (Martin, D. W., Munoz, R. M., Oliver, D., Subler, M. A., and Deb, S. (1994) Virology 198, 71-80) reported that a monomer of UL9 binds to a single high affinity site, and Stabell and Olive (Stabell, E. C., and Olive, P. D. (1993) Nucleic Acids Res. 21, 5203-5211) concluded that a dimer of UL9 binds to a single high affinity site. We have directly measured the stoichiometry of binding of the carboxyl terminal DNA binding domain of UL9 (t-UL9) to the origin of replication using a double-label gel shift assay. Using a short synthetic double-stranded oligonucleotide containing a single UL9 binding site, one protein-DNA complex was detected in the gel shift assay, and the molar ratio of UL9 DNA binding domains to DNA binding sites in this complex was determined to be 2.0 +/- 0.1 (n = 13). Using the minimal origin sequence excised from plasmid DNA, two protein-DNA complexes were detected, The binding stoichiometry of the faster migrating complex was 1.8 +/- 0.1 (n = 15), and the stoichiometry of the more slowly migrating band was 3.7 +/- 0.4 (n = 15), The simplest explanation for these data is that UL9 binds to the origin of replication as a homodimer with one dimer bound at both high affinity sites.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Fierer, Daniel/0000-0002-3427-8022				ALLEN FS, 1972, BIOPOLYMERS, V11, P853, DOI 10.1002/bip.1972.360110410; ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DABROWSKI CE, 1994, MOL CELL BIOL, V14, P2545, DOI 10.1128/MCB.14.4.2545; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENSTEIN D, 1990, J MOL BIOL, V211, P91, DOI 10.1016/0022-2836(90)90013-C; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; KORNBERG A, 1992, DNA REPLICATION, P615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MALIK AK, 1992, VIROLOGY, V190, P702, DOI 10.1016/0042-6822(92)90908-8; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MARTINEZ R, 1993, PROTEIN EXPRES PURIF, V4, P32, DOI 10.1006/prep.1993.1005; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P46; PERRY HC, 1993, VIROLOGY, V193, P73, DOI 10.1006/viro.1993.1104; SCHNEIDER GJ, 1990, J BIOL CHEM, V265, P10198; STABELL EC, 1993, NUCLEIC ACIDS RES, V21, P5203, DOI 10.1093/nar/21.22.5203; TIAN GL, 1992, J MOL BIOL, V226, P387, DOI 10.1016/0022-2836(92)90954-I; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379	40	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7330	7334		10.1074/jbc.270.13.7330	http://dx.doi.org/10.1074/jbc.270.13.7330			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706274	hybrid			2022-12-25	WOS:A1995QQ43100047
J	IGLESIAS, T; LLANOS, S; LOPEZBARAHONA, M; SELIGER, B; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A				IGLESIAS, T; LLANOS, S; LOPEZBARAHONA, M; SELIGER, B; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A			INDUCTION OF PLATELET-DERIVED GROWTH-FACTOR B/C-SIS BY THE V-ERBA ONCOGENE IN GLIAL-CELLS	ONCOGENE			English	Article						ERBA ONCOGENE; PDGF B/C-SIS; GLIAL CELLS; THYROID HORMONE RECEPTOR; AUTOCRINE STIMULATION	THYROID-HORMONE RECEPTOR; HUMAN-MALIGNANT GLIOMA; CENTRAL-NERVOUS-SYSTEM; C-ERBA; OLIGODENDROCYTE DEVELOPMENT; GENE-EXPRESSION; AB HETERODIMER; MESSENGER-RNA; PDGF-A; PROTEIN	The v-erbA oncogene codes for a mutated form of the thyroid hormone receptor TRlc-eubA-alpha, Thyroid hormone (triiodothyronine, T3) regulates glial functions such as myelination and both astrocytes and oligodendrocytes have been shown to express thyroid hormone receptors (TRs). To study putative effects of v-erbA on glial precursors, we have expressed it in a glial clonal cell line established from early embryonal mouse brain, We have found that v-erbA increases cell survival in serum-free conditions. Moreover, v-erbA-expressing cells show a substantial growth in the presence of insulin or IGF-I, whereas normal and TR/c-erbA-over-expressing cells progressively degenerate. By Northern blotting, immuno-fluorescence, immunoprecipitation, and neutralization experiments, we show that v-erbA actions are mediated by an increase in the levels of PDGF B/c-sis mRNA and protein. We used anti-PDGF receptor and antiphosphotyrosine antibodies to show the constitutive activation of PDGF receptors in B3.1+v-erbA cells, and neutralizing anti-PDGF antibodies to demonstrate that v-erbA enhances the secretion of active PDGF into the culture medium. Our data indicate that v-erbA induces PDGF B/c-sis, a factor involved in the generation df gliomas, the most common central nervous system tumor in humans.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; UNIV MAINZ,DIV HAMATOL ONKOL,INNERE MED KLIN 3,D-55131 MAINZ,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Johannes Gutenberg University of Mainz			Munoz, Alberto/O-6393-2014; , Susana/AAA-9282-2019; Bernal, Juan/J-6086-2014	Munoz, Alberto/0000-0003-3890-4251; Bernal, Juan/0000-0002-5867-4951; Llanos, Susana/0000-0002-8555-9326; Iglesias, Teresa/0000-0002-4326-9005; Rodriguez-Pena, Angeles/0000-0002-2515-4626				ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1989, GENE DEV, V5, P2033; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V137, P266; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GANDRILLON O, 1994, ONCOGENE, V9, P749; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HERMANSON M, 1992, CANCER RES, V52, P3213; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; IGLESIAS T, 1994, ENDOCR REV, V5, P697; Legrand J, 1984, NEUROBEHAVIORAL TERA, P331; LENS PF, 1986, MOL CELL BIOL, V6, P3537, DOI 10.1128/MCB.6.10.3537; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1986, CANCER RES, V46, P332; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NISTER M, 1991, J BIOL CHEM, V266, P16755; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PAIN B, 1990, New Biologist, V2, P284; PASTOR R, 1994, ONCOGENE, V9, P1081; PEDERSEN PH, 1994, INT J CANCER, V56, P255, DOI 10.1002/ijc.2910560219; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; PRESS RD, 1989, CANCER RES, V49, P2914; PUYMIRAT J, 1986, NEUROSCI LETT, V68, P299, DOI 10.1016/0304-3940(86)90506-9; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RICHARDSON W D, 1991, Current Biology, V1, P162, DOI 10.1016/0960-9822(91)90220-Q; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WESTPHAL M, 1988, CANCER LETT, V38, P283, DOI 10.1016/0304-3835(88)90020-1; YUSTA B, 1988, ENDOCRINOLOGY, V122, P2278, DOI 10.1210/endo-122-5-2278; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	55	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1103	1110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700635				2022-12-25	WOS:A1995QN35300010
J	HAN, JH; LEE, JD; TOBIAS, PS; ULEVITCH, RJ				HAN, JH; LEE, JD; TOBIAS, PS; ULEVITCH, RJ			ENDOTOXIN INDUCES RAPID PROTEIN-TYROSINE PHOSPHORYLATION IN 70Z/3 CELLS EXPRESSING CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; SIGNAL TRANSDUCTION; LIPOPOLYSACCHARIDE LPS; MACROPHAGES; RECEPTOR; ACTIVATION; COMPLEXES; ELEMENT; SERUM	CD14, a glycosylphosphatidylinositol-anchored glycoprotein of leukocytes, binds endotoxin (lipopolysaccharide (LPS)) with high affinity. After the murine pre-B cell line 70Z/3 is transfected with DNA encoding human CD14 (hCD14), the resultant stably transfected cell line, 70Z/3-hCD14, responds to 1000-fold lower LPS concentrations than the parental CD14-negative line. We have used 70Z/3-hCD14 cells, RAW264.7 cells, and elicited murine peritoneal exudate macrophages (PEM) to study LPS-induced protein tyrosine phosphorylation. LPS induces the rapid tyrosine phosphorylation of a 38-kDa protein (p38) in 70Z/3-hCD14 cells, PEM, and RAW264.7 cells and of two isoforms of mitogen-activated protein kinases (MAPK) in only RAW264.7 cells and PEM. p38 can be distinguished from the MAPK isoforms based on differences in mobilities on SDS-polyacrylamide gel electrophoresis and the lack of reactivity of p38 with anti-MAPK antibody even after dephosphorylation with potato acid phosphatase. Synthetic lipid A induces p38 phosphorylation in 70Z/3-hCD14 cells, whereas phorbol 12-myristate 13-acetate and interferon-gamma fail to induce tyrosine phosphorylation of p38. Pretreatment of 70Z/3-hCD14 cells with anti-hCD14 monoclonal antibody or the tyrosine kinase inhibitor herbimycin A inhibits LPS-induced tyrosine phosphorylation of p38. These results suggest that increased protein tyrosine phosphorylation occurs rapidly after LPS binds to CD14 and is likely to be an important event in mediating LPS-induced cell activation.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute			Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, R37GM028485, P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM28485, GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; EMERY DW, 1989, MOL CELL BIOL, V9, P5231, DOI 10.1128/MCB.9.11.5231; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MARTIN TR, 1992, J CLIN INVEST, V90, P2209, DOI 10.1172/JCI116106; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MOLLITOR JAS, 1990, P NATL ACAD SCI USA, V87, P10028; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; ROBIAS PS, 1993, J IMMUNOL, V150, P3011; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; VOGEL SN, 1990, IMMUNOPHYSIOLOGY ROL, P238; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	29	288	311	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25009	25014						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693711				2022-12-25	WOS:A1993MG67300073
J	WADHWA, R; KAUL, SC; SUGIMOTO, Y; MITSUI, Y				WADHWA, R; KAUL, SC; SUGIMOTO, Y; MITSUI, Y			INDUCTION OF CELLULAR SENESCENCE BY TRANSFECTION OF CYTOSOLIC MORTALIN CDNA IN NIH-3T3-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR SUPPRESSOR GENES; INDEFINITE DIVISION; MOUSE FIBROBLASTS; GROWTH ARREST; HUMAN-CELLS; PROTEIN; ACTIN; IMMORTALITY; MECHANISMS; CANCER	We have recently identified a novel member of hsp70 family (mortalin) as a mortality marker (Wadhwa, R., Kaul, S. C., Ikawa, Y., and Sugimoto, Y. (1993) J. Biol. Chem. 268, 6615-6621). It has distinct intracellular distribution in mortal and immortal fibroblasts. Here, we report that the cytosolic (mot-1) and the perinuclear (mot-2) forms of mortalin cDNA cloned from mortal and immortal cells, respectively, differ by only two bases in the open reading frame, resulting in two amino acid changes. The induced expression of the cytosolic form by transfection of mot-1 cDNA (isolate from CD1-ICR mouse embryonic fibroblasts) to NIH 3T3 cells induced cellular senescence. However, the perinuclear form expressed by mot-2 cDNA (isolate from NIH 3T3 cells) did not yield an equivalent effect. The data suggest the senescence-inductive function of cytosolic mortalin and implicitly point to a genetic event involved in immortalization.	SHIRAKAWA INST ANIM GENET,JAPAN LIVESTOCK TECHNOL ASSOC,NISHI SHIRAKAWA,FUKUSHIMA 961,JAPAN		WADHWA, R (corresponding author), NATL INST BIOSCI & HUMAN TECHNOL,AGCY IND SCI & TECHNOL,TSUKUBA,IBARAKI 305,JAPAN.		Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYFLICK L, 1991, MUTAT RES, V256, P69, DOI 10.1016/0921-8734(91)90002-S; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAUL SC, 1993, BIOCHEM BIOPH RES CO, V193, P348, DOI 10.1006/bbrc.1993.1630; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NING Y, 1991, MUTAT RES, V256, P303, DOI 10.1016/0921-8734(91)90021-3; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PECHAN PM, 1991, FEBS LETT, V280, P1, DOI 10.1016/0014-5793(91)80190-E; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TROFATTE RJA, 1993, CELL, V72, P791; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; WADHWA R, 1991, BIOCHEM BIOPH RES CO, V178, P269, DOI 10.1016/0006-291X(91)91809-Q; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	30	88	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22239	22242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693662				2022-12-25	WOS:A1993MD34800007
J	CONESA, C; SWANSON, RN; SCHULTZ, P; OUDET, P; SENTENAC, A				CONESA, C; SWANSON, RN; SCHULTZ, P; OUDET, P; SENTENAC, A			ON THE SUBUNIT COMPOSITION, STOICHIOMETRY, AND PHOSPHORYLATION OF THE YEAST TRANSCRIPTION FACTOR-TFIIIC/TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; FACTOR-TAU; GENE; PURIFICATION; POLYPEPTIDE; TFIIIB; MUTAGENESIS	Saccharomyces cerevisiae transcription factor IIIC/tau is a multisubunit DNA-binding protein that plays key roles in tRNA and 5 S rRNA gene activation. Subunit composition, stoichiometry, and in vivo phosphorylation of TFIIIC/tau factor were investigated using factor prepared from strains carrying modified forms of TFC1, the gene encoding the 95-kDa TFIIIC/tau subunit (tau95). Using an epitope-tagged TFC1 as well as a TFC1-lacZ fusion, TFIIIC was shown to contain a single 95-kDa subunit, which was localized by electron microscopy into tauA, the A block-binding domain of TFIIIC/tau. Three S-35-labeled polypeptides (at 138, 131, and 91 kDa) coimmunoprecipitated with a tau95-beta-galactosidase fusion protein. The coprecipitation of the 91-kDa polypeptide makes it a likely subunit of the factor. Immunoprecipitation from P-32-labeled extracts revealed that three of the subunits (138, 131, and 95 kDa), but not the 91-kDa component, are phosphorylated in vivo.	CTR ETUD SACLAY, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; LAB GENET MOLEC EUCARYOTES, F-67085 STRASBOURG, FRANCE					schultz, patrick/0000-0002-7310-6186				BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; CHIANNILKULCHAI N, 1992, J BIOL CHEM, V267, P23099; CLARK ME, 1990, MOL CELL BIOL, V10, P5106, DOI 10.1128/MCB.10.10.5106; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FRADKIN LG, 1989, MOL CELL BIOL, V9, P4941, DOI 10.1128/MCB.9.11.4941; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; MARCK C, 1993, IN PRESS P NATL ACAD; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Miller J.H., 1972, EXPT MOL GENETICS; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SHERMAN F, 1986, LABORATORY COURSE MA; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	41	33	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18047	18052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688737				2022-12-25	WOS:A1993LT74300061
J	WILLIAMS, R; SANGHERA, J; WU, F; CARBONAROHALL, D; CAMPBELL, DL; WARBURTON, D; PELECH, S; HALL, F				WILLIAMS, R; SANGHERA, J; WU, F; CARBONAROHALL, D; CAMPBELL, DL; WARBURTON, D; PELECH, S; HALL, F			IDENTIFICATION OF A HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR-ASSOCIATED PROTEIN-KINASE AS A NEW MEMBER OF THE MITOGEN-ACTIVATED PROTEIN-KINASE EXTRACELLULAR SIGNAL-REGULATED PROTEIN-KINASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; SERINE THREONINE PHOSPHORYLATION; MAP KINASES; TYROSYL PHOSPHORYLATION; MATURATION; RAF-1; PURIFICATION; SUBSTRATE; RESIDUES; TISSUES	A putative mitogen-activated protein kinase (MAPK) has recently been identified, which potentially phosphorylates the human epidermal growth factor (EGF) receptor at a physiological site (Thr-669) and is distinguished from other MAPKs/extracellular signal-regulated protein kinases (ERKs) on the basis of chromatographic, immunological, and kinetic data. Here we report that this newly discovered MAPK is physically associated with the EGF receptor in A431 cells and with the related receptor/tyrosine kinase HER2 (encoded by c-neu) in enzyme preparations obtained from Wilm's tumors. This human EGF receptor-associated kinase is characterized as a 40-kDa Thr-669 kinase that exists in a high molecular mass complex with the respective growth factor receptor. EGF treatment of A431 cells stimulates the tyrosine phosphorylation of p40 and increases Thr-669 kinase activity in p40-containing fractions. The 40-kDa kinase is recognized by affinity-purified polyclonal antibodies directed against the sea star p44mpk and a Pan-ERK antibody directed against the conserved subdomain VIII of MAPKs/ERKs, but is not recognized by antibodies selective for the rat p44erk1 and/or the p42mapk/erk2 isoforms, thus identifying the EGF receptor-associated kinase as a novel MAPK that may regulate receptor function in vivo.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV ORTHOPAED SURG,ORTHOPAED SURG RES LAB,LOS ANGELES,CA 90054; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV NEONATOL & PEDIAT PULMONOL,LOS ANGELES,CA 90054; UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90054; KINETEK BIOTECHNOL CORP,BIOMED RES LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of British Columbia								ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HALL F L, 1989, Journal of Cell Biology, V109, p217A; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; MIKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRESS MF, 1990, ONCOGENE, V5, P953; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILLIAMS RT, 1992, ONCOGENE, V7, P423	40	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18213	18217						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688742				2022-12-25	WOS:A1993LT74300084
J	THIMMIG, RL; MCHENRY, CS				THIMMIG, RL; MCHENRY, CS			HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE - EXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND CHARACTERIZATION OF A FUNCTIONALLY AND STRUCTURALLY ASYMMETRIC DIMERIC POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; PHOSPHOROTHIOATE-MODIFIED DNA; SACCHAROMYCES-CEREVISIAE; TRANSFER-RNALYS; RIBONUCLEASE-H; III HOLOENZYME; AIDS VIRUS; METHIONINE AMINOPEPTIDASE; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE	Human immunodeficiency virus (HIV) reverse transcriptase isolated from viral particles contains two subunits, p51 and p66. We have produced both subunits in separate Escherichia coli strains using expression vectors. Stop codons were placed immediately after the codon for the carboxyl-terminal residue of the mature processed p51 and p66 subunits found in viral particles. Insertion of a methionine in front of the HIV protease cleavage site in the recombinant protein enabled synthesis of both subunits with the natural amino-terminal proline, since E. coli methionine aminopeptidase cleaves a Met-Pro amino-terminal linkage. That this occurred to an extent greater than 95% was confirmed by sequencing the purified subunits. Examination of the activities of the individual p51 and p66 subunits on a variety of templates and under solution conditions optimized for each subunit revealed a significant catalytic activity for the natural p51 subunit. This result contrasts to results reported earlier for many recombinant forms without the natural amino and/or carboxyl termini. As expected from earlier work, the optimal homopolymeric template for the p66 subunit was poly(rA). For the p51 subunit, poly(dC) was found to be the optimal template; its activity is 2- to 4-fold greater than p66 on poly(dC). The p51 subunit is 13- to 50-fold less active on poly(rC). These findings are discussed in the context of our earlier hypothesis (McHenry, C. S. (1989) in Molecular Biology of Chromosome Function (Adolph, K., ed) Chap. 5, Springer-Verlag, New York) that the HIV reverse transcriptase might be functionally asymmetric with distinct plus- and minus-strand polymerases.			THIMMIG, RL (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80262 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026600] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26600] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARR PJ, 1987, BIO-TECHNOL, V5, P486, DOI 10.1038/nbt0587-486; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; BUISER RG, 1991, J BIOL CHEM, V266, P13103; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; DEVLIN PE, 1988, GENE, V65, P13, DOI 10.1016/0378-1119(88)90412-X; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLD L, 1990, METHOD ENZYMOL, V185, P89; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kornberg A., 1974, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1987, GENE, V55, P95, DOI 10.1016/0378-1119(87)90252-6; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCHENRY CS, 1988, CANCER CELL, V6, P35; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; ROWLEY GL, 1990, BIOCHEM BIOPH RES CO, V167, P673, DOI 10.1016/0006-291X(90)92078-E; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STARNES M, 1988, J BIOL CHEM, V263, P1; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1986, J VIROL, V59, P743, DOI 10.1128/JVI.59.3.743-745.1986; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEISS R, 1984, RNA TUMOR VIRUSES MO; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074	80	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16528	16536						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688366				2022-12-25	WOS:A1993LQ33600065
J	DEBIEC, H; RONCO, PM				DEBIEC, H; RONCO, PM			IDENTIFICATION AND EPITOPE ANALYSIS OF THE RENAL NA+/P(I) COTRANSPORT PROTEIN USING MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; DEPENDENT PHOSPHATE-TRANSPORT; OPOSSUM KIDNEY-CELLS; PARATHYROID-HORMONE; CONFORMATIONAL-CHANGES; FUNCTIONAL ASYMMETRY; RAT; VESICLES; CORTEX; SYSTEM	Seven monoclonal antibodies (mAbs) were raised against a rabbit renal brush-border glycoprotein (molecular mass, 63-66 kDa), presumably involved in Na+/P(i) cotransport, which we had previously purified and reconstituted in active form in proteoliposomes (Debiec, H., Lorenc, R., and Ronco, P. M. (1992) Biochem. J. 286, 97-102). Antibody specificity for the 63-66-kDa protein was analyzed by enzyme-linked immunosorbent assay and confirmed by Western blotting and immunoaffinity chromatography of solubilized brush-border membranes (BBM), which both yielded a single 63-66-kDa band. Enzyme-linked immunosorbent assay and immunoblotting of renal cortical cell subfractions localized the immunoreactive protein to the brush-border membrane. This location was confirmed by indirect immunofluorescence of kidney cortex sections. Binding of two of the seven mAbs (63A20 and 206A126) to native BBM only occurred when the related epitope was exposed in the presence or absence of Na+, respectively; the other mAbs did not react with native BBM probably because of intramembranous orientation of the epitopes. mAb 63A20 inhibited dose-dependently Na+/P(i) cotransport when preincubation of BBM was carried out in the presence of Na+ but did not affect Na+/D-glucose cotransport. Proteoliposomes formed from BBM proteins depleted of the 63-66-kDa protein by affinity chromatography with mAb 63A20 showed an 85% reduction in Na+/P(i) cotransport, whereas Na+/D-glucose cotransport was not modified. These results thus establish that the 63-66-kDa BBM protein is the essential component of the Na+/P(i) cotransport system. The present study also provides the first immunologic tools available for immunohistochemical localization of the Na+/P(i) cotransporter. Finally, the identification of a functional epitope by mAb 63A20 opens up new ways to explore the molecular aspects of P(i) uptake.			DEBIEC, H (corresponding author), HOP TENON, INSERM, U64, 4 RUE CHINE, F-75970 PARIS 20, FRANCE.		Ronco, Pierre/AAC-8390-2022; Debiec, Hanna/AAL-8144-2021	Debiec, Hanna/0000-0002-8946-8245				ALMAHROUQ HA, 1991, J BIOL CHEM, V266, P1422; AMIEL C, 1970, PFLUG ARCH EUR J PHY, V317, P93, DOI 10.1007/BF00592495; AMSTUTZ M, 1985, AM J PHYSIOL, V248, pF705, DOI 10.1152/ajprenal.1985.248.5.F705; BAGINSKY ML, 1969, J BIOL CHEM, V244, P5313; BELIVEAU R, 1987, J BIOL CHEM, V262, P16885; BELIVEAU R, 1990, BIOCHEM J, V268, P195, DOI 10.1042/bj2680195; BELIVEAU R, 1988, AM J PHYSIOL, V23, pF329; BERNER W, 1976, BIOCHEM J, V160, P467, DOI 10.1042/bj1600467; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BOUMENDILPODEVIN EF, 1983, BIOCHIM BIOPHYS ACTA, V735, P86, DOI 10.1016/0005-2736(83)90263-8; BRUNETTE MG, 1985, PEDIATR RES, V19, P1179, DOI 10.1203/00006450-198511000-00013; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CAVERZASIO J, 1988, CALCIFIED TISSUE INT, V43, P83, DOI 10.1007/BF02555151; CROSS HS, 1990, MINER ELECTROL METAB, V16, P115; DEBIEC H, 1992, BIOCHEM J, V286, P97, DOI 10.1042/bj2860097; DEBIEC H, 1991, Journal of the American Society of Nephrology, V2, P759; DEBIEC H, 1988, BIOCHEM J, V255, P185, DOI 10.1042/bj2550185; DEBOLAND AR, 1983, BIOCHIM BIOPHYS ACTA, V733, P264, DOI 10.1016/0005-2736(83)90531-X; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; FORSTNER GG, 1968, BIOCHEM J, V106, P381, DOI 10.1042/bj1060381; GORG A., 1985, SCI TOOLS, V32, P5; HAMMERMAN MR, 1983, KIDNEY INT, V23, P100; HRUSKA K, 1984, ADV EXP MED BIOL, V178, P3; JACK MG, 1989, J BIOL CHEM, V264, P3904; KAPLAN RS, 1989, METHOD ENZYMOL, V172, P393; KEMPSON SA, 1986, BIOCHEM PHARMACOL, V35, P721, DOI 10.1016/0006-2952(86)90237-6; KOEPSELL H, 1988, J BIOL CHEM, V263, P18419; KOHLER G, 1975, NATURE, V256, P498; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JT, 1984, BIOCHIM BIOPHYS ACTA, V774, P254, DOI 10.1016/0005-2736(84)90299-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK JI, 1988, P NATL ACAD SCI USA, V85, P7877, DOI 10.1073/pnas.85.21.7877; MIZGALA CL, 1985, PHYSIOL REV, V65, P431, DOI 10.1152/physrev.1985.65.2.431; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PEERCE BE, 1989, AM J PHYSIOL, V256, pG645, DOI 10.1152/ajpgi.1989.256.4.G645; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; PIMPLIKAR SW, 1988, J BIOL CHEM, V263, P4485; QUAMME GA, 1990, AM J PHYSIOL, pF356; QUIGLEY JP, 1969, BIOCHIM BIOPHYS ACTA, V173, P456, DOI 10.1016/0005-2736(69)90010-8; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P624, DOI 10.1007/BF00370606; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; RONCO P, 1986, AM J PHYSIOL, V250, pC506, DOI 10.1152/ajpcell.1986.250.3.C506; SCHALI C, 1986, BIOCHEM J, V235, P189, DOI 10.1042/bj2350189; SCHWAB SJ, 1984, AM J PHYSIOL, V246, pF663, DOI 10.1152/ajprenal.1984.246.5.F663; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; WALKER JJ, 1987, AM J PHYSIOL, V252, pF226, DOI 10.1152/ajprenal.1987.252.2.F226; WELLS RG, 1990, J AM SOC NEPHROL, V1, P746; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WU JSR, 1987, BIOCHEMISTRY-US, V26, P5783, DOI 10.1021/bi00392a030; WUARIN F, 1989, BIOCHIM BIOPHYS ACTA, V981, P185, DOI 10.1016/0005-2736(89)90027-8	53	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13356	13363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685760				2022-12-25	WOS:A1993LH55300051
J	KIRCHHAUSEN, T; TOYODA, T				KIRCHHAUSEN, T; TOYODA, T			IMMUNOELECTRON MICROSCOPIC EVIDENCE FOR THE EXTENDED CONFORMATION OF LIGHT-CHAINS IN CLATHRIN TRIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEX AP-2; HEAVY-CHAIN; ELECTRON-MICROSCOPY; UNCOATING ATPASE; BINDING; DOMAINS; INTERMEDIATE; SEQUENCES; COATS	Clathrin is a major component of the basket-like network of hexagons and pentagons that forms the ''coat'' on the cytoplasmic face of the plasma membrane and the trans Golgi network during the invagination of coated pits. Soluble clathrin is a three-legged structure (triskelion) comprising three identical heavy chains and three different light chains located toward the center of the triskelion on the proximal segment of the leg. All mammalian light chains contain a central domain of 10 heptad repeats, which is necessary for the interaction with heavy chain. Because the repeats are characteristic of alpha helical coiled coils, we proposed that the central domain had an extended conformation (Kirchhausen, T., Scarmato, P., and Harrison, S. C. et al. (1987) Science 236, 320-324). However, an alternative model has recently been proposed (Nathke, I. S., Heuser, J., Lupas, A., Stock, J., Turck, C. W., and Brodsky, F. M. (1992) Cell 68, 899-910). Here, we use single-molecule electron microscopy of clathrin decorated with monoclonal antibodies directed against different epitopes on light chains to show that the light chain central domain has an extended conformation and reaches along most of the proximal segment of the heavy chain leg.	HARVARD UNIV, SCH MED, DEPT ANAT & CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	KIRCHHAUSEN, T (corresponding author), HARVARD UNIV, SCH MED, CTR BLOOD RES, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.							BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; FLAHERTY CD, 1990, CELL, V62, P875; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LISANTI MP, 1982, BIOCHEM J, V201, P297, DOI 10.1042/bj2010297; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; UNGEWICKELL E, 1981, COLD SPRING HARB SYM, V46, P723, DOI 10.1101/SQB.1982.046.01.069; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x	26	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10268	10273						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683673				2022-12-25	WOS:A1993LB80000048
J	KLARMANN, GJ; SCHAUBER, CA; PRESTON, BD				KLARMANN, GJ; SCHAUBER, CA; PRESTON, BD			TEMPLATE-DIRECTED PAUSING OF DNA-SYNTHESIS BY HIV-1 REVERSE-TRANSCRIPTASE DURING POLYMERIZATION OF HIV-1 SEQUENCES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL RECOMBINATION; PLUS-STRAND; PROCESSIVITY; REPLICATION; MECHANISM; KINETICS	Replication of human immunodericiency virus type 1 (HIV-1) requires reverse transcriptase (RT) to synthesize double-stranded proviral DNA (9.7 kilobases) through a complex mechanism utilizing both RNA and DNA templates. We have examined DNA synthesis by HIV-1 RT on RNA and DNA templates derived from the HIV-1 genome using a primer extension assay in vitro. Analysis of polymerization products on sequencing gels revealed strong pauses in synthesis, on both RNA and DNA templates, in homopolymeric nucleotide runs, and at regions of predicted secondary structure. Polymerization pauses occurred in runs of template rGs (greater-than-or-equal-to 4 bases) and rCs (greater-than-or-equal-to 3 bases) during minus-strand synthesis on RNA templates, and in most runs (greater-than-or-equal-to 4 bases) of template dTs and dAs during plus-strand synthesis on DNA templates. Pausing also occurred on both templates within the first few nucleotides of the predicted hairpin structures of the Rev response element. The locations of pauses were dependent on template sequence and were unaffected by primer positioning, RT concentration, and ionic strength. Recombinant and virion-derived HIV-1 RTs showed similar pausing patterns. DNA products that accumulated at HIV-1 RT pause sites on RNA templates were extended by continued incubation with excess RT from Moloney murine leukemia virus, showing that the RNA templates were not broken or otherwise unable to support polymerization. Polymerizations conducted in the presence of a poly(rA).oligo(dT) trap showed that pausing results from two mechanisms: 1) RT remaining bound to the primer-template and polymerizing at a greatly reduced rate, or 2) RT dissociating from the primer-template. These results demonstrate that specific HIV-1 RNA and DNA template sequences are capable of interrupting processive DNA synthesis by HIV-1 RT in vitro. Pausing may serve specific functions in HIV-1 replication and mutagenesis. Moreover, these data suggest that one or more accessory factors are required to complete proviral DNA synthesis in vivo and that efficient HIV-1 DNA synthesis may require multiple origins.	RUTGERS UNIV,COLL PHARM,CANC RES LAB,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick					NATIONAL CANCER INSTITUTE [R29CA048174, S15CA051339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA48174, S15 CA51339] Funding Source: Medline; NIEHS NIH HHS [P30 ES05022] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BORROTOESODA K, 1991, J VIROL, V65, P1952, DOI 10.1128/JVI.65.4.1952-1959.1991; BUISER RG, 1991, J BIOL CHEM, V266, P13103; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; Coffin J. M., 1990, VIROLOGY, P1437; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DECLERCQ E, 1991, J ACQ IMMUN DEF SYND, V4, P207; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON C, 1984, RNA TUMOR VIRUSES MO, P513; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HIZI A, 1991, J BIOL CHEM, V266, P6230; HOUTS GE, 1979, J VIROL, V29, P517, DOI 10.1128/JVI.29.2.517-522.1979; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUBER HE, 1989, J BIOL CHEM, V264, P4669; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; LE SY, 1988, NUCLEIC ACIDS RES, V16, P5153, DOI 10.1093/nar/16.11.5153; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SAENGER W, 1984, PRINCIPLES NUCLEIC A; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; YU H, 1992, J BIOL CHEM, V267, P10888; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	48	181	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9793	9802						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683663				2022-12-25	WOS:A1993LA68900093
J	SIMONSON, MS; HERMAN, WH				SIMONSON, MS; HERMAN, WH			PROTEIN-KINASE-C AND PROTEIN-TYROSINE KINASE-ACTIVITY CONTRIBUTE TO MITOGENIC SIGNALING BY ENDOTHELIN-1 - CROSS-TALK BETWEEN G-PROTEIN-COUPLED RECEPTORS AND PP60C-SRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; VASCULAR SMOOTH-MUSCLE; CHROMOSOMAL ASSIGNMENT; DNA-SYNTHESIS; VASOCONSTRICTOR PEPTIDE; DEPENDENT MECHANISM; PHOSPHOLIPASE-C; CDNA CLONING; RAT-KIDNEY; EXPRESSION	Endothelin (ET) peptides are potent growth factors that bind to G protein-coupled receptors. Although short-term signals activated by ET receptors have been extensively characterized, relatively little is known about mitogenic signal transduction. We investigated the ET receptor subtype involved in mitogenic signaling in glomerular mesangial cells and the role of protein kinase C (PKC) and protein tyrosine kinase (PTK) activity. Pertussis toxin attenuates increases in [Ca2+]i by ET-1 but not [H-3]thymidine uptake. An ET(A)-selective receptor antagonist, BQ 123, blocks increments in [Ca2+]i by ET-1 and inhibits [H-3]thymidine uptake. A nonselective ET(A)-ET(B) receptor antagonist (PD 142893) blocked [H-3]thymidine uptake, but ET(B) receptor-selective agonists (S6c and [Ala1,Ala3,Ala11,Ala15]ET-1(6-21)) were unable to increase [Ca2+]i or [H-3]thymidine uptake. Collectively, these data suggest that mitogenic signaling occurs through an ET(A) receptor subtype in mesangial cells. Experiments with both PKC inhibition and depletion demonstrate that PKC was necessary but not sufficient for mitogenic signaling. ET-1 increased tyrosine phosphorylation of cellular proteins in quiescent mesangial cells that was blocked by preincubation with herbimycin A. Two chemically and mechanistically dissimilar PTK inhibitors (herbimycin A and genistein) blocked [H-3]thymidine uptake by ET-1. In addition, herbimycin A attenuated c-fos induction, AP-1 DNA binding, and transcription directed by an AP-1 cis-element in response to ET-1. Taken together, these data suggest that mitogenic signaling by ET-1 also involves a PTK-based mechanism. We further demonstrated that ET-1 stimulated autophosphorylation of pp60c-src and pp60c-arc-catalyzed phosphorylation of a peptide substrate specific for PTK activity. That the dose-response relationship for ET-1-induced pp60c-src activation and [H-3]thymidine uptake were similar suggests that these events might be functionally linked. Thus, cross-talk between G protein-coupled receptors and nonreceptor PTK such as pp60c-src might be involved in transcriptional regulation and mitogenic signaling by ET-1.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, DIV NEPHROL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046939] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46939-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BALDI E, 1991, J PHARMACOL EXP THER, V256, P581; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BLOCH KD, 1991, GENOMICS, V10, P236, DOI 10.1016/0888-7543(91)90505-9; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BOBIK A, 1990, AM J PHYSIOL, V258, pC408, DOI 10.1152/ajpcell.1990.258.3.C408; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CODY WL, 1992, J MED CHEM, V35, P3301, DOI 10.1021/jm00095a029; Dubin D, 1989, J VASC MED BIOL, V1, P150; EGUCHI S, 1992, FEBS LETT, V302, P243, DOI 10.1016/0014-5793(92)80451-L; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JAFFER FE, 1990, KIDNEY INT, V38, P1193, DOI 10.1038/ki.1990.333; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KUSUHARA M, 1992, CANCER RES, V52, P3011; LANDAN G, 1991, TOXICON, V29, P237, DOI 10.1016/0041-0101(91)90108-4; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; MACRAE AD, 1992, TRENDS ENDOCRIN MET, V3, P153, DOI 10.1016/1043-2760(92)90164-V; MARSDEN PA, 1991, AM J PHYSIOL, V261, pF117, DOI 10.1152/ajprenal.1991.261.1.F117; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; OHLSTEIN EH, 1992, EUR J PHARM-MOLEC PH, V225, P347, DOI 10.1016/0922-4106(92)90109-9; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RUBANYI GM, 1992, ENDOTHELIN; SAEKI T, 1991, BIOCHEM BIOPH RES CO, V179, P286, DOI 10.1016/0006-291X(91)91367-L; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIMONSON MS, 1991, EXP CELL RES, V192, P148, DOI 10.1016/0014-4827(91)90169-U; TAKEDA M, 1992, KIDNEY INT, V41, P1713, DOI 10.1038/ki.1992.245; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; THOMAS CP, 1991, AM J PHYSIOL, V260, pF347, DOI 10.1152/ajprenal.1991.260.3.F347; TORTI M, 1992, BIOCHEM BIOPH RES CO, V186, P440, DOI 10.1016/S0006-291X(05)80827-7; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; WILKES BM, 1991, AM J PHYSIOL, V260, pF913, DOI 10.1152/ajprenal.1991.260.6.F913; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG W, 1991, NEUROSCI LETT, V123, P164, DOI 10.1016/0304-3940(91)90921-F	66	229	232	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9347	9357						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683650				2022-12-25	WOS:A1993LA68900033
J	RODRIGUEZPARIS, JM; NOLTA, KV; STECK, TL				RODRIGUEZPARIS, JM; NOLTA, KV; STECK, TL			CHARACTERIZATION OF LYSOSOMES ISOLATED FROM DICTYOSTELIUM-DISCOIDEUM BY MAGNETIC FRACTIONATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; ENDOSOMES; SEPARATION; VACUOLES; CELLS; IRON; PHOSPHATIDYLGLYCEROL; QUANTITATION	Superparamagnetic particles were prepared with iron oxide cores of congruent-to 8 nm diameter and dextran coats. After feeding the probe to the amoeba, Dictyostelium discoideum, for 15 min and chasing for 15 min, a lysosome fraction was isolated magnetically. Isolates contained 76% of ingested iron, 82% of ingested fluorescent dextran, 1.3% of cell protein, 4% of the lipid, 28% of acid phosphatase, and 5% of the vacuolar H+-ATPase. Enrichment in endocytic markers was congruent-to 60-fold; markers for other organelles were <0.5%. The lysosomes were homogeneous, round (0.4-1.1 mum in diameter), and frequently adherent to one another through zones of intimate apposition. Cells were also fed the iron probe continuously for 3 h to fill their entire endocytic pathway; in this case, isolates contained 3.3% of cell protein, 11% of lipid, and 49% of cell acid phosphatase. Bis(monoacylglycerol)phosphate (BMP), a lipid characteristic of lysosomes in animal cells, comprised congruent-to 6% of biosynthetically labelled cell lipids and up to half of the lipid in the endocytic pathway. Essentially all of the cellular BMP was recovered in isolates prepared after 3 h of feeding. The specificity and abundance of BMP in the endocytic organelles of this early diverged protist suggests that this phospholipid serves a universal and essential function in endocytosis.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM 07183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; BANERJEE P, 1990, BIOCHIM BIOPHYS ACTA, V1044, P305, DOI 10.1016/0005-2760(90)90074-8; BAUER A, 1990, BIOL CELL, V70, P61, DOI 10.1016/0248-4900(90)90361-6; BEAUFAY H, 1969, LYSOSOM BIOL PATHOL, P515; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BECICH MJ, 1991, EUR J CELL BIOL, V55, P71; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECHASTELLIER C, 1983, EUR J CELL BIOL, V30, P233; FERBER E, 1970, EUR J BIOCHEM, V14, P253, DOI 10.1111/j.1432-1033.1970.tb00284.x; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FUCHS R, 1989, J BIOL CHEM, V264, P2212; HEFTMANN E, 1960, ARCH BIOCHEM BIOPHYS, V91, P266, DOI 10.1016/0003-9861(60)90500-2; Holtzman E, 1989, LYSOSOMES; HOSTETLER KY, 1992, METHOD ENZYMOL, V209, P104; HUTERER SJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P68, DOI 10.1016/0005-2760(89)90308-1; Kates M, 1972, TECHNIQUES LIPIDOLOG, P351; KHALAFALLA SE, 1980, IEEE T MAGN, V16, P178, DOI 10.1109/TMAG.1980.1060578; KLEIN G, 1986, BIOCHEM BIOPH RES CO, V138, P1146, DOI 10.1016/S0006-291X(86)80402-8; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOHDEN U, 1989, ANAL BIOCHEM, V182, P77, DOI 10.1016/0003-2697(89)90721-5; LONG BH, 1974, J BIOL CHEM, V249, P521; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATSUZAWA Y, 1980, J LIPID RES, V21, P202; MATSUZAWA Y, 1978, J BIOL CHEM, V353, P6650; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; OHKUMA S, 1987, LYSOSOMES THEIR ROLE, P115; OWEN CS, 1987, CELL SEPARATION METH, V4, P259; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1993, J BIOL CHEM, V268, P6742; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; POORTHUIS BJHM, 1976, J BIOL CHEM, V251, P4596; RENKONEN O, 1965, J AM OIL CHEM SOC, V42, P298, DOI 10.1007/BF02540133; SAKO Y, 1990, J BIOCHEM-TOKYO, V107, P846, DOI 10.1093/oxfordjournals.jbchem.a123136; SATO SB, 1986, J BIOCHEM-TOKYO, V100, P1481, DOI 10.1093/oxfordjournals.jbchem.a121855; SKIPSKI VP, 1974, METHOD ENZYMOL, V34, P396; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1983; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; THILO L, 1983, METHOD ENZYMOL, V98, P415; THILO L, 1980, P NATL ACAD SCI-BIOL, V77, P1015, DOI 10.1073/pnas.77.2.1015; THOMPSON GA, 1969, J PROTOZOOL, V16, P397, DOI 10.1111/j.1550-7408.1969.tb02287.x; THORNBURG T, 1991, J BIOL CHEM, V266, P6834; WAITE M, 1990, J BIOL CHEM, V265, P21720; WETZEL MG, 1969, J CELL BIOL, V43, P90, DOI 10.1083/jcb.43.1.90; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; Whitesides G.M., 1983, TRENDS BIOTECHNOL, V1, P144, DOI [DOI 10.1016/0167-7799(83)90005-7, 10.1016/0167-7799(83)90005-7]; WOODING A, 1988, IEEE T MAGN, V24, P1650, DOI 10.1109/20.11559; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	50	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9110	9116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682559				2022-12-25	WOS:A1993KX81100103
J	SALI, A; MATSUMOTO, R; MCNEIL, HP; KARPLUS, M; STEVENS, RL				SALI, A; MATSUMOTO, R; MCNEIL, HP; KARPLUS, M; STEVENS, RL			3-DIMENSIONAL MODELS OF 4 MOUSE MAST-CELL CHYMASES - IDENTIFICATION OF PROTEOGLYCAN BINDING REGIONS AND PROTEASE-SPECIFIC ANTIGENIC EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSTATIC INTERACTIONS CONTRIBUTE; CHONDROITIN SULFATE PROTEOGLYCAN; SECRETORY GRANULE PROTEOGLYCANS; MOLECULAR-CLONING; SERINE PROTEASE; BONE-MARROW; HEPARIN PROTEOGLYCANS; PROTEOLYTIC-ENZYMES; HOMOLOGOUS PROTEINS; NEUTRAL PROTEASES	Mouse mast cell protease (mMCP) 1, mMCP-2, MMCP-4, and mMCP-5 are serine proteases which are predicted to have chymotryptic specificity (chymases). They are bound to negatively charged heparin or chondroitin sulfate proteoglycans and are stored in secretory granules. Three-dimensional (3D) models of these four proteases were constructed with a comparative molecular modeling technique based on satisfaction of spatial constraints. The models were used to predict immunogenic epitopes and surface regions that are likely to interact with proteoglycans. Nine potential antigenic segments in the four chymases were identified on the basis of solvent accessibility, protrusion, flexibility, and sequence variability. These segments are suitable epitopes for preparation of protease-specific antipeptide immunoglobulin. Two regions with net charges ranging from +6 to +10 at neutral pH were found on the surfaces of mMCP-4 and mMCP-5. The two regions are located far from the substrate binding cleft at diametrically opposite ends of the folded proteases. A strong positive electrostatic potential surrounds the two regions. Thus, they are good candidates for binding sites that interact with heparin proteoglycan in the granules of serosal mast cells. In contrast, mMCP-1 and mMCP-2, which are present in granules of mucosal mast cells that contain chondroitin sulfate, lack one of these regions and have a lower charge density in the other. The differences between the 3D models provide a structural basis for the selective localization of specific chymases within mouse mast cells that contain different proteoglycans.	HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				McNeil, Hugh Patrick/0000-0003-4336-2960	NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-31599, AI-23483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI023483, U19AI031599] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1992, PROTEIN SCI, V1, P426; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BRIGGAMAN RA, 1984, J EXP MED, V160, P1027, DOI 10.1084/jem.160.4.1027; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BURKS C, 1985, COMPUT APPL BIOSCI, V1, P225; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAKRABARTI B, 1980, CRC CR REV BIOCH MOL, V8, P225, DOI 10.3109/10409238009102572; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DAOPIN S, 1991, J MOL BIOL, V221, P873, DOI 10.1016/0022-2836(91)80181-S; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FORSBERG LS, 1988, BIOCHIM BIOPHYS ACTA, V416, P416; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; FROMMEL C, 1988, J THEOR BIOL, V132, P171, DOI 10.1016/S0022-5193(88)80155-3; FUJINAGA M, 1987, J MOL BIOL, V195, P373, DOI 10.1016/0022-2836(87)90658-9; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P4918, DOI 10.1073/pnas.89.11.4918; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRUBER BL, 1988, J IMMUNOL, V140, P3936; GUO NH, 1992, J BIOL CHEM, V267, P19349; GURISH MF, 1992, FASEB J, V6, pA1723; HEUCK CC, 1985, J BIOL CHEM, V260, P4598; HORN D, 1980, POLYM AMINES AMMONIU, P333; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUBBARD TJP, 1987, PROTEIN ENG, V1, P159, DOI 10.1093/protein/1.3.159; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MAIER M, 1983, J IMMUNOL, V130, P2352; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RAZIN E, 1982, J BIOL CHEM, V257, P7229; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; REYNOLDS RA, 1985, ACTA CRYSTALLOGR B, V41, P139, DOI 10.1107/S010876818500177X; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SALEMME FR, 1976, J MOL BIOL, V102, P562; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; SALI A, 1991, THESIS U LONDON LOND; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; Seppa H, 1979, Acta Histochem, V64, P64; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STEVENS FL, 1992, ARTHRITIS RHEUM, V35, P325; STEVENS RL, 1986, J IMMUNOL, V137, P291; SUMMERS NL, 1989, J MOL BIOL, V210, P785, DOI 10.1016/0022-2836(89)90109-5; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; Swindells MB, 1991, CURR OPIN STRUC BIOL, V1, P219, DOI 10.1016/0959-440X(91)90064-Z; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; THORNTON JM, 1986, EMBO J, V5, P409, DOI 10.1002/j.1460-2075.1986.tb04226.x; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; URATA H, 1990, J BIOL CHEM, V265, P22348; VARTIO T, 1981, J BIOL CHEM, V256, P471; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WENDOLOSKI JJ, 1989, PROTEINS, V5, P313, DOI 10.1002/prot.340050407; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144; YURT RW, 1977, J BIOL CHEM, V252, P518; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	97	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9023	9034						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682557				2022-12-25	WOS:A1993KX81100092
J	SIMONET, WS; BUCAY, N; LAUER, SJ; TAYLOR, JM				SIMONET, WS; BUCAY, N; LAUER, SJ; TAYLOR, JM			A FAR-DOWNSTREAM HEPATOCYTE-SPECIFIC CONTROL REGION DIRECTS EXPRESSION OF THE LINKED HUMAN APOLIPOPROTEIN-E AND C-I GENES IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; E MESSENGER-RNA; PERIPHERAL-TISSUES; NONHUMAN-PRIMATES; NEGATIVE ELEMENTS; ENHANCER ELEMENTS; GLOBIN GENE; HIGH-LEVEL; LIVER; LIPOPROTEINS	The human apolipoprotein (apo) E and apoC-I genes are located 5 kilobases apart in the same transcriptional orientation on chromosome 19, and they are expressed at high levels in the liver with lower levels of expression in selected other tissues. Analysis of a series of overlapping human apoE and apoC-I genomic fragments in transgenic mice revealed that the expression of these transgenes in the liver requires a common cis-acting regulatory domain. This hepatic control region (HCR) was localized to a 764-base pair region that is located about 18 kilobases downstream of the apoE promoter and about 9 kilobases downstream of the apoC-I promoter. All the transgenic animals that had been prepared with a construct that contained this region had relatively high levels of transgene expression in the liver, whereas constructs that lacked this region showed no expression in the liver. In situ hybridization studies showed that the HCR directed apoE and apoC-I transgene expression in hepatocytes. When the HCR from the apoE/C-I gene locus was ligated proximal to a human apoA-IV gene fragment, which is not normally expressed in the liver, the resulting apoA-IV/HCR fusion construct was expressed at high levels in the liver, indicating that the HCR could direct high level liver expression of a heterologous promoter/gene construct. Expression of the apoE transgene in the liver and kidney, and perhaps other tissues, required the presence of a nonspecific proximal enhancer element in the apolipoprotein E gene promoter, located between 161 and 141 bp relative to the transcription initiation site. However, the proximal apoE gene promoter, including this enhancer element, contained no sequences capable of directing hepatocyte expression in the absence of the HCR. Thus, the far-downstream HCR appears to contain all of the sequences necessary for determining high level liver-specific gene expression.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 419100,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NHLBI NIH HHS [HL37063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; GILMAN M, 1990, CURRENT PROTOCOLS MO, V1; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LAUER SJ, 1991, ARTERIOSCLEROSIS, V11, pA1390; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Maniatis T., 1982, MOL CLONING; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RALL SC, 1982, J BIOL CHEM, V257, P4171; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMITH JD, 1988, J BIOL CHEM, V263, P8300; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	37	201	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8221	8229						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681840				2022-12-25	WOS:A1993KW97900092
J	MAGLIONE, D; GUERRIERO, V; VIGLIETTO, G; FERRARO, MG; APRELIKOVA, O; ALITALO, K; DELVECCHIO, S; LEI, KJ; CHOU, JY; PERSICO, MG				MAGLIONE, D; GUERRIERO, V; VIGLIETTO, G; FERRARO, MG; APRELIKOVA, O; ALITALO, K; DELVECCHIO, S; LEI, KJ; CHOU, JY; PERSICO, MG			2 ALTERNATIVE MESSENGER-RNAS CODING FOR THE ANGIOGENIC FACTOR, PLACENTA GROWTH-FACTOR (PIGF), ARE TRANSCRIBED FROM A SINGLE GENE OF CHROMOSOME-14	ONCOGENE			English	Article							ENDOTHELIAL-CELL MITOGEN; VASCULAR-PERMEABILITY FACTOR; FACTOR-A-CHAIN; ACID; CDNA; HYBRIDIZATION; SEQUENCES; INDUCTION	We have previously reported on the identification of a cDNA (placenta growth factor, PIGF) coding for a novel angiogenic factor expressed in placental tissue that is similar to vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). Biochemical and functional characterization of PIGF derived from transfected COS-1 celts revealed that it is a glycosylated dimeric secreted protein able to stimulate endothelial cell growth in vitro. Here, we report the isolation and characterization of the PIGF gene located on chromosome 14. At least two different mRNAs are produced from this single-copy gene in different cell lines and tissues. Sequence comparison of the polypeptides encoded by the two different isolated cDNAs indicates that they are identical except for the insertion of a highly basic 21 amino acid stretch at the carboxyl end of the protein. RNA expression analysis of several tissues, tumors and cell tines indicates differential distribution of the two PlGF mRNAs. Finally, preliminary results indicate that the PlGF gene has been conserved in evolution, since the human PlGF cDNA hybridizes to sequences present in the genomic DNA of Drosophila, Xenopus, chicken and mouse.	CNR,INT INST GENET & BIOPHYS,VIA G MARCONI 12,I-80125 NAPLES,ITALY; SIFI SPA,I-95020 LAVINAIO,ITALY; UNIV HELSINKI,DEPT PATHOL,SF-00290 HELSINKI 29,FINLAND; FDN G PASCALE,IST NAZL STUDIO CURA TUMORI,I-80131 NAPLES,ITALY; NICHHD,HUMAN GENET LAB,BETHESDA,MD 20892	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Helsinki; IRCCS Fondazione Pascale; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Alitalo, Kari K/J-5013-2014; Viglietto, Giuseppe/AAC-2852-2019; Del Vecchio, Silvana/F-4972-2012	Alitalo, Kari K/0000-0002-7331-0902; Viglietto, Giuseppe/0000-0003-2327-7515; DEL VECCHIO, Silvana/0000-0002-5466-1213				AUSPRUNK D, 1977, MICROVASC RES, V14, P52; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DONO R, 1991, AM J HUM GENET, V49, P555; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7913; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LEI KJ, 1992, MOL ENDOCRINOL, V6, P703, DOI 10.1210/me.6.5.703; LERACH H, 1977, BIOCHEMISTRY-US, V16, P4743; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1992, IN PRESS GROWTH FACT; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOUZEK CA, 1991, ENDOCRINOLOGY, V129, P950, DOI 10.1210/endo-129-2-950; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; ROCCHI M, 1986, HUMAN GEET, V74; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TISHER E, 1991, J BIOL CHEM, V266, P11974; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WESTERMARK B, 1991, CANCER RES, V51, P5087	35	276	314	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					925	931						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681160				2022-12-25	WOS:A1993KT22000014
J	SATOH, MS; POIRIER, GG; LINDAHL, T				SATOH, MS; POIRIER, GG; LINDAHL, T			NAD+-DEPENDENT REPAIR OF DAMAGED DNA BY HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; ESCHERICHIA-COLI; STRAND BREAKS; ADP-RIBOSYLATION; HUMAN-FIBROBLASTS; AP ENDONUCLEASES; EXCISION REPAIR; BINDING DOMAIN; CDNA SEQUENCE; ENZYME	Rejoining of DNA single-strand breaks generated by treatment of plasmids with gamma-rays, neocarzinostatin, or bleomycin was catalyzed inefficiently by human cell extracts. The reaction was strongly promoted by the addition of NAD+, which was employed for rapid and transient synthesis of poly(ADP-ribose). The DNA rejoining reaction was accompanied by DNA repair replication, apparently due to replacement of damaged residues at termini. Selective depletion of poly(ADP-ribose) polymerase from cell extracts improved the repair of DNA exposed to a variety of DNA-damaging agents by removing the NAD+ dependence of the repair reaction. NAD+-promoted DNA repair by soluble cell extracts also occurred with alkylated DNA as substrate and was suppressed by 3-aminobenzamide. A similar stimulatory effect by NAD+ was observed for repair of ultraviolet-irradiated DNA, and this could be ascribed to the presence of pyrimidine hydrates as minor radiation-induced DNA lesions. No effect was observed on the sealing of gamma-irradiated DNA by supplementation of cell extracts with purified mammalian DNA ligase I or DNA ligase II. The results indicate that poly(ADP-ribose) polymerase interferes with base excision-repair processes because bound enzyme molecules block DNA strand interruptions. Release of bound poly(ADP-ribose) polymerase following automodification, or physical removal of the protein from reaction mixtures, facilitates DNA repair.	LAVAL UNIV,MED CTR,DEPT MOLEC ENDOCRINOL,ST FOY G1V 4G2,PQ,CANADA	Laval University	SATOH, MS (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Poirier, Guy/0000-0002-4869-1424				ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P1; AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BAILLY V, 1989, NUCLEIC ACIDS RES, V17, P3617, DOI 10.1093/nar/17.9.3617; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; CHATTERJEE S, 1989, EXP CELL RES, V184, P1, DOI 10.1016/0014-4827(89)90358-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FERRO AM, 1982, J BIOL CHEM, V257, P7808; HECHT SM, 1986, FASEB J, V45, P2784; HENNER WD, 1983, J BIOL CHEM, V258, P5198; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUET J, 1985, CANCER RES, V45, P987; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JAMES MR, 1982, BIOCHEMISTRY-US, V21, P4007, DOI 10.1021/bi00260a016; JONSSON GG, 1988, CANCER RES, V48, P4233; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KAPPEN LS, 1982, P NATL ACAD SCI-BIOL, V79, P744, DOI 10.1073/pnas.79.3.744; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LJUNGQUIST S, 1977, NUCLEIC ACIDS RES, V4, P2871, DOI 10.1093/nar/4.8.2871; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; PARK IS, 1989, BIOCHEM BIOPH RES CO, V164, P1226, DOI 10.1016/0006-291X(89)91800-7; REALINI CA, 1992, J BIOL CHEM, V267, P18858; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Sugimura T, 1980, Adv Enzyme Regul, V18, P195, DOI 10.1016/0065-2571(80)90016-3; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WARNER HR, 1980, P NATL ACAD SCI-BIOL, V77, P4602, DOI 10.1073/pnas.77.8.4602; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YOSHIHARA K, 1992, EXP CELL RES, V200, P126, DOI 10.1016/S0014-4827(05)80080-1; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	54	185	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5480	5487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680646				2022-12-25	WOS:A1993KR82200023
J	PAN, ZX; KRAVCHENKO, VV; YE, RD				PAN, ZX; KRAVCHENKO, VV; YE, RD			PLATELET-ACTIVATING-FACTOR STIMULATES TRANSCRIPTION OF THE HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR IN MONOCYTES - CORRELATION WITH AN INCREASED KAPPA-B BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE CELLS; FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; MESSENGER-RNA; EXPRESSION; CLONING; GENE; PAF; ACETYLHYDROLASE; INDUCTION	Human peripheral blood monocytes responded to stimulation of platelet-activating factor (PAF) with up-regulation of the transcript fro heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent mitogen for vascular smooth muscle cells. This function of PAF was observed at nanomolar concentrations of the ligand, starting at 30 min after stimulation. The PAF-induced up-regulation of HB-EGF mRNA was accompanied by an increase in kappa B binding activity. These functions of PAF appeared to be mediated through the cell surface PAF receptors, as two PAF receptors antagonists, WEB 2086 and L-659,989, blocked both the up-regulation of HB-EGF mRNA and kappa B binding activity induced by PAF. The antagonists, however, had no effect on phorbol ester-induced up-regulation of HB-EGF and mRNA and kappa B binding activity. Pretreatment of monocytes with pertussis toxin inhibited these functions of PAF, whereas cholera toxin had no inhibitory effect. Pyrrolidine dithiocarbamate, an inhibitor effect. Pyrrolidine dithiocarbamate, an inhibitor for NF-kappa B activation, markedly reduced PAF-stimulated kappa B binding activity as well as up-regulation of HB-EGF mRNA. These results suggest a potential role of PAF in HB-EGF expression and provide evidence that this stimulation may occur through increased kappa B binding activity.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NIGMS NIH HHS [GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BLANK ML, 1981, J BIOL CHEM, V256, P175; BOURGAIN RH, 1985, PROSTAGLANDINS, V30, P185, DOI 10.1016/0090-6980(85)90184-4; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1991, SCIENCE, V251, P986; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; HWANG SB, 1991, LIPIDS, V26, P1148, DOI 10.1007/BF02536520; Koltai M, 1992, Agents Actions Suppl, V37, P333; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAKANO T, 1993, J BIOL CHEM, V268, P22941; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STEINBERG D, 1987, CIRCULATION, V76, P508, DOI 10.1161/01.CIR.76.3.508; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; TRIPATHI YB, 1992, BIOCHEM J, V286, P527, DOI 10.1042/bj2860527; WEYRICH AS, 1995, IN PRESS J CLIN INVE; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, P149	37	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7787	7790		10.1074/jbc.270.14.7787	http://dx.doi.org/10.1074/jbc.270.14.7787			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713868	hybrid			2022-12-25	WOS:A1995QR52600002
J	ROSENBERG, HF				ROSENBERG, HF			RECOMBINANT HUMAN EOSINOPHIL CATIONIC PROTEIN - RIBONUCLEASE-ACTIVITY IS NOT ESSENTIAL FOR CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHISTOSOMA-MANSONI; GRANULE PROTEINS; HYPEREOSINOPHILIC SYNDROME; ENDOMYOCARDIAL DISEASE; COMPARATIVE TOXICITY; TRYPANOSOMA-CRUZI; MOLECULAR-CLONING; ESCHERICHIA-COLI; CATHEPSIN-G; NEUROTOXIN	Eosinophil cationic protein (ECP) is a toxin secreted by activated human eosinophils that has anti-parasitic, antibacterial, and neurotoxic activities; ECP also has ribonuclease activity and structural homology to other mammalian ribonucleases. To determine the relationship between the ribonuclease activity and cytotoxicity of ECP, a method for producing recombinant ECP (rECP) in a prokaryotic expression system was devised. Periplasmic isolates from induced bacterial transfectants contained enzymatically active rECP; micromolar concentrations of rECP were shown to be toxic for Staphylococcus aureus (strain 502A). In contrast; recombinant eosinophil-derived neurotoxin, with 67% amino acid sequence identity to ECP, had little to no toxicity for S. aureus; these findings are analogous to those obtained with purified, granule-derived ECP and eosinophil-derived neurotoxin. Two single base pair mutations were introduced into the coding sequence of rECP (Lys(38) to Arg and His(128) to Asp) to convert ribonuclease active-site residues into non-functional counterparts. These mutations eliminated the ribonuclease activity of rECP but had no discernible effect on the antibacterial activity of this protein, demonstrating that ribonuclease activity and cytotoxicity are, in this case, independent functions of ECP.			ROSENBERG, HF (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N104,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ACKERMAN SJ, 1985, AM J TROP MED HYG, V34, P735, DOI 10.4269/ajtmh.1985.34.735; ANFINSEN CB, 1954, J BIOL CHEM, V207, P201; ARDELT W, 1991, J BIOL CHEM, V266, P245; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; BANGALORE N, 1990, J BIOL CHEM, V265, P13584; BARKER RL, 1989, J IMMUNOL, V143, P952; BLACKBURN P, 1982, ENZYMES, P317; Blobel G, 1979, Symp Soc Exp Biol, V33, P9; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GRAY GL, 1985, GENE, V39, P247, DOI 10.1016/0378-1119(85)90319-1; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; HAMANN KJ, 1987, J PARASITOL, V73, P523, DOI 10.2307/3282130; LEHRER RI, 1989, J IMMUNOL, V142, P4428; MAKINO S, 1993, EOSINOPHILS BIOL CLI; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; MOLINA HA, 1989, IMMUNOLOGY, V66, P289; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NEWTON DL, 1994, J NEUROSCI, V14, P538; PARRILLO JE, 1979, AM J MED, V67, P572, DOI 10.1016/0002-9343(79)90227-4; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIN CH, 1992, BIOCHEM J, V283, P137, DOI 10.1042/bj2830137; SHAFER WM, 1991, J BIOL CHEM, V266, P112; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; Spry C J, 1983, Contrib Microbiol Immunol, V7, P212; Spry CJ, 1988, EOSINOPHILS COMPREHE; SPRY CJF, 1986, POSTGRAD MED J, V62, P609, DOI 10.1136/pgmj.62.728.609; TAI PC, 1987, LANCET, V1, P643; VENGE P, 1978, BRIT J HAEMATOL, V38, P475, DOI 10.1111/j.1365-2141.1978.tb01072.x; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	39	173	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7876	7881		10.1074/jbc.270.14.7876	http://dx.doi.org/10.1074/jbc.270.14.7876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713881	hybrid			2022-12-25	WOS:A1995QR52600017
J	BITTORF, SV; WILLIAMS, EC; MOSHER, DF				BITTORF, SV; WILLIAMS, EC; MOSHER, DF			ALTERATION OF VITRONECTIN - CHARACTERIZATION OF CHANGES INDUCED BY TREATMENT WITH UREA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; THROMBIN-ANTITHROMBIN-III; SERUM SPREADING FACTOR; TERMINAL COMPLEMENT COMPLEX; HEPARIN-BINDING PROPERTIES; MEMBRANE ATTACK COMPLEX; IMMUNOHISTOCHEMICAL DEMONSTRATION; GEL-ELECTROPHORESIS; BETA-ENDORPHIN; MESSENGER-RNA	Vitronectin circulates in blood as a 70-kDa monomer that interacts with complexes generated in the terminal steps of the coagulation and complement cascades. Vitronectin complexed to thrombin-antithrombin or C5b-9 is conformationally altered as evidenced by enhanced reactivity with monoclonal antibody 8E6 and binding to heparin; these same alterations also occur when vitronectin is treated with urea (Tomasini, B. R., and Mosher, D. F. (1988) Blood 72,903-912; Hogasenk, K., Molnes, T. E., and Harboe, M. (1992) J. BioL Chem. 267, 23076-23082). We have modified the purifications of native and urea-treated vitronectin to better control conformational state and characterized the alterations induced by urea. After treatment with N-ethylmaleimide to prevent formation of disulfide-linked multimers, purification in 8 M urea, and dialysis against physiological saline, vitronectin was largely oligomeric (approximately 800 kDa) as assessed by gel filtration and polyacrylamide gel electrophoresis in the absence of sodium dodecyl sulfate. Oligomeric urea-treated vitronectin reacted more strongly with the 8E6 antibody, bound biotinylated heparin more strongly, and neutralized the anticoagulant activity of heparin better than monomeric altered vitronectin or native vitronectin. After incubation with urea at 25-degrees-C, native vitronectin, treated during purification with dithionitrobenzoic acid to force free sulfhydryls to intramolecular disulfides, exhibited increased reactivity with antibody 8E6, increased binding to heparin, and oligomerization. In addition, incubation in urea caused rearrangement of disulfides as assessed by loss of the light chain of two-chain vitronectin. The transition for these effects occurred between 2 and 4 M urea. Thus, an irreversible conformational alteration occurs upon treatment of vitronectin with urea, resulting in oligomers that bind avidly to heparin.	UNIV WISCONSIN,DEPT MED,4285A MED SCI CTR,1300 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL29586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; BARNES DW, 1985, J BIOL CHEM, V260, P9117; CANN JR, 1976, BIOCHEMISTRY-US, V15, P4614, DOI 10.1021/bi00666a011; CONLAN MG, 1988, BLOOD, V72, P185; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAHLBACK K, 1987, HISTOCHEMISTRY, V87, P511, DOI 10.1007/BF00492465; DAHLBACK K, 1989, J INVEST DERMATOL, V92, P727, DOI 10.1111/1523-1747.ep12721619; DAMUS PS, 1975, METHOD ENZYMOL, V45, P653; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEROMEUF C, 1993, THROMB HAEMOSTASIS, V69, P436; FALK RJ, 1987, AM J PATHOL, V127, P182; GUTTIER C, 1989, VIRCHOWS ARCH A, V414, P309; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1138; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HILDEBRAND A, 1989, BIOCHEM BIOPH RES CO, V159, P799, DOI 10.1016/0006-291X(89)90065-X; HINTNER H, 1990, BRIT J DERMATOL, V123, P39, DOI 10.1111/j.1365-2133.1990.tb01822.x; HINTNER H, 1991, J INVEST DERMATOL, V96, P747, DOI 10.1111/1523-1747.ep12470980; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; ILL CR, 1985, J BIOL CHEM, V260, P5610; INAZUKA S, 1992, HEPATOLOGY, V15, P629; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, J BIOL CHEM, V262, P16343; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P79; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PEISSNER KT, 1991, ANN REV CELL BIOL, V7, P275; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PREISSNER KP, 1989, EUR J IMMUNOL, V19, P69, DOI 10.1002/eji.1830190112; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; PREISSNER KT, 1988, THROMB HAEMOSTASIS, V60, P309; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; SATO R, 1990, J BIOL CHEM, V266, P11227; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SHAFFER MC, 1984, J LAB CLIN MED, V103, P783; SOLEM M, 1991, MOL CELL BIOCHEM, V100, P141; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SUN X, 1992, SEMIN THROMB HEMOST, V18, P243, DOI 10.1055/s-2007-1002430; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; WILLIAMS EC, 1992, J LAB CLIN MED, V120, P159; YAHTOHGO T, 1988, CELL STRUCT FUNCT, V13, P281	58	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24838	24846						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693706				2022-12-25	WOS:A1993MG67300050
J	NAKAO, T; KON, K; ANDO, S; MIYATAKE, T; YUKI, N; LI, YT; FURUYA, S; HIRABAYASHI, Y				NAKAO, T; KON, K; ANDO, S; MIYATAKE, T; YUKI, N; LI, YT; FURUYA, S; HIRABAYASHI, Y			NOVEL LACTO-GANGLIO TYPE GANGLIOSIDES WITH G(M2)-EPITOPE IN BOVINE BRAIN WHICH REACT WITH IGM FROM A PATIENT OF THE AMYOTROPHIC LATERAL SCLEROSIS-LIKE DISORDER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING GLYCOSPHINGOLIPIDS; HANGANUTZIU-DEICHER ANTIGENS; GUILLAIN-BARRE-SYNDROME; MONOCLONAL-ANTIBODY; CHROMATOGRAPHY; NEUROPATHY; DISEASE; SERIES; CELLS; GM1	A motor neuron disorder resembling that of amyotrophic lateral sclerosis was found in a patient who had received the intramuscular administration of a mixture of bovine brain gangliosides (Yuki, N., Sato, S., Miyatake, T., Sugiyama, K., Katagiri, T., and Sasaki, H. (1991) Lancet 337, 1109-1110). A very high titer of anti-G(M2) IgM was detected in the patient's serum and the patient quickly recovered after plasmapheresis. The clinical course of the patient appeared to be different from amyotrophic lateral sclerosis and the anti-G(M2) IgM was thought to be the culprit. The IgM reacted with G(M2), G(M1b)-GalNAc, SPG(alpha2-3)-GalNAc, and G(D1a)-GalNAc, but not with G(A2) or G(D2), meaning that the epitope recognized by the IgM was the G(M2)-like terminal structure, GalNAcbeta1-4(Neu-Acalpha2-3)Galbeta1-. In this study, we found two novel G(M2)-epitope containing gangliosides, X1 and X2, in bovine brain gangliosides by TLC immunostaining using the patient's IgM. They were characterized as unique lacto-ganglio type gangliosides containing the following branching structures. Their unusual structures may be immunogenic to humans to induce anti-G(M2) antibody.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT MEMBRANE BIOCHEM, ITABASHI KU, TOKYO 173, JAPAN; TULANE UNIV, SCH MED, DEPT BIOCHEM, NEW ORLEANS, LA 70112 USA; TOKYO MED & DENT UNIV, SCH MED, DEPT NEUROL, BUNKYO KU, TOKYO 113, JAPAN; INST PHYS & CHEM RES, GLYCOCELL BIOL LAB, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN	Tulane University; Tokyo Medical & Dental University (TMDU); RIKEN	NAKAO, T (corresponding author), TAISHO PHARMACEUT CO LTD, RES CTR, DEPT APPL BIOL, 1-350 YOSHINO CYO, OMIYA, SAITAMA 330, JAPAN.		Yuki, Nobuhiro/H-3187-2012	Furuya, Shigeki/0000-0001-9020-3597; Hirabayashi, Yoshio/0000-0002-5774-7354	NINDS NIH HHS [NS09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; BRADLEY WG, 1990, MUSCLE NERVE, V13, P833, DOI 10.1002/mus.880130910; DEGASPERI R, 1987, J BIOL CHEM, V262, P17149; DOHI T, 1991, J BIOL CHEM, V266, P24038; FREDDO L, 1986, NEUROLOGY, V36, P454, DOI 10.1212/WNL.36.4.454; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRABAYASHI Y, 1991, J BIOL CHEM, V266, P10268; ILYAS AA, 1988, J BIOL CHEM, V263, P4369; ITOH T, 1981, J BIOL CHEM, V256, P165; KANNAGI R, 1984, J BIOL CHEM, V259, P8444; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; NAKAO T, 1991, BIOCHIM BIOPHYS ACTA, V1086, P305, DOI 10.1016/0005-2760(91)90174-G; NOBILEORAZIO E, 1992, J NEUROL SCI, V109, P200, DOI 10.1016/0022-510X(92)90169-L; PESTRONK A, 1988, ANN NEUROL, V24, P73, DOI 10.1002/ana.410240113; QUARLES RH, 1989, METHOD ENZYMOL, V179, P291; SCHONHOFER PS, 1991, LANCET, V338, P757; SCHONHOFER PS, 1992, NEW ENGL J MED, V326, P493; SHIGETA K, 1987, J BIOL CHEM, V262, P1358; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKI T, 1986, J BIOL CHEM, V261, P3075; YUKI N, 1992, MUSCLE NERVE, V15, P1371; YUKI N, 1991, LANCET, V337, P1109, DOI 10.1016/0140-6736(91)91767-O; YUKI N, 1991, LANCET, V338, P314	31	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21028	21034						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691804				2022-12-25	WOS:A1993MA28800061
J	HOLT, EH; VASAVADA, RC; BANDER, NH; BROADUS, AE; PHILBRICK, WM				HOLT, EH; VASAVADA, RC; BANDER, NH; BROADUS, AE; PHILBRICK, WM			REGION-SPECIFIC METHYLATION OF THE PARATHYROID HORMONE-RELATED PEPTIDE GENE DETERMINES ITS EXPRESSION IN HUMAN RENAL-CARCINOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING-PROTEIN; DNA METHYLATION; HUMORAL HYPERCALCEMIA; TRANSCRIPTIONAL REGULATION; CHROMATIN STRUCTURE; DENOVO METHYLATION; MESSENGER-RNAS; IDENTIFICATION; MALIGNANCY; PROMOTER	Tumor production of a parathyroid hormone-related peptide (PTHrP) is a common cause of the syndrome of humoral hypercalcemia of malignancy, which is frequently associated with renal cell carcinomas. Why certain renal cell carcinomas produce PTHrP while others do not is unknown. Using a system of 12 human renal carcinoma cell lines which either do (n = 6) or do not (n = 6) produce PTHrP, we found that the expression of the PTHrP gene in these cell lines is controlled at the transcriptional level. Transfection studies failed to demonstrate variation in PTHrP promoter activity in these cell lines sufficient to account for the differential PTHrP expression, implicating a cis-acting mechanism. Transcription of the PTHrP gene in these cell lines was found to correlate with the methylation state of specific CpG dinucleotides located within the promoter region but outside a CpG island. The functional importance of this mechanism of control was confirmed by the ability of the demethylating agent, 5-azacytidine, to induce PTHrP mRNA expression in previously nonexpressing cell lines.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; MEM SLOAN KETTERING CANC CTR,DEPT SURG,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021	Yale University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital	HOLT, EH (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,DIV ENDOCRINE,FITKIN 1,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BONNEROT C, 1990, J IMMUNOL, V144, P323; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DRAHOVSKY D, 1971, J MOL BIOL, V61, P343, DOI 10.1016/0022-2836(71)90384-6; EDWARDS YH, 1990, PHILOS T R SOC B, V326, P207, DOI 10.1098/rstb.1990.0005; GOUNARI F, 1987, GENE DEV, V1, P899, DOI 10.1101/gad.1.9.899; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IKEDA K, 1988, J CLIN INVEST, V81, P2010, DOI 10.1172/JCI113551; IKEDA K, 1989, J BIOL CHEM, V264, P15743; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JONES PA, 1990, PHILOS T R SOC B, V326, P277, DOI 10.1098/rstb.1990.0011; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; Sambrook J, 1989, MOL CLONING LABORATO; SNELLER MC, 1987, J IMMUNOL, V138, P3505; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P4605, DOI 10.1073/pnas.85.13.4605; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; TURKER MS, 1989, J BIOL CHEM, V264, P11632; VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WEIR EC, 1988, J CLIN INVEST, V81, P818, DOI 10.1172/JCI113389; YASUDA T, 1989, J BIOL CHEM, V264, P7720; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20639	20645						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690760				2022-12-25	WOS:A1993LY01900102
J	SHUMAN, S; TURNER, J				SHUMAN, S; TURNER, J			SITE-SPECIFIC INTERACTION OF VACCINIA VIRUS TOPOISOMERASE-I WITH BASE AND SUGAR MOIETIES IN DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLEAVAGE; BINDING	Vaccinia DNA topoisomerase specifically binds and forms a covalent adduct at DNA sites containing a conserved sequence element 5'(C/T)CCTT down in the scissile strand. The molecular interactions that contribute to recognition of the CCCTT motif in a synthetic DNA substrate have been examined using modification interference, modification protection, and analog substitution techniques. We report that topoisomerase makes contact with guanine nucleotide bases of the pentamer motif complementary strand (3'GGGAA) within the major groove of the DNA helix and that alteration of the binding surface by chemical modification is deleterious to the interaction. Additional contacts are made with guanine residues located outside the pentamer element. The enzyme is unable to form a covalent adduct with synthetic RNA substrates. Analysis of the cleavage of DNA duplexes containing 2'OMe sugars suggests that the inability of the vaccinia topoisomerase to cleave either an RNA duplex or an RNA:DNA hybrid can be accounted for by the interfering effects of a 2' sugar substituent at two or more sites within the pentamer. Interaction with the sugar at the +2T nucleotide appears to be the most critical, as judged by the effects of single sugar substitutions.			SHUMAN, S (corresponding author), SLOAN KETTERING INST CANC RES,MOLEC BIOL PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E	9	47	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18943	18950						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689562				2022-12-25	WOS:A1993LV65900085
J	LANDRY, D; SULLIVAN, S; NICOLAIDES, M; REDHEAD, C; EDELMAN, A; FIELD, M; ALAWQATI, Q; EDWARDS, J				LANDRY, D; SULLIVAN, S; NICOLAIDES, M; REDHEAD, C; EDELMAN, A; FIELD, M; ALAWQATI, Q; EDWARDS, J			MOLECULAR-CLONING AND CHARACTERIZATION OF P64, A CHLORIDE CHANNEL PROTEIN FROM KIDNEY MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS GENE; EXPRESSION; CONDUCTANCE; ACIDIFICATION; VESICLES; CELLS; IDENTIFICATION; RECONSTITUTION; PURIFICATION; EPITHELIA	Chloride channels were previously purified from bovine kidney cortex membranes using a drug affinity column. Reconstitution of the purified proteins into artificial liposomes and planar bilayers yielded chloride channels. A 64-kDa protein, p64, identified as a component of this chloride channel was used to generate antibodies which depleted solubilized kidney membranes of all chloride channel activity. This antibody has now been used to identify a clone, H2B, from a kidney cDNA library. Antibodies, affinity-purified against the fusion protein of H2B also depleted solubilized kidney cortex from all chloride channel activity. The predicted amino acid sequence of p64 shows that it contains two and possibly four putative transmembrane domains and potential phosphorylation sites by protein kinase A, protein kinase C, and casein kinase II. There was no significant homology to other protein (or DNA) sequences in the data base. The protein is expressed in all cells tested. Expression of its mRNA in Xenopus laevis oocytes led to the insertion of a protein with the appropriate molecular mass in microsomes but not in the plasma membrane. It is likely that p64 represents the chloride channel of intracellular organelles.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NIDDK NIH HHS [DK41146, DK39532, DK01336] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041146, K12DK001336, R01DK039532] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; BRETAG AH, 1987, PHYSIOL REV, V65, P310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS R, 1982, NUCLEIC ACIDS RES, V10, P6353, DOI 10.1093/nar/10.20.6353; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FRIZZELL RA, 1986, FASEB J, V45, P2727; GARTY H, 1983, J BIOL CHEM, V258, P3094; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GREGER R, 1988, ANNU REV PHYSIOL, V50, P111; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; RAN S, 1991, J BIOL CHEM, V266, P4782; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REENSTRA WW, 1992, BIOCHEMISTRY-US, V31, P175, DOI 10.1021/bi00116a026; RIORDAN JR, 1989, SCIENCE, V245, P1066; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; Sambrook J, 1989, MOL CLONING LABORATO; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STONE DK, 1983, J BIOL CHEM, V258, P4059; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TOYOSHIMA Y, 1975, BIOCHEMISTRY-US, V14, P1525, DOI 10.1021/bi00678a028; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	43	123	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14948	14955						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686908				2022-12-25	WOS:A1993LL75900063
J	REDDY, GL; IWAMOTO, T; TOMICH, JM; MONTAL, M				REDDY, GL; IWAMOTO, T; TOMICH, JM; MONTAL, M			SYNTHETIC PEPTIDES AND 4-HELIX BUNDLE PROTEINS AS MODEL SYSTEMS FOR THE PORE-FORMING STRUCTURE OF CHANNEL PROTEINS .2. TRANSMEMBRANE SEGMENT M2 OF THE BRAIN GLYCINE RECEPTOR IS A PLAUSIBLE CANDIDATE FOR THE PORE-LINING STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; IONIC CHANNELS; CHOLINERGIC RECEPTOR; H-3 CHLORPROMAZINE; CHLORIDE CHANNEL; XENOPUS OOCYTES; ALPHA-HELICES; BINDING-SITE; SPINAL-CORD	A synthetic 23-mer peptide (M2GlyR) with the amino acid sequence of the putative transmembrane segment M2 of the strychnine-binding alpha subunit of the inhibitory glycine receptor forms anion-selective channels in phospholipid bilayers. The most frequent events show single-channel conductances, gamma, of 25 pS and 49 pS in symmetric 0.5 M KCl with channel open lifetimes, tau(o), in the millisecond time range. These properties match those of authentic glycine receptors studied in inside-out patches of cultured rat spinal cord neurons, namely gamma = 27 pS and gamma = 45 pS, and tau(o) in the millisecond time range. The channel activity of M2GlyR is sequence-specific: 1) a synthetic peptide with the sequence of putative transmembrane segment M1 (M1GlyR), not considered to contribute to the channel lining, does not form channels; 2) an analog of M2GlyR with site-specific substitutions displays distinct channel properties: 2 arginine residues at the N and C termini of M2, postulated to contribute to the anion selectivity of the channel, are substituted by glutamic acids, and the analog peptide ([Glu3,22]M2GlyR) forms cation-selective channels. Further, a four-helix bundle protein (T4M2GlyR) formed by tethering four identical M2GlyR modules to a carrier template forms homogeneous anion-selective channels with gamma = 25 pS in 0.5 M KCl. These channels are blocked by picrotoxin and by the anion channel blockers 9-anthracene carboxylic acid and niflumic acid, but not by an analog of the local anesthetic lidocaine (QX-222), a cation channel blocker. Observed single-channel properties suggest that a pentameric assembly of alpha and beta subunits with a central pore lined by M2 segments would account for conductance properties of the authentic glycine receptor and the 2 arginines at either end of M2 could confer anion specificity to the receptor channel.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, CHILDRENS HOSP, LOS ANGELES, CA 90027 USA	University of California System; University of California San Diego; University of Southern California; University of Southern California; Children's Hospital Los Angeles; University of Southern California				TOMICH, JOHN/0000-0001-7848-8307	NIGMS NIH HHS [GM-43617, GM-42340] Funding Source: Medline; NIMH NIH HHS [MH-44638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042340, R29GM043617, R01GM043617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE N, 1985, EXPERIENTIA, V41, P70; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; EISENMAN G, 1990, PROG CELL R, V1, P195; GARCIACALVO M, 1989, BIOCHEMISTRY-US, V28, P6405, DOI 10.1021/bi00441a037; GESELL J, 1992, 6TH S PROT SOC, V52; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; GROVE A, 1992, METHOD ENZYMOL, V207, P510; GROVE A, 1991, P NATL ACAD SCI USA, V88, P6418, DOI 10.1073/pnas.88.15.6418; GROVE A, 1991, BIOTECHNOLOGY CELL R, V4, P89; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; KRNJEVIC K, 1974, PHYSIOL REV, V54, P418, DOI 10.1152/physrev.1974.54.2.418; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABARCA P, 1985, BIOPHYS J, V47, P469, DOI 10.1016/S0006-3495(85)83939-4; LANGOSCH D, 1991, BIOCHIM BIOPHYS ACTA, V1063, P36, DOI 10.1016/0005-2736(91)90350-H; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; MONTAL M, 1986, ION CHANNEL RECONSTI, P157; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; NUMA S, 1989, HARVEY LECT, V83, P121; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OIKI S, 1990, PROTEINS, V8, P226, DOI 10.1002/prot.340080305; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; TWYMAN RE, 1991, J PHYSIOL-LONDON, V435, P303, DOI 10.1113/jphysiol.1991.sp018512; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE MM, 1990, MOL PHARMACOL, V37, P720	39	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14608	14615						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686901				2022-12-25	WOS:A1993LL75900015
J	ODA, A; DRUKER, BJ; ARIYOSHI, H; SMITH, M; SALZMAN, EW				ODA, A; DRUKER, BJ; ARIYOSHI, H; SMITH, M; SALZMAN, EW			PP60SRC IS AN ENDOGENOUS SUBSTRATE FOR CALPAIN IN HUMAN BLOOD-PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; CA-2+-DEPENDENT PROTEASE; STIMULATED PLATELETS; INHIBITOR CALPEPTIN; PLASMA-MEMBRANE; ACTIVATION; THROMBIN; AGGREGATION; PHOSPHORYLATION; PP60C-SRC	Calpain is distributed ubiquitously in virtually every tissue (Croall, D. E., and DeMartino, G. N. (1991) Physiol. Rev. 71, 813-846), but its physiological role remains to be determined. The identification of its natural endogenous substrates would be of great interest. Since pp60src, a major tyrosine kinase in platelets, is known to be easily cleaved during purification from cells (Feder, D., and Bishop, J. M. (1990) J. Biol. Chem. 265, 8205-8211), we examined the possibility that it is an endogenous substrate of calpain. In the whole cell lysate from resting platelets, which was analyzed by Western blotting with monoclonal antibody 327, we found pp60src almost exclusively in a 60-kDa form, with a trace of 52-kDa form. Addition of A23187 (a calcium ionophore) or dibucaine, which are known to be activators of platelet calpain (Croall and DeMartino, 1991; Fox, J. E., Reynolds, C., Morrow, J. S., and Phillips, D. R. (1987) Blood 76, 2510-2519; Fox, J. E., Austin, C. D., Boyles, J. K., and Steffen, P. K. (1990b) J. Cell Biol. 111, 483-493), caused dose- and time-dependent cleavage of actin-binding protein and p235 protein (talin). At the same time, loss of the 60-kDa species of pp60src and generation of the 52-kDa (occasionally seen as doublets) and 47-kDa species were detected by the Western blotting. In platelets aggregated by 1 unit/ml thrombin, apparently identical cleavage products were found. The cleavage of pp60src was inhibited by calpeptin (20 muM), an inhibitor of calpain (Tsujinaka, T., Kajiwara, Y., Kambayashi, J., Sakon, M., Higuchi, N., Tanaka, T., and Mori, T. (1988) Biochem. Biophys. Res. Commun. 153,1201-1208; Tsujinaka, T., Ariyoshi, H., Uemura, Y., Sakon, M., Kambayashi, J., and Mori, T. (1990) Life Sci. 46, 1059-1066; Fox, J. E., Clifford, C. C., and Austin, C. D. (1990) Blood 76, 2510-2519; Fox, J. E., Austin, C. D., Boyles, J. K., and Steffen, P. K. (1990) J. Cell. Biol. 111, 483-493; Fox, J. E., Austin, C. D., Clifford, C. C., and Steffen, P. K. (1991) J. Biol. Chem. 266, 13289-13295). Addition of EGTA (3 mM) to the extracellular media completely inhibited the cleavage of actin-binding protein, talin, and pp60src in response to A23187 (1 muM). Intact pp60src was distributed in both cytosolic and particulate (membrane) fractions. Cleaved species were found exclusively in the cytosolic fraction. pp60src-associated enolase kinase activity was reduced. Thus, pp60src is an endogenous substrate for calpain, the cleavage of which may have regulatory effects on the kinase.	BETH ISRAEL HOSP,DEPT SURG,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR MOLEC BIOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Druker, Brian/0000-0001-8331-8206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DHAR A, 1991, J BIOL CHEM, V266, P18797; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NACHMIAS VT, 1979, BLOOD, V53, P63; ODA A, 1992, AM J PHYSIOL, V262, pC701, DOI 10.1152/ajpcell.1992.262.3.C701; ODA A, 1992, J BIOL CHEM, V267, P20075; OKITA JR, 1989, BLOOD, V74, P715; PEERSCHKE EIB, 1986, BLOOD, V68, P463; RESH MD, 1990, ONCOGENE, V5, P1437; TSUJINAKA T, 1990, LIFE SCI, V46, P1059, DOI 10.1016/0024-3205(90)90414-M; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WENCELDRAKE JD, 1991, ARTERIOSCLER THROMB, V11, P882, DOI 10.1161/01.ATV.11.4.882; WHEELERJONES CPD, 1989, BIOCHEM J, V263, P969, DOI 10.1042/bj2630969; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005	33	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12603	12608						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685344				2022-12-25	WOS:A1993LG65800057
J	PARK, HY; RUSSAKOVSKY, V; OHNO, S; GILCHREST, BA				PARK, HY; RUSSAKOVSKY, V; OHNO, S; GILCHREST, BA			THE BETA ISOFORM OF PROTEIN-KINASE-C STIMULATES HUMAN MELANOGENESIS BY ACTIVATING TYROSINASE IN PIGMENT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN MELANOCYTES; PHORBOL-ESTER; RAT FIBROBLASTS; MELANOMA-CELLS; 3T3-L1 CELLS; CYCLIC-AMP; PHOSPHORYLATION; DIACYLGLYCEROL; EXPRESSION	We have investigated the role of protein kinase C (PKC) in human melanogenesis. The level of PKC activity paralleled the total melanin content in cultured newborn melanocytes. Activation of PKC by treatment with 5 x 10(-7) M phorbol dibutyrate acutely caused a doubling in the activity of tyrosinase, the rate-limiting enzyme in melanogenesis, known to correlate directly with melanin synthesis in these cells. When PKC was depleted to 5-10% of initial levels, there was a 40-50% parallel reduction in tyrosinase activity; and regeneration of PKC activity was associated with the recovery of tyrosinase activity. By Northern blot analysis, the alpha and beta but not the gamma isoforms were detectable in melanocytes. By Western blot analysis, the racially determined pigment level in cultured melanocytes correlated with PKC-beta protein expression. In a pigmented human melanoma line (P-MM4, 20-30 ng melanin/mug protein) and its nonpigmented subclone (NP-MM4, undetectable melanin), PKC-alpha mRNA was expressed in both, whereas PKC-beta mRNA was detectable only in P-MM4 cells. Tyrosinase protein level was comparable in both cell lines. When NP-MM4 cell lysate was incubated with melanocyte lysate known to contain PKC-beta, tyrosinase activity per mug of melanocyte protein in the combined lysate increased, consistent with activation of the previously inactive tyrosinase of NP-MM4 origin. Moreover, NP-MM4 cells transiently transfected with PKC-beta cDNA increased tyrosinase activity from undetectable to detectable levels. These combined data show that PKC-beta regulates human melanogenesis by activating tyrosinase.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOLEC BIOL,KANAZAWA KU,YOKOHAMA 236,JAPAN	Yokohama City University	PARK, HY (corresponding author), BOSTON UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02118, USA.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024538] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24538] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS G, 1991, CANCER RES, V51, P3281; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; GILCHREST BA, 1984, J INVEST DERMATOL, V83, P370, DOI 10.1111/1523-1747.ep12264638; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JENG AY, 1987, BIOCHEM BIOPH RES CO, V145, P782, DOI 10.1016/0006-291X(87)91033-3; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORELLI JG, 1992, J INVEST DERMATOL, V98, P55, DOI 10.1111/1523-1747.ep12494602; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P2597; NILES RM, 1989, CANCER RES, V49, P4483; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PARK HY, 1990, CANCER RES, V50, P7145; PARK HY, 1992, J INVEST DERMATOL, V98, P562; PARK HY, 1992, IN PRESS CLIN RES; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; POMERANT.SH, 1966, J BIOL CHEM, V241, P161; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UEDA H, 1991, FEBS LETT, V292, P57, DOI 10.1016/0014-5793(91)80833-O; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	50	133	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11742	11749						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685020				2022-12-25	WOS:A1993LF28400044
J	GREGSON, JM; CRAIN, PF; EDMONDS, CG; GUPTA, R; HASHIZUME, T; PHILLIPSON, DW; MCCLOSKEY, JA				GREGSON, JM; CRAIN, PF; EDMONDS, CG; GUPTA, R; HASHIZUME, T; PHILLIPSON, DW; MCCLOSKEY, JA			STRUCTURE OF THE ARCHAEAL TRANSFER-RNA NUCLEOSIDE-G-ASTERISK-15 (2-AMINO-4,7-DIHYDRO-4-OXO-7-BETA-D-RIBOFURANOSYL-1H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBOXIMIDAMIDE (ARCHAEOSINE))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; ARCHAEBACTERIAL TRANSFER-RNA; TRANSFER RIBONUCLEIC-ACID; COLI TRANSFER-RNA; LIQUID-CHROMATOGRAPHY; HALOBACTERIUM-VOLCANII; MODIFIED NUCLEOSIDE; GAS-PHASE; SEQUENCES; IONS	A number of post-transcriptional modifications in tRNA are phylogenetically characteristic of the bacterial, eukaryal, or archaeal domains, both with respect to sequence location and molecular structure at the nucleoside level. One of the most distinct such modifications is nucleoside G*, located in archaeal tRNA at position 15, which in bacterial and eukaryal tRNAs is a conserved site involved in maintenance of the dihydrouridine loop-T-loop tertiary interactions. G* occurs widely in nearly every branch of the archaeal phylogenetic domain, in contrast to its absence in all reported bacterial and eukaryal tRNA sequences. The structure of G*- 15 is 2-amino-4,7-dihydro-4-oxo-7-beta-D-ribofuranosyl-1H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide (7-formamidino-7-deazaguanosine), which is a non-purine, non-pyrimidine ribonucleoside; its structure thus reflects extensive modification beyond the guanine-15 specified by corresponding gene sequences. The structure was established by mass spectrometry, and in particular from collision-induced dissociation mass spectra of derivatives formed by microscale permethylation, and is confirmed by chemical synthesis.	UNIV UTAH,DEPT MED CHEM,311A SKAGGS HALL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; SO ILLINOIS UNIV,DEPT MED BIOCHEM,CARBONDALE,IL 62901	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Southern Illinois University System; Southern Illinois University					NIGMS NIH HHS [GM29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORK GR, 1984, PROCESSING RNA, P291; BROCK TD, 1972, ARCH MIKROBIOL, V84, P554; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CHENG CS, 1981, THESIS U UTAH; CRAIN PF, 1990, MASS SPECTROM REV, V9, P505, DOI 10.1002/mas.1280090504; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; CRAIN PF, 1990, BIOLOGICAL MASS SPECTROMETRY /, P509; CRAIN PF, 1980, ADV MASS SPECTROM, V8, P1135; CROW FW, 1984, ANAL BIOCHEM, V139, P243, DOI 10.1016/0003-2697(84)90412-3; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; EDMONDS CG, 1988, ANAL CHEM, V60, P2314, DOI 10.1021/ac00171a034; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; EDMONDS CG, 1988, 36TH P ANN C MASS SP, P1256; GUPTA R, 1984, J BIOL CHEM, V259, P9461; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; GUPTA R, 1980, CURR MICROBIOL, V4, P245, DOI 10.1007/BF02605865; GUPTA R, 1985, BACTERIA, V8, P311; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HINSHAW BC, 1975, J CHEM SOC PERK T 1, P1248, DOI 10.1039/p19750001248; HINSHAW BC, 1970, J ORG CHEM, V35, P236, DOI 10.1021/jo00826a049; HOLMES JL, 1985, ORG MASS SPECTROM, V20, P169, DOI 10.1002/oms.1210200302; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KAWAI G, 1992, NUCLEOS NUCLEOT, V11, P759, DOI 10.1080/07328319208021740; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KILPATRICK MW, 1982, ZBL BAKT MIK HYG I C, V3, P79, DOI 10.1016/S0721-9571(82)80056-2; LEVSEN K, 1976, ANGEW CHEM INT EDIT, V15, P509, DOI 10.1002/anie.197605091; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P825, DOI 10.1016/0076-6879(90)93453-R; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P771, DOI 10.1016/0076-6879(90)93449-U; MCCLOSKEY JA, 1986, SYST APPL MICROBIOL, V7, P246; NELSON CC, 1992, J AM CHEM SOC, V114, P3661, DOI 10.1021/ja00036a014; NOGUCHI S, 1978, NUCLEIC ACIDS RES, V5, P4215, DOI 10.1093/nar/5.11.4215; OKADA N, 1978, NUCLEIC ACIDS RES, V5, P2289, DOI 10.1093/nar/5.7.2289; PANG H, 1982, J BIOL CHEM, V257, P3589; PHILLIPSON DW, 1987, J BIOL CHEM, V262, P3462; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; REDDY DM, 1992, NUCLEIC ACIDS RES, V20, P5607, DOI 10.1093/nar/20.21.5607; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; Schram K. H., 1979, GLC HPLC DETERMINA 3, P1149; SCHRAM KH, 1975, J CHEM SOC PERK T 1, P1253, DOI 10.1039/p19750001253; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; STETTER KO, 1993, EARLY LIFE EARTH; STETTER KO, 1986, THERMOPHILES GENERAL, P39; von Ehrenstein G, 1967, METHOD ENZYMOL, V12, P588; VONMINDE.DL, 1973, J AM CHEM SOC, V95, P7480, DOI 10.1021/ja00803a044; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	49	90	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10076	10086						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683667				2022-12-25	WOS:A1993LB80000023
J	STINDL, A; KELLER, U				STINDL, A; KELLER, U			THE INITIATION OF PEPTIDE FORMATION IN THE BIOSYNTHESIS OF ACTINOMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE; ACID ACTIVATING ENZYME; STREPTOMYCES-CHRYSOMALLUS; PROTEINS; GENE; PURIFICATION; EXPRESSION; BINDING; PATHWAY; LIGASE	Actinomycin Synthetase II (ACMS II), which activates threonine and valine by a thioltemplate mechanism during the synthesis of the actinomycin half-molecule 4-methyl-3-hydroxyanthranilic acid (4-MHA) pentapeptide lactone, was purified to near homogeneity from Streptomyces chrysomallus. It is a single polypeptide chain of M(r) 280,000 and contains 4'-phosphopantetheine as a covalently bound prosthetic group. ACMS II charges itself with threonine but not with the 4-MHA analogue p-toluic acid via a specific sulfhydryl group at the expense of ATP. Charging of ACMS II with p-toluic acid in thioester linkage took place, however, only when actinomycin synthetase I (ACMS I), a 4-MHA-AMP ligase, was present. In the additional presence Of L-threonine, enzyme-bound P-toluyl-L-threonine was formed on ACMS II. The latter compound was also formed when chemically synthesized p-toluic acid adenylate was added instead of ACMS I and p-toluic acid. This indicates that p-toluic acid adenylate is a free intermediate in the reaction and that charging of the enzyme and acylation of threonine are both catalyzed by ACMS II rather than by ACMS I. Chemically synthesized thioesters of p-toluic acid and coenzyme A, pantetheine, or beta-alanyl-cysteamine reacted with ACMS II, threonine, and ATP with formation of enzyme-bound p-toluyl-threonine. In contrast, p-toluyl-cysteamine thioester was inactive, which indicates structural constraints in the reactivity of free thioesters of p-toluic acid with ACMS II. Such constraints obviously require structural similarity of the artificial substrate to a p-toluic acid thioester formed on the enzyme's surface in the course of the reaction. Since free coenzyme A was not involved in the charging of p-toluic acid or in p-toluyl-threonine formation, the sulfhydryl group of the 4'-phosphopantetheine cofactor is most likely the primary acceptor of p-toluic acid (or 4-MHA) in the initiation of peptide lactone formation.	TECH UNIV BERLIN,INST BIOCHEM & MOLEC BIOL,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY	Technical University of Berlin								BARDEN RE, 1983, METHOD ENZYMOL, V91, P633; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1988, BIOL ACTINOMYCETES 8, P395; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GILHUUSMOE CC, 1970, FEBS LETT, V7, P287, DOI 10.1016/0014-5793(70)80183-1; GLUND K, 1990, BIOCHEMISTRY-US, V29, P3522, DOI 10.1021/bi00466a015; HAESE A, 1988, J BACTERIOL, V170, P1360, DOI 10.1128/jb.170.3.1360-1368.1988; HAESE A, 1993, IN PRESS MOL MICROBI; JAEGER E, 1974, METHODEN ORGANIC CHE, V2, P721; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; KELLER U, 1985, J GEN MICROBIOL, V131, P1181; KELLER U, 1992, J BIOL CHEM, V267, P11745; KELLER U, 1993, GENETICS BIOCH ANTIB, P71; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; LYNEN F, 1961, FED PROC, V20, P941; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MAJERUS PW, 1969, METHOD ENZYMOL, V14, P43; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; PUGH EL, 1965, J BIOL CHEM, V240, P4727; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCHLUMBOHM W, 1990, J BIOL CHEM, V265, P2156; STAAB JF, 1989, FEMS MICROBIOL LETT, V59, P15; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; STAHL E, 1967, DUNNSCHICHT CHROMATO, P843; STOOPS JK, 1990, J BIOL CHEM, V265, P16971; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; Vagelos P. R., 1973, ENZYMES, V8, P155; VATER J, 1976, BIOCHIM BIOPHYS ACTA, V429, P1062, DOI 10.1016/0005-2744(76)90351-X; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008	37	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10612	10620						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683683				2022-12-25	WOS:A1993LB80000091
J	TAIEB, J; VITTEMONY, I; AUFFREDOU, MT; DORSEUIL, O; GACON, G; BERTOGLIO, J; VAZQUEZ, A				TAIEB, J; VITTEMONY, I; AUFFREDOU, MT; DORSEUIL, O; GACON, G; BERTOGLIO, J; VAZQUEZ, A			REGULATION OF P56LCK KINASE EXPRESSION AND CONTROL OF DNA-SYNTHESIS IN ACTIVATED HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASES; CELL ANTIGEN RECEPTOR; PROLIFERATION; ASSOCIATION; PHOSPHORYLATION; MODULATION; FAMILY; CD4	In this study, we analyzed the expression and regulation of src kinase p56lck expression during human B lymphocyte activation. We show that upon mitogenic stimulation with anti-IgM antibodies and interleukin-2, specific mRNA for p56lck becomes detectable in B cells after 24 h of activation and is followed by an increase in p56lck protein expression on days 2 and 3. This up-regulation is specific for p56lck since expression of other src kinases such as fyn, lyn, or yes was not modified. Furthermore, immune complex kinase assays show that p56lck protein expressed on day 2 is associated with kinase activity. Experiments using lck-specific antisense oligonucleotides show that the G0-G1 transition does not require p56lck, whereas DNA synthesis is dependent upon its expression. Thus, our data demonstrate that p56lck expression is up-regulated during human B cell stimulation and this kinase plays an important role during the control of late steps of B lymphocyte activation such as S phase entry.	INSERM,U131,32 RUE CARNETS,F-92140 CLAMART,FRANCE; IGR,INSERM,U333,F-94805 VILLEJUIF,FRANCE; ICGM,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LEPRINCE C, 1992, EUR J IMMUNOL, V22, P2093, DOI 10.1002/eji.1830220820; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VAZQUEZ A, 1989, J IMMUNOL, V142, P94; VAZQUEZ A, 1991, J IMMUNOL, V146, P4222; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	20	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9169	9171						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683644				2022-12-25	WOS:A1993LA68900004
J	LEE, YM; BEINBORN, M; MCBRIDE, EW; LU, M; KOLAKOWSKI, LF; KOPIN, AS				LEE, YM; BEINBORN, M; MCBRIDE, EW; LU, M; KOLAKOWSKI, LF; KOPIN, AS			THE HUMAN BRAIN CHOLECYSTOKININ-B GASTRIN RECEPTOR - CLONING AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; ANTAGONIST; CELLS; CCK; L-365,260; POTENT; ANALGESIA; PEPTIDES; PANCREAS; ANXIETY	The predominant brain cholecystokinin receptor (CCK-B/gastrin) has been implicated in mediating many of the central effects of cholecystokinin, including anxiety, panic attacks, satiety, and analgesia, suggesting it is an important pharmacologic target. We now report the cloning and characterization of the cDNA encoding the human brain CCK-B/gastrin receptor. The cDNA was isolated from a human brain library by low stringency screening using the canine ''gastrin'' receptor cDNA as a hybridization probe. Nucleotide sequence analysis revealed an open reading frame encoding a 447-amino-acid protein with seven putative hydrophobic transmembrane domains and significant homology with other known members of the gastrin/cholecystokinin receptor family. Agonist and antagonist affinities of the recombinant human brain receptor expressed in COS-7 cells are consistent with a classical ''CCK-B'' receptor as defined by the literature. In COS-7 cells expressing the cloned receptor, CCK-8-stimulated phosphatidylinositol hydrolysis and intracellular Ca2+ mobilization suggesting second messenger signaling through phospholipase C. CCK-B/gastrin receptor transcripts were identified in human brain, stomach, and pancreas using high stringency Northern blot analysis. Southern blot hybridization analysis of human genomic DNA indicates that a single gene encodes both the brain and the stomach CCK-B/gastrin receptors. Our data suggest that the CCK-B and gastrin receptors are identical and that the long standing distinction between them may no longer apply.	TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,GRASP DIGEST DIS CTR,BOSTON,MA 02111; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77035; MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114; MED SCH HANNOVER,DEPT GEN PHARMACOL,W-3000 HANNOVER 61,GERMANY	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Baylor College of Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Hannover Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001934, P30DK034928, R01DK046767] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK34928, DK01934, DK46767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOURISH CT, 1989, SCIENCE, V245, P1509, DOI 10.1126/science.2781294; DOURISH CT, 1990, EUR J PHARMACOL, V176, P35, DOI 10.1016/0014-2999(90)90129-T; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURMY D, 1987, EUR J BIOCHEM, V165, P683, DOI 10.1111/j.1432-1033.1987.tb11495.x; HAYS SE, 1980, NEUROPEPTIDES, V1, P53, DOI 10.1016/0143-4179(80)90009-8; HILL DR, 1990, J NEUROSCI, V10, P1070; HILL DR, 1990, BRAIN RES, V526, P276, DOI 10.1016/0006-8993(90)91232-6; HUGHES J, 1990, P NATL ACAD SCI USA, V87, P6728, DOI 10.1073/pnas.87.17.6728; INNIS RB, 1980, P NATL ACAD SCI-BIOL, V77, P6917, DOI 10.1073/pnas.77.11.6917; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; JENSEN RT, 1990, GASTROINTEST ENDOSC, P95; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RAVARD S, 1990, TRENDS PHARMACOL SCI, V11, P271, DOI 10.1016/0165-6147(90)90004-R; REHFELD JF, 1978, J BIOL CHEM, V253, P4022; SAITO A, 1980, SCIENCE, V208, P1155, DOI 10.1126/science.6246582; SINGH L, 1991, P NATL ACAD SCI USA, V88, P1130, DOI 10.1073/pnas.88.4.1130; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; SWAROOP A, 1988, NUCLEIC ACIDS RES, V16, P8739, DOI 10.1093/nar/16.17.8739; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WATSON S, 1992, TRENDS PHARM SCI S, V11, P11; WIERTELAK EP, 1992, SCIENCE, V256, P830, DOI 10.1126/science.1589765; WOODRUFF GN, 1991, NEUROPEPTIDES S, V19, P57	38	249	264	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8164	8169						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681836				2022-12-25	WOS:A1993KW97900083
J	SHAPIRO, SD; KOBAYASHI, DK; PENTLAND, AP; WELGUS, HG				SHAPIRO, SD; KOBAYASHI, DK; PENTLAND, AP; WELGUS, HG			INDUCTION OF MACROPHAGE METALLOPROTEINASES BY EXTRACELLULAR-MATRIX EVIDENCE FOR ENZYME-SPECIFIC AND SUBSTRATE-SPECIFIC RESPONSES INVOLVING PROSTAGLANDIN-DEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; STROMELYSIN GENE-EXPRESSION; HUMAN ALVEOLAR MACROPHAGES; HUMAN SYNOVIAL-CELLS; STIMULATES COLLAGENASE; INHIBITOR; LIPOPOLYSACCHARIDE; DEXAMETHASONE; BIOSYNTHESIS; MODULATION	Many cellular properties are influenced by the surrounding environment of extracellular matrix. To better define the interaction between mononuclear phagocytes and the extracellular matrix components they contact, we studied the effect of various matrices on the biosynthesis and secretion of metalloenzymes and the tissue inhibitor of metalloproteinases in human alveolar macrophages. We found that native and denatured collagen types I and III markedly augmented production of interstitial collagenase (>25-fold) and increased tissue inhibitor of metalloproteinases to a lesser degree (2.5-fold). In contrast, the biosynthesis of another major secreted macrophage metalloproteinase, 92-kDa gelatinase, was unaffected by contact with extracellular matrices. Furthermore, other matrix components (i.e. type IV collagen, laminin, fibronectin, elastin) failed to induce collagenase production. Maximal stimulation of macrophage collagenase production was achieved with 1-5 mug/ml (3-15 x 10(-9) M) denatured collagen in contact with cells for 2 h. Increased biosynthesis of collagenase was detected within 24 h of cell contact with native or denatured collagen and was accompanied by marked induction of collagenase mRNA levels. Our studies of signal transduction mechanisms demonstrated that indomethacin decreased gelatin-induced collagenase production by 90%, with enzyme levels completely restored by the addition of exogenous prostaglandin E2. Prostaglandin E2 Was only effective when added within the first 2 h after indomethacin treatment. These results indicate that extracellular matrix can directly influence its remodeling and repair via regulation of the production of metalloenzymes by resident inflammatory cells. Furthermore, matrix-metalloproteinase inductive interactions are both enzyme- and matrix-specific, and are mediated, at least in part, by a prostaglandin-dependent mechanism.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	SHAPIRO, SD (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,216 S KINGSHIGHWAY,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805, P01AR032087] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAMS NIH HHS [AR-35805, AR-32087] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BISWAS C, 1979, CELL, V18, P1035, DOI 10.1016/0092-8674(79)90216-2; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TW, 1982, COLLAGEN REL RES, V3, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CURY JD, 1988, J IMMUNOL, V141, P4306; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1979, J CLIN INVEST, V64, P1386, DOI 10.1172/JCI109596; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GROSS J, 1958, J EXP MED, V108, P215, DOI 10.1084/jem.108.2.215; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; KING J, 1971, J MOL BIOL, V62, P464; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; PIEZ KA, 1963, BIOCHEMISTRY-US, V2, P58, DOI 10.1021/bi00901a012; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; TRELSTAD RL, 1976, ANAL BIOCHEM, V71, P114, DOI 10.1016/0003-2697(76)90016-6; WAHL LM, 1984, ARCH BIOCHEM BIOPHYS, V230, P661, DOI 10.1016/0003-9861(84)90447-8; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	31	124	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8170	8175						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681837				2022-12-25	WOS:A1993KW97900084
J	CERVANTESLAUREAN, D; LOFLIN, PT; MINTER, DE; JACOBSON, EL; JACOBSON, MK				CERVANTESLAUREAN, D; LOFLIN, PT; MINTER, DE; JACOBSON, EL; JACOBSON, MK			PROTEIN MODIFICATION BY ADP-RIBOSE VIA ACID-LABILE LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ISLET-ACTIVATING PROTEIN; ADENYLATE-CYCLASE; MEMBRANE-PROTEIN; RIBOSYLATION; RIBOSYLTRANSFERASE; INVIVO; SUBSTRATE; RESIDUE; CELLS	As substrate for protein-mono-ADP-ribosyltransferases, NAD has been shown to be the donor of ADP-ribose to many different nucleophiles found in proteins. This post-translational modification of proteins has been implicated in the regulation of membrane associated processes including signal transduction, muscle cell differentiation, and protein trafficking and secretion. Described here is the preparation and chemical characterization of low molecular weight conjugates that were used as models for an acetal linkage between ADP-ribose and the hydroxyl group of a protein acceptor such as serine, threonine, tyrosine, hydroxyproline, or hydroxylysine residues. Model conjugates of ADP-ribose containing an acetal linkage were prepared, their structures were established by NMR, and the chemical stability of the linkage to ADP-ribose was studied and compared to the other known ADP-ribosyl-amino acid linkages. The rapid release of intact ADP-ribose from the acetal model conjugates in 44% formic acid distinguished them chemically from all the other known ADP-ribosyl-amino acid modifications. Rat liver proteins were shown to be modified by ADP-ribose in vivo by acid-labile linkages, providing evidence for a new class of endogenous ADP-ribose modification of animal cell proteins. The amount of modification was approximately 16 pmol of ADP-ribose per mg of total protein, and proteins modified by acid-labile linkages were detected in all subcellular fractions examined, suggesting that the scope of this modification in vivo is broad.	UNIV KENTUCKY,DEPT CLIN SCI,LEXINGTON,KY 40536; UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536; TEXAS CHRISTIAN UNIV,DEPT CHEM,FT WORTH,TX 76129; UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,FT WORTH,TX 76107	University of Kentucky; University of Kentucky; Texas Christian University; University of North Texas System; University of North Texas Health Science Center	CERVANTESLAUREAN, D (corresponding author), UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536, USA.				NCI NIH HHS [CA43894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAON MA, 1985, BICOH J, V229, P269; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P12; ANDERSON B, 1964, NATURE, V239, P2716; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BRADFORD M, 1976, ANAL BIOCHEM, V72, P633; Burzio L.O., 1982, P103; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; Collier RJ, 1982, ADP RIBOSYLATION REA, P575; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; FERRO AM, 1978, P NATL ACAD SCI USA, V75, P809, DOI 10.1073/pnas.75.2.809; HUANG HY, 1993, BIOCHEM BIOPH RES CO, V197, P570, DOI 10.1006/bbrc.1993.2517; JACOBSON MK, 1984, METHOD ENZYMOL, V106, P483; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; JACOBSON MK, 1990, ADP RIBOSYLATING TOX, P479; KATADA T, 1982, J BIOL CHEM, V257, P7210; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KUROSAWA M, 1994, J PHARMACOL TOXICOL, V31, P135, DOI 10.1016/1056-8719(94)90075-2; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; MCDONALD LJ, 1993, J BIOL CHEM, V268, P17878; MIWA M, 1977, NUCLEIC ACIDS RES, V4, P3997, DOI 10.1093/nar/4.11.3997; MOSS J, 1978, P NATL ACAD SCI USA, V75, P3621, DOI 10.1073/pnas.75.8.3621; MOSS J, 1977, J BIOL CHEM, V52, P2455; OBARA S, 1991, EUR J BIOCHEM, V200, P75, DOI 10.1111/j.1432-1033.1991.tb21050.x; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SUZUKI H, 1986, J BIOL CHEM, V261, P6048; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILLIAMSON KC, 1990, ADP RIBOSYLATING TOX, P479; YOST DA, 1982, J BIOL CHEM, V257, P767; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273	36	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7929	7936		10.1074/jbc.270.14.7929	http://dx.doi.org/10.1074/jbc.270.14.7929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713889	Green Submitted, hybrid			2022-12-25	WOS:A1995QR52600025
J	FLETCHER, MC; SAMELSON, LE; JUNE, CH				FLETCHER, MC; SAMELSON, LE; JUNE, CH			COMPLEX EFFECTS OF PHENYLARSINE OXIDE IN T-CELLS - INDUCTION OF TYROSINE PHOSPHORYLATION AND CALCIUM MOBILIZATION INDEPENDENT OF CD45 EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYL-INOSITOL PATHWAY; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; HIGH-AFFINITY; TUBULE CELLS; ACTIVATION; KINASE; STIMULATION; PHOSPHOTYROSINE	The effects of phenylarsine oxide, a phosphotyrosine phosphatase inhibitor, on early signal transduction events in human T cells were studied. Simultaneous stimulation of T cells with anti-CD3 monoclonal antibody and phenylarsine oxide prevented increased tyrosine phosphorylation of phospholipase Cgamma1. In contrast, treatment of resting T cells with phenylarsine oxide alone resulted in increased tyrosine phosphorylation of a number of other intracellular substrates. Further, phenylarsine oxide was able to cause an immediate disruption of signal transduction in T cells after anti-CD3 stimulation, as measured by a return of intracellular calcium concentration and inositol 1,4,5-trisphosphate production to base-line levels. Surprisingly, in view of the inhibitory effects of phenylarsine oxide on T cell receptor signal transduction, treatment of T cells with phenylarsine oxide alone caused a dose-dependent increase in intracellular-free calcium concentration that was not accompanied with detectable increases in inositol 1,4,5-trisphosphate production. The phenylarsine oxide-induced increase in free calcium had distinct kinetics from antigen receptor-activated calcium mobilization and was derived from both intracellular sources and increased plasma membrane calcium permeability. This effect was independent of the CD45 transmembrane tyrosine phosphatase. Phenylarsine oxide thus has complex effects on signal transduction in T cells that suggests multiple intracellular targets, and these should be considered in the interpretation of experiments using this agent to study cellular kinase and phosphatase interactions. Finally, the effects of phenylarsine oxide on cellular calcium homeostasis may provide a mechanism of action for the therapeutic and/or toxic effects of arsenicals used for various forms of chemotherapy.	USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20889; NIH,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FELL HB, 1946, BRIT J EXP PATHOL, V27, P310; FELL HB, 1946, BRIT J EXP PATHOL, V27, P305; FREED BM, 1991, TOXICOL APPL PHARM, V107, P173, DOI 10.1016/0041-008X(91)90341-B; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GOLDMAN SJ, 1992, J BIOL CHEM, V267, P6197; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIAO K, 1991, J BIOL CHEM, V266, P6544; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEEK JL, 1986, P NATL ACAD SCI USA, V83, P4162, DOI 10.1073/pnas.83.12.4162; NICOTERA P, 1989, FASEB J, V3, P59, DOI 10.1096/fasebj.3.1.2910738; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PHELPS PC, 1989, LAB INVEST, V60, P630; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SMITH MW, 1992, AM J PHYSIOL, V262, pF647, DOI 10.1152/ajprenal.1992.262.4.F647; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	46	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23697	23703						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693695				2022-12-25	WOS:A1993MF51500110
J	DIMARCO, E; MATHOR, M; BONDANZA, S; CUTULI, N; MARCHISIO, PC; CANCEDDA, R; DELUCA, M				DIMARCO, E; MATHOR, M; BONDANZA, S; CUTULI, N; MARCHISIO, PC; CANCEDDA, R; DELUCA, M			NERVE GROWTH-FACTOR BINDS TO NORMAL HUMAN KERATINOCYTES THROUGH HIGH AND LOW-AFFINITY RECEPTORS AND STIMULATES THEIR GROWTH BY A NOVEL AUTOCRINE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN KERATINOCYTES; HUMAN MELANOCYTE GROWTH; FACTOR NGF RECEPTOR; TRK PROTOONCOGENE; TYROSINE PHOSPHORYLATION; NEUROTROPHIN RECEPTORS; MONOCLONAL-ANTIBODIES; INTEGRIN RECEPTORS; KINASE-ACTIVITY; MESSENGER-RNA	Normal human keratinocytes synthesize and secrete biologically active nerve growth factor (NGF) in a growth regulated fashion (Di Marco, E., Marchisio, P. C., Bondanza, S., Franzi, A. T., Cancedda, R., and De Luca, M. (1991) J. Biol. Chem. 266, 21718-21722). Here we show that the same human keratinocytes bind NGF via low and high affinity receptors. In parallel with the course of NGF synthesis, the expression of low affinity NGF receptor (p75NGFr) decreases when a confluent, differentiated, and fully stratified epithelium is obtained. In skin sections, p75NGFr is present in basal keratinocytes and absent from suprabasal, terminally differentiated cells. The trkA protooncogene product (p140trkA), a component of the NGF receptor, is not expressed by keratinocytes. Instead, keratinocytes express a new member of the trk family (that we termed trkE), which generates 3.9-kilobase transcripts. Keratinocyte-derived NGF plays a key role in the autocrine epidermal cell proliferation. This has been proven by (i) direct effect of NGF on [H-3]thymidine incorporation, (ii) inhibition of autocrine keratinocyte growth by monoclonal antibodies (alphaD11) inhibiting human NGF biological activity, and (iii) inhibition of autocrine keratinocyte proliferation by a trk-specific inhibitor, the natural alkaloid K252a. These data provide evidence that NGF, in addition to its effect as a survival and differentiation factor, is a potent regulator of cell proliferation, at least in human epithelial cells.	IST NAZL RIC CANC, DIFFERENZIAMENTO CELLULARE LAB, VIALE BENEDETTO XV 10, I-16132 GENOA, ITALY; UNIV TURIN, DIPARTIMENTO SCI BIOMED & ONCOL, I-10124 TURIN, ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Turin			De Luca, Michele/N-5883-2014; Mathor, Monica B/C-3975-2012	De Luca, Michele/0000-0002-0850-8445; Mathor, Monica B/0000-0002-7294-9106				BARKER PA, 1992, MOL CELL BIOCHEM, V110, P1, DOI 10.1007/BF02385000; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERG MM, 1992, J BIOL CHEM, V267, P13; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; CATTANEO A, 1988, J NEUROCHEM, V50, P1003, DOI 10.1111/j.1471-4159.1988.tb10565.x; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DELUCA M, 1988, EUR J CELL BIOL, V46, P176; DELUCA M, 1988, J CELL BIOL, V107, P1919, DOI 10.1083/jcb.107.5.1919; DELUCA M, 1990, TRANSPLANTATION, V50, P454, DOI 10.1097/00007890-199009000-00019; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DELUCA M, 1992, BURNS, V18, pS5, DOI 10.1016/0305-4179(92)90103-2; DELUCA M, 1993, KERATINOCYTE HDB; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; EISINGER M, 1988, P NATL ACAD SCI USA, V85, P1937, DOI 10.1073/pnas.85.6.1937; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FANTINI F, 1992, J INVEST DERMATOL, V99, P734, DOI 10.1111/1523-1747.ep12614465; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; Green H, 1980, Harvey Lect, V74, P101; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KORSCHING S, 1985, EMBO J, V4, P1389, DOI 10.1002/j.1460-2075.1985.tb03791.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MCPHERSON GA, 1985, KINETIC EBDA LIGAND, P14; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PARVINEN M, 1992, J CELL BIOL, V117, P629, DOI 10.1083/jcb.117.3.629; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WHEELER EF, 1992, J NEUROSCI, V12, P930; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	74	151	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22838	22846						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693679				2022-12-25	WOS:A1993MD34800096
J	DOI, R; CHOWDHURY, P; RAYFORD, PL				DOI, R; CHOWDHURY, P; RAYFORD, PL			AGONIST-REGULATED ALTERATION OF THE AFFINITY OF PANCREATIC MUSCARINIC CHOLINERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SECRETION; CHOLECYSTOKININ RECEPTOR; AMYLASE SECRETION; DOWN-REGULATION; ACINAR-CELLS; CHICK HEART; PHOSPHORYLATION; DESENSITIZATION; HYDROLYSIS; BINDING	Heterologous desensitization is a term that indicates that exposure of a cell to an agonist attenuates the response of that cell to other agonists. We examined heterologous desensitization of muscarinic cholinergic receptors of pancreatic acini and characterized mechanisms that might be responsible for desensitization. Muscarinic cholinergic receptor binding was measured by using N-[H-3]methscopolamine bromide ([H-3]NMS). N-Methscopolamine bromide (NMS), a receptor antagonist, bound to a single class of receptors with an affinity of 0.22 +/- 0.04 nM and a capacity of 61.5 +/- 5.1 fmol/mg of protein. These parameters of NMS binding sites were not altered by an addition of cholecystokinin (CCK) octapeptide, CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, thapsigargin, or 12-O-tetradecanoylphorbol-13-acetate (TPA). Analysis of competitive inhibition curve of [H-3] NMS binding by carbachol showed apparently two classes of carbachol binding sites with high affinity (38.6%) and low affinity (61.4%). Simultaneous incubation of carbachol with CCK or TPA increased the relative affinity of [H-3]NMS binding, and the competitive inhibition curves showed a single class of carbachol binding site. L-364,718 blocked the effect of CCK, and staurosporine blocked the effects of TPA and partially blocked the effect of CCK. CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, and thapsigargin had no effects on the competitive binding. Second, the carbachol-induced sequestration of the receptors was examined. Incubation of acini with carbachol resulted in a decrease of [H-3] NMS binding sites, and the addition of CCK or TPA caused an inhibition of the carbachol-induced disappearance of [H-3]NMS binding sites. Finally, studies that examined the biological response of the acinar cells showed that biphasic amylase release in response to carbachol was completely suppressed by 10 nM CCK for entire range of carbachol. Taken together, these results suggest that the effect of CCK on carbachol-induced sequestration is important for the alteration of the apparent affinity of carbachol binding sites and the biological response of acinar cells to carbachol. Further, the results suggest that another factor that induces uncoupling of receptor from effector might be involved in agonist-regulated desensitization. The results, that CCK-JMV-180 or other agonists that activate the adenylate cyclase pathway did not exert these effects of CCK, suggest that protein kinase C may be one of the key factors involved in heterologous desensitization by CCK on the carbachol binding sites and the suppression of carbachol-induced amylase release.	UNIV ARKANSAS MED SCI HOSP,DEPT PHYSIOL & BIOPHYS,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences				Doi, Ryuichiro/0000-0002-7298-2301	NIDDK NIH HHS [DK30415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272, DOI 10.1152/ajpgi.1980.239.4.G272; ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; BAUMGOLD J, 1989, NEUROPHARMACOLOGY, V28, P1253, DOI 10.1016/0028-3908(89)90219-0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BRUZZONE R, 1990, GASTROENTEROLOGY, V99, P1157, DOI 10.1016/0016-5085(90)90640-M; DEHAYE JP, 1984, J BIOL CHEM, V259, P294; DOI RH, 1993, J PHARMACOL EXP THER, V264, P873; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; HONDA T, 1987, AM J PHYSIOL, V252, pG77, DOI 10.1152/ajpgi.1987.252.1.G77; HOOTMAN SR, 1991, AM J PHYSIOL, V261, pG128, DOI 10.1152/ajpgi.1991.261.1.G128; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIGNON MF, 1987, J BIOL CHEM, V262, P7226; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MERRITT JE, 1985, BIOCHEM J, V230, P151, DOI 10.1042/bj2300151; MINNEMAN KP, 1979, MOL PHARMACOL, V16, P34; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PANDOL SJ, 1986, J BIOL CHEM, V261, P4438; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; STREB H, 1985, J BIOL CHEM, V260, P7309; THOMPSON AK, 1991, J BIOL CHEM, V266, P5004; VINAYEK R, 1990, AM J PHYSIOL, V258, pG107, DOI 10.1152/ajpgi.1990.258.1.G107; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22436	22443						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693670				2022-12-25	WOS:A1993MD34800040
J	MOUSTAKAS, A; LIN, HY; HENIS, YI; PLAMONDON, J; OCONNORMCCOURT, MD; LODISH, HF				MOUSTAKAS, A; LIN, HY; HENIS, YI; PLAMONDON, J; OCONNORMCCOURT, MD; LODISH, HF			THE TRANSFORMING GROWTH-FACTOR BETA-RECEPTORS TYPE-I, TYPE-II, AND TYPE-III FORM HETEROOLIGOMERIC COMPLEXES IN THE PRESENCE OF LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INHIBITORY RESPONSES; EXPRESSION CLONING; CELLULAR RECEPTOR; CRYSTAL-STRUCTURE; CONCOMITANT LOSS; RECENT PROGRESS; RAT-1 CELLS; BINDING; GROWTH-FACTOR-BETA-2; RESPONSIVENESS	Transforming growth factors beta (TGF-betas) are disulfide-linked dimers. In Rat-1 cells both radioiodinated TGF-beta1 and -beta2 bind to and can be chemically cross-linked to type I and II receptors (which are thought to mediate effects of cell growth suppression and gene activation), to type III proteoglycan receptors, and to a novel approximately 50-kDa protein. After detergent solubilization of cells that were cross-linked with radioiodinated TGF-beta, antibodies specific for the type II receptor precipitated labeled receptor types I and III as well as type II. In these cells, the type III receptor is the predominant TGF-beta-binding protein, and antibodies specific for it precipitate mainly this cross-linked receptor. Thus, in the presence of TGF-beta ligand, receptor types II and III and types II and I form heteromeric complexes. The majority of the type III receptor does not associate with receptor types I and II, probably reflecting the relative amounts of the three receptors on the surface of Rat-1 cells. Since TGF-beta1 but not TGF-beta2 binds to the exoplasmic domain of the type II receptor in the absence of the type III receptor, and since both TGF-beta1 and -beta2 bind with high affinity to the type III receptor, we suggest that TGF-beta2, and possibly TGF-beta1, bind initially to the type III receptor. The TGF-beta2-type III receptor complex would then interact with a type II receptor, thus modulating the affinity of the type II receptor for TGF-beta2.	WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; NATL RES COUNCEL CANADA, BIOTECHNOL RES INST, CELL SURFACE RECOGNIT GRP, MONTREAL H4P 2R2, PQ, CANADA; TEL AVIV UNIV, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Research Council Canada; Tel Aviv University				Henis, Yoav/0000-0002-1408-3877	NHLBI NIH HHS [HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHINKERS M, 1987, J CELL PHYSIOL, V130, P1, DOI 10.1002/jcp.1041300102; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MITCHELL EJ, 1992, J CELL PHYSIOL, V150, P334, DOI 10.1002/jcp.1041500217; MITCHELL EJ, 1991, BIOCHEMISTRY-US, V30, P4350, DOI 10.1021/bi00231a034; MITCHELL EJ, 1992, MOL BIOL CELL, V3, P1295, DOI 10.1091/mbc.3.11.1295; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SIEPL C, 1991, J IMMUNOL, V146, P3063; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	40	184	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22215	22218						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693660				2022-12-25	WOS:A1993MD34800001
J	LIU, C; ROTH, KE; SHEPARD, BAL; SHAFFER, JB; DIAS, JA				LIU, C; ROTH, KE; SHEPARD, BAL; SHAFFER, JB; DIAS, JA			SITE-DIRECTED ALANINE MUTAGENESIS OF PHE(33), ARG(35), AND ARG(42)-SER(43)-LYS(44) IN THE HUMAN GONADOTROPIN ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; FOLLICLE-STIMULATING-HORMONE; BETA-SUBUNIT; RECEPTOR-BINDING; GLYCOPROTEIN HORMONES; SEQUENCE-ANALYSIS; IDENTIFICATION; LUTROPIN; FOLLITROPIN; THYROTROPIN	Residues Phe33 and Arg35, individually, and a composite mutation of residues Arg42, Ser43, and Lys44 were changed to alanine in the human glycoprotein hormone common alpha-subunit using site-directed mutagenesis. These specific residues are highly conserved across species and have by chemical modification and synthetic peptide approaches been implicated in the binding of human chorionic gonadotropin (hCG) to leutinizing hormone (LH) receptor. In the present study we tested the hypothesis that specific alpha-subunit amino acid residues which stabilize the hormone receptor interaction for hCG have the same function in human follicle-stimulating hormone (hFSH). Wild type or mutant alpha-subunit cDNAs were coexpressed with wild type hFSH or hCGbeta cDNA in sialylation defective Chinese hamster ovary cells. Recombinant hormones were tested in a radioligand receptor competition assay, using rat testis membranes as a source of FSH and LH receptors. Mutant hFSH heterodimers F33A-FSH, R35A-FSH, Arg42-Ser43-Lys44/Ala42-Ala43-Ala44-FSH all displaced I-125-hFSH in a similar fashion, indicating that these residues are not important for binding of hFSH to the rat FSH receptor. On the other hand, F33A-CG evidenced a 5-fold decrease in binding, while R35A-CG had over a 100-fold decrease in binding to the rat LH receptor when compared to the wild type recombinant hCG. These data demonstrate that a receptor-binding site on the common alpha-subunit which is very important for hCG binding to LH receptor is not important for the binding of hFSH to FSH receptor. Our interpretation of these findings is that there are fundamental structural differences in the receptor interface contacts of the common alpha-subunit, which stabilize receptor binding among members of the glycoprotein hormone family.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, EMPIRE STATE PLAZA, POB 509, ALBANY, NY 12201 USA; SUNY ALBANY, SCH PUBL HLTH, DEPT BIOMED SCI, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Dias, James A/0000-0002-9792-5469	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018407] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18407] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIDART JM, 1988, J BIOL CHEM, V263, P10364; BIELINSKA M, 1990, Journal of Cell Biology, V111, p330A; BIELINSKA M, 1992, MOL ENDOCRINOL, V6, P267; BOORSTEIN WR, 1982, NATURE, V300, P419, DOI 10.1038/300419a0; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; DIAS JA, 1992, TRENDS ENDOCRIN MET, V3, P24, DOI 10.1016/1043-2760(92)90088-I; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FIDDES JC, 1979, NATURE, V281, P351, DOI 10.1038/281351a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAYASHIZAKI Y, 1985, FEBS LETT, V188, P394, DOI 10.1016/0014-5793(85)80409-9; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; KARDANA A, 1991, ENDOCRINOLOGY, V129, P1541, DOI 10.1210/endo-129-3-1541; KRYSTEK SR, 1992, PEPTIDE RES, V5, P165; KRYSTEK SR, 1991, BIOCHEMISTRY-US, V30, P1858, DOI 10.1021/bi00221a019; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; NISHIMURA R, 1986, Journal of Biological Chemistry, V261, P10475; PENTECOST BT, 1990, MOL ENDOCRINOL, V4, P1000, DOI 10.1210/mend-4-7-1000; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; REED DK, 1991, J BIOL CHEM, V266, P14251; ROTH KE, 1993, ENDOCRINOLOGY, V132, P2571, DOI 10.1210/en.132.6.2571; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TALMADGE K, 1992, DNA CELL BIOL, V2, P281; VANDIJK S, 1993, ENDOCRINOLOGY, V132, P534, DOI 10.1210/en.132.2.534; Ward DM, 1989, MICROHETEROGENEITY G, P2; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WEINER RS, 1990, ENDOCRINOLOGY, V127, P573, DOI 10.1210/endo-127-2-573; WEINER RS, 1991, ENDOCRINOLOGY, V128, P1485, DOI 10.1210/endo-128-3-1485; WEINER RS, 1992, ENDOCRINOLOGY, V131, P1026, DOI 10.1210/en.131.3.1026; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; YANAGISHITA M, 1978, ANAL BIOCHEM, V88, P1, DOI 10.1016/0003-2697(78)90393-7; YOO J, 1991, J BIOL CHEM, V266, P17741	36	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21613	21617						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691814				2022-12-25	WOS:A1993MC80900030
J	STEFANOVA, I; CORCORAN, ML; HORAK, EM; WAHL, LM; BOLEN, JB; HORAK, ID				STEFANOVA, I; CORCORAN, ML; HORAK, EM; WAHL, LM; BOLEN, JB; HORAK, ID			LIPOPOLYSACCHARIDE INDUCES ACTIVATION OF CD14-ASSOCIATED PROTEIN-TYROSINE KINASE P53/56LYN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATED HUMAN MONOCYTES; MONOCLONAL-ANTIBODIES; SRC FAMILY; CD14; MOLECULES	Bacterial lipopolysaccharide (LPS) induces a pleiotropic activation of the immune system which might subsequently result in septic shock. One of the cell surface receptors for LPS is the glycophosphatidylinositol-anchored protein CD14. Binding of LPS to CD14 induces production of lymphokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-8, and CD14 is subsequently released from the cell surface. However, the mechanism of signaling via CD14 is still not known. We report here that protein tyrosine kinase (PTK) p56lyn is coupled to the LPS receptor CD14 in human monocytes. LPS rapidly activates CD14-associated p56lyn simultaneously with PTKs p58hck and p59c-fgr. Inhibition of PTKs by herbimycin A completely blocks LPS-induced down-modulation of CD14 and production of TNF-alpha and IL-1. These data suggest a critical role of PTKs in the LPS/CD14-mediated signal transduction pathway in human monocytes.	NIH, INST DENT RES, IMMUNOL LAB, BETHESDA, MD 20892 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	National Institutes of Health (NIH) - USA; Bristol-Myers Squibb	STEFANOVA, I (corresponding author), NCI, DIV CANC BIOL DIAG & CTR, METAB BRANCH, BLDG 10-4N115, BETHESDA, MD 20892 USA.							BAZIL V, 1991, J IMMUNOL, V147, P1567; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; COUTURIER C, 1992, EUR J IMMUNOL, V22, P1461, DOI 10.1002/eji.1830220619; DENTENER MA, 1993, J IMMUNOL, V150, P2885; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUENER RP, 1990, J IMMUNOL, V145, P1390; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; SCHUTT C, 1988, IMMUNOL LETT, V19, P321, DOI 10.1016/0165-2478(88)90162-9; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL LM, 1991, CURRENT PROTOCOLS IM; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1991, SCIENCE, V252, P1321, DOI 10.1126/science.252.5010.1321-a; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	19	299	300	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20725	20728						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691802				2022-12-25	WOS:A1993MA28800012
J	LI, WX; HOWARD, RJ; LEUNG, LLK				LI, WX; HOWARD, RJ; LEUNG, LLK			IDENTIFICATION OF SVTCG IN THROMBOSPONDIN AS THE CONFORMATION-DEPENDENT, HIGH-AFFINITY BINDING-SITE FOR ITS RECEPTOR, CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; HUMAN MALARIA PARASITE; GLYCOPROTEIN-IV CD36; CELL-ADHESION; MONOCLONAL-ANTIBODIES; PROTEIN-G; AGGREGATION; FIBRINOGEN; MOLECULES; PROPERDIN	Thrombospondin (TSP) binds to its cellular receptor, CD36 (glycoprotein IV or IIIb), and participates in many adhesive cell interactions. We have shown that the CD36-TSP interaction occurs in a stepwise, conformation-dependent process. CD36 sequence 139-155 binds TSP and induces a second CD36-binding site, which binds CD36 sequence 93-110 with high affinity. To characterize this high affinity CD36-binding site on TSP, an anti-TSP monoclonal antibody (mAb), 7A-1e, was identified that showed augmentation of TSP binding in the presence of CD36 peptide P139-155. Purified mAb 7A-1e IgG specifically blocked both P139-155-augmented CD36 binding and P139-155-dependent CD36 peptide P93-110 binding to TSP, indicating that the binding sites on TSP for mAb 7A-1e and P93-110 are closely related. mAb 7A-1e IgG inhibited collagen-induced platelet aggregation in platelet-rich plasma. SVTCG is a cell adhesive motif in TSP. Both mAb 7A-1e and P93-110 specifically bound to a TSP peptide containing SVTCG, and the binding of mAb 7A-1e or P93-110 to TSP was inhibited by soluble SVTCG peptide. The SVTCG cell adhesive domain in TSP is the conformation-dependent, high affinity binding site for CD36 sequence 93-110.	STANFORD UNIV,MED CTR,SCH MED,DIV HEMATOL,STANFORD,CA 94305; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042943] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL42943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; CLEZARDIN P, 1986, EUR J BIOCHEM, V154, P95, DOI 10.1111/j.1432-1033.1986.tb09363.x; COLIGAN JE, 1984, J BIOL CHEM, V259, P3944; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; FREDRIKSON G, 1987, J IMMUNOL METHODS, V97, P65, DOI 10.1016/0022-1759(87)90106-2; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; IAN RH, 1992, LANCET, V399, P1453; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; ZAMARRON C, 1991, J BIOL CHEM, V266, P16193	32	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16179	16184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688364				2022-12-25	WOS:A1993LQ33600017
J	BREUER, W; GLICKSTEIN, H; KARTNER, N; RIORDAN, JR; AUSIELLO, DA; CABANTCHIK, IZ				BREUER, W; GLICKSTEIN, H; KARTNER, N; RIORDAN, JR; AUSIELLO, DA; CABANTCHIK, IZ			PROTEIN-KINASE-C MEDIATES DOWN-REGULATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR LEVELS IN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; R-DOMAIN; GENE; TRANSPORT; PHOSPHORYLATION; EXPRESSION	Expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in epithelial cells is known to be down-regulated by the action of phorbol myristate acetate (PMA). We show here that in addition to suppressing the rate of transcription of the CFTR gene, PMA treatment stimulates degradation of the CFTR protein. HT-29 colon epithelial cells and the CFTR-transfected pancreatic cells PLJ-4.7 lost 55-80% of their CFTR protein after 3-6 h of treatment with 100 nm PMA, as analyzed by quantitative Western blotting. In contrast to PMA, actinomycin D and cycloheximide reduced the CFTR protein content by 19 and 9% in HT-29 cells and by 22 and 40% in PLJ-4.7 cells, respectively, while inhibiting total cellular RNA and protein synthesis by over 80%. The PMA-induced loss of CFTR was partially reversed by the protein kinase C inhibitor GF109203X. The PMA-induced degradation of CFTR may represent a regulatory pathway for terminating CFTR-mediated chloride and mucin secretion.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,RENAL SECT,CHARLESTON,MA 02113	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Massachusetts General Hospital	BREUER, W (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BLACKSHEAR PJ, 1988, AM J MED SCI, V296, P231, DOI 10.1016/S0002-9629(15)40866-3; BREUER W, 1992, J BIOL CHEM, V267, P10465; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHOU JL, 1991, J BIOL CHEM, V266, P24471; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P71; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; KUNZELMANN K, 1993, UNPUB PFLUGERS ARCH; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; MCCOOL DJ, 1990, BIOCHEM J, V267, P491, DOI 10.1042/bj2670491; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1059; SARKADI B, 1992, J BIOL CHEM, V267, P2087; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	35	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13935	13939						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686146				2022-12-25	WOS:A1993LJ82500027
J	VELCICH, A; AUGENLICHT, LH				VELCICH, A; AUGENLICHT, LH			REGULATED EXPRESSION OF AN INTESTINAL MUCIN GENE IN HT29 COLONIC-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SODIUM-BUTYRATE; MOLECULAR-CLONING; ADENOCARCINOMA CELLS; CANCER-CELLS; ENTEROCYTIC DIFFERENTIATION; ALKALINE-PHOSPHATASE; COLORECTAL-CARCINOMA; OKADAIC ACID; CALPHOSTIN-C	We have investigated the regulation of the intestinal mucin gene MUC2 in HT29 cells. Surprisingly, sodium butyrate, an effective inducer of aspects of colonic cell differentiation in HT29 cells, fails to induce MUC2 during short-term exposure, despite the fact that it has been used to select stably differentiated clones of HT29 that resemble goblet cells and produce mucin. However, 12-O-tetradecanoylphorbol-13-acetate and forskolin, which trigger the protein kinase C- and A-dependent signal transduction pathways, respectively, are potent inducers of MUC2 gene expression. 12-O-Tetradecanoylphorbol-13-acetate and forskolin operate through distinct mechanisms, with the former requiring de novo protein synthesis and the latter not. Experiments using specific protein kinase inhibitors suggest that both inducers operate by triggering their respective signal transduction pathways. Nuclear run-off analyses suggest that post-transcriptional (rather than transcriptional) mechanisms are important in the accumulation of MUC2 mRNA. Finally, we show that in several cell lines from human mucinous tumors, characterized by elevated levels of mucin production, MUC2 expression is very high and constitutive compared to forskolin-treated HT29 cells. Thus, the different regulation of MUC2 in HT29 cells and in mucinous tumor cell lines may reflect molecular pathways that characterize colon carcinomas of different histology and pathology.			VELCICH, A (corresponding author), ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R29CA055913, R01CA056081, K04CA001330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55913, CA-56081, P30-CA-1330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; AUGENLICHT LH, 1989, CELL MOL BIOL COLON, P166; AUGERON C, 1984, CANCER RES, V44, P3961; AUGERON C, 1986, ION GRADIENT COUPLED, P363; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1987, J BIOL CHEM, V262, P1092; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUM JR, 1992, J BIOL CHEM, V267, P21375; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; HEERDT BG, 1991, J BIOL CHEM, V266, P19120; HEERDT BG, 1991, ONCOGENE, V6, P125; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JARRY A, 1992, DIGEST DIS SCI, V37, P1170, DOI 10.1007/BF01296556; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAN MS, 1990, J BIOL CHEM, V265, P15294; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NISHIZUKA Y, 1984, RECENT PROG HORM RES, V40, P301; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; PARK JG, 1987, CANCER RES, V47, P6710; PINTO M, 1982, BIOL CELL, V44, P193; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SILVER G, 1990, MOL CELL BIOL, V10, P6765, DOI 10.1128/MCB.10.12.6765; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TIBBETTS LM, 1988, CANCER RES, V48, P3751; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TSAO D, 1982, CANCER RES, V42, P1052; VANCONG N, 1990, HUM GENET, V86, P167; VELCICH A, 1989, ONCOGENE RES, V5, P31; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	70	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13956	13961						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686147				2022-12-25	WOS:A1993LJ82500030
J	KAUFMANN, J; HAASEMANN, M; MODROW, S; MULLERESTERL, W				KAUFMANN, J; HAASEMANN, M; MODROW, S; MULLERESTERL, W			STRUCTURAL DISSECTION OF THE MULTIDOMAIN KININOGENS - FINE MAPPING OF THE TARGET EPITOPES OF ANTIBODIES INTERFERING WITH THEIR FUNCTIONAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; PREKALLIKREIN BINDING DOMAIN; MONOCLONAL-ANTIBODIES; CYSTEINE PROTEINASES; LIGHT CHAIN; ANTIIDIOTYPIC ANTIBODIES; PLASMA PREKALLIKREIN; HEAVY-CHAIN; EGG-WHITE; SITE	Kininogens, the large precursor molecules of the vasoactive kinin peptides, are prototypic multidomain proteins serving numerous functions. To investigate their structure-function relationships, we have raised a panel of monoclonal antibodies against human H-kininogen and L-kininogen and fragments thereof and characterized them with respect to their target epitopes. Of 35 antibodies, 12 were directed to the aminoterminal domains (D1 to D3) of cystatin-like structure, 3 recognized domain D4 bearing the kinin segment, 17 bound to the carboxyl-terminal domains of H-kininogen (D5H and D6H), and 3 bound to the carboxyl-terminal domain D5L of L-kininogen. At least 14 distinct epitopes spread over the kininogen molecules were identified: 9 epitopes located on L-kininogen and 13 epitopes harbored by H-kininogen. Of these, 8 are shared by the two types of kininogens. Fine mapping of the epitopes by proteolytic fragments, recombinant proteins, and anti-idiotypic antibodies demonstrated that most but not all of the antibodies recognize linear epitopes. Synthesis of 28 peptides covering more than one-third of the entire kininogen sequences allowed us to narrow down seven major epitopes to 7-31 residues. Functional analyses identified 14 antibodies interfering with specific biological roles of the kininogens, i.e. cysteine proteinase inhibition, platelet attachment, cofactor binding, contact activation, and kinin delivery. Cross-reactivity studies indicated that three of the epitopes are present throughout the mammalian kininogens and further identified a unique epitope characteristic for the H/L-type of kininogens not present in their T-type. The panel of mapped antibodies provides powerful tools for the characterization of relevant interaction sites exposed by the pleiotropic kininogens and for the development of molecular surrogates mimicking these functional loci.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, W-6500 MAINZ 1, GERMANY; UNIV MUNICH, MAX VONPETTENKOFER INST, W-8000 MUNICH 2, GERMANY	Johannes Gutenberg University of Mainz; University of Munich								ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; ATASSI MZ, 1984, EUR J BIOCHEM, V145, P1, DOI 10.1111/j.1432-1033.1984.tb08516.x; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BERRETTINI M, 1986, BLOOD, V68, P455; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; CADENA RAD, 1991, TRENDS PHARMACOL SCI, V12, P272, DOI 10.1016/0165-6147(91)90569-E; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; COLMAN RW, 1992, THROMB HAEMOSTASIS, V68, P99; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; ENJYOJI K, 1988, J BIOL CHEM, V263, P973; ERLANGER BF, 1991, BIOCHEM SOC T, V19, P138, DOI 10.1042/bst0190138; FIGUEROA CD, 1992, BLOOD, V79, P754; FONG D, 1991, HUM GENET, V87, P189, DOI 10.1007/BF00204179; GARCIA KC, 1992, SCIENCE, V257, P528, DOI 10.1126/science.1636087; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HAYASHI I, 1985, J BIOL CHEM, V260, P6115; HIGASHIYAMA S, 1987, BIOCHEMISTRY-US, V26, P7450, DOI 10.1021/bi00397a038; HOCK J, 1990, J BIOL CHEM, V265, P12005; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P7021, DOI 10.1021/bi00396a025; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JIANG YP, 1992, THROMB HAEMOSTASIS, V68, P143; KATO H, 1981, METHOD ENZYMOL, V80, P172; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LOTTSPEICH F, 1985, EUR J BIOCHEM, V152, P307, DOI 10.1111/j.1432-1033.1985.tb09199.x; MODROW S, 1986, P NATL ACAD SCI USA, V83, P5703, DOI 10.1073/pnas.83.15.5703; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; OKAMOTO H, 1983, BIOCHEM BIOPH RES CO, V112, P701, DOI 10.1016/0006-291X(83)91519-X; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; REDDIGARI SR, 1989, BLOOD, V74, P695; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCARSDALE JN, 1990, J PROTEIN CHEM, V9, P647, DOI 10.1007/BF01025019; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCOTT CF, 1985, J BIOL CHEM, V260, P856; STROSBERG AD, 1985, CURR TOP MICROBIOL, V119, P91; SUGO T, 1980, BIOCHEMISTRY-US, V19, P3215, DOI 10.1021/bi00555a018; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; VOGEL R, 1988, J BIOL CHEM, V263, P12661; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WALLMARK A, 1984, P NATL ACAD SCI-BIOL, V81, P5690, DOI 10.1073/pnas.81.18.5690; YOU JL, 1991, J PROTEIN CHEM, V10, P301, DOI 10.1007/BF01025629	59	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9079	9091						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682558				2022-12-25	WOS:A1993KX81100099
J	KICKHOEFER, VA; SEARLES, RP; KEDERSHA, NL; GARBER, ME; JOHNSON, DL; ROME, LH				KICKHOEFER, VA; SEARLES, RP; KEDERSHA, NL; GARBER, ME; JOHNSON, DL; ROME, LH			VAULT RIBONUCLEOPROTEIN-PARTICLES FROM RAT AND BULLFROG CONTAIN A RELATED SMALL RNA THAT IS TRANSCRIBED BY RNA POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-ASSOCIATED RNAI; ADENOVIRUS VAI-RNA; INITIATION-FACTOR; SILK-GLAND; TAR RNA; GENES; DROSOPHILA; SEQUENCES; EXTRACT; DNA	Vaults are large cytoplasmic ribonucleoprotein particles with a sedimentation value of about 150 S. These particles contain a unique small RNA (vault RNA (vRNA)). We have determined the sequence of the RNA associated with vaults purified from both rat and bullfrog. The rat vRNA is 141 bases in length, whereas the bullfrog vRNA is present as two highly related species of 89 and 94 bases. Despite the differences in length the predicted secondary structures of the three vRNAs are clearly related. All of the vRNAs contain sequences related to the internal promoter elements necessary for transcription by RNA polymerase III. The gene for the rat vRNA was isolated and sequenced from a rat genomic library, and its transcription by RNA polymerase III was verified using an in vitro transcription assay. The rat vRNA gene was efficiently transcribed in vitro, producing a single transcript of about 140 bases. Unlike most RNA polymerase III genes, the rat vRNA is present as a single copy gene and has a distinct tissue-specific expression pattern.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, 33-257 CHS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, MENTAL RETARDAT RES CTR, LOS ANGELES, CA 90024 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH PHARM, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of Southern California			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NIGMS NIH HHS [GM45299, GM40623, GM38097] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040623, R01GM045299, R01GM038097] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CHUGANI D C, 1991, Journal of Cell Biology, V115, p458A; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; England T E, 1980, Methods Enzymol, V65, P65; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUILFOYLE R, 1981, P NATL ACAD SCI-BIOL, V78, P3378, DOI 10.1073/pnas.78.6.3378; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; JOHNSON DL, 1991, J BIOL CHEM, V266, P16037; JOHNSONBURKE DL, 1983, J BIOL CHEM, V258, P15224; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MEZA L, 1977, FEBS LETT, V77, P255, DOI 10.1016/0014-5793(77)80246-9; MONSTEIN HJ, 1981, NUCLEIC ACIDS RES, V9, P4239, DOI 10.1093/nar/9.17.4239; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SCHNEIDER RJ, 1986, CURRENT COMMUNICATIO; SIEKIERKA J, 1986, CURRENT COMMUNICATIO; SPRAGUE KU, 1977, CELL, V11, P561, DOI 10.1016/0092-8674(77)90074-5; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	38	96	109	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7868	7873						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681830				2022-12-25	WOS:A1993KW97900045
J	TAMURA, M; ARAKAKI, N; TSUBOUCHI, H; TAKADA, H; DAIKUHARA, Y				TAMURA, M; ARAKAKI, N; TSUBOUCHI, H; TAKADA, H; DAIKUHARA, Y			ENHANCEMENT OF HUMAN HEPATOCYTE GROWTH-FACTOR PRODUCTION BY INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA AND TUMOR-NECROSIS-FACTOR-ALPHA BY FIBROBLASTS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULMINANT HEPATIC-FAILURE; NF-KAPPA-B; SCATTER FACTOR; MESSENGER-RNA; BIOLOGICAL-ACTIVITIES; TRANSCRIPTION FACTOR; PARTIAL-HEPATECTOMY; LIVER-REGENERATION; MOLECULAR-CLONING; CYTOTOXIC FACTOR	Human hepatocyte growth factor (hHGF) was first purified from plasma of patients with fulminant hepatic failure (Gohda, E., Tsubouchi, H., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., Miyazaki, H., Hashimoto, S., and Daikuhara, Y. (1988) J. Clin. Invest. 81, 414-419) and is now identified to be the same protein as the scatter factor (Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., Daikuhara, Y., and Birchmeier, W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7001-7005) and tumor cytotoxic factor (Shima, N., Nakao, M., Ogaki, F., Tsuda, E., Murakami, A., and Higashio, K. (1991) Biochem. Biophys. Res. Commun. 180, 1151-1158), and it is known to be produced by fibroblasts in culture. Here we report that inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) stimulate production of hHGF from human embryonic lung fibroblasts, MRC-5, and human gingival fibroblasts, GF-5. Recombinant human IL-1alpha (rhIL-1alpha) and recombinant human TNF-alpha (rhTNF-alpha) increased hHGF levels in culture supernatants of MRC-5 and GF-5 cells dose-dependently as determined by an enzyme-linked immunosorbent assay for hHGF. The half-maximal stimulatory concentrations of rhIL-1alpha and rhTNF-alpha were about 1 ng/ml and 10 units/ml, respectively. rhIL-1beta showed almost the same effect as IL-1alpha on stimulation of production of immunoreactive hHGF from the two cell lines. However, rhIL-6 failed to show the stimulatory effect on hHGF production by the cells in the range of 2-200 units/ml. Human interferon-beta and -gamma also did not show the stimulatory activity. Stimulation of hHGF production was observed 6-12 h after addition of rhIL-1alpha or rhTNF-alpha and lasted at least 48 h, and the observed stimulation of hHGF production by cytokines was suppressed by addition of corresponding antiserum. hHGF mRNA levels of MRC-5 cells increased by addition of rhIL-1alpha and rhTNF-alpha in a dose-dependent manner as determined by Northern blot analysis using cDNA for hHGF as a probe. In addition, results from nuclear run-off transcription experiments showed that the two cytokines regulated increasing hHGF gene expression at transcriptional levels rather than a change in mRNA stability. These observations indicate that the inflammatory cytokines modulate the production and secretion of hHGF by fibroblasts and may play an important role for tissue repair and regeneration.	KAGOSHIMA UNIV, SCH DENT, DEPT BIOCHEM, 35-1 SAKURAGAOKA 8, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, SCH DENT, DEPT MICROBIOL, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 2, KAGOSHIMA 890, JAPAN	Kagoshima University; Kagoshima University; Kagoshima University			Tamura, Masato/B-7304-2009	Tamura, Masato/0000-0003-3700-5203				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BHARGAVA MM, 1991, EXP SUPPL, V59, P63; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; DINARELLO CA, 1991, CYTOKINE HDB, P47; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUYAMA R, 1991, GENOMICS, V11, P410, DOI 10.1016/0888-7543(91)90149-9; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1990, BIOCHIM BIOPHYS ACTA, V1053, P21, DOI 10.1016/0167-4889(90)90020-E; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOHDA E, 1992, J PHARMACOBIO-DYNAM, V15, P131, DOI 10.1248/bpb1978.15.131; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1989, CURRENT PROGR MOL BI; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JAATTELA M, 1991, LAB INVEST, V64, P724; JOPLIN R, 1992, J CLIN INVEST, V90, P1284, DOI 10.1172/JCI115992; KAMALATI T, 1992, J CELL SCI, V101, P323; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; LE JM, 1987, LAB INVEST, V56, P234; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MANOGUE KR, 1991, CYTOKINE HDB, P241; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAYAMA H, 1985, BIOMED RES-TOKYO, V6, P231; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J, 1989, MOL CLONING LABORATO; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STOKER M, 1985, J CELL SCI, V77, P209; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TAKADA H, 1991, INFECT IMMUN, V59, P295, DOI 10.1128/IAI.59.1.295-301.1991; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUBOUCHI H, 1989, HEPATOLOGY, V9, P875, DOI 10.1002/hep.1840090615; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOLF HK, 1991, AM J PATHOL, V138, P1035; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314	59	213	217	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8140	8145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681834				2022-12-25	WOS:A1993KW97900079
J	CATAPANO, CV; PERRINO, FW; FERNANDES, DJ				CATAPANO, CV; PERRINO, FW; FERNANDES, DJ			PRIMER RNA CHAIN TERMINATION INDUCED BY 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-TRIPHOSPHATE - A MECHANISM OF DNA-SYNTHESIS INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA; RIBONUCLEOTIDE REDUCTASE; HUMAN-LYMPHOCYTES; PRIMASE ACTIVITY; CALF THYMUS; TRIPHOSPHATE; FIDELITY; INVITRO; CELLS	The studies described herein were aimed at defining the mechanism by which 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate (FaraATP), the active intracellular metabolite of fludarabine phosphate, inhibits the synthesis of primer RNA and RNA-primed DNA by the polymerase alpha-primase complex. Incubation of the purified DNA polymerase alpha-primase complex with a poly(dT) template, 500 muM ATP, and increasing concentrations of FaraATP from 2.5 to 50 muM resulted in the progressive accumulation of smaller oligoribonucleotides (2-6 nucleotides) at the expense of the full-length products of DNA primase (7-10 nucleotides). Comparison of the k(cat)/K(M) values for incorporation of FaraATP and ATP into oligoribonucleotides revealed that DNA primase incorporated FaraATP 30-fold more efficiently than ATP. FaraAMP was present exclusively at the 3'-termini of the growing primer RNA chains, which prevented further elongation of the primers by DNA primase (primer RNA chain termination). At all FaraATP concentrations tested, inhibition of RNA-primed DNA synthesis was accompanied by primer chain termination. In contrast, DNA polymerase alpha added FaraATP onto full-length primer RNAs about 8-fold less efficiently than dATP, and the incorporation of FaraAMP at the 3'-termini of the primers did not prevent further elongation of these primers by DNA polymerase alpha. These results indicate that primer RNA chain termination is the major effect responsible for the inhibition of RNA-primed DNA synthesis by fludarabine phosphate.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center				Catapano, Carlo V./0000-0002-7079-557X				BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CATAPANO CV, 1991, CANCER RES, V51, P1829; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; Fersht A., 1985, ENZYME STRUCTURE MEC; FURTH JJ, 1968, CANCER RES, V28, P2061; HUANG P, 1990, J BIOL CHEM, V265, P16617; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; KUCHTA RD, 1991, BIOCHEMISTRY-US, V30, P797, DOI 10.1021/bi00217a033; PARKER WB, 1987, MOL PHARMACOL, V31, P146; PARKER WB, 1991, CANCER RES, V51, P2386; PERRELLA FW, 1988, ANAL BIOCHEM, V135, P841; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Sambrook J, 1989, MOL CLONING LABORATO; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSENG BY, 1977, CELL, V12, P483, DOI 10.1016/0092-8674(77)90124-6; TSENG BY, 1982, J BIOL CHEM, V257, P7280; TSENG WC, 1982, MOL PHARMACOL, V21, P474; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; YANG SW, 1992, J BIOL CHEM, V267, P2345; YOSHIDA S, 1977, BIOCHIM BIOPHYS ACTA, V477, P144, DOI 10.1016/0005-2787(77)90230-1; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	24	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7179	7185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	7681821				2022-12-25	WOS:A1993KV14100056
J	MATSUDA, M; NAGATA, S; TANAKA, S; NAGASHIMA, K; KURATA, T				MATSUDA, M; NAGATA, S; TANAKA, S; NAGASHIMA, K; KURATA, T			STRUCTURAL REQUIREMENT OF CRK SH2 REGION FOR BINDING TO PHOSPHOTYROSINE-CONTAINING PROTEINS - EVIDENCE FROM REACTIVITY TO MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL-3 KINASE; CATALYTIC DOMAINS; ONCOGENE PRODUCT; SARCOMA-VIRUS; SRC; SEQUENCE	The SH2 region of signal-transducing proteins mediates binding to phosphotyrosine-containing proteins. We analyzed the structure-function relationship of the SH2 region of the human CRK protein by using a series of monoclonal antibodies (mAbs). Seventeen mAbs against the CRK SH2 region were classified into 5 groups according to the reactivity with mutant CRK proteins expressed in COS7 cells and in Escherichia coli and by epitope scanning with synthetic nonapeptides. Two groups of mAbs (groups A and B) were reactive only with intact SH2. Mutation(s) in either the amino-terminal B box or the carboxyl-terminal C box, which are the two subdomains of SH2, abolished the reactivity of the CRK mutants to the mAbs of groups A and B. Group A mAbs competed the binding of the CRK SH2 region to the phosphotyrosine-containing proteins. Moreover, the spectrum of the CRK mutants which were recognized by group A mAbs coincided with that of the CRK mutants which could bind phosphotyrosine-containing proteins, suggesting that group A mAbs were directed against the site of binding to phosphotyrosine-containing proteins. Group C mAbs, directed against the region between the B and C boxes, were reactive with both wild-type and mutant CRK proteins and did not affect the capacity of SH2 to bind phosphotyrosine-containing proteins. Contrary to group A and B mAbs, mAbs belonging to groups D and E, which were mapped onto the C box, did not bind well to the native CRK proteins, but bound to CRK mutants with mutation(s) in either the B or the C box. These results suggest that the B and C boxes, which are separated by a hinge region, coordinately form the functional SH2 domain that binds to the phosphotyrosine-containing proteins and to the group A mAbs.	RES DEV CORP JAPAN,CELL & INFORMAT,SHIMOGYO KU,KYOTO 600,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PATHOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Japan Science & Technology Agency (JST); Hokkaido University	MATSUDA, M (corresponding author), NATL INST HLTH,DEPT PATHOL,1-23-1 TOYAMA,SHINJUKU KU,TOKYO 162,JAPAN.		Tanaka, Shinya/D-3586-2011	Matsuda, Michiyuki/0000-0002-5876-9969; Nagata, Satoshi/0000-0001-9156-5215				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2354; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAGATA S, 1991, HYBRIDOMA, V10, P369, DOI 10.1089/hyb.1991.10.369; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4441	4446						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680038				2022-12-25	WOS:A1993KN53300090
J	CHOI, SY; SIVARAM, P; WALKER, DE; CURTISS, LK; GRETCH, DG; STURLEY, SL; ATTIE, AD; DECKELBAUM, RJ; GOLDBERG, IJ				CHOI, SY; SIVARAM, P; WALKER, DE; CURTISS, LK; GRETCH, DG; STURLEY, SL; ATTIE, AD; DECKELBAUM, RJ; GOLDBERG, IJ			LIPOPROTEIN-LIPASE ASSOCIATION WITH LIPOPROTEINS INVOLVES PROTEIN-PROTEIN INTERACTION WITH APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEPARIN-BINDING-SITES; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; IDENTIFICATION; RECEPTOR; TISSUE; MACROPHAGES; DEGRADATION; LOCALIZE	Lipoprotein lipase (LPL) hydrolyzes chylomicron and very low density lipoprotein (VLDL) triglycerides and potentiates the cellular uptake of lipoproteins. These LPL-lipoprotein associations could involve only protein-lipid interaction, or they could be modulated by apolipoproteins (ape), ApoB is the major protein component of chylomicrons, VLDL, and low density lipoprotein (LDL), ApoB100, a large glycoprotein with a molecular mass of 550 kDa, is composed of several functional domains, A carboxyl terminal region of the protein is the ligand for the LDL receptor, There are several hydrophobic domains that are believed to be important in lipid binding, The relatively hydrophilic amino-terminal region of apoB, however, has no known function, Using solid phase assays we quantified LPL lipoprotein complex formation, On a molar basis, severalfold greater amounts of LPL bound to LDL and VLDL than to high density lipoprotein at all the concentrations of LPL tested (0.9-55 nM). To assess the roles of LDL protein versus lipid, we performed competition and ligand blotting experiments, LDL and an amino-terminal fragment of apoB competed better for I-125-LPL binding to LDL than did lipid emulsion particles, Delipidation of LDL-coated plates did not alter LPL binding, On ligand blots, LPL bound to amino-terminal fragments of apoB generated by thrombin digestion but not to apoA1, apoE, or carboxyl-terminal fragments of apoB, Further evidence for LPL interaction with the amino-terminal region of apoB was obtained using anti-apoB monoclonal antibodies, Antibodies directed against the amino-terminal regions of apoB blocked LPL interaction with LDL, whereas those against the carboxyl-terminal region of apoB did not inhibit LPL interaction with LDL, Thus, we conclude that a specific interaction between LPL and the amino-terminal region of apoB may facilitate LPL association with circulating lipoproteins.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	Columbia University; Columbia University; Scripps Research Institute; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL 45095, HL 21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R37HL045095, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHAN L, 1992, J BIOL CHEM, V267, P25621; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1985, CIRCULATION, V72, P93; DELOOF H, 1987, J LIPID RES, V28, P1455; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EKMAN R, 1975, CLIN CHIM ACTA, V63, P29, DOI 10.1016/0009-8981(75)90374-5; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FIELDING CJ, 1980, BIOCHIM BIOPHYS ACTA, V620, P440, DOI 10.1016/0005-2760(80)90135-6; GALEANO NF, 1994, J BIOL CHEM, V269, P511; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIETANEN E, 1977, J LIPID RES, V18, P480; HUI DY, 1986, J BIOL CHEM, V255, P1804; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHOO JC, 1981, J BIOL CHEM, V256, P7105; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRUL ES, 1988, J LIPID RES, V29, P937; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILNE R, 1989, J BIOL CHEM, V264, P19754; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PATTON JG, 1982, J IMMUNOL METHODS, V55, P193, DOI 10.1016/0022-1759(82)90031-X; PEASE RJ, 1990, J BIOL CHEM, V265, P553; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMADA K, 1982, BIOCHIM BIOPHYS ACTA, V710, P117, DOI 10.1016/0005-2760(82)90140-0; SHIRAI K, 1981, BIOCHIM BIOPHYS ACTA, V665, P504; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SIVARAM P, 1993, ANAL BIOCHEM, V214, P511, DOI 10.1006/abio.1993.1531; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VILELLA E, 1993, J LIPID RES, V34, P1555; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; YANG CY, 1989, J BIOL CHEM, V264, P16822	53	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8081	8086		10.1074/jbc.270.14.8081	http://dx.doi.org/10.1074/jbc.270.14.8081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713910	hybrid			2022-12-25	WOS:A1995QR52600048
J	HSIEH, JC; ZINNEN, S; MODRICH, P				HSIEH, JC; ZINNEN, S; MODRICH, P			KINETIC MECHANISM OF THE DNA-DEPENDENT DNA-POLYMERASE-ACTIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; I KLENOW; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; H ACTIVITY; RNASE-H; HIV-1; EXPRESSION; FIDELITY; BINDING	The kinetic pathway of DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase (HIV RT) as determined by pre-steady-state methods using a defined primer/template is as follows, [GRAPHICS] where E is RT, D(n,n+1) is primer/template, dNTP is deoxyribonucleoside triphosphate, and PP(i) is pyrophosphate. The rate-determining step for enzyme turnover in single nucleotide addition is the dissociation of enzyme from DNA (k6 = 0.11 s-1). The observation of an E'.DNA.dNTP intermediate by pulse-chase analysis and the absence of a phosphorothioate elemental effect identified the rate-limiting step for nucleotide addition as a conformational change of the E.DNA.dNTP complex (k3 = 83 s-1) prior to the chemical step. Biphasic kinetics of single-turnover pyrophosphorolysis suggested that this conformational change (k-3 = 0.3 s-1) is also rate-limiting for the reverse reaction. The equilibrium constant for the chemical step (K4) is 3.8, in slight favor of the forward reaction. The large equilibrium constant (K3 = 280) for the conformational change effectively renders nucleotide addition kinetically irreversible. The dissociation constant for primer/template is 26 nM, and the association rate of enzyme and DNA (k1) is 2.3 x 10(6) M-1 s-1. Equilibrium dissociation constants for dTTP and PP(i) are 18 muM and 7.2 mM, respectively. Mg2+ enhances productive interaction of RT with DNA as judged by a 50% increase in burst amplitude in the single nucleotide addition reaction and by an 8-fold decrease in K(D) for the RT.DNA complex as determined by gel mobility shift assay. Secondary interactions of the RT.DNA complex with free DNA were observed in the absence of Mg2+.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University				Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; Benkovic S. J, 1973, ENZYMES, P201; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MULLER B, 1989, J BIOL CHEM, V264, P13975; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RESTLE T, 1990, J BIOL CHEM, V265, P8986; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2, P75; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	34	177	184	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24607	24613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693703				2022-12-25	WOS:A1993MG67300018
J	BLAIN, SW; GOFF, SP				BLAIN, SW; GOFF, SP			NUCLEASE ACTIVITIES OF MOLONEY MURINE LEUKEMIA-VIRUS REVERSE-TRANSCRIPTASE - MUTANTS WITH ALTERED SUBSTRATE SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA-POLYMERASE; AVIAN MYELOBLASTOSIS VIRUS; SITE-DIRECTED MUTAGENESIS; RIBONUCLEASE-H DOMAIN; RNA TUMOR-VIRUSES; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACID; RETROVIRUSES; REPLICATION	RNases H are traditionally thought to degrade RNA only in RNA-DNA hybrid form. We found that the wild-type Moloney murine leukemia virus (M-MuLV) reverse transcriptase (RT) was capable of degrading RNA in RNA-RNA duplexes as well as in RNA-DNA hybrids, as assayed by in situ gel techniques. Escherichia coli RNase H does not degrade the RNA-RNA duplex in this assay, while E. coli RNase III, a double-strand-specific ribonuclease, does. The apparent specific activity of M-MuLV RT on RNA-RNA duplexes is similar to that on RNA-DNA hybrids. Neither the DNA polymerase domain nor the RNase H domain of RT expressed individually exhibited this RNA-RNA activity. We have generated a series of mutations in the RNase H domain of M-MuLV RT, expressed the mutant enzymes in E. coli, and assayed these mutants for various activities. All RTs were as active as the wild type in the oligo(dT):poly(rA) DNA polymerase assay, and many retained both nuclease activities. Two enzymes with mutations at the carboxyl terminus of the RNase H domain retained RNA-DNA activity, but not RNA-RNA activity. Another mutant enzyme showed the opposite phenotype, retaining RNA-RNA, but not RNA-DNA, nuclease activity. Thus, we were able to genetically separate the two activities. These results may be helpful in defining enzyme-substrate interactions.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [CA 30488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030488, R37CA030488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTIMORE D, 1972, J BIOL CHEM, V247, P7282; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P937; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CROUCH R J, 1990, New Biologist, V2, P771; CROUCH RJ, 1970, J BIOL CHEM, V249, P1314; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; GERARD GF, 1986, DNA-J MOLEC CELL BIO, V5, P271, DOI 10.1089/dna.1986.5.271; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARLOW E, 1988, ANTIBODIES LABORATOR, P70; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HOSTOMSKY Z, 1992, NUCLEIC ACIDS RES, V20, P5819, DOI 10.1093/nar/20.21.5819; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6354; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA S, 1984, P NATL ACAD SCI-BIOL, V81, P3447, DOI 10.1073/pnas.81.11.3447; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1991, DNA REPLICATION, P29; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; KUNKEL TA, 1987, METHOD ENZYMOL, V155, P166; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; MCCLURE MA, 1993, REVERSE TRANSCRIPTAS, P425; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MOELLING K, 1976, J VIROL, V18, P418, DOI 10.1128/JVI.18.2.418-425.1976; MOELLING K, 1971, NATURE, V234, P240; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; Sambrook J, 1989, MOL CLONING LABORATO; SKALKA A, 1993, REVERSE TRANSCRIPTAS; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1992, J VIROL, V66, P615, DOI 10.1128/JVI.66.2.615-622.1992; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VERMA IM, 1975, J VIROL, V15, P843, DOI 10.1128/JVI.15.4.843-854.1975; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	54	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23585	23592						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693692				2022-12-25	WOS:A1993MF51500096
J	DIRNHOFER, S; KLIEBER, R; DELEEUW, R; BIDART, JM; MERZ, WE; WICK, G; BERGER, P				DIRNHOFER, S; KLIEBER, R; DELEEUW, R; BIDART, JM; MERZ, WE; WICK, G; BERGER, P			FUNCTIONAL AND IMMUNOLOGICAL RELEVANCE OF THE COOH-TERMINAL EXTENSION OF HUMAN CHORIONIC GONADOTROPIN-BETA - IMPLICATIONS FOR THE WHO BIRTH-CONTROL VACCINE	FASEB JOURNAL			English	Note						WHO; BIRTH CONTROL VACCINE; HCG; HCG-BETA-CTP	MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; HUMAN CHORIOGONADOTROPIN; ANTIFERTILITY VACCINES; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; SUBUNIT; HCG	The World Health Organisation (WHO) Task Force on Birth Control Vaccines has selected the pregnancy hormone human chorionic gonadotropin (hCG) as a target molecule for a contraceptive vaccine. A synthetic peptide antigen corresponding to the amino acid sequence 109-145 of the carboxyl-terminal portion of the hCGbeta-subunit (hCGbetaCTP), which is supposed to elicit hCG-immunoneutralizing antibodies, has been submitted to clinical trails. Recent findings suggest that hCGbetaCTP does not play a role in the biological activity of hCG. This raises the question concerning the assumed mechanism of action of the hCGbetaCTP-based birth control vaccine. We therefore investigated the immunoneutralizing capacity of antibodies directed against hCGbetaCTP. Although it is possible to generate specific monoclonal and polyclonal antibodies for hCG by using hCGbetaCTP as an immunogen, it appeared that the biological response to hCG was not affected by such antibodies. The reason for this is that the hCG-antibody-complex is still able to bind to target cell receptors and therefore the intended contraceptive effect should not occur. In addition there is a risk of hazardous possible side effects such as an autoimmune reaction against the ovary because we found that at least one epitope is still accessible for antibody binding on receptor-bound hCG. We conclude from our results that both the efficacy and safety of the WHO vaccine are not yet ensured.	AUSTRIAN ACAD SCI, INST BIOMED AGING RES, RENNWEG 10, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK HOSP, DEPT OBSTET & GYNECOL, INNSBRUCK, AUSTRIA; ORGANON INT BV, DEPT ENDOCRINOL, OSS, NETHERLANDS; INST GUSTAVE ROUSSY, DEPT CLIN BIOL, F-94805 VILLEJUIF, FRANCE; UNIV HEIDELBERG, INST BIOCHEM 2, W-6900 HEIDELBERG, GERMANY; UNIV INNSBRUCK, INST GEN & EXPTL PATHOL, A-6020 INNSBRUCK, AUSTRIA	Austrian Academy of Sciences; Medical University of Innsbruck; UNICANCER; Gustave Roussy; Ruprecht Karls University Heidelberg; University of Innsbruck								BERGER P, 1987, NATURE, V326, P648, DOI 10.1038/326648a0; BERGER P, 1988, ENDOCRINOLOGY, V123, P2351, DOI 10.1210/endo-123-5-2351; BERGER P, 1990, J ENDOCRINOL, V125, P301, DOI 10.1677/joe.0.1250301; BERGER P, 1984, AM J REPROD IMMUNOL, V5, P157, DOI 10.1111/j.1600-0897.1984.tb00188.x; BERGER P, 1992, FOLLICLE STIMULATING, P319; BIDART JM, 1987, MOL IMMUNOL, V24, P339, DOI 10.1016/0161-5890(87)90175-1; BIRKEN S, 1982, ENDOCRINOLOGY, V110, P1555, DOI 10.1210/endo-110-5-1555; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN W, 1991, J BIOL CHEM, V266, P6264; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRIFFIN PD, 1991, STAT MED, V10, P177, DOI 10.1002/sim.4780100204; JONES WR, 1988, LANCET, V1, P1295; KOFLER R, 1982, AM J REPROD IMMUNOL, V2, P212, DOI 10.1111/j.1600-0897.1982.tb00168.x; KOFLER R, 1981, IMMUNOBIOLOGY, V160, P196, DOI 10.1016/S0171-2985(81)80047-2; MANNAERTS BMJ, 1987, NEUROENDOCRINOLOGY R, P49; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; ROSE NR, 1991, VACCINES FERTILITY R, P121; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHWARZ S, 1986, ENDOCRINOLOGY, V118, P189, DOI 10.1210/endo-118-1-189; SCHWARZ S, 1988, J RECEPTOR RES, V8, P437, DOI 10.3109/10799898809049003; STAHLI C, 1980, J IMMUNOL METHODS, V32, P297, DOI 10.1016/0022-1759(80)90194-5; STEVENS VC, 1986, IMMUNOL TODAY, V7, P369, DOI 10.1016/0167-5699(86)90029-0; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; YAMAMOTO Y, 1984, AM J REPROD IMMUNOL, V5, P164, DOI 10.1111/j.1600-0897.1984.tb00190.x	25	39	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1381	1385		10.1096/fasebj.7.14.7693535	http://dx.doi.org/10.1096/fasebj.7.14.7693535			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7693535				2022-12-25	WOS:A1993MH00800011
J	YAKUBOV, L; KHALED, Z; ZHANG, LM; TRUNEH, A; VLASSOV, V; STEIN, CA				YAKUBOV, L; KHALED, Z; ZHANG, LM; TRUNEH, A; VLASSOV, V; STEIN, CA			OLIGODEOXYNUCLEOTIDES INTERACT WITH RECOMBINANT CD4 AT MULTIPLE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTI-HIV AGENT; BINDING-SITE; DEXTRAN SULFATE; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; SYNCYTIUM FORMATION; AURINTRICARBOXYLIC ACID; PENTOSAN POLYSULFATE; HIV-GP120 BINDING; ATOMIC-STRUCTURE	Phosphodiester oligodeoxynucleotides bearing the 5'-alkylating moiety 4-(N-2-chloroethyl-N-methyl)aminobenzylamine specifically modify recombinant soluble CD4 (rsCD4) in solution. This reaction is saturable with respect to the alkylating oligonucleotide reagent. The existence of at least two binding sites, with different affinities, on the rsCD4 molecule, were demonstrated. The values of apparent K(d) for the sites are approximately 0.1 and 1 muM. The existence of two sites was confirmed by electrophoretic analysis of the modified protein, in which two distinct gel bands were seen. The modification is inhibited hy excess non-alkylating oligonucleotide, as well as by phosphorothioate oligonucleotides. Quantitative estimates of the competition constants (K(c)), for the binding of these competitors of the binding of the alkylating oligonucleotide reagent with rsCD4, have been made. By use of this method, several anionic dyes as well as potential anti-HIV therapeutic agents were also demonstrated to interact with rsCD4. Phosphorothioate oligonucleotides also inhibit binding of rsCD4 with the monoclonal antibody L71.1.1 This monoclonal antibody recognizes the CDR3-like loop (D1 domain) of the rsCD4 molecule. Thus, oligonucleotide binding sites exist on two remote regions (i.e. both the CDR2- and CDR3-like loops) of the D1 domain of CD4.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; SMITHKLINE BEECHAM PHARMACEUT, MOLEC GENET, KING OF PRUSSIA, PA 19406 USA; NOVOSIBIRSK BIOORGAN CHEM INST, NOVOSIBIRSK 630090, RUSSIA	Columbia University; GlaxoSmithKline; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS			Truneh, Alem/ABB-7891-2020; Vlassov, Valentin/F-4720-2013	Vlassov, Valentin/0000-0003-2845-2992				ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BALZARINI J, 1986, INT J CANCER, V37, P451, DOI 10.1002/ijc.2910370318; Bayever E, 1992, Antisense Res Dev, V2, P109; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CARDIN AD, 1991, J BIOL CHEM, V266, P13355; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOE HR, 1992, J ACQ IMMUN DEF SYND, V5, P204; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; CUSHMAN M, 1991, J MED CHEM, V34, P329, DOI 10.1021/jm00105a052; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; GAO WY, 1992, MOL PHARMACOL, V41, P223; KALYANARAMAN VS, 1990, J IMMUNOL, V145, P4072; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KNORRE DG, 1985, ADV ENZYME REGUL, V24, P277, DOI 10.1016/0065-2571(85)90082-2; KOZLOWSKI MR, 1992, ANTIVIR CHEM CHEMOTH, V3, P49, DOI 10.1177/095632029200300107; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LEDERMAN S, 1992, AIDS RES HUM RETROV, V8, P1599, DOI 10.1089/aid.1992.8.1599; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LIFSON JD, 1991, AIDS RES HUM RETROV, V7, P521, DOI 10.1089/aid.1991.7.521; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; NAKASHIMA H, 1987, JPN J CANCER RES, V78, P1164; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; PARISH CR, 1990, J IMMUNOL, V145, P1188; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RAUSCH DM, 1990, ANN NY ACAD SCI, V616, P125; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SCHOLS D, 1989, P NATL ACAD SCI USA, V86, P3322, DOI 10.1073/pnas.86.9.3322; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEC WJ, 1991, NUCLEIC ACIDS RES, V19, P5883, DOI 10.1093/nar/19.21.5883; Stein C A, 1993, Antisense Res Dev, V3, P19; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; STEIN CA, 1989, AIDS RES HUM RETROV, V5, P639, DOI 10.1089/aid.1989.5.639; STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; THIELE B, 1989, EUR J IMMUNOL, V19, P1161, DOI 10.1002/eji.1830190630; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEAVER JL, 1990, AIDS RES HUM RETROV, V6, P1125, DOI 10.1089/aid.1990.6.1125; WEAVER JL, 1992, ANTIVIR CHEM CHEMOTH, V3, P147, DOI 10.1177/095632029200300303; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454	54	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18818	18823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689560				2022-12-25	WOS:A1993LV65900068
J	LAROSE, L; GISH, G; SHOELSON, S; PAWSON, T				LAROSE, L; GISH, G; SHOELSON, S; PAWSON, T			IDENTIFICATION OF RESIDUES IN THE BETA PLATELET-DERIVED GROWTH-FACTOR RECEPTOR THAT CONFER SPECIFICITY FOR BINDING TO PHOSPHOLIPASE C-GAMMA-1	ONCOGENE			English	Article							PDGF RECEPTOR; V-SRC; TYROSINE KINASES; CDNA CLONING; SH2 DOMAINS; PHOSPHOTYROSINE; PROTEINS; PHOSPHORYLATION; SITE; GAP	The SH2 domains of cytoplasmic signaling proteins bind to autophosphorylated growth factor receptors by direct recognition of specific phosphotyrosine-containing sites. To identify the phosphotyrosine involved in association of phospholipase C (PLC)-gamma1 with the beta platelet-derived growth factor receptor (PDGFR), and to investigate which contiguous residues confer specificity for PLC-gamma1, phosphotyrosine-containing glutathione S-transferase (GST) fusion proteins possessing different regions of the beta-PDGFR were incubated with lysates of Rat-2 cells that overexpress PLC-gamma1. The phosphorylated C-terminal tail of the PDGFR bound PLC-gamma1, but did not associate with phosphatidylinositol (PI) 3'-kinase or GTPase-activating protein (GAP). High-affinity binding of PLC-gamma1 was dependent on phosphorylation of Tyr-1021. Creation of a new phosphorylation site by replacing Asp-1018 with tyrosine did not restore binding of PLC-gamma1 in the absence of Tyr-1021, indicating that the location of the phosphorylated tyrosine is important for PLC-gamma1 binding. Substitution of the proline at the +3 position relative to Tyr-1021 with methionine (Y1021IIP-->Y1021IIM) in the phosphorylated PDGFR tail did not alter PLC-gamma1 association, but conferred binding activity towards PI 3'-kinase, indicating that this residue is critical in discriminating between PLC-gamma1 and PI 3'-kinase. Progressive conversion of the three residues C-terminal to Tyr-1021 to the consensus for PI 3'-kinase binding (YMDM) allowed PI 3'-kinase association, but did not block PLC-gamma1 binding, suggesting that additional residues other than the three residues immediately following the phosphotyrosine may contribute to the association of PLC-gamma1 with the PDGFR. These results indicate that phosphorylation at Tyr-1021 in the tail of the PDGFR creates a specific binding site for PLC-gamma1. Proline at the +3 position relative to Tyr-1021 is crucial in conferring specificity for binding to PLC-gamma1.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X5,ON,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,JOSLEN DIABET CTR,DIV RES,BOSTON,MA 02115	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; ECK M, 1993, IN PRESS CELL; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMPS MP, 1988, ONCOGENE, V2, P305; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1993, IN PRESS P NATL ACAD; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SONGYANG Z, 1993, CELL, V72, P1; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	32	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2493	2499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689724				2022-12-25	WOS:A1993LT36800021
J	SUWANICKUL, A; MORRIS, SL; POWELL, DR				SUWANICKUL, A; MORRIS, SL; POWELL, DR			IDENTIFICATION OF AN INSULIN-RESPONSIVE ELEMENT IN THE PROMOTER OF THE HUMAN GENE FOR INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; HUMAN AMNIOTIC-FLUID; HEPATOMA-CELLS; IGF-I; MULTIHORMONAL REGULATION; PHENOTYPIC SELECTION; MAMMALIAN-CELLS; DOMINANT ROLE; TRANSCRIPTION; FOS	Insulin inhibits the hepatic transcription of insulin-like growth factor binding protein-1 (IGFBP-1). In the present studies, human HEP G2 hepatoma cells were transiently transfected with human IGFBP-1 gene promoter constructs in order to identify cis elements and trans-acting factors that confer the insulin effect. Transfections of IGFBP-1 promoter deletion constructs localized an insulin responsive element (IRE) between approximately 140- and approximately 103-base pair (bp) 5' to the mRNA capsite. This region contains a 25-bp sequence which is 100% conserved in the rat IGFBP-1 promoter and which has two AT-rich, 8-bp elements exhibiting dyad symmetry. Site-directed mutagenesis of both elements in the same 1205-bp IGFBP-1 promoter construct abolished the inhibitory effect of insulin on promoter activity. Also, the native but not the mutant IGFBP-1 IRE conferred the inhibitory effect of insulin to the heterologous thymidine kinase promoter. Gel mobility shift assays identified a DNA binding activity which specifically binds the native IGFBP-1 IRE and which is not altered by prior insulin treatment. The IGFBP-1 IRE sequence is similar to those of functionally mapped IREs from other gene promoters, suggesting that this common IRE and the protein(s) which it binds confer the insulin effect to a number of insulin-sensitive genes.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; ALEXANDERBRIDGES M, 1992, MOL CELL BIOCHEM, V109, P99; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BRISMAR K, 1993, GROWTH REGULAT, V3, P98; BRISMAR K, 1988, J ENDOCRINOL INVEST, V11, P599, DOI 10.1007/BF03350189; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; CHEN L, 1989, P NATL ACAD SCI USA, V86, P1367, DOI 10.1073/pnas.86.4.1367; CONOVER CA, 1990, J CLIN ENDOCR METAB, V70, P1062, DOI 10.1210/jcem-70-4-1062; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, DIABETES, V39, P1251, DOI 10.2337/diabetes.39.10.1251; CONOVER CA, 1993, IN PRESS ACTA ENDOCR; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P908, DOI 10.1210/jcem-59-5-908; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Montminy M R, 1990, Recent Prog Horm Res, V46, P219; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POWELL DR, 1989, INT CONGR SER, V881, P3; POWELL DR, 1991, J BIOL CHEM, V266, P18868; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; UNTERMAN TG, 1992, BIOCHEM BIOPH RES CO, V185, P993, DOI 10.1016/0006-291X(92)91725-6; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; YEOH SI, 1988, ACTA ENDOCRINOL-COP, V128, P140; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	53	110	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17063	17068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688722				2022-12-25	WOS:A1993LQ98800030
J	LI, W; HANDSCHUMACHER, RE				LI, W; HANDSCHUMACHER, RE			SPECIFIC INTERACTION OF THE CYCLOPHILIN-CYCLOSPORINE COMPLEX WITH THE B-SUBUNIT OF CALCINEURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSIVE AGENT; RECEPTOR; EXPRESSION; FK506	Calcineurin (CaN), a Ca2+/calmodulin-dependent serine/threonine phosphatase, has been shown to be inhibited by the complex of the immunosuppressant cyclosporin A (CsA) and its receptor, cyclophilin (CyP), but not by either alone. In the current study, the topological relationship between cyclophilin and the subunits of CaN has been explored using chemical crosslinking agents. In the presence of cyclosporin, I-125-CyP, shown to bind to CsA, is extensively cross-linked to the B subunit of CaN but not the catalytic A subunit. However, the A subunit is required for binding of the CyP.CsA complex, since cross-linking to recombinant B subunit alone does not occur. The kinetics of association indicate a saturable reaction with a K(d) of less than 70 nM. Cross-linking to the B subunit occurs with cross-linkers that span from 0 to 16 angstrom and employ different cross-linking chemistry, indicating direct contact between the B subunit and CyP. Similar cross-linking to the B subunit has been observed with the complex of I-125-labeled FK506 binding protein (FKBP) and FK506 but not with the FKBP-rapamycin complex. CyP.CsA cross-linking to CaN is Ca2+/calmodulin-dependent with intact CaN, but Ca2+/calmodulin-independent after digestion to remove the calmodulin binding and autoinhibitory domain.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University					NIGMS NIH HHS [GM40660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FOOR F, 1992, NATURE, V360, P682; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MERKER M, 1983, TRANSPLANT P S1, V4, P2265; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1	27	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14040	14044						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686148				2022-12-25	WOS:A1993LJ82500041
J	REZAEE, M; ISOKAWA, K; HALLIGAN, N; MARKWALD, RR; KRUG, EL				REZAEE, M; ISOKAWA, K; HALLIGAN, N; MARKWALD, RR; KRUG, EL			IDENTIFICATION OF AN EXTRACELLULAR 130-KDA PROTEIN INVOLVED IN EARLY CARDIAC MORPHOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUSHION TISSUE; ADHESION MOLECULES; HEART DEVELOPMENT; FLOOR PLATE; EXPRESSION; PATTERN; CELLS; GENE; CYTODIFFERENTIATION; DIFFERENTIATION	Previous studies indicate that the transformation of cardiac endothelium into mesenchyme is dependent upon a developmentally regulated signal expressed by its associated myocardium. This process can be mimicked in culture by substituting a non-cytolytic EDTA extract of embryonic heart tissue for the presence of myocardium. Polyclonal antibodies (ES1) generated against the EDTA-extractable proteins both localized to the cardiac extracellular matrix preceding the transformation of endothelium and blocked this process in culture. Based on these observations, we hypothesized that ES1 antigens participate in the formation of cardiac mesenchyme. The present study was undertaken to prepare cDNA and antibody probes for individual ES1 antigens to better characterize their involvement in this important morphogenetic event. An expression library was constructed in Uni-ZAP using poly(A+) RNA from embryonic cardiocyte cultures that had been shown previously to secrete proteins that engender the formation of cardiac mesenchyme. Screening of this expression library with ES1 antibodies resulted in several clones, one of which (''ES1-2.1a'') is described in this report. ES1-2.1a has a 2.6-kilobase pair insert, the sequence of which exhibits no apparent homology to those in data banks. A fragment (852 base pairs) from the 5' region of ES1-2.1a cDNA was subcloned into the expression vector pGEX-2T, and a 20-kDa fragment of the resulting protein used to prepare affinity-purified antibodies. Immunoblotting detected a 130-kDa protein (''ES/130'') in two preparations that elicit mesenchyme formation, i.e. EDTA extracts of embryonic hearts and conditioned medium of cardiocyte cultures. Functional studies showed that antibodies to ES/130 inhibited the epithelial-mesenchymal transformation of cardiac endothelium in culture. Immunohistochemistry of cardiocyte cultures localized ES/130 protein to the vacuolar system and secretory granules. By polymerase chain reaction analysis, the message for ES/130 was detected in the developing heart just prior to and during mesenchyme formation. These results are consistent with ES/130 being involved at a critical step in the initiation of the epithelial-mesenchymal transformation of cardiac endothelium.	MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,MILWAUKEE,WI 53226	Medical College of Wisconsin				Krug, Edward/0000-0002-4345-6580; Isokawa, Keitaro/0000-0002-7955-7252	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033756, R37HL033756, R01HL044928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44928, HL33756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BERNANKE DH, 1982, DEV BIOL, V91, P235, DOI 10.1016/0012-1606(82)90030-6; CROSSIN KL, 1991, DEV BIOL, V145, P277, DOI 10.1016/0012-1606(91)90126-N; Davis CL, 1924, ANAT REC, V27, P201; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FUNDERBURG FM, 1986, J CELL BIOL, V103, P2475, DOI 10.1083/jcb.103.6.2475; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; KRUG EL, 1987, DEV BIOL, V120, P348, DOI 10.1016/0012-1606(87)90237-5; KRUG EL, 1985, DEV BIOL, V112, P414, DOI 10.1016/0012-1606(85)90414-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, DECONTAMINATION DILU; MARKWALD RR, 1977, AM J ANAT, V148, P85, DOI 10.1002/aja.1001480108; MARKWALD RR, 1975, DEV BIOL, V42, P160, DOI 10.1016/0012-1606(75)90321-8; MARKWALD RR, 1990, ANN NY ACAD SCI, V588, P13, DOI 10.1111/j.1749-6632.1990.tb13193.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE PG, 1992, DEV DYNAM, V193, P24, DOI 10.1002/aja.1001930105; MJAATVEDT CH, 1987, DEV BIOL, V119, P59, DOI 10.1016/0012-1606(87)90206-5; MJAATVEDT CH, 1991, DEV BIOL, V145, P219, DOI 10.1016/0012-1606(91)90121-I; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLURSH M, 1984, CELL DIFFER DEV, V15, P17, DOI 10.1016/0045-6039(84)90025-3; STERN CD, 1990, DEVELOPMENT, V110, P1271; WEIDNER KM, 1990, J CELL BIOL, V111, P2094; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; [No title captured]	37	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14404	14411						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686155				2022-12-25	WOS:A1993LJ82500089
J	YEE, NS; LANGEN, H; BESMER, P				YEE, NS; LANGEN, H; BESMER, P			MECHANISM OF KIT-LIGAND, PHORBOL ESTER, AND CALCIUM-INDUCED DOWN-REGULATION OF C-KIT RECEPTORS IN MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; EPIDERMAL GROWTH-FACTOR; PERITONEAL-EXUDATE MACROPHAGES; STIMULATING FACTOR CSF-1; TYROSINE KINASE; SIGNAL TRANSDUCTION; W-LOCUS; INDEPENDENT MECHANISMS; TRANSMEMBRANE KINASE; INSULIN-RECEPTOR	The proto-oncogene c-kit is allelic with the white spotting locus (W) on mouse chromosome 5 and it encodes a transmembrane protein tyrosine kinase which belongs to the platelet-derived growth factor and macrophage-colony stimulating factor (CSF-1) receptor subfamily. In an effort to study the function of the c-kit receptor, specifically the physiological mechanism of controlling the signal induced by the ligand, the effect and mechanism of down-regulation of the c-kit receptor by the kit ligand (KL) was investigated in mast cells. Following preincubation with KL, the capacity of mast cells to bind kit antibody was reduced and binding of radiolabeled KL to mast cells decreased with similar kinetics, suggesting that KL stimulates the loss of c-kit receptor from the cell surface. After binding to the c-kit receptor, KL was rapidly internalized, and degradation of the receptor was accelerated. The c-kit receptor was transmodulated by the protein kinase C activator 12-O-tetradecanoylphorbol-13-acetate (TPA) and by the calcium ionophore ionomycin. TPA- and ionomycin-induced down-regulation of the c-kit receptor was accompanied by release of the extracellular domain of the receptor, presumably by proteolytic cleavage near the transmembrane domain. Release of the extracellular domain of the c-kit receptor occurred also in untreated cells but at a slow rate. In addition, ionomycin induced shedding of the intact c-kit receptor. In mast cells depleted of protein kinase C, the c-kit receptor remained sensitive to down-regulation induced by KL and ionomycin, but not by treatment with TPA. Therefore, the down-regulation of the c-kit receptor induced by KL, activated protein kinase C, and an increased level of intracellular calcium is mediated through independent mechanisms.	MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,1275 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	Memorial Sloan Kettering Cancer Center; Cornell University; Roche Holding					NATIONAL CANCER INSTITUTE [R37CA032926] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 32926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BRIZZI MF, 1991, J CELL PHYSIOL, V148, P24, DOI 10.1002/jcp.1041480104; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN BDM, 1985, J CELL PHYSIOL, V124, P305, DOI 10.1002/jcp.1041240221; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRUNBERGER G, 1982, AM J PHYSIOL, V243, pE319, DOI 10.1152/ajpendo.1982.243.4.E319; GUILBERT LJ, 1983, J CELL PHYSIOL, V115, P276, DOI 10.1002/jcp.1041150310; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KING AC, 1982, J BIOL CHEM, V257, P3053; KITAMURA Y, 1989, BIOESSAYS, V10, P193, DOI 10.1002/bies.950100604; LEE LS, 1979, P NATL ACAD SCI USA, V76, P5168, DOI 10.1073/pnas.76.10.5168; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LIU CM, 1978, J BIOL CHEM, V253, P5892; MAGUN BE, 1980, J BIOL CHEM, V255, P6373; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MORI S, 1992, J BIOL CHEM, V267, P6429; NAKAHATA T, 1986, NATURE, V324, P65, DOI 10.1038/324065a0; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PAWSON T, 1991, TRENDS GENET, V7, P343, DOI 10.1016/0168-9525(91)90252-L; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHIEH JH, 1991, J IMMUNOL, V146, P2648; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; Silvers W.K., 1979, COAT COLORS MICE, P206; STEIN J, 1991, ONCOGENE, V6, P601; TAKAGI M, 1992, J IMMUNOL, V148, P3446; THOMOPOULOS P, 1982, EUR J BIOCHEM, V29, P389; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; WHITE JR, 1985, P NATL ACAD SCI USA, V82, P8193, DOI 10.1073/pnas.82.23.8193; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YUNG YP, 1982, J IMMUNOL, V129, P1256; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	60	118	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14189	14201						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686152				2022-12-25	WOS:A1993LJ82500061
J	MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; NYKJAER, A; ANDREASEN, PA; RASMUSSEN, HH; SOTTRUPJENSEN, L; GLIEMANN, J				MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; NYKJAER, A; ANDREASEN, PA; RASMUSSEN, HH; SOTTRUPJENSEN, L; GLIEMANN, J			ALPHA-2-MACROGLOBULIN-PROTEINASE COMPLEXES, PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1-PLASMINOGEN ACTIVATOR COMPLEXES, AND RECEPTOR-ASSOCIATED PROTEIN BIND TO A REGION OF THE ALPHA-2-MACROGLOBULIN RECEPTOR-CONTAINING A CLUSTER OF 8 COMPLEMENT-TYPE REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; MONOCLONAL-ANTIBODIES; LIGAND RECOGNITION; HIGH-AFFINITY; DOMAIN; LRP; DNA	A region containing sites for ligand binding was localized in the 4525-amino acid residue alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP) by ligand- and immunoblotting of proteinase and CNBr digests of the purified human placental protein. I-125-Labeled rat alpha1-macroglobulin light chain, urokinase-plasminogen activator inhibitor type-1 complex, and alpha2MR-associated protein all bound to a 75-kDa CNBr-generated fragment (68 kDa after deglycosylation). In addition to the three ligands, the fragment bound a novel monoclonal antibody reacting in the region defined by amino acid residues 1165-1246 as determined by binding to recombinant fragments of alpha2MR/LRP. The positions of methionine residues in alpha2MR/LRP suggested that the ligand-binding CNBr fragment contained three disulfide-linked peptides comprising the residues 776-1399. This origin was confirmed by partial amino acid sequencing of the electroblotted fragment and polypeptides generated by reduction of the fragment. The identified region represents 13.6% of the molecular mass (nonglycosylated) of alpha2MR/LRP and contains one of three large clusters of complement-type repeats.	AARHUS UNIV, INST MOLEC BIOL, DK-8000 AARHUS, DENMARK; AARHUS UNIV, GENE EXPRESS LAB, DK-8000 AARHUS, DENMARK	Aarhus University; Aarhus University	MOESTRUP, SK (corresponding author), AARHUS UNIV, INST MED BIOCHEM, DK-8000 AARHUS, DENMARK.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736				BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1988, EMBO J, V7, P4419; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JENSEN PH, 1992, FEBS LETT, V305, P129, DOI 10.1016/0014-5793(92)80879-L; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P438; MARYNEN P, 1982, FEBS LETT, V137, P241, DOI 10.1016/0014-5793(82)80358-X; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1980, FEBS LETT, V221, P55; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	35	117	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13691	13696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685767				2022-12-25	WOS:A1993LH55300094
J	WEINER, KXB; WEINER, RS; MALEY, F; MALEY, GF				WEINER, KXB; WEINER, RS; MALEY, F; MALEY, GF			PRIMARY STRUCTURE OF HUMAN DEOXYCYTIDYLATE DEAMINASE AND OVEREXPRESSION OF ITS FUNCTIONAL PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEOSIDE TRIPHOSPHATE POOLS; T7 RNA-POLYMERASE; DCMP DEAMINASE; HAMSTER-CELLS; EXPRESSION; BACTERIOPHAGE-T4; SEQUENCE; GENE; PURIFICATION; DIAGNOSIS	The cDNA encoding human dCMP deaminase was isolated from a lambdaZAPII expression library using an antibody generated against highly purified HeLa cell dCMP deaminase. The cloned cDNA consists of 1856 base pairs and encodes a protein of 178 amino acids with a calculated molecular mass of 19,985 daltons. The sequence of several cyanogen bromide-cleaved peptides derived from HeLa cell dCMP deaminase are all contained within the deduced amino acid sequence. A zinc binding region is present in the enzyme, similar to that reported for cytidine deaminase (Yang, E. C., Carlow, D., Wolfenden, R., and Short, S. A. (1992) Biochemistry 31, 4168-4174). Northern blot analysis revealed a predominant messenger RNA species of 1.9 kilobases. Expression of the active protein to about 10% of Escherichia coli's total protein was achieved by subcloning the open reading frame into a high expression system using the polymerase chain reaction. Polyacrylamide gel electrophoresis revealed a prominent protein band which comigrated with affinity purified HeLa dCMP deaminase, while Western blot analysis yielded an immunoreactive band which comigrated with the single immunoreactive affinity column purified dCMP deaminase band. The enzyme which possesses a k(cat) of 1.02 x 10(3) s-1 was purified to homogeneity in over 60% yield. The overexpression of dCMP deaminase should permit more exacting studies on the regulation of this important allosteric enzyme which provides substrate for DNA synthesis.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, EMPIRE STATE PLAZA, POB 509, ALBANY, NY 12201 USA; SUNY Albany, SCH PUBL HLTH, DEPT BIOMED SCI, ALBANY, NY 12222 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BIRNBOIM HC, 1988, NUCLEIC ACIDS RES, V16, P1487, DOI 10.1093/nar/16.4.1487; CHIU CS, 1977, J BIOL CHEM, V252, P8603; DESAINTVINCENT BR, 1980, J BIOL CHEM, V255, P162; ELLIMS PH, 1981, J BIOL CHEM, V256, P6335; GELBARD AS, 1969, BIOCHIM BIOPHYS ACTA, V182, P564, DOI 10.1016/0005-2787(69)90209-3; GEORGIADES C, 1985, ACTA CARDIOL, V40, P247; GERACI G, 1967, BIOCHEMISTRY-US, V6, P183, DOI 10.1021/bi00853a030; JACKSON RC, 1978, J BIOL CHEM, V253, P7440; JONES DD, 1982, BRIT J OBSTET GYNAEC, V89, P314, DOI 10.1111/j.1471-0528.1982.tb04703.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1960, J BIOL CHEM, V235, P2968; MALEY F, 1961, CANCER RES, V21, P1421; MALEY F, 1967, METHOD ENZYMOL, V12, P170; MALEY F, 1972, CURR TOP CELL REGUL, V5, P177; MALEY GF, 1983, J BIOL CHEM, V258, P8290; MALEY GF, 1959, J BIOL CHEM, V234, P2975; MALEY GF, 1990, J BIOL CHEM, V265, P47; MALEY GF, 1993, BIOCHIM BIOPHYS ACTA, V1162, P161, DOI 10.1016/0167-4838(93)90143-F; MALEY GF, 1972, J BIOL CHEM, V247, P931; MALEY GF, 1970, ADV ENZYMES REGULATI, V8, P55; MCINTOSH EM, 1986, MOL CELL BIOL, V6, P1711, DOI 10.1128/MCB.6.5.1711; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MILLER RL, 1969, CLIN CHIM ACTA, V26, P405, DOI 10.1016/0009-8981(69)90067-9; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MOLLGAARD H, 1978, J BIOL CHEM, V253, P3536; MOORE JT, 1993, J BIOL CHEM, V268, P2288; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; REDMAN CWG, 1977, BRIT J OBSTET GYNAEC, V84, P904, DOI 10.1111/j.1471-0528.1977.tb12519.x; ROBERTS RG, 1978, ANN CLIN BIOCHEM, V15, P316, DOI 10.1177/000456327801500175; Rosen K., 1990, FOCUS, V12, P23; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; STEERS E, 1965, J BIOL CHEM, V240, P2478; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; WEINER KXB, 1990, MOL ENDOCRINOL, V4, P1249, DOI 10.1210/mend-4-8-1249; WEINER RS, 1992, ENDOCRINOLOGY, V131, P1026, DOI 10.1210/en.131.3.1026; WILLIAMS GF, 1975, BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5961.10; WILLIAMS GF, 1982, BRIT J OBSTET GYNAEC, V89, P309, DOI 10.1111/j.1471-0528.1982.tb04702.x; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; XU YZ, 1992, BIOCHEM PHARMACOL, V44, P1819; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	50	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12983	12989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685356				2022-12-25	WOS:A1993LG65800109
J	SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL				SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL			RNA-DIRECTED RNA-POLYMERASE FROM TOMATO LEAVES .2. CATALYTIC INVITRO PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBER VIROID PSTV; FULL-LENGTH COPIES; SACCHAROMYCES-CEREVISIAE; LEAF TISSUE; DNA; TRANSCRIPTION; TEMPLATES; PURIFICATION; REPLICATION; SPECIFICITY	The catalytic properties of electrophoretically homogeneous RNA-directed RNA polymerase (RdRP, EC 2.7.7.48) from tomato leaf tissue were studied with the aid of oligonucleotides of defined sequence. It was found that RdRP catalyzes in vitro the transcription of short single-stranded RNA and DNA molecules into precisely complementary RNA copies up to the full length of these templates. The transcription of RNA- and DNA-oligonucleotide templates was equally effective. Differences in transcription efficiency were found to depend on nucleotide sequence rather than on the RNA or DNA nature of the single-stranded nucleic acid. Double-stranded nucleic acids such as poly(A) . poly(U) and a double-stranded DNA 14-mer were not transcribed. The RdRP-directed transcription could be primed because RNA and DNA dinucleotides and trinucleotides complementary to the 3'-terminal nucleotides of the template were extended by the enzyme. The unprimed transcription was shown to start preferentially at the 3'-terminal nucleotides of the template. RdRP is capable of adding a single noncomplementary nucleotide to the 3' terminus of about 50% of the runoff transcripts. AMP was preferred over GMP, whereas CMP and UMP were terminally added at very low frequency.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	Max Planck Society								ASTIERMA.S, 1971, BIOCHIM BIOPHYS ACTA, V232, P484, DOI 10.1016/0005-2787(71)90602-2; ASTIERMANIFACIER S, 1978, CR ACAD SCI D NAT, V287, P1043; BAUSCH JN, 1983, J BIOL CHEM, V258, P1978; BIEBRICH.CK, 1973, P NATL ACAD SCI USA, V70, P934, DOI 10.1073/pnas.70.3.934; BLAKE RD, 1967, J MOL BIOL, V30, P291; BOEGE F, 1980, FEBS LETT, V121, P91, DOI 10.1016/0014-5793(80)81273-7; BOEGE F, 1982, BIOSCIENCE REP, V2, P185, DOI 10.1007/BF01116382; BROWNLEE GG, 1969, EUR J BIOCHEM, V11, P395, DOI 10.1111/j.1432-1033.1969.tb00786.x; COLLMER CW, 1985, P NATL ACAD SCI USA, V82, P3110, DOI 10.1073/pnas.82.10.3110; DIAMOND A, 1983, METHOD ENZYMOL, V100, P431; DIENER TO, 1972, NATURE-NEW BIOL, V235, P218, DOI 10.1038/newbio235218a0; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DORSSERS L, 1983, VIROLOGY, V125, P155, DOI 10.1016/0042-6822(83)90071-5; DUDA CT, 1973, BIOCHIM BIOPHYS ACTA, V319, P62, DOI 10.1016/0005-2787(73)90041-5; DUDA CT, 1979, VIROLOGY, V92, P180, DOI 10.1016/0042-6822(79)90223-X; EVANS DMA, 1984, ANN BOT-LONDON, V54, P271, DOI 10.1093/oxfordjournals.aob.a086791; FRAENKELCONRAT H, 1986, CRC CR REV PLANT SCI, V4, P213, DOI 10.1080/07352688609382224; FRANK R, 1982, CHEM ENZYMATIC SYNTH, P225; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; HAAS B, 1988, NUCLEOS NUCLEOT, V7, P713, DOI 10.1080/07328318808056315; IKEGAMI M, 1979, J BIOL CHEM, V254, P149; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KELLY JL, 1986, J BIOL CHEM, V261, P340; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; KONARSKA MM, 1990, CELL, V63, P609, DOI 10.1016/0092-8674(90)90456-O; KUSMIEREK JT, 1982, BIOCHEMISTRY-US, V21, P5723, DOI 10.1021/bi00265a051; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LOEB LA, 1969, J BIOL CHEM, V244, P1672; MARCOS JF, 1992, VIROLOGY, V186, P481, DOI 10.1016/0042-6822(92)90013-F; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; RACKWITZ HR, 1981, NATURE, V291, P297, DOI 10.1038/291297a0; RANDERATH E, 1983, METHODS DNA RNA SEQU, P169; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; Richards E. G, 1975, HDB BIOCH MOL BIOL, V1, P596; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROBERTSON HD, 1987, VIROIDS VIROID LIKE, P49; ROMAINE CP, 1978, VIROLOGY, V86, P241, DOI 10.1016/0042-6822(78)90024-7; SANGER F, 1965, J MOL BIOL, V14, P303, DOI 10.1016/S0022-2836(65)80253-4; SANGER HL, 1982, ENCY PLANT PHYSL B, V14, P368; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11851; SCHINDLER IM, 1992, PLANT SCI, V84, P221, DOI 10.1016/0168-9452(92)90138-C; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SCHNOLZER M, 1985, EMBO J, V4, P2181, DOI 10.1002/j.1460-2075.1985.tb03913.x; SELIGER H, 1980, NUCLEIC ACIDS RES S, V7, P191; SEMANCIK JS, 1984, P NATL ACAD SCI-BIOL, V81, P4429, DOI 10.1073/pnas.81.14.4429; SHARMEEN L, 1987, NUCLEIC ACIDS RES, V15, P6705, DOI 10.1093/nar/15.16.6705; SINGER B, 1983, P NATL ACAD SCI-BIOL, V80, P969, DOI 10.1073/pnas.80.4.969; SPIESMACHER E, 1985, BIOSCIENCE REP, V5, P251, DOI 10.1007/BF01119595; STECK TL, 1968, J BIOL CHEM, V243, P2769; TABLER M, 1985, EMBO J, V4, P2191, DOI 10.1002/j.1460-2075.1985.tb03914.x; TAKANAMI Y, 1982, BIOCHEMISTRY-US, V21, P3161, DOI 10.1021/bi00256a020; TAYLOR JM, 1991, CURR TOP MICROBIOL, V168, P141; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214	61	115	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11858	11867						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685023				2022-12-25	WOS:A1993LF28400061
J	JASPARD, E; WEI, L; ALHENCGELAS, F				JASPARD, E; WEI, L; ALHENCGELAS, F			DIFFERENCES IN THE PROPERTIES AND ENZYMATIC SPECIFICITIES OF THE 2 ACTIVE-SITES OF ANGIOTENSIN I-CONVERTING ENZYME (KININASE-II) - STUDIES WITH BRADYKININ AND OTHER NATURAL PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS DOMAINS; MOLECULAR-CLONING; ACTIVATION; INHIBITORS; HYDROLYSIS; ISOZYME; BINDING	Angiotensin I-converting enzyme (ACE, E.C.3.4.15.1) has been recently shown to contain two very similar domains, each of which bears a functional active site hydrolyzing Hip-His-Leu or angiotensin I (AI). The substrate specificity of the two active sites of ACE was compared using wild-type recombinant ACE and mutants, where one active site is suppressed by deletion or inactivated by mutations of 2 histidines coordinating an essential zinc atom. Both active sites converted bradykinin (BK) to BK1-7 and BK1-5 with similar kinetics and with K(m)app at least 30 times lower and k(cat)/K(m)app 10 times higher than for AI. The carboxyl-terminal active site, but not the amino-terminal site, was activated by chloride; however, chloride activation was minimal compared with AI. Both domains also hydrolyzed substance P and cleaved a carboxyl-terminal protected dipeptide and tripeptide. The carboxyl-terminal active site was more readily activated by chloride and hydrolyzed substance P faster. Luteinizing-hormone releasing hormone was hydrolyzed by both active sites, but hydrolysis by the amino-terminal active site was faster. It performed the endoproteolytic amino-terminal cleavage of this peptide at least 30 times faster than the carboxyl-terminal active site. Both active sites cleaved a carboxyl-terminal tripeptide from luteinizing hormone-releasing hormone. Thus, both active sites of ACE possess dipeptidyl carboxypeptidase and endopeptidase activities. However, only the carboxyl-terminal active site can undergo a chloride-induced alteration that greatly enhances the hydrolysis of Al or substance P, and the amino-terminal active site possesses an unusual amino-terminal endoproteolytic specificity for a natural peptide. This suggests physiologically important differences between the subsites of the two active centers, and different substrate specificity, despite the high degree of sequence homology.	INSERM,U367,17 RUE FER MOULIN,F-75005 PARIS,FRANCE; INSERM,U36,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Alhenc-Gelas, Francois/F-9511-2017					Alberts B., 1983, MOL BIOL CELL, V4; ALHENCGELAS F, 1981, BIOCHIM BIOPHYS ACTA, V677, P477, DOI 10.1016/0304-4165(81)90262-2; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; CHEN YNP, 1992, BIOCHEM BIOPH RES CO, V184, P306, DOI 10.1016/0006-291X(92)91193-T; DAUTRYVARSAT A, 1981, BIOCHEMISTRY-US, V20, P1396, DOI 10.1021/bi00508a056; Dixon M., 1979, ENZYMES, Vthird; DORER FE, 1974, CIRC RES, V34, P824, DOI 10.1161/01.RES.34.6.824; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ISHIDA H, 1989, J PHARMACOL EXP THER, V251, P817; Kenny AJ, 1987, MAMMALIAN ECTOENZYME, P169; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; Lehninger A. L., 1972, BIOCH MOL BASIS CELL; MOMBOULI JV, 1991, J CARDIOVASC PHARM, V18, P926, DOI 10.1097/00005344-199112000-00021; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P5315, DOI 10.1021/bi00292a010; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SKIDGEL RA, 1987, NEUROPEPTIDES THEIR, P165; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEWART TA, 1981, PEPTIDES, V2, P145, DOI 10.1016/S0196-9781(81)80027-7; SUBISSI A, 1990, BRIT J PHARMACOL, V100, P502, DOI 10.1111/j.1476-5381.1990.tb15837.x; TAKADA Y, 1982, JPN CIRC J, V46, P503, DOI 10.1253/jcj.46.503; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YOSHIDA T, 1990, J NEUROCHEM, V55, P1861, DOI 10.1111/j.1471-4159.1990.tb05769.x	34	280	289	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9496	9503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683654				2022-12-25	WOS:A1993LA68900054
J	LEE, H; HSU, S; WINAWER, S; FRIEDMAN, E				LEE, H; HSU, S; WINAWER, S; FRIEDMAN, E			SIGNAL TRANSDUCTION THROUGH EXTRACELLULAR SIGNAL-REGULATED KINASE-LIKE PP57 BLOCKED IN DIFFERENTIATED COLON-CARCINOMA CELLS HAVING LOW-LEVELS OF C-SRC KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PP60C-SRC PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; FACTOR RECEPTORS; ACTIVATION; MITOGEN; INSULIN; ERKS; AUTOPHOSPHORYLATION; ANTIBODIES	Basic fibroblast growth factor (FGF) induced a rapid increase in tyrosine phosphorylation of a 57-kDa cytoplasmic protein with functional myelin basic protein kinase activity and antigenic properties common to mitogen-activated kinases or extracellular signal-regulated kinases. Basic and acidic FGFs and the diacylglycerol diolein used the same signal transduction pathway to activate pp57. These FGFs, like diolein (Lee, H., Ghose-Dastidar, J., Winawer, S., and Friedman, E. (1993) J. Biol. Chem., 268, 5255-5263), increased the cellular concentration of long-chain diacylglycerols within the same short time period as they increased pp57 tyrosine phosphorylation. Both FGF and diolein increased phosphorylation of pp57 on the same V8 protease-generated fragments, suggesting a common pathway for the phosphorylation of pp57. FGF-induced signal transduction through pp57 mitogen-activated kinase led to cell growth in two undifferentiated colon carcinoma cell lines. In contrast, basic FGF neither increased tyrosine phosphorylation of pp57 nor increased cell growth in two colon goblet cell differentiated lines derived from the same parental line as the undifferentiated cells. Both goblet cell lines exhibited levels of protein-tyrosine kinase activity about one-fifth that of the undifferentiated lines. The decrease in tyrosine kinase activity was not due to down-regulation of FGF receptors or their tyrosine kinase activities. c-src kinase-specific activity was decreased 4-5-fold in both goblet cell lines, suggesting a role for c-src in pp57-mediated signal transduction.	MEM SLOAN KETTERING CANC CTR, GASTROINTESTINAL TUMOR BIOL LAB, POB 244, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01 CA50645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOWEN HJ, 1991, FOCUS, V12, P105; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FOSS FM, 1989, ONCOGENE RES, V5, P13; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARIAN B, 1989, CANCER RES, V49, P4231; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; RAY LB, 1988, J BIOL CHEM, V263, P12721; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SAFRAN A, 1990, ONCOGENE, V5, P635; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1992, ONCOGENE, V7, P801; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8181	8187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681838				2022-12-25	WOS:A1993KW97900086
J	ZIMMER, Y; GIVOL, D; YAYON, A				ZIMMER, Y; GIVOL, D; YAYON, A			MULTIPLE STRUCTURAL ELEMENTS DETERMINE LIGAND-BINDING OF FIBROBLAST GROWTH-FACTOR RECEPTORS - EVIDENCE THAT BOTH IG DOMAIN-2 AND DOMAIN-3 DEFINE RECEPTOR SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FGF RECEPTOR; BASIC-FGF; EXPRESSION; CLONING; FAMILY; MEMBER; GENES; FORMS; DNA; PROTEINS	The murine fibroblast growth factor receptor 2 (FGFR2) and keratinocyte growth factor receptor (KGFR) are two products of the same gene which display distinct binding specificities. We and others have shown that a major structural element underlying this functional divergence is a variable 50 amino acids long region constituting the C-terminal half of the third immunoglobulin (Ig)-like domain of the receptor. This region of the two receptors is encoded by two distinct exons which are alternatively used in cells of different tissues and origin. To further investigate the role of this confined variable region in determining ligand binding specificity we have generated a chimeric molecule between FGFR1 and KGFR where the variable segment of KGFR replaces the homologous region in FGFR1. Binding studies as well as chemical cross-linking of radiolabeled ligands revealed that the recombinant FGFR1/KGFR chimera has retained the binding affinity to acidic FGF and FGF4 (hst/kfgf) but lost the capacity to bind basic FGF (bFGF). This chimeric receptor bound keratinocyte growth factor (KGF), however, with significantly lower affinity as compared with KGFR. High affinity binding of KGF was acquired only when also domain 2 in this chimera was replaced by its homologous domain from FGFR2. These results demonstrate that ligand binding and specificity involves multiple receptor elements which are located at both Ig-like domain 2 and 3 of FGF receptors.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AVIVI A, 1991, ONCOGENE, V6, P1089; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	29	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7899	7903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681832				2022-12-25	WOS:A1993KW97900049
J	SAEKI, T; UEDA, K; TANIGAWARA, Y; HORI, R; KOMANO, T				SAEKI, T; UEDA, K; TANIGAWARA, Y; HORI, R; KOMANO, T			HUMAN P-GLYCOPROTEIN TRANSPORTS CYCLOSPORINE-A AND FK506	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIDRUG-RESISTANT CELLS; MEMBRANE-VESICLES; PLASMA-MEMBRANE; K562 CELLS; BINDING; VINCRISTINE; VINBLASTINE; COLCHICINE; PROTEIN	Cyclosporin A, a cyclic undecapeptide, and FK506 are efficient immunosuppressive agents. They also attract attention as effective P-glycoprotein modulators that inhibit P-glycoprotein from binding to anticancer drugs and overcome multidrug resistance. Cyclosporin A itself interacts with a common binding site of P-glycoprotein to which Vinca alkaloids and verapamil bind. We were interested to determine whether cyclosporin A and FK506 are substrates for P-glycoprotein to transport, and we studied their transcellular transport. In LLC-PK1 cells, derived from porcine kidney proximal tubule and forming a highly polarized epithelium, cyclosporin A was transported in a saturable manner. LLC-GA5-COL300, a transformant cell line derived by transfecting LLC-PK1 with human MDR1 cDNA isolated from normal adrenal gland, expresses P-glycoprotein specifically on the apical surface and shows a typical multidrug-resistant phenotype. LLC-GA5-COL300 cells showed increased transport of cyclosporin A from the basal to the apical side. Kinetic analysis showed that this transport was a typical saturable transport with the calculated apparent Michaelis constant (K(m)app) and the maximum flux (V(max)) as 8.4 gm and 2.4 nmol/mg protein/h, respectively. LLC-GA5-COL300 also showed increased transport of FK506 from the basal to the apical side. These results indicate that P-glycoprotein transports the immunosuppressive agents cyclosporin A and FK506.	KYOTO UNIV,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,KYOTO 60601,JAPAN; KYOTO UNIV HOSP,FAC MED,DEPT PHARM,KYOTO 60601,JAPAN	Kyoto University; Kyoto University				Ueda, Kazumitsu/0000-0003-2980-6078				BLAIR JT, 1982, J PATHOL, V138, P163, DOI 10.1002/path.1711380206; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; GOLDBERG H, 1988, BIOCHEM BIOPH RES CO, V152, P552, DOI 10.1016/S0006-291X(88)80073-1; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; NAITO M, 1989, CANCER RES, V49, P1452; NAITO M, 1988, J BIOL CHEM, V263, P11887; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; NAITO M, 1991, J CELL PHARM, V2, P263; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RYFFEL B, 1985, TRANSPLANT P, V17, P1430; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; TWENTYMAN PR, 1988, BRIT J CANCER, V57, P254, DOI 10.1038/bjc.1988.55; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; UEDA K, 1992, J BIOL CHEM, V267, P24248	25	614	638	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6077	6080						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681059				2022-12-25	WOS:A1993KT36800004
J	RATHANASWAMI, P; HACHICHA, M; SADICK, M; SCHALL, TJ; MCCOLL, SR				RATHANASWAMI, P; HACHICHA, M; SADICK, M; SCHALL, TJ; MCCOLL, SR			EXPRESSION OF THE CYTOKINE RANTES IN HUMAN RHEUMATOID SYNOVIAL FIBROBLASTS - DIFFERENTIAL REGULATION OF RANTES AND INTERLEUKIN-8 GENES BY INFLAMMATORY CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ACTIVATING FACTOR MCAF; MESSENGER-RNA; RECOMBINANT INTERLEUKIN-1; LYMPHOCYTES-T; CELLS; IL-4; STIMULATION; CLONING	A chronic inflammatory disease may be characterized by an accumulation of activated leukocytes at the site of inflammation. Since the chemokine RANTES may play an active role in recruiting leukocytes into inflammatory sites, we investigated the ability of cultured human synovial fibroblasts isolated from patients suffering from rheumatoid arthritis to produce this chemokine and compared its regulation to that of the closely related chemokine gene, interleukin-8 (IL-8). In unstimulated synovial fibroblasts, the expression of mRNA for both chemokines was undetectable, but was increased in both a time- and dose-dependent manner upon stimulation with the monokines tumor necrosis factor alpha (TNFalpha) and interleukin-1beta (IL-1beta). Preincubation of the cells with cycloheximide ''superinduced'' the level of IL-8 mRNA stimulated by TNFalpha and IL-1beta and RANTES mRNA stimulated by IL-1beta, but decreased the expression of RANTES mRNA in response to TNFalpha. In addition, differential regulation of these genes was noted when synovial fibroblasts were stimulated with a combination of cytokines. IL-4 down-regulated and IFNgamma enhanced the TNFalpha- and IL-1beta-induced increase in RANTES mRNA, whereas the induction of IL-8 mRNA by TNFalpha or IL-1beta was inhibited by IFNgamma and augmented by IL-4. Moreover, a combination of TNFalpha and IL-1beta synergistically induced IL-8 mRNA expression, whereas under the same conditions, the level of expression of RANTES mRNA was less than that induced by TNFalpha alone. These observations were also reflected at the level of chemokine secretion. These studies demonstrate that by expressing the chemokines RANTES and IL-8, synovial fibroblasts may participate in the ongoing inflammatory process in rheumatoid arthritis. In addition, the observation that these chemokine genes are differentially regulated, depending upon the presence of different cytokines, indicates that the type of cellular infiltrate and the progress of the inflammatory disease is likely to depend on the relative levels of stimulatory and inhibitory cytokines.	UNIV LAVAL,CHUL,CTR RECH INFLAMMAT IMMUNOL & RHUMATOL,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; GENENTECH INC,S SAN FRANCISCO,CA 94080	Laval University; Roche Holding; Genentech			Rathanaswami, Palaniswami/AAL-3979-2021; Rathanaswami, Palaniswami/AAL-7192-2021					AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; AREND WP, 1989, J IMMUNOL, V143, P118; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BECKER S, 1990, CELL IMMUNOL, V129, P351, DOI 10.1016/0008-8749(90)90211-9; CASE JP, 1990, J IMMUNOL, V145, P3755; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GALY AHM, 1991, J IMMUNOL, V147, P3823; HACHICHA M, 1993, IN PRESS ARTHRITIS R; HAMILTON JA, 1992, BLOOD, V79, P1413; HAMILTON JA, 1981, J IMMUNOL, V126, P851; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; KOCH AE, 1991, J IMMUNOL, V147, P2187; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LAFYATIS R, 1989, J CLIN INVEST, V83, P1267, DOI 10.1172/JCI114011; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEIZER T, 1987, ARTHRITIS RHEUM, V30, P562, DOI 10.1002/art.1780300511; LIEZER T, 1990, BLOOD, V76, P1989; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RUGGIERO V, 1987, J IMMUNOL, V138, P661; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL T, 1991, Arthritis and Rheumatism, V34, pS117; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID J, 1987, J IMMUNOL, V139, P250; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SICA A, 1990, IMMUNOLOGY, V69, P548; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STASHENKO P, 1987, J IMMUNOL, V138, P1464; TAN PLJ, 1990, J RHEUMATOL, V17, P1608; VILLIGER PM, 1992, J IMMUNOL, V149, P722; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	43	305	309	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5834	5839						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680648				2022-12-25	WOS:A1993KR82200072
J	MIDURA, RJ; CALABRO, A; YANAGISHITA, M; HASCALL, VC				MIDURA, RJ; CALABRO, A; YANAGISHITA, M; HASCALL, VC			NONREDUCING END STRUCTURES OF CHONDROITIN SULFATE CHAINS ON AGGRECAN ISOLATED FROM SWARM RAT CHONDROSARCOMA CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE; CARTILAGE PROTEOGLYCAN; EMBRYONIC CHICKEN; CORNEAL EXPLANTS; URONIC-ACID; BIOSYNTHESIS; OLIGOSACCHARIDES; CHROMATOGRAPHY	Chondrocyte cultures derived from the Swarm rat chondrosarcoma were metabolically labeled with [S-35]sulfate or [6-H-3]GlcN. Radiolabeled aggrecan was purified from the cell layer and exhaustively digested with chondroitin ABC lyase. Digestion products were resolved into disaccharide and monosaccharide residues using Toyopearl HW40S chromatography. The separated saccharide pools were reduced with NaBH4 and applied onto a CarboPAC PA1 column to resolve all of the internal disaccharide alditols (unsaturated) from the nonreducing end disaccharide (saturated) and monosaccharide alditols. Mercuric acetate treatment was used prior to carbohydrate analysis to identify unambiguously the saturated from the unsaturated disaccharides. The chondroitin sulfate (CS) chains from these aggrecan preparations contained: (a) an internal disaccharide composition of unsulfated (3-4 per chain), 4-sulfated (similar to 32 per chain), 6-sulfated (similar to 1 per 14 chains), and 4,6-sulfated disaccharides (similar to 1 per 6 chains) and (b) a nonreducing terminal composition of 4-sulfated GalNAc (similar to 4 out of every 7 chains), 4,6-disulfated GalNAc (similar to 2 out of every 7 chains), and GlcUA adjacent to a 4-sulfated GalNAc residue (similar to 1 out of every 7 chains). Thus, the vast majority of these CS chains terminated with a sulfated GalNAc residue. The presence of 4,6-disulfated GalNAc at nonreducing termini is 60-fold more abundant than 4,6-disulfated GalNAc in interior disaccharides. This observation is consistent with the suggestion that disulfation of terminal GalNAc residues is involved in chain termination.	UNIV IOWA,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242; NIDR,PROTEOGLYCAN CHEM SECT,BETHESDA,MD 20892	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	MIDURA, RJ (corresponding author), CLEVELAND CLIN FDN,DEPT BIOMED ENGN,WB3,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CALABRO A, 1994, J BIOL CHEM, V269, P22764; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CATERSON B, 1990, J CELL SCI, V97, P411; CATERSON B, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P415; DELFERT DM, 1985, J BIOL CHEM, V260, P4446; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HEINEGARD D, 1973, CHEM SCRIPTA, V4, P199; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; JENKINS RB, 1981, J BIOL CHEM, V256, P8279; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MARK MP, 1989, DEV BIOL, V133, P475, DOI 10.1016/0012-1606(89)90051-1; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; MIDURA RJ, 1994, GLYCOBIOLOGY, V4, P333, DOI 10.1093/glycob/4.3.333; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; RODEN L, 1972, METHODS ENZYMOLOGY B, V28, P638; SAITO H, 1968, J BIOL CHEM, V243, P1536; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SILBERT JE, 1978, J BIOL CHEM, V253, P6888; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; SJOBERG I, 1973, BIOCHEM BIOPH RES CO, V54, P1125, DOI 10.1016/0006-291X(73)90809-7; SLATER RR, 1994, T ORTHOPAED RES SOC, V17, P277; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; TELSER A, 1966, ARCH BIOCHEM BIOPHYS, V116, P458, DOI 10.1016/0003-9861(66)90053-1; TSUJI M, 1980, BIOCHIM BIOPHYS ACTA, V612, P373, DOI 10.1016/0005-2744(80)90120-5; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	37	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8009	8015		10.1074/jbc.270.14.8009	http://dx.doi.org/10.1074/jbc.270.14.8009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713901	hybrid			2022-12-25	WOS:A1995QR52600037
J	ROUSELL, J; HADDAD, EB; MAK, JCW; BARNES, PJ				ROUSELL, J; HADDAD, EB; MAK, JCW; BARNES, PJ			TRANSCRIPTIONAL DOWN-REGULATION OF M2 MUSCARINIC RECEPTOR GENE-EXPRESSION IN HUMAN EMBRYONIC LUNG (HEL-299) CELLS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; ACETYLCHOLINE-RECEPTOR; DIFFERENTIAL REGULATION; BINDING-PROPERTIES; ADENYLYL CYCLASE; AGONIST EXPOSURE; PHORBOL ESTERS; PHOSPHORYLATION; ACTIVATION; M1	m2 muscarinic receptor gene expression was investigated following stimulation of protein kinase C (PKC) with the phorbol ester 4 beta-phorbol dibutyrate (PDBu) in HEL 299 cells. PDBu (100 nM) caused a time dependent decrease in the steady-state levels of m2 receptor mRNA and in specific [H-3]N-methyl scopolamine binding. Preincubation with the PKC inhibitor GF-109203X inhibited the reduction in M(2) receptor and mRNA levels induced by PDBu, confirming the involvement of PKC, Chronic PDBu treatment also caused desensitization of the receptor as forskolin-stimulated cAMP accumulation, inhibited by carbachol in control cells, was lost upon treatment with PDBu for 24 h. Co-incubation with PDBu and the protein synthesis inhibitor cycloheximide, inhibited PDBu-mediated reduction of m2 receptor mRNA, indicating new protein synthesis is required for down-regulation. Half-life studies using the transcriptional inhibitor actinomycin D suggested that the stability of the m2 receptor mRNA was not altered by PDBu treatment (t(1/2) = 2 h) Nuclear run on assays showed a 50% reduction in the rate of m2 receptor gene transcription after treatment with PDBu for 12 h. In conclusion we have provided evidence for heterologous regulation of m2 receptor gene expression through changes in gene transcription resulting in uncoupling of M(2) receptors. Furthermore, the synthesis of an unidentified factor is required for the down-regulation process.	NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND	Imperial College London				Mak, Judith/0000-0002-8234-1313; Barnes, Peter/0000-0002-5122-4018				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; FUKAMAUCHI F, 1994, FEBS LETT, V348, P263, DOI 10.1016/0014-5793(94)00611-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABECKER BA, 1993, BIOCHEMISTRY-US, V32, P4986, DOI 10.1021/bi00070a003; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA T, 1993, LIFE SCI, V52, P421, DOI 10.1016/0024-3205(93)90297-G; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JONES SVP, 1988, MOL PHARMACOL, V34, P421; KOMAN A, 1990, BIOCHEM J, V270, P409, DOI 10.1042/bj2700409; KOMAN A, 1993, NEUROSCI LETT, V149, P79, DOI 10.1016/0304-3940(93)90352-L; KOPP R, 1990, BIOCHEM J, V269, P73, DOI 10.1042/bj2690073; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKINNEY M, 1984, MOL PHARMACOL, V26, P156; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; ROZENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; STEEL MC, 1993, MOL PHARMACOL, V43, P694; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WANG SZ, 1990, FEBS LETT, V276, P185, DOI 10.1016/0014-5793(90)80538-T; ZHANG LB, 1993, BRIT J PHARMACOL, V108, P613, DOI 10.1111/j.1476-5381.1993.tb12850.x	40	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7213	7218		10.1074/jbc.270.13.7213	http://dx.doi.org/10.1074/jbc.270.13.7213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706260	hybrid			2022-12-25	WOS:A1995QQ43100032
J	LAUREYS, G; SPELEMAN, F; VERSTEEG, R; VANDERDRIFT, P; CHAN, A; LEROY, J; FRANCKE, U; OPDENAKKER, G; VANROY, N				LAUREYS, G; SPELEMAN, F; VERSTEEG, R; VANDERDRIFT, P; CHAN, A; LEROY, J; FRANCKE, U; OPDENAKKER, G; VANROY, N			CONSTITUTIONAL TRANSLOCATION T(1-17)(P36.31-P36.13-Q11.2Q12.1) IN A NEUROBLASTOMA PATIENT. ESTABLISHMENT OF SOMATIC-CELL HYBRIDS AND IDENTIFICATION OF PND/A12M2 ON CHROMOSOME-1 AND NF1/SCYA7 ON CHROMOSOME-17 AS BREAKPOINT FLANKING SINGLE-COPY MARKERS	ONCOGENE			English	Article						NEUROBLASTOMA; SOMATIC CELL HYBRIDS; PRONATRIODILATIN; MONOCYTE CHEMOTACTIC PROTEIN; ADENOVIRUS INTEGRATION SITE; NEUROFIBROMATOSIS; SUPPRESSOR GENE	TUMOR-NECROSIS-FACTOR; CUTANEOUS MALIGNANT-MELANOMA; SHORT ARM; LINKAGE MAP; RNA GENES; N-MYC; REGION; 1P36; CANCER; EXPRESSION	Cytogenetic and molecular studies in neuroblastoma suggest the presence of a tumor suppressor gene at the distal band p36 of human chromosome 1, We described a constitutional translocation t(1;17)(p36;q12-q21), involving the critical region 1p36, in a patient with neuroblastoma, and hypothesized that the translocation predisposed the patient to tumor development, Here we report the molecular delineation of the translocation breakpoints, Somatic cell hybrids were generated by fusion of the patient's fibroblasts with the thymidine kinase deficient hamster cell line, a3, In hybrid cell lines which retained the human derivative chromosomes, the position of chromosome 1p and 17q DNA probes respective to the translocation breakpoints was determined by fluorescence in situ hybridization and Southern blot analysis, The chromosome Ip breakpoint was localized within a repetitive region encoding t-RNA genes, with 12A-2 (PND) as most distal and pHE2.6 (A12M2) as most proximal single-copy breakpoint flanking markers, For the chromosome 17 breakpoint, the proximal and distal flanking markers were identified as 7G4 (NF1) and cMCP-3 (SCYA7), respectively, In this study, cMCP-3 (SCYA7), encoding the human monocyte chemotactic protein-3, was mapped between NF1 and ERBB2, As a pivotal step towards breakpoint cloning, at present these flanking markers optimally delineate the breakpoint regions of both chromosomes 1 and 17 at the molecular level.	STATE UNIV GHENT HOSP, DEPT MED GENET, B-9000 GHENT, BELGIUM; STATE UNIV GHENT HOSP, DEPT PEDIAT, B-9000 GHENT, BELGIUM; UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN GENET, 1105 AZ AMSTERDAM, NETHERLANDS; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, STANFORD, CA 94305 USA; CATHOLIC UNIV LEUVEN, REGA INST MED RES, LOUVAIN, BELGIUM	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Howard Hughes Medical Institute; Stanford University; KU Leuven	LAUREYS, G (corresponding author), STATE UNIV GHENT HOSP, DEPT PEDIAT ONCOL, B-9000 GHENT, BELGIUM.		Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017; Versteeg, Rogier/AAQ-1765-2020; laureys, genevieve/AAG-2390-2021	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Versteeg, Rogier/0000-0001-7172-0388				BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BARKER PE, 1993, ONCOGENE, V8, P3353; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BOYD E, 1989, HUM GENET, V81, P153, DOI 10.1007/BF00293892; BRODEUR GM, 1981, CANCER RES, V41, P4678; BUCKLAND RA, 1992, CYTOGENET CELL GENET, V61, P1, DOI 10.1159/000133358; CARON H, 1994, AM J HUM GENET, V55, P341; CHENG NC, 1995, ONCOGENE, V10, P291; CORSARO CM, 1978, SOMAT CELL GENET, V4, P541, DOI 10.1007/BF01542925; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888-7543(87)90034-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUNTAIN JW, 1989, AM J HUM GENET, V44, P58; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GILBERT F, 1984, CANCER RES, V44, P5444; GOILLOT E, 1992, CANCER RES, V52, P3194; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JORDE LB, 1993, AM J HUM GENET, V53, P1038; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1966, CANCER, V19, P1032, DOI 10.1002/1097-0142(196607)19:7<1032::AID-CNCR2820190719>3.0.CO;2-7; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LEISTER I, 1990, CANCER RES, V50, P7232; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LENGAUER C, 1992, CANCER RES, V52, P2590; LINDGREN V, 1985, MOL CELL BIOL, V5, P2172, DOI 10.1128/MCB.5.9.2172; LINDGREN V, 1985, NATURE, V314, P115, DOI 10.1038/314115a0; LUND E, 1983, MOL CELL BIOL, V3, P2211, DOI 10.1128/MCB.3.12.2211; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MCBRIDE OW, 1989, GENOMICS, V5, P561, DOI 10.1016/0888-7543(89)90024-4; MCDOUGALL JK, 1971, J GEN VIROL, V12, P43, DOI 10.1099/0022-1317-12-1-43; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; OCONNELL P, 1993, GENOMICS, V15, P38, DOI 10.1006/geno.1993.1007; OPDENAKKER G, 1994, GENOMICS, V21, P403, DOI 10.1006/geno.1994.1283; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PONZONI M, 1992, CANCER RES, V52, P931; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; ROSEN ST, 1987, LAB INVEST, V56, P302; Sambrook J, 1989, MOL CLONING LABORATO; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SOLOMON E, 1991, CYTOGENET CELL GENET, V58, P1, DOI 10.1159/000133157; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TANAKA K, 1993, ONCOGENE, V8, P2253; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WAYE JS, 1986, NUCLEIC ACIDS RES, V14, P6915, DOI 10.1093/nar/14.17.6915; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; WITZLEBEN CL, 1974, CANCER-AM CANCER SOC, V34, P786, DOI 10.1002/1097-0142(197409)34:3<786::AID-CNCR2820340339>3.0.CO;2-9	66	46	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1087	1093						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700633				2022-12-25	WOS:A1995QN35300008
J	CHOWRIRA, BM; BERZALHERRANZ, A; KELLER, CF; BURKE, JM				CHOWRIRA, BM; BERZALHERRANZ, A; KELLER, CF; BURKE, JM			4 RIBOSE 2'-HYDROXYL GROUPS ESSENTIAL FOR CATALYTIC FUNCTION OF THE HAIRPIN RIBOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE BINDING; RNA CLEAVAGE; TETRAHYMENA; SEQUENCE; DNA; COMPLEMENTARY; RESOLUTION; REQUIREMENT; LIGATION; DOMAIN	The hairpin ribozyme catalyzes site-specific cleavage of an RNA substrate using a magnesium-dependent transphosphorylation mechanism. Here, we describe experiments designed to test the importance of ribose 2/-hydroxyl groups for ribozyme function. Ribozymes for this work were synthesized in two segments using solid-phase RNA phosphoramidite chemistry. 2'-Deoxyribonucleotides were systematically introduced at each of the 50 positions within the ribozyme, and the catalytic activity of the resulting mixed RNA-DNA polymers was measured. Deletion of the 2'-hydroxyl group at each of four sites (A10, G11, A24, and C25) was found to result in severe inhibition of cleavage activity (k(cat/K(M) decreased by 100- to 1000-fold), although K(M) measurements and mobility-shift assays showed that substrate binding was not affected. Identical results were obtained upon substitution of these ribonucleotides with 2'-O-methyl derivatives. Inhibition by 2'-modified sugars at G11 or A24 was rescued by increased Mg2+ concentrations, suggesting that these 2'-hydroxyls may function in magnesium binding. Our results demonstrate that the 2'-hydroxyl groups at A10, G11, A24, and C25 provide essential functions for catalysis, possibly forming important tertiary contacts or magnesium coordination sites that are necessary for active site architecture.	UNIV VERMONT, DEPT MICROBIOL & MOLEC GENET, MARKEY CTR MOLEC GENET, STAFFORD HALL, BURLINGTON, VT 05405 USA	University of Vermont			Berzal-Herranz, Alfredo/K-8614-2014; , John/AAB-5945-2021	Berzal-Herranz, Alfredo/0000-0003-3722-7973; 				BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2435, DOI 10.1021/bi00432a014; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CHOWRIRA BM, 1992, NUCLEIC ACIDS RES, V20, P2835, DOI 10.1093/nar/20.11.2835; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; EGLI M, 1992, P NATL ACAD SCI USA, V89, P534, DOI 10.1073/pnas.89.2.534; EGLI M, 1993, BIOCHEMISTRY-US, V32, P3221, DOI 10.1021/bi00064a004; England T E, 1980, Methods Enzymol, V65, P65; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KLEINEIDAM RG, 1993, NUCLEIC ACIDS RES, V21, P1097, DOI 10.1093/nar/21.5.1097; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; WALKER GT, 1988, NUCLEIC ACIDS RES, V16, P3091, DOI 10.1093/nar/16.7.3091; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; ZMUDZKA B, 1969, BIOCHEM BIOPH RES CO, V37, P895, DOI 10.1016/0006-291X(69)90215-0	39	71	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19458	19462						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690032				2022-12-25	WOS:A1993LW81900049
J	FERBER, A; CHANG, CD; SELL, C; PTASZNIK, A; CRISTOFALO, VJ; HUBBARD, K; OZER, HL; ADAMO, M; ROBERTS, CT; LEROITH, D; DUMENIL, G; BASERGA, R				FERBER, A; CHANG, CD; SELL, C; PTASZNIK, A; CRISTOFALO, VJ; HUBBARD, K; OZER, HL; ADAMO, M; ROBERTS, CT; LEROITH, D; DUMENIL, G; BASERGA, R			FAILURE OF SENESCENT HUMAN FIBROBLASTS TO EXPRESS THE INSULIN-LIKE GROWTH FACTOR-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CULTURED HUMAN-FIBROBLASTS; SIMIAN VIRUS-40; SOMATOMEDIN PRODUCTION; CELLULAR SENESCENCE; DNA-SYNTHESIS; T-ANTIGEN; CELLS; IMMORTALIZATION; TRANSLOCATION	Senescent human diploid fibroblasts express several growth-regulated genes but fail to express others. In this paper we show, by a very sensitive technique (reverse transcriptase-polymerase chain reaction), that senescent cells fail to express insulin-like growth factor-1 (IGF-1) mRNA, which is expressed in moderate amounts by young cells. Human fibroblasts immortalized by transfection with a temperature-sensitive SV40 T antigen gene regain the ability to express IGF-1 mRNA, but only at the permissive temperature of 34-degrees-C. Under these conditions, the immortalized human fibroblasts grow even in 1% serum. At the restrictive temperature of 39-degrees-C, the temperature-sensitive T antigen is nonfunctional, IGF-1 RNA is not detectable, and the cells fail to grow even in 10% serum. The failure to express IGF-1 mRNA in postsenescent cells can be ascribed, at least in part, to a transcriptional mechanism. Despite the correlation among immortalization by SV40 T antigen, expression of IGF-1, and growth, it seems unlikely that the failure to express IGF-1 is the sole cause of cellular senescence; other requirements must be postulated.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,BLSB ROOM 624A,PHILADELPHIA,PA 19107; MED COLL PENN,CTR GERONTOL RES,PHILADELPHIA,PA 19129; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; NIDDKD,DIABET BRANCH,BETHESDA,MD 20892	Jefferson University; Drexel University; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Dumenil, Guillaume/N-3377-2019; Dumenil, Guillaume/F-7567-2015; Roberts, Charles/K-6953-2017	Dumenil, Guillaume/0000-0001-9174-9110; Dumenil, Guillaume/0000-0001-9174-9110; Roberts, Charles/0000-0003-1756-5772	NIA NIH HHS [AG 00378, AG 04821] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMO M, 1993, IN PRESS ENDOCRINOLO; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; CLEMMONS DR, 1981, J CLIN INVEST, V67, P10, DOI 10.1172/JCI110001; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; DAI ZH, 1992, J BIOL CHEM, V267, P19565; DEPPERT W, 1991, ONCOGENE, V6, P1931; FOYT HL, 1991, INSULIN LIKE GROWTH, P1; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; MOATSSTAATS BM, 1993, MOL ENDOCRINOL, V7, P171, DOI 10.1210/me.7.2.171; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REISS K, 1991, CANCER RES, V51, P5997; REISS K, 1992, ONCOGENE, V7, P2243; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; WERNER H, 1991, INSULIN LIKE GROWTH, P17; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	35	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17883	17888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688732				2022-12-25	WOS:A1993LT74300039
J	LI, RK; CUTLER, JE				LI, RK; CUTLER, JE			CHEMICAL DEFINITION OF AN EPITOPE ADHESIN MOLECULE ON CANDIDA-ALBICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1,2-LINKED OLIGOMANNOSYL RESIDUES; PHOSPHOMANNAN-PROTEIN COMPLEX; CELL-SURFACE HYDROPHOBICITY; BUCCAL EPITHELIAL-CELLS; SEROTYPE-A; NIH B-792; NIH-B-792 STRAIN; MOUSE-TISSUES; D-MANNAN; ADHERENCE	An antigen (Ag), as defined by reactivity with a monoclonal antibody (mAb 10G), was found on the cell wall surface and on the plasma membrane of Candida albicans yeast cells (Li, R. K., and Cutler, J. E. (1991) J. Gen. Microbiol. 137, 455-464). The 10G Ag from the cell surface location was solubilized by treatment with beta-mercaptoethanol and Zymolyase. Antigenic activity of the extract was lost following periodate oxidation, but was stable to proteolytic enzyme and heat treatments. Mannoproteins in the extract were fractionated by hexadecyltrimethylammonium bromide. A fraction containing the 10G Ag was degraded by mild acid hydrolysis and a tetrahexose eluted from a P-2 size exclusion column was found to be the epitope (10G epitope) part of the 10G Ag. By use of gas-liquid chromatography, mass spectroscopy, and H-1 proton NMR analysis, the 10G epitope was determined to be a linear beta-1,2-linked tetramannose. The 10G Ag, which was immunopurified from the Zymolyase extract, and the 10G epitope were involved in the attachment of C. albicans to mouse spleen marginal zone macrophages. Both the 10G Ag and the purified 10G epitope specifically inhibited C. albicans adherence in an ex vivo binding assay. Latex beads adsorbed with the 10G Ag or the 10G epitope adhered specifically to the splenic marginal zone macrophages. These data show that a beta-1,2-linked mannotetraose part of a C. albicans cell wall mannoprotein is an adhesin site that may play a role in pathogenesis of disseminated candidiasis.	MONTANA STATE UNIV, DEPT MICROBIOL, BOZEMAN, MT 59717 USA	Montana State University System; Montana State University Bozeman					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024912] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24912] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BRAWNER DL, 1987, MICROB PATHOGENESIS, V2, P249, DOI 10.1016/0882-4010(87)90123-9; BRAWNER DL, 1986, INFECT IMMUN, V51, P327, DOI 10.1128/IAI.51.1.327-336.1986; BRAWNER DL, 1986, INFECT IMMUN, V51, P337, DOI 10.1128/IAI.51.1.337-343.1986; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CARROW EW, 1985, INFECT IMMUN, V49, P172, DOI 10.1128/IAI.49.1.172-181.1985; Cassone A, 1989, Curr Top Med Mycol, V3, P248; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P629; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P637; CUTLER JE, 1990, INFECT IMMUN, V58, P1902, DOI 10.1128/IAI.58.6.1902-1908.1990; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DOWNS F, 1967, METHOD CARBOHYD CHEM, V7, P200; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDWARDS JE, 1992, INFECT IMMUN, V60, P3087, DOI 10.1128/IAI.60.8.3087-3091.1992; Fleet G H, 1985, Curr Top Med Mycol, V1, P24; HAZEN BW, 1988, INFECT IMMUN, V56, P2521, DOI 10.1128/IAI.56.9.2521-2525.1988; HAZEN KC, 1990, INFECT IMMUN, V58, P3469, DOI 10.1128/IAI.58.11.3469-3476.1990; HAZEN KC, 1991, INFECT IMMUN, V59, P907, DOI 10.1128/IAI.59.3.907-912.1991; KANBE T, 1993, INFECT IMMUN, V61, P2578, DOI 10.1128/IAI.61.6.2578-2584.1993; KANBE T, 1972, INFECT IMMUN, V60, P1978; KOBAYASHI H, 1987, ARCH BIOCHEM BIOPHYS, V256, P381, DOI 10.1016/0003-9861(87)90459-0; KOBAYASHI H, 1990, ARCH BIOCHEM BIOPHYS, V278, P195, DOI 10.1016/0003-9861(90)90248-W; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; LI RK, 1991, J GEN MICROBIOL, V137, P455, DOI 10.1099/00221287-137-3-455; LLOYD KO, 1970, BIOCHEMISTRY-US, V9, P3446, DOI 10.1021/bi00819a025; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; MIYAKAWA Y, 1989, YEAST, V5, P225; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; PODZORSKI RP, 1989, ARCH SURG-CHICAGO, V124, P1290, DOI 10.1001/archsurg.1989.01410110044009; RIESSELMAN MH, 1991, J IMMUNOL METHODS, V145, P153, DOI 10.1016/0022-1759(91)90321-6; SANDIN RL, 1982, INFECT IMMUN, V35, P79, DOI 10.1128/IAI.35.1.79-85.1982; SANDIN RL, 1987, MYCOPATHOLOGIA, V98, P179, DOI 10.1007/BF00437653; SHEPHERD MG, 1987, CRC CR REV MICROBIOL, V15, P7, DOI 10.3109/10408418709104445; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; TOJO M, 1988, CLIN CHEM, V34, P539; TOJO M, 1990, CARBOHYD RES, V199, P215, DOI 10.1016/0008-6215(90)84263-T; TOSH FD, 1992, INFECT IMMUN, V60, P4734, DOI 10.1128/IAI.60.11.4734-4739.1992; TRONCHIN G, 1988, INFECT IMMUN, V56, P1987, DOI 10.1128/IAI.56.8.1987-1993.1988; YORK WS, 1986, METHOD ENZYMOL, V118, P3	42	110	118	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18293	18299						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688744				2022-12-25	WOS:A1993LT74300095
J	YU, H; ERITJA, R; BLOOM, LB; GOODMAN, MF				YU, H; ERITJA, R; BLOOM, LB; GOODMAN, MF			IONIZATION OF BROMOURACIL AND FLUOROURACIL STIMULATES BASE MISPAIRING FREQUENCIES WITH GUANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE INSERTION FIDELITY; PROTON NMR; MAGNETIC-RESONANCE; DYNAMIC PROPERTIES; DNA-SYNTHESIS; PAIR; OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDES; EQUILIBRIUM; MUTAGENESIS	To test whether ionized base pairs influence polymerase-catalyzed misinsertion rates, we measured the efficiency of forming 5-bromouracil (B), 5-fluorouracil (F), and thymine base pairs with guanine and adenine as a function of pH using avian myeloblastosis reverse transcriptase. When B, F, and T were present as dNTP substrates, misincorporation efficiencies opposite G, normalized to incorporation of C opposite G, increased by about 20-, 13-, and 7-fold, respectively, as reaction pH increased from 7.0 to 9.5. Incorporation efficiencies to form the correct base pairs, B.A and F.A, normalized to T.A, decreased by 4- and 8-fold, respectively; with increasing pH. The effects of pH on mis-incorporation efficiencies were about 10-fold greater when B, F, and T were present as template bases. The relative misincorporation efficiencies of G opposite template B, F, and T, normalized to incorporation of A opposite B, F, and T, increased by about 430-, 370-, and 70-fold, respectively, as pH was increased from 6.5 to 9.5, while correct incorporation of A opposite template B and F decreased about 10-fold over the same pH range. Plots depicting incorrect and correct incorporation efficiencies versus pH were fit to a pH titration equation giving the fraction of ionized base as a function of pH. We conclude that avian myeloblastosis reverse transcriptase forms B.G and F.G mispairs in an ionized Watson-Crick conformation in preference to a neutral wobble structure containing favored keto tautomers of B or F. Although participation of disfavored enol tautomers in enzyme-catalyzed base mispair formation cannot be ruled out, the results are inconsistent with the ''standard'' disfavored tautomer model of mutagenesis. Instead, the data support a model in which ionization of halouracil bases is primarily responsible for B- and F-induced mutagenesis.	CTR RES & DEV,DEPT MOLEC GENET,E-08034 BARCELONA,SPAIN		YU, H (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089, USA.		Eritja, Ramon/B-5613-2008; Bloom, Linda B/F-3684-2014	Eritja, Ramon/0000-0001-5383-9334; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015034, R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15034, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOULARD Y, 1992, NUCLEIC ACIDS RES, V620, P1933; BRENNAN CA, 1985, NUCLEIC ACIDS RES, V13, P8665, DOI 10.1093/nar/13.24.8665; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; DRIGGERS PH, 1988, BIOCHEMISTRY-US, V27, P1729, DOI 10.1021/bi00405a052; DUNN DB, 1975, HDB BIOCH MOL BIOL, V1, P76; FAZAKERLEY GV, 1987, J BIOMOL STRUCT DYN, V5, P639, DOI 10.1080/07391102.1987.10506417; FERNANDEZFORNER D, 1990, NUCLEIC ACIDS RES, V18, P5729, DOI 10.1093/nar/18.19.5729; FREESE E, 1959, J MOL BIOL, V1, P87, DOI 10.1016/S0022-2836(59)80038-3; GOLDMAN D, 1983, NUCLEOS NUCLEOT, V2, P175, DOI 10.1080/07328318308081257; HANSCH C, 1973, J MED CHEM, V16, P1207, DOI 10.1021/jm00269a003; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KREMER AB, 1987, BIOCHEMISTRY-US, V26, P391, DOI 10.1021/bi00376a009; LAWLEY P. D., 1962, JOUR MOLECULAR BIOL, V4, P216, DOI 10.1016/S0022-2836(62)80053-9; MASSOULIE J, 1966, BIOCHIM BIOPHYS ACTA, V114, P16, DOI 10.1016/0005-2787(66)90249-8; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; PATEL DJ, 1984, FED PROC, V43, P2663; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SCHULHOF JC, 1987, NUCLEIC ACIDS RES, V15, P397, DOI 10.1093/nar/15.2.397; SOWERS LC, 1989, J MOL BIOL, V205, P437, DOI 10.1016/0022-2836(89)90353-7; SOWERS LC, 1986, BIOCHEMISTRY-US, V25, P3983, DOI 10.1021/bi00362a002; SOWERS LC, 1987, J BIOL CHEM, V262, P15436; SOWERS LC, 1988, J BIOL CHEM, V263, P14794; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; SOWERS LC, 1987, MUTAT RES, V177, P201, DOI 10.1016/0027-5107(87)90003-0; STRAZEWSKI P, 1990, ANGEW CHEM INT EDIT, V29, P36; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; VU H, 1990, TETRAHEDRON LETT, V31, P7269, DOI 10.1016/S0040-4039(00)88541-X; WANG C, 1991, J AM CHEM SOC, V113, P5486, DOI 10.1021/ja00014a068; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WATSON JD, 1953, COLD SPRING HARB SYM, V18, P123, DOI 10.1101/SQB.1953.018.01.020	34	90	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15935	15943						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7688001				2022-12-25	WOS:A1993LN30500087
J	ALTHAUS, IW; GONZALES, AJ; CHOU, JJ; ROMERO, DL; DEIBEL, MR; CHOU, KC; KEZDY, FJ; RESNICK, L; BUSSO, ME; SO, AG; DOWNEY, KM; THOMAS, RC; ARISTOFF, PA; TARPLEY, WG; REUSSER, F				ALTHAUS, IW; GONZALES, AJ; CHOU, JJ; ROMERO, DL; DEIBEL, MR; CHOU, KC; KEZDY, FJ; RESNICK, L; BUSSO, ME; SO, AG; DOWNEY, KM; THOMAS, RC; ARISTOFF, PA; TARPLEY, WG; REUSSER, F			THE QUINOLINE U-78036 IS A POTENT INHIBITOR OF HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SULFATED POLYSACCHARIDES; SELECTIVE-INHIBITION; PENTOSAN POLYSULFATE; ANTIVIRAL ACTIVITY; ENZYME-KINETICS; DNA-POLYMERASE; RNASE-H; TYPE-1; DERIVATIVES	The quinoline U-78036 represents a new class of non-nucleoside human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitors. The agent possesses excellent antiviral activity at nontoxic doses in HIV-1-infected lymphocytes grown in tissue culture. Enzymatic kinetic studies of the HIV-1 reverse transcriptase (RT)-catalyzed RNA-directed DNA polymerase function were carried out in order to determine whether the inhibitor interacts with the template-primer or deoxyribonucleotide triphosphate (dNTP) binding sites of the polymerase. The data were analyzed using steady-state or Briggs-Haldane kinetics assuming that the template-primer binds to the enzyme first followed by the dNTP and that the polymerase functions processively. The calculated rate constants are in agreement with this model. The results show that the inhibitor acts as a mixed to noncompetitive inhibitor with respect to both the template-primer and the dNTP binding sites of the enzyme. Hence, U-78036 inhibits the RNA-directed DNA polymerase activity of RT by interacting with a site distinct from the template-primer and dNTP binding sites. Moreover, the potency of U-78036 is dependent on the base composition of the template-primer. The equilibrium constants for various enzyme-substrate-inhibitor complexes were at least seven times lower for the poly(rC) . (dG)10-catalyzed system than the one catalyzed by poly(rA).(dT)10. In addition, the inhibitor does not impair the DNA-dependent DNA polymerase activity and the RNase H function of HIV-1 RT nor does it inhibit the RNA-directed DNA polymerase activity of the HIV-2, avian myoblastoma virus, and murine leukemia virus RT enzymes.	UPJOHN CO,7295-25-2,KALAMAZOO,MI 49001; MT SINAI MED CTR,MIAMI BEACH,FL 33140; UNIV MIAMI,MIAMI,FL 33101	Pfizer; Mount Sinai Medical Center; University of Miami			Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Chou, Kuo-Chen/A-8340-2009	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; 				ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; ALTHAUS IW, 1992, EXPERIENTIA, V48, P1127, DOI 10.1007/BF01948005; ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679; BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BUSSO M, 1988, AIDS RES HUM RETROV, V4, P449, DOI 10.1089/aid.1988.4.449; BUSSO ME, 1990, ANTIMICROB AGENTS CH, V34, P1991, DOI 10.1128/AAC.34.10.1991; CHA S, 1968, J BIOL CHEM, V243, P820; CHOU KC, 1976, SCI SINICA, V19, P505; CHOU KC, 1989, J BIOL CHEM, V264, P12074; CHOU KC, 1990, BIOPHYS CHEM, V35, P1, DOI 10.1016/0301-4622(90)80056-D; CHOU KC, 1982, J AM CHEM SOC, V104, P1409, DOI 10.1021/ja00369a043; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; GERARD M, 1990, INTERSCI C ANTIMICRO, V176; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; POPP FD, 1961, J ORG CHEM, V26, P4930, DOI 10.1021/jo01070a036; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SHARMA SK, 1991, BIOTECHNOL APPL BIOC, V14, P69; SOSA MAG, 1991, BIOCHEM BIOPH RES CO, V174, P489, DOI 10.1016/0006-291X(91)91443-G; TAN CK, 1986, J BIOL CHEM, V261, P2310; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	36	175	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14875	14880						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686907				2022-12-25	WOS:A1993LL75900053
J	CIRINO, NM; KALAYJIAN, RC; JENTOFT, JE; LEGRICE, SFJ				CIRINO, NM; KALAYJIAN, RC; JENTOFT, JE; LEGRICE, SFJ			FLUOROMETRIC ANALYSIS OF RECOMBINANT P15 HIV-1 RIBONUCLEASE-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SITE-DIRECTED MUTAGENESIS; METAL CHELATE ADSORBENT; DNA-POLYMERASE-ACTIVITY; AMINO-ACID-RESIDUES; REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; RNASE-H; HISTIDINE-RESIDUES; DOMAIN	We have exploited the sole tryptophan residue (Trp535) in the ribonuclease H (RNase H) domain of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) to study features of the isolated polypeptide (p15 RNase H) by fluorescence spectroscopy. Incubation of purified p15 RNase H with a synthetic RNA/DNA hybrid was accompanied by an alteration in Trp535 fluorescence intensity. This property was used to determine an apparent binding constant (K(app)) of 3.5 x 10(6) M-1 for p15 RNase H complexed with poly(rA)/oligo(dT)12-18 and an occluded site size of 4 nucleotides. A cooperativity coefficient (omega) of 910 was also determined which indicated that nearly three logs of the K(app) were due to cooperativity effects. Recombinant p15 RNase H preparations containing mutations at position 478 (Glu478 --> Gln 478) or 539 (His539 --> Phe539), which are highly conserved between bacterial and retroviral RNases H, were also analyzed. Under the same conditions, these mutants failed to bind the RNA/DNA hybrid, although they were structurally similar to the wild type polypeptide. Fluorescence spectroscopy thus appears to be an alternative and sensitive means of analyzing functional properties of the purified RNase H domain of HIV-1 RT under a variety of conditions.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07381] Funding Source: Medline; NIGMS NIH HHS [GM 46623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; CERTA U, 1986, EMBO J, V5, P51; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; EVANS DB, 1991, J BIOL CHEM, V266, P20583; HAFKEMEYER P, 1991, NUCLEIC ACIDS RES, V19, P4059, DOI 10.1093/nar/19.15.4059; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKA Z, 1991, J BIOL CHEM, V266, P14697; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1991, EUR J BIOCHEM, V198, P437, DOI 10.1111/j.1432-1033.1991.tb16033.x; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LOYA S, 1990, ANTIMICROB AGENTS CH, V34, P2009, DOI 10.1128/AAC.34.10.2009; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MIZHRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; MOELLING K, 1971, NATURE, V234, P240; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHATZ O, 1990, ONCOGENESIS AIDS, P304; SCHWARZ G, 1983, J MOL BIOL, V163, P467, DOI 10.1016/0022-2836(83)90069-4; STAMMERS DK, 1991, FEBS LETT, V283, P298, DOI 10.1016/0014-5793(91)80613-8; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; WANG W, 1990, SCIENCE, V249, P1398	39	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14743	14749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686904				2022-12-25	WOS:A1993LL75900034
J	BASU, M; HAKIMI, J; DHARM, E; KONDAS, JA; TSIEN, WH; PILSON, RS; LIN, P; GILFILLAN, A; HARING, P; BRASWELL, EH; NETTLETON, MY; KOCHAN, JP				BASU, M; HAKIMI, J; DHARM, E; KONDAS, JA; TSIEN, WH; PILSON, RS; LIN, P; GILFILLAN, A; HARING, P; BRASWELL, EH; NETTLETON, MY; KOCHAN, JP			PURIFICATION AND CHARACTERIZATION OF HUMAN RECOMBINANT IGE-FC FRAGMENTS THAT BIND TO THE HUMAN HIGH-AFFINITY IGE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-CHAIN FRAGMENT; HUMAN IMMUNOGLOBULIN-E; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; MURINE IGE; EXPRESSION; CELLS; PROTEIN; SITE	The Fc-region of immunoglobulin E (IgE) comprising C(epsilon)2, C(epsilon)3, and C(epsilon)4 domains is sufficient for binding to the alpha chain of the high affinity IgE-Fc receptor (FcepsilonRIalpha). In order to identify the smallest Fc fragment capable of binding to the FcepsilonRIalpha with high affinity, various regions of the IgE-Fc molecule were expressed in COS cells and investigated for their ability to bind FcepsilonRIalpha. The smallest fragment that showed FcepsilonRIalpha binding activity spans amino acids 329-547 and lacks the entire C(epsilon)2 domain. Two active fragments, viz. Fc(epsilon)(315-547) (containing Cys328 which is responsible for interchain S-S bonding) and Fc(epsilon)(329-547), have been overexpressed in CHO cells and purified to homogeneity. The purified proteins bind to the FcepsilonRIalpha with high affinity, similar to native IgE. SDS-polyacrylamide gel electrophoresis analyses indicate that Fc(epsilon)(315-547) is an S-S-linked dimer of apparent molecular mass of 68 kDa. Fc(epsilon)(329-547) appears on SDS-gel as three distinct bands at approximately 32 kDa, both under reducing and nonreducing conditions. However, size exclusion chromatography and analytical ultracentrifugation studies suggest that Fc(epsilon)(329-547) also remains associated as a dimer. The presence of N-linked glycosylation was detected in both proteins. The deglycosylated form of Fc(epsilon)(315-547) was isolated after Endo F/N-glycosidase F digestion and demonstrated to have binding activity comparable to that of the mock-digested protein. These results suggest that the presence of N-linked sugars is not necessary for FcepsilonRIalpha binding. Both proteins blocked the release of histamine from RBL cells expressing human FcepsilonRIalpha in a dose-dependent manner. The availability of these recombinant IgE-Fc proteins will be helpful in elucidating the key epitopes essential for the binding of IgE to its high affinity receptor.	HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT IMMUNOPHARMACOL, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT BRONCHOPULM RES, NUTLEY, NJ 07110 USA; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; UNIV CONNECTICUT, STORRS, CT 06269 USA	Roche Holding; Roche Holding; Roche Holding; Roche Holding; University of Connecticut	BASU, M (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT PROT BIOCHEM, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.							ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BASU M, 1991, ARCH BIOCHEM BIOPHYS, V286, P638, DOI 10.1016/0003-9861(91)90093-X; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DORDAL MS, 1985, ENDOCRINOLOGY, V116, P2293, DOI 10.1210/endo-116-6-2293; DORRINGTON KJ, 1978, IMMUNOL REV, V41, P3, DOI 10.1111/j.1600-065X.1978.tb01458.x; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; GILFILLAN AM, 1992, J IMMUNOL, V149, P2445; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HANZJURGEN H, 1986, THERMODYNAMIC DATA B, P70; HAYES MP, 1988, BIOCHEM BIOPH RES CO, V150, P1096, DOI 10.1016/0006-291X(88)90742-5; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IKEYAMA S, 1987, MOL IMMUNOL, V24, P1039; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; JOHNSON ML, 1981, BIOPHYS J, V36, P578; KENTEN J, 1984, P NATL ACAD SCI-BIOL, V81, P2955, DOI 10.1073/pnas.81.10.2955; KUROKAWA T, 1983, NUCLEIC ACIDS RES, V11, P3077, DOI 10.1093/nar/11.10.3077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1984, P NATL ACAD SCI-BIOL, V81, P5369, DOI 10.1073/pnas.81.17.5369; MORRISVASIOS C, 1988, J VIROL, V62, P349, DOI 10.1128/JVI.62.1.349-353.1988; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; PAN YCE, 1986, METHODS PROTEIN MICR, P105; PEREZMONTFORT R, 1982, MOL IMMUNOL, V19, P1113, DOI 10.1016/0161-5890(82)90322-4; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; RISKE F, 1991, J BIOL CHEM, V266, P11245; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKOV PS, 1985, ALLERGY, V40, P213; WEETALL M, 1990, J IMMUNOL, V145, P3849	39	78	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13118	13127						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685756				2022-12-25	WOS:A1993LH55300019
J	SAWADA, R; LOWE, JB; FUKUDA, M				SAWADA, R; LOWE, JB; FUKUDA, M			E-SELECTIN-DEPENDENT ADHESION EFFICIENCY OF COLONIC-CARCINOMA CELLS IS INCREASED BY GENETIC MANIPULATION OF THEIR CELL-SURFACE LYSOSOMAL MEMBRANE GLYCOPROTEIN-1 EXPRESSION LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASN-LINKED OLIGOSACCHARIDES; SIALYL-LEX DETERMINANT; CARBOHYDRATE STRUCTURES; HUMAN-GRANULOCYTES; MOLECULE-1 ELAM-1; SUGAR CHAINS; TUMOR-CELLS; LEWIS-X; ANTIGEN; ANTIBODY	Lysosomal membrane glycoprotein (lamp)-1 and lamp-2 are the most abundant glycoproteins within the lysosomal membrane. A small amount of lamp-1 and lamp-2 molecules, however, can be present on the cell surface. We have shown previously that highly metastatic colonic carcinoma L4 cells express more lamp-1 and lamp-2 on the cell surface than low metastatic SP cells (Saitoh, O., Wang, W.-L., Lotan, R., and Fukuda, M. (1992) J. Biol. Chem. 267, 5700-5711). Since lamp-1 and lamp-2 are the major carriers for poly-N-acetyllactosamines that are able to display sialyl-Le(x) termini, we sought to determine if an increased amount of lamp-1 on the cell surface would lead to increased expression of cell surface sialyl-Le(x) determinants and to the increased adhesion of those cells to E-selectin. Expression of increased amounts of lamp-1 on the cell surface was achieved either by overexpression of lamp-1 or by expressing a mutant lamp-1 molecule preferentially at the plasma membrane, rather than in lysosomes. Cells that express variable amounts of cell surface lamp-1 were tested for their adhesion to activated endothelial cells or E-selectin expressing Chinese hamster ovary cells. The results clearly show that the extent of adhesion to E-selectin and cell surface sialyl-Le(x) determinants is proportional to the amount of cell surface lamp-1. Moreover, it was demonstrated that such adhesion can be inhibited by soluble lamp-1 generated from Chinese hamster ovary cells expressing sialyl-Le(x) structures. These results indicate that lamp-1 can efficiently present ligands for E-selectin and at the same time can be a useful reagent for inhibition of E-selectin (and possibly P-selectin)-mediated interaction.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV MICHIGAN,HOWARD HUGHES,MED INST,ANN ARBOR,MI 48109	Sanford Burnham Prebys Medical Discovery Institute; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48737] Funding Source: Medline; NIAID NIH HHS [P01 AI33189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG EL, 1991, J BIOL CHEM, V266, P14869; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; KAMEYAMA A, 1991, CARBOHYD RES, V209, pC1, DOI 10.1016/0008-6215(91)80171-I; KIM YS, 1988, CANCER RES, V48, P475; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE N, 1990, J BIOL CHEM, V265, P20476; LEY K, 1991, BLOOD, V77, P2553; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MORIKAWA K, 1988, CANCER RES, V48, P1943; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873	53	111	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12675	12681						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685349				2022-12-25	WOS:A1993LG65800067
J	CARTWRIGHT, CA; MAMAJIWALLA, S; SKOLNICK, SA; ECKHART, W; BURGESS, DR				CARTWRIGHT, CA; MAMAJIWALLA, S; SKOLNICK, SA; ECKHART, W; BURGESS, DR			INTESTINAL CRYPT CELLS CONTAIN HIGHER LEVELS OF CYTOSKELETAL-ASSOCIATED PP60C-SRC PROTEIN TYROSINE KINASE-ACTIVITY THAN DO DIFFERENTIATED ENTEROCYTES	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; HUMAN-COLON CARCINOMA; GAP JUNCTION PROTEIN; ISOLATED MICROVILLUS CYTOSKELETON; INSOLUBLE CELLULAR MATRIX; EXPRESSED RAT FIBROBLASTS; CHICK-EMBRYO DEVELOPMENT; MIDDLE TUMOR-ANTIGEN; HERBIMYCIN-A; MORPHOLOGICAL TRANSFORMATION	Undifferentiated crypt cells from chicken small intestine contain 15-fold higher levels of tyrosine-phosphorylated proteins than do differentiated enterocytes located at the villus apex. The tyrosine kinase activity and the tyrosine-phosphorylated proteins are associated with the Triton-insoluble cytoskeleton. To determine whether: (1) pp60c-src is an active tyrosine kinase in crypt cell cytoskeletons and (2) cytoskeletal-associated pp60c-src activity decreases as crypt cells differentiate, we isolated pp60c-src from subcellular fractions of cells along the crypt-villus axis of chicken small intestine and measured its protein kinase activity. We observed that pp60c-src activity in crypt cytoskeleton was higher (on average, fourfold as measured by enolase phosphorylation or sevenfold as measured by autophosphorylation) than that in cytoskeletons from differentiated enterocytes. Moreover, nearly 70% of pp60c-src activity in crypt cells, like that of pp60v-src, pp60c-src mutants with elevated kinase, activity or pp60v-src from activated platelets, localized to the cellular cytoskeleton. In contrast, less than 20% of pp60c-src activity in differentiated enterocytes, like that of kinase-inactive pp60v-src or pp60c-src from fibroblasts or resting platelets, associated with the cytoskeleton. Furthermore, in crypt cells, unlike differentiated enterocytes, cytoskeletal-associated pp60c-src appeared to have higher specific protein tyrosine kinase activity than did soluble pp60c-src. The data suggest that a kinase-active form of pp60c-src located in the cytoskeleton of crypt cells may be responsible for phosphorylating proteins on tyrosine and regulating growth and differentiation of the cells.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Salk Institute	CARTWRIGHT, CA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,MED SCH LAB,SURGE BLDG,P304,STANFORD,CA 94305, USA.				NCI NIH HHS [CA-13884] Funding Source: Medline; NIDDK NIH HHS [P30-DK38707, R29 DK43743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA013884, R01CA013884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R29DK043743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BREIMER ME, 1981, EXP CELL RES, V135, P1, DOI 10.1016/0014-4827(81)90293-7; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; FATH KR, 1990, DEVELOPMENT, V109, P449; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; FOSS FM, 1989, ONCOGENE RES, V5, P13; GARCIA R, 1991, ONCOGENE, V6, P1983; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GOULD KL, 1984, J CELL BIOL, V98, P487, DOI 10.1083/jcb.98.2.487; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KMIECK TE, 1987, CELL, V49, P75; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MURAKAMI Y, 1988, CANCER RES, V48, P1587; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SUZUKAKETSUCHIY.K, 1989, J ANTIBIIOT, V12, P1831; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WEISER MM, 1986, INT REV CYTOL, V101, P1, DOI 10.1016/S0074-7696(08)60245-4; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	54	58	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1033	1039						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681158				2022-12-25	WOS:A1993KT22000027
J	MISEVIC, GN; BURGER, MM				MISEVIC, GN; BURGER, MM			CARBOHYDRATE-CARBOHYDRATE INTERACTIONS OF A NOVEL ACIDIC GLYCAN CAN MEDIATE SPONGE CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIQUE PROTEOGLYCAN COMPLEX; AGGREGATION FACTOR; MICROCIONA-PROLIFERA; GEL-ELECTROPHORESIS; SELF-ASSOCIATION; HEPARAN-SULFATE; MELANOMA-CELLS; BINDING; RECOGNITION; AFFINITY	Cell recognition and adhesion were first demonstrated in marine sponges. These phenomena were later shown in Microciona prolifera sponge to be mediated by a Ca2+-dependent self-association of adhesion proteoglycans (APs) attached in a species-specific manner to cell-surface receptors. Using the same experimental system we now provide three lines of evidence that highly polyvalent Ca2+-dependent carbohydrate-carbohydrate interactions of a novel AP glycan represent the basis of AP-AP self-binding and thus of cell adhesion. 1) A specific monoclonal antibody which blocks cell aggregation and AP bead adhesion identified a highly repetitive novel carbohydrate epitope (2500 sites) in an acidic glycan of M(r) = 200 x 10(3) (g200) from AP. 2) Reconstitution of the Ca2+-dependent self-interaction activity of AP was achieved by cross-linking the purified protein-free g200 glycan into polymers of similar valency as the native AP. 3) Beads coated with the protein-free g200 glycan showed a Ca2+-dependent aggregation equivalent to that of AP beads. Carbohydrate and amino acid analyses of the g200 glycan purified by gel electrophoresis, high performance liquid chromatography gel filtration, and ion exchange chromatography yielded six components in the following proportions; 68 fucose, 32 glucuronic acid, 2 mannose, 18 galactose, 19 N-acetylglucosamine, and 1 asparagine residue. These unique chemical features together with immunological and enzymological analyses suggest that the g200 glycan is a large highly fucosylated, acidic, N-linked polysaccharide with a novel structure distinct from that of other known glycosaminoglycans.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Friedrich Miescher Institute for Biomedical Research; Marine Biological Laboratory - Woods Hole	MISEVIC, GN (corresponding author), UNIV HOSP BASEL, DEPT RES, HEBELSTR 20, CH-4031 BASEL, SWITZERLAND.		Misevic, Gradimir/D-8294-2016	Misevic, Gradimir/0000-0001-5047-2936				AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CAULDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051, DOI 10.1021/bi00740a017; CHAPLIN MF, 1982, ANAL BIOCHEM, V123, P336, DOI 10.1016/0003-2697(82)90455-9; DISCHE Z, 1947, J BIOL CHEM, V167, P189; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; Galtsoff PS, 1923, BIOL BULL-US, V45, P153, DOI 10.2307/1536625; HAMPSON IN, 1984, BIOCHEM J, V221, P697, DOI 10.1042/bj2210697; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HENRIKSON RL, 1984, ANAL BIOCHEM, V136, P65; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KOEHLER G, 1975, NATURE, V256, P495; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; Malinowski K, 1981, Methods Enzymol, V73, P418; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1990, J CELL BIOCHEM, V43, P307, DOI 10.1002/jcb.240430403; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MISEVIC GN, 1989, METHOD ENZYMOL, V179, P95; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; SHIELDS R, 1960, ANAL CHEM, V32, P885, DOI 10.1021/ac60163a053; SPENCER B, 1960, BIOCHEM J, V75, P435, DOI 10.1042/bj0750435; STEWART DJ, 1974, ANAL BIOCHEM, V62, P349, DOI 10.1016/0003-2697(74)90167-5; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TURLEY EA, 1980, NATURE, V283, P268, DOI 10.1038/283268a0; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204	38	107	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4922	4929						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680344				2022-12-25	WOS:A1993KP88400056
J	CHOU, CF; OMARY, MB				CHOU, CF; OMARY, MB			MITOTIC ARREST-ASSOCIATED ENHANCEMENT OF O-LINKED GLYCOSYLATION AND PHOSPHORYLATION OF HUMAN KERATIN-8 AND KERATIN-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; N-ACETYLGLUCOSAMINE RESIDUES; CYTOPLASMIC GLYCOPROTEINS; VIMENTIN FILAMENTS; MESSENGER-RNA; KINASE-C; CELLS; EXPRESSION; NUCLEAR; INVITRO	Arrest of the human colonic cell line HT29 at the G2/M phase of the cell cycle resulted in changes in keratin assembly that were coupled with a significant increase in the O-linked glycosylation and serine phosphorylation of keratin polypeptides 8 and 18 (K8/18). With mitotic arrest, enhanced keratin phosphorylation occurred preferentially on K8, whereas K18 showed a higher glycosylation level than K8. Removal of the arresting agent allowed cells to proceed through the cell cycle with a concomitant decrease in K8/18 glycosylation. In contrast, keratins isolated from S phase-enriched cells, obtained after synchronization with aphidicolin, did not show enhanced glycosylation. Tryptic peptide analysis of keratins in G2/M-arrested cells showed changes in the glycopeptide pattern of K8 and in the phosphopeptide patterns of K8 and K18. Labeling of K8/18 immunoprecipitates, isolated from G2/M-arrested cells, with [H-3]galactose followed by beta-elimination showed that K8/18 glycosylation consisted of single N-acetylglucosamine residues. Threonine was identified as the site of glycosylation after comparing acid hydrolysis products of beta-eliminated and non-beta-eliminated K8 and K18. Specific cleavage at tryptophan residues indicated that K18 glycosylation and phosphorylation were restricted to the head and proximal rod domains, whereas K8 did not show the same restriction. Our results show a unique association of the single O-linked N-acetylglucosamine type of modification of keratins with mitotic arrest in HT29 cells. There was no reciprocal relationship between K8/18 glycosylation and phosphorylation, and each keratin showed a preferential G2/M cell cycle-associated increase in either serine phosphorylation or threonine glycosylation.	VET ADM MED CTR, PALO ALTO, CA 94304 USA; STANFORD UNIV, MED CTR, SCH MED, CTR DIGEST DIS, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University				Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK 38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashihara T, 1979, Methods Enzymol, V58, P248; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; GILMARTIN ME, 1984, J CELL BIOL, V98, P1144, DOI 10.1083/jcb.98.3.1144; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, CIBA F SYMP, V145, P102; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KING IA, 1989, J BIOL CHEM, V264, P14022; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1975, J BIOL CHEM, V250, P4007; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; QUARONI A, 1991, J BIOL CHEM, V266, P11923; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Savige W E, 1977, Methods Enzymol, V47, P459; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; STARR CM, 1990, J BIOL CHEM, V265, P6868; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; TANAKA K, 1965, J BIOL CHEM, V240, P1487; TOLLE HG, 1987, EUR J CELL BIOL, V43, P35; TORRES CR, 1984, J BIOL CHEM, V259, P3308; YAMAMOTO R, 1990, MOL ENDOCRINOL, V4, P370, DOI 10.1210/mend-4-3-370; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	48	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4465	4472						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680039				2022-12-25	WOS:A1993KN53300094
J	ISOGAI, Y; IIZUKA, T; SHIRO, Y				ISOGAI, Y; IIZUKA, T; SHIRO, Y			THE MECHANISM OF ELECTRON DONATION TO MOLECULAR-OXYGEN BY PHAGOCYTIC CYTOCHROME B(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE PRODUCTION; MICROBICIDAL OXIDASE; NEUTROPHILS; AUTOXIDATION; MYOGLOBIN; CHAIN; COMPONENT; REDUCTION; KINETICS	Phagocytic cytochrome b(558) is a unique heme-containing enzyme, which catalyzes one electron reduction of molecular oxygen to produce a superoxide anion with a six-coordinated heme iron. To clarify the mechanism of the superoxide production, we have analyzed oxidation-reduction kinetics of cytochrome b(558) purified from porcine neutrophils by stopped-flow and rapid-scanning spectroscopy. Reduced cytochrome b(558) was rapidly reoxidized by O-2 showing spectral changes with clear isosbestic points, which were also observed during the reduction of ferric cytochrome b(558) with Na2S2O4 under anaerobic conditions. The single turnover rate for the reaction with O-2 linearly depended on the O-2 concentration but was not affected by addition of CO. The rate of the reaction decreased with an increase of pH giving a pK(a) of 9.7. Under complete anaerobic conditions, ferrous cytochrome b(558) was oxidized by ferricyanide at a rate faster than by O-2. The thermodynamic analysis shows that the enthalpic energy barriers for the reactions of cytochrome b(558) are significantly lower when compared to the autoxidation of native and modified myoglobins through the formation of the iron-O-2 complex. These findings are most consistent with the electron transfer from the heme to O-2 by an outer-sphere mechanism.			ISOGAI, Y (corresponding author), INST PHYS & CHEM RES,BIOPHYS CHEM LAB,HIROSAWA 2-1,WAKO,SAITAMA 35101,JAPAN.			Isogai, Yasuhiro/0000-0001-6905-4208				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BUTLER J, 1982, J BIOL CHEM, V257, P747; Castro C. E., 1978, PORPHYRINS, V5, P1; CHU MML, 1978, BIOCHEMISTRY-US, V17, P481, DOI 10.1021/bi00596a017; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DICKERSON LD, 1993, J AM CHEM SOC, V115, P3623, DOI 10.1021/ja00062a028; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; FULTON GP, 1976, J AM CHEM SOC, V98, P2119, DOI 10.1021/ja00424a017; GLASSTONE S, 1941, THEORY RATE PROCESSE; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KAMIYA N, 1991, J AM CHEM SOC, V118, P1826; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MIKI T, 1992, J BIOL CHEM, V267, P19673; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; POU S, 1992, J BIOL CHEM, V267, P24173; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHIRO Y, 1993, J BIOL CHEM, V268, P19983; SUGAWARA Y, 1980, EUR J BIOCHEM, V110, P241, DOI 10.1111/j.1432-1033.1980.tb04861.x; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966	32	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7853	7857		10.1074/jbc.270.14.7853	http://dx.doi.org/10.1074/jbc.270.14.7853			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713877	hybrid			2022-12-25	WOS:A1995QR52600013
J	NISHIMURA, K; TAKETANI, S; INOKUCHI, H				NISHIMURA, K; TAKETANI, S; INOKUCHI, H			CLONING OF A HUMAN CDNA FOR PROTOPORHYRINOGEN OXIDASE BY COMPLEMENTATION IN-VIVO OF A HEMG MUTANT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; FULL-LENGTH CDNA; MOLECULAR-CLONING; PROTOPORPHYRINOGEN OXIDASE; NUCLEOTIDE-SEQUENCE; STRUCTURAL RELATIONSHIP; BIOSYNTHETIC-PATHWAY; FERROCHELATASE; PURIFICATION; GENE	Protoporphyrinogen oxidase (PPO; EC 1.3.3.4) is the enzyme that catalyzes in the penultimate step in the heme biosynthetic pathway. Hemes are essential components of redox enzymes, such as cytochromes. Thus, a hemG mutant strain of Escherichia coli deficient in PPO is defective in aerobic respiration and grows poorly even in rich medium. By complementation with a human placental cDNA Library, we were able to isolate a clone that enhanced the poor growth of such a hemG mutant strain. The clone encoded the gene for human PPO. Sequence analysis revealed that PPO consists of 477 amino acids with a calculated molecular mass of 50.8 kilodaltons. The deduced protein exhibited a high degree of homology over its entire length to the amino acid sequence of PPO encoded by the hemY gene of Bacillus subtilis. The NH2-terminal amino acid sequence of the deduced PPO contains a conserved amino acid sequence that forms the dinucleotide-binding site in many flavin-containing proteins. Northern blot analysis revealed the synthesis of a 1.8-kilobase pair mRNA for PPO. A homogenate of the monkey kidney COS-1 cells that had been transfected with the cDNA had much higher PPO activity than an extract of control cells, and this activity was inhibited by acifluorfen, a specific inhibitor of PPO. Furthermore, the cDNA was expressed in vitro as 51-kilodalton protein, and after incubation with isolated mitochondria the protein was found to be located in the mitochondria, having just the same size as before, an indication that PPO is a mitochondrial enzyme and has no apparent transport-specific leader sequence.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 60601,JAPAN; KANSAI MED UNIV,DEPT HYG,MORIGUCHI,OSAKA 570,JAPAN	Kyoto University; Kansai Medical University								ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; CHIU JT, 1989, J AM CHEM SOC, V111, P7046, DOI 10.1021/ja00200a023; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY TA, 1994, J BIOL CHEM, V269, P813; DAYBACH JC, 1985, EUR J BIOCHEM, V149, P431; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; FRUSTACI JM, 1993, J BACTERIOL, V175, P2154, DOI 10.1128/JB.175.7.2154-2156.1993; GARI E, 1992, FEMS MICROBIOL LETT, V93, P103, DOI 10.1016/0378-1097(92)90497-C; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; Hendrix R. W, 1983, LAMBDA, VII; HSU J, 1971, PHOTOCHEM PHOTOBIOL, V13, P67, DOI 10.1111/j.1751-1097.1971.tb06092.x; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ITO A, 1988, BIOCHEM BIOPH RES CO, V157, P970, DOI 10.1016/S0006-291X(88)80969-0; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS NJ, 1982, ENZYME, V28, P206, DOI 10.1159/000459103; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHNO H, 1993, J BIOL CHEM, V268, P21359; LABBE P, 1990, BIOSYNTHESIS HEME CH, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; MARTASEK P, 1994, P NATL ACAD SCI USA, V91, P3024, DOI 10.1073/pnas.91.8.3024; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, J BIOCHEM-TOKYO, V115, P545, DOI 10.1093/oxfordjournals.jbchem.a124373; MORI M, 1985, EUR J BIOCHEM, V149, P181, DOI 10.1111/j.1432-1033.1985.tb08909.x; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; NISHIMURA K, 1993, GENE, V133, P109; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; O'NEILL G P, 1990, Biofactors, V2, P227; POULSON R, 1976, J BIOL CHEM, V251, P3730; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; RAICH N, 1992, NUCLEIC ACIDS RES, V14, P5955; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROMEO PH, 1986, J BIOL CHEM, V261, P9825; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASARMAN A, 1993, CAN J MICROBIOL, V39, P1155, DOI 10.1139/m93-174; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; TSAI SF, 1988, P NATL ACAD SCI USA, V85, P7049, DOI 10.1073/pnas.85.19.7049; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	55	97	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8076	8080		10.1074/jbc.270.14.8076	http://dx.doi.org/10.1074/jbc.270.14.8076			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713909	hybrid			2022-12-25	WOS:A1995QR52600047
J	AHOMADEGBE, JC; BARROIS, M; FOGEL, S; LEBIHAN, ML; DOUCRASY, S; DUVILLARD, P; ARMAND, JP; RIOU, G				AHOMADEGBE, JC; BARROIS, M; FOGEL, S; LEBIHAN, ML; DOUCRASY, S; DUVILLARD, P; ARMAND, JP; RIOU, G			HIGH-INCIDENCE OF P53 ALTERATIONS (MUTATION, DELETION, OVEREXPRESSION) IN HEAD AND NECK PRIMARY TUMORS AND METASTASES - ABSENCE OF CORRELATION WITH CLINICAL OUTCOME - FREQUENT PROTEIN OVEREXPRESSION IN NORMAL EPITHELIUM AND IN EARLY NONINVASIVE LESIONS	ONCOGENE			English	Article						P53 ALTERATIONS; HEAD AND NECK METASTASES; PROGNOSIS	SQUAMOUS-CELL CARCINOMA; SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; OVER-EXPRESSION; CANCER PATIENTS; POOR-PROGNOSIS; BREAST-CANCER; TP53 GENE; ACCUMULATION; CARCINOGENESIS	We have analysed 78 head and neck carcinomas (50 node metastases and 28 primary tumors including 13 matched specimens) in 65 patients for p53 alterations. Mutations were found in 54 (69%) tumors. Of the 53 mutations within exons, 40 (76%) were missense, five (9%) nonsense and eight (15%) microdeletions or microinsertions. Twenty-five (47%) mutations were transitions mostly G-->A (40%) and 20 (38%) were transversions, mostly G-->T (25%), thus confirming the role of tobacco carcinogens in the induction of these mutations. The incidence of mutations was not different in primary tumors (68%) and node metastases (70%) indicating that this gene alteration was not related to the metastatic dissemination, For eight patients, mutations were observed in matched primary tumors and metastases, indicating clonal dissemination of tumor cells in most of these carcinomas. There was a good correlation between mutation and protein overexpression (Fisher's exact test P < 10(-4)). Immunostaining was also observed in basal cells from normal epithelium and in early lesions adjacent to the primary tumor in 11/15 (73%) specimens irrespective of the presence of mutation in the corresponding tumors. These data confirm that p53 overexpression is an early event in the multistep process of epithelial cell carcinogenesis. Loss of heterozygosity for the TP53 locus was detected in 54% of tumors but no association was found with mutation (Fisher's exact test P = 0.14). No mdm-2 amplification was detected in any tumors. No correlation was found between mutation and clinical parameters, the 5-year survival rates were not different (log rank test P = 0.39) in patients with and without mutation. In conclusion, we have shown that p53 gene mutations and deletions and protein overexpression are frequent in the most aggressive head and neck carcinomas but are not associated with disease progression. The presence of protein in normal mucosa and in non-invasive lesions may constitute a biomarker for early stages of carcinogenesis.	INST GUSTAVE ROUSSY,PHARMACOL CLIN & MOLEC LAB,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT ANATOMOPATHOL,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94800 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy								ADAMSON R, 1994, ONCOGENE, V9, P2077; ANWAR K, 1993, INT J CANCER, V53, P952; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BENNETT WP, 1992, CANCER RES, V52, P6092; BENNETT WP, 1993, CANCER RES, V53, P4817; BOURHIS J, 1994, INT J CANCER, V57, P458, DOI 10.1002/ijc.2910570403; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1993, CANCER RES, V53, P3667; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHUNG KY, 1993, CANCER RES, V53, P1676; CORDONCARDO C, 1994, CANCER RES, V54, P794; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DENG G, 1994, CANCER RES, V54, P499; DOLCETTI R, 1992, INT J CANCER, V52, P178, DOI 10.1002/ijc.2910520204; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207; Hill C., 1993, EVOLUTION MORTALITE; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEES M, 1993, CANCER RES, V53, P4189; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PUISIEUX A, 1991, CANCER RES, V51, P6185; RICHARD JM, 1987, LARYNGOSCOPE, V97, P97; RIOU G, 1993, J NATL CANCER I, V85, P1765, DOI 10.1093/jnci/85.21.1765; RIOU G, 1995, IN PRESS MOL CARCINO; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SHENG ZM, 1990, BRIT J CANCER, V62, P398, DOI 10.1038/bjc.1990.306; SHIN DM, 1994, CANCER RES, V54, P321; SLOOTWEG PJ, 1994, ORAL ONCOL, V30B, P138; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG LD, 1993, CANCER RES, V53, P1783; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	57	216	219	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1217	1227						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700647				2022-12-25	WOS:A1995QN35300024
J	MILARSKI, KL; ZHU, GC; PEARL, CG; MCNAMARA, DJ; DOBRUSIN, EM; MACLEAN, D; THIEMESEFLER, A; ZHANG, ZY; SAWYER, T; DECKER, SJ; DIXON, JE; SALTIEL, AR				MILARSKI, KL; ZHU, GC; PEARL, CG; MCNAMARA, DJ; DOBRUSIN, EM; MACLEAN, D; THIEMESEFLER, A; ZHANG, ZY; SAWYER, T; DECKER, SJ; DIXON, JE; SALTIEL, AR			SEQUENCE SPECIFICITY IN RECOGNITION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY PROTEIN-TYROSINE PHOSPHATASE-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; PHOSPHOLIPASE-C; SH2 DOMAINS; TRANSFORMING ACTIVITY; CYTOPLASMIC PROTEIN; KINASE-ACTIVITY; HOMOLOGY; CLONING; CDNA; EXPRESSION	Protein tyrosine phosphatases all contain a conserved cysteine that forms an intermediate thiophosphate ester bond during tyrosine phosphate hydrolysis. A bacterial glutathione S-transferase fusion protein containing rat brain phosphatase PTP1b was constructed in which this conserved cysteine was mutated to serine. The resulting catalytically inactive enzyme was labeled in vivo to high specific activity with S-35, and the binding of this labeled fusion protein to the immunoprecipitated epidermal growth factor (EGF) receptor was evaluated. The binding was ligand-dependent, and saturation analysis revealed a nonlinear Scatchard plot, with a K(d) for high affinity binding of approximately 100 nM. A number of glutathione S-transferase fusion proteins containing src homology 2 (SH2) domains attenuated phosphatase binding in a concentration-dependent manner. Phospholipase C (PLC)gamma and the GTPase-activating protein of ras were the most potent inhibitors. Tyrosine-phosphorylated EGF receptor peptide fragments were evaluated for specific inhibition of PTP1b and PLCgamma SH2 binding to the activated receptor. One such peptide, modeled on EGF receptor tyrosine 992, blocked the binding of both fusion proteins. Another phosphopeptide, modeled on tyrosine 1148, inhibited the binding of PTP1b but not the PLCgamma fusion protein. This site specificity was confirmed by analysis of equilibrium binding of the fusion proteins to EGF receptors mutated in each of these phosphorylation sites. The results revealed clear sequence specificity in the binding of proteins involved in the regulation of intracellular signaling by receptor tyrosine kinases.	PARKE DAVIS & CO,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,2800 PLYMOUTH RD,ANN ARBOR,MI 48105; PARKE DAVIS & CO,DIV PHARMACEUT RES,DEPT CHEM,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Pfizer; Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCNAMARA DJ, 1993, IN PRESS INT J PEPT; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	44	95	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23634	23639						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693694				2022-12-25	WOS:A1993MF51500102
J	COOK, SP; BABCOCK, DF				COOK, SP; BABCOCK, DF			SELECTIVE MODULATION BY CGMP OF THE K+ CHANNEL ACTIVATED BY SPERACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERMATOZOA; EGG PEPTIDE SPERACT; DEPENDENT PROTEIN-KINASE; POTASSIUM CHANNELS; GUANYLATE-CYCLASE; CYCLIC-GMP; HEMICENTROTUS-PULCHERRIMUS; PLASMA-MEMBRANE; RECEPTOR; CALCIUM	The egg peptide speract stimulates sperm guanylyl cyclase and presumably enhances fertilization, but the roles of cGMP in sperm responses are yet undetermined. Here we show that speract-induced accumulation of cGMP or cAMP is selectively enhanced by the phosphodiesterase inhibitors, 3-isobutyl-1-methylxanthine (IBMX) or papaverine, respectively. These inhibitors provided the unusual opportunity to examine the consequences of manipulating cGMP- and cAMP-dependent responses. The following observations suggest that cGMP mediates activation of K channels, the earliest known ionic event in speract signal transduction: 1) both cGMP content and K+ permeability are maximal within 15 s of speract stimulation and both decline after intracellular pH (pH(i)) increases in response to hyperpolarization; 2) IBMX prolongs elevation of cGMP and sustains K+ permeability after pH(i) increases; 3) both cGMP accumulation and K+ permeability also are enhanced when the pH(i) increase is prevented by an elevated concentration of external K+ (K(o)); 4) elevating pH(i) with NH4Cl bypasses the blockade imposed by high K(o) and decreases K+ permeability. Because IBMX antagonizes this action of NH4Cl, these results further suggest that elevation of pH(i) initiates an inactivation of guanylyl cyclase that leads to K channel closure. However, K+ permeability is restored upon subsequent elevation of intracellular [Ca2+] (Ca(i)), indicating either that sperm K channels possess an alternate regulatory mode, or that a distinct Ca2+-activated K permeability also participates in speract signal transduction. Regardless of the mechanism that mediates Ca(i) action, sperm K channels are identified as downstream targets of cGMP and are implicated in a feedback loop that both terminates guanylyl cyclase activity and leads to their own inactivation.	UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Babcock, Donner/0000-0002-4461-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; BABCOCK DF, 1992, P NATL ACAD SCI USA, V89, P6001, DOI 10.1073/pnas.89.13.6001; BENTLEY JK, 1986, BIOL REPROD, V35, P1249, DOI 10.1095/biolreprod35.5.1249; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COOK SP, 1993, J BIOL CHEM, V268; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DANGOTT LJ, 1984, J BIOL CHEM, V259, P3712; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOMINO SE, 1988, J BIOL CHEM, V263, P690; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GARBERS DL, 1982, J BIOL CHEM, V257, P2734; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; GARBERS DL, 1992, CELL, V71, P1; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P2235; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P163; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P151; LEE HC, 1988, DEV BIOL, V126, P91, DOI 10.1016/0012-1606(88)90242-4; LEE HC, 1986, J BIOL CHEM, V261, P6026; LEE HC, 1984, J BIOL CHEM, V259, P5315; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIEVANO A, 1986, DEV BIOL, V112, P253; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; OGRADY SM, 1991, J MEMBRANE BIOL, V124, P159, DOI 10.1007/BF01870460; POTTER LR, 1992, J BIOL CHEM, V267, P14531; REINHART PH, 1991, J NEUROSCI, V11, P1627; SCHACKMANN RW, 1986, J BIOL CHEM, V261, P8719; SCHACKMANN RW, 1989, CELL BIOL FERTILIZAT, P3; SHIMOMURA H, 1986, J BIOL CHEM, V261, P5778; SUZUKI N, 1992, COMP BIOCHEM PHYS B, V102, P679, DOI 10.1016/0305-0491(92)90064-X; SUZUKI N, 1981, BIOCHEM BIOPH RES CO, V99, P1238, DOI 10.1016/0006-291X(81)90752-X; SUZUKI N, 1984, J BIOL CHEM, V259, P4874; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; TOOWICHARANONT P, 1988, J BIOL CHEM, V263, P6877; WELLS JN, 1976, BIOL REPROD, V15, P46, DOI 10.1095/biolreprod15.1.46; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YOSHINO K, 1992, EUR J BIOCHEM, V206, P887, DOI 10.1111/j.1432-1033.1992.tb16997.x; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	43	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22402	22407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693667				2022-12-25	WOS:A1993MD34800035
J	LECHLEIDER, RJ; SUGIMOTO, S; BENNETT, AM; KASHISHIAN, AS; COOPER, JA; SHOELSON, SE; WALSH, CT; NEEL, BG				LECHLEIDER, RJ; SUGIMOTO, S; BENNETT, AM; KASHISHIAN, AS; COOPER, JA; SHOELSON, SE; WALSH, CT; NEEL, BG			ACTIVATION OF THE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SH-PTP2 BY ITS BINDING-SITE, PHOSPHOTYROSINE-1009, ON THE HUMAN PLATELET-DERIVED GROWTH-FACTOR RECEPTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE-PHOSPHATASE; PDGF RECEPTOR; SH3 DOMAINS; PHOSPHORYLATION; IDENTIFICATION; CORKSCREW; SUBUNIT; SIGNAL	Much progress has been made in elucidating early events in signal transduction by growth factor receptors with intrinsic tyrosine kinase activity. Upon ligand addition, these receptors dimerize and activate, becoming phosphorylated at a number of tyrosyl residues. These phosphorylation sites serve as docking points for proteins containing src homology-2 (SH2) domains. However, little is known about how phosphotyrosine phosphatases (PTPs), participate in these events. Recently, we and others molecularly cloned a ubiquitously expressed SH2 domain-containing PTP, SH-PTP2 (Syp, PTP1D, PTP2C), and found that it interacts directly with several activated growth factor receptors via its SH2 domains. Using a peptide competition assay, we now demonstrate that the major binding site for SH-PTP2 on the platelet-derived growth factor receptor is phosphotyrosine 1009. Immunoprecipitation studies indicate that SH-PTP2 is the previously unidentified ''64-kDa'' protein known to bind at this site. Addition of a phosphotyrosyl peptide comprising the region around Tyr-1009 stimulates SH-PTP2 activity 5-10-fold, whereas other phosphotyrosyl peptides from the platelet-derived growth factor receptor have no stimulatory effect. Our data suggest that binding of SH-PTP2 to the activated receptor in vivo should result in stimulation of SH-PTP2 activity.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DIV PULM MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Fred Hutchinson Cancer Center				Bennett, Anton/0000-0001-5187-7599	NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152, R01CA054786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER; NCI NIH HHS [CA54786, CA49152] Funding Source: Medline; NIGMS NIH HHS [GM20011] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1993, IN PRESS P NATL ACAD; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	292	296	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21478	21481						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691811				2022-12-25	WOS:A1993MC80900007
J	VANDERGOOT, FG; AUSIO, J; WONG, KR; PATTUS, F; BUCKLEY, JT				VANDERGOOT, FG; AUSIO, J; WONG, KR; PATTUS, F; BUCKLEY, JT			DIMERIZATION STABILIZES THE PORE-FORMING TOXIN AEROLYSIN IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-HYDROPHILA; MEMBRANE-INSERTION; COLICIN-A; PROTEIN; CHANNEL; OLIGOMERIZATION; IDENTIFICATION; SEDIMENTATION; MUTAGENESIS; RECEPTOR	Aerolysin is a channel-forming protein secreted as a protoxin by Aeromonas hydrophila. Analytical centrifugation measurements showed that proaerolysin is a dimer in solution, and this was confirmed by chemical cross-linking with dimethyl suberimidate. Dissociation of proaerolysin with low concentrations of SDS resulted in the loss of tertiary structure, assessed by near ultraviolet circular dichroism. This was accompanied by an increase in the protein's ability to bind the hydrophobic dye 1-anilino-8-naphthalene sulfonate, as well as by increased sensitivity to proteolytic degradation. However, the monomer was not fully unfolded by the detergent, as the tryptophans remained in a hydrophobic environment, and the secondary structure measured by far ultraviolet circular dichroism did not seem to be affected. Aerolysin, the active form of the protein, was also shown to be a dimer, and its stability was found to be no different from the stability of the protoxin dimer. Substituting tryptophan 371 or tryptophan 373 with leucine greatly reduced the stability of dimeric proaerolysin. These substitutions are known to increase the protein's ability to oligomerize, supporting the conclusion that dimer dissociation is necessary for oligomerization to occur.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,BOX 3055,VICTORIA V8W 3P6,BC,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Victoria; European Molecular Biology Laboratory (EMBL)			van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X				AUSIO J, 1992, BIOPHYS J, V61, P1656, DOI 10.1016/S0006-3495(92)81969-0; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1992, FEBS LETT, V307, P30, DOI 10.1016/0014-5793(92)80896-O; CHAKRABORTY T, 1987, INFECT IMMUN, V55, P2274, DOI 10.1128/IAI.55.9.2274-2280.1987; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P5, DOI 10.1016/0959-440X(91)90004-D; DIRR HW, 1991, BIOCHEM BIOPH RES CO, V180, P294, DOI 10.1016/S0006-291X(05)81291-4; EDELSTEIN SJ, 1967, J BIOL CHEM, V242, P306; EISENBERG H, 1990, EUR J BIOCHEM, V187, P7, DOI 10.1111/j.1432-1033.1990.tb15272.x; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HASCHEMEYER R, 1973, PROTEINS, P206; HOWARD SP, 1985, J BACTERIOL, V161, P1118, DOI 10.1128/JB.161.3.1118-1124.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JANDA JM, 1988, REV INFECT DIS, V10, P980; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; KHARDORI N, 1988, ANNU REV MICROBIOL, V42, P395, DOI 10.1146/annurev.mi.42.100188.002143; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Ptitsyn Oleg B., 1992, P243; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; TANFORD C, 1961, PHYSICAL CHEM MACROM, P327; TUCKER AD, 1990, J MOL BIOL, V212, P561, DOI 10.1016/0022-2836(90)90222-8; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WONG KR, 1991, J BIOL CHEM, V266, P14450; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	33	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18272	18279						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688743				2022-12-25	WOS:A1993LT74300092
J	SANDER, P; LANGERT, W; MUELLER, K				SANDER, P; LANGERT, W; MUELLER, K			MECHANISMS OF UPSTREAM ACTIVATION OF THE RRND PROMOTER P(1) OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; RATE-DEPENDENT REGULATION; PROTEIN; INITIATION; INVITRO; FIS; POLYMERASE; OPERONS; INVIVO; REGION	The rrn promoter regions of Escherichia coli contain a stretch of DNA, rich in A(n) and T(n) homopolymer sequences, which is located upstream of the tandem promoters P1 and P2. We have studied the effects of the upstream sequence of the rrnD operon on promoter function, using deletion variants for in vitro transcription. The presence of the upstream activating sequence (UAS) was found to increase P1 promoter strength without influencing P2. Two modes of P1 activation could be distinguished: a stimulation of P1 depending on the interaction of the factor of inversion stimulation (FIS) with the UAS (within the deletion boundaries of -50 and -112) and second, a factor-independent activation requiring the proximal part of the UAS (within the boundaries of -50 and -89). Both modes of activation were previously observed in the case of the rrnB operon and were ascribed to increased constants of RNA polymerase binding to P1 (Leirmo, S., and Gourse, R. L. (1991) J. Mol. Biol. 220, 555-568; Zacharias, M., Theissen, G., Bradaczek, C., and Wagner, R. (1991) Biochimie 73, 699-712). Our results show, however, that the mechanisms of upstream activation may vary with the reaction conditions. In a complex transcription system, originally designed for the use of cell extracts, FIS enhances first-order reactions that convert binary (open) complexes to transcribing complexes. Initiated complexes are stabilized by FIS. The factor-independent mode of P1 activation involves influences of the UAS on complex isomerizations as well as on binary complex formation. The results show that low molecular weight components of the complex transcription system change the function of the RNA polymerase at the rrn promoters (not at the reference promoter P(tac)), so that the conversion of open to transcribing P1-complexes becomes dependent on the UAS and FIS.	INST ALLGEMEINE ZOOL & GENET,SCHLOSSPL 5,W-4400 MUNSTER,GERMANY				Sander, Peter/D-2548-2009	Sander, Peter/0000-0003-1581-0682				Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CICHON C, 1990, THESIS WESTF WILHELM; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; ESCHERT H, 1992, THESIS WESTF WILHELM; GAAL T, 1989, J BACTERIOL, V171, P4852, DOI 10.1128/jb.171.9.4852-4861.1989; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HUBNER P, 1989, EMBO J, V8, P577, DOI 10.1002/j.1460-2075.1989.tb03412.x; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; JOSAITIS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P312; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; LANGERT W, 1991, J BIOL CHEM, V266, P21608; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OZAKI M, 1992, NUCLEIC ACIDS RES, V20, P257, DOI 10.1093/nar/20.2.257; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDER P, 1992, THESIS WESTF WILHELM; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SCHAFER R, 1973, EUR J BIOCHEM, V33, P207, DOI 10.1111/j.1432-1033.1973.tb02671.x; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; VERBEEK H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P302, DOI 10.1016/0167-4781(90)90185-5; VERBEEK H, 1992, NUCLEIC ACIDS RES, V20, P4077, DOI 10.1093/nar/20.15.4077; YOUNG RA, 1979, CELL, V17, P225, DOI 10.1016/0092-8674(79)90310-6; ZACHARIAS M, 1991, BIOCHIMIE, V73, P699, DOI 10.1016/0300-9084(91)90050-B	35	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16907	16916						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688719				2022-12-25	WOS:A1993LQ98800010
J	KWATRA, MM; SCHWINN, DA; SCHREURS, J; BLANK, JL; KIM, CM; BENOVIC, JL; KRAUSE, JE; CARON, MG; LEFKOWITZ, RJ				KWATRA, MM; SCHWINN, DA; SCHREURS, J; BLANK, JL; KIM, CM; BENOVIC, JL; KRAUSE, JE; CARON, MG; LEFKOWITZ, RJ			THE SUBSTANCE-P RECEPTOR, WHICH COUPLES TO GQ/11, IS A SUBSTRATE OF BETA-ADRENERGIC-RECEPTOR KINASE-1 AND KINASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; ALPHA-SUBUNITS; BINDING-PROTEIN; PURIFICATION; PHOSPHORYLATION; IDENTIFICATION; ARRESTIN; AFFINITY; FAMILY; GTP	The agonist-occupied forms of several G-protein-coupled receptors that modulate the activity of adenylylcyclase via G(s) (e.g. beta2-adrenergic) or G(i) (e.g. alpha2-adrenergic and cardiac muscarinic) are phosphorylated by beta-adrenergic receptor kinases (betaARK 1 and betaARK 2). BetaARK-catalyzed phosphorylation of these receptors appears to correlate with their agonist-induced desensitization. The possibility that betaARK isozymes may also be involved in the desensitization of other G-protein-coupled receptors such as those mediating phosphoinositide (PI) hydrolysis was tested by determining the phosphorylation of the substance P receptor (SPR), which is coupled to PI hydrolysis in numerous tissues. Rat SPR was expressed in Sf9 cells, partially purified, and reconstituted in phospholipid vesicles. The reconstituted SPR bound the SPR agonist substance P, I-125-labeled with Bolton-Hunter reagent, with low affinity. However, addition of purified Gq/11 to the reconstituted SPR resulted in the conversion of all the receptors to a high affinity state, suggesting that SPR couples to Gq/11. Phosphorylation of the reconstituted SPR with purified betaARK 1 or 2 in the absence and presence of substance P (SP) was then studied. In the presence of 100 muM SP, both kinases promoted phosphorylation of the receptor to a stoichiometry of 9 +/- 2 mol of phosphate/mol of receptor. However, no phosphorylation of the receptor could be detected in the absence of agonist. Agonist-induced phosphorylation of the receptor was blocked by coincubation with the SPR antagonist spantide. These results show that. BetaARK isozymes may regulate the function both adenylylcyclase as well as PI-coupled receptors, and suggest a role for betaARK isozymes in SPR signal transduction.	DUKE UNIV,MED CTR,DEPT ANESTHESIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DURHAM,NC 27710; CHIRON CORP,EMERYVILLE,CA 94608; VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Duke University; Duke University; Duke University; Novartis; Howard Hughes Medical Institute; Vanderbilt University; Jefferson University; Washington University (WUSTL)	KWATRA, MM (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3821,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021; Kwatra, Madan/ABD-2008-2020	Schwinn, Debra/0000-0002-9696-5231	NHLBI NIH HHS [4R37-HL 16037, HL 02490] Funding Source: Medline; NINDS NIH HHS [NS 29343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002490, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MACDONALD SG, 1989, J NEUROCHEM, V53, P264, DOI 10.1111/j.1471-4159.1989.tb07323.x; MORISHIMA Y, 1989, J NEUROCHEM, V53, P1428, DOI 10.1111/j.1471-4159.1989.tb08534.x; NAKATA Y, 1988, J NEUROCHEM, V50, P522, DOI 10.1111/j.1471-4159.1988.tb02942.x; PANG IH, 1990, J BIOL CHEM, V265, P18707; PUTNEY JW, 1991, ANN NY ACAD SCI, V632, P94, DOI 10.1111/j.1749-6632.1991.tb33097.x; REILANDER H, 1991, FEBS LETT, V282, P441, DOI 10.1016/0014-5793(91)80532-8; SEGAWA T, 1991, COMP BIOCH PHYSL C, V98, P146; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; VEENMAN CL, 1992, NEUR ABSTR, V18, P1165; WEBB N R, 1990, Technique (Philadelphia), V2, P173; YAKOTA Y, 1989, J BIOL CHEM, V264, P17649	30	192	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9161	9164						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683643				2022-12-25	WOS:A1993LA68900002
J	BRAUNINGER, A; KARN, T; STREBHARDT, K; RUBSAMENWAIGMANN, H				BRAUNINGER, A; KARN, T; STREBHARDT, K; RUBSAMENWAIGMANN, H			CHARACTERIZATION OF THE HUMAN CSK LOCUS	ONCOGENE			English	Note							PROTEIN-TYROSINE KINASE; RECEPTOR GENE; SEQUENCE; PHOSPHORYLATION; PP60C-SRC; PROTOONCOGENE; EXPRESSION; ONCOGENES; CLONING; DOMAINS	The CSK-gene encodes an intracellular protein-tyrosine kinase (PTK). In contrast to members of the src-family, an autophosphorylation site corresponding to Tyr416, as well as the equivalent of the regulatory Tyr527 in p60c-src are missing in the amino acid sequence deduced from the gene. CSK phosphorylates other members of the src-family of tyrosine kinases at their regulatory carboxy-terminus. By regulating the activity of these kinases, CSK may play an important role in cell growth and development. Here we describe the structure of the human CSK gene. The entire coding region spans a genomic distance of only 4.9 kb. It encompasses 12 exons ranging between 66 and 220 bp in size. The introns between coding exons vary between 76 and 920 bp in length. An exon coding for the 5'-untranslated region of CSK is separated from the first coding exon by an intron of more than 6400 bp. Based on comparisons of sequence homologies within the catalytic domains, the intracellular PTKs are divided into the src-family, the fes/fer- and the abl/arg-group. The genomic structure of four members of the SRC-family revealed nearly identical exon/intron boundaries within the catalytic domain of this family. They differ from those described for FES. Comparing the genomic structure of CSK with the exon/intron organisation of both, it is obvious that the exon/intron boundaries are in common either with those of the SRC-type or the FES boundaries. This intermediate exon/intron structure of CSK between FES and the SRC-family agrees with the position of CSK in a phylogenetic tree based on sequence homology within the kinase domain.	CHEMOTHERAPEUT FORSCHUNGSINST,GEORG SPEYER HAUS,PAUL EHRLICH STR 42-44,W-6000 FRANKFURT 70,GERMANY	Octapharma			karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019; Strebhardt, Klaus/E-8765-2011	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ANDRE C, 1992, ONCOGENE, V7, P685; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HRADETZKY D, 1992, GENE, V113, P275, DOI 10.1016/0378-1119(92)90407-G; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATEL M, 1990, ONCOGENE, V5, P201; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	37	23	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1365	1369						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683131				2022-12-25	WOS:A1993KY32800030
J	ZANDER, NF; COOL, DE; DILTZ, CD; ROHRSCHNEIDER, LR; KREBS, EG; FISCHER, EH				ZANDER, NF; COOL, DE; DILTZ, CD; ROHRSCHNEIDER, LR; KREBS, EG; FISCHER, EH			SUPPRESSION OF V-FMS-INDUCED TRANSFORMATION BY OVEREXPRESSION OF A TRUNCATED T-CELL PROTEIN TYROSINE PHOSPHATASE	ONCOGENE			English	Article							FELINE SARCOMA-VIRUS; MCDONOUGH STRAIN; GROWTH-FACTOR; EXPRESSION; RECEPTOR; ACTIVATION; BINDING; CLONING; ANTIGEN; KINASE	Rat 2 cells stably transformed by murine v-fms (pB5 cells) were infected with retroviruses containing a human cDNA encoding either a full-length human T-cell protein tyrosine phosphatase (TC.PTP) or a truncated form (DELTAC11.PTP) in which an 11-kDa carboxy-terminal extension had been removed. This segment is responsible for enzyme localization and regulation. Clonal cell lines were isolated following G418 selection and their transforming properties analysed; pB5 cells containing the vector alone or TC.PTP remained transformed. These cells grew readily in soft agar, formed tumors in nude mice and were morphologically indistinguishable from the parental pB5 cells. In contrast, cells expressing DELTAC11.PTP showed dramatic changes in cell morphology, loss of anchorage-independent growth in soft agar and reduced or lack of tumor formation in nude mice. Both increases and decreases in tyrosine phosphorylation of specific proteins in the cells overexpressing the truncated enzyme were detected. These results indicate that coexpression of the deregulated, soluble tyrosine phosphatase with a constitutively active, oncogenic receptor tyrosine kinase leads to the suppression of the transformed phenotype.	UNIV WASHINGTON,DEPT BIOCHEM,SJ 70,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT PHARMACOL,SL 15,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								ALEXANDER D R, 1990, New Biologist, V2, P1049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BROWNSHIMER S, 1992, CANCER RES, V52, P1234; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHERR CJ, 1991, SEMIN HEMATOL, V28, P143; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORDTHOMAS T, 1992, J CELL BIOL, V117, P401; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	34	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1175	1182						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683129				2022-12-25	WOS:A1993KY32800008
J	DAGA, A; MICOL, V; HESS, D; AEBERSOLD, R; ATTARDI, G				DAGA, A; MICOL, V; HESS, D; AEBERSOLD, R; ATTARDI, G			MOLECULAR CHARACTERIZATION OF THE TRANSCRIPTION TERMINATION FACTOR FROM HUMAN MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNALEU(UUR) GENE; SODIUM DODECYL-SULFATE; STROKE-LIKE EPISODES; RIBOSOMAL-RNA; INVITRO TRANSCRIPTION; GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; LACTIC-ACIDOSIS; MELAS SUBGROUP; POINT MUTATION	The transcription termination factor (mTERF), which plays a central role in the control of mitochondrial rRNA and mRNA synthesis in mammalian mitochondria, has been previously identified and purified by DNA affinity chromatography from a human mitochondrial lysate (Kruse, B., Narasimhan, N., and Attardi, G. (1989) Cell 58, 391-397). In the present work, this factor has been characterized as to its protein composition and the activities of the protein components. Three polypeptides, two of approximately 34-kDa molecular mass and one of approximately 31 kDa, were shown to be associated with the specific DNA binding and footprinting activity of the factor, with the 31-kDa component having a much lower affinity for the recognition sequence than the 34-kDa components. On the other hand, the transcription termination activity, as assayed in an in vitro system, was found to be associated exclusively with the two 34-kDa polypeptides. Mass spectroscopic analysis of tryptic peptides derived from highly purified polypeptides indicated that all three polypeptides share regions with common sequences. The evidence obtained suggests that differential phosphorylation is not responsible for the difference in electrophoretic mobility of the three polypeptides.			DAGA, A (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Micol, Vicente/K-6841-2014; daga, andrea/J-1865-2018	daga, andrea/0000-0001-8935-5489; Micol, Vicente/0000-0001-8089-0696	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GAINES G, 1987, J BIOL CHEM, V262, P1907; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; MAHURAN D, 1983, ANAL BIOCHEM, V129, P513, DOI 10.1016/0003-2697(83)90585-7; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI USA, V79, P7179; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; SHUEY DJ, 1985, J BIOL CHEM, V260, P1952; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; YOZA BK, 1984, J BIOL CHEM, V259, P3909	27	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8123	8130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681833				2022-12-25	WOS:A1993KW97900077
J	LAVAN, BE; LIENHARD, GE				LAVAN, BE; LIENHARD, GE			THE INSULIN-ELICITED 60-KDA PHOSPHOTYROSINE PROTEIN IN RAT ADIPOCYTES IS ASSOCIATED WITH PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; ENDOGENOUS SUBSTRATE; SEQUENCE-ANALYSIS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PURIFICATION; PI3-KINASE; TRANSPORT; LIPOLYSIS	Insulin stimulates the tyrosine phosphorylation of a 60-kDa protein (pp60) in rat adipocytes. After insulin treatment of these cells, pp60, as well as the 160-kDa insulin receptor substrate-1 (IRS-1), were found to be associated with the enzyme phosphatidylinositol 3-kinase (PtdIns-3-kinase) in separate complexes. By contrast, pp60 was not detected in insulin-treated mouse 3T3-L1 adipocytes, which contain abundant IRS-1.PtdIns-3-kinase complex. The pp60.PtdIns 3-kinase complex was located in both the soluble and membrane fractions of the rat adipocytes. Fusion proteins containing the isolated src homology 2 domains from the 85-kDa subunit of PtdIns-3-kinase bound to pp60 in lysates of insulin-treated rat adipocytes. This finding indicates that the most likely mode of association of pp60 with PtdIns-3-kinase is through binding of phosphotyrosine residues in pp60 to these domains. By immunoaffinity chromatography on a monoclonal antibody against phosphotyrosine, pp60 was purified in high percentage yield from insulin-stimulated rat adipocytes, but the low amount of the protein obtained (about 3 ng from the adipocytes of one rat) precluded sequence analysis.	DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College					NIDDK NIH HHS [DK 42816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABLER A, 1992, J BIOL CHEM, V267, P3946; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EZAKI O, 1989, J BIOL CHEM, V264, P16118; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; KASAHARA T, 1990, BIOCHIM BIOPHYS ACTA, V1054, P89, DOI 10.1016/0167-4889(90)90209-V; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1992, DIABETES S1, V41, pA167; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OKAMOTO M, 1991, DIABETES, V40, P66, DOI 10.2337/diabetes.40.1.66; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROTHENBERG PL, 1991, DIABETES S1, V40, pA242; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	42	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5921	5928						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680652				2022-12-25	WOS:A1993KR82200085
J	AUSSEL, C; BREITTMAYER, JP; PELASSY, C; BERNARD, A				AUSSEL, C; BREITTMAYER, JP; PELASSY, C; BERNARD, A			CALMODULIN, A JUNCTION BETWEEN 2 INDEPENDENT IMMUNOSUPPRESSIVE PATHWAYS IN JURKAT T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; PHOSPHATIDYLSERINE SYNTHESIS; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID-METABOLISM; INTERLEUKIN-2 SYNTHESIS; ANTIGEN RECEPTOR; PROTEIN PHOSPHATASES; INTRACELLULAR CA-2+; AMPHIPHILIC CATIONS; PLASMA-MEMBRANE	Calmodulin (CaM) antagonists chlorpromazine, trifluoperazine, and N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide HCl inhibit Jurkat T cell activation, as monitored by measuring interleukin-2 synthesis in cells treated by a combination of CD3 monoclonal antibody and phorbol myristate acetate. T cell activation with CD3 monoclonal antibody is accompanied by a decreased synthesis of phosphatidylserine due to the release of Ca2+ from the endoplasmic reticulum, CaM antagonists reverse the phosphatidylserine (PtdSer) inhibition induced by CD3. This increase of PtdSer synthesis was observed in the absence of any modification of CD3 induced Ca2+ movements, Both in intact cells and in an acellular system, the increase of PtdSer synthesis induced by CaM antagonists was abolished in the presence of EGTA, indicating that the base exchange enzyme system responsible for PtdSer synthesis is regulated by CaM provided that Ca2+ is present, By contrast, cyclosporin A that inhibits T cell activation through the interaction of cyclophilin cyclosporin A complexes with the calmodulin-activated phosphatase, calcineurin, had no effect on PtdSer synthesis, Calmodulin thus appears as a junction leading to at least two independent pathways of regulation of T cell activation, one involving the calcineurin phosphatase and the other the base exchange enzyme system responsible for PtdSer synthesis.			AUSSEL, C (corresponding author), HOP ARCHET,INSERM,U343,BP 79,F-06202 NICE 03,FRANCE.							AUSSEL C, 1992, FEBS LETT, V304, P281, DOI 10.1016/0014-5793(92)80638-W; AUSSEL C, 1993, J LIPID MEDIATOR, V7, P99; AUSSEL C, 1991, J LIPID MEDIATOR, V3, P267; AUSSEL C, 1990, IMMUNOPHARMACOLOGY, V20, P97, DOI 10.1016/0162-3109(90)90012-4; AUSSEL C, 1994, CELL IMMUNOL, V155, P436, DOI 10.1006/cimm.1994.1136; AUSSEL C, 1992, CELL IMMUNOL, V139, P333, DOI 10.1016/0008-8749(92)90075-Z; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITTMAYER JP, 1993, CELL IMMUNOL, V149, P248, DOI 10.1006/cimm.1993.1152; BUCHANAN AG, 1980, J NEUROCHEM, V34, P814; CZARNY M, 1992, BIOCHEM BIOPH RES CO, V186, P1582, DOI 10.1016/S0006-291X(05)81588-8; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; FERRUA B, 1987, J IMMUNOL METHODS, V97, P215, DOI 10.1016/0022-1759(87)90462-5; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GELFAND EW, 1989, ADV REGULATION CELL, V1, P119; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMBODEN JB, 1985, J IMMUNOL, V134, P663; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANFER JN, 1993, J NEUROCHEM, V60, P1228, DOI 10.1111/j.1471-4159.1993.tb03281.x; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARY D, 1987, J IMMUNOL, V139, P1179; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NIWA Y, 1986, ARCH BIOCHEM BIOPHYS, V250, P345, DOI 10.1016/0003-9861(86)90736-8; PELASSY C, 1991, J LIPID MEDIATOR, V4, P199; PELASSY C, 1992, BIOCHEM J, V288, P785, DOI 10.1042/bj2880785; PELASSY C, 1992, BIOCHEM J, V282, P443, DOI 10.1042/bj2820443; PELASSY C, 1989, CELL SIGNAL, V1, P99, DOI 10.1016/0898-6568(89)90024-7; RASMUSSEN C, 1994, EMBO J, V13, P2545, DOI 10.1002/j.1460-2075.1994.tb06544.x; SINGH IN, 1992, J LIPID MEDIATOR, V5, P301; SINGH IN, 1992, FEBS LETT, V2, P166; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	37	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8032	8036		10.1074/jbc.270.14.8032	http://dx.doi.org/10.1074/jbc.270.14.8032			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713904	hybrid			2022-12-25	WOS:A1995QR52600040
J	FREEDMAN, SJ; FURIE, BC; FURIE, B; BALEJA, JD				FREEDMAN, SJ; FURIE, BC; FURIE, B; BALEJA, JD			STRUCTURE OF THE METAL-FREE GAMMA-CARBOXYGLUTAMIC ACID-RICH MEMBRANE-BINDING REGION OF FACTOR-IX BY 2-DIMENSIONAL NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO ANTICOAGULANT ACTIVITY; COAGULATION FACTOR-IX; ACTIVATED PROTEIN-C; PROTHROMBIN FRAGMENT-1; BLOOD-COAGULATION; GLA DOMAIN; SITE; SEQUENCE; RESIDUES; VARIANT	The gamma-carboxyglutamic acid-rich domain of blood coagulation Factor IX is required for the binding of the protein to phospholipid membranes. To investigate the three-dimensional structure of this domain, a synthetic peptide corresponding to residues 1-47 of Factor IX was studied by H-1 NMR spectroscopy. In the absence of metal ions, the proton chemical shift dispersion in the one-dimensional NMR spectrum indicated that the peptide contains regular structural elements. Upon the addition of Ca(II) or Mg(II), large chemical shift changes were observed in the amide proton and methyl proton regions of the spectrum, consistent with the conformational transitions that metal ions are known to induce in native Factor IX. The apopeptide was studied by two-dimensional NMR spectroscopy at 500 MHz to determine its solution structure. Protons were assigned using total correlation spectroscopy, nuclear Overhauser effect spectroscopy, and double quantum-filtered correlation spectroscopy experiments. Intensities of cross-peaks in the nuclear Overhauser effect spectrum were used to generate a set of interproton distance restraints. The structure of the apopeptide was then calculated using distance geometry methods. There are three structural elements in the apopeptide that are linked by a flexible polypeptide backbone. These elements include a short amino-terminal tetrapeptide loop (amino acids 6-9), the disulfide-containing hexapeptide loop (amino acids 18-23), and a carboxyl-terminal alpha helix (amino acids 37-46). Amide hydrogen exchange kinetics indicate that the majority of the peptide is solvent accessible, except in the carboxyl-terminal element. The structured regions in the apopeptide are insufficient to support phospholipid binding, indicating the importance of additional structural features in the Ca(II)-stabilized conformer.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; SACKLER SCH BIOMED SCI,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111	Tufts University; Tufts University; Tufts Medical Center					NHLBI NIH HHS [HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; FREEDMAN SJ, 1994, BLOOD, V84, P531; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HARLOS K, 1987, FEBS LETT, V224, P97, DOI 10.1016/0014-5793(87)80429-5; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JACOBS M, 1994, J BIOL CHEM, V269, P25494; JONES ME, 1985, BIOCHEMISTRY-US, V24, P8064, DOI 10.1021/bi00348a034; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; MORITA T, 1984, J BIOL CHEM, V259, P5698; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; SPERLING R, 1978, J BIOL CHEM, V253, P3898; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAPATA GA, 1987, FASEB J, V46, P2230; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1994, J BIOL CHEM, V269, P3590; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	29	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7980	7987		10.1074/jbc.270.14.7980	http://dx.doi.org/10.1074/jbc.270.14.7980			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713897	hybrid			2022-12-25	WOS:A1995QR52600033
J	HOLMES, EH; XU, ZH; SHERWOOD, AL; MACHER, BA				HOLMES, EH; XU, ZH; SHERWOOD, AL; MACHER, BA			STRUCTURE-FUNCTION ANALYSIS OF HUMAN ALPHA-1-]3FUCOSYLTRANSFERASES - A GDP-FUCOSE-PROTECTED, N-ETHYLMALEIMIDE-SENSITIVE SITE IN FUCT-III AND FUCT-V CORRESPONDS TO SER(178) IN FUCT-IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; SUBSTRATE SPECIFICITIES; CARBOHYDRATE ANTIGENS; DETERMINES EXPRESSION; NEGATIVE INDIVIDUALS; LACTOSE SYNTHETASE; MOLECULAR-CLONING; HUMAN-MILK; LEWIS-X; TRANSFERASE	Human alpha 1-->3fucosyltransferases constitute a family of closely related membrane-bound enzymes distinguished by differences in acceptor specificities and inherent protein biochemical properties. One such biochemical property is sensitivity to enzyme inactivation by sulfhydral-group modifying reagents such as N-ethylmaleimide. The basis for this property has been studied using a fusion protein of FucT-III anf FucT-V composed of protein A coupled to the catalytic domain of the enzyme. The results indicate that modification of FucT-V by 5,5'-dithiobis(2-nitrobenzoic acid) resulted in efficient enzyme inactivation that could be reversed by excess thiol reagent suggesting that the free sulfhydral group on the enzyme was required for activity. Recombinant forms of both FucT-III and FucT-V were irreversibly inactivated by N-ethylmaleimide and could be effectively protected from inactivation by GDP-fucose and GDP but not by UDP-galactose, fucose, or N-acetyllactosamine. Analysis of the distribution of Cys residues in aligned sequences of cloned human alpha 1-->3fucosyltransferases indicated one site, Cys(143) of FucT-III and Cys(156) of FucT-V, corresponded to the highly conservative replacement of Ser(178) in FucT-IV, an enzyme insensitive to N-ethylmaleimide. A site-directed mutagenesis experiment was performed to replace Ser(178) of FucT-IV with a Cys residue. The mutant FucT-IV enzyme was active; however, the K-m for GDP-fucose was increased about 3-fold compared to the native enzyme to 28 +/- 3 mu M. This enzyme was N-ethylmaleimide sensitive and could be partially protected by GDP-fucose but not N-acetyllactosamine. These results support the importance of Ser(178) of FucT-IV in donor substrate binding and strongly suggest analogous Cys residues are the GDP-fucose protectable, N-ethylmaleimide-sensitive sites present in FucT-III and -V.	SAN FRANCISCO STATE UNIV, DEPT CHEM & BIOCHEM, SAN FRANCISCO, CA 94132 USA	California State University System; San Francisco State University	HOLMES, EH (corresponding author), PACIFIC NW RES FDN, 720 BROADWAY, SEATTLE, WA 98122 USA.				NCI NIH HHS [CA41521, CA32826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041521, R01CA032826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALHADEFF JA, 1989, CRIT REV ONCOL HEMAT, V9, P37, DOI 10.1016/S1040-8428(89)80014-9; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DEVRIES T, 1995, IN PRESS J BIOL CHEM; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; GINSBURG V, 1966, METHOD ENZYMOL, V8, P293; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HEDA GD, 1992, NUCLEIC ACIDS RES, V20, P5241, DOI 10.1093/nar/20.19.5241; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; HOLMES EH, 1985, J BIOL CHEM, V260, P7619; KITCHEN BJ, 1974, BIOCHEM J, V141, P173, DOI 10.1042/bj1410173; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MAGEE SC, 1974, J BIOL CHEM, V249, P6992; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; OKEEFFE ET, 1980, BIOCHEMISTRY-US, V19, P4954, DOI 10.1021/bi00563a003; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P14730; STROUP GB, 1990, CANCER RES, V50, P6787; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257	43	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8145	8151		10.1074/jbc.270.14.8145	http://dx.doi.org/10.1074/jbc.270.14.8145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713918	hybrid			2022-12-25	WOS:A1995QR52600057
J	SYMES, AJ; RAJAN, P; CORPUS, L; FINK, JS				SYMES, AJ; RAJAN, P; CORPUS, L; FINK, JS			C/EBP-RELATED SITES IN ADDITION TO A STAT SITE ARE NECESSARY FOR CILIARY NEUROTROPHIC FACTOR-LEUKEMIA FACTOR-DEPENDENT TRANSCRIPTIONAL ACTIVATION BY THE VASOACTIVE-INTESTINAL-PEPTIDE CYTOKINE RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; ACUTE-PHASE RESPONSE; NEUROBLASTOMA CELL-LINE; INHIBITORY FACTOR; TYROSINE PHOSPHORYLATION; NUCLEAR FACTOR; ONCOSTATIN-M; SIGNAL-TRANSDUCTION; LEUCINE ZIPPER; CNTF RECEPTOR	The neuropoietic cytokines ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) regulate VIP gene expression through a cytokine response element (CyRE) which interacts with members of the STAT transcription factor family. The CyRE STAT site is, however, insufficient to mediate full transcriptional activation by CNTF/LIF, suggesting that other sequences and nuclear proteins are also important. As C/EBP proteins participate in the transcriptional effects of the related cytokine, interleukin-6, we investigated the role of possible C/EBP-binding sites in the response of the VIP CyRE to CNTF/LIF. Using DNase I footprinting, transactivation studies, DNA mobility shift assays, and mutational analysis, three sites within the VIP CyRE were identified as C/EBP-related binding sites and shown to be important to CNTF/LIF-mediated transcriptional activation. The CyRE C/EBP-related sites interact with nuclear proteins from the human neuroblastoma cell Line, NBFL, including a novel, protein synthesis-dependent, nuclear protein complex, induced by CNTF treatment, These nuclear proteins are not, however, recognized by antisera to known C/EBP proteins, Therefore, other nuclear proteins regulated by independent pathways act in concert with the JAK-STAT pathway to mediate CNTF/LIF regulation of VIP gene expression through the CyRE.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,MOLEC NEUROBIOL LAB,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital			Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	NINDS NIH HHS [NS27514] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FANN MJ, 1993, J NEUROCHEM, V61, P1349, DOI 10.1111/j.1471-4159.1993.tb13628.x; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HALL AK, 1992, TRENDS NEUROSCI, V15, P35, DOI 10.1016/0166-2236(92)90022-Z; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Ip Nancy Y., 1994, Current Opinion in Neurobiology, V4, P400, DOI 10.1016/0959-4388(94)90102-3; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LO DC, 1993, P NATL ACAD SCI USA, V90, P2557, DOI 10.1073/pnas.90.7.2557; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUDLAM WH, 1994, DEV BIOL, V164, P528, DOI 10.1006/dbio.1994.1221; MONTMINY M, 1986, J NEUROSCI, V6, P1161; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; NAWA H, 1990, COLD SH Q B, V55, P247; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAITO T, 1991, J IMMUNOL, V147, P168; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TSUKADA T, 1985, DNA-J MOLEC CELL BIO, V4, P293, DOI 10.1089/dna.1985.4.293; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	76	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8068	8075		10.1074/jbc.270.14.8068	http://dx.doi.org/10.1074/jbc.270.14.8068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713908	hybrid			2022-12-25	WOS:A1995QR52600046
J	ABE, T; ARAKAWA, Y; RAJASEKARAN, AK; YU, TH; WADA, O				ABE, T; ARAKAWA, Y; RAJASEKARAN, AK; YU, TH; WADA, O			INTERACTION OF ATRIAL-NATRIURETIC-PEPTIDE WITH ITS RECEPTORS IN BOVINE LUNG MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PARTICULATE GUANYLATE-CYCLASE; VASCULAR SMOOTH-MUSCLE; CYCLIC-GMP ACCUMULATION; LEYDIG TUMOR-CELLS; LIGAND-BINDING; PURIFICATION; RAT; ENDOPEPTIDASE-24.11; INTERNALIZATION	In bovine lung membranes, atrial natriuretic peptide (ANP) showed temperature-dependent binding to guanylate cyclase-natriuretic peptide receptor (NPR-GC). Photoaffinity labeling of the receptors with 4-azidobenzoyl (AZB)-I-125-ANP and competitive binding studies with I-125-ANP, ANP and atriopeptin I (API) revealed that NPR-GC was detected as the predominant ANP-binding protein at 0 degrees C, whereas at 37 degrees C natriuretic peptide clearance receptor (NPR-C) was detected as the predominant protein. The ratio of NPR-GC and NPR-C was 89:11 at 0 degrees C for 40 min, respectively, whereas 6:94 at 37 degrees C, AZB-I-125-ANP bound to NPR-GC dissociated from the binding site within 5 min at 37 degrees C but not at 6 degrees C, whereas ANP bound to NPR-C did not dissociate from the binding site at 0 and 37 degrees C, The dissociated AZB-I-125-ANP rapidly rebound to NPR-GC at 37 degrees C but not to NPR-C, and the dissociated NPR-GC was capable of binding. Some AZB-I-125-ANP was hydrolyzed by a membrane-bound proteinase(s). Phosphoramidon inhibited the hydrolysis of AZB-I-125-ANP, Thus, the dissociated AZB-I-125-ANP rebound to NPR-GC and NPR-C. These results suggest that usually intact ANP repeatedly binds to NPR-GC until hydrolysis, Furthermore, the majority of ANP bind to NPR-GC before binding to NPR-C under physiological temperature.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; UNIV TOKYO,FAC MED,DEPT HYG & PREVENT MED,BUNKYO KU,TOKYO 113,JAPAN	Cornell University; University of Tokyo	ABE, T (corresponding author), UNIV SHIZUOKA,SCH FOOD & NUTR SCI,DEPT HYG & PREVENT MED,52-1 YADA,SHIZUOKA 422,JAPAN.							ABE T, 1992, EUR J BIOCHEM, V209, P717, DOI 10.1111/j.1432-1033.1992.tb17340.x; ABE T, 1993, EUR J BIOCHEM, V217, P295, DOI 10.1111/j.1432-1033.1993.tb18246.x; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; BALLERMANN BJ, 1988, BIOCHEM BIOPH RES CO, V157, P755, DOI 10.1016/S0006-291X(88)80314-0; BOURNE A, 1990, BIOCHEM J, V271, P381, DOI 10.1042/bj2710381; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEVALIER RL, 1991, AM J PHYSIOL, V260, pR1218, DOI 10.1152/ajpregu.1991.260.6.R1218; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; FULLER F, 1988, J BIOL CHEM, V263, P9395; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; JOHNSON GR, 1989, J BIOL CHEM, V264, P11637; KOH GY, 1992, J BIOL CHEM, V267, P11987; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNO T, 1986, J BIOL CHEM, V261, P5817; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFERTY HM, 1989, CIRC RES, V65, P640, DOI 10.1161/01.RES.65.3.640; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MISONO KS, 1985, BIOCHEM BIOPH RES CO, V130, P994, DOI 10.1016/0006-291X(85)91713-9; MISONO KS, 1988, BIOCHEM BIOPH RES CO, V152, P658, DOI 10.1016/S0006-291X(88)80089-5; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OLINS GM, 1988, J BIOL CHEM, V263, P10989; PANDEY KN, 1986, BIOCHEMISTRY-US, V25, P8467, DOI 10.1021/bi00374a022; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; PANDEY KN, 1993, J BIOL CHEM, V268, P4382; POTTER LR, 1992, J BIOL CHEM, V267, P14531; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1987, P NATL ACAD SCI USA, V84, P1521, DOI 10.1073/pnas.84.6.1521; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; VANNESTE Y, 1990, BIOCHEM J, V269, P801, DOI 10.1042/bj2690801; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661	44	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7672	7678		10.1074/jbc.270.13.7672	http://dx.doi.org/10.1074/jbc.270.13.7672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706315	hybrid			2022-12-25	WOS:A1995QQ43100093
J	CHAN, PY; ARUFFO, A				CHAN, PY; ARUFFO, A			VLA-4 INTEGRIN MEDIATES LYMPHOCYTE MIGRATION ON THE INDUCIBLE ENDOTHELIAL-CELL LIGAND VCAM-1 AND THE EXTRACELLULAR-MATRIX LIGAND FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; NATURAL-KILLER-CELLS; LEUKOCYTE ADHESION DEFICIENCY; AMINO-ACID-SEQUENCE; T-CELL; TRANSENDOTHELIAL MIGRATION; ALPHA-4-BETA-1 INTEGRIN; BINDING-SITE; VASCULAR ENDOTHELIUM; PLASMA FIBRONECTIN	We herein tested the ability of lymphocytes to utilize the beta1 integrin VLA-4 to mediate cell migration when adhering to its cytokine-inducible endothelial cell ligand VCAM-1 or its extracellular matrix ligand fibronectin. We used an in vitro system consisting of purified VCAM-1/Fc fusion protein or fibronectin immobilized on porous polycarbonate membranes to quantitatively measure the migration efficiency of an Epstein-Barr virus-transformed B cell line (SLA) and T lymphoblasts derived from normal donors. We found that both SLA cells and T lymphoblasts migrated across membranes coated with VCAM-1/Fc or fibronectin in a site density-dependent manner. Above and below an optimal site density of VCAM-1/Fc or fibronectin, the migration efficiency decreased. A 6-20-fold higher number of lymphocytes migrated across membranes coated with VCAM-1/Fc than with fibronectin. The differential migration efficiency is consistent with a higher number of adherent lymphocytes and a higher avidity of adhesion for VCAM-1/Fc than for fibronectin when the ligands were immobilized on plastic, and is independent of the activation state of the cells. These results demonstrated a stringent regulation of migratory response by cell adhesion strength and a delicate balance between stationary and migratory behaviors of a cell on the adhesive substrates. Like the beta2 integrin LFA-1, VLA-4 may be a locomotive adhesion receptor which is involved in the transendothelial migration of lymphocytes and the infiltration of lymphocytes into lymphoid or peripheral tissues by binding to VCAM-1 and fibronectin.			CHAN, PY (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT CELLULAR INTERACT,3005 1ST AVE,SEATTLE,WA 98121, USA.							ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANICHINI A, 1990, INT J CANCER, V46, P508, DOI 10.1002/ijc.2910460330; ARENCIBIA I, 1989, EUR J IMMUNOL, V19, P929, DOI 10.1002/eji.1830190521; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1990, BLOOD, V76, P965; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DAVIS JM, 1990, CELL IMMUNOL, V129, P67, DOI 10.1016/0008-8749(90)90187-V; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUBAND JL, 1991, J CELL SCI, V98, P517; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HORVATH AR, 1990, J CELL SCI, V97, P307; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; IIGO Y, 1991, J IMMUNOL, V147, P4167; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; ISSEKUTZ TB, 1991, FASEB J, V5, pA1335; ISSEKUTZ TB, 1992, CURR OPIN IMMUNOL, V4, P287, DOI 10.1016/0952-7915(92)90078-S; ISSEKUTZ TB, 1991, CELL IMMUNOL, V138, P300, DOI 10.1016/0008-8749(91)90155-5; JONJIC N, 1992, J EXP MED, V176, P1165, DOI 10.1084/jem.176.4.1165; KAVANAUGH AF, 1991, J IMMUNOL, V146, P4149; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KOCH AE, 1991, LAB INVEST, V64, P313; KOOPMAN G, 1992, EUR J IMMUNOL, V22, P1851, DOI 10.1002/eji.1830220726; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; MOSER R, 1992, J IMMUNOL, V149, P1432; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MURRAY J, 1992, CELL MOTIL CYTOSKEL, V22, P211, DOI 10.1002/cm.970220308; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OHTSUKA A, 1992, CELL TISSUE RES, V269, P403, DOI 10.1007/BF00353895; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PELLETIER RP, 1992, J IMMUNOL, V149, P2473; PICKER LJ, 1992, CURR OPIN IMMUNOL, V4, P277, DOI 10.1016/0952-7915(92)90077-R; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RICE GE, 1991, AM J PATHOL, V138, P385; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIOHARA T, 1991, J IMMUNOL, V146, P840; SOMERSALO K, 1992, J IMMUNOL, V149, P590; SOMERSALO K, 1991, EUR J IMMUNOL, V21, P35, DOI 10.1002/eji.1830210107; SWERLICK RA, 1992, J IMMUNOL, V149, P698; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; VANEPPS DE, 1989, J IMMUNOL, V143, P3207; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1992, J BIOL CHEM, V267, P7352	91	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24655	24664						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693704				2022-12-25	WOS:A1993MG67300025
J	WATSON, N; WILLIAMS, KL; ALEXANDER, S				WATSON, N; WILLIAMS, KL; ALEXANDER, S			A DEVELOPMENTALLY-REGULATED GLYCOPROTEIN COMPLEX FROM DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; EXTRACELLULAR-MATRIX; SIZE POLYMORPHISMS; PROTEINS; GLYCOSYLATION; PHASE; PSA	The monoclonal antibody MUD50 recognizes an epitope on a family of developmentally regulated proteins in Dictyostelium discoideum (Alexander, S., Smith, E., Davis, L., Gooley, A., Por, S. B., Browne, L., and Williams, K. L. (1988) Differentiation 38, 82-90). This epitope is an O-linked oligosaccharide that requires the wild-type modB allele for expression. These glycoproteins are structurally diverse. Some are integral membrane proteins, while others are soluble and do not require detergent for solubilization. One of the soluble glycoproteins, PsB, is also recognized by the monoclonal antibody MUD102, which binds to the polypeptide backbone. The antibody recognizes a single 100-kDa band in Western analysis. In this report we demonstrate that the PsB molecule is part of a specific developmentally regulated multiprotein complex containing six different proteins. The complex is held together by both covalent and non-covalent bonds. Interestingly, only the PsB glycoprotein has the MUD50 O-linked oligosaccharide determinant. None of the proteins in the complex is N-glycosylated as assessed by sensitivity to peptide N-glycosidase F. Only one of the complex proteins is heavily phosphorylated. This work establishes the foundation for additional studies on the biosynthesis, processing, and assembly of the O-glycosylated PsB protein.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA; MACQUIRE UNIV, SCH BIOL SCI, SYDNEY, NSW 2109, AUSTRALIA	University of Missouri System; University of Missouri Columbia; Macquarie University								ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; Alexander S., 1992, P29; ALEXANDER S, 1984, J IMMUNOL, V133, P315; ALEXANDER S, 1989, METHOD ENZYMOL, V179, P505; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREEN EJ, 1987, DEVELOPMENT, V101, P313; CHAMPION A, 1991, J GEN MICROBIOL, V137, P2431, DOI 10.1099/00221287-137-10-2431; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FREEZE HH, 1992, CELL SURFACE CARBOHY, P285; GOOLEY AA, 1992, GENETICS, V130, P749; GOOLEY AA, 1992, THESIS MACQUARIE U S; GRANT WN, 1983, EMBO J, V2, P935, DOI 10.1002/j.1460-2075.1983.tb01524.x; GRANT WN, 1985, MOL CELL BIOL, V5, P2559, DOI 10.1128/MCB.5.10.2559; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HARLOW E, 1988, ANTIBODIES LABORATOR, P460; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; KYHEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loomis W., 2012, DEV DICTYOSTELIUM DI; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; SMITH E, 1989, GENETICS, V122, P59; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEST CM, 1985, J BIOL CHEM, V260, P3803; WEST CM, 1990, DEV GENET, V11, P492, DOI 10.1002/dvg.1020110526; ZHOUCHOU AT, 1993, THESIS MACQUARIE U S	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22634	22641						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693675				2022-12-25	WOS:A1993MD34800067
J	BOBEK, LA; TSAI, H; BIESBROCK, AR; LEVINE, MJ				BOBEK, LA; TSAI, H; BIESBROCK, AR; LEVINE, MJ			MOLECULAR-CLONING, SEQUENCE, AND SPECIFICITY OF EXPRESSION OF THE GENE ENCODING THE LOW-MOLECULAR-WEIGHT HUMAN SALIVARY MUCIN (MUC7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMANDIBULAR-SUBLINGUAL SALIVA; POLYMORPHIC EPITHELIAL MUCIN; INTESTINAL MUCIN; TERMINAL REGION; CDNA; GLYCOPROTEINS; PURIFICATION; PROTEIN; PEPTIDE; CHAIN	Previous biochemical studies have determined that human saliva contains high and low molecular weight mucin glycoproteins (MG1 and MG2, respectively) that are structurally distinct. In this study, we describe the isolation and characterization of overlapping cDNA clones which code for the MG2 protein core. DNA sequencing revealed a translated region of 1131 nucleotides encoding a protein of 377 amino acid residues with a molecular mass of 39 kDa. The first 20 N-terminal residues were very hydrophobic and probably comprise the MG2 leader peptide. The region encoding the secreted protein can be divided into three distinct domains; unique 5'- and 3'-translated regions containing 4 and 1 potential N-glycosylation sites, respectively, and a central region of six almost perfect tandem repeats of 23 amino acid residues with a high number of Thr and Ser. No sequence homology with any other human or animal mucins, and no significant homology to any other proteins was found. MG2 mRNA is about 2.5 kilobases long, and its expression appear to be species-, tissue-, and cell-specific. We propose to name this gene MUC7 in accordance with the mucin genes cloned to date named MUC1-MUC6.	SUNY Buffalo, SCH DENT MED, INST DENT RES, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	BOBEK, LA (corresponding author), SUNY Buffalo, SCH DENT MED, DEPT ORAL BIOL, 112 FOSTER HALL, BUFFALO, NY 14214 USA.				NIDCR NIH HHS [DE08240, DE07585] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008240, P01DE007585] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre A, 1989, Dysphagia, V4, P95, DOI 10.1007/BF02407152; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOBEK LA, 1991, BIOCHEM J, V278, P627, DOI 10.1042/bj2780627; Cohen R. E., 1989, HUMAN SALIVA CLIN CH, P101; COHEN RE, 1990, ARCH ORAL BIOL, V35, P347; COHEN RE, 1991, ARCH ORAL BIOL, V36, P127; CREPIN M, 1990, BIORHEOLOGY, V27, P471; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HEINRICH P, 1991, CURRENT PROTOCOLS S, V16, pCH7; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P1565; KINGSTON RE, 1991, CURRENT PROTOCOLS S, V14; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAN MS, 1990, J BIOL CHEM, V265, P15294; LEVINE MJ, 1987, J DENT RES, V66, P436, DOI 10.1177/00220345870660020901; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOOMIS RE, 1987, ARCH BIOCHEM BIOPHYS, V258, P452, DOI 10.1016/0003-9861(87)90366-3; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PRAKOBPHOL A, 1982, CARBOHYD RES, V108, P111, DOI 10.1016/S0008-6215(00)81896-0; RAMASUBBU N, 1991, BIOCHEM J, V280, P341, DOI 10.1042/bj2800341; REDDY MS, 1992, BIOCHEM J, V287, P639, DOI 10.1042/bj2870639; SAMBROOK J, 1989, MOL CLONING LAB MANU, pCH9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCANNAPIECO FA, 1993, CARIOLOGY 90, P85; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401	38	425	432	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20563	20569						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690757				2022-12-25	WOS:A1993LY01900092
J	COCIANCICH, S; GHAZI, A; HETRU, C; HOFFMANN, JA; LETELLIER, L				COCIANCICH, S; GHAZI, A; HETRU, C; HOFFMANN, JA; LETELLIER, L			INSECT DEFENSIN, AN INDUCIBLE ANTIBACTERIAL PEPTIDE, FORMS VOLTAGE-DEPENDENT CHANNELS IN MICROCOCCUS-LUTEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; PERMEABLE CHANNELS; LIPID BILAYERS; ION CHANNELS; PATCH-CLAMP; MEMBRANE; EXPRESSION; LIPOSOMES; PRESSURE; IMMUNITY	Insect defensins are cationic, cysteine-rich peptides (approximately 4 kDa) that appear after bacterial challenge or injury in the hemolymph of insects belonging to a large variety of orders. These peptides possess anti-Gram-positive activity and participate in the potent antibacterial defense reactions of insects. Using recombinant insect defensin and the strain Micrococcus luteus as a test organism, we have investigated the mode of action of this peptide. We show that defensin disrupts the permeability barrier of the cytoplasmic membrane of M. luteus, resulting in a loss of cytoplasmic potassium, a partial depolarization of the inner membrane, a decrease in cytoplasmic ATP, and an inhibition of respiration. Potassium loss is inhibited below the order-disorder transition of the lipid hydrocarbon chains. It is also inhibited by divalent cations and by a decrease in the membrane potential below a threshold of 110 mV. We propose that these permeability changes reflect the formation of channels in the cytoplasmic membrane by defensin oligomers. This proposal is supported by patch-clamp experiments that show that insect defensins form channels in giant liposomes.	UNIV PARIS 11,CNRS,URA 1116,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	COCIANCICH, S (corresponding author), UNIV STRASBOURG 1,BIOL GEN LAB,CNRS,F-67070 STRASBOURG,FRANCE.		COCIANCICH, Stéphane/C-4267-2014	COCIANCICH, Stéphane/0000-0001-8601-3598				ASHE GB, 1971, BIOCHIM BIOPHYS ACTA, V233, P810, DOI 10.1016/0005-2736(71)90182-9; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; BARSUKOV LI, 1978, EUR J BIOCHEM, V90, P331, DOI 10.1111/j.1432-1033.1978.tb12609.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BUCHANAN RE, 1982, BERGEYS MANUAL DETER, P1004; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; DUZGUNES N, 1983, MEMBRANE FLUIDITY BI, V2, P187; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GHAZI A, 1981, FEBS LETT, V125, P197, DOI 10.1016/0014-5793(81)80717-X; GUIHARD G, 1993, J BIOL CHEM, V268, P17775; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KASHKET ER, 1981, J BACTERIOL, V146, P369, DOI 10.1128/JB.146.1.369-376.1981; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LETELLIER L, 1993, ALKALI CATION TRANSP, P359; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; REICHHART JM, 1992, INVERTEBR REPROD DEV, V21, P15, DOI 10.1080/07924259.1992.9672215; Rottenberg H, 1979, Methods Enzymol, V55, P547; URRUTIA R, 1989, FEBS LETT, V247, P17, DOI 10.1016/0014-5793(89)81230-X; VAARAM, 1992, MICROBIOL REV, V56, P395; WESTERHOFF HV, 1989, BIOCHIM BIOPHYS ACTA, V975, P361, DOI 10.1016/S0005-2728(89)80344-5	35	268	289	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19239	19245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690029				2022-12-25	WOS:A1993LW81900017
J	MCPHERSON, PS; CAMPBELL, KP				MCPHERSON, PS; CAMPBELL, KP			CHARACTERIZATION OF THE MAJOR BRAIN FORM OF THE RYANODINE RECEPTOR CA2+ RELEASE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM-INDUCED RELEASE; SKELETAL-MUSCLE; H-3 RYANODINE; INOSITOL 1,4,5-TRISPHOSPHATE; CA-2+ RELEASE; RAT-BRAIN; DEPENDENT PHOSPHORYLATION; MALIGNANT HYPERTHERMIA; MICROSOMAL-MEMBRANES	At least three distinct ryanodine receptor genes appear to be expressed in mammalian brain. We have used biochemical and immunological methods to characterize the major form of ryanodine binding protein purified from brain. [H-3]Ryanodine binding to the purified brain receptor is stimulated by Ca2+, ATP, KCl, and phosphorylation and is inhibited by calmodulin, Mg2+, and ruthenium red. Immunoblot and immunoprecipitation analysis using a panel of monoclonal and polyclonal antibodies against skeletal and cardiac muscle ryanodine receptors, and two novel polyclonal antibodies against the brain ryanodine receptor, reveals that the major form of ryanodine receptor expressed in brain is immunologically similar to the cardiac ryanodine receptor, but is distinct from the skeletal muscle receptor. Digestion of cardiac and brain ryanodine receptors with trypsin or alpha-chymotrypsin generates similar proteolytic patterns as detected by immunoblot analysis or by autoradiography after labeling with a hydrophobic probe, suggesting that the two proteins are similar in both their large cytoplasmic and hydrophobic transmembrane domains. Taken together, these data indicate that the cardiac ryanodine receptor/Ca2+ release channel is the major form of ryanodine receptor expressed in brain, and that it likely functions in releasing Ca2+ from caffeine-sensitive intracellular Ca2+ stores in neurons by a mechanism of regulated Ca2+-induced Ca2+ release.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa	MCPHERSON, PS (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, PROGRAM NEUROSCI, IOWA CITY, IA 52242 USA.			Campbell, Kevin/0000-0003-2066-5889				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BURGOYNE RD, 1991, TRENDS BIOCHEM SCI, V16, P319, DOI 10.1016/0968-0004(91)90131-E; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; KAWAI T, 1991, BRAIN RES, V540, P331, DOI 10.1016/0006-8993(91)90531-Y; KAWAI T, 1989, PFLUEGERS ARCH EUR J, V413, P473; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PADUA RA, 1991, BRAIN RES, V542, P135, DOI 10.1016/0006-8993(91)91007-N; PADUA RA, 1992, J CHEM NEUROANAT, V5, P63, DOI 10.1016/0891-0618(92)90034-N; PALADE P, 1989, MOL PHARMACOL, V36, P673; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; SHARP AH, 1993, J NEUROSCI, V13, P3051; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAYER SA, 1988, J NEUROSCI, V8, P4089; THAYER SA, 1988, MOL PHARMACOL, V34, P664; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; YOSHIDA A, 1992, J NEUROSCI, V12, P1094; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q	55	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19785	19790						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690041				2022-12-25	WOS:A1993LW81900094
J	THOMAS, JE; AGUZZI, A; SORIANO, P; WAGNER, EF; BRUGGE, JS				THOMAS, JE; AGUZZI, A; SORIANO, P; WAGNER, EF; BRUGGE, JS			INDUCTION OF TUMOR-FORMATION AND CELL-TRANSFORMATION BY POLYOMA MIDDLE T-ANTIGEN IN THE ABSENCE OF SRC	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; RAT-CELLS; ONCOGENIC TRANSFORMATION; YES PROTEIN; VIRUS; PP60C-SRC; ASSOCIATION; EXPRESSION; BINDING; MICE	In polyomavirus-transformed cells, middle T antigen binds to and activates the protein tyrosine kinase, Src. To determine whether this interaction is critical for middle T transformation, we examined the ability of middle T to transform cells that lack endogenous Src (because of a targeted disruption of both Src alleles). Infection of newborn or 2-week-old Src-negative mice with a retrovirus encoding middle T led to the induction of visceral hemangiomas that were indistinguishable from tumors in wild-type mice with respect to their morphology, frequency or latency period. In addition, middle T was able to induce foci formation on cell monolayers and colony formation in soft agar in Src-negative immortalized fibroblasts. These results indicated that Src is not essential for middle T-induced transformation of the cells targeted in these assays. To examine the protein tyrosine kinases that interact with middle T in the absence of Src, we compared the level of middle T phosphorylation in immune complex kinase assays from Src-negative and Src-positive cell lysates, and identified the middle T-associated kinases in these cells. In Src-positive cell lysates, there was a similar level of middle T phosphorylation in Src and Yes immunoprecipitates, suggesting that middle T can bind to Src and Yes to a similar extent in this cell type. Fyn immunoprecipitates displayed fourfold lower levels of middle T phosphorylation than that detected in the Src and Yes immunoprecipitates. In Src-negative cells, the level of middle T phosphorylation in Yes and Fyn immunoprecipitates was not significantly different from that detected in the Src-positive cells, suggesting that the absence of Src does not lead to a compensating increase in the proportion of middle T associated with these kinases. The level of middle T-associated phosphatidylinositol 3'-kinase was also examined since this kinase is known to interact with middle T-kinase complexes. Phosphatidylinositol 3'-kinase activity associated with middle T was reduced 30-60% in Src-negative cells, suggesting that Src contributes at least one-third of the total middle T associated in wild-type cells. Taken together, these results indicate that Src is not required for middle T-induced hemangiomas in mice or for focus induction in immortalized fibroblasts, and that the residual level of Yes, Fyn and phosphatidylinositol kinase activity associated with middle T in Src-negative cells may compensate for the absence of Src.	UNIV PENN, HOWARD HUGHES MED INST, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST MOLEC GENET, HOUSTON, TX 77030 USA; UNIV ZURICH, DEPT PATHOL, INST NEUROPATHOL, CH-8006 ZURICH, SWITZERLAND; RES INST MOLEC PATHOL, VIENNA, AUSTRIA	Howard Hughes Medical Institute; University of Pennsylvania; Baylor College of Medicine; University of Zurich; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008; Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOO D, 1988, CELL GROWTH DIVISION, P17; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAPTIS L, 1985, MOL CELL BIOL, V6, P1545; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS RL, 1988, CELL, V52, P121; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; ZHAO YH, 1990, ONCOGENE, V5, P1629	42	37	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2521	2529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689725				2022-12-25	WOS:A1993LT36800024
J	REARDON, DB; HUNG, MC				REARDON, DB; HUNG, MC			DOWNSTREAM SIGNAL-TRANSDUCTION DEFECTS THAT SUPPRESS TRANSFORMATION IN 2 REVERTANT CELL-LINES EXPRESSING ACTIVATED RAT NEU ONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE-ACTIVITY; MURINE LEUKEMIA-VIRUS; PHOSPHOLIPASE-C-GAMMA; HUMAN-BREAST CANCER; PDGF BETA-RECEPTOR; MOLECULAR-CLONING; POINT MUTATION; PROTO-ONCOGENE; NIH3T3 CELLS	The neu gene encodes the transmembrane tyrosine kinase growth factor receptor, p185. To study neu-induced cellular transformation, we developed revertant cells from the neu-transformed NIH 3T3 cell line, B 104-1-1, by treating the cells with the chemical mutagen ethyl methanesulfonate. The morphologically normal revertant cells were first selected by their ability either to attach to culture plates or to survive in the presence of the cytotoxic reagents colchicine or 5-fluoro-2-deoxyuridine. Two of the 21 candidate revertant cell lines isolated were further characterized and were found to lose their anchorage independence and ability to grow in 1% calf serum, indicating that they were nontransformed even though they still expressed p185 oncoprotein. The tyrosine residues of p185 in these two revertants were underphosphorylated, which may have contributed to their nontransformed status. In addition, these revertants also resisted transformation by neu and several additional oncogenes (H-ras, N-ras, v-mos, v-abl, and v-fos) as determined by focus forming assays. These results indicated that we had successfully developed, from neu-transformed cells, revertants exhibiting defective tyrosine phosphorylation of the neu oncoprotein. The results also suggested that neu and several other oncogenes may share common elements in their pathways for the induction of cellular transformation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,GRAD SCH BIOMED SCI,HOUSTON,TX 77225	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	PHS HHS [58880] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACUS SS, 1990, ARCH PATHOL LAB MED, V114, P164; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; GLASS DJ, 1990, ONCOGENE RES, V5, P175; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; MATIN A, 1990, ONCOGENE, V5, P111; MCGUIRE WL, 1987, BREAST CANCER RES TR, V10, P5, DOI 10.1007/BF01806129; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PARKES HC, 1990, BRIT J CANCER, V61, P39, DOI 10.1038/bjc.1990.9; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TALBOT N, 1988, CYTOGENET CELL GENET, V48, P112, DOI 10.1159/000132602; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANDEWOUDE GF, 1979, P NATL ACAD SCI USA, V76, P4464; VARLEY JM, 1987, ONCOGENE, V1, P423; WEINER DB, 1989, ONCOGENE, V4, P1175; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	56	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18136	18142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688739				2022-12-25	WOS:A1993LT74300073
J	OOI, GT; BROWN, DR; SUH, DS; TSENG, LYH; RECHLER, MM				OOI, GT; BROWN, DR; SUH, DS; TSENG, LYH; RECHLER, MM			CYCLOHEXIMIDE STABILIZES INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1 (IGFBP-1) MESSENGER-RNA AND INHIBITS IGFBP-1 TRANSCRIPTION IN H4-II-E RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; GENE-EXPRESSION; C-FOS; MULTIHORMONAL REGULATION; TRANSFERRIN RECEPTOR; REGENERATING LIVER; DOMINANT ROLE; BETA-TUBULIN; 3T3 CELLS	The insulin-like growth factor-binding proteins (IGFBPs) are a family of six proteins that modulate the biological activity of IGF-I and IGF-II and determine their bioavailability to tissues. One of the IGFBPs, IGFBP-1, is distinctive in the dynamic response of its levels in human plasma to metabolic changes. Parallel changes occur in IGFBP-1 mRNA and IGFBP-1 transcription in rat liver. Using the well differentiated H4-II-E rat hepatoma cell line as a model system, we demonstrated previously that IGFBP-1 transcription is positively regulated by dexamethasone and negatively regulated by insulin. We now examine the effect of the protein synthesis inhibitor, cycloheximide, on the hormonal regulation of IGFBP-1 gene expression. Preincubation of H4-II-E cells with 10.7 muM cycloheximide for 1.5 h did not prevent the induction of IGFBP-1 mRNA and IGFBP-1 transcription (determined in nuclear run-on assays) by dexamethasone. By contrast, cycloheximide treatment abolished the decrease in IGFBP-1 mRNA induced by insulin. Insulin rapidly decreased IGFBP-1 transcription in the absence of cycloheximide (>50% inhibition in 20 min) and caused a similar decrease in cells pretreated with cycloheximide. Cycloheximide alone also decreased IGFBP-1 transcription. Similar results were observed with a second protein synthesis inhibitor, anisomycin, which also prevented the insulin-induced decrease in IGFBP-1 mRNA without abolishing the insulin-induced inhibition of IGFBP-1 transcription. These results suggest that although insulin decreases IGFBP-1 gene transcription in the presence of protein synthesis inhibitors, IGFBP-1 mRNA levels are maintained because of stabilization of the mRNA. Stabilization was demonstrated directly in actinomycin D-treated cells, where the t1/2 of IGFBP-1 mRNA increased from approximately 2 to approximately 20 h in the presence of cycloheximide; insulin did not affect IGFBP-1 mRNA turnover. Thus, cycloheximide-sensitive labile proteins contribute to the maintenance of basal IGFBP-1 promoter activity and the rapid turnover of IGFBP-1 mRNA, which determine the dynamic regulation of IGFBP-1 gene expression.			OOI, GT (corresponding author), NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,GROWTH & DEV SECT,BLDG 10,RM 8D14,BETHESDA,MD 20892, USA.							ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGERVO M, 1992, BIOCHEM BIOPH RES CO, V189, P1177, DOI 10.1016/0006-291X(92)92328-U; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BAR RS, 1990, ENDOCRINOLOGY, V127, P1078, DOI 10.1210/endo-127-3-1078; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLUME JE, 1989, NUCLEIC ACIDS RES, V17, P9003, DOI 10.1093/nar/17.22.9003; BORTOFF KD, 1992, MOL CELL ENDOCRINOL, V84, P39, DOI 10.1016/0303-7207(92)90069-I; BRISMAR K, 1988, J ENDOCRINOL INVEST, V11, P599, DOI 10.1007/BF03350189; BROWN AL, 1986, J BIOL CHEM, V261, P3144; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DTW, 1988, J BIOL CHEM, V263, P13007; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COTTERILL AM, 1988, J CLIN ENDOCR METAB, V67, P882, DOI 10.1210/jcem-67-5-882; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; ERNEST MJ, 1982, BIOCHEMISTRY-US, V21, P6761, DOI 10.1021/bi00269a022; FARESE RV, 1984, J BIOL CHEM, V259, P7094; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GRANNER DK, 1987, KIDNEY INT, V32, pS82; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JULKUNEN M, 1988, FEBS LETT, V236, P295, DOI 10.1016/0014-5793(88)80041-3; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1992, ARCH BIOCHEM BIOPHYS, V298, P56, DOI 10.1016/0003-9861(92)90093-C; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; MESSINA JL, 1991, J BIOL CHEM, V266, P17995; MESSINA JL, 1992, BIOCHIM BIOPHYS ACTA, V1137, P225, DOI 10.1016/0167-4889(92)90205-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MURPHY LJ, 1990, MOL ENDOCRINOL, V4, P329, DOI 10.1210/mend-4-2-329; NAKAMURA T, 1987, J BIOL CHEM, V262, P727; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NAWA K, 1986, J BIOL CHEM, V261, P6883; NELSON K, 1980, J BIOL CHEM, V255, P8509; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; OOI GT, 1993, GROWTH REGULAT, V3, P12; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; UNTERMAN TG, 1990, ENDOCRINOLOGY, V127, P789, DOI 10.1210/endo-127-2-789; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; VAZQUEZ D, 1979, INHIBITORS PROTEIN S, P136; WIDMAIER EP, 1985, MOL CELL ENDOCRINOL, V43, P181, DOI 10.1016/0303-7207(85)90082-6; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANG YWH, 1990, MOL ENDOCRINOL, V4, P29, DOI 10.1210/mend-4-1-29; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	78	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16664	16672						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688368				2022-12-25	WOS:A1993LQ33600083
J	OXVIG, C; SAND, O; KRISTENSEN, T; GLEICH, GJ; SOTTRUPJENSEN, L				OXVIG, C; SAND, O; KRISTENSEN, T; GLEICH, GJ; SOTTRUPJENSEN, L			CIRCULATING HUMAN PREGNANCY-ASSOCIATED PLASMA PROTEIN-A IS DISULFIDE-BRIDGED TO THE PROFORM OF EOSINOPHIL MAJOR BASIC-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; PAPP-A; FOLLICULAR-FLUID; HUMAN-PLACENTA; ALPHA-2-MACROGLOBULIN; PURIFICATION; LOCALIZATION; PRECURSOR; CLEAVAGE; CELLS	A previously unrecognized association between pregnancy-associated plasma protein-A (PAPP-A) and the proform of eosinophil major basic protein (proMBP) is demonstrated. PAPP-A isolated from pooled pregnancy serum is shown to be a disulfide-bridged complex with proMBP (PAPP-A/proMBP) in which the subunits of the constituents are present in a 1:1 molar ratio. The results are the outcome of analysis of tryptic and CNBr/tryptic peptides from PAPP-A/ProMBP, sequence analysis of intact and reduced and carboxymethylated PAPP-A/proMBP, and reaction with monoclonal antibodies directed against MBP and its proform. In addition, it is shown that commercial polyclonal anti-PAPP-A is polyspecific, also reacting with MBP.	AARHUS UNIV,DEPT MOLEC BIOL,BLDG 130,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT CHEM,DK-8000 AARHUS,DENMARK; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905	Aarhus University; Aarhus University; Mayo Clinic; Mayo Clinic				Oxvig, Claus/0000-0002-4715-9719	NIAID NIH HHS [AI 09728, AI 15231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI015231, R01AI009728, R37AI009728] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BISCHOF P, 1979, ARCH GYNECOL, V227, P315, DOI 10.1007/BF02109920; BISCHOF P, 1983, J CLIN ENDOCR METAB, V56, P359, DOI 10.1210/jcem-56-2-359; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; DAVEY MW, 1983, ANAL BIOCHEM, V131, P18, DOI 10.1016/0003-2697(83)90130-6; FOLKERSEN J, 1981, AM J OBSTET GYNECOL, V139, P910, DOI 10.1016/0002-9378(81)90957-1; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; HAMANN KJ, 1991, AIRWAY EPITHELIUM PH, P255; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TM, 1976, SCIENCE, V193, P1249, DOI 10.1126/science.60782; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MADDOX DE, 1984, J EXP MED, V160, P29, DOI 10.1084/jem.160.1.29; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; SINOSICH MJ, 1990, BIOCHEM INT, V20, P579; SINOSICH MJ, 1984, J CLIN ENDOCR METAB, V58, P500, DOI 10.1210/jcem-58-3-500; SJOBERG J, 1984, FERTIL STERIL, V41, P551; SJOBERG J, 1984, ARCH ANDROLOGY, V14, P253; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8293; SUTCLIFFE RG, 1980, BIOCHEM J, V191, P799, DOI 10.1042/bj1910799; TORNEHAVE D, 1984, PLACENTA, V5, P427, DOI 10.1016/S0143-4004(84)80023-5; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; WASMOEN TL, 1989, J EXP MED, V170, P2051, DOI 10.1084/jem.170.6.2051; WASMOEN TL, 1991, AM J OBSTET GYNECOL, V165, P416, DOI 10.1016/0002-9378(91)90107-3; WASMOEN TL, 1987, P NATL ACAD SCI USA, V84, P3029, DOI 10.1073/pnas.84.9.3029; WESTERGAARD JG, 1983, ARCH GYNECOL, V233, P211, DOI 10.1007/BF02114602	33	156	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12243	12246						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685339				2022-12-25	WOS:A1993LG65800004
J	SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL				SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL			RNA-DIRECTED RNA-POLYMERASE FROM TOMATO LEAVES .1. PURIFICATION AND PHYSICAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBER VIROID PSTV; NUCLEOTIDE-SEQUENCE; REPLICATION COMPLEX; POLYACRYLAMIDE GELS; PROTEIN-SYNTHESIS; COWPEA; PLANTS; HOST; OLIGORIBONUCLEOTIDES; IDENTIFICATION	An RNA-directed RNA polymerase (RdRP, EC 2.7.7.48) from tomato leaf tissue was purified to electrophoretic homogeneity. A terminal transferase activity that was found to cofractionate with RdRP from DEAE-Sepharose and DNA-cellulose columns was removed by chromatography on a Mono Q column. The highly purified RdRP exhibits a specific activity of 500 nmol x mg-1 x 30 min-1, which corresponds to a 100,000-fold enrichment of the enzyme. In buffer containing 50% glycerol, its activity decreased by about 15%/month. RdRP activity coincided with the silver staining intensity of a single 128-kDa polypeptide when the fractions eluted from the Mono Q column were analyzed by electrophoresis in a SDS-polyacrylamide gel. Its molecular mass and its sedimentation coefficient of 6.6 S indicate that RdRP is a nearly globular molecule. The catalytic activity of RdRP is resistant to alpha-amanitin and actinomycin D. In tomato leaves systemically infected with potato spindle tuber viroid, the activity of RdRP was found to be increased about 3-fold compared with RdRP isolated from healthy leaf tissue.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society								ASTIERMA.S, 1971, BIOCHIM BIOPHYS ACTA, V232, P484, DOI 10.1016/0005-2787(71)90602-2; ASTIERMANIFACIER S, 1978, CR ACAD SCI D NAT, V287, P1043; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIEBRICHER CK, 1983, EVOL BIOL, V16, P1; BOEGE F, 1980, FEBS LETT, V121, P91, DOI 10.1016/0014-5793(80)81273-7; BOEGE F, 1982, BIOSCIENCE REP, V2, P379, DOI 10.1007/BF01119300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDRESSE T, 1986, VIROLOGY, V152, P322, DOI 10.1016/0042-6822(86)90135-2; CONSIGLIO E, 1970, European Journal of Biochemistry, V17, P408, DOI 10.1111/j.1432-1033.1970.tb01180.x; DAVIES JW, 1974, VIROLOGY, V61, P281, DOI 10.1016/0042-6822(74)90262-1; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; DORSSERS L, 1984, P NATL ACAD SCI-BIOL, V81, P1951, DOI 10.1073/pnas.81.7.1951; DORSSERS L, 1983, VIROLOGY, V125, P155, DOI 10.1016/0042-6822(83)90071-5; DORSSERS L, 1982, VIROLOGY, V116, P236, DOI 10.1016/0042-6822(82)90416-0; DUDA CT, 1973, BIOCHIM BIOPHYS ACTA, V319, P62, DOI 10.1016/0005-2787(73)90041-5; DUDA CT, 1979, VIROLOGY, V92, P180, DOI 10.1016/0042-6822(79)90223-X; EDMONDS M, 1982, ENZYMES, V15, P217; FRAENKELCONRAT H, 1983, P NATL ACAD SCI-BIOL, V80, P422, DOI 10.1073/pnas.80.2.422; FRAENKELCONRAT H, 1986, CRC CR REV PLANT SCI, V4, P213, DOI 10.1080/07352688609382224; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; GROSS HJ, 1978, NATURE, V273, P203, DOI 10.1038/273203a0; HALL TC, 1974, VIROLOGY, V61, P486, DOI 10.1016/0042-6822(74)90284-0; HALL TC, 1982, ADV PLANT PATHOL, V1, P233; HAYES RJ, 1990, CELL, V63, P363, DOI 10.1016/0092-8674(90)90169-F; KHAN ZA, 1986, P NATL ACAD SCI USA, V83, P2383, DOI 10.1073/pnas.83.8.2383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUIS B G, 1972, Biochemical Journal, V128, P755; MANDAHAER CL, 1989, PLANT VIRUSES, V1, P125; MARSH LE, 1991, OXFORD SURV PLANT MO, V7, P297; MARTIN FH, 1971, J MOL BIOL, V57, P201, DOI 10.1016/0022-2836(71)90341-X; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MILDVAN AS, 1979, CRC CR REV BIOCH MOL, V6, P219, DOI 10.3109/10409237909102564; MIRAULT ME, 1971, EUR J BIOCHEM, V23, P372, DOI 10.1111/j.1432-1033.1971.tb01631.x; MOUCHES C, 1984, VIROLOGY, V134, P78, DOI 10.1016/0042-6822(84)90274-5; MUHLBACH HP, 1979, NATURE, V278, P185, DOI 10.1038/278185a0; NEER EJ, 1974, J BIOL CHEM, V249, P6527; OCHOA S, 1961, P NATL ACAD SCI USA, V47, P670, DOI 10.1073/pnas.47.5.670; QUADT R, 1989, MOL PLANT MICROBE IN, V2, P219, DOI 10.1094/MPMI-2-219; QUADT R, 1990, VIROLOGY, V178, P189, DOI 10.1016/0042-6822(90)90393-6; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RICHARDS O, 1990, CURR TOP MICROBIOL I, V161, P90; ROMAINE CP, 1978, VIROLOGY, V86, P241, DOI 10.1016/0042-6822(78)90024-7; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11858; SCHINDLER IM, 1992, PLANT SCI, V84, P221, DOI 10.1016/0168-9452(92)90138-C; SELIGER H, 1980, NUCLEIC ACIDS RES S, V7, P191; SEMANCIK JS, 1977, VIROLOGY, V80, P218, DOI 10.1016/0042-6822(77)90395-6; SMITH MH, 1970, HDB BIOCH, pC3; SOUTHERN EM, 1971, BIOCHEM J, V123, P613, DOI 10.1042/bj1230613; SPIESMACHER E, 1985, BIOSCIENCE REP, V5, P251, DOI 10.1007/BF01119595; TABLER M, 1984, EMBO J, V3, P3055, DOI 10.1002/j.1460-2075.1984.tb02257.x; TAKANAMI Y, 1982, BIOCHEMISTRY-US, V21, P3161, DOI 10.1021/bi00256a020; van Duin J., 1988, BACTERIOPHAGES, P117; VANDERMEER J, 1984, VIROLOGY, V132, P413, DOI 10.1016/0042-6822(84)90046-1; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; VOLLOCH V, 1987, J CELL BIOL, V105, P137, DOI 10.1083/jcb.105.1.137; VOLLOCH V, 1991, P NATL ACAD SCI USA, V88, P10671, DOI 10.1073/pnas.88.23.10671; WARD CD, 1988, J VIROL, V62, P558, DOI 10.1128/JVI.62.2.558-562.1988; WEISSBACH A, 1974, METHOD ENZYMOL, V34, P363; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZABEL P, 1976, J VIROL, V17, P679, DOI 10.1128/JVI.17.3.679-685.1976; ZABEL P, 1981, NUCLEIC ACIDS RES, V9, P2433, DOI 10.1093/nar/9.11.2433	61	78	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11851	11857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685022				2022-12-25	WOS:A1993LF28400060
J	FUJIMOTO, T; STROUD, E; WHATLEY, RE; PRESCOTT, SM; MUSZBEK, L; LAPOSATA, M; MCEVER, RP				FUJIMOTO, T; STROUD, E; WHATLEY, RE; PRESCOTT, SM; MUSZBEK, L; LAPOSATA, M; MCEVER, RP			P-SELECTIN IS ACYLATED WITH PALMITIC ACID AND STEARIC-ACID AT CYSTEINE-766 THROUGH A THIOESTER LINKAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; PLASMA-MEMBRANE; COVALENT MODIFICATION; MONOCLONAL-ANTIBODY; VIRAL GLYCOPROTEIN; ENDOTHELIAL-CELLS; CELLULAR PROTEINS; GMP-140; ACTIVATION	We report that the adhesion receptor P-selectin can be metabolically labeled with [H-3]palmitic acid in human platelets. Analysis of alkaline methanolysis products from labeled protein demonstrated that the radioactivity associated with P-selectin was covalently bound palmitic acid. [H-3]Palmitic acid was cleaved by hydroxylamine treatment at neutral pH and by reducing agents, indicating that acylation occurred through a thioester linkage. Both stearic acid and palmitic acid were detected by gas chromatography-mass spectrometry analysis of alkaline hydrolysates of purified P-selectin. Deletion or mutation of Cys766 eliminated [H-3] palmitic acid labeling of P-selectin in transfected COS-7 cells. We conclude that the cytoplasmic domain of P-selectin is acylated at Cys766 through a thioester bond. Fatty acid acylation may regulate intracellular trafficking or other functions of P-selectin.	UNIV OKLAHOMA HLTH SCI CTR,WK WARREN MED RES INST,DEPT MED,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; VET AFFAIRS MED CTR,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT MED,NORA ECCLE HARRISON CARDIOVASC RES & TRAINING INST,SALT LAKE CITY,UT 84112; UNIV SCH MED DEBRECEN,DEPT CLIN CHEM,H-4012 DEBRECEN,HUNGARY; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114; UNIV OKLAHOMA HLTH SCI CTR,WK WARREN MED RES INST,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Debrecen; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NHLBI NIH HHS [HL 45510, HL 34363, HL 34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034363, R01HL034363, R01HL045510, R01HL034127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BERGER M, 1984, J BIOL CHEM, V259, P7245; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; BONFANTI R, 1989, BLOOD, V73, P1109; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Capriotti A, 1986, J TISSUE CULTURE MET, V10, P219, DOI 10.1007/BF01404480; DEYKIN D, 1968, J CLIN INVEST, V47, P1590, DOI 10.1172/JCI105851; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRETCH DR, 1987, ANAL BIOCHEM, V163, P270, DOI 10.1016/0003-2697(87)90123-0; HATTORI R, 1989, J BIOL CHEM, V264, P7768; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MAGEE AI, 1990, J CELL SCI, V97, P581; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; MUSZBEK L, 1989, BLOOD, V74, P1339; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NEWMAN JP, 1992, J CELL BIOL, V119, P239; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1985, J BIOL CHEM, V260, P3784; SANDERS WE, 1992, BLOOD, V80, P795; SCHMIDT M, 1988, J BIOL CHEM, V263, P18635; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SCULLION BF, 1987, J CELL BIOL, V105, P69, DOI 10.1083/jcb.105.1.69; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; WELLER A, 1992, J BIOL CHEM, V267, P15176	44	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11394	11400						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684381				2022-12-25	WOS:A1993LD46600098
J	GREEN, GR; LEE, HJ; POCCIA, DL				GREEN, GR; LEE, HJ; POCCIA, DL			PHOSPHORYLATION WEAKENS DNA-BINDING BY PEPTIDES CONTAINING MULTIPLE SPKK SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; HISTONE VARIANTS; LINKER DNA; CHROMATIN DECONDENSATION; CHROMOSOMAL-PROTEINS; CORE HISTONE; MOTIFS; KINASE; H-1; H2B	Sea urchin testis-specific H1 and H2B histones (Sp H1 and Sp H2B) are characterized by reversibly phosphorylated N-terminal regions consisting largely of multiple clustered ''SPKK'' tetrapeptides (serine-proline adjacent to two basic amino acids). This report presents data showing differences in DNA affinities between peptides containing dephosphorylated and phosphorylated N-terminal regions. Sp H1 and its phosphorylated derivative (pSp H1) were purified by hydroxylapatite chromatography. Peptides containing the N-terminal regions of Sp H1 and pSp H1 (NP and pNP, respectively) were produced by digestion with Staphylococcus aureus protease. NP and two forms of pNP differing in phosphate content were purified by DNA-cellulose chromatography. The DNA affinities of the peptides were compared using several criteria. NP was bound more tightly by DNA-cellulose than pNPs. NP precipitated DNA under a broad range of NaCl concentrations; pNPs did not. Both NP and pNPs protected DNA against thermal denaturation, but NP created a more stable DNA-peptide complex. Thirty to sixty times more pNP than NP was required to obtain equivalent inhibition of Hoechst 33258 binding to DNA. NP did not behave as a competitive inhibitor of DNA binding by Hoechst 33258 binding to DNA. We conclude that during spermatogenesis, dephosphorylation of the Sp H1 N-terminal region increases its basicity and thus its affinity for DNA.			GREEN, GR (corresponding author), AMHERST COLL,WEBSTER CTR BIOL SCI,DEPT BIOL,AMHERST,MA 01002, USA.							ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BERNARDI G, 1960, BIOCHIM BIOPHYS ACTA, V44, P96, DOI 10.1016/0006-3002(60)91527-4; BRANDT WF, 1988, EUR J BIOCHEM, V173, P547, DOI 10.1111/j.1432-1033.1988.tb14033.x; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CARRONDO MAAFDT, 1989, BIOCHEMISTRY-US, V28, P7849, DOI 10.1021/bi00445a047; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; GREEN GR, 1985, DEV BIOL, V108, P235, DOI 10.1016/0012-1606(85)90026-0; GREEN GR, 1989, DEV BIOL, V134, P413, DOI 10.1016/0012-1606(89)90113-9; GREEN GR, 1988, BIOCHEMISTRY-US, V27, P619, DOI 10.1021/bi00402a019; GREEN GR, 1990, PLANT PHYSIOL, V93, P1241, DOI 10.1104/pp.93.3.1241; GREEN GR, 1983, BIOCHIM BIOPHYS ACTA, V741, P251, DOI 10.1016/0167-4781(83)90066-0; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAPLAN LJ, 1984, J BIOL CHEM, V259, P8777; LINDSEY GG, 1992, J BIOL CHEM, V267, P14622; LOONTIENS FG, 1990, BIOCHEMISTRY-US, V29, P9029, DOI 10.1021/bi00490a021; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OZAKI H, 1971, DEV BIOL, V26, P209, DOI 10.1016/0012-1606(71)90123-0; PAOLETTI RA, 1969, BIOCHEMISTRY-US, V8, P1615, DOI 10.1021/bi00832a043; PJURA PE, 1987, J MOL BIOL, V197, P257, DOI 10.1016/0022-2836(87)90123-9; POCCIA D, 1990, EXP CELL RES, V188, P226, DOI 10.1016/0014-4827(90)90164-6; POCCIA D, 1981, DEV BIOL, V82, P287, DOI 10.1016/0012-1606(81)90452-8; POCCIA DL, 1987, DEV BIOL, V121, P445, DOI 10.1016/0012-1606(87)90181-3; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; POCCIA DL, 1986, METHOD CELL BIOL, V27, P153, DOI 10.1016/S0091-679X(08)60347-7; PORTER DC, 1988, J BIOL CHEM, V263, P2750; REEVES R, 1990, J BIOL CHEM, V265, P8573; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; STRICKLAND WN, 1977, EUR J BIOCHEM, V77, P277, DOI 10.1111/j.1432-1033.1977.tb11666.x; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TENG M, 1988, NUCLEIC ACIDS RES, V16, P2671, DOI 10.1093/nar/16.6.2671; VANHOLDE KE, 1989, CHROMATIN, P247; VODICKA M, 1990, J EXP ZOOL, V256, P179, DOI 10.1002/jez.1402560208; ZALENSKAYA IA, 1981, NUCLEIC ACIDS RES, V9, P473, DOI 10.1093/nar/9.3.473; [No title captured]	44	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11247	11255						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684375				2022-12-25	WOS:A1993LD46600078
J	KNOFLER, M; WALTNER, C; WINTERSBERGER, E; MULLNER, EW				KNOFLER, M; WALTNER, C; WINTERSBERGER, E; MULLNER, EW			TRANSLATIONAL REPRESSION OF ENDOGENOUS THYMIDINE KINASE MESSENGER-RNA IN DIFFERENTIATING AND ARRESTING MOUSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; SERUM-STIMULATED CELLS; GENE PROMOTER; CYCLE REGULATION; MUSCLE-CELLS; HELA-CELLS; EXPRESSION; BINDING; PURIFICATION; FERRITIN	We observed that decline of thymidine kinase (TK) enzyme activity was severalfold faster than the decay of full length TK mRNA during growth arrest of 3T6 mouse fibroblasts or during differentiation of myoblasts (C2Cl12) or F9 embryonal carcinoma cells. In order to study the molecular mechanism of this disparate behavior, a polyclonal antiserum against mouse TK was raised in rabbit. High level expression of mouse TK polypeptide in Escherichia coli was achieved with a T7 RNA polymerase-directed expression system. Using the antiserum in immunoblotting, no indication for a pool of inactive enzyme was found during differentiation of F9 or growth arrest of 3T6 cells. Pulse labeling of these cells in vivo with [S-35]methionine showed a more than 6-fold decrease in the rate of TK-protein synthesis of in F9 cells after 3 days of treatment with retinoic acid as well as in 3T6 cells after 16 h under low serum. This was not due to increased turnover of the protein as measured in pulse chase experiments. In addition, full length TK mRNA stayed associated with polysomes under these conditions in F9 as well as 3T6 cells. Taken together the results suggest that endogenous TK mRNA becomes translationally repressed under a variety of conditions when mouse cells cease to grow.	UNIV VIENNA, VIENNA BIOCTR, INST MOLEC BIOL, DR BOHR GASSE 9, A-1030 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)								ARCOT SS, 1989, J BIOL CHEM, V264, P2343; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY DW, 1990, P NATL ACAD SCI USA, V87, P9310, DOI 10.1073/pnas.87.23.9310; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1982, EUR J BIOCHEM, V123, P539; Favaloro J, 1980, Methods Enzymol, V65, P718; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; ITO M, 1990, J BIOL CHEM, V265, P6954; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1991, ONCOGENE, V6, P1427; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; LEE LS, 1976, J BIOL CHEM, V251, P2600; LIANG HM, 1991, NUCLEIC ACIDS RES, V19, P2289, DOI 10.1093/nar/19.9.2289; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MULLNER E, 1983, BIOCHIM BIOPHYS ACTA, V740, P436, DOI 10.1016/0167-4781(83)90092-1; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RINGERTZ NR, 1978, EXP CELL RES, V113, P233, DOI 10.1016/0014-4827(78)90363-4; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; WEICHSELBRAUN I, 1990, FEBS LETT, V275, P49, DOI 10.1016/0014-5793(90)81436-R; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; YONG KK, 1988, P NATL ACAD SCI USA, V85, P5894, DOI 10.1073/pnas.85.16.5894	51	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11409	11416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684382				2022-12-25	WOS:A1993LD46600100
J	CHERNY, RC; HONAN, MA; THIAGARAJAN, P				CHERNY, RC; HONAN, MA; THIAGARAJAN, P			SITE-DIRECTED MUTAGENESIS OF THE ARGININE-GLYCINE-ASPARTIC ACID IN VITRONECTIN ABOLISHES CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SERUM SPREADING FACTOR; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIIA; HUMAN FIBRONECTIN; HUMAN-FIBRINOGEN; BINDING DOMAIN; S-PROTEIN; RECOGNITION	Vitronectin (VN), a major cell adhesion protein, is found in Plasma and in the extracellular matrix. At least three distinct cell surface receptors for vitronectin belonging to the integrin superfamily have been identified in normal and neoplastic cells. Many cell adhesion ligands, including vitronectin, contain an Arg-Gly-Asp (RGD) sequence mediating, in part, the ligand-receptor interaction. These ligands bind different integrins with varying specificity and affinity. The mechanism of receptor specificity remains controversial. To determine the role of the RGD sequence in receptor specificity, we amplified the cDNA for human vitronectin from a liver cDNA library and generated two separate mutants by utilizing site-directed mutagenesis resulting in aspartic acid (Asp47) to glutamic acid (Glu47) substitution and glycine (Gly46) to alanine (Ala46) substitution. The mammalian expression vector, pZEM229R, was used to transfect baby hamster kidney cells which secreted recombinant proteins into the supernatant. All recombinant proteins were isolated by heparin-agarose chromatography and tested for interaction with three known vitronectin receptors, namely, alpha(IIb)beta3 on thrombin-activated platelets, alpha(v)beta3 on human umbilical vein endothelial cells and alpha(v)beta5 on Panc-1 cells. Recombinant wild-type vitronectin behaved in a fashion similar to plasma-derived vitronectin. Both the RGE-VN and RAD-VN recombinant mutant proteins showed complete loss of cell adhesion activity, regardless of the receptor. These results confirm the essential and central role of the RGD sequence in vitronectin for cell adhesion. This expression system allows further structure/function analysis of vitronectin.	UNIV WASHINGTON,DEPT MED,DIV HEMATOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [K08CA001600] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040860, R01HL016919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01600] Funding Source: Medline; NHLBI NIH HHS [HL 16919, HL 40860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1983, P NATL ACAD SCI-BIOL, V80, P1362, DOI 10.1073/pnas.80.5.1362; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; FARRELL DH, 1986, BIOCHEM J, V27, P907; FITZGERALD LA, 1985, J BIOL CHEM, V260, P893; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HAYMAN EG, 1982, J CELL BIOL, V95, P20, DOI 10.1083/jcb.95.1.20; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; OBARA M, 1987, FEBS LETT, V213, P261, DOI 10.1016/0014-5793(87)81502-8; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLOW EF, 1990, HEMOSTASIS THROMB, V9, P117; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, CELL, V52, P229; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; THIAGARAJAN P, 1985, J CLIN INVEST, V75, P896, DOI 10.1172/JCI111789; THIAGARAJAN P, 1988, THROMB HAEMOSTASIS, V60, P514; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	41	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9725	9729						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683657				2022-12-25	WOS:A1993LA68900084
J	SILENCE, K; COLLEN, D; LIJNEN, HR				SILENCE, K; COLLEN, D; LIJNEN, HR			INTERACTION BETWEEN STAPHYLOKINASE, PLASMIN(OGEN), AND ALPHA-2-ANTIPLASMIN - RECYCLING OF STAPHYLOKINASE AFTER NEUTRALIZATION OF THE PLASMIN-STAPHYLOKINASE COMPLEX BY ALPHA-2-ANTIPLASMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOLYTIC PROPERTIES; ACTIVATION; UROKINASE; CHAIN; STREPTOKINASE; PURIFICATION; MECHANISM; KINETICS; PROTEIN; SITE	Although the plasminogen activating equimolar complex of staphylokinase (STA) with human plasmin is very rapidly inhibited by alpha2-antiplasmin, STA is a potent fibrinolytic agent in a human plasma milieu which contains 1 muM alpha2-antiplasmin. In the present study, it was found that the complex of plasmin with recombinant STA (STAR), after neutralization with alpha2-antiplasmin, retained the full plasminogen activating potential of STAR when added to a plasminogen solution (93 +/- 5% residual activity). When added to human plasma containing a I-125-fibrin-labeled plasma clot, equi-effective concentrations (causing 50% lysis in 2 h) were 17 +/- 3.0, 13 +/- 1.0, and 20 +/- 1.0 nM for STAR, equimolar plasmin-STAR mixtures, and plasmin-STAR mixtures neutralized by alpha2-antiplasmin, respectively. Gel filtration of mixtures of plasmin(ogen) and STAR revealed elution as plasmin-STAR complex (M(r) almost-equal-to 100,000), whereas after addition of alpha2-antiplasmin, STAR eluted with an apparent M(r) of 20,000. When mixtures of plasmin and STAR were adsorbed to lysine-Sepharose, STAR adsorbed quantitatively (96 +/- 1%) to the gel, whereas it was nearly quantitatively recovered in the unbound fraction (92 +/- 4%) after addition of alpha2-antiplasmin to the mixture. Scatchard analysis of the binding of STAR to plasmin-Sepharose yielded a dissociation constant of 55 nM, whereas no specific binding of STAR to plasmin-alpha2-antiplasmin-Sepharose could be demonstrated. These findings indicate that, both in purified systems and in a human plasma milieu containing a I-125-fibrin-labeled plasma clot, neutralization of the plasmin-STAR complex by alpha2-antiplasmin results in dissociation of functionally active STAR from the complex and recycling of STAR to other plasminogen molecules. This dissociation-recycling process may explain the high fibrinolytic potency of STAR in a plasma milieu in the presence of high concentrations of alpha2-antiplasmin.	CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, CAMPUS GASTHUISBERG, O & N HERESTR 49, B-3000 LOUVAIN, BELGIUM	KU Leuven			Lijnen, Roger/AAA-4085-2020					BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1992, FIBRINOLYSIS, V6, P232, DOI 10.1016/0268-9499(92)90076-T; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ERICSON R, 1977, CHEM ABSTR, V86, P202; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LEWIS JH, 1951, AM J PHYSIOL, V166, P594, DOI 10.1152/ajplegacy.1951.166.3.594; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, BIOCHIM BIOPHYS ACTA, V1118, P144, DOI 10.1016/0167-4838(92)90142-Z; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P468; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; MATSUO O, 1990, BLOOD, V76, P925; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; WIMAN B, 1977, EUR J BIOCHEM, V76, P129, DOI 10.1111/j.1432-1033.1977.tb11578.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P19	26	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9811	9816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683664				2022-12-25	WOS:A1993LA68900095
J	BAUMANN, H; ZIEGLER, SF; MOSLEY, B; MORELLA, KK; PAJOVIC, S; GEARING, DP				BAUMANN, H; ZIEGLER, SF; MOSLEY, B; MORELLA, KK; PAJOVIC, S; GEARING, DP			RECONSTITUTION OF THE RESPONSE TO LEUKEMIA INHIBITORY FACTOR, ONCOSTATIN-M, AND CILIARY NEUROTROPHIC FACTOR IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-PROTEIN GENES; ACUTE PHASE RESPONSE; RAT ALPHA-1-ACID GLYCOPROTEIN; COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; FACTOR RECEPTOR; EXPRESSION; INTERLEUKIN-6; GP130; CLONING	Ciliary neurotrophic factor (CNTF) has been described as a neuro-active cytokine that shares functional similarities with the leukemia inhibitory factor (LIF). We demonstrate here that, like LIF, CNTF stimulates expression of acute phase plasma proteins in rat H-35 hepatoma cells. Transfection of the LIF receptor into Hep3B hepatoma cells reconstituted LIF and oncostatin M regulation of acute phase plasma protein genes. Co-expression of the LIF receptor and the CNTF receptor, but not expression of either subunit alone, generated CNTF responsiveness in Hep3B cells, suggesting cooperativity of these receptor subunits. Evidence is presented for direct interaction of the LIF receptor with the intracellular signal transduction machinery.	IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	BAUMANN, H (corresponding author), NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1992, CIBA F SYMP, V167, P100; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Fey G H, 1990, Prog Liver Dis, V9, P89; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL AK, 1992, TRENDS NEUROSCI, V15, P35, DOI 10.1016/0166-2236(92)90022-Z; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242; ZIEGLER SF, 1993, IN PRESS MOL CELL BI	32	130	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8414	8417						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682551				2022-12-25	WOS:A1993KX81100009
J	NING, YM; SANCHEZ, ER				NING, YM; SANCHEZ, ER			POTENTIATION OF GLUCOCORTICOID RECEPTOR-MEDIATED GENE-EXPRESSION BY THE IMMUNOPHILIN LIGANDS FK506 AND RAPAMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEIN; BINDING; ACTIVATION; COMPLEXES; FK-506; PHOSPHOPROTEIN; CYTOSOL; DOMAINS; CLONING; EXISTS	It has recently been discovered that the steroid receptor-associated heat shock protein, hsp56, belongs to the FK506 family of immunophilin proteins. The ability of hsp56 to bind the immunosuppressive macrolide FK506 has led to the speculation that the steroid receptor and immunophilin signal transduction pathways are functionally interrelated. We have tested this idea by assessing the effects of FK506 on glucocorticoid receptor (GR)-mediated expression of the murine mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid. We report that combined treatment with FK506 and low concentrations of dexamethasone (10(-8) or 10(-7) M) results in a large enhancement of MMTV-CAT gene expression over that seen in response to dexamethasone (Dex) alone. FK506 potentiation of MMTV-CAT expression did not occur at 10(-6) M Dex or in the complete absence of hormone. We also show that potentiation of Dex-mediated MMTV-CAT expression occurs in response to rapamycin, that glucocorticoid-regulated enhancer sequences are sufficient for the FK506-mediated potentiation effect, and that this effect can be blocked by RU486 antagonist. Finally, we provide evidence that FK506 potentiation of GR-mediated gene expression is the result of increased translocation to the nucleus of the GR.	MED COLL OHIO,DEPT PHARMACOL,POB 10008,TOLEDO,OH 43699						NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043867, R29DK043867] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK043867, DK43867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DUMONT FJ, 1991, TRANSPLANT P, V23, P2870; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTO T, 1991, TRANSPL P, V23, P2713; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAIN AB, 1991, TRANSPLANT P, V23, P3023; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; ROSBOROUGH SL, 1991, TRANSPLANT P, V23, P2890; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIEKIERKA JJ, TRANSPLANT P, V23, P2720; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; YEM AW, 1992, J BIOL CHEM, V267, P2868	35	128	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6073	6076						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681058				2022-12-25	WOS:A1993KT36800003
J	YANAGAWA, H; YOSHIDA, K; TORIGOE, C; PARK, JS; SATO, K; SHIRAI, T; GO, M				YANAGAWA, H; YOSHIDA, K; TORIGOE, C; PARK, JS; SATO, K; SHIRAI, T; GO, M			PROTEIN ANATOMY - FUNCTIONAL ROLES OF BARNASE MODULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; HYDRATION-DEHYDRATION CYCLES; SACCHAROMYCES-CEREVISIAE; ALZHEIMER-DISEASE; STRUCTURAL UNITS; IDENTIFICATION; RIBONUCLEASES; SEQUENCE; FAMILY; KINASE	Globular proteins are composed of several modules that are contiguous polypeptide segments of compact conformation. Module boundaries are closely correlated with the intron positions of genes that encode proteins. The modules may thus have a one-to-one correspondence with exons in primordial genes. They may also be vestiges of polypeptide segments that initially appeared as primordial proteins in prebiological evolution. Clarification as to whether modules disconnected from one another have functional potentiality may validate these possibilities. Thus, in this study, each module of a protein was synthesized and assessed for functional potentiality. For this purpose, barnase, a bacterial ribonuclease, was decomposed into six modules (M1-M6), which were examined to determine whether they have an affinity for RNA and RNase activity. M2, M3, and M6, all of which form a shallow but wide cavity for RNA binding in native barnase, were found to bind to RNA and to possess RNase activity. However, M1 and M5, which support the other modules from the back side, and M4 did not bind to RNA and had no RNase activity. Protein modules with catalytic functions are described in this paper for the first time. That some modules of barnase possess catalytic activity indicates that protein modules may possibly have functioned as primitive catalysts in prebiological evolution.	NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	YANAGAWA, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BARBIER B, 1992, J AM CHEM SOC, V114, P3511, DOI 10.1021/ja00035a053; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BRESLOW R, 1989, P NATL ACAD SCI USA, V86, P1746, DOI 10.1073/pnas.86.6.1746; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DAY AG, 1992, BIOCHEMISTRY-US, V31, P6390, DOI 10.1021/bi00143a005; EGEBJERG J, 1989, J MOL BIOL, V206, P651, DOI 10.1016/0022-2836(89)90573-1; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; Go M., 1985, Advances in Biophysics, V19, P91; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HARTLEY RW, 1972, NATURE-NEW BIOL, V235, P15, DOI 10.1038/newbio235015a0; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HOSHINO T, 1990, J BACTERIOL, V172, P5531, DOI 10.1128/jb.172.10.5531-5539.1990; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ITO M, 1990, J MOL EVOL, V31, P187, DOI 10.1007/BF02109495; JENSEN EO, 1981, NATURE, V291, P677, DOI 10.1038/291677a0; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NISHIMURA S, 1959, BIOCHEMISTRY-US, V46, P161; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSTERMAN HL, 1978, BIOCHEMISTRY-US, V17, P4124, DOI 10.1021/bi00613a003; PADDON CJ, 1986, GENE, V40, P231, DOI DOI 10.1016/0378-1119(85)90045-9; RICHARDS FM, 1971, ENZYMES, V4, P647; RUSHIZKY GW, 1963, BIOCHEMISTRY-US, V2, P787, DOI 10.1021/bi00904a028; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; YANAGAWA H, 1990, J MOL EVOL, V31, P180, DOI 10.1007/BF02109494	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5861	5865						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680649				2022-12-25	WOS:A1993KR82200076
J	MACLEOD, AR; SZYF, M				MACLEOD, AR; SZYF, M			EXPRESSION OF ANTISENSE TO DNA METHYLTRANSFERASE MESSENGER-RNA INDUCES DNA DEMETHYLATION AND INHIBITS TUMORIGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO METHYLATION; GENE-EXPRESSION; HUMAN NEOPLASIA; CELL-LINES; PATTERNS; GROWTH; HYPERMETHYLATION; CHROMOSOME-11; MUTATION; SEQUENCE	Many tumor cell lines overexpress DNA methyltransferase (MeTase) activity; however it is still unclear whether this increase in DNA MeTase activity plays a causal role in naturally occurring tumors and cell lines, whether it is critical for the maintenance of transformed phenotypes, and whether inhibition of the DNA MeTase in tumor cells can reverse transformation, To address these basic questions, we transfected a murine adrenocortical tumor cell line Y1 with a chimeric construct expressing 600 base pairs from the 5' of the DNA MeTase cDNA in the antisense orientation, The antisense transfectants show DNA demethylation, distinct morphological alterations, are inhibited in their ability to grow in an anchorage-independent manner, and exhibit decreased tumorigenicity in syngeneic mice. Ex vivo, cells expressing the antisense construct show increased serum requirements, decreased rate of growth, and induction of an apoptotic death program upon serum deprivation, 5-Azadeoxycytidine-treated cells exhibit a similar dose dependent reversal of the transformed phenotype, These results support the hypothesis that the DNA MeTase is actively involved in oncogenic transformation.	MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1993, CURR BIOL, V3, P384, DOI 10.1016/0960-9822(93)90209-7; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; ELDEIRY WA, 1990, P NATL ACAD SCI USA, V88, P3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PA, 1984, DNA METHYLATION BIOC, P165; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAYSINGER D, 1993, NEUROCHEM INT, V23, P123, DOI 10.1016/0197-0186(93)90089-N; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SZYF M, 1992, J BIOL CHEM, V267, P12831; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1989, P NATL ACAD SCI USA, V86, P6853, DOI 10.1073/pnas.86.18.6853; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; SZYF M, 1991, BIOCH CELL BIOL, V64, P764; TAMMAME M, 1983, MOL CELL BIOL, V3, P2287; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719; YASUMURA Y, 1966, CANCER RES, V26, P529; YISRAELI J, 1985, DNA METHYLATION BIOC, P353	41	147	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8037	8043		10.1074/jbc.270.14.8037	http://dx.doi.org/10.1074/jbc.270.14.8037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713905	hybrid			2022-12-25	WOS:A1995QR52600041
J	SEOL, JH; BAEK, SH; KANG, MS; HA, DB; CHUNG, CH				SEOL, JH; BAEK, SH; KANG, MS; HA, DB; CHUNG, CH			DISTINCTIVE ROLES OF THE 2 ATP-BINDING SITES IN CLPA, THE ATPASE COMPONENT OF PROTEASE TI IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE; ACTIVATED ATPASE; MUTAGENESIS; CONTAINS; SUBUNITS; PROTEINS	ClpA is the ATPase component of the ATP dependent protease Ti (Clp) in Escherichia coli and contains two ATP-binding sites, A ClpA variant (referred to as ClpAT) carrying threonine in place of the 169th methionine has recently been shown to be highly soluble but indistinguishable from the wild type, 84-kDa ClpA in its ability to hydrolyze ATP and to support the casein-degrading activity of ClpP, Therefore, site-directed mutagenesis was performed to generate mutations in either of the two ATP-binding sites of ClpAT (i.e, to replace the Lys(220) or Lys(501) with Thr), ClpAT/K220T hydrolyzed ATP and supported the ClpP-mediated proteolysis 10-50% as well as ClpAT depending on ATP concentration, while ClpAT/K501T was unable to cleave ATP or to support the proteolysis. Without ATP, ClpAT and both of its mutant forms behaved as trimeric molecules as analyzed by gel filtration on a Sephacryl S-300 column, With 0.5 mM ATP, ClpAT and ClpAT/K501T became hexamers, but ClpAT/K220T remained trimeric, With 2 mM ATP, however, ClpAT/K220T also behaved as a hexamer, These results suggest that the first ATP-binding site of ClpA is responsible for hexamer formation, while the second is essential for ATP hydrolysis, When trimeric ClpAT/K220T was incubated with the same amount of hexameric ClpAT/K501T (i,e, at 0.5 mM ATP) and then subjected to gel filtration as above, a majority of ClpAT/K220T ran together with ClpAT/K501T as hexameric molecules. Furthermore, ClpAT/K501T in the mixture strongly inhibited the ability of ClpAT/K220T to cleave ATP and to support the ClpP-mediated proteolysis, Similar results were obtained in the presence of 2 mM ATP and also with the mixture with ClpAT, On the other hand, the ATPase activity of the mixture of ClpAT and ClpAT/R220T was significantly higher than the sum of that of each protein, particularly in the presence of 2 mM ATP, although its ability to support the proteolysis by ClpP remained un changed, These results suggest that a rapid exchange of the subunits, possibly as a trimeric unit, occurs between the ClpAT proteins in the presence of ATP and leads to the formation of mixed hexameric molecules.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MOLEC BIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, SRC CELL DIFFERENTIAT, SEOUL 151742, SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; SEOL JH, 1994, J BIOL CHEM, V269, P29468; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	22	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8087	8092		10.1074/jbc.270.14.8087	http://dx.doi.org/10.1074/jbc.270.14.8087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713911	hybrid			2022-12-25	WOS:A1995QR52600049
J	BUCKLE, RS; MECHALI, M				BUCKLE, RS; MECHALI, M			ANALYSIS OF C-MYC AND MAX BINDING TO THE C-MYC PROMOTER - EVIDENCE THAT AUTOSUPPRESSION OCCURS VIA AN INDIRECT MECHANISM	ONCOGENE			English	Note						C-MYC/MAX; AUTOSUPPRESSION; DNA BINDING PROTEINS; XENOPUS; DNA REPLICATION	DNA-BINDING; REPLICATION ORIGIN; PROTEIN; GENE; SEQUENCE; AUTOREGULATION; TRANSCRIPTION; ONCOPROTEIN; ASSOCIATION; ACTIVATION	c-myc negatively autoregulates its expression at the level of transcriptional initiation, although the precise mechanism remains debated. While conclusive evidence for c-Myc binding in its own promoter has not been found, it has been proposed that c-Myc binds to a site upstream of the human c-myc gene which may also be a component of a replication origin (Ariga et al., 1989). In an attempt to clarify this issue, sequences flanking the c-myc gene were screened for c-Myc or Max binding sites using a novel procedure to facilitate the detection of DNA binding dependent upon long distance interactions or DNA secondary structure, Since the sequence specificity of DNA binding proteins may also be mediated by interaction with other proteins or by protein modification, this affinity capture assay was used in conjunction with nuclear extracts, potentially allowing the selection of novel in vivo DNA binding spcificities. Using conditions that gave strong binding to an internal control sequence, c-Myc or Max binding elements were not detected in genomic sequences extending 5.4 kb upstream of the Xenopus c-myc gene. Identical results were obtained using both purified proteins and a variety of nuclear extracts, suggesting c-myc autosuppression most likely involves an indirect pathway.	INST JACQUES MONOD,MOLEC EMBRYOL UNIT,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cleveland J L, 1988, Oncogene Res, V3, P357; CROUCH DH, 1990, ONCOGENE, V5, P683; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V5, P1475; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HALZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6612; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P85; KITAURA H, 1991, FEBS LETT, V290, P147, DOI 10.1016/0014-5793(91)81246-5; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; NEGISHI Y, 1992, ONCOGENE, V7, P543; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4916; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WRIGHT WE, 1993, TRENDS BIOCHEM SCI, V18, P77, DOI 10.1016/0968-0004(93)90156-H; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	40	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1249	1255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700652				2022-12-25	WOS:A1995QN35300029
J	TRIMBLE, MS; XIN, JH; GUY, CT; MULLER, WJ; HASSELL, JA				TRIMBLE, MS; XIN, JH; GUY, CT; MULLER, WJ; HASSELL, JA			PEA3 IS OVEREXPRESSED IN MOUSE METASTATIC MAMMARY ADENOCARCINOMAS	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DNA-BINDING DOMAIN; NEU ONCOGENE; POLYOMAVIRUS ENHANCER; GENE FAMILY; PROTOONCOGENE; EXPRESSION; PROMOTER; AP-1; ACTIVATION	Transgenic mice bearing the rat neu proto-oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter develop focal mammary adenocarcinomas after long latency that are metastatic to the lung in a high percentage of the tumor-bearing animals. Because expression of the neu gene in the mammary epithelium precedes the occurrence of tumors, it appears that another genetic event in addition to neu transgene expression is required for tumorigenesis. We have investigated the expression of PEA3, a new member of the ets oncogene family of transcriptional regulatory factors, in neu-induced mammary tumors to learn whether PEA3 plays a role in tumor progression in this organ. We observed high levels of PEA3 RNA in neu-induced tumors, but little, if any, PEA3 RNA in the surrounding mammary epithelium. Moreover, mammary tumors that had metastasized to the lung also overexpressed the PEA3 gene, whereas normal lung tissue did not. Similar results were obtained after analyses of other transgenic mouse lines bearing metastatic mammary tumors induced by polyomavirus middle T antigen. These findings suggest that enhanced expression of PEA3 may be required to facilitate mammary tumor progression and metastasis.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,1280 MAIN ST W,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University								ASANO M, 1990, J VIROL, V64, P5927, DOI 10.1128/JVI.64.12.5927-5938.1990; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER WJ, 1991, CANCER METAST REV, V10, P217, DOI 10.1007/BF00050793; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; NERLOV C, 1991, ONCOGENE, V6, P1583; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; Sambrook J, 1989, MOL CLONING LABORATO; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	28	100	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3037	3042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692372				2022-12-25	WOS:A1993MC09300018
J	WARREN, JB; WILSON, AJ; LOI, RK; COUGHLAN, ML				WARREN, JB; WILSON, AJ; LOI, RK; COUGHLAN, ML			OPPOSING ROLES OF CYCLIC-AMP IN THE VASCULAR CONTROL OF EDEMA FORMATION	FASEB JOURNAL			English	Note						ENDOTHELIUM; ADENYLATE CYCLASE; EDEMA; PERMEABILITY; VASODILATION	CYCLASE-ACTIVATING POLYPEPTIDE; PLASMA-PROTEIN EXTRAVASATION; HAMSTER-CHEEK POUCH; ENDOTHELIAL PERMEABILITY; RABBIT SKIN; BLOOD-FLOW; GUINEA-PIG; MACROMOLECULAR LEAKAGE; DIBUTYRYL-CAMP; NITRIC-OXIDE	Eight agents that increase the intracellular concentration of cyclic AMP were tested for their effect on edema formation. The specificity of the agents for vascular smooth muscle or the endothelium was determined by measuring vasodilation with a laser Doppler flow probe and cAMP production by endothelial cells and vascular smooth muscle cells in culture. The agents were injected intradermally in anesthetized rabbit skin and the local accumulation of I-125-labeled albumin in response to intradermal bradykinin was measured. Iloprost, prostaglandin E1, prostaglandin E2, pituitary adenylate cyclase activating polypeptide (PACAP), and vasoactive intestinal polypeptide (VIP) potentiated bradykinin-induced edema. These same agents also increased blood flow and vascular smooth muscle cAMP concentrations, but did not increase endothelial cell cAMP production. Albuterol suppressed edema formation, did not cause vasodilation, but did increase endothelial cell cAMP concentrations. The phosphodiesterase inhibitor rolipram did not cause vasodilation, but suppressed edema and potentiated the cAMP response to albuterol in cultured endothelial cells. L-Isoproterenol affected both cell types. At a lower concentration L-isoproterenol was a potent stimulus to endothelial cell cAMP production and inhibited edema formation; a higher dose had additional effects on vascular smooth muscle and significantly increased blood flow. These findings support the hypothesis that increasing intracellular cAMP concentrations in vascular smooth muscle promotes edema via increased blood flow. In contrast, increasing cAMP concentrations in endothelium may suppress edema by enhancing the permeability barrier.			WARREN, JB (corresponding author), NATL HEART & LUNG INST,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.			Wilson, Amanda/0000-0001-5681-9611				ADVENIER C, 1992, BRIT J PHARMACOL, V105, P792, DOI 10.1111/j.1476-5381.1992.tb09059.x; ALEXANDER JS, 1988, MICROVASC RES, V35, P308, DOI 10.1016/0026-2862(88)90085-4; AMELANG E, 1981, CIRC RES, V49, P298, DOI 10.1161/01.RES.49.2.298; AXELROD L, 1983, LANCET, V1, P904; BARRY BW, 1978, J CLIN PHARMACY, V3, P43, DOI 10.1111/j.1365-2710.1978.tb00102.x; BEETS JL, 1980, BRIT J PHARMACOL, V70, P461, DOI 10.1111/j.1476-5381.1980.tb08724.x; CAMBRIDGE H, 1992, BRIT J PHARMACOL, V106, P746, DOI 10.1111/j.1476-5381.1992.tb14404.x; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; CHANG SW, 1989, AM REV RESPIR DIS, V140, P1814, DOI 10.1164/ajrccm/140.6.1814; DOUKAS J, 1989, MICROVASC RES, V37, P125, DOI 10.1016/0026-2862(89)90032-0; FARRUKH IS, 1987, J APPL PHYSIOL, V62, P47, DOI 10.1152/jappl.1987.62.1.47; GOLDMAN G, 1991, SURGERY, V109, P533; GREEN KL, 1972, BRIT J PHARMACOL, V223, P1165; GUDGEON JR, 1989, BRIT J PHARMACOL, V98, P1267, DOI 10.1111/j.1476-5381.1989.tb12673.x; JOYNER WL, 1979, MICROVASC RES, V18, P301, DOI 10.1016/0026-2862(79)90038-4; KATORI M, 1979, MICROVASC RES, V17, pS161; KAUFMAN RP, 1987, ANN SURG, V205, P195, DOI 10.1097/00000658-198702000-00015; KENNEDY TP, 1989, J APPL PHYSIOL, V67, P2542, DOI 10.1152/jappl.1989.67.6.2542; KLAUSNER JM, 1989, ANN SURG, V209, P219, DOI 10.1097/00000658-198902000-00013; KOPANIAK MM, 1978, MICROVASC RES, V15, P77, DOI 10.1016/0026-2862(78)90007-9; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; MCEWAN JR, 1990, ENDOTHELIUM INTRO CU; MINNEAR FL, 1989, AM J PHYSIOL, V257, pH1613, DOI 10.1152/ajpheart.1989.257.5.H1613; MONCADA S, 1991, TRENDS PHARMACOL SCI, V12, P130, DOI 10.1016/0165-6147(91)90528-Z; MONCADA S, 1973, NATURE, V246, P217, DOI 10.1038/246217a0; PATTON WF, 1991, ANAL BIOCHEM, V196, P31, DOI 10.1016/0003-2697(91)90113-8; RAMPART M, 1986, AM J PATHOL, V124, P66; SEIBERT AF, 1992, J APPL PHYSIOL, V72, P389, DOI 10.1152/jappl.1992.72.1.389; SIMIONESCU N, 1978, MICROVASC RES, V15, P1, DOI 10.1016/0026-2862(78)90001-8; SVENSJO E, 1978, PROSTAG LEUKOTR ESS, V1, P397, DOI 10.1016/0161-4630(78)90126-X; UEDA S, 1990, CIRC RES, V66, P957, DOI 10.1161/01.RES.66.4.957; WARREN JB, 1988, CLIN ALLERGY, V18, P197, DOI 10.1111/j.1365-2222.1988.tb02859.x; WARREN JB, 1990, P ROY SOC B-BIOL SCI, V241, P127, DOI 10.1098/rspb.1990.0076; WARREN JB, 1991, NEW ENGL J MED, V325, P1658; WARREN JB, 1993, BRIT J PHARMACOL, V109, P802, DOI 10.1111/j.1476-5381.1993.tb13645.x; WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476-5381.1992.tb14336.x; WARREN JB, 1992, BRIT J PHARMACOL, V106, P953, DOI 10.1111/j.1476-5381.1992.tb14441.x; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; WARREN JB, 1992, BRIT J PHARMACOL, V107, pP98; WARREN JB, 1989, BR J CLIN PHARM, V7, P173; WARREN JB, 1990, ENDOTHELIUM INTRO CU, P263; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WHELAN CJ, 1992, BRIT J PHARMACOL, V105, P831, DOI 10.1111/j.1476-5381.1992.tb09065.x; WILLIAMS TJ, 1982, BRIT J PHARMACOL, V77, P505, DOI 10.1111/j.1476-5381.1982.tb09324.x; WILLIAMS TJ, 1977, NATURE, V270, P530, DOI 10.1038/270530a0; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; WISSIG SL, 1979, ACTA PHYSL SCAND S, V463, P43; YAMADA Y, 1990, ARTERIOSCLEROSIS, V10, P410, DOI 10.1161/01.ATV.10.3.410	49	57	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1394	1400		10.1096/fasebj.7.14.7693536	http://dx.doi.org/10.1096/fasebj.7.14.7693536			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7693536				2022-12-25	WOS:A1993MH00800013
J	PERI, KG; GERVAIS, FG; WEIL, R; DAVIDSON, D; GISH, GD; VEILLETTE, A				PERI, KG; GERVAIS, FG; WEIL, R; DAVIDSON, D; GISH, GD; VEILLETTE, A			INTERACTIONS OF THE SH2 DOMAIN OF LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56(LCK) WITH PHOSPHOTYROSINE-CONTAINING PROTEINS	ONCOGENE			English	Article								We have previously demonstrated that the non-catalytic Src homology 2 (SH2) domain is required for both positive and negative regulation of the catalytic function of the lymphocyte-specific tyrosine protein kinase p56lck. Indeed, the ability of activated p56lck molecules (tyrosine 505 to phenylalanine 505 mutants) to enhance T-cell receptor (TCR)-induced tyrosine protein phosphorylation is dramatically reduced by deletion of the SH2 domain. Paradoxically, removal of the SH2 sequence also results in constitutive elevation of the catalytic function of wild-type Lck polypeptides, rendering them capable of oncogenic transformation of rodent fibroblasts. As SH2 sequences can mediate binding to phosphotyrosine-containing peptides, the ability of the Lck SH2 domain to interact with tyrosine-phosphorylated proteins was tested. We found that the SH2 sequence of p56lck can bind several of the TCR-regulated tyrosine phosphorylation substrates in vitro. One of the substrates, an 80-kilodalton (kDa) phosphoprotein (p80) showed the tightest binding to the SH2 domain of Lck. Additionally, it was observed that the SH2 domain of Lck can bind a synthetic peptide containing the phosphorylated carboxy-terminal tyrosine 505 of p56lck. Indirect evidence indicating that the SH2 region interacts with the tyrosine-phosphorylated carboxy terminus of Lck in vivo was also obtained. As deletion of the SH2 domain or mutation of tyrosine 505 results in p56lck activation in vivo, it is conceivable that interactions between these two regions impose a conformation that is unfavorable to phosphorylation of intracellular substrates. Collectively, these findings suggest that the SH2 domain modulates the catalytic function of Lck through complex interactions with phosphotyrosine-containing proteins.	MCGILL UNIV, MCGILL CANC CTR,ROOM 715B,MCINTYRE MED SCI BLDG, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV MED ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University; McGill University			Gish, Gerald D/C-7228-2017	Weil, Robert/0000-0001-5235-0932				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGERTON M, 1992, J IMMUNOL, V149, P1847; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2765	2772						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690927				2022-12-25	WOS:A1993LX34300018
J	KOIVUNEN, E; GAY, DA; RUOSLAHTI, E				KOIVUNEN, E; GAY, DA; RUOSLAHTI, E			SELECTION OF PEPTIDES BINDING TO THE ALPHA-5-BETA-1 INTEGRIN FROM PHAGE DISPLAY LIBRARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SITE-DIRECTED MUTAGENESIS; IIB-IIIA COMPLEX; FIBRONECTIN RECEPTOR; CELL-ADHESION; RGD PEPTIDE; SYNTHETIC PEPTIDE; RECOGNITION SITE; EPITOPE LIBRARY; ACID SEQUENCE	The alpha5beta1 integrin binds fibronectin through the integrin recognition sequence Arg-Gly-Asp (RGD). We have used a 6-amino acid peptide library expressed on filamentous phage to identify peptide ligands for alpha5beta1. We found that this integrin selectively binds RGD-containing peptides from the library. Of the 32 different sequences obtained, 28 had the RGD motif, 3 contained sequences related to RGD, and only 1 had a clearly different sequence. One of the RGD-containing phage encoded a potentially cyclic insert CRGDCL. The cyclic peptide GAC*RGDC*LGA (where * denotes cysteines forming a disulfide bond) was 10-fold more efficient than any of the linear RGD-containing hexapeptides in inhibiting the binding of RGD-expressing phage to alpha5beta1 or the attachment of alpha5beta1-expressing cells to fibronectin. This peptide also inhibited cell attachment mediated by the alpha(v)beta1, alpha(v)beta3, and alpha(v)beta5, integrins with about 10-fold higher efficiency than linear GRGDSP. One peptide containing an RGD-related sequence, NGRAHA, was also found to inhibit phage attachment and cell adhesion, especially adhesion mediated by the alpha(v)beta5 integrin. These results indicate that novel and high affinity ligands for integrins can be isolated from a random peptide library.	LA JOLLA CANC RES FDN,CTR CANC RES,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA42507, CA30199, CA28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R35CA042507, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALEXANDER H, 1992, P NATL ACAD SCI USA, V89, P3352, DOI 10.1073/pnas.89.8.3352; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GURRATH M, 1992, EUR J BIOCHEM, V270, P911; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HUANG TF, 1987, J BIOL CHEM, V262, P16157; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMURA Y, 1992, BLOOD, V80, P1247; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SAIKI I, 1989, CANCER RES, V49, P3815; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCHREINER C, 1991, CANCER RES, V51, P1738; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1987, VECTORS SURVEY MOL C, P61; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TSCHOPP JF, 1993, IN PRESS CORONARY AR; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	62	317	363	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20205	20210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690752				2022-12-25	WOS:A1993LY01900045
J	SPERANZA, MJ; BAGLEY, AC; LYNCH, RE				SPERANZA, MJ; BAGLEY, AC; LYNCH, RE			CELLS ENRICHED FOR CATALASE ARE SENSITIZED TO THE TOXICITIES OF BLEOMYCIN, ADRIAMYCIN, AND PARAQUAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; ACTIVATED BLEOMYCIN; ESCHERICHIA-COLI; OXYGEN; IRON; DRUG; EXPRESSION; ANALOGS; COMPLEX; ASSAY	L cells were enriched about 100-fold for catalase by the transcription of the transfected cDNA for human catalase. In spite of substantial enrichment for catalase, the transfected cells (LFN7C/B3) were not resistant to the cytotoxicity of a variety of agents which reduce dioxygen, including paraquat, menadione, adriamycin, phenazine methosulfate, and bleomycin. Instead, they were more sensitive to paraquat, bleomycin, and adriamycin than the untransfected cells from which they derived. Desferrioxamine afforded the cells enriched for catalase modest protection from the toxicities of bleomycin, paraquat, or adriamycin, suggesting that enrichment for iron as a consequence of the increased cellular content of catalase accounted for some of the increased sensitivities. The increased sensitivity of the LFN7C/B3 cells to bleomycin and paraquat was also attributed to the ability of catalase in cells to prevent the drug-induced consumption of O2; by capturing H2O2 before it can escape the cell and converting it to O2, catalase can maintain the concentration of O2 either for repeated rounds of chemical reduction or for direct interaction with the toxin. As predicted by this formulation, the toxicities of paraquat and of bleomycin were increased in an atmosphere of 40% dioxygen in comparison with an atmosphere of 20% dioxygen.	VET ADM MED CTR, RES SERV, 500 FOOTHILL DR, SALT LAKE CITY, UT 84148 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah								BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BEERS RF, 1952, J BIOL CHEM, V195, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1982, J BIOL CHEM, V257, P3372; BURGER RM, 1979, J BIOL CHEM, V254, P906; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CARMAGNOL F, 1983, BIOCHIM BIOPHYS ACTA, V759, P49, DOI 10.1016/0304-4165(83)90188-5; CLARE DA, 1984, ANAL BIOCHEM, V140, P532, DOI 10.1016/0003-2697(84)90204-5; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DHAUNSI GS, 1992, J BIOL CHEM, V267, P6870; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P237, DOI 10.1021/bi00568a037; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; ROOS DS, 1987, P NATL ACAD SCI USA, V84, P4860, DOI 10.1073/pnas.84.14.4860; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WANDERS RJA, 1992, BIOCHIM BIOPHYS ACTA, V1115, P259, DOI 10.1016/0304-4165(92)90063-Z	28	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19039	19043						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689565				2022-12-25	WOS:A1993LV65900099
J	BUSCONI, L; MICHEL, T				BUSCONI, L; MICHEL, T			ENDOTHELIAL NITRIC-OXIDE SYNTHASE - N-TERMINAL MYRISTOYLATION DETERMINES SUBCELLULAR-LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN ALPHA-SUBUNIT; KINASE-C; MEMBRANE; PURIFICATION; BINDING; PHOSPHORYLATION; FLAVOPROTEIN; ASSOCIATION; SUBSTRATE; CELLS	Nitric oxide synthases in diverse mammalian tissues catalyze the oxidation Of L-arginine to L-citrulline plus nitric oxide (NO). In the vascular endothelium, synthesis of NO yields a labile intercellular messenger molecule with potent biological activities, including vascular smooth muscle relaxation. We have recently documented that the endothelial cell NO synthase (EC-NOS) constitutes a genetically distinct tissue-specific enzyme isoform. In further contrast to the soluble NO synthases found in neural tissues and in macrophages , the endothelial enzyme is associated primarily with the particulate fraction. Analysis of molecular clones for the endothelial NO synthase reveals no obvious transmembrane-spanning region, but a consensus motif for N-terminal myristoylation was identified; such a consensus sequence is not evident in the primary sequence of the soluble macrophage and neural NO synthases. We performed oligonucleotide-directed mutagenesis of the myristoylation consensus sequence in the endothelial NO synthase cDNA, and studied the pattern of expression of the wild-type and mutant EC-NOS cDNAs in transient transfection experiments in COS-7 cells. The subcellular localization of heterologous endothelial NO synthase was determined using analyses of enzyme activity as well as immunoprecipitation of biosynthetically labeled NO synthase with a highly specific antipeptide antibody. Expression of the wild-type endothelial NO synthase cDNA in COS-7 cells results in targeting of both enzyme activity and NO synthase immunoreactivity primarily to the particulate fraction. By contrast, transient expression of the myristoylation- mutant cDNA in COS-7 cells yields NO synthase enzyme activity and immunoreactivity associated exclusively with the cytosol fraction. Following biosynthetic labeling with [H-3]myristate, the NO synthase can be specifically immunoprecipitated from the particulate fraction in endothelial and in COS-7 cells transfected with the wild-type cDNA, but not in cells transfected with the myristoylation- mutant EC-NOS cDNA. N-terminal myristoylation of the endothelial NO synthase may provide a potential point of regulation of the biological functions of endothelium-derived NO in situ.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School								ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BOJE KM, 1990, J PHARMACOL EXP THER, V253, P20; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P66; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	26	265	273	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8410	8413						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682550				2022-12-25	WOS:A1993KX81100008
J	RUFFJAMISON, S; MCGLADE, J; PAWSON, T; CHEN, K; COHEN, S				RUFFJAMISON, S; MCGLADE, J; PAWSON, T; CHEN, K; COHEN, S			EPIDERMAL GROWTH-FACTOR STIMULATES THE TYROSINE PHOSPHORYLATION OF SHC IN THE MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTORS; PROTEINS; KINASE	Previous studies have demonstrated that the administration of epidermal growth factor (EGF) to neonatal mice results in the tyrosine phosphorylation of multiple substrates in all organs examined (Donaldson, R. W., and Cohen, S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8477-8481). One of these substrates, a 55-kDa protein, was shown to associate with the receptor for EGF (EGFR). We now report the identification of this receptor-associated protein as SHC. Immunoprecipitation and Western blotting analyses have revealed that SHC associates only with the activated EGFR. In the absence of EGF stimulation, SHC exists in the liver as a cytoplasmic monomer. Intraperitoneal injection of EGF results, within minutes, in the translocation of 50-80% of SHC to the liver plasma membrane. The membrane-associated SHC was found to be tyrosine-phosphorylated; the subsequent release of SHC from the membrane correlated with a tyrosine dephosphorylation. We conclude that SHC is a physiological substrate that appears to participate in the in vivo signaling response to EGF.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, 607 LIGHT HALL, NASHVILLE, TN 37232 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA	Vanderbilt University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000700] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-00700] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSAKISADCOCK M, 1992, NATURE, V360, P689; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	19	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7610	7612						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681824				2022-12-25	WOS:A1993KW97900003
J	BOSE, S; SEETHARAM, S; SEETHARAM, B				BOSE, S; SEETHARAM, S; SEETHARAM, B			MEMBRANE EXPRESSION AND INTERACTIONS OF HUMAN TRANSCOBALAMIN-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC FACTOR-COBALAMIN; HUMAN-PLACENTA; RAT-KIDNEY; BINDING; CELLS; PROTEINS; LIVER; PURIFICATION	Antiserum raised to purified 62-kDa human placental transcobalamin II receptor (TC II-R) has been used to study its synthesis and membrane expression. The anti-serum immunoprecipitated a 45-kDa protein from the cell-free translation using human kidney mRNA and recognized a single 124-kDa band on immunoblotting of placental and other human tissue membranes, and quantitation of the blots revealed high levels of TC II-R expression in the human kidney followed by placenta, intestine, and liver. Triton X-100 extraction of placental membranes resulted in the complete (100%) solubilization of the receptor, and immunoblotting of the Triton X-100-soluble fraction revealed a single band of 62 kDa. Lipid extraction of placental membranes with a mixture of chloroform:methanol (2:1) followed by immunoblotting revealed a single band of molecular mass 62 kDa. The molecular mass of the pure Triton X-100-bound receptor increased on SDS-polyacrylamide gel electrophoresis from 62 to 124 kDa upon its insertion in liposomes prepared using egg phosphatidylcholine and cholesterol. Chemical cross-linking of native membrane- or lipid vesicle-bound TC II-R or detergent-soluble extracts of the membrane with I-125-TC II-cobalamin revealed that both the 124- and 62-kDa forms of the receptor were active in ligand binding. Based on these results we suggest that TC II-R is synthesized as a single polypeptide of 45 kDa, and following its maturation (involving N- and O-glycosylation) the 62-kDa mature receptor is expressed in plasma membranes as a noncovalent dimer of 124 kDa. The dimerization of TC II-R in the plasma membranes is due to its interactions with annular lipids.	MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK26638] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen R H, 1975, Prog Hematol, V9, P57; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; BURNETTE WN, 1981, ANAL BIOCHEM, V7, P195; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRYDEN LP, 1966, J NUTR, V90, P382, DOI 10.1093/jn/90.4.382; FIDLERNAGY C, 1975, BRIT J HAEMATOL, V31, P311; FRIEDMAN PA, 1977, J CLIN INVEST, V59, P51, DOI 10.1172/JCI108621; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GROSSOWICZ N, 1970, AM J CLIN NUTR, V23, P127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P21, DOI 10.1016/0167-4781(93)90264-E; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LOW MG, 1980, BIOCHEMISTRY-US, V19, P3913, DOI 10.1021/bi00558a004; NEXO E, 1980, BIOCHIM BIOPHYS ACTA, V628, P190, DOI 10.1016/0304-4165(80)90366-9; OKUDA K, 1962, NATURE, V195, P292, DOI 10.1038/195292a0; OKUDA K, 1962, J NUTR, V77, P131, DOI 10.1093/jn/77.2.131; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; QUADROS EV, 1994, ARCH BIOCHEM BIOPHYS, V308, P192, DOI 10.1006/abbi.1994.1027; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1991, BIOCHEM BIOPH RES CO, V179, P543, DOI 10.1016/0006-291X(91)91405-2; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCOTT JSD, 1984, CLIN SCI, V67, P299, DOI 10.1042/cs0670299; SCOTT JSD, 1985, CLIN SCI, V68, P357, DOI 10.1042/cs0680357; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM S, 1991, BIOCHEM BIOPH RES CO, V177, P751, DOI 10.1016/0006-291X(91)91852-4; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; YAMADA S, 1991, KIDNEY INT, V19, P289; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	30	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8152	8157		10.1074/jbc.270.14.8152	http://dx.doi.org/10.1074/jbc.270.14.8152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713919	hybrid			2022-12-25	WOS:A1995QR52600058
J	CHATHAM, JC; FORDER, JR; GLICKSON, JD; CHANCE, EM				CHATHAM, JC; FORDER, JR; GLICKSON, JD; CHANCE, EM			CALCULATION OF ABSOLUTE METABOLIC FLUX AND THE ELUCIDATION OF THE PATHWAYS OF GLUTAMATE LABELING IN PERFUSED RAT-HEART BY C-13 NMR-SPECTROSCOPY AND NONLINEAR LEAST-SQUARES ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID-CYCLE; NUCLEAR-MAGNETIC-RESONANCE; NADP MALATE DEHYDROGENASE; GLUCOSE-METABOLISM; PYRUVATE CARBOXYLATION; BRAIN INVIVO; CARBON FLUX; MITOCHONDRIAL; MUSCLE; MYOCARDIUM	Absolute metabolic fluxes in isolated perfused hearts have been determined by a nonlinear least squares analysis of glutamate labeling kinetics from [1-C-13]glucose, [4-C-13]beta-hydroxybutyrate, or [2-C-13]acetate using C-13 NMR spectroscopy. With glucose as substrate, the malate-aspartate shuttle flux was too slow to account for the reducing equivalents generated by glycolysis and to predict the observed oxygen consumption rate. For acetate and beta-hydroxybutyrate, the malate-aspartate shuttle had to be reversed for the network to agree with the observed oxygen consumption and glutamate labeling. Thus, an additional redox shuttle was required to reoxidize the NADH produced by cytoplasmic malate dehydrogenase. Using this model there was good agreement between the experimentally determined oxygen consumption and glutamate labeling and the calculated values of these parameters from the model for all substrates. The contribution of exogenous substrate to the overall tricarboxylic acid (TCA) cycle flux, 89.6 +/- 6.5% (mean +/- S.D.) as measured in the tissue extracts compared well with 91.4 +/- 4.2% calculated by the model. The ratio of TCA cycle flux to oxygen consumption for acetate, was 2.2 +/- 0.1, indicating that NADH production is principally accounted for by TCA cycle flux. For glucose or beta-hydroxybutyrate, this ratio was 2.9 +/- 0.2, consistent with the existence of other NADH producing reactions (e.g. glycolysis, beta-hydroxybutyrate oxidation).	JOHNS HOPKINS UNIV, SCH MED, DEPT RADIOL & RADIOL SCI, DIV NMR RES, BALTIMORE, MD 21205 USA; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Johns Hopkins University; University of London; University College London			Glickson, Jerry/AAR-7116-2021		NATIONAL CANCER INSTITUTE [R01CA051950, R01CA051935] Funding Source: NIH RePORTER; NCI NIH HHS [CA51950, CA51935] Funding Source: Medline; NHLBI NIH HHS [HL30579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY IA, 1981, FEBS LETT, V123, P315, DOI 10.1016/0014-5793(81)80317-1; BARKER PB, 1990, 9TH ANN SCI M NEW YO; BECKMANN N, 1991, BIOCHEMISTRY-US, V30, P6362, DOI 10.1021/bi00240a002; Bergmeyer H.U., 1985, METHODS ENZYMATIC AN; BERS DM, 1991, EXCITATION CONTRACTI; BRDICZKA D, 1971, EUR J BIOCHEM, V19, P546, DOI 10.1111/j.1432-1033.1971.tb01347.x; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHANCKO VP, 1993, AM J PHYSIOL, V264, pC755; CHATHAM JC, 1992, BIOCHIM BIOPHYS ACTA, V1138, P1, DOI 10.1016/0925-4439(92)90143-B; CHATHAM JC, 1990, J MOL CELL CARDIOL, V22, P1187, DOI 10.1016/0022-2828(90)90082-D; CHATHAM JC, 1993, J MOL CELL CARDIOL, V25, P1203, DOI 10.1006/jmcc.1993.1133; CHATHAM JC, 1994, J MOL CELL CARDIOL, V26, pR176; COHEN DM, 1994, COMPUT BIOMED RES, V27, P130, DOI 10.1006/cbmr.1994.1013; COHEN DM, 1994, AM J PHYSIOL, V266, pE341, DOI 10.1152/ajpendo.1994.266.3.E341; DAHLEN JV, 1968, ARCH BIOCHEM BIOPHYS, V127, P207, DOI 10.1016/0003-9861(68)90218-X; DAVIS EJ, 1980, EUR J BIOCHEM, V110, P255, DOI 10.1111/j.1432-1033.1980.tb04863.x; DENHOLLANDER JA, 1981, P NATL ACAD SCI-BIOL, V78, P2693; DICKINSON JR, 1983, P NATL ACAD SCI-BIOL, V80, P5847, DOI 10.1073/pnas.80.19.5847; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; HOEKENGA DE, 1988, CIRC RES, V62, P1065, DOI 10.1161/01.RES.62.6.1065; ISAACS GH, 1969, BIOCHIM BIOPHYS ACTA, V177, P196, DOI 10.1016/0304-4165(69)90128-7; Jans A W, 1989, NMR Biomed, V1, P171, DOI 10.1002/nbm.1940010404; JUE T, 1989, P NATL ACAD SCI USA, V86, P4489, DOI 10.1073/pnas.86.12.4489; KUCHEL PW, 1990, BIOMED BIOCHIM ACTA, V49, P757; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LYON RC, 1988, CANCER RES, V48, P870; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MOWBRAY J, 1973, EUR J BIOCHEM, V36, P362, DOI 10.1111/j.1432-1033.1973.tb02920.x; NAGEL WO, 1980, J BIOL CHEM, V255, P3849; NEWSHOLME EA, 1978, BIOCHEM J, V176, P623, DOI 10.1042/bj1760623; NOLTE J, 1972, BIOCHIM BIOPHYS ACTA, V284, P497, DOI 10.1016/0005-2744(72)90148-9; NUUTINEN EM, 1981, BIOCHEM J, V194, P867, DOI 10.1042/bj1940867; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; PEUHKURINEN KJ, 1982, BIOCHEM J, V208, P577, DOI 10.1042/bj2080577; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; PEUHKURINEN KJ, 1983, AM J PHYSIOL, V244, pH281, DOI 10.1152/ajpheart.1983.244.2.H281; PISRARENKO OI, 1986, BIOCHIM BIOPHYS ACTA, V885, P154; REO NV, 1984, J BIOL CHEM, V259, P3664; ROBITAILLE PML, 1993, J BIOL CHEM, V268, P26296; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; SAFER B, 1971, J MOL CELL CARDIOL, V2, P111, DOI 10.1016/0022-2828(71)90065-4; TAKALA T, 1980, BIOCHEM J, V192, P285, DOI 10.1042/bj1920285; WEISS RG, 1989, P NATL ACAD SCI USA, V86, P6426, DOI 10.1073/pnas.86.16.6426; WEISS RG, 1992, CIRC RES, V70, P392, DOI 10.1161/01.RES.70.2.392; [No title captured]	48	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7999	8008		10.1074/jbc.270.14.7999	http://dx.doi.org/10.1074/jbc.270.14.7999			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713900	hybrid			2022-12-25	WOS:A1995QR52600036
J	FRASER, IDC; MARSTON, SB				FRASER, IDC; MARSTON, SB			IN-VITRO MOTILITY ANALYSIS OF ACTIN-TROPOMYOSIN REGULATION BY TROPONIN AND CALCIUM - THE THIN FILAMENT IS SWITCHED AS A SINGLE COOPERATIVE UNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; SKELETAL-MUSCLE; MYOSIN SUBFRAGMENT-1; BINDING; MOVEMENT; COMPLEX; CONTRACTION; INVITRO; CA-2+	In striated muscles, contractility is controlled by Ca2+ binding to the regulatory protein complex troponin, which is a component of the thin filaments. Troponin is an allosteric inhibitor acting on tropomyosin to switch the thin filament between ''on'' and ''off'' states. We have used an in vitro motility assay to examine troponin regulation of individual actin-tropomysin filaments moving over immobilized skeletal muscle heavy meromyosin. The most striking observation is that the actin-tropomyosin filament appears to be regulated as a single unit. At pCa 9.0, addition of up to 4 nM troponin causes the proportion of filaments motile to decrease from >85% to 20% with no dissociation of the filaments from the heavy meromyosin surface or change in velocity. Increasing Ca2+ concentration causes the filaments to be switched back on the half-maximal increase in the proportion of filaments motile at pCa 5.8-6.0 and a modest increase in filament velocity. This is an ''all or none'' process in which an entire filament, up to 15 mu M long, switches rapidly as a single cooperative unit. Thus, the effect of Ca2+ upon the thin filament is to recruit motile filaments.	NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND	Imperial College London			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907				BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRENNER B, 1986, BASIC RES CARDIOL, V81, P54, DOI 10.1007/BF01907427; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; BRENNER B, 1980, BASIC RES CARDIOL, V75, P40, DOI 10.1007/BF02001392; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; EBASHI S, 1968, J BIOCHEM-TOKYO, V64, P465, DOI 10.1093/oxfordjournals.jbchem.a128918; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; GREENE LE, 1986, J BIOL CHEM, V261, P1279; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HILL LE, 1992, J BIOL CHEM, V267, P16106; HONDA H, 1989, J MOL BIOL, V205, P677, DOI 10.1016/0022-2836(89)90313-6; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; VANEERD JP, 1973, BIOCHEMISTRY-US, V12, P4972, DOI 10.1021/bi00748a024; WANG F, 1993, J BIOL CHEM, V268, P3776; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048	29	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7836	7841		10.1074/jbc.270.14.7836	http://dx.doi.org/10.1074/jbc.270.14.7836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713874	hybrid			2022-12-25	WOS:A1995QR52600010
J	DONG, F; GOGOL, EP; VONHIPPEL, PH				DONG, F; GOGOL, EP; VONHIPPEL, PH			THE PHAGE T4-CODED DNA-REPLICATION HELICASE (GP41) FORMS A HEXAMER UPON ACTIVATION BY NUCLEOSIDE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; RNA PRIMER SYNTHESIS; BACTERIOPHAGE-T4-DNA PRIMASE-HELICASE; ESCHERICHIA-COLI; PHYSICAL-PROPERTIES; GENE-41 PROTEIN; FUNCTIONAL INTERACTIONS; LIGAND COFACTORS; DEPENDENT ATPASE; PURIFICATION	Sedimentation and high performance liquid chromatography studies show that the functional DNA replication helicase of bacteriophage T4 (gp41) exists primarily as a dimer at physiological protein concentrations, assembling from gp41 monomers with an association constant of similar to 10(6) M(-1). Cryoelectron microscopy, analytical ultracentrifugation, and protein-protein cross-linking studies demonstrate that the binding of ATP or GTP drives the assembly of these dimers into monodisperse hexameric complexes, which redissociate following depletion of the purine nucleotide triphosphatase (PuTP) substrates by the DNA-stimulated PuTPase activity of the helicase. The hexameric state of gp41 can be stabilized for detailed study by the addition of the nonhydrolyzable PuTP analogs ATP(gamma)S and GTP(gamma)S and is not significantly affected by the presence of ADP, GDP, or single-stranded or forked DNA template constructs, although some structural details of the hexameric complex may be altered by DNA binding. Our results also indicate that the active gp41 helicase exists as a hexagonal trimer of asymmetric dimers, and that the hexamer is probably characterized by D3 symmetry. The assembly pathway of the gp41 helicase has been analyzed, and its structure and properties compared with those of other helicases involved in a variety of cellular processes. Functional implications of such structural organization are also considered.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA; UNIV MISSOURI, DIV CELL BIOL & BIOPHYS, KANSAS CITY, MO 64110 USA	University of Oregon; University of Oregon; University of Missouri System; University of Missouri Kansas City				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R37GM015792, R01GM029158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1988, CANCER CELL, V6, P1; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; HINGORANI MM, 1994, J CELL BIOCHEM, P151; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HINTON DM, 1987, UCLA S MOL CELLULAR, V47, P173; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2933; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; Kornberg A., 1992, DNA REPLICATION; KUROSAWA Y, 1979, J MOL BIOL, V135, P841, DOI 10.1016/0022-2836(79)90515-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MANIATIS T, 1982, MOL CLONING LABORATO, P178; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; OH EY, 1989, J BIOL CHEM, V264, P1336; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VANHOLDE KE, 1976, PROTEINS, P225; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG Y, 1993, J BIOL CHEM, V268, P13947; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEBER K, 1969, J BIOL CHEM, V244, P4406; Weber K., 1975, PROTEINS, VI, P179; WOOD ER, 1987, J BIOL CHEM, V262, P15269; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; Young Mark C., 1994, P313; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	73	150	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7462	7473		10.1074/jbc.270.13.7462	http://dx.doi.org/10.1074/jbc.270.13.7462			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706292	hybrid			2022-12-25	WOS:A1995QQ43100067
J	MULLER, E; SCHEIDTMANN, KH				MULLER, E; SCHEIDTMANN, KH			PURIFICATION AND CHARACTERIZATION OF A PROTEIN-KINASE WHICH IS ACTIVATED BY SV40 LARGE T-ANTIGEN AND PHOSPHORYLATES THE TUMOR-SUPPRESSOR PROTEIN P53	ONCOGENE			English	Article						T-ANTIGEN; LT-ACTIVATED KINASE; P53 PHOSPHORYLATION; CELL CYCLE; TRANSFORMATION	WILD-TYPE P53; CELL-CYCLE CONTROL; DNA-REPLICATION; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; 3T3 CELLS; SITE; TRANSFORMATION; BINDING	In SV40-transformed or infected rat cells phosphorylation of the tumor suppressor protein p53 is enhanced due to activation of kinases. At least three different kinases can be co-precipitated with p53-large T (LT) immune complexes, casein kinase II representing the major activity, a cyclin dependent kinase (Cdk), and a kinase which appears to be specifically activated by LT (E Muller, B Boldyreff and KH Scheidtmann, Oncogene 8: 2193-2205, 1993). In this paper we describe the purification and identification of the LT-activated kinase that phosphorylates a site adjacent to the Cdk site in rat p53. To monitor the activity a synthetic peptide was used containing glutamic acid at the position of Ser-313, thus mimicking a phosphorylated Cdk site, With a combination of Mono Q chromatography and subsequent affinity chromatographies with p13(suc1) and a p53-fragment as ligands a 42 kDa protein kinase was purified to near homogeneity from SV40-transformed rat cells, This kinase phosphorylated both the peptide substrate and the native rat p53, Interestingly, phosphorylation of the specific site seemed to depend on prior phosphorylation of the Cdk site. On the other hand, the kinase seemed to be activated by LT, as the activity towards the peptide substrate was significantly higher in extracts from wildtype LT-transformed cells than from normal or mutant LT-transformed cells, This activation was not restricted to rat cells but occurred in SV40-transformed mouse and infected monkey cells as well, Phosphorylation of the specific site by LT-activated kinase was not dependent on the presence of LT in vitro suggesting that activation of the LT-activated kinase is probably indirect rather than through direct interaction with LT. Cell cycle studies revealed that the LT-activated kinase is cell cycle regulated, since its activity was not detectable in M phase but increased during G1 phase after which it remained relatively constant.	UNIV BONN, INST GENET, DEPT MOLEC GENET, D-53117 BONN, GERMANY	University of Bonn								BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MULLER E, 1993, ONCOGENE, V8, P2193; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; OROURKE RW, 1990, ONCOGENE, V5, P1829; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SCHEIDTMANN KH, 1989, CURR TOP MICROBIOL, V144, P85; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU JS, 1994, J BIOL CHEM, V269, P14341; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	74	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1175	1185						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700642				2022-12-25	WOS:A1995QN35300019
J	ZHAN, X; HU, XG; HAMPTON, B; BURGESS, WH; FRIESEL, R; MACIAG, T				ZHAN, X; HU, XG; HAMPTON, B; BURGESS, WH; FRIESEL, R; MACIAG, T			MURINE CORTACTIN IS PHOSPHORYLATED IN RESPONSE TO FIBROBLAST GROWTH FACTOR-I ON TYROSINE RESIDUES LATE IN THE G(1) PHASE OF THE BALB/C 3T3 CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL TRANSDUCTION; CDNA CLONING; RECEPTOR; BINDING; IDENTIFICATION; SUBSTRATE; ASSOCIATION; PI3-KINASE; SEQUENCE	We have previously reported that BALB/c 3T3 cells require a prolonged exposure to fibroblast growth factor (FGF)-1 for the stimulation of maximal DNA synthesis, and this event correlates with the tyrosine phosphorylation of novel proteins late in G, including a protein termed p80/p85 (Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 9611-9620). We have purified, sequenced, and cloned the cDNA encoding p80/p85 and report that it is the murine homolog of the chicken cortactin gene and a member of the human hematopoietic specific-1 gene family. Immunochemical analysis of m-cortactin-tyrosine phosphorylation in response to FGF-1 demonstrates a biphasic phosphorylation pattern both as a weak immediate-early and strong mid to late G1 response protein. Because the chicken cortactin gene was originally isolated as a substrate for v-Src, FGF-1 may influence the enzymatic activity of other cell-associated tyrosine kinases which utilize p80/p85 (cortactin) as a polypeptide substrate.	AMER RED CROSS, HOLLAND LAB, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA	American Red Cross			Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, P50HL044336, R01HL035762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32348, HL44336, HL35762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; EGERTON M, 1992, J IMMUNOL, V149, P1847; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAA MC, 1992, ONCOGENE, V7, P2429; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAPP UR, 1991, ONCOGENE, V6, P495; Sambrook J, 1989, MOL CLONING LABORATO; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHAN X, 1993, J BIOL CHEM, V268, P9611	23	116	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24427	24431						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693700				2022-12-25	WOS:A1993MF29400105
J	NYKJAER, A; BENGTSSONOLIVECRONA, G; LOOKENE, A; MOESTRUP, SK; PETERSEN, CM; WEBER, W; BEISIEGEL, U; GLIEMANN, J				NYKJAER, A; BENGTSSONOLIVECRONA, G; LOOKENE, A; MOESTRUP, SK; PETERSEN, CM; WEBER, W; BEISIEGEL, U; GLIEMANN, J			THE ALPHA(2)-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN BINDS LIPOPROTEIN-LIPASE AND BETA-MIGRATING VERY-LOW-DENSITY LIPOPROTEIN ASSOCIATED WITH THE LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; LIGAND RECOGNITION; APOLIPOPROTEIN-E; CELL-SURFACE; LRP; CHYLOMICRONS; PURIFICATION; CONFORMATION; MECHANISM	Lipoprotein lipase (LPL) causes a marked increase in the cellular binding of beta-migrating very low density lipoprotein (beta-VLDL) to a large receptor compatible with the alpha2-macroglobulin receptor (alpha2MR)/low density lipoprotein receptor-related protein (LRP) (Beisiegel, U., Weber, W., and Bengtsson-Olivecrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346). Here we demonstrate that LPL binds to the alpha-chain of purified alpha2MR/LRP immobilized on microtiter plates. The binding, apparently to multiple sites, was blocked by heparin and inhibited by the alpha2MR-associated protein (alpha2MRAP) and by EDTA. Immobilized LPL bound alpha2MR/LRP in solution as well as beta-VLDL prepared from cholesterol-fed rabbits. Both binding reactions were dependent on an intact carboxyl-terminal folding domain of LPL, but were independent of its dimeric structure and intact catalytical function. Dimeric LPL could mediate binding of beta-VLDL to immobilized alpha2MR/LRP and to cells, e.g. monocytes. In contrast, LPL monomers were not able to mediate binding to immobilized alpha2MR/LRP, presumably because of cross-inhibition due to close relation between the binding regions for the lipoprotein and for the receptor in the carboxyl-terminal domain of the LPL monomer. Heparin, but not alpha2MRAP, inhibited cellular binding of I-125-LPL or I-125-beta-VLDL supplemented with LPL. However, alpha2MRAP inhibited degradation of the two ligands by about 90% and 40-50%, respectively. The results show that LPL is a ligand for alpha2MR/LRP and, because of its affinity for lipoprotein particles, dimeric LPL can mediate or strengthen binding of beta-VLDL to this receptor. It is proposed that LPL binds primarily to cell surface heparan sulfate in monocytes and is presented for endocytosis and degradation by alpha2MR/LRP. Moreover, beta-VLDL may be further supplemented with LPL at the cell surface and achieve affinity for alpha2MR/LRP.	UMEA UNIV, DEPT MED BIOCHEM & BIOPHYS, S-90187 UMEA, SWEDEN; UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, W-2000 HAMBURG 20, GERMANY	Umea University; University of Hamburg	NYKJAER, A (corresponding author), AARHUS UNIV, INST MED BIOCHEM, OLD WORMS ALLE, DK-8000 AARHUS, DENMARK.		Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CELIS JE, 1992, ELECTROPHORESIS, V13, P893, DOI 10.1002/elps.11501301198; CHAJEKSHAUL T, 1982, BIOCHIM BIOPHYS ACTA, V712, P200, DOI 10.1016/0005-2760(82)90103-5; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1981, BIOCHIM BIOPHYS ACTA, V665, P454, DOI 10.1016/0005-2760(81)90258-7; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; FOJO SS, 1992, CURRENT OPINION LIPI, V3, P186; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HADVARY P, 1991, J BIOL CHEM, V266, P2021; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; JENSEN PH, 1992, FEBS LETT, V305, P129, DOI 10.1016/0014-5793(92)80879-L; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1991, FEBS LETT, V288, P33, DOI 10.1016/0014-5793(91)80997-H; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	48	176	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15048	15055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686910				2022-12-25	WOS:A1993LL75900075
J	YAJNIK, V; GODSON, GN				YAJNIK, V; GODSON, GN			SELECTIVE DECAY OF ESCHERICHIA-COLI DNAG MESSENGER-RNA IS INITIATED BY RNASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INT GENE-EXPRESSION; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; SIGMA-SUBUNIT; POLYMERASE; STABILITY; AMS; PRIMASE; INVIVO; TRANSCRIPTION	The rpsU-dnaG-rpoD operon messenger RNA that encodes S21, primase, and sigma-70 is cleaved under normal physiological conditions. The dnaG coding portion of the mRNA is then rapidly degraded. An endonuclease activity has been isolated from wild type Escherichia coli cells that cleaves dnaG mRNA. This activity has been identified as RNase E, and the identity confirmed by the accumulation of the unprocessed operon polycistronic mRNA in RNase E mutants, rne-3071 and ams-1, when incubated at nonpermissive temperatures. Extracts prepared from RNase E mutant strains failed to cleave dnaG mRNA in vitro. The dnaG mRNA RNase E cleavage site (5'-AAGUGAUUUA-3') is only 50% homologous to the ribosomal RNA RNase E cleavage site. By using computer programs predicting secondary structure, the dnaG RNase E cleavage site appears to be in a single stranded RNA loop.	NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA	New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, GENETICS, V90, P659; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; DEUTSCHER M, 1990, METHOD ENZYMOL, V182, P291; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; ENGBAEK F, 1976, MOL GEN GENET, V143, P291, DOI 10.1007/BF00269405; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GUARNEROS G, 1982, P NATL ACAD SCI-BIOL, V79, P238, DOI 10.1073/pnas.79.2.238; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; KJELDGAARD NO, 1974, RIBOSOMES, P368; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUPSKI JR, 1982, MOL GEN GENET, V185, P120, DOI 10.1007/BF00333800; LUPSKI JR, 1984, CELL, V30, P251; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NAKAMURA Y, 1984, MOL GEN GENET, V196, P179, DOI 10.1007/BF00334114; NILSSON G, 1988, EMBO J, V7, P2269, DOI 10.1002/j.1460-2075.1988.tb03067.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PANAYOTATOS N, 1985, NUCLEIC ACIDS RES, V13, P2227, DOI 10.1093/nar/13.7.2227; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; PRAGAI B, 1982, J MOL BIOL, V154, P465, DOI 10.1016/S0022-2836(82)80007-7; REGINIER P, 1991, J MOL BIOL, V217, P283; ROWEN L, 1978, J BIOL CHEM, V253, P758; Sambrook J, 1989, MOL CLONING LABORATO; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; SMILEY BL, 1982, P NATL ACAD SCI-BIOL, V79, P4550, DOI 10.1073/pnas.79.15.4550; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TAYLOR WE, 1984, CELL, V38, P371, DOI 10.1016/0092-8674(84)90492-6; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P4907, DOI 10.1073/pnas.79.16.4907; WONG HC, 1986, P NATL ACAD SCI USA, V83, P3233, DOI 10.1073/pnas.83.10.3233; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13253	13260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685758				2022-12-25	WOS:A1993LH55300037
J	MA, JT; WU, JJ; TZENG, CM; PAN, RL				MA, JT; WU, JJ; TZENG, CM; PAN, RL			FUNCTIONAL SIZE ANALYSIS OF F-ATPASE FROM ESCHERICHIA-COLI BY RADIATION INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; CATALYTIC SITES; BETA-SUBUNITS; H+-ATPASE; HYDROLYSIS; F1-ATPASE; PURIFICATION; MECHANISM	A radiation inactivation technique was employed to determine the functional size of adenosine triphosphatase from Escherichia coli (EF0EF1-ATPase). Functional units of the membrane-bound and the soluble ATPases were estimated to be 300 +/- 39 and 295 +/- 32 kDa, respectively. The presence of the free radical scavenger dithiothreitol was crucial in measuring the radiation inactivation size of ATPase. When gramicidin and carbonyl cyanide p-trifluoromethoxyphenylhydrazone were added, an increase in the functional mass of membrane-bound ATPase was observed. In contrast, valinomycin and KCl had hardly any effect on the functional size of ATPase. We also determined a functional unit of 355 +/- 33 kDa for proton translocation by a fluorescence quenching technique. A reconstitution study using irradiated coupling factor 1 (EF1)-depleted membrane revealed that the functional mass of the proton channel was 96 +/- 11 kDa. A similar functional size for ATP-P(i) exchange and ATP hydrolysis implies that both reactions might utilize identical machinery. Furthermore, functional units of soluble EF1 for unisite (nonsteady state) and multisite (steady state) ATP hydrolysis were calculated as 200 +/- 32 and 298 +/- 32 kDa, respectively. A working hypothesis was proposed from radiation inactivation analysis to elucidate the structure and mechanism of F1-ATPase.	NATL TSING HUA UNIV, COLL NUCL SCI, INST RADIAT BIOL, HSINCHU 30043, TAIWAN; NATL TSING HUA UNIV, COLL NUCL SCI, DEPT NUCL SCI, HSINCHU 30043, TAIWAN	National Tsing Hua University; National Tsing Hua University								AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BEAUREGARD G, 1985, ANAL BIOCHEM, V150, P117, DOI 10.1016/0003-2697(85)90448-8; BERDEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1057, P151, DOI 10.1016/S0005-2728(05)80099-4; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DAVENPORT JW, 1981, J BIOL CHEM, V256, P8947; DILLEY RA, 1987, ANNU REV PLANT PHYS, V38, P347; DOWNIE JA, 1979, ANNU REV BIOCHEM, V48, P103, DOI 10.1146/annurev.bi.48.070179.000535; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; FRIEDL P, 1979, EUR J BIOCHEM, V100, P175, DOI 10.1111/j.1432-1033.1979.tb02046.x; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HART EJ, 1967, RAD DOSIMETRY, V2, P167; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; LUNARDI J, 1979, BIOCHEMISTRY-US, V18, P5310, DOI 10.1021/bi00591a008; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; MAY YW, 1988, J BIOL CHEM, V263, P8838; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PAN RS, 1987, PLANT PHYSIOL, V85, P158, DOI 10.1104/pp.85.1.158; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WANG JH, 1984, BIOCHEMISTRY-US, V23, P6350, DOI 10.1021/bi00321a010; WANG JH, 1985, J BIOL CHEM, V260, P1374; WESTERHOFF HV, 1984, FEBS LETT, V165, P1, DOI 10.1016/0014-5793(84)80002-2; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	36	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10802	10807						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684367				2022-12-25	WOS:A1993LD46600017
J	ZHAN, X; HU, XG; FRIESEL, R; MACIAG, T				ZHAN, X; HU, XG; FRIESEL, R; MACIAG, T			LONG-TERM GROWTH-FACTOR EXPOSURE AND DIFFERENTIAL TYROSINE PHOSPHORYLATION ARE REQUIRED FOR DNA-SYNTHESIS IN BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR FAMILY; FIBROBLAST GROWTH; HEPARIN-BINDING; FACTOR-I; ENDOTHELIAL-CELLS; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; TRANSFORMED-CELLS; KINASE-ACTIVITY; DOWN-REGULATION	The importance of growth factor-mediated immediate-early cellular events to the cell cycle has influenced the development and identity of oncogenes and tumor suppressor genes as well as the concept that growth factors commit mammalian cells to enter a biochemical program that ultimately yields DNA synthesis. However, the mid and late events involved in the regulation of growth factor-induced signal transduction remain largely unknown. In this report we demonstrate that BALB/c 3T3 cells require continuous exposure to fibroblast growth factor (FGF)-1 for a minimum of 12 h to achieve near maximal DNA synthesis. This correlates with the continuous internalization of radiolabeled FGF-1 into the cytosol and nucleus of BALB/c 3T3 cells and the maintenance of a low level of FGF receptors on the cell surface during the entire G1 phase of the cell cycle. Further analysis demonstrates the maintenance of a continuous series of differential FGF-1-induced tyrosine phosphorylation events including the phosphorylation of phospholipase C-gamma as well as novel FGF receptor polypeptide substrates, p60, p85, p90, and p130 throughout the G1 phase of the BALB/c 3T3 cell cycle. The tyrosine phosphorylation events are biphasic during the 12-h period after the administration of FGF-1, and the second phase is characterized by hyper-tyrosine phosphorylation of p60, p85, and p130. Interestingly, NIH 3T3 cells which overexpress the FGF receptor-1 polypeptide demonstrate exaggerated tyrosine phosphorylation of p60 and p85 but not p90 and exhibit growth factor-independent cell proliferation. These results suggest that the initiation of DNA synthesis in BALB/c 3T3 cells by FGF-1 is regulated by a complex biochemical program that involves the continuous tyrosine phosphorylation of known and novel polypeptides throughout the G0 to G1 transition period of the cell cycle.	AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [HL32348, HL44336] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIESEL R, 1988, BIOCHEM BIOPH RES CO, V151, P957, DOI 10.1016/S0006-291X(88)80459-5; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GAY CG, 1990, J BIOL CHEM, V265, P3284; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARICS I, 1989, ONCOGENE, V4, P335; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; QUARTO N, 1989, ONCOGENE RES, V5, P101; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAPP UR, 1991, ONCOGENE, V6, P495; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RYBAK SM, 1988, J CELL PHYSIOL, V136, P312, DOI 10.1002/jcp.1041360214; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STARK KL, 1991, DEVELOPMENT, V113, P641; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKAHASHI JA, 1991, FEBS LETT, V288, P65, DOI 10.1016/0014-5793(91)81004-R; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	79	117	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9611	9620						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683656				2022-12-25	WOS:A1993LA68900070
J	LEEBLUNDBERG, LMF; SONG, XH				LEEBLUNDBERG, LMF; SONG, XH			IDENTIFICATION OF P125, A COMPONENT OF A GROUP OF 120-KDA PROTEINS THAT ARE PHOSPHORYLATED ON TYROSINE RESIDUES IN RESPONSE TO BRADYKININ AND BOMBESIN STIMULATION, IN ANTI-RAS-GTPASE-ACTIVATING PROTEIN IMMUNOPRECIPITATES OF SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL TURNOVER; SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; RECEPTOR NUMBER; KINASE-C; GAP; ONCOGENE	Bradykinin (BK) and bombesin (BN) stimulate an increase in the tyrosine phosphorylation of a 120-kDa group of proteins (pps120) in Swiss 3T3 cells (Leeb-Lundberg, L. M. F., and Song X.-H. (1991) J. Biol. Chem. 266, 7746-7749). Here, we show that a component of pps120, p125, was specifically immunoprecipitated with antibodies against the p21ras GTPase-activating protein (GAP). The major portion of GAP in nonstimulated cells (96%) was located in the cytosol, and this distribution was not affected by exposure of cells to 1 muM BK for 1 min. A significant amount of GAP in nonstimulated cells was recovered in anti-phosphotyrosine (anti-Tyr(P)) immunoprecipitates, and the cellular distribution of this GAP essentially paralleled that of total GAP. Recovery of GAP in anti-Tyr(P) immunoprecipitates of nonstimulated cells appeared to be caused at least in part by the presence of GAP complexed to a 190-kDa tyrosine-phosphorylated protein (p190). Exposure of cells to 1 muM BK for 1 min resulted in an increase in the recovery of a portion of the cellular GAP in anti-Tyr(P) immunoprecipitates. This increase was paralleled by the appearance of a tyrosine-phosphorylated protein species of 125 kDa (p125) in anti-GAP immunoprecipitates. Tyrosine-phosphorylated p125 was present also in anti-GAP immunoprecipitates after exposure of cells to 1 muM BN. High performance gel exclusion liquid chromatography of the anti-GAP-immunoprecipitated proteins on a Protein-Pak 300SW column revealed that p125 is not GAP. Anti-GAP immunoprecipitation of p125 was prevented by prior denaturation of cell lysates in sodium dodecyl sulfate suggesting that p125 is physically associated with GAP. Chromatography of cell lysates revealed that the pps120 group of tyrosine phosphoproteins includes a 125- and a 120-kDa protein. The anti-GAP-immunoprecipitable p125 migrated identically to the 125-kDa phosphoprotein component of pps120. These observations show that the pps120 group of tyrosine phosphoproteins is composed of at least two physically distinct protein components, p125 and p120. p125 is associated in some manner with a portion of the cellular GAP after exposure of cells to BK and BN.			LEEBLUNDBERG, LMF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FITZGERALD TJ, 1986, J BIOL CHEM, V261, P6871; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; IKEDA M, 1984, LIFE SCI, V34, P529, DOI 10.1016/0024-3205(84)90485-5; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MATHIS SA, 1991, BIOCHEM J, V276, P141, DOI 10.1042/bj2760141; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLSEN R, 1988, J BIOL CHEM, V263, P18030; PANDIELLA A, 1989, J BIOL CHEM, V264, P3122; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; ROBERTS RA, 1989, J CELL SCI, V94, P527; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	45	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8151	8157						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681835				2022-12-25	WOS:A1993KW97900081
J	WILLIAMS, KP; SHOELSON, SE				WILLIAMS, KP; SHOELSON, SE			A PHOTOAFFINITY SCAN MAPS REGIONS OF THE P85 SH2 DOMAIN INVOLVED IN PHOSPHOPROTEIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHOTYROSINE; PROTEINS	Src homology 2 (SH2) domains are modular phosphotyrosine binding pockets found within a wide variety of cytoplasmic signaling molecules. Here we develop a new approach to analyzing protein-protein interfaces termed photoaffinity scanning, and apply the method to map regions of the phosphatidylinositol 3-kinase p85 SH2 domain that participate in phosphoprotein binding. Each residue except phosphotyrosine (pY) within a tightly binding, IRS-1-derived phosphopeptide (GNGDpYMPMSPKS) was substituted with the photoactive amino acid, benzoylphenylalanine (Bpa). Whereas most substitutions had little effect on binding affinity, Bpa substitution of either Met (+1 and +3 with respect to pY) reduced affinity 50-100-fold to confirm their importance in the pYMXM recognition motif. In three cases photolysis of SH2 domain/Bpa phosphopeptide complexes led to cross-linking of >50% of the SH2 domain; cross-link positions were identified by microsequence, amino acid composition, and electrospray mass spectrometric analyses. Bpa-1 cross-links within alpha-helix I, whereas Bpa+1 and Bpa+4 cross-link the SH2 domain within the flexible loop C-terminal to alpha-helix II. Moreover, cross-linking at any position prevents SH2 domain cleavage at a trypsin-sensitive site within the flexible loop between beta-strands 1 and 2. Therefore, at least three distinct SH2 regions in addition to the beta-sheet participate in phosphoprotein binding; the loop cross-linked by phosphopeptide residues C-terminal to pY appears to confer specificity to the phosphoprotein/SH2 domain interaction.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, IN PRESS MOL CELL BI; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAUER JC, 1986, J BIOL CHEM, V261, P695; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICCIONE E, 1993, IN PRESS BIOCHEMISTR; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	22	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5361	5364						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680644				2022-12-25	WOS:A1993KR82200006
J	EHLERS, M; DEHON, FD; BOS, HK; HORSTEN, U; KURAPKAT, G; VANDELEUR, HS; GROTZINGER, J; WOLLMER, A; BRAKENHOFF, JPJ; ROSEJOHN, S				EHLERS, M; DEHON, FD; BOS, HK; HORSTEN, U; KURAPKAT, G; VANDELEUR, HS; GROTZINGER, J; WOLLMER, A; BRAKENHOFF, JPJ; ROSEJOHN, S			COMBINING 2 MUTATIONS OF HUMAN INTERLEUKIN-6 THAT AFFECT GP130 ACTIVATION RESULTS IN A POTENT INTERLEUKIN-6 RECEPTOR ANTAGONIST ON HUMAN MYELOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; BIOLOGICAL-ACTIVITY; SIGNAL TRANSDUCER; BINDING SITE; INVOLVEMENT; EXPRESSION; CYTOKINES; TERMINUS; IL-6; PRODUCE	The pleiotropic cytokine interleukin-6 (IL-6) interacts with the specific ligand binding subunit (IL-6R alpha) of the IL-6 receptor, and this complex associates with the signal-transducing subunit gp130 (IL-6R beta). Human IL-6 acts on human and murine cells, whereas murine IL-6 is only active on murine cells. The construction of a set of chimeric human/murine IL-6 proteins has recently allowed us to define a region (residues 43-55) within the human IL-6 protein, which is important for the interaction with gp130. Subdividing this region shows that mainly residues 50-55 of the human IL-6 are necessary for this interaction. Recently, another human IL-6 double mutant (Q159E and T162P) showed reduced affinity to gp130 but residual activity on the human myeloma cell line XG-1. Into this IL-6 mutant we introduced the murine residues 43-49 or 50-55 together with two point mutations, F170L and S176A, which had been reported to increase the affinity of IL-6 to the IL-6R alpha. The resulting IL-6 molecule, which contained the murine residues 50-55, was inactive on human myeloma cells and in addition completely inhibited wild type IL-6 activity on these cells. Such an antagonist may be used as a specific inhibitor of IL-6 activity in vivo.	UNIV MAINZ, I MED CLIN, PATHOPHYSIOL SECT, D-55101 MAINZ, GERMANY; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT AUTOIMMUNE DIS, 1066 CX AMSTERDAM, NETHERLANDS; RHEIN WESTFAL TH AACHEN, DEPT BIOCHEM, D-52057 AACHEN, GERMANY	Johannes Gutenberg University of Mainz; RWTH Aachen University			Ehlers, Marc/C-9441-2011; Rose-John, Stefan/A-7998-2010	Ehlers, Marc/0000-0002-5383-8603; Rose-John, Stefan/0000-0002-7519-3279				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; BRAKENHOFF JPJ, 1992, SERONO S PUBLICATION, V88, P33; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; EHLERS M, 1994, J IMMUNOL, V153, P1744; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEIN B, 1991, BLOOD, V78, P1198; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1993, FEBS LETT, V332, P174, DOI 10.1016/0014-5793(93)80507-Q; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, CANCER RES, V53, P851; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VANDAM M, 1993, J BIOL CHEM, V268, P15285; WARD LD, 1994, J BIOL CHEM, V269, P23286; WENDLING D, 1993, J RHEUMATOL, V20, P259; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	35	35	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8158	8163		10.1074/jbc.270.14.8158	http://dx.doi.org/10.1074/jbc.270.14.8158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713920	hybrid			2022-12-25	WOS:A1995QR52600059
J	TROPF, S; KARCHER, B; SCHRODER, G; SCHRODER, J				TROPF, S; KARCHER, B; SCHRODER, G; SCHRODER, J			REACTION-MECHANISMS OF HOMODIMERIC PLANT POLYKETIDE SYNTHASES (STILBENE AND CHALCONE SYNTHASE) - A SINGLE ACTIVE-SITE FOR THE CONDENSING REACTION IS SUFFICIENT FOR SYNTHESIS OF STILBENES, CHALCONES, AND 6'-DEOXYCHALCONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; PUTATIVE REGULATORY ELEMENTS; PINE PINUS-SYLVESTRIS; NUCLEOTIDE-SEQUENCE; FLAVANONE SYNTHASE; MULTIGENE FAMILY; PETROSELINUM-HORTENSE; SUBSTRATE-SPECIFICITY; PURIFICATION; BIOSYNTHESIS	Stilbene (STS) and chalcone (CHS) synthases are homodimeric, related plant-specific polyketide synthases. Both perform a sequential condensation of three acetate units to a starter residue to form a tetraketide intermediate that is folded to the ring systems specific to the different products. Protein cross-linking and site-directed mutagenesis identified a subunit contact site in position 158, close to the active site (Cys(169)). This suggested that the active site pockets may be neighboring, possibly alternating in the condensing reactions rather than acting independently. This was investigated by coexpression of active site mutants with differently mutated, inactive proteins. With both STS and CHS, the heterodimers synthesized the end products, indicating that each subunit performed all three condensations. In co-action with a monomeric reductase, CHS also synthesizes 6'-deoxychalcone, but with the chalcone as second product when using plant preparations. The two enzymes expressed as single species in Escherichia coli synthesized both products, and both were also obtained with a CHS heterodimer containing a single active site. The results showed that 6'-deoxychalcone synthesis required no other plant factor and that the formation of two products may be an intrinsic property of the interaction between dimeric CHS and monomeric reductase.	UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University of Freiburg								AKADA S, 1990, NUCLEIC ACIDS RES, V18, P3398, DOI 10.1093/nar/18.11.3398; AKADA S, 1993, PLANT PHYSIOL, V102, P321, DOI 10.1104/pp.102.1.321; AKADA S, 1993, PLANT PHYSIOL, V102, P317, DOI 10.1104/pp.102.1.317; AKADA S, 1993, PLANT PHYSIOL, V102, P699, DOI 10.1104/pp.102.2.699; AKADA S, 1991, PLANT MOL BIOL, V16, P751, DOI 10.1007/BF00023443; AKADA S, 1990, NUCLEIC ACIDS RES, V18, P5899, DOI 10.1093/nar/18.19.5899; AYABE SI, 1988, ARCH BIOCHEM BIOPHYS, V261, P458, DOI 10.1016/0003-9861(88)90362-1; BOREJSZAWYSOCKI W, 1994, PHYTOCHEMISTRY, V35, P623, DOI 10.1016/S0031-9422(00)90575-2; CROWE J, 1992, QIA EXPRESSIONIS; FLIEGMANN J, 1992, PLANT MOL BIOL, V18, P489, DOI 10.1007/BF00040665; GEHLERT R, 1990, MOL PLANT MICROBE IN, V3, P444, DOI 10.1094/MPMI-3-444; HAKAMATSUKA T, 1988, CHEM PHARM BULL, V36, P4225, DOI 10.1248/cpb.36.4225; HARANO K, 1993, PLANT CELL REP, V12, P66, DOI 10.1007/BF00241936; HELLER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P617, DOI 10.1016/0003-9861(80)90395-1; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1979, EUR J BIOCHEM, V99, P89, DOI 10.1111/j.1432-1033.1979.tb13235.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZ T, 1991, J BIOL CHEM, V266, P9971; Martson F.A.O., 1986, BIOCHEM J, V240, P1; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; PITTRIVE.R, 1968, BIOCHEM J, V109, P825, DOI 10.1042/bj1090825; REINECKE T, 1994, PHYTOCHEMISTRY, V35, P63, DOI 10.1016/S0031-9422(00)90510-7; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHANZ S, 1992, FEBS LETT, V313, P71, DOI 10.1016/0014-5793(92)81187-Q; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; SCHRODER G, 1992, J BIOL CHEM, V267, P20558; SCHRODER J, 1990, Z NATURFORSCH C, V45, P1; SCHRODER J, 1993, DEV PLANT PATHOL, V2, P257; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; TROPF S, 1994, J MOL EVOL, V38, P610; Weber K, 1972, Methods Enzymol, V26, P3; WELLE R, 1988, FEBS LETT, V236, P221, DOI 10.1016/0014-5793(88)80318-1; WELLE R, 1991, EUR J BIOCHEM, V196, P423, DOI 10.1111/j.1432-1033.1991.tb15833.x; WELLE R, 1987, Z NATURFORSCH C, V42, P1200; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	41	110	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7922	7928		10.1074/jbc.270.14.7922	http://dx.doi.org/10.1074/jbc.270.14.7922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713888	hybrid			2022-12-25	WOS:A1995QR52600024
J	HANASAKI, K; POWELL, LD; VARKI, A				HANASAKI, K; POWELL, LD; VARKI, A			BINDING OF HUMAN PLASMA SIALOGLYCOPROTEINS BY THE B-CELL-SPECIFIC LECTIN CD22 - SELECTIVE RECOGNITION OF IMMUNOGLOBULIN-M AND HAPTOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ANTIGEN RECEPTOR; ALPHA-2->6 SIALYLTRANSFERASE; SIALIC ACIDS; T-CELLS; ADHESION; OLIGOSACCHARIDE; GLYCOPROTEINS; LYMPHOCYTES; LIVER	CD22 is a cell-surface receptor of resting mature B cells that recognizes sialic acid (Sia) in the natural structure Sia alpha 2-GGal beta 1-4GlcNAc (Powell, L. D., Jain, Il. K., Matta, K. L., Sabesan, S., and Varki, A. (1995) J. Biol. Chem. 270, 7523-7532). Human umbilical vein endothelial cells (HEC) treated with inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) display increases in cell-surface CD22 ligands, caused by increased expression of the enzyme beta-galactoside alpha 2,6-sialyltransferase (Hanasaki, K., Varki, A., Stamenkovic, I., and Bevilacqua, M. P. (1994) J. Biol. Chem. 269, 10637-10643; Hanasaki, H., Varki, A., and Powell, L. D. (1995) J. Biol Chem. 270, 7533-7542). Thus, CD22 could direct potential interactions between mature B cells and endothelial cells during inflammatory states. However, this would have to occur in the presence of blood plasma, which contains many sialoglycoproteins known to carry alpha 2-6-linked sialic acids. We show here that human plasma can indeed inhibit Sia-dependent binding of a recombinant soluble chimeric form of human CD22 (CD22Rg) to TNF-alpha activated HEC. Affinity adsorption of individual human plasma samples with immobilized CD22Rg showed that, of the numerous alpha 2-6-sialic acid containing glycoproteins in plasma, only three polypeptides with apparent molecular mass (under reducing conditions) of 74, 44, and 25 kDa bound, and were spe specifically eluted with alpha 2-6-sialyllactose. NH2-terminal amino acid sequencing of these high affinity CD22 ligands revealed that they are subunits of immunoglobulin M (IgM) and haptoglobin. Purified human IgM from pooled human plasma can be quantitatively bound by CD22Rg, and binding is blocked by alpha 2-6-sialyllactose, but not by alpha 2-3-sialyllactose. Pretreatment by sialidase or by mild periodate oxidation of sialic acid side chains abolishes these interactions. IgM at physiological concentrations also inhibits CD22Rg binding to TNF-alpha-activated HEC in a manner dependent not only upon its sialylation but also requiring its intact multimeric structure. These data show that CD22 is capable of highly selective recognition of certain multimeric plasma sialoglycoproteins that carry alpha 2-6-linked sialic acids. Notably, the two proteins that are selectively recognized are known to be involved in immune and inflammatory responses. Haptoglobin synthesis by the liver is markedly increased during the ''acute phase response'' to systemic inflammation, while IgM is the major product resulting from activation of resting CD22-positive B cells.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,DIV CELLULAR & MOLEC MED,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego					NCI NIH HHS [KO1 CA01649] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P4063; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; BOWMAN BH, 1982, ADV HUM GENET, V12, P453; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; CAHOUR A, 1983, BIOCHEM J, V211, P55, DOI 10.1042/bj2110055; CHEN JZ, 1993, CURR OPIN IMMUNOL, V5, P194, DOI 10.1016/0952-7915(93)90004-C; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CLARK EA, 1993, J IMMUNOL, V150, P4715; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DOUBET S, 1992, GLYCOBIOLOGY, V2, P505, DOI 10.1093/glycob/2.6.505; ENGEL P, 1993, J IMMUNOL, V150, P4719; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HICKMAN S, 1972, J BIOL CHEM, V247, P2156; JAMIESON JC, 1993, COMP BIOCHEM PHYS B, V105, P29, DOI 10.1016/0305-0491(93)90165-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MAEDA N, 1986, ANNU REV GENET, V20, P81; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; MILLER F, 1970, IMMUNOCHEMISTRY, V7, P423, DOI 10.1016/0019-2791(70)90224-7; OLSZEWSKI W, 1989, PERIPHERAL LYMPH FOR; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; REUTER G, 1989, GLYCOCONJUGATE J, V6, P35, DOI 10.1007/BF01047888; Ritzmann SE., 1982, SERUM PROTEIN ABNORM; SASSO EH, 1989, J IMMUNOL, V142, P2778; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SOLIS D, 1994, J BIOL CHEM, V269, P11555; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; WANG XC, 1993, J BIOL CHEM, V268, P4355; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	49	125	142	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7543	7550		10.1074/jbc.270.13.7543	http://dx.doi.org/10.1074/jbc.270.13.7543			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706301	hybrid			2022-12-25	WOS:A1995QQ43100076
J	LEW, AM; ELSHOLTZ, HP				LEW, AM; ELSHOLTZ, HP			A DOPAMINE-RESPONSIVE DOMAIN IN THE N-TERMINAL SEQUENCE OF PIT-1 - TRANSCRIPTIONAL INHIBITION IN ENDOCRINE CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; POU-SPECIFIC DOMAIN; PROLACTIN PROMOTER; GROWTH-HORMONE; GENE PROMOTERS; ALPHA-SUBUNITS; D2 RECEPTOR; PITUITARY; EXPRESSION; PROTEIN	The POU transcription factor Pit-1 activates the prolactin gene in pituitary lactotrophs and may integrate responses of the gene to external signals, To study the role of Pit-1 in dopaminergic inhibition of the prolactin gene, we transiently transfected Pit-1 and dopamine D2 receptor vectors into a series of heterologous cell lines and examined dopamine regulation of the prolactin gene promoter. Regulation was Pit-1-dependent in all cell lines tested, Moreover, dopamine responsiveness was cell type-specific: stimulatory in fibroblasts (COS-7) and muscle-type cells (P19/M(2)SO-induced) and inhibitory in pancreatic endocrine (RIN, InR1-G9) and neural-like (P19/retinoic acid-induced) cells, Because dopaminergic responses in Pit-1-transfected RIN cells paralleled those in pituitary GH4 cells, the islet cell line was used to test for sequences in Pit-1 that mediate negative hormone signals, Dopamine responsiveness of the Pit-1 transactivation domain (residues 8-80) was examined using a chimeric LexA construct, LxPit-1, LxSp1, and Lx-glucocorticoid receptor fusions all activated basal transcription, but only LxPit-1 was regulated by dopamine, Regulatory responses of LxPit-1 and full-length Pit-1 were quantitatively similar, In addition, gain-of-function G(alpha) mutants that inhibit Pit-1-dependent promoters in GH4 cells also suppressed selectively Pit-l or LxPit-1-dependent promoters in RIN cells, This demonstrates that Pit-1 can function as a specific target for distinct inhibitory G protein signals. Interestingly, Pit-1 sequences N-terminal to the DNA-binding POU domain appear to be sufficient in mediating regulation by these pathways.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,BANTING & BEST DIABET CTR,TORONTO,ON M5G 1L5,CANADA	University of Toronto; University of Toronto								ALBERT PR, 1990, J BIOL CHEM, V265, P2098; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BAERTSCHI AJ, 1992, MOL ENDOCRINOL, V6, P2257, DOI 10.1210/me.6.12.2257; BARTON RE, 1994, ENDOCRINE, V2, P639; BORRELLI E, 1994, TRENDS GENET, V10, P222, DOI 10.1016/0168-9525(94)90154-6; CHIO CL, 1994, MOL PHARMACOL, V45, P51; CORMONT M, 1991, DIABETES, V40, P1170, DOI 10.2337/diabetes.40.9.1170; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FUXE K, 1969, NEUROENDOCRINOLOGY, V5, P257, DOI 10.1159/000121887; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HAYES G, 1992, MOL ENDOCRINOL, V6, P920, DOI 10.1210/me.6.6.920; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JONG MTC, 1994, MOL ENDOCRINOL, V8, P1320, DOI 10.1210/me.8.10.1320; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KIM MK, 1993, J BIOL CHEM, V268, P23366; LEW AM, 1994, J BIOL CHEM, V269, P12007; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIU YF, 1994, J BIOL CHEM, V269, P13880; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RICHARDSON PM, 1991, J VIROL, V65, P31222; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	44	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7156	7160		10.1074/jbc.270.13.7156	http://dx.doi.org/10.1074/jbc.270.13.7156			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706253	hybrid			2022-12-25	WOS:A1995QQ43100024
J	REICH, Z; WACHTEL, EJ; MINSKY, A				REICH, Z; WACHTEL, EJ; MINSKY, A			IN-VIVO QUANTITATIVE CHARACTERIZATION OF INTERMOLECULAR INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA DOUBLE HELICES; HYDRATION FORCES; CHROMATIN; MOLECULES; BILAYERS; WATER	Extensive effort has been directed toward a quantitative evaluation of forces which operate between biomacromolecules since the characterization of such forces is essential to a thorough understanding of fundamental biological processes, However, all studies hitherto reported were conducted in vitro, using isolated species, Here we report the first quantitative characterization of forces operating between DNA molecules within living bacteria. Evaluation of x-ray scattering studies conducted on intact bacteria indicates that, at DNA-DNA surface separations characteristic of DNA assemblies, interactions are dominated by repulsive hydration forces which originate from the structuring of water molecules. The results support the notion that the mechanisms by means of which macromolecules function, fold, and interact with each other crucially depend upon their hydration properties.	WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,CHEM SERV UNIT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								BOHRMANN B, 1993, ULTRAMICROSCOPY, V49, P235, DOI 10.1016/0304-3991(93)90230-U; BRIAN AA, 1981, BIOPOLYMERS, V20, P1305, DOI 10.1002/bip.1981.360200615; GRUEN DWR, 1981, CHEM PHYS LETT, V82, P315, DOI 10.1016/0009-2614(81)85163-9; ISRAELACHVILI JN, 1988, SCIENCE, V241, P795, DOI 10.1126/science.241.4867.795; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; LENEVEU DM, 1976, NATURE, V259, P601, DOI 10.1038/259601a0; LIS LJ, 1982, BIOPHYS J, V37, P657; LIVOLANT F, 1988, BIOCHEMISTRY-US, V27, P3056, DOI 10.1021/bi00408a058; MARCELJA S, 1976, CHEM PHYS LETT, V42, P129, DOI 10.1016/0009-2614(76)80567-2; PARSEGIAN VA, 1985, CHEM SCRIPTA, V25, P28; RADIC N, 1978, CHEM PHYS LETT, V55, P377, DOI 10.1016/0009-2614(78)87043-2; RAND RP, 1981, ANNU REV BIOPHYS BIO, V10, P277, DOI 10.1146/annurev.bb.10.060181.001425; RAU DC, 1992, BIOPHYS J, V61, P246, DOI 10.1016/S0006-3495(92)81831-3; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; REICH Z, 1994, SCIENCE, V264, P1460, DOI 10.1126/science.8197460; STEUTER AA, 1981, PLANT PHYSIOL, V67, P64, DOI 10.1104/pp.67.1.64; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0	18	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7045	7046		10.1074/jbc.270.13.7045	http://dx.doi.org/10.1074/jbc.270.13.7045			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706241	hybrid			2022-12-25	WOS:A1995QQ43100009
J	TOBIMATSU, T; HARA, T; SAKAGUCHI, M; KISHIMOTO, Y; WADA, Y; ISODA, M; SAKAI, T; TORAYA, T				TOBIMATSU, T; HARA, T; SAKAGUCHI, M; KISHIMOTO, Y; WADA, Y; ISODA, M; SAKAI, T; TORAYA, T			MOLECULAR-CLONING, SEQUENCING, AND EXPRESSION OF THE GENES ENCODING ADENOSYLCOBALAMIN-DEPENDENT DIOL DEHYDRASE OF KLEBSIELLA-OXYTOCA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; COENZYME; PURIFICATION; MECHANISM; CLEAVAGE	The pdd genes encoding adenosylcobalamin-dependent diol dehydrase of Klebsiella oxytoca were cloned by using a synthetic oligodeoxyribonucleotide as a hybridization probe followed by measuring the enzyme activity of each clone. Five clones of Escherichia coli exhibited diol dehydrase activity. At least one of them was shown to express diol dehydrase genes under control of their own promoter, Sequence analysis of the DNA fragments found in common in the inserts of these five clones and the flanking regions revealed four open reading frames separated by 10-18 base pairs. The sequential three open reading frames from the second to the fourth (pddA, pddB, and pddC genes) encoded polypeptides of 554, 224, and 173 amino acid residues with predicted molecular weights of 60,348 (alpha), 24,113 (beta), and 19,173 (gamma), respectively, Overexpression of these three genes in E. coli produced more than 50 fold higher level of functional apodiol dehydrase than that in K. oxytoca. The recombinant enzyme was indistinguishable from the wild-type one of R. oxytoca by the criteria of polyacrylamide gel electrophoretic and immunochemical properties. It was thus concluded that these three gene products are the subunits of functional diol dehydrase. Comparisons of the deduced amino acid sequences of the three subunits with other proteins failed to reveal any apparent homology.			TOBIMATSU, T (corresponding author), OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,OKAYAMA 700,JAPAN.		TOBIMATSU, Takamasa/B-2646-2011					Abeles R. H., 1979, Vitamin B12, P373; BABIOR B M, 1988, Biofactors, V1, P21; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ESSENBERG MK, 1971, J AM CHEM SOC, V93, P1242; FREY PA, 1967, J BIOL CHEM, V242, P5369; FREY PA, 1970, J AM CHEM SOC, V92, P4488, DOI 10.1021/ja00717a074; FREY PA, 1966, J BIOL CHEM, V241, P2732; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JOHNSTONDOW L, 1987, BIOTECHNIQUES, V5, P754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCGEE DE, 1981, BIOCHEMISTRY-US, V20, P4293, DOI 10.1021/bi00518a009; MCGEE DE, 1982, BIOCHEM BIOPH RES CO, V108, P547, DOI 10.1016/0006-291X(82)90863-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUI T, 1988, AGR BIOL CHEM TOKYO, V52, P983; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIZAWA K, 1987, Z NATURFORSCH C, V42, P353; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1973, BIOCHEM BIOPH RES CO, V52, P350, DOI 10.1016/0006-291X(73)90718-3; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1974, BIOCHEMISTRY-US, V13, P3895, DOI 10.1021/bi00716a012; TORAYA T, 1988, BIOCHEMISTRY-US, V27, P7677, DOI 10.1021/bi00420a016; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; Toraya T., 1982, B12, P233; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	34	64	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7142	7148		10.1074/jbc.270.13.7142	http://dx.doi.org/10.1074/jbc.270.13.7142			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706251	hybrid			2022-12-25	WOS:A1995QQ43100022
J	WAGNER, JP; QUILL, DM; PETTIJOHN, DE				WAGNER, JP; QUILL, DM; PETTIJOHN, DE			INCREASED DNA-BENDING ACTIVITY AND HIGHER AFFINITY DNA-BINDING OF HIGH-MOBILITY GROUP PROTEIN HMG-1 PREPARED WITHOUT ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; CHROMOSOMAL-PROTEINS; ELECTROPHORESIS; TRANSCRIPTION; STORAGE; DOMAIN	Recently, DNA ring closure assays showed that high mobility group protein HMG-1 and its close homolog HMG-2 mediate sequence-independent DNA flexion, This DNA-bending activity appears to be central to at least some of the recently elucidated functions of HMG-1/2, such as the enhancement of progesterone receptor DNA binding, Here we show that standard purification procedures utilizing perchloric and trichloroacetic acid can produce HMG-1 significantly deficient in its abilities to bind and bend double stranded DNA, while acid-independent methods purify HMG-1 that is superior in these respects, Significant losses of DNA ring closure activity were seen upon limited 2-5-h exposures of nonacid-purified HMG-1/2 to perchloric acid and/or trichloroacetic acid, Measurements of the apparent DNA dissociation binding constant (R(d(app))) of acid extracted preparations of HMG-1 gave a wide range of values, and only those preparations demonstrating little DNA ring closure activity had K-d values near the previously published value (similar to 10(-6) M). The highest ring closure activities and lowest K-d(app) (<3 x 10(-9) M) were obtained for HMG-1 purified without acids. These combined results support the use of alternative, non-acid purification procedures for preserving the DNA-bending activity of HMG-1/2 and suggest that past procedures utilizing acids have led to an underestimation of the affinity of HMG-1 for DNA.	UNIV COLORADO,CTR CANC,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [R01 GM 18243] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018243] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; COCKERILL PN, 1983, BIOCHIM BIOPHYS ACTA, V745, P70, DOI 10.1016/0167-4838(83)90171-1; ELTON TS, 1985, ANAL BIOCHEM, V149, P316, DOI 10.1016/0003-2697(85)90576-7; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; KOHLSTAEDT LA, 1986, BIOCHEMISTRY-US, V25, P4562, DOI 10.1021/bi00364a016; KOHLSTAEDT LA, 1994, BIOCHEMISTRY-US, V33, P570, DOI 10.1021/bi00168a023; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; OKA T, 1992, BIOCHEM BIOPH RES CO, V189, P179, DOI 10.1016/0006-291X(92)91541-W; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEYEDIN SM, 1981, P NATL ACAD SCI-BIOL, V78, P5988, DOI 10.1073/pnas.78.10.5988; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1989, FEBS LETT, V242, P346, DOI 10.1016/0014-5793(89)80499-5; WAGNER JP, 1994, IDENTIFICATION HIGH; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4; WATANABE F, 1994, BIOCHEM BIOPH RES CO, V202, P736, DOI 10.1006/bbrc.1994.1992; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; 1983, MERCK INDEX, P1028	31	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7394	7398		10.1074/jbc.270.13.7394	http://dx.doi.org/10.1074/jbc.270.13.7394			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706284	hybrid			2022-12-25	WOS:A1995QQ43100057
J	HUANG, QQ; HARVEY, CM; PATERSON, ARP; CASS, CE; YOUNG, JD				HUANG, QQ; HARVEY, CM; PATERSON, ARP; CASS, CE; YOUNG, JD			FUNCTIONAL EXPRESSION OF NA+-DEPENDENT NUCLEOSIDE TRANSPORT-SYSTEMS OF RAT INTESTINE IN ISOLATED OOCYTES OF XENOPUS-LAEVIS - DEMONSTRATION THAT RAT JEJUNUM EXPRESSES THE PURINE-SELECTIVE SYSTEM N1 (CIF) AND A 2ND, NOVEL SYSTEM N3 HAVING BROAD-SPECIFICITY FOR PURINE AND PYRIMIDINE NUCLEOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOMA-CELLS; BORDER MEMBRANE-VESICLES; BRUSH-BORDER; NITROBENZYLTHIOINOSINE-BINDING; GUINEA-PIG; LEUKEMIA-CELLS; CHOROID-PLEXUS; ERYTHROCYTE NUCLEOSIDE; NUCLEOBASE TRANSPORT; URIDINE TRANSPORT	Isolated stage VI oocytes from Xenopus laevis expressed uridine transport activity after microinjection of mRNA from rat jejunum. Uridine uptake during 30 min (10 muM, 20-degrees-C) by mRNA-injected oocytes reached 2.5 pmol/oocyte, compared with endogenous uptake by water-injected oocytes of about 0.05 pmol/oocyte. The expressed transport activity was 96% Na+-dependent, saturable (apparent K(m) = 15 muM) and inhibited by phloridzin (IC50 = 100 muM). Nucleoside inhibition studies resolved the expressed transport activity into two components: 1) a novel Na+-dependent system of broad purine and pyrimidine specificity that was inhibited by low concentrations of guanosine, inosine, adenosine, uridine, thymidine, and cytidine and 2) a Na+-dependent system of narrower specificity that was inhibited by low concentrations of guanosine, inosine, adenosine, and uridine and by high concentrations of thymidine and cytidine. The characteristics of the latter system are consistent with those of the Na+-dependent nucleoside transport system N1 (cif), previously identified in a number of cell types and tissues, including intestinal epithelia and cultured cells of intestinal origin. The broad specificity system, which was also detected in mRNA-injected oocytes using thymidine as permeant, has been given the provisional designation N3 to distinguish it from the previously described N1 (purine-selective) and N2 (pyrimidine-selective) Na+-linked nucleoside transporters. Rat jejunal transporters N1 and N3 were both expressed maximally by the same mRNA size fraction (1.6-3.0 kb, peak 2.3 kb).	UNIV ALBERTA,DEPT PHYSIOL,7-55 MED SCI BLDG,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta; University of Alberta; University of Alberta								BAER HP, 1990, BIOCHIM BIOPHYS ACTA, V1026, P241, DOI 10.1016/0005-2736(90)90070-5; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1988, J BIOL CHEM, V263, P13819; BELT JA, 1983, BIOCHEM BIOPH RES CO, V110, P417, DOI 10.1016/0006-291X(83)91165-8; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; BETCHER SL, 1990, AM J PHYSIOL, V259, pG504, DOI 10.1152/ajpgi.1990.259.3.G504; BRONK JR, 1988, J PHYSIOL-LONDON, V3695, P349; CASS CE, 1981, BIOCHIM BIOPHYS ACTA, V649, P769, DOI 10.1016/0005-2736(81)90182-6; DAGNINO L, 1987, P AM ASSOC CANC RES, V28, P15; DAGNINO L, 1991, J BIOL CHEM, V266, P6312; DARNOWSKI JW, 1986, CANCER RES, V46, P3490; DARNOWSKI JW, 1987, CANCER RES, V47, P2614; GATI WP, 1989, MOL PHARMACOL, V36, P134; GATI WP, 1986, BIOCHEM J, V236, P665, DOI 10.1042/bj2360665; GUTIERREZ MM, 1992, BIOCHIM BIOPHYS ACTA, V1105, P1, DOI 10.1016/0005-2736(92)90156-G; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; JACOBS ES, 1990, J BIOL CHEM, V265, P22210; JAKOBS ES, 1986, BIOCHEM BIOPH RES CO, V140, P1028, DOI 10.1016/0006-291X(86)90738-2; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1987, PHARMACOL THERAPEUT, V32, P339, DOI 10.1016/0163-7258(87)90080-5; JARVIS SM, 1985, J NEUROCHEM, V44, P183, DOI 10.1111/j.1471-4159.1985.tb07129.x; JARVIS SM, 1991, BIOCHEM J, V278, P605, DOI 10.1042/bj2780605; JARVIS SM, 1987, TOPICS PERSPECTIVES, P102; KWAN KF, 1984, AM J PHYSIOL, V245, P710; KWONG FYP, 1986, BIOCHEM J, V240, P349, DOI 10.1042/bj2400349; LEE CW, 1990, AM J PHYSIOL, V258, pF1203, DOI 10.1152/ajprenal.1990.258.5.F1203; LEHIR M, 1985, PFLUG ARCH EUR J PHY, V404, P238, DOI 10.1007/BF00581245; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PATERSON ARP, 1979, MOL PHARMACOL, V16, P900; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PATERSON ARP, 1983, REGULATORY FUNCTION, P203; PATERSON ARP, 1983, DEV TARGET ORIENTED, P41; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1986, J CELL PHYSIOL, V128, P491, DOI 10.1002/jcp.1041280319; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PLAGEMANN PGW, 1986, BIOCHEM PHARMACOL, V35, P2559, DOI 10.1016/0006-2952(86)90054-7; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P32, DOI 10.1016/0005-2736(90)90187-S; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1989, BIOCHIM BIOPHYS ACTA, V981, P315, DOI 10.1016/0005-2736(89)90043-6; RODEN M, 1988, Naunyn-Schmiedeberg's Archives of Pharmacology, V337, pR48; SCHWENK M, 1984, BIOCHIM BIOPHYS ACTA, V805, P370, DOI 10.1016/0167-4889(84)90020-X; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P594, DOI 10.1016/0006-291X(84)91344-5; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; SPECTOR R, 1982, ARCH BIOCHEM BIOPHYS, V216, P693, DOI 10.1016/0003-9861(82)90259-4; STEIN WD, 1986, TRANSPORT DIFFUSION, P397; UNGEMACH FR, 1978, H-S Z PHYSIOL CHEM, V359, P845, DOI 10.1515/bchm2.1978.359.2.845; VERMA A, 1985, LIFE SCI, V36, P283, DOI 10.1016/0024-3205(85)90071-2; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19149; WILLIAMS EF, 1984, CAN J PHYSIOL PHARM, V62, P31, DOI 10.1139/y84-005; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WILLIAMS TC, 1989, BIOCHEM J, V264, P223, DOI 10.1042/bj2640223; WOFFENDIN C, 1987, J MEMBRANE BIOL, V98, P89, DOI 10.1007/BF01871048; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; WU XC, 1992, J BIOL CHEM, V267, P8813; YOUNG JD, 1984, J BIOL CHEM, V259, P8363	60	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20613	20619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690759				2022-12-25	WOS:A1993LY01900099
J	NISHIMURA, H; ZARNOWSKI, MJ; SIMPSON, IA				NISHIMURA, H; ZARNOWSKI, MJ; SIMPSON, IA			GLUCOSE-TRANSPORTER RECYCLING IN RAT ADIPOSE-CELLS - EFFECTS OF POTASSIUM-DEPLETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COATED PIT FORMATION; FACTOR-II BINDING; PLASMA-MEMBRANE; POTENTIAL MECHANISM; STIMULATORY ACTION; 3T3-L1 ADIPOCYTES; CLATHRIN LATTICES; INSULIN-RECEPTORS; TRANSLOCATION	Depletion of intracellular potassium (K+) induced a 4-fold increase in basal and 1 muM phorbol-12-myristate-13-acetate (PMA)-stimulated 3-O-methylglucose transport in rat adipose cells. K+ depletion had no effect on the maximum insulin (0.7 muM)-stimulated transport rate but enhanced the sensitivity to insulin 3-fold (EC50= 0.05 versus 0.15 nM) by a mechanism that did not result from changes in the insulin receptor binding, autophosphorylation, or tyrosine kinase activity. Western blotting analysis revealed that K+ depletion induced a 2.2-fold increase in GLUT4 in plasma membranes from basal cells, enhanced the PMA-stimulated GLUT4 translocation by 4-fold, and increased the 5-fold insulin-stimulated GLUT4 translocation by 15%, indicating the presence of an inactive GLUT4 intermediate. The time course for insulin's stimulation of transport activity was accelerated by K+ depletion (t1/2 = 3 versus 1.5 min). Conversely, the reversal of transport activity, on removal of insulin, was delayed (t1/2 = 11 versus 22 min). The corresponding t1/2 values for the loss of GLUT4 were 22 min in control cells and 40 min in K+-depleted cells, again indicating the existence of an inactive intermediate. Photolabeling intact cells with the impermeant, exofacial photolabel 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine in the continuous presence of insulin revealed that K+ depletion had no effect on the GLUT4 externalization rate but halved the rate of internalization. K+ depletion elicited entirely analogous effects on the recycling of insulin-like growth factor II/mannose 6-phosphate receptor, strongly supporting the involvement of a coated pit mechanism in the recycling of GLUT4 transporters. An inactive conformation of GLUT4 has been detected in plasma membranes from insulin-stimulated cells, which is enhanced by K+ depletion, suggesting a limitation in the adipose cells' capacity to express active GLUT4 transporters.	NIDDK, DIABET BRANCH, EDMNS, BLDG 10, RM 5N102, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								APPELL KC, 1988, J BIOL CHEM, V263, P10824; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BURNS CP, 1984, J CELL BIOL, V98, P1082, DOI 10.1083/jcb.98.3.1082; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLAUSEN T, 1969, BIOCHIM BIOPHYS ACTA, V183, P625, DOI 10.1016/0005-2736(69)90175-8; CORVERA S, 1989, J BIOL CHEM, V264, P10133; CULLEN MR, 1985, LINEAR MODELS BIOL; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; GLIEMANN J, 1972, BIOCHIM BIOPHYS ACTA, V286, P1, DOI 10.1016/0304-4165(72)90082-7; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HOKIN LE, 1976, TRENDS BIOCHEM SCI, V1, P233, DOI 10.1016/S0968-0004(76)80099-0; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; ILONDO MM, 1986, P NATL ACAD SCI USA, V83, P6460, DOI 10.1073/pnas.83.17.6460; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LETARTE J, 1969, BIOCHIM BIOPHYS ACTA, V183, P357, DOI 10.1016/0005-2736(69)90092-3; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SALTIS J, 1991, J BIOL CHEM, V266, P261; SATOH S, 1993, IN PRESS J BIOL CHEM, V268; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEER CJ, 1992, INTRACELLULAR TRAFFI; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WEBER TM, 1991, CELL SIGNAL, V3, P51, DOI 10.1016/0898-6568(91)90007-H; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809	45	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19246	19253						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690030				2022-12-25	WOS:A1993LW81900018
J	VILLAMORUZZI, E; LAPI, S; PRAT, M; GAUDINO, G; COMOGLIO, PM				VILLAMORUZZI, E; LAPI, S; PRAT, M; GAUDINO, G; COMOGLIO, PM			A PROTEIN-TYROSINE-PHOSPHATASE ACTIVITY ASSOCIATED WITH THE HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET PROTEIN; HUMAN-PLACENTA; PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR; KINASE; PROTOONCOGENE; AUTOPHOSPHORYLATION; DEPHOSPHORYLATION; PURIFICATION; PHOSPHORYLATION	The receptor for the growth and motility factor, hepatocyte growth factor/scatter factor (HGF/SF), is a transmembrane tyrosine kinase encoded by the MET oncogene. Previous work has shown that receptor phosphorylation on tyrosine is critical for both kinase activation and association with intracellular signal transducers. In this paper, we report that a protein tyrosine phosphatase activity (PTP) coprecipitates with the HGF/SF receptor. The associated PTP activity correlates with the kinase activation of the receptor, increasing up to 5-fold over the basal level after HGF/SF stimulation. The increase is reversible and time- and dose-dependent. A comparable level of activity is associated with constitutively tyrosine-phosphorylated receptors immunoprecipitated from cells where the MET oncogene is amplified and overexpressed. In these cells, a parallel decrease in PTP activity is observed after inhibition of receptor tyrosine phosphorylation following protein kinase C activation. The associated PTP activity is effective in dephosphorylating the HGF/SF receptor. These data show that a protein tyrosine phosphatase is functionally coupled to the HGF/SF receptor.	UNIV TURIN, SCH MED, DEPT BIOMED SCI & ONCOL, I-10124 TURIN, ITALY	University of Turin	VILLAMORUZZI, E (corresponding author), UNIV PISA, DEPT EXPTL BIOMED, I-56100 PISA, ITALY.			Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PERALDI P, 1992, BIOCHEM J, V285, P71, DOI 10.1042/bj2850071; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; VILLAMORUZZI E, 1991, FEBS LETT, V293, P67, DOI 10.1016/0014-5793(91)81154-Z; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; WANG JYJ, 1985, J BIOL CHEM, V260, P64; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18176	18180						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688741				2022-12-25	WOS:A1993LT74300078
J	HERNANDEZ, VJ; BREMER, H				HERNANDEZ, VJ; BREMER, H			CHARACTERIZATION OF RNA AND DNA-SYNTHESIS IN ESCHERICHIA-COLI STRAINS DEVOID OF PPGPP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-RATE CONTROL; RIBOSOMAL-RNA; GUANOSINE TETRAPHOSPHATE; B-R; DEOXYRIBONUCLEIC-ACID; STRINGENT CONTROL; RIBONUCLEIC-ACID; CHROMOSOME-REPLICATION; FEEDBACK-REGULATION; POLYMERASE ACTIVITY	The synthesis rates of DNA, rRNA, bulk mRNA, protein, and RNA polymerase beta- and beta'-subunits were determined as functions of growth rate in a wild-type Escherichia coli strain, which produces guanosine tetraphosphate (ppGpp), and in a DELTArelA DELTAspoT mutant which does not produce ppGpp. The rate of stable RNA synthesis per amount of protein depends on three factors: RNA polymerase concentration, RNA polymerase activity, and the distribution of active RNA polymerase between stable and mRNA genes, measured as the stable RNA synthesis rate/total RNA synthesis rate, r(s)/r(t). In the wild-type strain, all three factors increase with growth rate. In the ppGpp-deficient strains, only RNA polymerase synthesis and activity, but not r(s)/r(t), increased with growth rate. Thus, adjustments of r(s)/r(t) require ppGpp. In the absence of ppGpp, the synthesis of rRNA and bulk mRNA both varied in direct proportion to the concentration of active RNA polymerase, in contrast to the wild-type strain, in which only rRNA synthesis increased with growth rate, while mRNA synthesis remained constant. Thus, a control specific for rRNA is absent in strains lacking ppGpp. In rich media, the ppGpp-deficient strain synthesized up to 4-fold more mRNA than wild-type bacteria, which was associated with a similarly increased RNA polymerase activity. We propose that RNA polymerase is rendered inactive in wild-type bacteria due to ppGpp-dependent transcriptional pausing during the synthesis of mRNA. Finally, the control of replication initiation was altered in ppGpp-less bacteria, apparently reflecting indirect changes in the cell physiology, rather than a direct effect of ppGpp on replication initiation.	UNIV TEXAS,MOLEC PROGRAMS,RICHARDSON,TX 75083; UNIV TEXAS,CELL BIOL PROGRAM,RICHARDSON,TX 75083	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas								BARACCHINI E, 1988, MOL GEN GENET, V213, P379, DOI 10.1007/BF00339606; BARACCHINI E, 1991, J BIOL CHEM, V266, P11753; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARACCHINI E, 1987, ANAL BIOCHEM, V167, P245, DOI 10.1016/0003-2697(87)90160-6; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BREMER H, 1982, J GEN MICROBIOL, V128, P2865; BREMER H, 1977, J BACTERIOL, V130, P692, DOI 10.1128/JB.130.2.692-697.1977; BREMER H, 1968, J MOL BIOL, V38, P163, DOI 10.1016/0022-2836(68)90404-X; BREMER H, 1975, J THEOR BIOL, V53, P115, DOI 10.1016/0022-5193(75)90106-X; BREMER H, 1979, J THEOR BIOL, V74, P69; BREMER H, 1987, CELLULAR MOL BIOL, P1527; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1987, CELLULAR MOL BIOL, P1410; CHIARAMELLO AE, 1989, J BACTERIOL, V171, P4272, DOI 10.1128/JB.171.8.4272-4280.1989; CHIARAMELLO AE, 1990, J BACTERIOL, V172, P2013, DOI 10.1128/jb.172.4.2013-2019.1990; CHURCHWARD G, 1982, J BACTERIOL, V150, P572, DOI 10.1128/JB.150.2.572-581.1982; CHURCHWARD G, 1977, J BACTERIOL, V130, P1206, DOI 10.1128/JB.130.3.1206-1213.1977; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; DENNIS PD, 1972, J BIOL CHEM, V247, P2842; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; DOWNING W, 1991, J BIOL CHEM, V266, P1304; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GALLANT J, 1977, CELL, V11, P181, DOI 10.1016/0092-8674(77)90329-4; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GENTRY DR, 1989, J BACTERIOL, V171, P1271, DOI 10.1128/jb.171.3.1271-1277.1989; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HELMSTETTER CE, 1967, J MOL BIOL, V24, P417, DOI 10.1016/0022-2836(67)90228-8; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JINKSROBERTSON S, 1987, CELLULAR MOL BIOL, P1358; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2878; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LINDAHL L, 1986, ANNU REV GENET, V20, P297; LITTLE R, 1983, J BACTERIOL, V155, P1426, DOI 10.1128/JB.155.3.1426-1428.1983; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maaloe O, 1969, DEVELOP BIOL       S, V3, P33; Miller JH., 1972, EXPT MOL GENETICS; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; PRITCHARD RH, 1970, NATURE, V226, P126, DOI 10.1038/226126a0; ROKEACH LA, 1986, CELL, V46, P763, DOI 10.1016/0092-8674(86)90352-1; RYALS J, 1982, J BACTERIOL, V151, P1425, DOI 10.1128/JB.151.3.1425-1432.1982; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; SCHLEIF R, 1967, J MOL BIOL, V27, P41, DOI 10.1016/0022-2836(67)90350-6; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHAY JW, 1990, J BIOL CHEM, V265, P14802; SHEN V, 1977, J BACTERIOL, V130, P1109, DOI 10.1128/JB.130.3.1109-1116.1977; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; XIAO H, 1991, J BIOL CHEM, V266, P5980; ZYSKIND J, 1990, CELL, V69, P5; [No title captured]	72	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10851	10862						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684368				2022-12-25	WOS:A1993LD46600024
J	ABBOTTS, J; BEBENEK, K; KUNKEL, TA; WILSON, SH				ABBOTTS, J; BEBENEK, K; KUNKEL, TA; WILSON, SH			MECHANISM OF HIV-1 REVERSE-TRANSCRIPTASE - TERMINATION OF PROCESSIVE SYNTHESIS ON A NATURAL DNA-TEMPLATE IS INFLUENCED BY THE SEQUENCE OF THE TEMPLATE-PRIMER STEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I LARGE FRAGMENT; POLYMERASE-I; OLIGONUCLEOTIDES; ALPHA; IDENTIFICATION; SPECIFICITY; REPLICATION; BINDING; SITE	During processive DNA synthesis in vitro, the human immunoefficiency virus, type 1 (HIV-1) reverse transcriptase encounters template nucleotide positions at which continued synthesis is difficult. At these positions, the enzyme has a relatively high probability of dissociating from the template, and product molecules of corresponding length accumulate as the incubation proceeds. These positions, which are known as termination sites, could be associated with template secondary structures in some cases, but many termination sites appear to be template sequence-related rather than secondary structure-related. Mechanisms producing these blocks in processive DNA synthesis are not well understood. In this study, to examine further the effects of template sequence on termination, we engineered selected single-base changes in the M13mp2 template, and we found that such changes can influence termination. Several general trends emerged from the study. First, strong termination sites rarely correspond to dATP as the ''incoming'' substrate opposite template T. Second, the sequence of the template-primer stem is more important for termination than the sequence of the single-stranded template ahead of the primer. Thus, we note the phenomenon of action at a distance: changing sequence at one nucleotide position in the template-primer stem alters termination at other positions, a few nucleotides distant at the primer 3' end. A and C as template bases in the template-primer stem have opposite effects. A is the strongest terminator residue, and C is the weakest terminator residue, followed by G. Since termination sites are produced by reverse transcriptase dissociation from the template-primer, the results suggest that the HIV-1 reverse transcriptase has properties reminiscent of a sequence-specific double-stranded DNA-binding protein in that its binding mechanism can distinguish both base residues and positions in the double-stranded DNA template-primer stem.	NIEHS, MOLEC GENET LAB E3-01, POB 12233, RES TRIANGLE PK, NC 27709 USA; NIH, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA			Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1991, J BIOL CHEM, V266, P3937; ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ABBOTTS J, 1991, GWUMC DEPT, P1; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DETERA SD, 1982, J BIOL CHEM, V257, P9770; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOYCE CM, 1986, UCLA S MOL ELL BIOL, V39, P197; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDENHALL W, 1981, MATH STATISTICS APPL, P287; NEVINSKY GA, 1990, BIOCHEMISTRY-US, V29, P1200, DOI 10.1021/bi00457a016; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEAVER DT, 1982, J BIOL CHEM, V257, P2075	25	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10312	10323						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683674				2022-12-25	WOS:A1993LB80000053
J	SIMON, PL; KUMAR, V; LILLQUIST, JS; BHATNAGAR, P; EINSTEIN, R; LEE, J; PORTER, T; GREEN, D; SATHE, G; YOUNG, PR				SIMON, PL; KUMAR, V; LILLQUIST, JS; BHATNAGAR, P; EINSTEIN, R; LEE, J; PORTER, T; GREEN, D; SATHE, G; YOUNG, PR			MAPPING OF NEUTRALIZING EPITOPES AND THE RECEPTOR-BINDING SITE OF HUMAN INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-BETA; BIOLOGICAL-ACTIVITY; H-1-NMR SPECTRA; HUMAN IL-1-BETA; IL-1 RECEPTOR; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC SELECTION; MONOCLONAL-ANTIBODY; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE	Antibodies to synthetic peptides of human interleukin 1beta (IL-1beta) and to recombinant human IL-1beta were used to identify epitopes of IL-1beta associated with the neutralization of its biological activity. Analysis of antisera raised to 17 synthetic peptides derived from the mature IL-1beta sequence showed that five regions (residues 6-15, 49-80, 58-80,92-101, and 120-133) were both immunoprecipitating and neutralizing. Using a hexamer epitope mapping method, comparison of the regions recognized by four neutralizing rabbit antisera with those recognized by a rabbit antiserum raised to denatured IL-1beta suggested two further neutralizing epitopes, residues 39-48 and 83-95. Finally, a neutralizing monoclonal antibody was shown to bind to the peptides 6-11 and 87-95 by peptide binding and mutagenesis. All of these regions appear predominantly on one face of IL-1beta. The effect of mutations in residues 4-11 and 88-97, which lie within this face, on receptor binding and biological activity was determined. Most of the mutations tested affected both receptor binding and activity, whereas mutations in another face of IL-1beta (residues 74-80) had no effect. Purification of two of the mutants with reduced bioactivity and receptor binding and analysis by two-dimensional NMR indicated no gross changes in tertiary structure. A third mutant had reduced bioactivity in two different bioassays but no change in receptor binding. Although two-dimensional NMR revealed no gross changes in conformation, small changes did occur at a site distal from that mutated. The data are consistent with other epitope mapping and receptor binding mutagenesis data and suggest that the neutralizing antibodies and receptor recognize different but overlapping regions of IL-1beta.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,POB 1539,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PEPTIDE CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AURON PE, 1992, BIOCHEMISTRY-US, V31, P6632, DOI 10.1021/bi00144a002; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHANG JY, 1992, BIOCHEMISTRY-US, V31, P2874, DOI 10.1021/bi00126a005; CHOLLET A, 1990, J IMMUNOL METHODS, V127, P179, DOI 10.1016/0022-1759(90)90067-6; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; DAUMY GO, 1991, FEBS LETT, V278, P98, DOI 10.1016/0014-5793(91)80093-I; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1989, J IMMUNOL, V142, P4314; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GAFFNEY EW, 1987, BIOTECHNIQUES, V5, P652; Gait M. J, 1984, OLIGONUCLEOTIDE SYNT; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GOFF SA, 1987, DNA-J MOLEC CELL BIO, V6, P381, DOI 10.1089/dna.1987.6.381; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRONENBORN AM, 1988, FEBS LETT, V231, P135, DOI 10.1016/0014-5793(88)80717-8; GRONENBORN AM, 1986, EUR J BIOCHEM, V161, P37, DOI 10.1111/j.1432-1033.1986.tb10121.x; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; HERZBECK H, 1989, SCAND J IMMUNOL, V30, P549, DOI 10.1111/j.1365-3083.1989.tb02462.x; HORLICK RA, 1992, PROTEIN ENG, V5, P427, DOI 10.1093/protein/5.5.427; HORUK R, 1987, J BIOL CHEM, V262, P16275; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KAMOGASHIRA T, 1988, J BIOCHEM-TOKYO, V104, P837, DOI 10.1093/oxfordjournals.jbchem.a122559; KAMOGASHIRA T, 1988, BIOCHEM BIOPH RES CO, V150, P1106, DOI 10.1016/0006-291X(88)90743-7; KAWASHIMA H, 1992, PROTEIN ENG, V5, P171, DOI 10.1093/protein/5.2.171; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LILLQUIST JS, 1988, J IMMUNOL, V141, P1975; LIVI GP, 1991, J BIOL CHEM, V266, P15348; LIVI GP, 1990, GENE, V88, P297, DOI 10.1016/0378-1119(90)90048-V; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MACDONALD HR, 1986, FEBS LETT, V209, P295, DOI 10.1016/0014-5793(86)81130-9; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASSONE A, 1988, J IMMUNOL, V140, P3812; MASUI Y, 1989, THERAPEUTIC PEPTIDES, P167; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEYERS CA, 1987, J BIOL CHEM, V262, P11176; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAITO Y, 1990, BIOCHEM BIOPH RES CO, V167, P103, DOI 10.1016/0006-291X(90)91736-C; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SIMON PL, 1985, J IMMUNOL METHODS, V84, P85, DOI 10.1016/0022-1759(85)90417-X; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; TAM JP, 1987, PEPTIDES, V9, P185; VANOOSTRUM J, 1991, J STRUCT BIOL, V107, P189; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WINGFIELD P, 1989, EUR J BIOCHEM, V179, P565, DOI 10.1111/j.1432-1033.1989.tb14584.x; WINGFIELD P, 1987, FEBS LETT, V215, P160, DOI 10.1016/0014-5793(87)80133-3; WOLFSON AJ, 1991, PROTEIN ENG, V4, P313, DOI 10.1093/protein/4.3.313; YAMAYOSHI M, 1990, LYMPHOKINE RES, V9, P405; YANOFSKY SD, 1990, J BIOL CHEM, V265, P13000; YEM AW, 1989, J BIOL CHEM, V264, P17691; YOUNG P R, 1992, Current Opinion in Biotechnology, V3, P408, DOI 10.1016/0958-1669(92)90170-N; YOUNG PR, 1989, PROTEIN ENG, V2, P545, DOI 10.1093/protein/2.7.545	72	28	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9771	9779						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683661				2022-12-25	WOS:A1993LA68900090
J	YANG, BH; ZANG, LY; TURLEY, EA				YANG, BH; ZANG, LY; TURLEY, EA			IDENTIFICATION OF 2 HYALURONAN-BINDING DOMAINS IN THE HYALURONAN RECEPTOR RHAMM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINK PROTEIN; HOMING RECEPTOR; CELL-ADHESION; PROTEOGLYCANS; ACID; GLYCOSAMINOGLYCANS; SEQUENCE	We have identified two discrete hyaluronan- (HA) binding domains in the HA receptor RHAMM (Receptor for HA-Mediated Motility) that mediates the locomotion of H-ras transformed fibroblasts. A complete RHAMM cDNA (1.43 kilobases (kb)) was expressed as a fusion protein with pGEX-2T in Escherichia coli HB101 and was shown to bind specifically to both biotin-labeled HA in a transblot assay and to HA-Sepharose. The complete cDNA was truncated with restriction endonucleases from the 3' end resulting in 1.30-, 1.02-, 0.71-, and 0.41-kb cDNAs which were then expressed in HB101. Only the fusion peptide expressed from the complete cDNA and the 1.30-kb cDNA bound to HA indicating that the region located between 1.02-1.30 kb of RHAMM cDNA was critical for recognition of this glycosaminoglycan. Deletion of 114 bases in this region virtually eliminated HA binding activity thus defining the major glycosaminoglycan binding region to amino acids 400-434 located near the carboxyl terminus of RHAMM. Two domains containing clusters of basic amino acids were identified within this region. Synthetic peptides mimicking these two domains both inhibited HA binding to the complete 1.43-kb expressed glutathione s-transferase-RHAMM fusion protein, and also directly bound to HA-Sepharose. Random peptides and peptides mimicking other regions in RHAMM did not inhibit HA-RHAMM interactions and bound weakly to HA-Sepharose. Oligonucleotides encoding either of these two peptides were linked to the NH2-terminal 0.71 kb of RHAMM which encoded a peptide that did not contain HA binding activity. Fusion proteins containing either of these recombinant peptides acquired HA binding activity as assessed with a transblot assay. Thus, we have identified two domains within RHAMM that are responsible for its HA binding activity.	UNIV MANITOBA, MANITOBA INST CELL BIOL, 100 OLIVIA ST, WINNIPEG R3E 0V9, MANITOBA, CANADA; UNIV MANITOBA, DEPT PEDIAT & CHILD HLTH, WINNIPEG R3E 0V9, MANITOBA, CANADA	University of Manitoba; University of Manitoba					NCI NIH HHS [CA 51540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bayer E A, 1980, Methods Biochem Anal, V26, P1; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EHRLICH HJ, 1992, J BIOL CHEM, V267, P8857; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; IOZZO RV, 1985, LAB INVEST, V53, P373; ISACSSON U, 1974, ANAL CHIM ACTA, V68, P339, DOI 10.1016/S0003-2670(01)82590-3; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KOST C, 1992, J BIOL CHEM, V267, P12098; KVIST TN, 1970, J EXP ZOOL, V175, P221, DOI 10.1002/jez.1401750209; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MARKWALD RR, 1978, DEV BIOL, V62, P292, DOI 10.1016/0012-1606(78)90218-X; MCCARTHY MT, 1989, J CELL PHYSIOL, V141, P191, DOI 10.1002/jcp.1041410127; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; Roswell D. F., 1978, METHOD ENZYMOL, V57, P409, DOI [10.1016/0076-6879(78)57038-9, DOI 10.1016/0076-6879(78)57038-9]; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOOLE BP, 1982, CONNECT TISSUE RES, V10, P93, DOI 10.3109/03008208209034409; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1984, CANCER METAST REV, V3, P325, DOI 10.1007/BF00051458; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1987, BIOCHEMISTRY-US, V26, P2997, DOI 10.1021/bi00385a007	34	134	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8617	8623						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682552				2022-12-25	WOS:A1993KX81100038
J	CHEN, L; GARRETT, TPJ; FINCHER, GB; HOJ, PB				CHEN, L; GARRETT, TPJ; FINCHER, GB; HOJ, PB			A TETRAD OF IONIZABLE AMINO-ACIDS IS IMPORTANT FOR CATALYSIS IN BARLEY BETA-GLUCANASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; BACTERIOPHAGE-T4 LYSOZYME; PROTEINS; RESIDUES; BINDING; ENZYME; 4-GLUCANOHYDROLASE; ENDOHYDROLASES; IDENTIFICATION	Determination of the crystal structures of a 1,3-beta-D-glucanase (E.C. 3.2.1.39) and a 1,3-1,4-beta-D-glucanase (E.C. 3.2.1.73) from barley (Hordeum vulgare) (Varghese, J. N, Garrett, T. P. J., Cohnan, P. M., Chen, L., Hoj, P. B., and Fincher, G. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2785-2789) showed the spatial positions of the catalytic residues in the substrate-binding clefts of the enzymes and also identified highly conserved neighboring amino acid residues. Site-directed mutagenesis of the 1,3-beta-glucanase has now been used to investigate the importance of these residues. Substitution of glutamine for the catalytic nucleophile Glu(231) (mutant E231Q) reduced the specific activity about 20,000-fold. In contrast, substitution of glutamine for the catalytic acid Glu(288) (mutant E288Q) had less severe consequences, reducing k(cat) approximately 350-fold with little effect on K-m. Substitution of two neighboring and strictly conserved active site-located residues Glu(279) (mutant E279Q) and Lys(282) (mutant K282M) led to 240- and 2500-fold reductions of k(cat), respectively, with small increases in K-m. Thus, a tetrad of ionizable amino acids is required for efficient catalysis in barley beta-glucanases. The active site-directed inhibitor 2,3-epoxypropyl beta-laminaribioside was soaked into native crystals. Crystallographic refinement revealed all four residues (Glu(231), Glu(279), Lys(282), and Glu(288)) to be in contact with the bound inhibitor, and the orientation of bound substrate in the active site of the glucanase was deduced.	LA TROBE UNIV,DEPT BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA; BIOMOLEC RES INST,PARKVILLE,VIC 3052,AUSTRALIA; UNIV ADELAIDE,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA; UNIV ADELAIDE,DEPT HORT VITICULTURE & OENOL,GLEN OSMOND,SA 5064,AUSTRALIA	La Trobe University; University of Adelaide; University of Adelaide			Hoj, Peter B/E-8526-2011					ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BRUNGER AT, 1992, X PLOR VERSION 3 3; CHEN L, 1993, J MOL BIOL, V234, P888, DOI 10.1006/jmbi.1993.1635; CHEN L, 1993, J BIOL CHEM, V268, P13318; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EDINGTON BV, 1991, PLANT MOL BIOL, V16, P81, DOI 10.1007/BF00017919; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; HOJ PB, 1992, J BIOL CHEM, V267, P25059; HOJ PB, 1991, J BIOL CHEM, V266, P11628; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HOJ PB, 1989, J BIOL CHEM, V264, P4939; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; LEGLER G, 1993, CARBOHYD RES, V250, P7; LIU L, 1993, P NATL ACAD SCI USA, V90, P8604, DOI 10.1073/pnas.90.18.8604; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MALEHORN DE, 1993, PLANT MOL BIOL, V22, P347, DOI 10.1007/BF00014941; OLSEN O, 1990, THESIS AARHUS U DENM; PAYNE G, 1990, PLANT MOL BIOL, V15, P797, DOI 10.1007/BF00039420; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; RING M, 1990, ARCH BIOCHEM BIOPHYS, V286, P342; ROBINSON AB, 1991, P NATL ACAD SCI USA, V88, P8880, DOI 10.1073/pnas.88.20.8880; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P665, DOI 10.1071/CH9900665; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P9235, DOI 10.1073/pnas.90.20.9235; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SLAKESKI N, 1990, MOL GEN GENET, V224, P437, DOI 10.1007/BF00262439; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; SVENSSON B, 1990, EUR J BIOCHEM, V188, P29, DOI 10.1111/j.1432-1033.1990.tb15367.x; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; URRY DW, 1993, J AM CHEM SOC, V115, P7509, DOI 10.1021/ja00069a063; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WORRALL D, 1992, PLANT CELL, V7, P759; XU PL, 1992, GENE, V120, P157, DOI 10.1016/0378-1119(92)90089-8	43	37	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8093	8101		10.1074/jbc.270.14.8093	http://dx.doi.org/10.1074/jbc.270.14.8093			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713912	hybrid			2022-12-25	WOS:A1995QR52600050
J	SHEPHERD, RM; HENQUIN, JC				SHEPHERD, RM; HENQUIN, JC			THE ROLE METABOLISM, CYTOPLASMIC CA2+, AND PH-REGULATING EXCHANGERS IN GLUCOSE-INDUCED RISE OF CYTOPLASMIC PH IN NORMAL MOUSE PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; BETA-CELLS; INTRACELLULAR PH; NA+/H+ EXCHANGE; B-CELL; SECRETION; AMILORIDE; ATP; ELECTROPHYSIOLOGY; INCREASE	Intact mouse islets were loaded with 2',7'-bis(2-car boxyethyl)-5(6)-carboxyfluorescein to study the effects of glucose on cytoplasmic pH (pH(i)) in pancreatic B-cells. In HCO3- buffer, glucose produced a steady-state increase in pH(i) that required metabolism of the sugar and was concentration-dependent between 0 and 10 mM (K-m similar to 5 mM) before plateauing at a maximum value of similar to 0.2 pH units. In HEPES buffer, glucose concentrations above 7 mM caused an initial rise followed by a secondary decrease and an eventual return to about initial values. Inhibition of Ca2+ influx had little effect on the pH(i) changes produced by glucose in HCO3- medium, but unmasked an alkalinizing effect in HEPES buffer. Raising cytoplasmic Ca2+ by 30 mM potassium caused a larger acidification in HEPES than in HCO3- buffer, but a subsequent rise in glucose now increased pH(i) in both types of buffer. In the presence of 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS; inhibitor of HCO3-/ Cl- exchange), the effect of glucose on pH(i) in HCO3- buffer became similar to that in HEPES buffer. After inhibition of the Na+/H+ exchanger by dimethylamiloride, glucose produced a marked and sustained fall in pH(i) in HEPES buffer. A similar fall was seen in HCO3- buffer only when DIDS and dimethylamiloride were present together. However, if Ca2+ influx was prevented when both exchangers were blocked, glucose increased pH(i). In conclusion, the metabolism of glucose tends to increase pH(i) in B-cells, whereas the concomitant rise in [Ca2+](i) exerts an acidifying action. In HEPES buffer, this acidifying effect of Ca2+ is offset by the operation of the Na+/H+ exchanger. In physiological HCO3- buffer, the activity of the HCO3-/Cl- exchanger overcompensates and leads to an increase in pH(i).	UNIV CATHOLIQUE LOUVAIN,FAC MED,UNITE ENDOCRINOL & METAB,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain								ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; BEST L, 1992, NUTR REGULATION INSU, P157; BIDEN TJ, 1986, AM J PHYSIOL, V250, pC207, DOI 10.1152/ajpcell.1986.250.2.C207; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BUSA WB, 1984, AM J PHYSIOL, V246, pF409; CABANTCHIK ZI, 1978, BIOCH BIOPHSY ACTA, V515, P289; COOK DL, 1990, DIABETES MELLITUS TH, P89; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; DELEERS M, 1983, FEBS LETT, V154, P97, DOI 10.1016/0014-5793(83)80882-5; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1992, J BIOL CHEM, V267, P20713; GRAPENGIESSER E, 1989, BIOCHIM BIOPHYS ACTA, V1014, P219, DOI 10.1016/0167-4889(89)90215-2; HENQUIN JC, 1978, NATURE, V271, P271, DOI 10.1038/271271a0; HENQUIN JC, 1976, AM J PHYSIOL, V231, P713, DOI 10.1152/ajplegacy.1976.231.3.713; HENQUIN JC, 1992, NUTRIENT REGULATION, P173; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LEBRUN P, 1986, BIOCHIM BIOPHYS ACTA, V886, P448, DOI 10.1016/0167-4889(86)90181-3; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; MALAISSE WJ, 1984, EXPERIENTIA, V40, P1035, DOI 10.1007/BF01971449; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; PACE CS, 1983, AM J PHYSIOL, V244, pE3, DOI 10.1152/ajpendo.1983.244.1.E3; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SEHLIN J, 1978, AM J PHYSIOL, V235, pE501, DOI 10.1152/ajpendo.1978.235.5.E501; SUGIMOTO Y, 1988, BIOMED RES-TOKYO, V9, P383, DOI 10.2220/biomedres.9.383; THELER JM, 1992, J BIOL CHEM, V267, P18110; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VIGNE P, 1984, MOL PHARMACOL, V25, P131; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; ZAWALICH WS, 1979, DIABETES, V28, P252, DOI 10.2337/diab.28.3.252	35	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7915	7921		10.1074/jbc.270.14.7915	http://dx.doi.org/10.1074/jbc.270.14.7915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713887	hybrid			2022-12-25	WOS:A1995QR52600023
J	BOISCLAIR, YR; BROWN, AL; CASOLA, S; RECHLER, MM				BOISCLAIR, YR; BROWN, AL; CASOLA, S; RECHLER, MM			3 CLUSTERED SP1 SITES ARE REQUIRED FOR EFFICIENT TRANSCRIPTION OF THE TATA-LESS PROMOTER OF THE GENE FOR INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-2 FROM THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; ACTIVATOR INHIBITOR-1 GENE; RECEPTOR GENE; SYNERGISTIC ACTIVATION; IGF-I; EXPRESSION; BOX; SEQUENCE; DNA; CLONING	Insulin-like growth factor-binding protein-2 (IGFBP-2) transcription in rat liver varies with developmental age and fasting. To define the DNA elements required for efficient expression of the TATA-less rat IGFBP-2 gene, the native or mutated promoter was fused to a promoterless luciferase reporter gene and transfected into BRL-3A rat liver and 293 human embryonic kidney cell lines. Luciferase activity decreased approximately 25-fold with progressive 5' promoter deletions from nucleotide (nt) -581 to nt -189 (relative to ATG, +1). The smallest construct, however, still had >21-fold greater luciferase activity than the promoterless construct. In DNase I footprinting assays using native nt -276 to -36 promoter fragments or fragments containing block substitution mutations, BRL-3A nuclear extract and purified human transcription factor Sp1 protected a region from nt -234 to -215 containing one GC box and a broad region from nt -189 to -125 that contained three clustered but independent GC boxes. In gel retardation assays using an Spl oligonucleotide probe, BRL-3A extract formed two closely migrating complexes that were immunologically related to Spl; Spl gave a single complex that co-migrated with the more retarded BRL-3A complex. Binding was competitively inhibited by oligonucleotides corresponding to each of the four GC boxes. The proximal three GC boxes were sufficient to allow trans-activation of the IGFBP-2 promoter by Spl in Drosophila SL2 cells. Independent block mutations indicated that all three of the GC boxes are required for promoter activity and are equally important. Thus, binding of Spl or Sp1-related proteins to three clustered GC boxes in the proximal IGFBP-2 promoter is essential for promoter activity. Multiple upstream regions also contribute to the full expression of the IGFBP-2 gene.			BOISCLAIR, YR (corresponding author), NIDDKD, MOLEC & CELLULAR ENDOCRINOL BRANCH, GROWTH & DEV SECT, BLDG 10, RM 8D-14, BETHESDA, MD 20892 USA.		Casola, Stefano/AAN-8319-2021	Casola, Stefano/0000-0001-5580-0986				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BINKERT C, 1992, MOL ENDOCRINOL, V6, P826, DOI 10.1210/me.6.5.826; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN AL, 1989, J BIOL CHEM, V264, P5148; BROWN AL, 1990, MOL ENDOCRINOL, V4, P2039, DOI 10.1210/mend-4-12-2039; CHEN XR, 1992, ONCOGENE, V7, P1805; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DONOVAN SM, 1989, ENDOCRINOLOGY, V125, P2621, DOI 10.1210/endo-125-5-2621; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HILL DJ, 1992, ADV EXP MED BIOL, V321, P113; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON MR, 1992, J BIOL CHEM, V267, P12202; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMPT M, 1992, DEVELOPMENT, V115, P765; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEE WH, 1992, MOL CELL NEUROSCI, V3, P36, DOI 10.1016/1044-7431(92)90006-N; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; ORLOWSKI CC, 1990, ENDOCRINOLOGY, V126, P644, DOI 10.1210/endo-126-1-644; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; TSENG LYH, 1992, MOL ENDOCRINOL, V6, P1195, DOI 10.1210/me.6.8.1195; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOOD TL, 1992, DEVELOPMENT, V114, P59; YU CY, 1991, J BIOL CHEM, V266, P8907; ZAPF J, 1990, J CLIN INVEST, V86, P952, DOI 10.1172/JCI114797; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	62	120	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24892	24901						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693708				2022-12-25	WOS:A1993MG67300058
J	DONATE, LE; VALPUESTA, JM; MIER, C; ROJO, F; CARRASCOSA, JL				DONATE, LE; VALPUESTA, JM; MIER, C; ROJO, F; CARRASCOSA, JL			CHARACTERIZATION OF AN RNA-BINDING DOMAIN IN THE BACTERIOPHAGE-PHI-29 CONNECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS PHAGE-PHI-29; PHI-29 CONNECTOR; 3-DIMENSIONAL STRUCTURE; RESTRICTION FRAGMENTS; NUCLEOTIDE-SEQUENCE; COLIPHAGE-LAMBDA; DNA-BINDING; PROTEIN; PROHEAD; IDENTIFICATION	The connector of bacteriophage phi29 is known to promote the viral prohead assembly, to bind DNA, and to drive DNA packaging into preformed viral shells in an RNA-dependent process. In this report, the phi29 connector protein, p10, is shown to bind RNA in a sequence-independent fashion, and to possess an RNA recognition motif comprised approximately the region between residues 21 and 94 of the p10 sequence. Substitution mutants in specific amino acids of the RNA-binding domain obtained by site-directed mutagenesis showed that amino acids Phe23, His57, Phe59, and Tyr61 are critical for RNA binding and, subsequently, for DNA packaging into proheads. Proteolytic modified forms of the phi29 connector have allowed us to conclude that the DNA- and RNA-binding domains are separated within the p10 sequence. It is also shown that RNA is stably associated to DNA-filled proheads during the DNA-packaging process.	UNIV AUTONOMA MADRID,CTR BIOL MOLEC SEVERO OCHOA,CSIC,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Valpuesta, Jose M/AAA-6002-2019; Rojo, Fernando/A-7038-2008; Valpuesta, José M/T-1977-2017	Rojo, Fernando/0000-0003-1848-7745; Valpuesta, José M/0000-0001-7468-8053				BAILEY S, 1990, J BIOL CHEM, V265, P22365; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; BUCHWALD M, 1970, VIROLOGY, V42, P390, DOI 10.1016/0042-6822(70)90282-5; CAMACHO A, 1977, EUR J BIOCHEM, V73, P39, DOI 10.1111/j.1432-1033.1977.tb11290.x; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CARRASCOSA JL, 1990, COMPUT MATH APPL, V20, P57, DOI 10.1016/0898-1221(90)90314-A; CARRUTH JAS, 1986, IEEE ENG MED BIOL, V5, P37, DOI 10.1109/MEMB.1986.5006254; Casjens S., 1988, BACTERIOPHAGES, VI; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DONATE LE, 1988, J MOL BIOL, V201, P91, DOI 10.1016/0022-2836(88)90441-X; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; DONATE LE, 1991, VIROLOGY, V182, P534, DOI 10.1016/0042-6822(91)90594-2; DONATE LE, 1992, J BIOL CHEM, V267, P10919; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; ESCARMIS C, 1981, P NATL ACAD SCI-BIOL, V78, P1446, DOI 10.1073/pnas.78.3.1446; GARCIA JA, 1984, GENE, V30, P87, DOI 10.1016/0378-1119(84)90108-2; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GRIMES S, 1989, J MOL BIOL, V209, P91, DOI 10.1016/0022-2836(89)90172-1; GUO P, 1987, NUCLEIC ACIDS RES, V17, P7081; GUO PX, 1987, J MOL BIOL, V197, P219, DOI 10.1016/0022-2836(87)90120-3; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; HERRANZ L, 1986, VIROLOGY, V155, P289, DOI 10.1016/0042-6822(86)90191-1; HERRANZ L, 1990, J MOL BIOL, V213, P263, DOI 10.1016/S0022-2836(05)80189-5; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HSIAO CL, 1978, VIROLOGY, V91, P15, DOI 10.1016/0042-6822(78)90351-3; IBANEZ C, 1984, NUCLEIC ACIDS RES, V12, P2351, DOI 10.1093/nar/12.5.2351; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KOCHAN J, 1984, J MOL BIOL, V174, P175; MURIALDO H, 1978, MICROBIOL REV, V42, P529, DOI 10.1128/MMBR.42.3.529-576.1978; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; MURIALDO H, 1971, BACTERIOPHAGE LAMBDA, P711; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAKASU S, 1985, VIROLOGY, V143, P422, DOI 10.1016/0042-6822(85)90382-4; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; RAJ AS, 1974, MOL GEN GENET, V135, P175, DOI 10.1007/BF00264784; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; VALCARCEL J, 1991, J GEN VIROL, V72, P1301, DOI 10.1099/0022-1317-72-6-1301; VALPUESTA JM, 1992, J MOL BIOL, V224, P103, DOI 10.1016/0022-2836(92)90579-9; VALPUESTA JM, 1992, NUCLEIC ACIDS RES, V20, P5549, DOI 10.1093/nar/20.21.5549; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K	46	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20198	20204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690751				2022-12-25	WOS:A1993LY01900044
J	MUSTAEV, A; KASHLEV, M; ZAYCHIKOV, E; GRACHEV, M; GOLDFARB, A				MUSTAEV, A; KASHLEV, M; ZAYCHIKOV, E; GRACHEV, M; GOLDFARB, A			ACTIVE-CENTER REARRANGEMENT IN RNA-POLYMERASE INITIATION COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; FUNCTIONAL TOPOGRAPHY; PHOSPHORYLATING DERIVATIVES; TRANSCRIPTION ELONGATION; PRIMER OLIGONUCLEOTIDES; VISUALIZATION; CONTACTS; INVITRO	His1237 in the beta subunit of Escherichia coli RNA polymmerase marks the ''5' face'' of the active center since it can be cross-linked to the gamma-phosphate of the priming substrate. It is demonstrated that RNA chains up to 9 nucleotides in length can be synthesized using His1237-cross-linked nucleotide as a primer. Thus, a substantial mass of RNA can be accommodated in the active center between His1237 and the site of catalysis that remains juxtaposed to the growing 3' end. The apparent ''filling'' of the active center with RNA precedes promoter clearance and suggests a mechanism of coupling between catalysis and saltatory translocation of RNA polymerase.	PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016; RUSSIAN ACAD SCI,INST LIMINOL,IRKUTSK 664033,RUSSIA	Russian Academy of Sciences			Grachev, Mikhail/J-9279-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; FIC NIH HHS [TW00258] Funding Source: Medline; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; CHAN CL, 1993, IN PRESS TRANSCRIPTI; GODOVIKOVA TS, 1987, EUR J BIOCHEM, V166, P611, DOI 10.1111/j.1432-1033.1987.tb13557.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GRACHEV MA, 1986, BIOORG KHIM+, V12, P1678; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1981, FEBS LETT, V130, P23, DOI 10.1016/0014-5793(81)80657-6; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HEUMANN H, 1986, EUR J BIOCHEM, V158, P575, DOI 10.1111/j.1432-1033.1986.tb09793.x; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; LEE J, 1990, CELL, V66, P793; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SERPINSKI OI, 1982, BIOORG KHIM+, V8, P840; SPASSKY A, 1986, J MOL BIOL, V188, P99, DOI 10.1016/0022-2836(86)90484-5; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TSAREV IG, 1990, BIOORG KHIM+, V16, P765; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	31	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19185	19187						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690028				2022-12-25	WOS:A1993LW81900007
J	KENYON, K; MODI, WS; CONTENTE, S; FRIEDMAN, RM				KENYON, K; MODI, WS; CONTENTE, S; FRIEDMAN, RM			A NOVEL HUMAN CDNA WITH A PREDICTED PROTEIN SIMILAR TO LYSYL OXIDASE MAPS TO CHROMOSOME-15Q24-Q25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; MARFAN-SYNDROME; MESSENGER-RNA; GENE; LOCALIZATION; ASSIGNMENT; CLONING; INSITU	A novel human cDNA with a predicted protein homologous to the carboxyl end of lysyl oxidase, an extracellular enzyme involved in the maturation of collagen and elastin, has been isolated. The homology to lysyl oxidase begins exactly at the position of the exon 1/exon 2 boundary in the mouse gene (Contente, S., Csiszar, K., Kenyon, K., and Friedman, R. M. (1993) Genomics 16, 395-400). This lysyl oxidase-like gene, which appears to be no larger than 22.1 kilobases, codes for a single poly-adenylated RNA species of 2.48 kilobases and has been mapped to chromosome 15q24-q25.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KENYON, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.			Contente, Sara/0000-0002-8099-2817	NCI NIH HHS [R01 CA37351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CONTENTE S, 1993, GENOMICS, V16, P395, DOI 10.1006/geno.1993.1202; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LAWRENCE JB, 1988, CELL, V52, P51; LAYFIELD R, 1992, EUR J BIOCHEM, V204, P591, DOI 10.1111/j.1432-1033.1992.tb16672.x; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MAGENIS RE, 1991, GENOMICS, V11, P346, DOI 10.1016/0888-7543(91)90142-2; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; SAKAI LY, 1990, ELASTIN CHEM BIOL AS, P215; Sambrook J, 1989, MOL CLONING LABORATO; SCHWEIZER D, 1981, HUM GENET, V57, P1; SHARMA RC, 1993, BIOTECHNIQUES, V14, P176; SVINARICH DM, 1992, J BIOL CHEM, V267, P14382; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHOU J, 1992, PLANT MOL BIOL, V20, P5, DOI 10.1007/BF00029144	25	83	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18435	18437						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689553				2022-12-25	WOS:A1993LV65900010
J	SHEN, BQ; BARTHELSON, RA; SKACH, W; GRUENERT, DC; SIGAL, E; MRSNY, RJ; WIDDICOMBE, JH				SHEN, BQ; BARTHELSON, RA; SKACH, W; GRUENERT, DC; SIGAL, E; MRSNY, RJ; WIDDICOMBE, JH			MECHANISM OF INHIBITION OF CAMP-DEPENDENT EPITHELIAL CHLORIDE SECRETION BY PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; CELL-LINE; TRACHEAL EPITHELIUM; TRANSPORT; CHANNEL; EXPRESSION; CFTR; IDENTIFICATION; LOCALIZATION	In T84 cells, we investigated how stimulation of protein kinase C leads to an inhibition of cAMP-dependent chloride secretion. Specifically, we tested the hypothesis that the inhibition was caused by loss of the cystic fibrosis transmembrane regulator (CFTR), an apical membrane chloride channel. As described by others (Trapnell, B. C., Zeitlin, P. L., Chu, C.-S., Yoshimura, K., Nakamura, H., Guggino, W. B., Bargon, J., Banks, T. C., Dalemans, W., Pavirani, A., Lecocq, J.-P., and Crystal, R. G. (1991) J. Biol. Chem. 266, 10319-10323), we found that treatment with the phorbol ester, phorbol myristate acetate (PMA), reduced CFTR mRNA levels by approximately 80% with a t1/2 of approximately 2 h. Chloride secretion, measured as forskolin-induced short circuit current, was also abolished by PMA with a t1/2 of approximately 2 h. Levels of mature glycosylated CFTR measured by Western blotting also declined to 50 +/- 8% (n = 7) of control after a 12-h PMA treatment. However, a 12-h exposure to PMA did not affect the forskolin-stimulated efflux of I-125 into high potassium medium, a measure of apical membrane CFTR activity. We conclude that increased turnover of apical membrane CFTR in PMA-treated cells compensates for the decline in anion channel numbers. By contrast to its lack of effect on I-125 effluxes, PMA reduced the cAMP-induced increase in Rb-86 efflux, suggesting that it inhibits chloride secretion mainly by an action on basolateral potassium channels.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,513 PARNASSUS AVE,BOX 0130,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL-42368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1991, SCIENCE, V253, P203; BARTHELSON RA, 1987, AM J PHYSIOL, V253, pC802, DOI 10.1152/ajpcell.1987.253.6.C802; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; LASKI F, 1982, NUCLEIC ACIDS RES, V210, P4609; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MCCANN JD, 1990, AM J PHYSIOL, V258, pL348; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1992, J BIOL CHEM, V267, P2087; Smith PK, 1985, ANAL BIOCHEM, V71, P1392; SUSSMAN I, 1985, J CELL BIOL, V101, P2316, DOI 10.1083/jcb.101.6.2316; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WELSH MJ, 1987, AM J PHYSIOL, V253, pC828, DOI 10.1152/ajpcell.1987.253.6.C828; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	28	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19070	19075						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689566				2022-12-25	WOS:A1993LV65900103
J	GUIHARD, G; BENEDETTI, H; BESNARD, M; LETELLIER, L				GUIHARD, G; BENEDETTI, H; BESNARD, M; LETELLIER, L			PHOSPHATE EFFLUX THROUGH THE CHANNELS FORMED BY COLICINS AND PHAGE T5 IN ESCHERICHIA-COLI-CELLS IS RESPONSIBLE FOR THE FALL IN CYTOPLASMIC ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVIVO PROPERTIES; CONTACT SITES; ION CHANNELS; MEMBRANE; TRANSLOCATION; INFECTION; PROTEIN; TRANSPORT; DNA; PERMEABILITY	Previous studies have shown that channel formation in the cytoplasmic membrane of Escherichia coli by colicin A and phage T5 leads to an efflux of cytoplasmic potassium and to a membrane depolarization. Here we show that upon opening of these channels, the intracellular ATP concentration is decreased to 10% of its original value in <5 min. ATP is not found in the external medium, but is hydrolyzed in the cytoplasm into ADP and AMP. The rate of ATP hydrolysis depends on the number of channels and on their activity. ATP hydrolysis takes place if the F1F0-ATPase is absent or inhibited. Depolarization of the inner membrane is not the main cause of ATP hydrolysis. Opening of the phage and colicin channels also leads to an efflux of inorganic phosphate. Conditions that prevent the efflux of phosphate (i.e. depolarization of the cells and high external phosphate concentration) prevent ATP hydrolysis. We propose that ATP is hydrolyzed as a consequence of a shift in the ATP equilibrium due to the efflux of phosphate through the channels. The consequences for the cells of this ATP depletion are discussed.	UNIV PARIS 11, BIOMEMBRANES LAB, CNRS, URA 1116, BAT 433, F-91405 ORSAY, FRANCE; CTR BIOCHIM & BIOL MOLEC, INGN & DYNAM SYST MEMBRANAIRES LAB, UPR 27, F-7113402 MARSEILLE 9, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ALTENDORF K, 1975, FEBS LETT, V59, P268, DOI 10.1016/0014-5793(75)80390-5; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BEPPU T, 1972, J BACTERIOL, V110, P485, DOI 10.1128/JB.110.2.485-493.1972; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; CAVARD D, 1981, FEMS MICROBIOL LETT, V12, P311; CAVARD D, 1979, EUR J BIOCHEM, V96, P519, DOI 10.1111/j.1432-1033.1979.tb13065.x; CHAPMAN AG, 1971, J BACTERIOL, V108, P1072, DOI 10.1128/JB.108.3.1072-1086.1971; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CONDIT RC, 1975, J MOL BIOL, V98, P45, DOI 10.1016/S0022-2836(75)80100-8; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FEINGOLD D S, 1970, Journal of Membrane Biology, V3, P372, DOI 10.1007/BF01868024; FEUCHT A, 1990, J BIOL CHEM, V265, P18561; FIELDS KL, 1969, J BACTERIOL, V97, P64, DOI 10.1128/JB.97.1.64-77.1969; FIELDS KL, 1969, J BACTERIOL, V97, P57, DOI 10.1128/JB.97.1.57-63.1969; GELI V, 1986, MOL GEN GENET, V202, P455, DOI 10.1007/BF00333276; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HIRATA H, 1969, J BIOCHEM-TOKYO, V65, P843, DOI 10.1093/oxfordjournals.jbchem.a129088; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024; KEWELOH HW, 1984, J BACTERIOL, V160, P354, DOI 10.1128/JB.160.1.354-359.1984; KOPECKY AL, 1975, P NATL ACAD SCI USA, V72, P4631, DOI 10.1073/pnas.72.11.4631; LABEDAN B, 1981, P NATL ACAD SCI-BIOL, V78, P215, DOI 10.1073/pnas.78.1.215; LANNI YT, 1958, VIROLOGY, V5, P481, DOI 10.1016/0042-6822(58)90041-2; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LETELLIER L, 1992, BIOCHIM BIOPHYS ACTA, V1101, P218; LETELLIER L, 1993, ALKALI CATION TRANSP, P359; LETELLIER L, 1992, BACTERIOCINS MICROCI, P119; LURIA SE, 1964, ANN I PASTEUR PARIS, VS, P67; NEU HC, 1965, J BIOL CHEM, V240, P3685; PATTUS F, 1990, EXPERIENTIA, V46, P180; PLATE CA, 1974, J BIOL CHEM, V249, P6138; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SINGH AP, 1974, J BACTERIOL, V119, P129, DOI 10.1128/JB.119.1.129-137.1974; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; WAGNER EF, 1980, J BIOL CHEM, V255, P540; WAGNER EF, 1980, J BIOL CHEM, V255, P534; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WILSON DB, 1982, J BACTERIOL, V152, P1091; ZILBERSTEIN D, 1979, BIOCHEMISTRY-US, V18, P669, DOI 10.1021/bi00571a018	44	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17775	17780						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688731				2022-12-25	WOS:A1993LT74300024
J	ELMOATASSIM, C; DUBYAK, GR				ELMOATASSIM, C; DUBYAK, GR			DISSOCIATION OF THE PORE-FORMING AND PHOSPHOLIPASE-D ACTIVITIES STIMULATED VIA P(2Z) PURINERGIC RECEPTORS IN BAC1.2F5 MACROPHAGES - PRODUCT INHIBITION OF PHOSPHOLIPASE-D ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PAROTID ACINAR-CELLS; EXTRACELLULAR ATP; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; GROWTH-FACTOR; D ACTIVATION; PHOSPHATIDYLCHOLINE BREAKDOWN; TYROSINE PHOSPHORYLATION; HUMAN NEUTROPHILS	We have previously reported that the occupancy of P2z purinergic receptors in BAC1.2F5 macrophages stimulates both the formation of nonselective membrane pores/channels and a novel phospholipase D (PLD) activity. In the present study, the relationship between these two P2z receptor-mediated responses was investigated. In [H-3]oleic acid-labeled macrophages, isoosmotic replacement of extracellular Na+ with choline completely abolished 3'-O-(4-benzoyl) benzoyl-ATP (BzATP)-stimulated [H-3]phosphatidylethanol ([H-3]PEt) accumulation. This inhibitory effect of choline was mimicked when Na+ was replaced with other amine-containing cations (N-methylglucamine, ethanolamine, Tris+), but not with inorganic cations (K+, Li+). In contrast, substitution of Na+ with choline (or other cationic amines) did not prevent BzATP-induced Ca2+ influx and membrane depolarization. Thus, choline, which enters the cells through the BzATP-induced pores, can act to inhibit P2z receptor-stimulated PLD activity but not pore formation. The two responses also exhibit differential sensitivities to the pH of the incubation medium, to depletion of intracellular ATP, and to chronic phorbol ester treatment. These observations indicate that P2z receptor-mediated pore formation can be functionally uncoupled from the activation of PLD. However, both pore formation and PLD activity are similarly inhibited when the cells are: 1) partially desensitized by previous treatment with P2z agonists and 2) preincubated with 2',3'-dialdehyde-ATP or 4',4'-diisothiocyanostilbene-2,2'-disulfonate. This suggests that these two distinct responses are mediated by the same, or similar, P2z receptors.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University				Dubyak, George/0000-0001-9720-4226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36387] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; ANTHES JC, 1991, ARCH BIOCHEM BIOPHYS, V287, P53, DOI 10.1016/0003-9861(91)90387-X; BALSINDE J, 1990, FEBS LETT, V259, P237, DOI 10.1016/0014-5793(90)80017-D; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; COLMAN RF, 1990, ENZYMES, V19, P283; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DALY PF, 1987, J BIOL CHEM, V262, P14875; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; ELMOATASSIM C, 1987, EUR J PHARMACOL, V18, P111; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRIEDBERG I, 1985, J MEMBRANE BIOL, V83, P251, DOI 10.1007/BF01868699; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GAY JC, 1991, BIOCHIM BIOPHYS ACTA, V1095, P236, DOI 10.1016/0167-4889(91)90105-7; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HUANG CF, 1992, J BIOL CHEM, V267, P16859; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1989, J BIOL CHEM, V264, P1483; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LIN PY, 1991, J IMMUNOL, V146, P1609; LIN PY, 1992, BIOCHEM J, V287, P325, DOI 10.1042/bj2870325; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NUTTLE LC, 1993, IN PRESS MOL PHARM; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PERRY DK, 1992, J IMMUNOL, V149, P2749; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; ROZENGURT E, 1979, J BIOL CHEM, V254, P708; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WEISMAN GA, 1989, METHOD ENZYMOL, V171, P857; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395	63	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15571	15578						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687997				2022-12-25	WOS:A1993LN30500040
J	KOUNNAS, MZ; CHAPPELL, DA; STRICKLAND, DK; ARGRAVES, WS				KOUNNAS, MZ; CHAPPELL, DA; STRICKLAND, DK; ARGRAVES, WS			GLYCOPROTEIN-330, A MEMBER OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR FAMILY, BINDS LIPOPROTEIN-LIPASE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; MESSENGER-RNA; LDL-RECEPTOR; MEMBRANE GLYCOPROTEIN; HIGH-AFFINITY; RAT-TISSUES; PROTEIN; IDENTIFICATION; LIGAND	Glycoprotein 330 (gp330), a cell-surface protein that is localized in clathrin-coated pits, is structurally related to both the low density lipoprotein receptor (LDLR) and the LDLR-related protein/alpha2-macroglobulin receptor (LRP). We recently demonstrated that gp330 and LRP may be functionally related as well; both bind the 39-kDa polypeptide referred to as receptor-associated protein (Kounnas, M. Z., Argraves, W. S., and Strickland, D. K. (1992) J. Biol. Chem. 267, 21162-21166). In this report, we tested several other LRP ligands for their ability to interact with human and rat gp330 in vitro. Gp330 did not exhibit detectable binding to the LRP ligands, alpha2-macroglobulin protease complex or Pseudomonas aeruginosa exotoxin A. However, we found that gp330 (purified from human or rat) bound the lipolytic enzyme lipoprotein lipase (LPL) with high affinity (K(d) = 6.1 and 2.7 nM, respectively). The binding was saturable, divalent cation dependent, and inhibited by heparin or receptor-associated protein. Because LRP has also been shown to bind LPL, the present findings further extend the functional similarities between gp330 and LRP. By analogy to the postulated role of the LRP-LPL interaction in facilitating hepatic clearance of LPL-associated lipoproteins from the blood (Beisiegel, U., Weber, W., and Bengtsson-Olivercrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346; Chappell, D. A., Fry, G. L., Waknitz, M. A., Iverius, P. H., Williams, S. E., and Strickland, D. K. (1992) J. Biol. Chem. 267, 25764-25767), we speculate that the gp330-LPL interaction described herein may contribute to the uptake of LPL-associated lipoproteins in tissues expressing gp330. Consistent with this possibility, we found that LPL promoted in vitro binding of I-125-lipoproteins to gp330.	AMER RED CROSS, DEPT BIOCHEM, ROCKVILLE, MD 20855 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	American Red Cross; University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912, R01GM042581] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42912, GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERHARD EE, 1986, BIOCHIM BIOPHYS ACTA, V875, P6, DOI 10.1016/0005-2760(86)90004-4; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUCCARON MH, 1987, ANN INST PASTEUR IMM, V138, P707, DOI 10.1016/S0769-2625(87)80026-0; CHAJEK T, 1977, ATHEROSCLEROSIS, V26, P549, DOI 10.1016/0021-9150(77)90122-8; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CORITSIDIS G, 1991, KIDNEY INT, V39, P858, DOI 10.1038/ki.1991.108; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DAUGHERTY A, 1985, J BIOL CHEM, V260, P4564; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; DOXSEY S, 1983, J CELL BIOL, V97, pA178; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GAL S, 1982, BIOCHIM BIOPHYS ACTA, V713, P222, DOI 10.1016/0005-2760(82)90239-9; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLLENBERG CH, 1962, J LIPID RES, V3, P445; Iverius P H, 1986, Methods Enzymol, V129, P691; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LEE LB, 1962, AM J PHYSIOL, V203, P27, DOI 10.1152/ajplegacy.1962.203.1.27; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LISTON TE, 1987, BIOCHIM BIOPHYS ACTA, V921, P449, DOI 10.1016/0005-2760(87)90071-3; MAHONEY EM, 1982, P NATL ACAD SCI-BIOL, V79, P1639, DOI 10.1073/pnas.79.5.1639; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OKABE T, 1984, BIOCHEM BIOPH RES CO, V125, P273, DOI 10.1016/S0006-291X(84)80364-2; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TEDDER TF, 1991, AM J RESP CELL MOL, V5, P305, DOI 10.1165/ajrcmb/5.4.305; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WRIGHT JR, 1987, AM REV RESPIR DIS, V136, P426, DOI 10.1164/ajrccm/136.2.426; YACOUB LK, 1990, J LIPID RES, V31, P1845; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	125	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14176	14181						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686151				2022-12-25	WOS:A1993LJ82500059
J	CHEN, SRW; ZHANG, L; MACLENNAN, DH				CHEN, SRW; ZHANG, L; MACLENNAN, DH			ANTIBODIES AS PROBES FOR CA2+ ACTIVATION SITES IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDUCED RELEASE; CA-2+ RELEASE; ADENINE-NUCLEOTIDES; PROTEINS; PURIFICATION; CAFFEINE; BINDING; EXPRESSION; MEMBRANE; SYSTEM	In earlier studies (Chen, S. R. W., Zhang, L., and MacLennan, D. H. (1992) J. Biol. Chem. 267,23318-23326), an amino acid sequence, designated 13c2, lying between amino acid residues 4478 and 4512 in the skeletal muscle ryanodine receptor was shown, through the use of a polyclonal antibody, to be involved in Ca2+ induced Ca2+ release. In the present study, an immobilized synthetic peptide, PEPEPEPEPE, corresponding to part of the predicted high affinity Ca2+ binding site between residues 4489 and 4499, was used to purify specific antibodies from an anti-13C2 rabbit antiserum. The effect of this affinity-purified, anti-peptide (anti-13c2p1) antibody on Ca2+ release channel function was then characterized using single channel recordings across planar lipid bilayers. The anti-peptide antibody inhibited Ca2+ or caffeine-activated channel activities without closing the channel but did not diminish ATP-activated channel activity. The addition of ATP reversed the inhibition of the Ca2+- or caffeine-activated channel by the antibody, and the antibody-bound, ATP-activated channel was further modulated by Mg2+, ryanodine, and ruthenium red. The major epitopes in the anti-13c2 antibody, previously shown to activate the Ca2+ release channel by increasing the Ca2+ sensitivity of the channel, did not lie in the PE repeat. These results suggest that the PE repeat sequence forms a site involved in the Ca2+ activation pathway.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, 112 COLL ST, TORONTO M5G 1L6, ONTARIO, CANADA	University of Toronto								ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALDIVIA HH, 1991, AM J PHYSIOL, V261, pC237, DOI 10.1152/ajpcell.1991.261.2.C237; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	35	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13414	13421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685761				2022-12-25	WOS:A1993LH55300058
J	DECHECCHI, MC; TAMANINI, A; BERTON, G; CABRINI, G				DECHECCHI, MC; TAMANINI, A; BERTON, G; CABRINI, G			PROTEIN-KINASE-C ACTIVATES CHLORIDE CONDUCTANCE IN C127 CELLS STABLY EXPRESSING THE CYSTIC-FIBROSIS GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-DOMAIN; CHANNELS; CFTR; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; TRANSPORT; EPITHELIA	The regulatory domain (R domain) of the cystic fibrosis transmembrane conductance regulator (CFTR) is phosphorylated by protein kinase A and protein kinase C (PKC) in vivo (Picciotto, M. R., Cohn, J. A., Bertuzzi, G., Greengard, P., and Nairn, A. C. (1992) J. Biol. Chem. 267, 12742-12752), but so far the functional effect of the PKC-dependent phosphorylation has not been clarified. We investigated the effect of PKC on the CFTR-mediated Cl- transport by treating with phorbol 12-myristate 13-acetate (PMA), the cell line C127i stably expressing CFTR wild type (C127 CFTRw/t), or CFTR bearing the most common mutation deltaF508 (C127 CFTRdF508). We show that PMA activates Cl- efflux in C127 CFTRw/t, but not in C127 CFTRdF508 and C127i. The PMA-dependent activation of CFTR is not mediated by increase of intracellular [cAMP] and is not the result of a primary activation of a K+ conductive pathway. These results strongly suggest that PKC activates directly CFTR-mediated Cl- transport.	OSPED CIVILE,CTR CYST FIBROSIS,PIAZZALE STEFANI 1,I-37126 VERONA,ITALY; UNIV VERONA,INST GEN PATHOL,I-37100 VERONA,ITALY	University of Verona			Dechecchi, Maria Cristina/K-5139-2016; Cabrini, Giulio/K-4761-2016	Dechecchi, Maria Cristina/0000-0002-5005-6585; Cabrini, Giulio/0000-0003-2720-0742; Tamanini, Anna/0000-0002-7427-0981				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BAJENATH RB, 1992, J MEMBRANE BIOL, V127, P81; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DECHECCHI MC, 1992, FEBS LETT, V311, P25, DOI 10.1016/0014-5793(92)81358-S; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KAHINTORN U, 1992, AM J PHYSIOL, V262, pC15; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LIN PY, 1987, J BIOL CHEM, V262, P15345; LINDEMAN RP, 1992, AM J PHYSIOL, V263, pC140, DOI 10.1152/ajpcell.1992.263.1.C140; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAMANINI A, 1991, ENZYME, V45, P97, DOI 10.1159/000468874; VAANDRAGER AB, 1992, AM J PHYSIOL, V262, pG249, DOI 10.1152/ajpgi.1992.262.2.G249; VANDENBERGHE N, 1992, BIOCHEM J, V285, P673, DOI 10.1042/bj2850673; VERKMAN AS, 1992, AM J PHYSIOL, V262, pC23, DOI 10.1152/ajpcell.1992.262.1.C23; WARHURST G, 1991, AM J PHYSIOL, V261, pG220, DOI 10.1152/ajpgi.1991.261.2.G220; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	35	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11321	11325						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684379				2022-12-25	WOS:A1993LD46600088
J	VANDENMAAGDENBERG, AMJM; HOFKER, MH; KRIMPENFORT, PJA; DEBRUIJN, I; VANVLIJMEN, B; VANDERBOOM, H; HAVEKES, LM; FRANTS, RR				VANDENMAAGDENBERG, AMJM; HOFKER, MH; KRIMPENFORT, PJA; DEBRUIJN, I; VANVLIJMEN, B; VANDERBOOM, H; HAVEKES, LM; FRANTS, RR			TRANSGENIC MICE CARRYING THE APOLIPOPROTEIN-E3-LEIDEN GENE EXHIBIT HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL DYSBETALIPOPROTEINEMIA; PLASMA; CHOLESTEROL; OVEREXPRESSION; EXPRESSION; E3-LEIDEN; PROTEIN; VARIANT; LOCUS; MOUSE	Apolipoprotein (apo) E3-Leiden, described in a large Dutch family, is associated with a dominantly inherited form of familial dysbetalipoproteinemia. To study the effect of the APOE*3-Leiden mutation in vivo, transgenic mice were generated using a genomic 27-kilobase DNA construct isolated from the APOE*3-Leiden proband. This construct carried the APOE gene, the APOC1 gene, and all known regulatory elements including an element that mediates liver expression. Three strains were generated that showed human APOE and APOC1 expression. All strains had significantly elevated levels of total plasma cholesterol and triglycerides on a regular diet. When mice of one strain were fed a semisynthetic cholesterol-rich diet, total plasma cholesterol and triglyceride levels increased dramatically. This increase was observed mainly in the very low density lipoprotein (VLDL)- and low density lipoprotein (LDL)-sized fractions. In cholesterol-fed mice, the apoE3-Leiden protein became equally distributed between the VLDL/LDL and HDL-sized fractions, while in mice kept on a regular diet, apoE3-Leiden protein was mainly associated with HDL-sized fractions. The presence of hyperlipoproteinemia in the APOE*3-Leiden-expressing transgenic mice supports our finding that the apoE3-Leiden variant behaves like a dominant trait in the expression of familial dysbetalipoproteinemia. ApoE3-Leiden transgenic mice may serve as a model to elucidate additional factors involved in the metabolism of apoE containing remnant lipoproteins in general and the etiology of familial dysbetalipoproteinemia in particular.	TNO,IVVO,GAUBIUS LAB,2300 RA LEIDEN,NETHERLANDS; GENE PHARMING EUROPE BV,LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research	VANDENMAAGDENBERG, AMJM (corresponding author), LEIDEN UNIV,MGC,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS.		van den Maagdenberg, Arn M.J.M./AAE-9052-2019					AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BURY J, 1986, CLIN CHEM, V32, P265; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HOFKER MH, 1986, HUM GENET, V74, P270, DOI 10.1007/BF00282547; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; HOGAN B, 1986, MANIPULATING MOUSE E; HORIUCHI K, 1989, J BIOCHEM-TOKYO, V106, P98, DOI 10.1093/oxfordjournals.jbchem.a122828; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KNOTT TJ, 1984, NUCLEIC ACIDS RES, V12, P3909, DOI 10.1093/nar/12.9.3909; KRUMLAUF R, 1991, METHODS MOL BIOL GEN, P307; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; NISHINA PM, 1990, J LIPID RES, V31, P859; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMIT M, 1990, J LIPID RES, V31, P45; SMITH JD, 1990, J BIOL CHEM, V265, P14709; UTERMANN G, 1985, DIABETES OBESITY HYP, V3, P1; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; WALSH A, 1989, J BIOL CHEM, V264, P6488; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495	30	193	197	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10540	10545						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683682				2022-12-25	WOS:A1993LB80000081
J	ZHOU, GC; CHARBONNEAU, H; COLMAN, RF; ZALKIN, H				ZHOU, GC; CHARBONNEAU, H; COLMAN, RF; ZALKIN, H			IDENTIFICATION OF SITES FOR FEEDBACK-REGULATION OF GLUTAMINE 5-PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE BY NUCLEOTIDES AND RELATIONSHIP TO RESIDUES IMPORTANT FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-PURF; AMINO-ACID-SEQUENCE; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; BINDING DOMAIN; 5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE; SYNTHETASE; PROTEINS; CLONING; ENZYME; KINASE	Glutamine phosphoribosylpyrophosphate amido-transferase, the key regulatory enzyme for de novo purine nucleotide synthesis, is subject to feedback regulation by adenine and guanine nucleotides. Affinity labeling with 5'-p-fluorosulfonylbenzoyladenosine (FSBA) and 8-azidoadenosine 5'-monophosphate (N3-AMP) was used to identify purine nucleotide sites for feedback control of the Escherichia coli amidotransferase. FSBA inactivated the amidotransferase with saturation kinetics. Specificity for inactivation was shown by the covalent attachment of 2.0-2.4 eq of [H-3] sulfobenzoyladenosine (SBA) per subunit and protection by GMP and AMP against inactivation and incorporation of [H-3]SBA. Six chymotryptic peptides modified with [H-3]SBA were isolated and identified by differential labeling followed by high performance liquid chromatography and radioactivity. Mass spectrometry and Edman degradation analysis were used to identify 5 residues that were covalently modified by [H-3]SBA: Tyr74, Tyr258, Lys326, Tyr329, and Tyr465. Tyr258 was also modified by N3-AMP. Mutant enzymes K326Q and Y329A had activity similar to that of the wild type enzyme. However, both mutants exhibited decreased sensitivity to inhibition by GMP and decreased binding of GMP but were inhibited by AMP. Mutant enzymes Y74A and Y258F were normally feedback-inhibited but were defective in glutamine amide transfer and synthase functions, respectively. Therefore Tyr74 and Tyr258 are important for activity and modification by FSBA and N3-AMP accounts for enzyme inactivation. These results localize residues important for catalysis in close proximity to a site for nucleotide binding. Two additional mutant enzymes, G331I and N351A, were constructed which were refractory to inhibition by GMP with little change in inhibition by AMP. A replacement of Tyr465 indicates that this residue is not essential for catalysis or feedback inhibition. Overall, these results are interpreted in terms of a two-nucleotide site model with Lys326, Tyr329, Gly331, and Asn351 defining a site required for inhibition by GMP. A second nucleotide site not affinity labeled by analogs is very close to or overlaps with the catalytic site.	PURDUE UNIV, DEPT BIOCHEM, 1153 BIOCHEM BLDG, W LAFAYETTE, IN 47907 USA; UNIV DELAWARE, DEPT CHEM & BIOCHEM, NEWARK, DE 19716 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Delaware					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK 20542] Funding Source: Medline; NIGMS NIH HHS [GM24685] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MEI B, 1989, J BIOL CHEM, V264, P16613; MEI BG, 1990, J BACTERIOL, V172, P3512, DOI 10.1128/jb.172.6.3512-3514.1990; MELOCHE HP, 1967, BIOCHEMISTRY-US, V6, P2273, DOI 10.1021/bi00860a002; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MEYER E, 1979, J BIOL CHEM, V254, P5397; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; SWITZER RL, 1989, ALLOSTERIC ENZYMES, P129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WYATT JL, 1977, BIOCHEMISTRY-US, V16, P1333, DOI 10.1021/bi00626a015; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	27	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10471	10481						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683680				2022-12-25	WOS:A1993LB80000072
J	BOUGERET, C; ROTHHUT, B; JULLIEN, P; FISCHER, S; BENAROUS, R				BOUGERET, C; ROTHHUT, B; JULLIEN, P; FISCHER, S; BENAROUS, R			RECOMBINANT CSK EXPRESSED IN ESCHERICHIA-COLI IS AUTOPHOSPHORYLATED ON TYROSINE RESIDUE(S)	ONCOGENE			English	Article							PROTEIN-KINASES; GENE-PRODUCT; PP60C-SRC; PHOSPHORYLATION; SITES; ACTIVATION; PP60V-SRC; MUTATION; INVITRO	The C-terminal src kinase (Csk) is responsible for the phosphorylation of the carboxy-terminal tyrosine of several tyrosine kinases of the Src family. This phosphorylation site has a negative regulatory function. Csk is unique among the members of the protein tyrosine kinase family because it lacks the conserved tyrosine autophosphorylation site and has been thought to be devoid of autophosphorylation activity. Using the glutathione S-transferase (GST) bacterial expression system, we have produced large amounts of a chimeric rat Csk protein. We have determined that the GST-Csk fusion protein isolated from bacteria is autophosphorylated on tyrosine residue(s). GST-Csk and purified Csk are capable of undergoing autophosphorylation on tyrosine residue(s) in vitro. The GST-Csk fusion protein also phosphorylates exogenous substrates, including the heteropolymer poly-Glu/Tyr and enolase. This is the first indication that Csk is autophosphorylated on tyrosine residue(s) both in vivo in bacteria expressing Csk cDNA and in vitro. These findings suggest that the autophosphorylation of Csk might play a role in the regulation of its kinase activity as well as its binding to other cellular proteins.	UNIV PARIS 05,INSERM,U332,INST COCHIN GENET MOLEC,22 RUE MECHAIN,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Rothhut, Bernard/0000-0001-6467-8134				BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHRISMAN TD, 1981, J BIOL CHEM, V256, P2981; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; COOPER JA, 1983, METHOD ENZYMOL, V99, P937; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARIN O, 1991, J BIOL CHEM, V266, P17798; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PATANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1990, ONCOGENE, V5, P1437; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; STERN DF, 1991, MOL CELL BIOL, V11, P937; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	27	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683130				2022-12-25	WOS:A1993KY32800015
J	HENDRIX, P; TUROWSKI, P; MAYERJAEKEL, RE; GORIS, J; HOFSTEENGE, J; MERLEVEDE, W; HEMMINGS, BA				HENDRIX, P; TUROWSKI, P; MAYERJAEKEL, RE; GORIS, J; HOFSTEENGE, J; MERLEVEDE, W; HEMMINGS, BA			ANALYSIS OF SUBUNIT ISOFORMS IN PROTEIN PHOSPHATASE-2A HOLOENZYMES FROM RABBIT AND XENOPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-T-ANTIGEN; CATALYTIC SUBUNIT; OKADAIC ACID; TYPE-2A PHOSPHATASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SKELETAL-MUSCLE; DNA-REPLICATION; KINASE ACTIVITY; LAEVIS OOCYTES	A dimeric and two trimeric forms of protein phosphatase 2A (PP2A) were purified from rabbit and Xenopus tissues and analyzed using antisera specific for the catalytic and regulatory subunits. The dimeric holoenzyme consists of a complex between a 36-kDa catalytic subunit associated with a approximately 65-kDa regulatory subunit. The two trimeric holoenzymes consist of the catalytic subunit complexed with 65- and 55-kDa subunits, or 65- and 72-kDa subunits. Antisera were raised against synthetic peptides specific for the alpha- and beta-isoforms of the 65-kDa (PR65alpha/beta) and 55-kDa (PR55alpha/beta) subunits identified by molecular cloning. Anti-peptide antisera to the 36-kDa catalytic subunit of PP2A were prepared against two selected regions: one specific for the alpha-isoform and one to a peptide common to both the alpha- and beta-isoforms. Immunochemical analysis of all three mammalian holoenzymes showed that the catalytic, 55- and 65-kDa subunits are both predominantly of the alpha-isoform, which is consistent with the peptide sequence data. The 65-kDa subunit of PP2A holoenzymes isolated from Xenopus skeletal muscle reacted with both anti-alpha and anti-beta PR65-specific antisera whereas the PP2A holoenzymes isolated from Xenopus oocytes reacted preferentially with the beta-specific antisera, indicating developmental changes in the expression of the 65-kDa subunit isoform. Taken together, these results show that the ''core'' subunits of the PP2A holoenzymes consist of the catalytic complexed with the 65-kDa subunit and that the association of the third subunit does not appear to be influenced by the isoform of these two core subunits.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND; CATHOLIC UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, B-3000 LOUVAIN, BELGIUM	Friedrich Miescher Institute for Biomedical Research; KU Leuven								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; AGOSTINIS P, 1987, BIOCHEM J, V248, P785, DOI 10.1042/bj2480785; AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; AGOSTINIS P, 1987, J BIOL CHEM, V262, P1061; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1986, ENZYMES, V17, P311; BASSIRI RM, 1979, METHOD HORM RADIOIMM, P46; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHEN SC, 1989, J BIOL CHEM, V264, P7267; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HEMMINGS BA, 1988, NUCLEIC ACIDS RES, V16, P11366, DOI 10.1093/nar/16.23.11366; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JESSUS C, 1989, EUR J BIOCHEM, V180, P15, DOI 10.1111/j.1432-1033.1989.tb14609.x; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYER RE, 1991, ADV PROTEIN PHOSPHAT, V6, P265; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; MAYERJAEKEL RE, 1993, IN PRESS CELL; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1669; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDE, 1988, FEBS LETT, V242, P106, DOI 10.1016/0014-5793(88)80995-5; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WAELKENS E, 1987, BIOCHEM INT, V15, P385; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WAELKENS E, 1987, ADV ENZYME REGUL, V2, P467; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	56	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7330	7337						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	7681822				2022-12-25	WOS:A1993KV14100073
J	FRATINI, A; POWELL, BC; ROGERS, GE				FRATINI, A; POWELL, BC; ROGERS, GE			SEQUENCE, EXPRESSION, AND EVOLUTIONARY CONSERVATION OF A GENE ENCODING A GLYCINE TYROSINE-RICH KERATIN-ASSOCIATED PROTEIN OF HAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; WOOL KERATIN; CDNA CLONES; SHEEP WOOL; DNA; ELEMENTS; ENHANCER; FAMILY; CELL; HYBRIDIZATION	In hair differentiation several families of keratin proteins with distinctive amino acid compositions are produced. To study the role and regulation of one of these families, the glycine/tyrosine-rich keratin-associated proteins encoded by the KAP6 gene family, a partial wool follicle cDNA clone encoding a sheep KAP6 protein was sequenced and the corresponding gene isolated from a sheep cosmid library. The KAP6.1 gene encodes a basic protein of 82 amino acids (M(r) = 8,296) with a combined glycine and tyrosine content of approximately 60 mol %. There are several KAP6 genes in the sheep genome, all located within a 1,050-kilobase SfiI fragment. Northern blot analysis demonstrated that at least one member of the KAP6 family is expressed in the wool follicle. A rabbit KAP6 gene was isolated and its sequence and expression patterns were compared with the sheep gene. The sheep and rabbit genes have a nucleotide sequence identity of 89%, suggesting that they are equivalent genes and indicating strong selection pressure during evolution. Both genes contain several conserved sequence motifs of 7-9 nucleotides in their 5'-flanking regions that may be involved in the regulation of their expression. Localization of KAP6 mRNAs in sheep wool and rabbit hair follicles by in situ hybridization suggests that the genes are expressed in the cells of the hair shaft cortex in varying expression patterns. KAP6 expression starts relatively late in hair follicle differentiation, and the proportion of hair cortical cells that express it may change from follicle to follicle.			FRATINI, A (corresponding author), UNIV ADELAIDE, DEPT BIOCHEM, GPO BOX 498, ADELAIDE, SA 5001, AUSTRALIA.							BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; CAMERON GN, 1988, NUCLEIC ACIDS RES, V16, P1865, DOI 10.1093/nar/16.5.1865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P244; DOPHEIDE TA, 1973, EUR J BIOCHEM, V34, P120, DOI 10.1111/j.1432-1033.1973.tb02737.x; DOWLING LM, 1990, 8TH P INT WOOL TEXT, V1, P205; DUNCAN CH, 1987, NUCLEIC ACIDS RES, V15, P1340, DOI 10.1093/nar/15.3.1340; ELIOPOULOS E, 1982, INT J BIOL MACROMOL, V4, P263, DOI 10.1016/0141-8130(82)90053-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER C, 1991, DEVELOPMENT, V111, P253; Fraser R.D.B., 1972, KERATINS THEIR COMPO; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; GALLI G, 1981, NATURE, V294, P626, DOI 10.1038/294626a0; Gillespie J.M., 1991, PHYSL BIOCH MOL BIOL, P625; GILLESPIE JM, 1974, COMP BIOCHEM PHYSIOL, V47, P339, DOI 10.1016/0305-0491(74)90063-7; GILLESPIE JM, 1971, AUST J BIOL SCI, V24, P1189, DOI 10.1071/BI9711189; GILLESPIE JM, 1972, COMP BIOCHEM PHYSIOL, V41, P723, DOI 10.1016/0305-0491(72)90085-5; Gillespie JM, 1990, CELLULAR MOL BIOL IN, P95; GILLESPIE JM, 1976, 5TH P INT WOOL TEXT, V1, P265; GOODMAN M, 1982, MACROMOLECULAR SEQUE, P114; GREGG K, 1984, EMBO J, V3, P175, DOI 10.1002/j.1460-2075.1984.tb01779.x; GUPTA RC, 1979, NUCLEIC ACIDS RES, V7, P959, DOI 10.1093/nar/7.4.959; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HOHL D, 1991, J BIOL CHEM, V266, P6626; INGLIS AS, 1988, PROTEIN STRUCTURE FU, P767; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUCZEK E, 1985, EUR J BIOCHEM, V146, P89, DOI 10.1111/j.1432-1033.1985.tb08623.x; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; LAWRENCE CB, 1985, NUCLEIC ACIDS RES, V13, P4239, DOI 10.1093/nar/13.12.4239; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; MARSHALL RC, 1980, 6TH P INT WOOL TEXT, V2, P147; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Overhauser J., 1987, FOCUS, V9, P8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWELL B, 1992, DEVELOPMENT, V114, P417; Powell B.C., 1990, CELLULAR MOL BIOL IN, P267; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; POWELL BC, 1986, P NATL ACAD SCI USA, V83, P5048, DOI 10.1073/pnas.83.14.5048; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Rogers G. E., 1989, BIOL WOOL HAIR, P69; ROGERS GE, 1959, ANN NY ACAD SCI, V83, P378; ROGERS GE, 1991, ANN NY ACAD SCI, V642, P64; SAKAMOTO K, 1985, J MOL EVOL, V22, P134, DOI 10.1007/BF02101691; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; Swift JA, 1977, CHEM NATURAL PROTEIN, P81; WATANABE Y, 1982, NUCLEIC ACIDS RES, V10, P1459, DOI 10.1093/nar/10.5.1459; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHITELEY KJ, 1977, J TEXT I, V68, P384, DOI 10.1080/00405007708631416; WILSON BW, 1988, GENE, V73, P21, DOI 10.1016/0378-1119(88)90309-5; WINTER G, 1980, NUCLEIC ACIDS RES, V8, P1965, DOI 10.1093/nar/8.9.1965	69	63	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4511	4518						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680040				2022-12-25	WOS:A1993KN53300101
J	SPINELLA, MJ; BRIGLE, KE; SIERRA, EE; GOLDMAN, ID				SPINELLA, MJ; BRIGLE, KE; SIERRA, EE; GOLDMAN, ID			DISTINGUISHING BETWEEN FOLATE RECEPTOR-ALPHA-MEDIATED TRANSPORT AND REDUCED FOLATE CARRIER-MEDIATED TRANSPORT IN L1210 LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; CCRF-CEM CELLS; BINDING-PROTEIN; METHOTREXATE TRANSPORT; MEMBRANE-TRANSPORT; WILD-TYPE; KB CELLS; SYSTEM; CANCER; EXPRESSION	L1210 leukemia cells transport reduced folates and methotrexate via a well defined reduced folate carrier system and, in the absence of low folate selective pressure, do not express an alternate endocytotic route mediated by cell surface folate receptors. This laboratory previously described an L1210 leukemia cell line, MTX(r)A with acquired resistance to methotrexate (MTX) due to the loss of mobility of the reduced folate carrier. We now report on the transfection of MTX(r)A with a cDNA encoding the murine homolog of the human folate receptor isoform of KB cells to produce MTX(r)A-TF1, which constitutively expresses high levels of FR-alpha. MTX(r)A-TF1 and L1210 cells were utilized to compare transport of methotrexate mediated by FR-alpha and the reduced folate carrier, respectively. Methotrexate influx in the two lines was similar when the extracellular level was 0.1 mu M, but as the methotrexate concentration increased, influx via the reduced folate carrier increased in comparison to influx mediated by FR-alpha. Transport kinetics indicated both a similar to 20-fold lower influx K-b and V-max for MTX(r)A-TF1 as compared to L1210 cells. The two cell Lines exhibited distinct influx properties. Methotrexate influx in MTX(r)A-TF1 was markedly inhibited by 50 mu M folic acid and metabolic poisons. In L1210 cells, 1.0 mu M folic acid did not affect MTX influx, and metabolic poisons either had no effect on or increased methotrexate influx. Removal of extracellular chloride markedly inhibited transport in MTX(r)A-TF1 but stimulated influx in L1210 cells. When the pH was decreased to 6.2, methotrexate influx was not altered in MTX(r)A-TF1 but was reduced in L1210 cells. Probenecid and sulfobromophthalein inhibit methotrexate influx in both L1210 and MTX(r)A-TF1 cell Lines; however, inhibition in MTX(r)A-TF1 could be accounted for on the basis of inhibition of methotrexate binding to FR-alpha. The data indicate that the reduced folate carrier and FR-alpha function independently and exhibit distinct properties. FR-alpha expressed at sufficient levels can mediate influx of MTX and folates into cells at rates comparable to the reduced folate carrier and hence has pharmacologic and physiologic importance.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, MASSEY CANC CTR, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University			Spinella, Michael/B-7210-2014		NCI NIH HHS [CA-09349, CA-39807, F32 CA009349, CA-09340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009349, R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1992, BLOOD, V79, P2807; BOWEN BJ, 1988, J CELL PHYSIOL, V134, P1, DOI 10.1002/jcp.1041340102; BRIGLE KE, 1994, J BIOL CHEM, V269, P4267; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CONEY LR, 1991, CANCER RES, V51, P6125; COWAN KH, 1984, J BIOL CHEM, V259, P793; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1992, J BIOL CHEM, V267, P24140; DIXON KH, 1994, J BIOL CHEM, V269, P17; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FLEMING GF, 1992, SEMIN ONCOL, V19, P707; FRY DW, 1980, BIOCHIM BIOPHYS ACTA, V603, P157, DOI 10.1016/0005-2736(80)90398-3; FRY DW, 1982, CANCER RES, V42, P2532; FRY DW, 1980, CANCER RES, V40, P3669; FRY DW, 1982, J MEMBRANE BIOL, V66, P87, DOI 10.1007/BF01868485; FRY DW, 1984, CANCER RES, V44, P3366; GEWIRTZ DA, 1980, CANCER RES, V40, P1852; GEWIRTZ DA, 1984, CANCER RES, V44, P3846; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, BIOCHIM BIOPHYS ACTA, V233, P624, DOI 10.1016/0005-2736(71)90162-3; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRANT SC, 1993, CANCER INVEST, V11, P36, DOI 10.3109/07357909309020259; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; HENDERSON GB, 1985, BIOCHEM PHARMACOL, V34, P1725, DOI 10.1016/0006-2952(85)90641-0; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1989, CANCER RES, V49, P2455; JENNETTE JC, 1975, J LAB CLIN MED, V86, P834; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMEN BA, 1986, BIOCHEM PHARMACOL, V35, P2323, DOI 10.1016/0006-2952(86)90458-2; KANE MA, 1989, LAB INVEST, V60, P737; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; Ratnam M., 1990, FOLIC ACID METABOLIS, P91; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SELHUB J, 1984, J BIOL CHEM, V259, P6601; SHEN F, 1994, BIOCHEMISTRY-US, V33, P1209, DOI 10.1021/bi00171a021; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1979, BIOCHEM PHARMACOL, V28, P2993, DOI 10.1016/0006-2952(79)90599-9; SIROTNAK FM, 1991, CANCER RES, V51, P1412; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; WEITMAN SD, 1992, CANCER RES, V52, P3396; WHITE JC, 1978, J BIOL CHEM, V253, P242; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067	66	103	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7842	7849		10.1074/jbc.270.14.7842	http://dx.doi.org/10.1074/jbc.270.14.7842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713875	hybrid			2022-12-25	WOS:A1995QR52600011
J	STOLTZ, M; RYSAVY, P; KALOUSEK, F; BRANDSCH, R				STOLTZ, M; RYSAVY, P; KALOUSEK, F; BRANDSCH, R			FOLDING, FLAVINYLATION, AND MITOCHONDRIAL IMPORT OF 6-HYDROXY-D-NICOTINE OXIDASE FUSED TO THE PRESEQUENCE OF RATE DIMETHYLGLYCINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND FLAVIN; ARTHROBACTER-OXIDANS; HOLOENZYME FORMATION; PRECURSOR PROTEINS; LIVER MITOCHONDRIA; BINDING; MATRIX; FAD; REQUIRES; SUBUNIT	We analyzed the folding, covalent flavinylation, and mitochondrial import of the rabbit reticulocyte lysate-translated bacterial 6-hydroxy-D-nicotine oxidase (6-HDNO) fused to the mitochondrial targeting sequence of rat Liver dimethylglycine dehydrogenase, Translation of 6-HDNO in FAD-supplemented reticulocyte lysate resulted in a protein that contained covalently incorporated FED, exhibited enzyme activity, and was trypsin-resistant, a characteristic of the tight conformation of the holoenzyme, The attached mitochondrial presequence did not prevent folding, binding of FAD, or enzyme activity of the 6-HDNO moiety of the fusion protein (pre-6-HDNO), Pre-6-HDNO was imported into rat liver mitochondria and processed by the mitochondrial processing peptidase, Incubation of the trypsin-resistant pre-holo-6-HDNO protein with deenergized rat Liver mitochondria demonstrated that upon contact with mitochondria, the protein was unfolded and became trypsin sensitive. Mitochondrial import assays showed that the unfolded pre-holo-6-HDNO with covalently attached FAD was imported into rat Liver mitochondria, Inside the mitochondrion the holo-6-HDNO was refolded into the trypsin-resistant conformation, However, when pre-apo-6-HDNO was imported only part of the protein became trypsin resistant (approximately 20%). Addition of FAD and the allosteric effector glycerol 3-phosphate to apo-6-HDNO containing mitochondrial matrix was required to transform the protein into the trypsin-resistant conformation characteristic of holo-6-HDNO,	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	University of Freiburg; Yale University					NIDDK NIH HHS [DK-09527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994; BARILE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P442, DOI 10.1006/abbi.1993.1444; BERNAUER H, 1992, MOL MICROBIOL, V6, P1809, DOI 10.1111/j.1365-2958.1992.tb01353.x; BRANDSCH R, 1989, BIOCHEM J, V258, P187, DOI 10.1042/bj2580187; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; BRANDSCH R, 1994, FLAVINS FLAVOPROTEIN, V11, P807; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; DECKER K, 1991, BIOFACTORS, V3, P69; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; EILERS M, 1986, NATURE, V332, P228; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x; HEDERSTEDT L, 1983, EUR J BIOCHEM, V132, P589, DOI 10.1111/j.1432-1033.1983.tb07404.x; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; LAIN B, 1994, J BIOL CHEM, V269, P15588; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P207, DOI 10.1093/oxfordjournals.jbchem.a123182; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; NAGAO M, 1992, J BIOL CHEM, V267, P17925; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; REED KE, 1991, J BIOL CHEM, V266, P11425; REYES AM, 1993, J BIOL CHEM, V268, P22281; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; SUZUKI H, 1991, J BIOCHEM-TOKYO, V198, P793; TARONI F, 1991, J BIOL CHEM, V266, P13267; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YANG LM, 1994, EUR J BIOCHEM, V244, P743; ZARA V, 1992, J BIOL CHEM, V267, P12077; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8016	8022		10.1074/jbc.270.14.8016	http://dx.doi.org/10.1074/jbc.270.14.8016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713902	hybrid			2022-12-25	WOS:A1995QR52600038
J	LANDER, HM; OGISTE, JS; PEARCE, SFA; LEVI, R; NOVOGRODSKY, A				LANDER, HM; OGISTE, JS; PEARCE, SFA; LEVI, R; NOVOGRODSKY, A			NITRIC OXIDE-STIMULATED GUANINE-NUCLEOTIDE EXCHANGE ON P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONONUCLEAR-CELLS; BINDING-PROTEINS; CARBON-MONOXIDE; PC12 CELLS; T-CELL; RAS; ACTIVATION; P21RAS; SUPERFAMILY; MESSENGER	The protooncogene p21(ras), a monomeric G protein family member, plays a critical role in converting extracellular signals into intracellular biochemical events. Here, we report that nitric oxide (NO) activates p21(ras) in human T cells as evidenced by an increase in GTP-bound p21(ras). In vitro studies using pure recombinant p21(ras) demonstrate that the activation is direct and reversible. Circular dichroism analysis reveals that NO induces a profound conformational change in p21(ras) in association with GDP/GTP exchange. The mechanism of activation is due to S-nitrosylation of a critical cysteine residue which stimulates guanine nucleotide exchange. Furthermore, we demonstrate that p21(ras) is essential for NO-induced downstream signaling, such as NF-KB activation, and that endogenous NO can activate p21(ras) in the same cell. These studies identify p21(ras) as a target of NO in T cells and suggest that NO activates p21P(ras) by an action which mimics that of guanine nucleotide exchange factors.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; FELSENSTEIN MED RES CTR, IL-49100 PETAH TIQWA, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, IL-69978 TEL AVIV, ISRAEL	Cornell University; Cornell University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine					NHLBI NIH HHS [HL34215, HL46403, HL07423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL034215, T32HL007423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUDAVARI S, 1989, MERCK INDEX, P275; CARTY DJ, 1994, METHOD ENZYMOL, V237, P38; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; GRAVES JD, 1991, J IMMUNOL, V146, P3709; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUROYA K, 1992, ONCOGENE, V7, P277; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOVOGRODSKY A, 1982, P NATL ACAD SCI-BIOL, V79, P1171, DOI 10.1073/pnas.79.4.1171; PINGOUD A, 1988, BIOCHEMISTRY-US, V27, P4735, DOI 10.1021/bi00413a023; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WHITACRE CM, 1992, CELL IMMUNOL, V144, P287, DOI 10.1016/0008-8749(92)90245-K; WILKINSON FE, 1993, BIOCHEM BIOPH RES CO, V190, P229, DOI 10.1006/bbrc.1993.1035; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	41	324	328	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7017	7020		10.1074/jbc.270.13.7017	http://dx.doi.org/10.1074/jbc.270.13.7017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706235	hybrid			2022-12-25	WOS:A1995QQ43100002
J	LEVINE, AD; RANGWALA, SH; HORN, NA; PEEL, MA; MATTHEWS, BK; LEIMGRUBER, RM; MANNING, JA; BISHOP, BF; OLINS, PO				LEVINE, AD; RANGWALA, SH; HORN, NA; PEEL, MA; MATTHEWS, BK; LEIMGRUBER, RM; MANNING, JA; BISHOP, BF; OLINS, PO			HIGH-LEVEL EXPRESSION AND REFOLDING OF MOUSE INTERLEUKIN-4 SYNTHESIZED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; DEPENDENT CELL-LINES; MONOCLONAL-ANTIBODY; MESSENGER-RNA; IGE RESPONSES; FOREIGN GENES; MAST-CELLS; IL-4; PROTEINS; IGG1	Mouse Interleukin 4 is a 20-kDa glycoprotein, synthesized by activated T lymphocytes and mast cells, which regulates the growth and/or differentiation of a broad spectrum of target cells of the immune system, including B and T lymphocytes, macrophages, and hematopoietic progenitor cells. Using an inducible recA promoter and the g10-L ribosome binding site, recombinant non-glycosylated interleukin 4 (IL-4) was expressed as 17% of total cellular protein in Escherichia coli inclusion bodies, as a reduced, inactive 14.5-kDa polypeptide. The protein was refolded and aggregates dissociated when three disulfide bonds were reformed by slowly decreasing the concentration of guanidine hydrochloride and cysteine. The oxidized monomer was purified to homogeneity by sequential ion-exchange and size exclusion chromatography. When compared with native IL-4, E. coli-derived IL-4 displayed an identical specific activity of 4-7 x 10(7) units/mg. This recombinant IL-4 contained a three-amino-acid NH2-terminal extension, which did not affect its biological activity. Purified biologically active protein consisted of three isoforms as shown by two-dimensional gel electrophoresis, with a pI greater than 9.0. These data suggest that neither glycosylation nor the NH2 terminus of mouse IL-4 play a critical role in contributing to its in vitro biological activity.	MONSANTO CO, MONSANTO CORP RES, ST LOUIS, MO 63198 USA; MONSANTO CO, AGR GRP, ST LOUIS, MO 63198 USA	Monsanto; Monsanto	LEVINE, AD (corresponding author), MONSANTO CO, SEARLE DISCOVERY RES, IMMUNOL, AA4G, 700 CHESTERFIELD VILLAGE PKWY N, ST LOUIS, MO 63198 USA.							BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CONRAD DH, 1988, J IMMUNOL, V141, P1091; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; Maniatis T., 1982, MOL CLONING; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OBUKOWICZ MG, 1988, MOL GEN GENET, V215, P19, DOI 10.1007/BF00331297; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHARA J, 1987, J IMMUNOL, V139, P1127; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1989, J BIOL CHEM, V264, P16973; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PADGETTE SR, 1987, ARCH BIOCHEM BIOPHYS, V258, P564, DOI 10.1016/0003-9861(87)90378-X; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; SNAPPER CM, 1991, J IMMUNOL, V147, P1163; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3	38	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7445	7452		10.1074/jbc.270.13.7445	http://dx.doi.org/10.1074/jbc.270.13.7445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706290	hybrid			2022-12-25	WOS:A1995QQ43100065
J	PREVIATO, JO; JONES, C; XAVIER, MT; WAIT, R; TRAVASSOS, LR; PARODI, AJ; MENDONCAPREVIATO, L				PREVIATO, JO; JONES, C; XAVIER, MT; WAIT, R; TRAVASSOS, LR; PARODI, AJ; MENDONCAPREVIATO, L			STRUCTURAL CHARACTERIZATION OF THE MAJOR GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE-ANCHORED GLYCOPROTEIN FROM EPIMASTIGOTE FORMS OF TRYPANOSOMA-CRUZI Y-STRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TRANS-SIALIDASE; NMR-SPECTROSCOPY; MAMMALIAN-CELLS; OLIGOSACCHARIDES; ACID; LIPOPEPTIDOPHOSPHOGLYCAN; MACROMOLECULES; SENSITIVITY; RESOLUTION	We have investigated the structure of the glycosylphosphatidylinositol (GPI) anchor and the O-linked glycan chains of the 40/45-kDa glycoprotein from the cell surface of the protozoan parasite Trypanosoma cruzi, This glycoconjugate is the major acceptor for sialic acid transferred by trans sialidase of T. cruzi Y-strain, epimastigote form. The GPI anchor was liberated by treatment with hot alkali, and the phosphoinositol-oligosaccharide moiety was characterized and shown to have the following structure. [GRAPHICS] STRUCTURE 1 Unusually the glucosamine was 6-O-substituted with 2-aminoethylphosphonate, and 2-aminoethylphosphonate was also present on the third mannose residue distal to glucosamine, partially replacing the ethanolamine phosphate, The beta-eliminated reduced oligosaccharide chains showed that two novel classes of O-linked N-acetylglucosamine oligosaccharide were present. The first series had the structures Galp beta 1-3GlcNAc-ol; Galp beta-6(Galp beta 1-3)GlcNAc-ol; and Galp beta 1-2Galp beta 1-6(Galp beta 1-3)GlcNAc-ol, whereas the other series had a 1-4 linkage to N-acetylglucosaminitol and had structures Galp beta 1-4GlcNAc-ol, Galp beta 1-6(Galp beta 1-4)GlcNAc-ol, and Galp beta 1-2Galp beta 1-6(Galp beta 1-4)GlcNAc-ol. We have also investigated the kinetics of in vitro sialylation of these O-linked oligosaccharides by the T. cruzi trans-sialidase and have shown that incorporation of one molecule of sialic acid hinders entry of a second molecule when two potential acceptor sites are present.	FED UNIV RIO DE JANEIRO, DEPT MICROBIOL GERAL, BR-21944970 RIO DE JANEIRO, BRAZIL; NATL INST BIOL STAND & CONTROLS, MOLEC STRUCT LAB, POTTERS BAR EN6 3QG, HERTS, ENGLAND; PUBL HLTH LAB SERV, CTR APPL MICROBIOL & RES, SALISBURY SP4 0JG, WILTS, ENGLAND; ESCOLA PAULISTA MED, DISCIPLINA BIOL CELULAR, BR-04023062 SAO PAULO, BRAZIL; FDN CAMPOMAR, INST INVEST BIOQUIM, RA-1405 BUENOS AIRES, DF, ARGENTINA	National Institute for Biological Standards & Control; Universidade Federal de Sao Paulo (UNIFESP); Leloir Institute			Travassos, Luiz R/J-3631-2012; Travassos, Luiz/V-2467-2019; Jones, Chris/AAF-4063-2021	Jones, Chris/0000-0001-7109-492X; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				ACOSTA A, 1994, BRAZ J MED BIOL RES, V27, P439; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; ALVES MJM, 1986, MOL BIOCHEM PARASIT, V21, P75, DOI 10.1016/0166-6851(86)90081-2; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDREWS NW, 1994, BRAZ J MED BIOL RES, V27, P471; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BELCHER R, 1954, ANALYST, V79, P201, DOI 10.1039/an9547900201; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BURROWS S, 1952, NATURE, V170, P800, DOI 10.1038/170800a0; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FAUCONNET M, 1978, ANAL BIOCHEM, V91, P403, DOI 10.1016/0003-2697(78)90525-0; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERREROGARCIA MA, 1993, EUR J BIOCHEM, V213, P765, DOI 10.1111/j.1432-1033.1993.tb17818.x; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GORIN PAJ, 1964, CAN J CHEM, V42, P1341, DOI 10.1139/v64-206; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HUMBEL R, 1975, CLIN CHIM ACTA, V60, P143, DOI 10.1016/0009-8981(75)90119-9; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERKREMER RM, 1976, BIOCHIM BIOPHYS ACTA, V444, P85; LEDERKREMER RMD, 1978, BIOCHEM BIOPH RES CO, V85, P1268, DOI 10.1016/0006-291X(78)91140-3; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; PARODI AJ, 1992, EMBO J, V11, P1765; PAZUR JH, 1953, SCIENCE, V117, P355, DOI 10.1126/science.117.3040.355; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PREVIATO JO, 1992, J BIOL CHEM, V267, P24279; PREVIATO JO, 1994, GLYCOCONJUGATE J, V11, P23, DOI 10.1007/BF00732429; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; READING CL, 1978, J BIOL CHEM, V253, P5600; ROUTIER F, 1994, BRAZ J MED BIOL RES, V27, P211; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SHER A, 1982, NATURE, V300, P636; SINGH BN, 1994, J BIOL CHEM, V269, P21972; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TOENNIES G, 1951, ANAL CHEM, V23, P823, DOI 10.1021/ac60054a002; TOMLINSON S, 1994, J IMMUNOL, V153, P3141; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WAIT R, 1994, ORG MASS SPECTROM, V29, P767, DOI 10.1002/oms.1210291209; WARREN L, 1959, J BIOL CHEM, V234, P1971; WING RE, 1972, METHODS CARBOHYD CHE, V6, P42	58	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7241	7250		10.1074/jbc.270.13.7241	http://dx.doi.org/10.1074/jbc.270.13.7241			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706263	hybrid			2022-12-25	WOS:A1995QQ43100036
J	SUGAHARA, K; OHKITA, Y; SHIBATA, Y; YOSHIDA, K; IKEGAMI, A				SUGAHARA, K; OHKITA, Y; SHIBATA, Y; YOSHIDA, K; IKEGAMI, A			STRUCTURAL STUDIES ON THE HEXASACCHARIDE ALDITOLS ISOLATED FROM THE CARBOHYDRATE-PROTEIN LINKAGE REGION OF DERMATAN SULFATE PROTEOGLYCANS OF BOVINE AORTA - DEMONSTRATION OF IDURONIC ACID-CONTAPNING COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; SWARM MOUSE-TUMOR; CHONDROITIN-6-SULFATE PROTEOGLYCANS; SHARK CARTILAGE; BIOSYNTHESIS; BINDING; DECORIN; FIBROBLASTS; INHIBITION; EPIMERASE	Five major hexasaccharide alditols were isolated from the carbohydrate-protein linkage region of bovine aorta dermatan sulfate peptidoglycans after reductive beta-elimination and subsequent chondroitinase ABC digestion. These molecules account for at least 55.3% of the total linkage region. Their structures were analyzed by enzymatic digestion in conjunction with high performance liquid chromatography, electrospray ionization mass spectrometry, and 500-MHz one- and two-dimensional H-1 NMR spectroscopy. Three of these compounds have the conventional hexasaccharide core; Delta HexA alpha(1)-3Gal-NAc beta 1-4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl-ol. One is nonsulfated, and the other two are monosulfated on C6 or C4 of the GalNAc residue. They represent at least 6.3, 5.2, and 28.8% of the total linkage region, respectively. The other two compounds have the following hitherto unreported hexasaccharide core with an internal iduronic acid residue in common; Delta HexA alpha 1-3-GalNac beta 1-4IdoA alpha 1-3Gal beta 1-3Gal beta 1-4Xyl-ol. One is monosulfated on C4 of the GalNAc, and the other is disulfated on C4 of the GalNAc and of the galactose residue substituted by the iduronic acid residue, These two compounds account for 35% of the five isolated hexasaccharide alditols and at least 4.3 and 10.7% of the total linkage region, respectively. The latter two structures form a striking contrast to the currently accepted conception that heparin, heparan sulfate, and chondroitin/dermatan sulfate share the common linkage tetrasaccharide core GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl. The biological significance of the isolated structures is discussed in relation to the biological functions and the biosynthetic mechanisms of dermatan sulfate.	SEIKAGAKU CORP,RES INST,HIGASHIYAMOTO,TOKYO 207,JAPAN	Seikagaku Corporation	SUGAHARA, K (corresponding author), KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE,HYOGO 658,JAPAN.							BELTING M, 1993, GLYCOCONJUGATE J, V10, P453, DOI 10.1007/BF00737966; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; CASU B, 1993, DERMATAN SULPHATE PR, P41; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; EHRLICH KC, 1975, ARCH BIOCHEM BIOPHYS, V171, P361, DOI 10.1016/0003-9861(75)90043-0; FONT B, 1993, J BIOL CHEM, V268, P25015; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; FRANSSON LA, 1968, BIOCHIM BIOPHYS ACTA, V156, P311, DOI 10.1016/0304-4165(68)90260-2; GALLAGHER JT, 1989, HEPARIN, P135; HELTING T, 1972, ACTA CHEM SCAND, V26, P3515, DOI 10.3891/acta.chem.scand.26-3515; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Lindahl U., 1989, HEPARIN, P159; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LYON M, 1994, J BIOL CHEM, V269, P11208; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTRO.A, 1971, FEBS LETT, V16, P105, DOI 10.1016/0014-5793(71)80344-7; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1982, BIOCHEM J, V201, P489, DOI 10.1042/bj2010489; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MALMSTROM A, 1993, DERMATAN SULFATE PRO, P129; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MEYER K, 1956, BIOCHIM BIOPHYS ACTA, V21, P506, DOI 10.1016/0006-3002(56)90188-3; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; REGISTER TC, 1990, CONNECT TISSUE RES, V25, P35, DOI 10.3109/03008209009009811; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SILBERT JE, 1993, DERMATAN SULFATE PRO, P147; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WESTERGRENTHORS.G, 1991, J CELL PHYSIOL, V147, P523; YAMADA S, 1992, J BIOCH, V112, P404; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	42	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7204	7212		10.1074/jbc.270.13.7204	http://dx.doi.org/10.1074/jbc.270.13.7204			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706259	hybrid			2022-12-25	WOS:A1995QQ43100031
J	FUTAMURA, M; MONDEN, Y; OKABE, T; FUJITAYOSHIGAKI, J; YOKOYAMA, S; NISHIMURA, S				FUTAMURA, M; MONDEN, Y; OKABE, T; FUJITAYOSHIGAKI, J; YOKOYAMA, S; NISHIMURA, S			TRICHOSTATIN-A INHIBITS BOTH RAS-INDUCED NEURITE OUTGROWTH OF PC12 CELLS AND MORPHOLOGICAL TRANSFORMATION OF NIH3T3 CELLS	ONCOGENE			English	Article						ONCOGENES; RAS; PC12; TRICHOSTATIN A HEURITE DIFFERENTIATION	NERVE GROWTH-FACTOR; C-FOS INDUCTION; NEURONAL DIFFERENTIATION; HISTONE ACETYLATION; BINDING AFFINITIES; DNA-BINDING; JUN; SEQUENCES; LINE; MICROINJECTION	During screening for inhibitors of ras-mediated differentiation of PC12 cells, trichostatin A (TSA) was isolated from the metabolites of Streptomyces as a potent inhibitor, TSA blocked both oncogenic ras- and NGF-induced neurite outgrowth from PC12 cells, However, addition of TSA 1 h after NGF-stimulation did not inhibit neuronal differentiation, suggesting that TSA affects an early step in the NGF- signaling pathway mediated by ras, Northern blotting analysis showed that TSA prolonged the maximum expression period of c-fos mRNA triggered by NGF and delayed its return to the basal level, TSA reduced c-jun mRNA induction by NGF but greatly enhanced c-myc mRNA induced by NGF, Yoshida et al, (J. Biol. Chem., 265, 17174-17179, 1990) showed that TSA inhibits histone deacetylation, which might influence the gene expression involved in cellular differentiation, In this study, we also found that TSA prevents histone deacetylation in PC12 cells as well as other cell lines, suggesting that inhibition of histone deacetylation by TSA might affect the expression of early-response genes, We also demonstrated that TSA induced reversion of oncogenic ras-transformed NIH3T3 cells to a normal morphology, suggesting that inhibitors of ras-mediated differentiation of PC12 cells may be effective as anticancer agents,	BANYU TSUKUBA RES INST MERCK, ONCOGENE RES LAB, TSUKUBA, IBARAKI 30033, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	Merck & Company; University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015; Yoshigaki, Junko/AAE-6702-2020	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJITAYOSHIGAKI J, 1992, ONCOGENE, V7, P2019; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; IZAWA M, 1992, CANCER RES, V52, P1628; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHINDOOKADA N, 1990, BASIC LIFE SCI, V52, P309; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; SUGITA K, 1992, CANCER RES, V52, P168; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; WU BY, 1989, J BIOL CHEM, V264, P9000; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1988, CELL TECHNOL S, V4, P91	34	63	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1119	1123						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700637				2022-12-25	WOS:A1995QN35300012
J	WANG, ZY; QIU, QQ; GURRIERI, M; HUANG, J; DEUEL, TF				WANG, ZY; QIU, QQ; GURRIERI, M; HUANG, J; DEUEL, TF			WT1, THE WILMS-TUMOR SUPPRESSOR GENE-PRODUCT, REPRESSES TRANSCRIPTION THROUGH AN INTERACTIVE NUCLEAR-PROTEIN	ONCOGENE			English	Note						WT1; TUMOR SUPPRESSOR; TRANSCRIPTION; INTERACTIVE PROTEIN	FACTOR-A-CHAIN; KIDNEY DEVELOPMENT; UROGENITAL SYSTEM; EXPRESSION; GROWTH; CELLS; KRUPPEL; DOMAINS; LOCUS; DNA	The Wilms' tumor suppressor gene, wt1, encodes a transcription factor of the zinc finger family, Mutations in WT1 have been detected in subsets of Wilm's tumor and in patients,vith the Denys-Drash Syndrome, In order to determine how WT1 regulates transcription and perhaps the consequences that mutations in WT1 may have, we established that residues 85-124 and 181-250 of WT1 constitute domains that function independently with DNA binding domain to repress or activate transcription, respectively, and function equally effectively with heterologous promoters, suggesting the activator and repressor domains interact with nuclear components of general importance, To seek evidence for such components, increasing concentrations of WT1 repressor domain without a zinc finger DNA binding domain were co-transfected with fixed concentrations of wild-type (wt) WT1 and PDGF A-chain promoter/reporter gene constructs, As levels of the repressor domain were increased, a progressive loss of wt WT1 repressor activity and a progressive increase in its activation were observed, suggesting that the repressor domain of WT1 competes with wt WT1 for an interactive protein that is an essential component of the repressor activity of wt WT1, Because the most common mutation associated with Denys-Drash Syndrome disrupts the zinc finger domains of WT1, the results also suggest that the mutant WT1 may have aberrant DNA binding activity and perhaps function as a dominant negative effector	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital			Huang, Jeffrey/J-5248-2017; Huang, Jeffrey K./AAH-2418-2021	Huang, Jeffrey/0000-0003-0996-9451; Huang, Jeffrey K./0000-0003-0996-9451	NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL031102, R01HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHARMA PM, 1992, CANCER RES, V52, P6407; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, P5828; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	29	62	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1243	1247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700651				2022-12-25	WOS:A1995QN35300028
J	KNIBBS, RN; OSBORNE, SE; GLICK, GD; GOLDSTEIN, IJ				KNIBBS, RN; OSBORNE, SE; GLICK, GD; GOLDSTEIN, IJ			BINDING DETERMINANTS OF THE SIALIC ACID-SPECIFIC LECTIN FROM THE SLUG LIMAX-FLAVUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPIC DEMONSTRATION; N-ACETYLNEURAMINIC ACID; MAACKIA-AMURENSIS; INFLUENZA-VIRUS; LINKED OLIGOSACCHARIDES; STRUCTURAL VARIATIONS; SAMBUCUS-NIGRA; RESIDUES; RECOGNITION; LOCALIZATION	The specific structural features of 24 N-acetylneuraminic acid derivatives required for the high affinity interaction of sialoglycoconjugates with the sialic acid-specific lectin from the slug Limax flavus were studied by hapten inhibition of precipitation. These results provide insight regarding the structure of the binding pocket for N-acetylneuraminic acid that exists in L. flavus agglutinin (LFA). The alpha-anomer of sialic acid is a very important factor in binding to the slug lectin. The carboxylic acid group makes only a moderate contribution to binding, since modifications of the carboxylic group decrease binding approximately 5-fold. Modification or removal of the hydroxyl group on carbon 4 does not affect binding. However, when the C4 epimer was tested, there was a dramatic decrease in binding, suggesting that whereas the equatorial hydroxyl at C4 does not contribute to binding, the introduction of an axial hydroxyl group at C4 sterically hinders the binding interaction. The substituent on the 5-amino group occupies an important role in binding of Neu5Ac to LFA as well. When the acetyl is modified by the addition of a hydroxyl group to yield the N-glycolyl derivative, we observed a 20-fold decrease, while the removal of the methyl to form the N-formyl derivative resulted in a 50-fold decrease. The 5-amino derivative was the poorest inhibitor of all compounds examined, indicating a critical role for the N-acetyl group in high affinity binding to LFA. The glyceryl tail also appears to be critical for binding inasmuch as acetylation of the C9 hydroxyl group or periodate cleavage of carbons 8 and 9 resulted in a 20- to 50-fold decrease in binding. The equilibrium constant (K(a)) for binding of Neu5Ac to LFA is 3.8 x 10(4) M-1, with a single binding site (n = 0.85) per monomer.	UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	KNIBBS, RN (corresponding author), UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA020424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20424] Funding Source: Medline; NIGMS NIH HHS [GM 29470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1977, P NATL ACAD SCI USA, V74, P1521, DOI 10.1073/pnas.74.4.1521; BRANDSTETTER HH, 1983, LIEBIGS ANN CHEM, P2055; BROSSMER R, 1992, J BIOL CHEM, V267, P8752; CHAVIN SI, 1984, J BIOL CHEM, V259, P3387; Cram D.J., 1986, ANGEW CHEM, V98, P1041, DOI DOI 10.1021/ja102148f; CZARNIECKI MF, 1977, J AM CHEM SOC, V99, P8273, DOI 10.1021/ja00467a025; FORSTNER M, 1989, CARBOHYD RES, V193, P294, DOI 10.1016/0008-6215(89)85130-4; GLICK GD, 1991, J BIOL CHEM, V266, P23660; GOLDSTEIN IJ, 1986, LECTINS PROPERTIES F, P209; GROSS HJ, 1990, ANAL BIOCHEM, V186, P127, DOI 10.1016/0003-2697(90)90585-W; GROSS HJ, 1988, BIOCHEMISTRY-US, V27, P4279, DOI 10.1021/bi00412a012; HAGEDORN HW, 1986, HELV CHIM ACTA, V69, P2127, DOI 10.1002/hlca.19860690837; HARTMANN M, 1989, MONATSH CHEM, V120, P899, DOI 10.1007/BF00811129; HARTMANN M, 1990, LIEBIGS ANN CHEM, P83; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; HEDMAN K, 1986, J HISTOCHEM CYTOCHEM, V34, P1069, DOI 10.1177/34.8.3734417; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDAL C, 1990, EXPERIENTIA, V46, P433, DOI 10.1007/BF01954221; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MILLER RL, 1982, J INVERTEBR PATHOL, V39, P210, DOI 10.1016/0022-2011(82)90012-X; MORELL AG, 1971, J BIOL CHEM, V246, P1461; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3213; OGURA H, 1986, CARBOHYD RES, V158, P37, DOI 10.1016/0008-6215(86)84004-6; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; ROGERS GN, 1985, J BIOL CHEM, V260, P7362; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; SATA T, 1989, J HISTOCHEM CYTOCHEM, V37, P1577, DOI 10.1177/37.11.2478613; SATA T, 1991, AM J PATHOL, V139, P1435; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Schauer R, 1978, Methods Enzymol, V50, P64; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHAUER R, 1984, PURE APPL CHEM, V56, P907, DOI 10.1351/pac198456070907; SCHULTE BA, 1984, HISTOCHEM J, V16, P1125, DOI 10.1007/BF01002899; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SMILEY ML, 1985, J VIROL, V55, P857, DOI 10.1128/JVI.55.3.857-861.1985; TACHIBANA M, 1990, EUR ARCH OTO-RHINO-L, V247, P240; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WAGNER M, 1990, LECTINS BIOL BIOCH C, V7, P83; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; YAMASHITA K, 1988, J BIOL CHEM, V263, P17482; YU RK, 1969, J BIOL CHEM, V244, P1306; ZENG FY, 1992, Z NATURFORSCH C, V47, P641	51	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18524	18531						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689555				2022-12-25	WOS:A1993LV65900026
J	VIETOR, I; SCHWENGER, P; LI, W; SCHLESSINGER, J; VILCEK, J				VIETOR, I; SCHWENGER, P; LI, W; SCHLESSINGER, J; VILCEK, J			TUMOR NECROSIS FACTOR-INDUCED ACTIVATION AND INCREASED TYROSINE PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MOLECULAR-CLONING; THREONINE KINASE; FACTOR RECEPTORS; CELLS; INTERLEUKIN-1; EXPRESSION; PATHWAYS; TNF; JUN	Tumor necrosis factor (TNF) is a pleiotropic cytokine whose many demonstrated actions include effects on cell growth and differentiation. TNF treatment of cells is known to lead to a rapid increase in serine/threonine phosphorylation of many cellular proteins, but the kinases responsible remain largely unidentified. We show that TNF treatment induces a rapid and transient increase in mitogen-activated protein kinase (MAPK) activity in the human diploid FS-4 cell line, for which TNF is known to be mitogenic. TNF-induced activation of MAPK was demonstrated by its enhanced ability to phosphorylate myelin basic protein in vitro and by a characteristic shift in the electrophoretic mobility of MAPK proteins. MAPK activation was accompanied by a significant increase of MAPK phosphorylation on tyrosine residues, which was demonstrated by P-32 labeling of cells and isolation of the labeled proteins after immunoprecipitation with antibodies to phosphotyrosine, and by direct immunoblotting of SDS-polyacrylamide gel electrophoresis-fractionated unlabeled cell lysates with antibodies to phosphotyrosine. The pp42 and pp44 MAPK were the only proteins whose tyrosine phosphorylation was demonstrably increased in FS-4 cells after TNF treatment. MAPK activation is likely to represent an important component in the cascade of signals that link TNF receptors to various TNF-elicited cellular responses.	NYU MED CTR, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA; SLOVAK ACAD SCI, INST EXPTL ENDOCRINOL, CS-83306 BRATISLAVA, CZECHOSLOVAKIA; NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University; Slovak Academy of Sciences; New York University					NCI NIH HHS [R35CA49731, 5-T32-CA09161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731, T32CA009161] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GUY GR, 1992, J BIOL CHEM, V267, P1846; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LI W, 1991, J BIOL CHEM, V266, P6808; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	43	141	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18994	18999						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689564				2022-12-25	WOS:A1993LV65900092
J	ISHII, K; HEIN, L; KOBILKA, B; COUGHLIN, SR				ISHII, K; HEIN, L; KOBILKA, B; COUGHLIN, SR			KINETICS OF THROMBIN RECEPTOR CLEAVAGE ON INTACT-CELLS - RELATION TO SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELETS; FIBROBLASTS; ACTIVATION; PROTEINS	Thrombin, a protease generated at sites of vascular injury, signals cellular responses vital for hemostasis and thrombosis. How thrombin, an enzyme rather than a classical ligand, effects graded and concentration-dependent responses in its target cells has been a long-standing question. Thrombin activates its receptor by cleaving off an activation peptide to unmask a tethered peptide ligand. We utilized a thrombin receptor with an epitope-tagged activation peptide to directly demonstrate thrombin receptor cleavage and to examine the kinetics of receptor activation on intact cells. The rate of thrombin receptor cleavage was proportional to thrombin concentration over the physiologic range, but low thrombin concentrations ultimately cleaved and activated all receptors. Cumulative phosphoinositide hydrolysis in response to thrombin correlated precisely with cumulative receptor cleavage. These data strongly suggest that each cleaved and activated thrombin receptor produces a ''quantum'' of phosphatidylinositol hydrolysis, then shuts off. Surprisingly, this shut off occurred despite the continued presence of cleaved and ''activated'' receptors on the cell surface and at a time when the cells were refractory to thrombin but sensitive to agonist peptide, suggesting that a novel shut off mechanism may have evolved to deal with the tethered ligand. Unlike the case with classical ligands, cells thus cannot detect differences in thrombin concentrations as differences in fractional occupancy but rather must sense different rates of receptor activation. Because each cleaved thrombin receptor generates a quantum of second messenger, the magnitude of the cell's response to thrombin must be determined by the balance between rates of receptor activation and second messenger clearance.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, BOX 0524, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907, HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BRASS LF, 1992, J BIOL CHEM, V267, P6044; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LIU LW, 1991, J BIOL CHEM, V266, P16977; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARIS S, 1988, J BIOL CHEM, V263, P11250; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REIMERS HJ, 1973, BRIT J HAEMATOL, V25, P675, DOI 10.1111/j.1365-2141.1973.tb01780.x; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; SIMON K, 1987, J CELL BIOL, V104, P1165, DOI 10.1083/jcb.104.5.1165; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	31	205	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9780	9786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683662				2022-12-25	WOS:A1993LA68900091
J	GOROSPE, M; KUMAR, S; BAGLIONI, C				GOROSPE, M; KUMAR, S; BAGLIONI, C			TUMOR-NECROSIS-FACTOR INCREASES STABILITY OF INTERLEUKIN-1 MESSENGER-RNA BY ACTIVATING PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; POSTTRANSCRIPTIONAL REGULATION; CELLS; FIBROBLASTS; EXPRESSION; INTERFERON; LYMPHOKINE; INDUCTION; LEVEL	The mRNAs coding for interleukin-1alpha (IL-1alpha) and IL-1beta are constitutively transcribed but do not accumulate in human diploid fibroblasts and in fibrosarcoma cells. Treatment of these cells with tumor necrosis factor (TNF) induces accumulation of IL-1 mRNA by an unknown mechanism. This induction of IL-1 mRNA was investigated in HT-1080 cells. The induction was quite fast, with maximum levels of IL-1alpha and beta mRNA reached 4 h after addition of TNF. Nuclear run-off experiment showed that TNF did not increase the rate of transcription of IL-1 mRNA. This mRNA was apparently unstable in untreated cells, but it accumulated in cycloheximide-treated cells. Phorbol esters induced IL-1 mRNA, suggesting that activation of protein kinase C was responsible for the accumulation of this mRNA. This hypothesis was confirmed by experiments with the PKC inhibitors staurosporine and calphostin C, which prevented the induction of IL-1 mRNA by TNF and accelerated the decay of this mRNA in cells pretreated with TNF. Both IL-1alpha and IL-1beta were detected in TNF-treated cells by Western blot analysis and enzyme-linked immunosorbent assay. These results indicate that the TNF-mediated induction of IL-1 can be entirely accounted for by stabilization of this mRNA.			GOROSPE, M (corresponding author), SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA.				NCI NIH HHS [CA-29895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; ELIAS JA, 1989, P NATL ACAD SCI USA, V86, P6171, DOI 10.1073/pnas.86.16.6171; GESSANI S, 1988, J BIOL CHEM, V263, P7454; GESSANI S, 1991, J VIROL, V65, P989, DOI 10.1128/JVI.65.2.989-991.1991; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUY GR, 1991, J BIOL CHEM, V266, P14343; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LEPEZUNIGA JL, 1984, CLIN IMMUNOL IMMUNOP, V31, P222, DOI 10.1016/0090-1229(84)90242-3; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	27	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6214	6220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681061				2022-12-25	WOS:A1993KT36800024
J	BLECHMAN, JM; LEV, S; BRIZZI, MF; LEITNER, O; PEGORARO, L; GIVOL, D; YARDEN, Y				BLECHMAN, JM; LEV, S; BRIZZI, MF; LEITNER, O; PEGORARO, L; GIVOL, D; YARDEN, Y			SOLUBLE C-KIT PROTEINS AND ANTIRECEPTOR MONOCLONAL-ANTIBODIES CONFINE THE BINDING-SITE OF THE STEM-CELL FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; TYROSINE KINASE RECEPTOR; INSULIN-RECEPTOR; PROTO-ONCOGENE; W-LOCUS; SIGNAL TRANSDUCTION; LIGAND; MOUSE; IDENTIFICATION	The binding of the stem cell factor (SCF) to the c-kit-encoded receptor tyrosine kinase stimulates a variety of biochemical responses that culminate in cellular proliferation, migration, or survival. The extracellular domain of p145kit consists of five immunoglobulin-like domains. To confine the ligand binding site to this portion of the receptor we generated a panel of murine monoclonal antibodies (mAbs) to the Kit protein and identified two mAbs that efficiently displaced receptor-bound SCF and also inhibited proliferation of SCF-dependent human megakaryocytes. To map the epitopes of these mAbs we constructed and expressed soluble portions of the extracellular domain of Kit, which included either the two amino-terminal Ig-like domains (denoted Kit 1-2), three Ig-like domains (Kit 1-2-3), or the entire extracellular portion (Kit-X). All three recombinant proteins were recognized by the ligand inhibitory mAbs, suggesting that the SCF binding site resides in the amino-terminal half of the ecto-domain. Consistent with this conclusion, all of the soluble proteins inhibited SCF binding to Kit-expressing cells, and they also underwent specific covalent cross-linking to the radiolabeled ligand. However, whereas Kit 1-2-3 and Kit-X displayed comparable ligand affinities, deletion of the third Ig-like domain, in Kit 1-2, involved significant reduction in SCF binding. Hence, the binding site of SCF probably includes Ig-like domains 1 and 2, but structural determinants distal to this portion may also participate in ligand recognition.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; UNIV TURIN, DIPARTMENTO SCI BIOMED & ONCOL UMANA, I-10126 TURIN, ITALY	Weizmann Institute of Science; University of Turin			Lev, Sima/AAP-7880-2020; YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016	Lev, Sima/0000-0002-2108-3330; 	NCI NIH HHS [CA 51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Silvers W.K., 1979, COAT COLORS MICE, P206; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	51	59	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4399	4406						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680037				2022-12-25	WOS:A1993KN53300085
J	DOWBENKO, D; ANDALIBI, A; YOUNG, PE; LUSIS, AJ; LASKY, LA				DOWBENKO, D; ANDALIBI, A; YOUNG, PE; LUSIS, AJ; LASKY, LA			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE MURINE GENE ENCODING GLYCAM-1 - A MUCIN-LIKE ENDOTHELIAL LIGAND FOR L-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; STEM-CELL ANTIGEN; HUMAN LEUKOSIALIN; LECTIN DOMAIN; MOUSE; IDENTIFICATION; EXPRESSION; PROTEINS; SEQUENCE; CD43	We recently described the molecular cloning of a murine cDNA encoding an endothelial cell surface ligand for the leukocyte adhesion molecule, L Selectin (Lasky, L. A., Singer, M., Dowbenko, D., Ima, Y., Henzel, W., Grimley, C., Gennie, C., Gillett, N., Watson, S., and Rosen, S. D (1992) Cell 69, 927-938). This glycoprotein ligand was found to resemble mucins in that it contained a large percentage of serine and threonine residues that were apparently O-glycosylated. At least one of the O-linked carbohydrates found on this endothelial ligand interacts with the lectin domain of L Selectin. These data suggest that this endothelial ligand is an adhesion molecule that accomplishes cell binding by presenting carbohydrate(s) to the lectin domain of L Selectin, and the name GLYCAM 1 (GLY-cosylation-dependent Cell Adhesion Molecule 1) has been proposed. In this paper we describe the genomic structure and chromosomal localization of this unique Selectin ligand. The gene has been found to be encoded on four separate exons, and it thus differs from the cell surface mucin leukosialin, whose coding region is contained on one exon, but is similar to glycophorin and CD34, other cell surface mucins whose genes are divided into multiple coding exons. While there is some correlation between exon division and protein domain structure, these relationships are not as clear as they are in other genes. The gene encoding GLYCAM 1 was found to map to murine chromosome 15.	GENENTECH INC,DEPT IMMUNOL,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; UNIV CALIF LOS ANGELES,DEPT MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Roche Holding; Genentech; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NHLBI NIH HHS [HL30568] Funding Source: Medline; PHS HHS [H42488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; HUPPI K, 1988, IMMUNOGENETICS, V27, P215, DOI 10.1007/BF00346589; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; KUDO S, 1991, J BIOL CHEM, V266, P8483; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1992, IN PRESS INFLAMMATIO; MOLGAARD HV, 1989, LEUKEMIA, V3, P773; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; Rosen SD, 1989, CURR OPIN CELL BIOL, V1, P913, DOI 10.1016/0955-0674(89)90058-6; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; VANCONG N, 1991, HUM GENET, V86, P77; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	24	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4525	4529						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680041				2022-12-25	WOS:A1993KN53300103
J	BANIK, U; AHMED, SA; MCPHIE, P; MILES, EW				BANIK, U; AHMED, SA; MCPHIE, P; MILES, EW			SUBUNIT ASSEMBLY IN THE TRYPTOPHAN SYNTHASE ALPHA(2)BETA(2) COMPLEX - STABILIZATION BY PYRIDOXAL-PHOSPHATE ALDIMINE INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BETA-SUBUNIT; ALPHA-2-BETA-2 COMPLEX; APO-BETA2 SUBUNIT; ALPHA-SUBUNIT; MECHANISM; BINDING; 5'-PHOSPHATE; FORMS	This work is aimed at understanding subunit assembly in the tryptophan synthase alpha(2) beta(2) complex and the importance of the internal aldimine between pyridoxal phosphate and lysine 87 of the beta(2) subunit of tryptophan synthase for subunit association. We utilize a mutant form of the beta(2) subunit that is unable to form the internal aldimine because lysine 87 is replaced by threonine (K87T). The K87T alpha(2) beta(2) complex is inactive in reactions catalyzed by the beta(2) subunit but retains activity in the reaction catalyzed by the alpha subunit. We find that dialysis removes pyridoxal phosphate much more rapidly from the K87T beta(2) subunit and alpha(2) beta(2) complex than from the wild type counterparts. Activity measurements, gel filtration, and subunit interchange experiments show that the alpha subunit dissociates more readily from the K87T beta(2) subunit than from the wild type beta(2) subunit. The reaction of L-serine to form an external aldimine with pyridoxal phosphate at the active site of the K87T beta(2) subunit markedly increases the affinity for the alpha subunit and slows removal of pyridoxal phosphate by dialysis. me propose that the external aldimine between L-serine and pyridoxal phosphate bridges the N-domain and the C-domain in the K87T beta(2) subunit. This interdomain bridge may mimic the internal aldimine bond in the wild type beta(2) subunit and stabilize pyridoxal phosphate binding. The interdomain bridges formed by the internal aldimine with the wild type Pa subunit and by the external aldimine with L-serine in the K87T beta(2) subunit may further stabilize interaction with the iv subunit because the alpha/beta interaction site contains residues from both N- and C-domains of the beta(2) subunit.	NIDDKD, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ADACHI O, 1974, J BIOL CHEM, V249, P7756; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BARTHOLMES P, 1980, BIOCHEMISTRY-US, V19, P4527, DOI 10.1021/bi00560a022; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; BARTHOLMES P, 1979, EUR J BIOCHEM, V95, P323, DOI 10.1111/j.1432-1033.1979.tb12968.x; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BODE W, 1992, PROTEIN SCI, V1, P426; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BRZOVLC P, 1991, INT UNION B, V199, P277; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles Edith Wilson, 1994, P127, DOI 10.1002/9783527615971.ch7; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1994, ADV LIF SCI-SERIES, P113; REMETA D P, 1992, Biophysical Journal, V61, pA213; REMETA DP, 1993, BIOPHYS J, V64, pA175; REMETA DP, 1995, IN PRESS PURE APPL C; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RUVINOV SB, 1994, J BIOL CHEM, V269, P11703; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4521, DOI 10.1021/bi00560a021; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4514, DOI 10.1021/bi00560a020; WADA H, 1962, J BIOL CHEM, V237, P127; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANOFSKY C, 1972, ENZYMES, V7, P1	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7944	7949		10.1074/jbc.270.14.7944	http://dx.doi.org/10.1074/jbc.270.14.7944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713891	hybrid			2022-12-25	WOS:A1995QR52600027
J	AARHUS, R; GEE, K; LEE, HC				AARHUS, R; GEE, K; LEE, HC			CAGED CYCLIC ADP-RIBOSE - SYNTHESIS AND USE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGG; INOSITOL TRISPHOSPHATE; CALCIUM RELEASE; CA2+ RELEASE; METABOLITE; ENZYME; NAD+; FERTILIZATION	Cyclic ADP-ribose (cADPR) is a recently discovered cyclic nucleotide with Ca2+ mobilizing activity. Caged cADPR was synthesized by reacting cADPR with 2-nitrophenethyldiazoethane. Elemental analyses, H-1 NMR, and extinction coefficient measurements indicate that the product contains only one caging group. Anion exchange high pressure liquid chromatography separated caged cADPR into two forms, which most likely represent isomers. Both forms could be uncaged with equal efficiency by UV exposure to regenerate cADPR. Photolysis of caged cADPR was accomplished effectively with a spectrofluorimeter. The efficiency of uncaging depended on wavelength with UV light shorter than about 320 nm being the most effective. Caged cADPR was biologically inactive and could induce Ca2+ release from sea urchin egg homogenates only after photolysis. Specificity of the Ca2+ release was shown by inhibition by 8-amino-cADPR, a specific antagonist of cADPR. To demonstrate its utility in live cells, caged cADPR was microinjected into sea urchin eggs. Photolysis using a mercury light source effectively regenerated cADPR and resulted in Ca2+ mobilization and activation of cortical exocytosis in the eggs.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; MOLEC PROBES INC,EUGENE,OR 97402	University of Minnesota System; University of Minnesota Twin Cities			Lee, Hon Cheung/C-4329-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032040, R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32040, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DOXSEY SJ, 1985, J CELL BIOL, V101, P19, DOI 10.1083/jcb.101.1.19; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GU QM, 1994, J AM CHEM SOC, V116, P7481, DOI 10.1021/ja00096a002; HAUGLAND RP, 1992, MOL PROBES HDB FLUOR, P182; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	22	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7745	7749		10.1074/jbc.270.13.7745	http://dx.doi.org/10.1074/jbc.270.13.7745			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706323	hybrid			2022-12-25	WOS:A1995QQ43100103
J	BOURGUIGNON, LYW; JIN, HT				BOURGUIGNON, LYW; JIN, HT			IDENTIFICATION OF THE ANKYRIN-BINDING DOMAIN OF THE MOUSE T-LYMPHOMA CELL INOSITOL 1,4,5-TRISPHOSPHATE (IP3) RECEPTOR AND ITS ROLE IN THE REGULATION OF IP3-MEDIATED INTERNAL CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TRANSMEMBRANE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; CYTOSKELETON; PROTEIN; GP85; INVOLVEMENT; CYTOPLASM	In this study we have used several complementary techniques to explore the interaction between the membrane linker molecule, ankyrin, and the inositol 1,4,5-trisphosphate (IP3) receptor in mouse T-lymphoma cells, Using double immunolabeling and laser confocal microscopy, we have found that both cytoplasmic IP3 receptor and ankyrin are preferentially accumulated within ligand-induced lymphocyte receptor capped structures, The binding between ankyrin and IP3 receptor appears to be very specific, Further analyses indicate that the amino acid sequence GGVGDVLRKPS in the IP3 receptor shares a great deal of structural homology with the ankyrin-binding domain located in certain well characterized ankyrin-binding proteins such as the cell adhesion molecule, CD44. Biochemical studies using competition binding assays and a synthetic peptide identical to GGVGDVLRKPS (a sequence detected in rat brain IP3 receptor (amino acids 2548-2558) and mouse brain IP3 receptor (amino acids 2546-2556)) indicate that this 11-amino acid peptide binds specifically to ankyrin (but not fodrin or spectrin), Furthermore, this peptide competes effectively for ankyrin binding to IP3 receptor-containing vesicles and/or purified IP3 receptor, and it blocks ankyrin-induced inhibitory effects on IP3 binding and IP3-mediated internal Ca2+ release in mouse T-lymphoma cells, These findings suggest that this amino acid sequence, GGVGDVLRKPS, which is located close to the C terminus of the IP3 receptor, resides on the cytoplasmic side (not the luminal side) of IP3 receptor-containing vesicles, This unique region appears to be an important part of the IP3 receptor ankyrin-binding domain and may play an important role in the regulation of IP3 receptor-mediated internal Ca2+ release during lymphocyte activation.			BOURGUIGNON, LYW (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,1600 NW 10TH AVE,MIAMI,FL 33101, USA.				NATIONAL CANCER INSTITUTE [R01CA036353, R01CA066163, R37CA036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66163, CA 36353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOURGUIGNON LYW, 1993, CELL BIOL INT, V17, P751, DOI 10.1006/cbir.1993.1136; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BOURGUIGNON LYW, 1992, ENCY IMMUNOLOGY, P1044; DAVIS L, 1989, J BIOL CHEM, V264, P9665; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; JESEPH SK, 1993, J BIOL CHEM, V268, P6477; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KRAUSFRIEDMANN N, 1994, CELL MOTIL CYTOSKEL, V28, P279, DOI 10.1002/cm.970280402; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MIGNERY GA, 1989, J BIOL CHEM, V265, P12679; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x	27	96	96	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7257	7260		10.1074/jbc.270.13.7257	http://dx.doi.org/10.1074/jbc.270.13.7257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706265	hybrid			2022-12-25	WOS:A1995QQ43100038
J	LIU, ZY; FULLER, GM				LIU, ZY; FULLER, GM			DETECTION OF A NOVEL TRANSCRIPTION FACTOR FOR THE A-ALPHA FIBRINOGEN GENE IN RESPONSE TO INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; NUCLEAR FACTOR; SIGNAL-TRANSDUCTION; C/EBP FAMILY; PROTEIN; PROMOTER; EXPRESSION; ELEMENTS; BINDING; GLUCOCORTICOIDS	The three fibrinogen genes belong to the class II hepatic acute phase proteins that are regulated in part by members of the interleukin-6 (IL-6) family of cytokines and glucocorticoids. The common DNA sequence that characterizes this group of proteins is a hexanucleotide CTGGGA residing in the promoter regions of these genes. Investigations of IL-6 control of the Aa fibrinogen gene by electrophoretic mobility shift assays using a 30-base pair DNA probe containing the CTGGGA element revealed that a novel protein is associated with this site during non-IL-6-stimulated conditions. Sensitive time-course studies of IL-6 stimulation using primary hepatocyte cultures, high resolution polyacrylamide gel electrophoresis, and site-directed mutagenesis show that upon IL-6 stimulation of hepatocytes, this DNA binding protein transiently leaves the CTGGGA site and binds 12 base pairs downstream but then begins to re-associate with the original DNA site at 1 h and is completed by 2 h. A recently characterized and cloned IL-6-activated transcription factor, Stat-3, which has been reported to bind a CTGGGAA site in the alpha-2 macroglobulin gene, another member of the class II acute phase proteins, does not bind to the CTGGGA sequence in the A alpha fibrinogen gene. These findings reveal the presence of a previously undefined IL-6-regulated event, which involves a new DNA binding protein and demonstrates for the first time additional details of the kinetics of IL-6 control of fibrinogen gene expression.	UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1993, J BIOL CHEM, V268, P25311; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; FULLER GM, 1988, METHOD ENZYMOL, V163, P474; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; NESBITT JE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P88, DOI 10.1016/0167-4781(91)90089-5; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROY SN, 1990, J BIOL CHEM, V265, P6389; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7580	7586		10.1074/jbc.270.13.7580	http://dx.doi.org/10.1074/jbc.270.13.7580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706306	hybrid			2022-12-25	WOS:A1995QQ43100082
J	BALDARI, CT; PELICCI, G; DISOMMA, MM; MILIA, E; GIULI, S; PELICCI, PG; TELFORD, JL				BALDARI, CT; PELICCI, G; DISOMMA, MM; MILIA, E; GIULI, S; PELICCI, PG; TELFORD, JL			INHIBITION OF CD4/P56LCK SIGNALING BY A DOMINANT-NEGATIVE MUTANT OF THE SHC ADAPTER PROTEIN	ONCOGENE			English	Article						T-CELL ACTIVATION; RAS; TYROSINE PHOSPHORYLATION	T-CELL ACTIVATION; CYCLOSPORINE-A; TYROSINE KINASES; LYMPHOCYTES-T; RAS PROTEIN; RECEPTOR; ASSOCIATION; TRANSFORMATION; PROLIFERATION; TRANSDUCTION	T-cell antigen receptor stimulation results in phosphorylation of the SH2 containing She proteins and recruitment of the Grb2/mSos complex suggesting that She proteins are involved in transducing T-cell activating signals to Ras, We have measured the effects of the isolated Shc-SH2 domain and the dominant negative Ras(N17) protein on activation of the T-cell specific transcription factor NF-AT, The isolated Shc-SH2 domain was designed to compete with endogenous She binding to upstream tyrosine phosphorylated proteins and to interfere with coupling to regulators of Ras activation, We have demonstrated that both the Shc-SH2 domain and the Ras(N17) protein significantly inhibited NF-AT activation by the CD4 coreceptor and the CD4 associated tyrosine kinase p56(lcK). Tn contrast, only the Ras(N17) protein reduced NF-AT activation by the TCR/CD3 complex, Furthermore, tyrosine kinase activity and p56(lcK) protein were found in complexes immunoprecipitated with She specific antisera after CD4 triggering but not after CD3 triggering, These results indicate that both CD4 and CD3 signal to Ras and that this signaling is mediated by independent pathways of activation of the She adaptor protein.	IMMUNOBIOL RES INST SIENA,I-53100 SIENA,ITALY; UNIV SIENA,DEPT EVOLUTIONARY BIOL,I-53100 SIENA,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY	University of Siena; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Telford, John Laird/ABG-8144-2020; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255; Baldari, Cosima/0000-0002-4414-6744				ALCALAY M, 1990, ONCOGENE, V5, P267; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; HAIGWOOD NL, 1990, VACCINES 90, P313; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PELICCI G, 1991, CELL, V70, P93; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J., 1989, MOL CLONING; SEFTON BM, 1991, ONCOGENE, V6, P683; Signoret N, 1993, Trends Microbiol, V1, P328, DOI 10.1016/0966-842X(93)90072-Y; STEIMER KS, 1988, VACCINES 88, P347; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS D, 1990, IMMUNOLOGY, V71, P10; WOODROW MA, 1993, J IMMUNOL, V9, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	31	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700640				2022-12-25	WOS:A1995QN35300015
J	LUTZ, HU; GIANORA, O; NATER, M; SCHWEIZER, E; STAMMLER, P				LUTZ, HU; GIANORA, O; NATER, M; SCHWEIZER, E; STAMMLER, P			NATURALLY-OCCURRING ANTI-BAND-3 ANTIBODIES BIND TO PROTEIN RATHER THAN TO CARBOHYDRATE ON BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; ALTERNATIVE COMPLEMENT PATHWAY; HUMAN ERYTHROCYTE-MEMBRANE; GEL ELECTROPHORESIS; SENESCENT ANTIGEN; IMMUNE-COMPLEXES; IGG-BINDING; AUTOANTIBODIES; PHAGOCYTOSIS; GLYCOPROTEIN	Naturally occurring anti-band 3 antibodies were affinity purified from pooled human IgG (Sandoglobulin(R)) (Lutz, H. U., Flepp, R., and Stringaro-Wipf, G. (1984) J. Immunol. 133,2610-2618). They bound to the major integral membrane protein of human red blood cells and its 55-kDa NH2-terminal chymotryptic fragment but not to the carbohydrate-rich 38-kDa fragment on blots. Likewise, neither an endo-beta-galactosidase nor a neuraminidase treatment of band 3 on intact red cells reduced their binding to the blotted antigen. Lactoferrin (10 mug/ml) had no significant effect on their binding to band 3 and to its 55-kDa chymotryptic fragment. Even in the presence of 20 mug/ml lactoferrin anti-band 3 antibodies bound specifically to chymotrypsin-pretreated and oxidatively stressed red cells. Thus, naturally occurring anti-band 3 antibodies bind to protein rather than carbohydrate within band 3 protein, irrespective of whether the antibodies were depleted of anti-idiotypic and other IgG-reactive antibodies or not.			LUTZ, HU (corresponding author), SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND.							ADIBCONQUY M, 1993, MOL IMMUNOL, V30, P119, DOI 10.1016/0161-5890(93)90083-N; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; BACHI T, 1977, SCAND J IMMUNOL, V6, P241, DOI 10.1111/j.1365-3083.1977.tb00390.x; BEPPU M, 1992, J BIOL CHEM, V267, P14691; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; EDBERG JC, 1988, J IMMUNOL, V141, P4258; ENDO T, 1990, BIOCHEMISTRY-US, V29, P9126, DOI 10.1021/bi00491a005; Fairbanks G, 1971, BIOCHEMISTRY-US, V10, P2607; FASLER S, 1988, ANAL BIOCHEM, V174, P593, DOI 10.1016/0003-2697(88)90061-9; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GEE AP, 1981, ANAL BIOCHEM, V116, P524, DOI 10.1016/0003-2697(81)90397-3; GUIGOU V, 1991, J IMMUNOL, V146, P1368; KAY MMB, 1992, J PROTEIN CHEM, V11, P595, DOI 10.1007/BF01024959; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; KAY MMB, 1981, NATURE, V289, P491, DOI 10.1038/289491a0; KAY MMB, 1990, GERONTOLOGY, V36, P293; KAY MMB, 1991, TRANSFUS MED REV, V3, P173; LUKACOVIC MF, 1981, BIOCHEMISTRY-US, V20, P3145, DOI 10.1021/bi00514a025; LUTZ H U, 1992, Transfusion Medicine Reviews, V6, P201, DOI 10.1016/S0887-7963(92)70170-9; LUTZ HU, 1988, BLOOD CELLS, V14, P175; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1981, SCHWEIZ MED WSCHR, V111, P1507; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUTZ HU, 1993, IMMUNOLOGY, V80, P191; LUTZ HU, 1984, J IMMUNOL, V133, P2610; Lutz HU, 1990, BLOOD CELL BIOCH, V1, P81; MCNEIL HP, 1990, CLIN EXP RHEUMATOL, V8, P525; MORGAN AC, 1982, CANCER RES, V42, P881; MUELLER H, 1983, Biochimica et Biophysica Acta, V729, P249; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OKADA N, 1983, IMMUNOLOGY, V50, P75; SANZ I, 1989, J IMMUNOL, V142, P4054; SCHENKEIN HA, 1981, J IMMUNOL, V126, P7; SCHLUTER K, 1986, P NATL ACAD SCI USA, V83, P6137, DOI 10.1073/pnas.83.16.6137; SCHWEIZER E, 1982, BIOCHEMISTRY-US, V21, P6807, DOI 10.1021/bi00269a029; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TURRINI F, 1991, J BIOL CHEM, V266, P23611; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WOOD PG, 1992, PROGR CELL RES, V2, P325	42	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23562	23566						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693690				2022-12-25	WOS:A1993MF51500092
J	GELMAN, IH; KHAN, S; HANAFUSA, H				GELMAN, IH; KHAN, S; HANAFUSA, H			MORPHOLOGICAL TRANSFORMATION, TUMORIGENICITY AND SRC-SPECIFIC CYTOTOXIC T-LYMPHOCYTE-MEDIATED TUMOR-IMMUNITY INDUCED BY MURINE 3T3 CELLS EXPRESSING SRC ONCOGENES ENCODING NOVEL NON-MYRISTYLATED N-TERMINAL DOMAINS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; ANTI-PHOSPHOTYROSINE ANTIBODIES; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; REJECTION ANTIGEN; FIBRO-SARCOMA; PROTEINS; PP60SRC; P60SRC; RECEPTOR	We previously reported the development of a src-specific tumor regression system in chickens in which preinfection with rASV1702, a mutant of Rous sarcoma virus (RSV) encoding non-myristylated src product with a novel N-terminal domain, results in the immune suppression of challenge tumors induced by RSV. In order to adapt this sytem to the mouse, we have developed NIH3T3 and Balb/c3T3 (B3T3) cell lines that express 1702src, v-src, c-src, and other src variants, either by transfection or by infection with packaged recombinant Moloney virus (MLV) vectors. The sequence of the 1702 src cDNA, produced by reverse transcription-polymerase chain reaction (RT-PCR), confirmed the previously suggested 1702src N-terminal domain structure, fusing six amino acids from Pr76gag and 39 amino acids of env signal peptide sequence to Ala-76 of src. These cell lines were characterized for src expression and activity, cell compartmentalization of src product, tyrosine phosphorylation substrate specificity and transforming and tumorigenic potential. Based on these parameters, murine cell lines expressing 1702src were characteristically similar to chicken embryo fibroblasts (CEFs) infected with rASV1702. Finally, B3T3/1702src expressors, or membrane fractions of these cells, induced src-specific tumor protection in syngeneic mice against v-src-transformed tumor challenges. Splenic lymphocytes isolated from Balb/c mice inoculated with B3T3/1702src cells showed in vitro cytotoxicity against B3T3/v-src cells but not against untransformed B3T3 cells. Antibodies specific for Lyt2, mouse CD3 and H-2D(d) blocked this cytotoxicity, whereas those specific for L3T4 did not, suggesting MHC class I-restricted, CD8-mediated cell killing. These data indicate that Balb/c3T3-expressed 1702src induces a cellular anti-tumor immunity based on src-specific tumor rejection antigens.	ROCKEFELLER UNIV,DEPT MOLEC ONCOL,NEW YORK,NY 10021	Rockefeller University	GELMAN, IH (corresponding author), MT SINAI MED CTR,DEPT MICROBIOL,BOX 1124,1 GUSTAVE L LEVY PLAZA,NEW YORK,NY 10029, USA.				NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; GARBER EA, 1983, NATURE, V302, P161, DOI 10.1038/302161a0; GARBER EA, 1987, P NATL ACAD SCI USA, V84, P80, DOI 10.1073/pnas.84.1.80; GELMAN IH, 1993, CANCER RES, V53, P915; GELMAN IH, 1986, J MOL BIOL, V191, P395, DOI 10.1016/0022-2836(86)90135-X; GELMAN IH, 1989, J VIROL, V63, P2461, DOI 10.1128/JVI.63.6.2461-2468.1989; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1987, ONCOGENES CANCER, P233; HORIO K, 1991, JPN J CANCER RES, V82, P676, DOI 10.1111/j.1349-7006.1991.tb01903.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KREUGER JG, 1982, CELL, V28, P889; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KUZUMAKI N, 1988, J NCI, V12, P959; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SHIMIZU J, 1991, J IMMUNOL, V146, P1708; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; SUDA T, 1989, JPN J CANCER RES, V80, P879, DOI 10.1111/j.1349-7006.1989.tb01730.x; SUDA T, 1988, JPN J CANCER RES, V79, P365, DOI 10.1111/j.1349-7006.1988.tb01600.x; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMITA Y, 1990, J IMMUNOL, V144, P2425; WANG LH, 1984, J VIROL, V49, P881, DOI 10.1128/JVI.49.3.881-891.1984; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	41	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2995	3004						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692370				2022-12-25	WOS:A1993MC09300013
J	MOYER, ML; BORROR, KC; BONA, BJ; DEFRANCO, DB; NORDEEN, SK				MOYER, ML; BORROR, KC; BONA, BJ; DEFRANCO, DB; NORDEEN, SK			MODULATION OF CELL SIGNALING PATHWAYS CAN ENHANCE OR IMPAIR GLUCOCORTICOID-INDUCED GENE-EXPRESSION WITHOUT ALTERING THE STATE OF RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; PHORBOL ESTER; CHLORAMPHENICOL ACETYLTRANSFERASE; IMMUNOAFFINITY PURIFICATION; PROGESTERONE-RECEPTOR; MONOCLONAL-ANTIBODIES; DNA-BINDING; C-JUN; TRANSCRIPTION; ELEMENT	We have stably introduced expression vectors for the glucocorticoid receptor and a sensitive, hormone-responsive reporter (mouse mammary tumor virus-luciferase) into a human breast carcinoma-derived cell line. Employing this cell line, we have conducted a detailed examination of the induction of glucocorticoid-regulated genes and the phosphorylation of glucocorticoid receptor following pharmacologic manipulation of cell signaling pathways. The hormone response can be enhanced from 2 to 10-fold by activators of protein kinase A, protein kinase C, and inhibitors of protein phosphatase. Forskolin and 8-bromoadenosine 3':5'-cyclic monophosphate (BrcAMP), but not BrcGMP, enhance the hormone effect, yet surprisingly, phosphodiesterase inhibitors, isobutylmethylxanthine and Ro20-1724, strongly inhibit hormone-mediated induction of the reporter gene. These treatments do not alter cellular receptor content, dexamethasone binding, nor hormone-mediated receptor down-regulation. Tryptic peptide analysis of P-32-labeled receptor reveals that neither BrcAMP, isobutylmethylxanthine, nor the tumor promoter and protein kinase C activator, 12-O-tetradecanoyl-phorbol-13-acetate, detectably alter the state of glucocorticoid receptor phosphorylation. The only agent which alters receptor phosphorylation is the protein phosphatase inhibitor okadaic acid, but only at concentrations higher than required for maximum effects on glucocorticoid receptor transactivation. We propose that these effectors do not modify receptor directly but alter its interaction with transcription complexes.	UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,BOX B216,4200 E 9TH AVE,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA043037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037061] Funding Source: NIH RePORTER; NCI NIH HHS [CA43037] Funding Source: Medline; NIDDK NIH HHS [DK37061] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONG Y, 1989, J BIOL CHEM, V264, P13679; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GROUL DJ, 1986, J BIOL CHEM, V261, P4909; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOGEAT F, 1985, BIOCHEMISTRY-US, V24, P1029, DOI 10.1021/bi00325a034; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHEPARD AR, 1992, BIOTECHNIQUES, V13, P702; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; SUGIMURA T, 1982, GANN, V73, P499; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; TOURAY M, 1991, ONCOGENE, V6, P1227; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	46	96	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22933	22940						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693681				2022-12-25	WOS:A1993MD34800108
J	GOLENBOCK, DT; LIU, YN; MILLHAM, FH; FREEMAN, MW; ZOELLER, RA				GOLENBOCK, DT; LIU, YN; MILLHAM, FH; FREEMAN, MW; ZOELLER, RA			SURFACE EXPRESSION OF HUMAN CD14 IN CHINESE-HAMSTER OVARY FIBROBLASTS IMPARTS MACROPHAGE-LIKE RESPONSIVENESS TO BACTERIAL-ENDOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; LIPOPOLYSACCHARIDE LPS; SCAVENGER RECEPTORS; BEARING PARTICLES; HUMAN MONOCYTES; CELL-LINE; RECOGNITION; ACCUMULATION; NEUTROPHILS; LIPOPROTEIN	Cardiovascular collapse associated with Gram-negative septicemia is believed to result from the stimulation of phagocytes by bacterial lipopolysaccharide (endotoxin, LPS). It remains unclear how endotoxin activates phagocytes, but recent evidence suggests the involvement of the glycosyl phosphatidylinositol-linked myelocyte antigen, CD14. We report that transfection of human CD14 into Chinese hamster ovary fibroblasts transfers macrophage-like responsiveness to otherwise LPS-unresponsive cells. These data demonstrate that LPS-induced responsiveness can be transferred to a heterologous non-responder cell type by expression of a single leukocyte-specific gene product.	BOSTON CITY HOSP,DEPT INTERNAL MED,DIV INFECT DIS,BOSTON,MA 02118; BOSTON CITY HOSP,DEPT SURG,CRIT CARE SECT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,LIPID METAB UNIT,BOSTON,MA 02114	Boston Medical Center; Boston Medical Center; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital				Zoeller, Raphael/0000-0002-6560-0993	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047127] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL45098] Funding Source: Medline; NIAID NIH HHS [P01-AI33087] Funding Source: Medline; NIGMS NIH HHS [R29GM47127] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battey, 1986, BASIC METHODS MOL BI; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COUTURIER C, 1991, J IMMUNOL, V147, P1899; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; KINGSTON RE, 1988, INTRO DNA MAMMALIAN, V1; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEI MG, 1991, J IMMUNOL, V147, P1925; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; LYNN WA, 1991, J IMMUNOL, V147, P3072; LYNN WA, 1992, UNPUB; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; Morrison D C, 1981, Contemp Top Mol Immunol, V8, P187; PARENT JB, 1990, J BIOL CHEM, V265, P3345; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RIETSCHEL ET, 1992, SCI AM, V267, P26; RIETVELD WJ, 1984, ANN REV CHRONOPHARMA, V1, P1; ROSENFELD ME, 1992, CURR OPIN LIPIDOL, V3, P318; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	36	128	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22055	22059						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691822				2022-12-25	WOS:A1993MC80900092
J	BARTFELD, NS; PASQUALE, EB; GELTOSKY, JE; LANGUINO, LR				BARTFELD, NS; PASQUALE, EB; GELTOSKY, JE; LANGUINO, LR			THE ALPHA-V-BETA-3 INTEGRIN ASSOCIATES WITH A 190-KDA PROTEIN THAT IS PHOSPHORYLATED ON TYROSINE IN RESPONSE TO PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; CELL-ADHESION; EMBRYO FIBROBLASTS; LAMININ RECEPTOR; KINASE-ACTIVITY; BETA-SUBUNIT; STEM-CELLS; PHOSPHOTYROSINE	Integrins are cell surface heterodimers that mediate cell adhesion to the extracellular matrix. We show that in mouse 3T3 fibroblasts the alpha(v)beta3 integrin (vitronectin receptor) coprecipitates with a tyrosine-phosphorylated 190-kDa protein, as detected by antibodies to phosphotyrosine. Three different antibodies to the vitronectin receptor, all of which precipitate the alpha/beta complex, coprecipitated a 190-kDa protein. The three antibodies were raised against the purified placental vitronectin receptor, the platelet alpha(IIb)beta3 integrin, and the cytoplasmic domain of the alpha(v) subunit. The association was specific for the vitronectin receptor, since an antibody to the alpha5beta1 integrin (fibronectin receptor) did not coprecipitate any tyrosine-phosphorylated protein. The phosphorylation of the 190-kDa protein was observed only following cell activation by platelet-derived growth factor, which is known to stimulate tyrosine kinase activity and to modulate cell adhesion. Antibodies raised against the platelet-derived growth factor alpha and beta receptors (M(r) = 170,000 and 190,000, respectively) did not recognize the 190-kDa, integrin-associated phosphorylated protein. Occupancy of the vitronectin receptor by one of its ligands, vitronectin, resulted in an increased amount of tyrosine phosphorylation of the 190-kDa protein. Our data suggest that the association of tyrosine-phosphorylated proteins with integrins may play an important role in growth factor-mediated modulation of cell adhesion.	RW JOHNSON PHARMACEUT RES INST, 3535 GEN ATOM CT, SUITE 100, SAN DIEGO, CA 92121 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute				Languino, Lucia/0000-0001-9011-7031				BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; COSSETTE LJ, 1992, MOL BIOL CELL, V3, pA147; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; FALCIONI R, 1989, MOL CARCINOGEN, V2, P361, DOI 10.1002/mc.2940020611; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PLOW EF, 1986, BIOCH PLATELETS, P226; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; [No title captured]	49	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17270	17276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688723				2022-12-25	WOS:A1993LQ98800060
J	KLATT, P; SCHMIDT, K; URAY, G; MAYER, B				KLATT, P; SCHMIDT, K; URAY, G; MAYER, B			MULTIPLE CATALYTIC FUNCTIONS OF BRAIN NITRIC-OXIDE SYNTHASE - BIOCHEMICAL-CHARACTERIZATION, COFACTOR-REQUIREMENT, AND THE ROLE OF N(G.W)-HYDROXY-L-ARGININE AS AN INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; HYDROXY-L-ARGININE; RELAXING FACTOR; MACROPHAGE OXIDATION; PORCINE CEREBELLUM; GUANYLYL CYCLASE; PURIFICATION; TETRAHYDROBIOPTERIN; BIOSYNTHESIS; NITRATE	Brain NO (nitric oxide) synthase contains FAD, FMN, heme, and tetrahydrobiopterin as prosthetic groups and represents a multi-functional oxidoreductase catalyzing oxidation of L-arginine to NO and L-citrulline, formation of H2O2, and reduction of cytochrome c. We show that substrate analogues and inhibitors interacting with the heme block both the reductive activation of oxygen and the oxidation of L-arginine without affecting cytochrome c reduction. We further demonstrate that N(omega)-hydroxy-L-arginine is an intermediate in enzymatic NO synthesis. The ratio of L-citrulline to free N(omega)-hydroxy-L-arginine was greater-than-or-equal-to 50 under various assay conditions, but could markedly be reduced down to 4 by redox active inhibitors. Brain NO synthase is shown to utilize both L-arginine and N(omega)-hydroxy-L-arginine for the formation of stoichiometric amounts of NO and L-citrulline. Tetrahydrobiopterin equally enhanced reaction rates from either substrate (approximately 5-fold), but its rate accelerating effects were only observed at NADPH concentrations greater-than-or-equal-to 3 muM. In the absence of L-arginine or tetrahydrobiopterin, brain NO synthase catalyzes the generation of H2O2. We now show that, in contrast to L-arginine, N(omega)-hydroxy-L-arginine fully blocked H2O2 formation in the absence of exogenous tetrahydrobiopterin, indicating that N(omega)-hydroxy-L-arginine is a direct inhibitor of enzymatic oxygen activation. Based on these data, a hypothetical mechanism of enzymatic NO formation is discussed.	GRAZ UNIV,INST PHARMACOL & TOXIKOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,INST ORGAN CHEM,A-8010 GRAZ,AUSTRIA	University of Graz; University of Graz			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P654; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KAUFMAN S, 1987, ENZYMES, P217; KLATT P, 1992, FEBS LETT, V305, P160, DOI 10.1016/0014-5793(92)80886-L; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LAMBERT LE, 1991, LIFE SCI, V48, P69, DOI 10.1016/0024-3205(91)90426-C; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1990, N-S ARCH PHARMACOL, V341, P143; MURPHY ME, 1991, J BIOL CHEM, V266, P19378; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V154, P213, DOI 10.1016/0014-2999(88)90101-X; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SUNDQVIST T, 1991, J CELL PHYSIOL, V148, P152, DOI 10.1002/jcp.1041480118; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; WALLACE GC, 1991, J MED CHEM, V34, P1746, DOI 10.1021/jm00109a032; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YUI Y, 1991, J BIOL CHEM, V266, P12544; ZEMBOWICZ A, 1991, P NATL ACAD SCI USA, V88, P11172, DOI 10.1073/pnas.88.24.11172	56	259	268	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14781	14787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686905				2022-12-25	WOS:A1993LL75900040
J	VITALE, N; MUKAI, H; ROUOT, B; THIERSE, D; AUNIS, D; BADER, MF				VITALE, N; MUKAI, H; ROUOT, B; THIERSE, D; AUNIS, D; BADER, MF			EXOCYTOSIS IN CHROMAFFIN CELLS - POSSIBLE INVOLVEMENT OF THE HETEROTRIMERIC GTP-BINDING PROTEIN-G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDES; WASP VENOM; MAST-CELLS; KINASE-C; CATECHOLAMINE RELEASE; ACTIN-FILAMENTS; SECRETORY-CELLS; PEPTIDE TOXIN; ALPHA-SUBUNIT; MASTOPARAN	The use of non-hydrolyzable analogues of GTP in permeabilized secretory cells suggests that guanine nucleotide-binding regulatory proteins (G proteins) may be involved in regulated exocytosis. Because GTP analogues are known to modulate both monomeric low molecular mass G proteins and heterotrimeric G proteins, we have examined the effect of mastoparan, an activator of heterotrimeric G proteins, on secretion from intact and permeabilized chromaffin cells. In intact cells, mastoparan inhibited catecholamine secretion evoked by nicotine but had no effect on release induced by other secretagogues. In permeabilized cells, mastoparan inhibited calcium-dependent secretion providing that the pores created in the plasma membrane allow the penetration of the peptide into the cytoplasm. These results indicate that mastoparan blocks the exocytotic machinery through an intracellular target protein that may not be located just beneath the plasma membrane. Accordingly, mastoparan was able to stimulate G proteins associated with purified chromaffin granule membranes, in a range of concentration and Mg2+ requirement that was similar to its inhibitory effect on secretion. Mas 17, a mastoparan analogue inactive on purified G proteins, neither modified catecholamine secretion nor stimulated chromaffin granule G proteins. The substance P-related peptide, GPAnt-2, known to antagonize the effects of mastoparan on G(o), blocked both the inhibitory effect of mastoparan on secretion and the mastoparan-stimulated GTPase activity in chromaffin granule membranes. Moreover, specific antibodies raised against the carboxyl terminus of G(oalpha) reversed in a dose-dependent manner the inhibition by mastoparan on catecholamine release and the stimulation by mastoparan of chromaffin granule-associated G proteins. These results suggest that the secretory machinery in chromaffin cells can be blocked by activating a G(o) protein. Consistent with this finding, two other known activators of heterotrimeric G proteins, aluminum fluoride and benzalkonium chloride, inhibited calcium-evoked catecholamine secretion in streptolysin O-permeabilized chromaffin cells. We conclude that an inhibitory G(o) protein, possibly located on the membrane of secretory granules, is involved in the final stages of exocytosis in chromaffin cells.	INSERM,U338,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE; UNIV MONTPELLIER 2,INSERM,U65,F-34095 MONTPELLIER 05,FRANCE; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Dominique, Aunis/W-1419-2019; Bader, Marie-France/O-2098-2016; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; ATHAYDE CM, 1990, BIOCHEM SOC T, V18, P452, DOI 10.1042/bst0180452; AUNIS D, 1988, J EXP BIOL, V139, P253; BADER MF, 1986, J BIOL CHEM, V261, P5777; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BADER MF, 1989, J BIOL CHEM, V264, P16426; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARNETTE MS, 1983, BIOCHEM PHARMACOL, V32, P2929, DOI 10.1016/0006-2952(83)90398-2; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BOKSA P, 1984, J NEUROCHEM, V42, P618, DOI 10.1111/j.1471-4159.1984.tb02727.x; BON S, 1990, EUR J BIOCHEM, V190, P221, DOI 10.1111/j.1432-1033.1990.tb15567.x; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BRUNING A, 1992, J BIOL CHEM, V267, P5052; BUEB JL, 1990, MOL PHARMACOL, V38, P816; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KNIGHT DE, 1985, FEBS LETT, V189, P345, DOI 10.1016/0014-5793(85)81053-X; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MUKAI H, 1987, AM J PHYSIOL, V252, pE765, DOI 10.1152/ajpendo.1987.252.6.E765; MUKAI H, 1992, J BIOL CHEM, V267, P16237; NEYLON CB, 1992, J BIOL CHEM, V267, P7295; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; OETTING M, 1986, FEBS LETT, V208, P99, DOI 10.1016/0014-5793(86)81540-X; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Sillen L.G., 1971, STABILITY CONSTANTS; SIMON JP, 1989, BIOCHEM J, V260, P915, DOI 10.1042/bj2600915; SONTAG JM, 1992, EUR J NEUROSCI, V4, P98, DOI 10.1111/j.1460-9568.1992.tb00112.x; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TOHKIN M, 1990, FEBS LETT, V260, P179, DOI 10.1016/0014-5793(90)80098-4; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WILSON SP, 1989, FEBS LETT, V247, P239, DOI 10.1016/0014-5793(89)81343-2; WU YN, 1992, J BIOL CHEM, V267, P8396; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4	63	128	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14715	14723						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686903				2022-12-25	WOS:A1993LL75900031
J	BRISTOW, J; GITELMAN, SE; TEE, MK; STAELS, B; MILLER, WL				BRISTOW, J; GITELMAN, SE; TEE, MK; STAELS, B; MILLER, WL			ABUNDANT ADRENAL-SPECIFIC TRANSCRIPTION OF THE HUMAN P450C21A PSEUDOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE GENES; MOLECULAR CHARACTERIZATION; POINT MUTATIONS; HYPERPLASIA; DEFICIENCY; FAMILY; HAPLOTYPES; CONVERSION; EVOLUTION; REARRANGEMENTS	Human adrenal steroid 21-hydroxylase (P450c21) is encoded by the CYP21A1 (21B) gene located in the class III region of the HLA locus. A tandemly duplicated gene designated CYP21A1P (21A), which lies 30 kilobases upstream, contains several point mutations and an 8-base pair deletion so that it cannot encode P450c21 protein; as a result, it is generally considered to be a pseudogene. We previously showed that two additional genes, XA and XB, lie on the opposite strand of DNA overlapping the 3'-ends of the 21A and 21B genes. We have now identified a third pair of duplicated overlapping genes in this locus, termed YA and YB, whose transcriptional orientation is the same as 21A and 21B and opposite to XA and XB. YA transcripts use the 21A promoter, have 5'-ends that are similar to 21B mRNA, and have approximately 10-20% of the abundance of 21B transcripts, but have unique 3'-ends. The YA gene encodes a 7.5-kilobase RNA that overlaps XA completely and a 3.0-kilobase RNA that excludes most of XA. The YB gene appears to be similar in size and organization to YA. The YA and YB genes extend beyond the limit of the duplication in this locus; hence, their cDNAs are distinguishable by differences in their 3'-sequences. YA and YB transcripts are expressed only in the fetal and adult adrenal glands, but their cDNAs do not contain a long open reading frame. Although the function of these genes is not yet clear, the complex genetic organization of three overlapping genes (21/X/Y) appears to be unique among higher eukaryotes. As YA transcription is initiated by the 21A 5'-flanking DNA and includes 21A sequences, the designation of 21A as a ''pseudogene'' merits reconsideration.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BRISTOW, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA.		Miller, Walter L/J-3696-2012; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, R01DK042154] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42154, T32-DK07171, DK-37922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; DONOHOUE PA, 1986, J CLIN ENDOCR METAB, V62, P995, DOI 10.1210/jcem-62-5-995; GILES CM, 1987, HUM GENET, V77, P359, DOI 10.1007/BF00291427; GITELMAN SE, 1990, PEDIATR RES, V27, pA76; GITELMAN SE, 1992, MOL CELL BIOL, V12, P2124, DOI 10.1128/MCB.12.5.2124; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HIGASHI Y, 1988, AM J HUM GENET, V42, P17; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HOOD L, 1975, ANNU REV GENET, V9, P305, DOI 10.1146/annurev.ge.09.120175.001513; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; MATTESON KJ, 1987, P NATL ACAD SCI USA, V84, P5858, DOI 10.1073/pnas.84.16.5858; McLean RH, 1988, GENOMICS, V2, P76, DOI 10.1016/0888-7543(88)90111-5; MELLON SH, 1989, J CLIN INVEST, V84, P1497, DOI 10.1172/JCI114325; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Morel Y, 1991, Adv Hum Genet, V20, P1; MOREL Y, 1989, J CLIN INVEST, V83, P527, DOI 10.1172/JCI113914; MOREL Y, 1989, J CLIN ENDOCR METAB, V68, P592, DOI 10.1210/jcem-68-3-592; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; PALSDOTTIR A, 1987, HUM GENET, V76, P220; PANG S, 1988, PEDIATRICS, V81, P866; RODRIGUES NR, 1987, EMBO J, V6, P1653, DOI 10.1002/j.1460-2075.1987.tb02414.x; SOLISH SB, 1989, J CLIN ENDOCR METAB, V69, P1148, DOI 10.1210/jcem-69-6-1148; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; XUN X, 1990, P NATL ACAD SCI USA, V87, P2097, DOI 10.1073/pnas.87.6.2097; YU CY, 1987, IMMUNOGENETICS, V25, P383	36	76	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12919	12924						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685353				2022-12-25	WOS:A1993LG65800099
J	FRIEDMAN, JE; YUN, JS; PATEL, YM; MCGRANE, MM; HANSON, RW				FRIEDMAN, JE; YUN, JS; PATEL, YM; MCGRANE, MM; HANSON, RW			GLUCOCORTICOIDS REGULATE THE INDUCTION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE-TRANSCRIPTION DURING DIABETES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; MESSENGER-RNA; CYCLIC-AMP; RAT-LIVER; MULTIHORMONAL REGULATION; PROMOTER ELEMENTS; TRANSGENIC MICE; GLUCOSE OUTPUT; INSULIN; CAMP	The hormonal regulation of transcription of the phosphoenolpyruvate carboxykinase (GTP) (4.1.1.32) (PEPCK) gene during diabetes was studied using transgenic mice containing a chimeric gene consisting of segments of the PEPCK promoter (-2000/+73, -460/+73, -355/+73) linked to bovine growth hormone (bGH) reporter gene. The effect of diabetes and insulin on transgenic mice containing a mutation in cAMP regulatory sequences at -90/-82 and -250/-234 was also studied. In addition, we analyzed the transcriptional response of the PEPCK gene to adrenalectomy, the administration of glucocorticoids, and alterations in dietary protein and carbohydrate. Our results indicate that deletion of the insulin regulatory sequence of the PEPCK promoter did not affect dietary control of PEPCK gene expression. However, glucocorticoids and the glucocorticoid regulatory unit appear to be essential for induction of PEPCK gene transcription by diabetes. By contrast, mutation of cAMP regulatory elements of the PEPCK promoter did not limit induction of PEPCK transcription by diabetes, nor did it affect negative regulation of transcription by insulin. These results provide evidence for the interaction of insulin and glucocorticoid regulatory elements in the control of PEPCK gene transcription and suggest an important role of glucocorticoids as a gluconeogenic activator during diabetes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45701	Case Western Reserve University; University System of Ohio; Ohio University	FRIEDMAN, JE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021859, F32DK008477, R37DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-F3208477, DK-21859, DK-2441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1987, DIABETES, V36, P274, DOI 10.2337/diabetes.36.3.274; BEALE EG, 1986, DIABETES, V35, P546, DOI 10.2337/diabetes.35.5.546; CHANG AY, 1970, DIABETOLOGIA, V6, P274, DOI 10.1007/BF01212238; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSOLI A, 1990, ANN MED, V22, P191, DOI 10.3109/07853899009147268; DEFRONZO R, 1982, DIABETOLOGIA, V23, P3113; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; EXTON JH, 1979, GLUCOCORTICOID HORMO, P517; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMANN N, 1967, BIOCHEM BIOPH RES CO, V29, P113, DOI 10.1016/0006-291X(67)90550-5; GIEBELHAUS DH, 1985, DEV BIOL, V107, P407, DOI 10.1016/0012-1606(85)90322-7; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GUNN JM, 1975, BIOCHEM J, V150, P195, DOI 10.1042/bj1500195; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HELMS SR, 1990, NUCLEIC ACIDS RES, V18, P255, DOI 10.1093/nar/18.2.255; HOD Y, 1988, J BIOL CHEM, V263, P7747; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; KUMARASIRI MH, 1985, J BIOL CHEM, V260, P4529; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; Long CNH, 1936, J EXP MED, V63, P465, DOI 10.1084/jem.63.4.465; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; NELSON K, 1980, J BIOL CHEM, V255, P8509; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PERET J, 1981, J NUTR, V111, P1173, DOI 10.1093/jn/111.7.1173; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASAKI K, 1988, P NATL ACAD SCI USA, V85, P2954, DOI 10.1073/pnas.85.9.2954; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHAFRIR E, 1988, FRONTIERS DIABETES R, P304; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; UNGER RH, 1970, J CLIN INVEST, V49, P837, DOI 10.1172/JCI106297; VENEZIALE CM, 1983, J BIOL CHEM, V257, P14257	45	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12952	12957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685354				2022-12-25	WOS:A1993LG65800104
J	KNUDSON, CM; STANG, KK; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP				KNUDSON, CM; STANG, KK; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP			PRIMARY STRUCTURE AND TOPOLOGICAL ANALYSIS OF A SKELETAL MUSCLE-SPECIFIC JUNCTIONAL SARCOPLASMIC-RETICULUM GLYCOPROTEIN (TRIADIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; H-3 RYANODINE RECEPTOR; CA-2+ RELEASE CHANNEL; AMINO-ACID SEQUENCE; DIHYDROPYRIDINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; MESSENGER-RNAS; FOOT PROTEIN; IDENTIFICATION; CALSEQUESTRIN	The primary amino acid sequence for a highly abundant junctional sarcoplasmic reticulum glycoprotein (triadin) has been deduced from the cDNA sequence. Based on both biochemical analysis and the predicted amino acid sequence we suggest that this protein is an intrinsic membrane glycoprotein containing a single transmembrane domain that separates the protein into cytoplasmic and luminal domains. The cytoplasmic domain is proposed to contain the amino-terminal 47 amino acids. The remainder of the protein including the carboxyl terminus is proposed to be found within the lumen of the sarcoplasmic reticulum and contains an extremely high concentration of basic residues. Protease analysis of intact triads was consistent with the topological predictions. Western and Northern blots suggest that the protein is specifically expressed in skeletal muscle and not cardiac muscle or brain. The abundance and localization of this protein suggest that it plays an important regulatory or structural role in excitation-contraction coupling in skeletal muscle.	UNIV IOWA, COLL MED, HHMI, DEPT PHYSIOL & BIOPHYS, 400A EMRB, IOWA CITY, IA 52242 USA; HOWARD HUGHES MED INST, BIOPOLYMER FACIL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute				Campbell, Kevin/0000-0003-2066-5889; Knudson, Charles Michael/0000-0003-3964-5466	NHLBI NIH HHS [HL39265, HL14388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039265] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1984, J BIOL CHEM, V259, P5384; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHADWICK CC, 1988, J BIOL CHEM, V263, P10872; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FILL M, 1989, ANN NY ACAD SCI, V560, P155, DOI 10.1111/j.1749-6632.1989.tb24092.x; FLIEGEL L, 1989, FEBS LETT, V242, P297, DOI 10.1016/0014-5793(89)80488-0; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1989, J BIOL CHEM, V264, P10795; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MITCHELL RD, 1983, J BIOL CHEM, V258, P9867; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SPIECKER W, 1979, NATURE, V280, P158, DOI 10.1038/280158a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG AS, 1983, METHOD ENZYMOL, V93, P12; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZAIDI NF, 1989, J BIOL CHEM, V264	39	128	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12646	12654						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685347				2022-12-25	WOS:A1993LG65800063
J	YAMAZAKI, T; TOBE, K; HOH, E; MAEMURA, K; KAIDA, T; KOMURO, I; TAMEMOTO, H; KADOWAKI, T; NAGAI, R; YAZAKI, Y				YAMAZAKI, T; TOBE, K; HOH, E; MAEMURA, K; KAIDA, T; KOMURO, I; TAMEMOTO, H; KADOWAKI, T; NAGAI, R; YAZAKI, Y			MECHANICAL LOADING ACTIVATES MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 PEPTIDE KINASE IN CULTURED RAT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LEFT-VENTRICULAR HYPERTROPHY; SERINE THREONINE KINASES; CELL-CYCLE CONTROL; MAP KINASE; PROGNOSTIC IMPLICATIONS; PHOSPHORYLATION SITES; HYPERTENSIVE PATIENTS; FIBROBLASTIC CELLS; PRESSURE OVERLOAD	The molecular mechanisms by which overloaded cardiac myocytes increase the cell size (hypertrophy) remain unknown. We have previously shown that mechanical loading increased the protein synthesis and the expression of proto-oncogene c-fos mRNA (Komuro, I., Kaida, T., Shibazaki, Y., Kurabayashi, M., Katoh, Y. Hoh, E., Takaku, F., and Yazaki, Y. (1990) J. Biol. Chem. 265, 3595-3598; Komuro, I., Katoh, Y., Kaida, T., Shibazaki, Y., Kurabayashi, M., Hoh, E., Takaku, F., and Yazaki, Y. (1991) J. Biol. Chem. 266, 1265-1268). It has been known that both mitogen-activated protein (MAP) kinase and S6 kinase can be activated by many kinds of growth factors. To clarify whether MAP kinase(s) and S6 kinase(s) are associated with the intracellular signaling of cardiac hypertrophy induced by mechanical loading, we cultured neonatal rat cardiac myocytes in deformable dishes and imposed an in vitro mechanical loading by stretching the adherent myocytes. In this study, we demonstrated that 1) myocyte stretching maximally activated a kinase activity toward myelin basic protein (MBP) at 10 min after stretching, and the kinase activity returned to the control level at 30 min after stretching; 2) kinase assays in MBP-containing gel, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, revealed that stretch-induced MBP kinase activity mainly migrated at 42 kDa in the immunoprecipitated fraction of anti-MAP kinase antibody, suggesting that the stretching mainly increased the 42-kDa MAP kinase activity in cardiac myocytes; 3) phosphorylation of MAP kinase was induced after stretching cardiac myocytes; 4) when protein kinase C was depleted by preincubating myocytes with 100 nm 12-O-tetradecanoyl-phorbol-13-acetate for 24 h or 2 nm staurosporin for 30 min, stretch-induced MBP kinase activity was decreased by approximately 60-70% as compared with the kinase activity in myocytes without protein kinase C depletion; 5) although the receptor tyrosine kinases were depleted by preincubating myocytes with 50 muM tyrphostin or 20 muM genistein for 30 min, there was no change in the stretch-induced MBP kinase activity; 6) stretch-induced MBP kinase activity was partially dependent on transsarcolemmal influx of Ca2+; 7) myocyte stretching also increased S6 peptide (RRLSSLRA) kinase activity in the anti-S6 kinase II antibody immunoprecipitates. From these results, we conclude that myocyte stretching increases the activities of MAP kinase and S6 peptide kinase, which may play an important role in the induction of the specific genes and the increase in the protein synthesis.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; AHN NG, 1990, J BIOL CHEM, V265, P11495; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anderson K, 1990, AM HEART J, V121, P293; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CODY RJ, 1978, CLIN SCI MOL MED, V55, P453, DOI 10.1042/cs0550453; DEVEREUX RB, 1987, MED CLIN N AM, V71, P813, DOI 10.1016/S0025-7125(16)30810-0; FAGARD R, 1980, AM J CARDIOL, V46, P295, DOI 10.1016/0002-9149(80)90074-0; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRADI AM, 1989, AM J CARDIOL, V63, P1093; GREGORY JS, 1989, J BIOL CHEM, V266, P22003; GUENNEC JYL, 1991, Q J EXP PHYSL, V76, P975; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P971; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASAKO H, 1992, EMBO J, V11, P2903; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KURABAYASHI M, 1990, J BIOL CHEM, V265, P19271; LAVIE CJ, 1991, DRUGS, V42, P945, DOI 10.2165/00003495-199142060-00004; LEENEN FHH, 1987, AM J MED, V82, P969, DOI 10.1016/0002-9343(87)90160-4; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LYALL RM, 1989, J BIOL CHEM, V264, P14503; NAGAI R, 1988, AM J PHYSIOL, V255, pH325, DOI 10.1152/ajpheart.1988.255.2.H325; NAKASHIMA Y, 1984, AM J CARDIOL, V53, P1044, DOI 10.1016/0002-9149(84)90634-9; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIGURDSON W, 1992, AM J PHYSIOL, V262, pH1110, DOI 10.1152/ajpheart.1992.262.4.H1110; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; TANAKA H, 1991, JPN CIRC J, V55, P1233, DOI 10.1253/jcj.55.1233; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VOGT PK, 1988, ONCOGENE, V3, P3; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; ZAK R, 1974, CIRC RES, V35, P17	65	257	260	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12069	12076						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685031				2022-12-25	WOS:A1993LF28400091
J	YOSHINO, H; WAKITA, M; IZUMI, Y				YOSHINO, H; WAKITA, M; IZUMI, Y			CALCIUM-DEPENDENT CHANGES IN STRUCTURE OF CALMODULIN WITH SUBSTANCE-P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; LIGHT-CHAIN KINASE; TROPONIN-C; CONFORMATIONAL CHANGE; SKELETAL-MUSCLE; BINDING DOMAIN; CENTRAL HELIX; MELITTIN; MASTOPARAN; PEPTIDES	Solution x-ray scattering using synchrotron radiation as an x-ray source has been used to study the solution structure of calmodulin complexed with substance P, a undecapeptide neurotransmitter. The x-ray data indicate that the complex has a compact globular structure, the formation of which is dependent upon, the binding of Ca2+ to calmodulin. In the Ca2+-saturated condition, the radius of gyration of complexed calmodulin was 4.2 angstrom smaller than that of uncomplexed calmodulin. The Ca2+-dependent change in radius of gyration of calmodulin with substance P is complete by the third and fourth Ca2+ binding. The behavior of the Guinier plot at small-to-moderate angles for uncomplexed calmodulin corresponds to a dumbbell shape. The Guinier plot for complexed calmodulin, however, corresponds to a non-dumbbell shape. The susceptibility of calmodulin to proteolytic attack with trypsin was used to examine the nature of the calmodulin complexed with substance P. In the presence of equimolar substance P, the first and second Ca2+ binding to calmodulin was enough to form a trypsin-resistant complex. These biochemical and x-ray data suggest that the binding of substance P to calmodulin is completed when the C-terminal half of calmodulin is occupied by Ca2+, while a significant structural change of calmodulin in the complex is still induced by successive Ca2+ occupancy on the N-terminal half of this molecule.	HOKKAIDO UNIV,FAC SCI,DEPT POLYMER SCI,SAPPORO,HOKKAIDO 060,JAPAN; YAMAGATA UNIV,FAC ENGN,MACROMOLEC RES LAB,YONEZAWA,YAMAGATA 992,JAPAN	Hokkaido University; Yamagata University	YOSHINO, H (corresponding author), SAPPORO MED COLL,DEPT CHEM,S-1,W-17,SAPPORO,HOKKAIDO 060,JAPAN.							BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; CADAY CG, 1986, BIOCHEM BIOPH RES CO, V135, P419, DOI 10.1016/0006-291X(86)90011-2; CHASSAING G, 1986, EUR J BIOCHEM, V154, P77, DOI 10.1111/j.1432-1033.1986.tb09361.x; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COX JA, 1985, J BIOL CHEM, V260, P2527; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; FUJISAWA T, 1987, J APPL CRYSTALLOGR, V20, P349, DOI 10.1107/S0021889887086497; GIEDROC DP, 1983, BIOCHEMISTRY-US, V22, P5584, DOI 10.1021/bi00293a020; Guinier A., 1955, SMALL ANGLE SCATTERI; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INAGAKI F, 1989, BIOCHEMISTRY-US, V28, P5985, DOI 10.1021/bi00440a040; IZUMI Y, 1992, BIOCHEMISTRY-US, V31, P12266, DOI 10.1021/bi00163a041; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MALENCIK DA, 1983, BIOCHEMISTRY-US, V22, P1995, DOI 10.1021/bi00277a040; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MINOWA O, 1988, J BIOCHEM-TOKYO, V103, P531, DOI 10.1093/oxfordjournals.jbchem.a122303; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; RAO U, 1992, PROTEINS, V14, P127, DOI 10.1002/prot.340140202; SASAKI T, 1992, J BIOL CHEM, V267, P21518; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SEATON BA, 1985, BIOCHEMISTRY-US, V24, P6740, DOI 10.1021/bi00345a002; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; TREWHELLA J, 1992, CELL CALCIUM, V13, P377, DOI 10.1016/0143-4160(92)90051-S; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; WALSH M, 1977, J BIOL CHEM, V252, P7440; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; YOSHINO H, 1989, J BIOL CHEM, V264, P19706	45	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12123	12128						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685032				2022-12-25	WOS:A1993LF28400098
J	CARPENTER, CL; AUGER, KR; CHANUDHURI, M; YOAKIM, M; SCHAFFHAUSEN, B; SHOELSON, S; CANTLEY, LC				CARPENTER, CL; AUGER, KR; CHANUDHURI, M; YOAKIM, M; SCHAFFHAUSEN, B; SHOELSON, S; CANTLEY, LC			PHOSPHOINOSITIDE 3-KINASE IS ACTIVATED BY PHOSPHOPEPTIDES THAT BIND TO THE SH2 DOMAINS OF THE 85-KDA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; RECEPTOR TYROSINE KINASES; FACTOR-I RECEPTOR; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PHOSPHORYLATION; POLYOMAVIRUS; TRANSFORMATION; PROTEIN	Tyrosine-phosphorylated peptides based on the regions of polyoma virus middle t antigen and the platelet-derived growth factor receptor that bind phosphoinositide 3-kinase are shown to activate this enzyme 2-3-fold in vitro. The concentrations of the peptides required to activate the enzyme are at least 10-1000-fold higher than the dissociation constants of these peptides for the individual SH2 domains of the 85-kDa subunit (K(D) < 100 nM). Doubly phosphorylated peptides are more effective than singly phosphorylated peptides. The results suggest that a fraction of the cellular phosphoinositide 3-kinase has SH2 domains with relatively low affinity for phosphopeptides and that binding of phosphopeptides to these enzymes causes activation. Thus, SH2 domains may be involved not only in recruiting the enzyme but also in regulating activity.	BETH ISRAEL HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA 34722, R01 CA034722] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM 36624, GM 41890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034722, R01CA034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890, R01GM036624] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN BS, 1985, VIROLOGY, V143, P671, DOI 10.1016/0042-6822(85)90410-6; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	331	343	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9478	9483						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683653				2022-12-25	WOS:A1993LA68900051
J	ARMSTRONG, SA; HANNAH, VC; GOLDSTEIN, JL; BROWN, MS				ARMSTRONG, SA; HANNAH, VC; GOLDSTEIN, JL; BROWN, MS			CAAX GERANYLGERANYL TRANSFERASE TRANSFERS FARNESYL AS EFFICIENTLY AS GERANYLGERANYL TO RHOB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN GERANYLGERANYLTRANSFERASE; CDNA CLONING; PEPTIDE-BINDING; ALPHA-SUBUNIT; BETA-SUBUNIT; COMPONENT-A; RAT-BRAIN; FARNESYLTRANSFERASE; PRENYLATION; CHOROIDEREMIA	RhoB, a small GTP-binding protein, was shown previously to contain farnesyl (C-15) as well as geranylgeranyl (C-20) groups (Adamson, P., Marshall, C. J., Hall, A. and Tilbrook, P. A. (1992) J. Biol. Chem. 267, 20033-20038). The COOH-terminal sequence of the protein is CCKVL. According to current rules of prenylation, the COOH-terminal leucine should render the protein a substrate for CAAX geranylgeranyl transferase (GGTase-1), but not for CAAX farnesyltransferase (FTase). To determine the mechanism of farnesylation, we prepared recombinant RhoB and incubated it with recombinant preparations of either FTase or GGTase-1. RhoB was neither farnesylated nor geranylgeranylated efficiently by FTase, but it was farnesylated as well as geranylgeranylated by GGTase-1. The enzyme attached farnesyl more efficiently than geranylgeranyl to RhoB. Neither farnesylation nor geranylgeranylation required the cysteine at the fifth position from the COOH terminus. However, replacement of the cysteine at the fourth position abolished attachment of both prenyl groups. We conclude that the previously observed farnesylation of RhoB is attributable to the FTase activity of GGTase-1. These data, and other accumulating data, indicate that GGTase-1 is a highly unusual enzyme that efficiently transfers both farnesyl and geranylgeranyl groups and that the choice of prenyl group is dictated by the nature of the protein acceptor.			ARMSTRONG, SA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V268, P27705; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	27	148	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7864	7868		10.1074/jbc.270.14.7864	http://dx.doi.org/10.1074/jbc.270.14.7864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713879	hybrid			2022-12-25	WOS:A1995QR52600015
J	TANG, PM; FOLTZ, LA; MAHONEY, WC; SCHUELER, PA				TANG, PM; FOLTZ, LA; MAHONEY, WC; SCHUELER, PA			A HIGH-AFFINITY DIGOXIN-BINDING PROTEIN DISPLAYED ON M13 IS FUNCTIONALLY IDENTICAL TO THE NATIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; MONOVALENT PHAGE DISPLAY; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; FILAMENTOUS PHAGE; CROSS-REACTIVITY; EXPRESSION; ANTIGEN; SITE; FV	Phage display of peptides and proteins has successfully been employed to produce binding molecules of altered affinity. Little is known, however, regarding the impact on affinity measurements of phage-displayed molecules compared to their native freely soluble configuration. That identical affinities can be obtained was shown by Scatchard analysis of the native antibody, its single chain derivative (scFv), and its phage-displayed single chain counterpart for the ligand digoxin. No significant difference, within one standard deviation, was detected in affinity for digoxin when the phage-displayed scFv was compared to either its soluble scFv form or the purified antibody. In addition, no change in binding specificity was detected, within two standard deviations, when the binding proteins were challenged with two commonly cross-reactive compounds (dihydrodigoxin and digitoxin). That phage-display can be employed for molecules having high binding affinities (K-d of 6 x 10(-11) M) is also known.	BOEHRINGER MANNHEIM CORP, RES & DEV, MOLEC DIAGNOST, INDIANAPOLIS, IN 46250 USA									ANTHONY J, 1992, MOL IMMUNOL, V29, P1237, DOI 10.1016/0161-5890(92)90060-B; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; COREY DR, 1993, GENE, V128, P129; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DJOJONEGORO BM, 1994, BIO-TECHNOL, V12, P169, DOI 10.1038/nbt0294-169; GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373; GO K, 1980, ACTA CRYSTALLOGR B, V36, P1811, DOI 10.1107/S0567740880007297; HECHEMY K, 1984, LAB MANAGE, V6, P27; HECHEMY K, 1984, LAB MANAGE, V7, P26; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; IBRAHIM S, 1993, SCAND J IMMUNOL, V37, P257, DOI 10.1111/j.1365-3083.1993.tb01764.x; KABAT EA, 1966, J IMMUNOL, V97, P1; Kabat EA, 1991, SEQUENCES PROTEINS I; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MALBY RL, 1993, PROTEINS, V16, P57, DOI 10.1002/prot.340160107; MARKS JD, 1992, J BIOL CHEM, V267, P16007; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MICELI RM, 1994, FASEB J, V8, pA1408; MILLER JJ, 1992, J CLIN IMMUNOASSAY, V15, P97; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; Rodbard D, 1973, P SER, V1, P165; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE P, 1993, BRIT J CANCER, V68, P738, DOI 10.1038/bjc.1993.420; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEPPALA I, 1990, J IMMUNOL, V145, P2989; SMITH GP, 1991, CURR OPIN BIOTECH, V2, P665; SWIMMER C, 1992, P NATL ACAD SCI USA, V89, P3756, DOI 10.1073/pnas.89.9.3756; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	42	6	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7829	7835		10.1074/jbc.270.14.7829	http://dx.doi.org/10.1074/jbc.270.14.7829			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713873	hybrid			2022-12-25	WOS:A1995QR52600009
J	KRAUT, N; FRAMPTON, J; GRAF, T				KRAUT, N; FRAMPTON, J; GRAF, T			REM-1, A PUTATIVE DIRECT TARGET GENE OF THE MYB-ETS FUSION ONCOPROTEIN IN HEMATOPOIETIC PROGENITORS, IS A MEMBER OF THE RECOVERIN FAMILY	ONCOGENE			English	Article						RETROVIRUS E26; ACUTE AVIAN LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELLS; V-ETS; TARGET GENE	CALCIUM-BINDING PROTEIN; CHICKEN ERYTHROID-CELLS; V-MYB; TRANSCRIPTION FACTORS; MYELOMONOCYTIC CELLS; MOLECULAR-CLONING; NERVOUS-SYSTEM; C-ETS-1 LOCUS; ONCOGENE; DIFFERENTIATION	The Myb-Ets oncoprotein encoded by the E26 avian leukaemia virus represents a fusion of two transcription factors which cooperate in transforming multipotent haematopoietic progenitors (MEPs) in vitro and in vivo, Previous studies with a temperature sensitive mutant in ets (ts1.1 E26) have suggested that the Ets part of the Myb-Ets fusion protein blocks multilineage differentiation of transformed MEPs, by regulating specific target genes, Using this system in a differential screening approach we have now identified a new gene, called rem-1, as a target for the E26 virus, Following shift of ts1.1 mutant transformed cells to the nonpermissive temperature a decreased expression of rem-1 was observed which increased upon downshift, The finding that this reexpression did not require new protein synthesis suggests that the Ets component of the fusion protein directly regulates rem-1 transcription, Rem-1 is related to a family of EF-hand-containing calcium-binding proteins that are predominantly expressed in the brain and in retinal cells, This family includes recoverin and visinin, proteins that have been implicated in regulating photoreception, Rem-1 is likewise expressed in these tissues but in addition in haematopoietic cells and in the gut, Enforced expression of rem-1 in ts1.1-transformed MEP cells, using a retroviral vector, showed that this gene is not sufficient to block their differentiation, but that it may provide them with a growth advantage.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSL S, V1, P195; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; QUEVA C, 1993, ONCOGENE, V8, P2511; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; STOKER AW, 1992, MOL VIROLOGY PRACTIC; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YAMAGATA K, 1990, NEURON, V2, P469; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1027	1036						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700627				2022-12-25	WOS:A1995QN35300001
J	COOPERMAN, BS; STAVRIDI, E; NICKBARG, E; RESCORLA, E; SCHECHTER, NM; RUBIN, H				COOPERMAN, BS; STAVRIDI, E; NICKBARG, E; RESCORLA, E; SCHECHTER, NM; RUBIN, H			ANTICHYMOTRYPSIN INTERACTION WITH CHYMOTRYPSIN - PARTITIONING OF THE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; REACTIVE SITE; NEUTROPHIL SUPEROXIDE; CRYSTAL-STRUCTURE; PORCINE TRYPSIN; CATHEPSIN-G; SERPINS	The interactions of bovine pancreatic chymotrypsin (Chtr) and recombinant alpha1-antichymotrypsin (rACT) and rACT variants were studied by kinetic and gel electrophoretic analyses, leading to the formulation of a general kinetic scheme that accounts for all known results concerning this serpin-protease pair, as well as for results obtained with other such pairs. Incubation of rACT and Chtr leads rapidly to the formation-of an inhibited complex, Chtr.rACT*, that is stable toward sodium dodecyl sulfate denaturation and boiling. The extent of release of active Chtr from this complex increases markedly as ionic strength, mu, is raised. The kinetic scheme quantitatively accounts for this effect on the basis of a partitioning of Chtr.rACT* between dissociation of the complex to yield active enzyme and cleaved rACT, and Chtr.catalyzed conversion of the complex to a form that is much more resistant to release of active enzyme. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses of reaction mixtures of rACT and Chtr are consistent with the scheme. Also consistent are the results of experiments measuring the effects of 1) Chtr.rACT* concentration, 2) uncomplexed Chtr, and 3) added alpha2-Macroglobulin on active Chtr release from Chtr.rACT*. Proteolysis of Chtr.rACT* to give a resistant complex is also catalyzed by human neutrophil elastase, a process with potential physiological relevance. Comparison of the rates of Chtr dissociation from the complexes formed with rACT and with rACT variants mutated at the P1 site suggests that such rates are more sensitive to P1 substitution at low mu than at high mu. Several equivalents of the L358R-rACT variant are required for full inhibition of Chtr. This observation is also quantitatively accounted for by the proposed kinetic scheme, on the basis of another partitioning step between L358R-rACT acting as a substrate or as an inhibitor toward Chtr.	UNIV PENN,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	COOPERMAN, BS (corresponding author), UNIV PENN,SCH ARTS & SCI,DEPT CHEM,CHEM BLDG,PHILADELPHIA,PA 19104, USA.				NIA NIH HHS [AG-10599] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BJORK I, 1982, J BIOL CHEM, V257, P9487; BOSWELL DR, 1985, BIOCHEM EDUC, V13, P98; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KASAFIREK E, 1976, EUR J BIOCHEM, V69, P1, DOI 10.1111/j.1432-1033.1976.tb10852.x; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KNOLLER S, 1991, THROMB RES, V63, P203, DOI 10.1016/0049-3848(91)90284-4; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE A, 1984, EUR J BIOCHEM, V140, P105, DOI 10.1111/j.1432-1033.1984.tb08072.x; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MORII M, 1983, J BIOL CHEM, V258, P2749; ODA K, 1977, BIOCHEM BIOPH RES CO, V76, P1062, DOI 10.1016/0006-291X(77)90964-0; OLSON ST, 1985, J BIOL CHEM, V260, P153; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; PRATT CW, 1990, J BIOL CHEM, V265, P6092; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Sambrook J, 1989, MOL CLONING LABORATO; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHUSTER MG, 1992, J BIOL CHEM, V267, P5056; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; WIMAN B, 1979, J BIOL CHEM, V254, P9291	39	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23616	23625						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693693				2022-12-25	WOS:A1993MF51500100
J	KIRKEN, RA; RUI, H; EVANS, GA; FARRAR, WL				KIRKEN, RA; RUI, H; EVANS, GA; FARRAR, WL			CHARACTERIZATION OF AN INTERLEUKIN-2 (IL-2)-INDUCED TYROSINE-PHOSPHORYLATED 116-KDA PROTEIN ASSOCIATED WITH THE IL-2 RECEPTOR BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; KINASE ACTIVATION; GAMMA-CHAIN; CELL-LINE; PROLACTIN RECEPTOR; GENE FAMILY; T-CELLS	In this paper we have extended previous results on interleukin-2 receptor (IL2-R) signal transduction and focused on the interleukin-2 (IL-2)-stimulated tyrosine phosphorylation of a 116-kDa protein (p116) observed in IL-2 responsive cells. This protein exhibited rapid and transient phosphorylation kinetics in both human T-lymphocytes and the YT cell line, attaining maximum tyrosine phosphorylation within 5 min of stimulation with IL-2. Tyrosine phosphorylated p116 co-purified with activated IL-2 receptor beta-chain (IL2-Rbeta) when IL2-R complexes were covalently stabilized with the membrane-permeable cleavable cross-linking agent dithiobis(succimidyl propionate) prior to detergent cell lysis and immunoprecipitation with monoclonal anti-IL2-Rbeta antibodies. Under these conditions comparable amounts of tyrosine-phosphorylated p116 were immuno-precipitated with either anti-IL2-Rbeta antibodies or antiphosphotyrosine antibodies, suggesting that a major portion of tyrosine phosphorylated p116 is associated with the IL2-Rbeta subunit. Furthermore, unphosphorylated p116 was also associated with unactivated IL2-Rbeta, based on the observation that p116 from unstimulated YT cells underwent tyrosine phosphorylation in IL2-Rbeta immune-complex tyrosine kinase assay as demonstrated by anti-phosphotyrosine immunoblotting. The presence of tyrosine kinase activity in affinity-purified IL2-Rbeta complexes supports the notion of a preformed receptor-kinase complex. The co-association of both p116 and tyrosine kinase activity with the IL2-Rbeta supports the critical role of the beta-chain in IL2-R signal transduction and suggests that p116 may have a role in the dynamics of IL2-R activation.	NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,CYTOKINE MECHANISM SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EINSPAHR KJ, 1992, J LEUKOCYTE BIOL, V52, P565, DOI 10.1002/jlb.52.5.565; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS GA, 1993, IN PRESS BIOCH J; FARRAR W L, 1990, Cytokine, V2, P77, DOI 10.1016/1043-4666(90)90001-A; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FERRIS DK, 1989, J IMMUNOL, V143, P870; FOXWELL BMJ, 1992, CLIN EXP IMMUNOL, V90, P161; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUNG MR, 1991, J IMMUNOL, V147, P1253; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; IZQUIERDO M, 1992, EUR J IMMUNOL, V22, P817, DOI 10.1002/eji.1830220328; KOGA Y, 1988, CANCER RES, V48, P856; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; ROBB RJ, 1987, P NATL ACAD SCI USA, V84, P2002, DOI 10.1073/pnas.84.7.2002; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1993, J CELL BIOL S B, V17, P118; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SHARON M, 1989, J IMMUNOL, V143, P2530; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STRED SE, 1990, ENDOCRINOLOGY, V127, P2505; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TORIGOE T, 1992, CYTOKINE, V4, P369, DOI 10.1016/1043-4666(92)90080-B; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; YAMASAKI K, 1988, SCIENCE, V241, P852; YODOI J, 1985, J IMMUNOL, V134, P1623	56	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22765	22770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693677				2022-12-25	WOS:A1993MD34800084
J	YARWOOD, NJ; GURR, JA; SHEPPARD, MC; FRANKLYN, JA				YARWOOD, NJ; GURR, JA; SHEPPARD, MC; FRANKLYN, JA			ESTRADIOL MODULATES THYROID-HORMONE REGULATION OF THE HUMAN GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RESPONSIVE ELEMENT; ANTERIOR-PITUITARY CELLS; GROWTH-HORMONE; LUTEINIZING-HORMONE; RECEPTOR BINDS; STIMULATING-HORMONE; NEGATIVE REGULATION; MOLECULAR-BIOLOGY; PROLACTIN GENE; THYROTROPIN	We have examined mechanisms of regulation of the human glycoprotein hormone alpha subunit gene by thyroid hormone (T3) and estradiol. Pituitary-derived GH3 cells were transiently transfected with chimeric constructs comprising between 1,500 and 98 base pairs of human alpha subunit gene 5'-flanking sequence fused to the bacterial gene encoding chloramphenicol acetyltransferase (halphaCAT) and treated with T3 and estradiol, alone and in combination. In pituitary cells, 98 base pairs of alpha gene 5'-flanking sequence were sufficient to mediate both inhibition of alpha gene promoter activity by T3 and stimulation by estradiol; inhibition of the alpha promoter by T3 was antagonized by estradiol. Mutation of nucleotides essential for T3 receptor binding to the alpha gene thyroid hormone response element abolished the response of halphaCAT expression to estradiol as well as T3. In contrast to pituitary GH3 cells, estradiol treatment alone had no effect on expression of either halphaCAT or the endogenous alpha gene in JEG-3 choriocarcinoma cells cotransfected with a human thyroid hormone receptor expression vector, but estradiol antagonized suppression of both endogenous and transfected alpha promoter activity by T3. Gel mobility shift assays demonstrated specific binding of in vitro synthesized human estrogen receptor (ER) to the alpha gene thyroid hormone response element. These findings suggest that estradiol modulates expression of the human alpha subunit gene in pituitary and choriocarcinoma cells by direct binding of ER to the alpha gene promoter, and that interaction of ER with the alpha gene negative TRE accounts for the antagonistic effects of estradiol and T3.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	University of Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ausubel F.M., 1987, CURRENT PROTOCOLS MO, P241; BALFOUR NJ, 1990, J MOL ENDOCRINOL, V4, P187, DOI 10.1677/jme.0.0040187; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FRANKLYN JA, 1987, ENDOCRINOLOGY, V120, P2279, DOI 10.1210/endo-120-6-2279; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; GURR JA, 1983, J BIOL CHEM, V258, P208; GURR JA, 1989, DNA-J MOLEC CELL BIO, V8, P473, DOI 10.1089/dna.1.1989.8.473; GURR JA, 1985, DNA-J MOLEC CELL BIO, V4, P301, DOI 10.1089/dna.1985.4.301; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; KAMEL F, 1987, ENDOCRINOLOGY, V120, P1651, DOI 10.1210/endo-120-4-1651; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERI RA, 1991, MOL ENDOCRINOL, V5, P725, DOI 10.1210/mend-5-5-725; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KNOBIL E, 1981, RECENT PROG HORM RES, V36, P703; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; PHILLIPS CL, 1988, MOL ENDOCRINOL, V2, P641, DOI 10.1210/mend-2-7-641; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAADE G, 1989, ENDOCRINOLOGY, V124, P1744, DOI 10.1210/endo-124-4-1744; SAMBROOK J, 1982, MOL CLONING LABORATO, P21; SAMUELS HH, 1979, BIOCHEMISTRY-US, V18, P715, DOI 10.1021/bi00571a025; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SHUPNIK MA, 1985, ENDOCRINOLOGY, V117, P1940, DOI 10.1210/endo-117-5-1940; SHUPNIK MA, 1983, J BIOL CHEM, V258, P5120; SHUPNIK MA, 1989, ENDOCR REV, V10, P459, DOI 10.1210/edrv-10-4-459; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; SHUPNIK MA, 1989, MOL ENDOCRINOL, V3, P474, DOI 10.1210/mend-3-3-474; SHUPNIK MA, 1987, ENDOCRINOLOGY, V121, P619, DOI 10.1210/endo-121-2-619; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636	50	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21984	21989						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691820				2022-12-25	WOS:A1993MC80900082
J	FERNANDEZ, JA; HEEB, MJ; GRIFFIN, JH				FERNANDEZ, JA; HEEB, MJ; GRIFFIN, JH			IDENTIFICATION OF RESIDUES 413-433 OF PLASMA PROTEIN-S AS ESSENTIAL FOR BINDING TO C4B-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIII; COFACTOR ACTIVITY; DEFICIENCY; INACTIVATION; THROMBOSIS; SEQUENCE; ARTERIAL; REGIONS; BOVINE; CELLS	Reversible association of protein S with C4b-binding protein (C4BP) in plasma down-regulates protein S activity, since free protein S but not the protein S.C4BP complex is an anticoagulant cofactor for activated protein C. To identify regions on the surface of protein S that mediate complex formation with C4BP, a number of nonoverlapping synthetic pentadecapeptides comprising protein S sequences were prepared and tested for their ability to inhibit complex formation. The most potent pentadecapeptide, residues 420-434 (PSP-420) (SGIKEIIQEKQNKHC), gave half-maximal effect at 20 muM. A peptide with the reverse sequence, 434-420, did not inhibit. A peptide containing the sequence of protein S residues 408-434 inhibited complex formation by >95% with 50% inhibition at 5 muM peptide. Biotinylated C4BP bound specifically to plates coated with PSP-420 but not with the 434-420 peptide; and biotinylated PSP-420 bound to plates coated with C4BP. Rabbit antibodies were raised against several keyhole limpet hemocyanin-conjugated peptides, and each was tested for ability to inhibit complex formation. Anti-PSP-420 antibody potently inhibited complex formation with half-maximal effect at 25 nM IgG. A monoclonal antibody (LJ-56) made against PSP-420 showed high affinity for protein S and inhibited complex formation; this monoclonal antibody specifically recognized free protein S but not the protein S.C4BP complex. These results imply that the PSP-420 sequence is surface-exposed, capable of binding to C4BP, and essential for protein S binding to C4BP.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, BCR-5, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROEKMANS AW, 1985, THROMB HAEMOSTASIS, V53, P273; BROWN JP, 1980, J BIOL CHEM, V255, P4980; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHANG GTG, 1992, THROMB HAEMOSTASIS, V67, P526; CHANG GTG, 1991, BLOOD, V78, P277; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FERNANDEZ JA, 1992, CIRCULATION, V86, P814; FERNANDEZ JA, 1991, THROMB HAEMOSTASIS, V65, P711; GARDINER JE, 1984, CIRCULATION, V70, P205; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; GREENGARD JS, 1992, BLOOD, V80, P266; GRIFFIN JH, 1992, BLOOD, V79, P3203; GRIFFIN JH, 1993, IN PRESS THROMB HAEM; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KIRSCHENBAUM DM, 1973, ANAL BIOCHEM, V56, P237, DOI 10.1016/0003-2697(73)90186-3; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LAURELL CB, 1965, ANAL BIOCHEM, V10, P358, DOI 10.1016/0003-2697(65)90278-2; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANNUCCI PM, 1986, THROMB HAEMOSTASIS, V55, P440; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MILLER M, 1992, CIRCULATION, V86, P674; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; NELSON RM, 1992, J BIOL CHEM, V267, P8140; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1986, THROMB HAEMOSTASIS, V56, P382; SCHWARZ HP, 1989, BLOOD, V74, P213; SIE P, 1989, THROMB HAEMOSTASIS, V62, P1040; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926	38	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16788	16794						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688369				2022-12-25	WOS:A1993LQ33600099
J	MIGLIACCIO, A; PAGANO, M; AURICCHIO, F				MIGLIACCIO, A; PAGANO, M; AURICCHIO, F			IMMEDIATE AND TRANSIENT STIMULATION OF PROTEIN-TYROSINE PHOSPHORYLATION BY ESTRADIOL IN MCF-7 CELLS	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; PHOSPHOTYROSINE-CONTAINING PROTEINS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; ESTROGEN-RECEPTOR; HORMONE BINDING; OWN RECEPTOR; STEROID-HORMONES; CELLULAR PROTEIN; ONCOGENE PRODUCT	Estradiol stimulates protein phosphorylation on tyrosine in human breast cancer MCF-7 cells under conditions of estradiol-stimulated cell growth. The stimulatory effect of estradiol has been observed by P-32-labeling of cells followed by purification of proteins using antiphosphotyrosine antibody coupled to agarose and confirmed by immunoblotting analysis with antiphosphotyrosine antibody. This stimulation is immediate (maximal in 10 s) and transient. In addition, it is receptor-mediated since estradiol stimulation is prevented by two well-known antiestrogens, OH-Tamoxifen and ICI 164 384. Estradiol fails to stimulate tyrosine protein phosphorylation of Cos cells which do not express the estradiol receptor. Two substrates of the estrogen stimulated phosphorylation on tyrosine with approximate mol wt of 55 and 60 kDa interact with a polyclonal antibody raised against amino acids 527-533 of pp60c-src (anti-cst.1 antibody). Tyrosine kinase activity of immunoprecipitates made using either anti cst.1 antibody or the monoclonal 327 antibody specific for pp60c-src shows that kinase(s) strongly related to pp60c-src are immediately and transiently stimulated by estradiol treatment of cells. The present findings provide the first demonstration that a steroid hormone rapidly stimulates tyrosine phosphorylation of target cells and induces functional modifications of substrates of this phosphorylation. These modifications might initiate the estradiol action on cell growth.	UNIV NAPOLI 2, FAC MED & CHIRURG,IST PATOL GEN & ONCOL, CATTEDRA PATOL GEN 2,VIA S ANDREA DAME 2, I-80138 NAPLES, ITALY	Universita della Campania Vanvitelli			Migliaccio, Antimo/AAB-3376-2019	Migliaccio, Antimo/0000-0002-4197-2055				AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; AURICCHIO F, 1987, EMBO J, V6, P2923, DOI 10.1002/j.1460-2075.1987.tb02596.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BISWAS R, 1987, CANCER RES, V47, P3509; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, PEPTIDES PROTEIN PHO; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; EK B, 1982, J BIOL CHEM, V257, P486; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MULDOON TG, 1988, J STEROID BIOCHEM, V30, P23, DOI 10.1016/0022-4731(88)90072-6; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARIKH I, 1980, J BIOL CHEM, V255, P266; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PRATT WB, 1988, J BIOL CHEM, V263, P267; REDDY KB, 1992, CANCER RES, V52, P3636; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; STERN DF, 1991, METHOD ENZYMOL, V198, P494; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WONG TW, 1984, J BIOL CHEM, V259, P8505; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1983, J BIOL CHEM, V258, P3431	52	114	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2183	2191						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687761				2022-12-25	WOS:A1993LP17100019
J	ZAKUT, R; PERLIS, R; ELIYAHU, S; YARDEN, Y; GIVOL, D; LYMAN, SD; HALABAN, R				ZAKUT, R; PERLIS, R; ELIYAHU, S; YARDEN, Y; GIVOL, D; LYMAN, SD; HALABAN, R			KIT-LIGAND (MAST-CELL GROWTH-FACTOR) INHIBITS THE GROWTH OF KIT-EXPRESSING MELANOMA-CELLS	ONCOGENE			English	Article							FACTOR RECEPTOR PROTOONCOGENE; TYROSINE KINASE RECEPTOR; ACTIVATED PROTEIN-KINASE; CYTOMETRIC DNA ANALYSIS; W-MUTANT MICE; C-KIT; SI-LOCUS; SIGNAL TRANSDUCTION; FUNCTION MUTATIONS; HUMAN MELANOCYTES	Previous studies in vivo and in vitro show that KIT kinase promotes normal melanocyte development and growth. However, the role of the KIT proto-oncogene in neoplastic melanocytes is not certain. We therefore examined KIT expression and function in human melanomas. Our results show that KIT mRNA was expressed in 12 of 28 melanoma cell lines (approximately 40%), mainly in those originating from pigmented tumors. Surprisingly, activation of KIT with mast cell growth factor (MGF) in melanoma cells produced biological responses opposite to those elicited in normal melanocytes. MGF inhibited rather than stimulated the growth of metastatic melanoma cell lines. The opposite effects may be due to aberrant signal transduction by KIT in melanoma cells in response to MGF. The in vitro inhibition of melanoma cells by MGF suggests that growth in vivo of this tumor is not promoted by KIT kinase activation, but rather that transformed melanocytes might regress when MGF is expressed in their immediate environment.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98103; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Yale University; Weizmann Institute of Science	ZAKUT, R (corresponding author), NCI,SURG BRANCH,BETHESDA,MD 20892, USA.		YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848] Funding Source: NIH RePORTER; NCI NIH HHS [5-R29-CA44542] Funding Source: Medline; NIAMS NIH HHS [1RO1-AR39848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CARROW CE, 1991, BLOOD, V78, P2216; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; Coppock D L, 1991, Cancer Treat Res, V54, P67; Cowan J M, 1991, Cancer Treat Res, V54, P3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1992, ONCOGENE, V7, P2195; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; Kock A, 1991, Cancer Treat Res, V54, P41; Kriegler M., 1990, GENE TRANSFER EXPRES; LASSAM N, 1992, ONCOGENE, V7, P51; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QUI F, 1988, EMBO J, V7, P1003; RATAJCZAK M, 1991, CLIN RES, V39, pA190; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sambrook J, 1989, MOL CLONING LABORATO; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; SZEBO KM, 1990, CELL, V63, P195; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3342; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	96	97	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2221	2229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687762				2022-12-25	WOS:A1993LP17100023
J	RAINES, MA; KOLESNICK, RN; GOLDE, DW				RAINES, MA; KOLESNICK, RN; GOLDE, DW			SPHINGOMYELINASE AND CERAMIDE ACTIVATE MITOGEN-ACTIVATED PROTEIN-KINASE IN MYELOID HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; EPIDERMAL GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; TYROSINE PHOSPHORYLATION; FACTOR-ALPHA; MAP KINASE; DIFFERENTIATION; IDENTIFICATION; INTERFERON; INSULIN	Mechanisms involved in tumor necrosis factor (TNF)-alpha signal transduction are incompletely understood. In some circumstances, TNF may use a signal transduction pathway involving hydrolysis of sphingomyelin to ceramide and stimulation of a ceramide-activated protein kinase. In HL-60 cells, TNF rapidly activates this pathway and induces monocytic differentiation. Here, we demonstrate that treatment of HL-60 cells with TNF selectively increases tyrosine phosphorylation of p42 mitogen-activated protein kinase (p42mapk) and stimulates its enzymatic activity. Induction of p42mapk phosphorylation was time- and dose-dependent and closely paralleled activation of sphingomyelin hydrolysis. Direct engagement of the sphingomyelin signal transduction pathway by addition of bacterial sphingomyelinase led to MAP kinase activation. The time course of p42mapk phosphorylation in the sphingomyelinase-treated cells was similar to that of TNF, with maximal response occurring at 5 min. A maximal concentration of sphingomyelinase (0.01 unit/ml) was more potent than TNF at inducing MAP kinase enzymatic activity (2.6-fold) and phosphorylation of MAP kinase and tyrosine. The cell-permeable ceramide analogs, C2- and C6-ceramide, which mimic effects of TNF, also induced p42mapk phosphorylation within seconds. These studies indicate that the sphingomyelin pathway can regulate MAP kinase activity and suggest that MAP kinase activation by this mechanism may be involved in TNF-induced signal transduction.	MEM SLOAN KETTERING CANC CTR,MOLEC PHARMACOL & THERAPEUT PROGRAM,1275 YORK AVE,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R37 CA30388, P30 CA08748] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R37CA030388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HALL FL, 1991, J BIOL CHEM, V266, P17430; HATTORI S, 1992, J BIOL CHEM, V267, P20346; KIM MY, 1991, J BIOL CHEM, V266, P484; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OKUDA K, 1992, BLOOD, V79, P2880; RAINES MA, 1992, BLOOD, V79, P3350; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SETH A, 1992, J BIOL CHEM, V267, P24796; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOLDKORN T, 1991, J BIOL CHEM, V266, P16092; TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632	38	276	281	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14572	14575						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686898				2022-12-25	WOS:A1993LL75900006
J	ZIEGLER, I; HULTNER, L; EGGER, D; KEMPKES, B; MAILHAMMER, R; GILLIS, S; RODL, W				ZIEGLER, I; HULTNER, L; EGGER, D; KEMPKES, B; MAILHAMMER, R; GILLIS, S; RODL, W			IN A CONCERTED ACTION KIT-LIGAND AND INTERLEUKIN-3 CONTROL THE SYNTHESIS OF SEROTONIN IN MURINE BONE MARROW-DERIVED MAST-CELLS - UP-REGULATION OF GTP CYCLOHYDROLASE-I AND TRYPTOPHAN 5-MONOOXYGENASE ACTIVITY BY THE KIT-LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ENHANCING ACTIVITY; C-KIT; STEEL LOCUS; T-CELL; MOUSE; TETRAHYDROBIOPTERIN; PROLIFERATION; HYDROXYLASE; FORMS; 5-HYDROXYTRYPTAMINE	Mouse bone marrow-derived mast cells (BMMC) store and release serotonin whose synthesis is initiated by tryptophan 5-monooxygenase. (6R)-H4biopterin serves as the natural cofactor for this reaction. GTP cyclohydrolase I catalyzes the first and rate-limiting step of its synthesis. In this study we demonstrate that among a panel of growth-promoting cytokines including kit ligand (KL), interleukin 3 (IL-3), IL-4, IL-9, and nerve growth factor, KL selectively enhances the synthesis of H4biopterin through up-regulation of GTP cyclohydrolase I activity to 6.2-fold levels. The activities of the subsequent enzymes 6-pyruvoyl-H4pterin synthase and sepiapterin reductase remain unaffected. The activity of tryptophan 5-monooxygenase was selectively enhanced 4.5-fold by the combination of IL-3 with KL. All other factors could not substitute for KL. The constitutive high activity of aromatic L-amino acid decarboxylase is not different in cells cultured in IL-3 and/or KL. In consequence, the concerted action of IL-3 and KL on the GTP cyclohydrolase I and the tryptophan 5-monooxygenase reaction enhances the production of serotonin to about 20-fold levels. Additionally, KL specifically causes the release of about half of total serotonin produced. Hence, our data demonstrate a novel role of these cytokines for the function of mouse BMMC and provide a coherent view of the regulation of serotonin synthesis in this cell type.	GSF MUNICH,INST EXPTL HAMATOL,W-8000 MUNICH 70,GERMANY; IMMUNEX CORP,SEATTLE,WA 98101	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Immunex Corporation	ZIEGLER, I (corresponding author), GSF MUNICH,INST KLIN MOLEK BIOL & TUMORGENET,MARCHIONINISTR 25,W-8000 MUNICH 70,GERMANY.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BURG AW, 1968, J BIOL CHEM, V243, P2349; COLUMBO M, 1992, J IMMUNOL, V149, P599; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAVIS MD, 1992, P NATL ACAD SCI USA, V89, P10109, DOI 10.1073/pnas.89.21.10109; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; DUTCH DS, 1991, J NUTR BIOCH, V2, P411; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1991, FASEB J, V5, pA1092; GERSHON MD, 1981, ANNU REV NEUROSCI, V4, P227, DOI 10.1146/annurev.ne.04.030181.001303; GUTLICH M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P133, DOI 10.1016/0167-4781(92)90112-D; HASEGAWA H, 1987, BIOCHEM J, V248, P501, DOI 10.1042/bj2480501; HOLGATE ST, 1988, ALLERGY PRINCIPLES P, V1, P135; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; HULTNER L, 1989, IMMUNOLOGY, V67, P408; IHLE JN, 1983, J IMMUNOL, V131, P282; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAUFMAN S, 1962, OXYGENASES, P285; KERLER F, 1989, BIOCHIM BIOPHYS ACTA, V990, P15, DOI 10.1016/S0304-4165(89)80005-4; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; Kitamura Y., 1989, MAST CELL BASOPHIL D, P15; KUHN DM, 1980, ARCH BIOCHEM BIOPHYS, V199, P355, DOI 10.1016/0003-9861(80)90291-X; KUHN DM, 1980, J BIOL CHEM, V255, P4137; KUHN DM, 1985, FOLATES PTERINS, V2, P354; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MILSTIEN S, 1986, P169; MOELLER J, 1990, J IMMUNOL, V144, P4231; MORRISON DC, 1974, J IMMUNOL, V112, P573; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; NAKAJIMA K, 1992, BIOCHEM BIOPH RES CO, V183, P1076, DOI 10.1016/S0006-291X(05)80300-6; NAKATA H, 1982, EUR J BIOCHEM, V124, P595; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; REISBACH G, 1993, EXP HEMATOL, V21, P74; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; STOLL J, 1990, GENOMICS, V7, P88, DOI 10.1016/0888-7543(90)90522-V; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TOGARI A, 1992, BIOCHEM BIOPH RES CO, V187, P359, DOI 10.1016/S0006-291X(05)81501-3; TRAIFFORT E, 1991, J CHROMATOGR-BIOMED, V571, P231, DOI 10.1016/0378-4347(91)80449-M; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; WEITZMAN G, 1985, INT ARCH ALLER A IMM, V77, P189, DOI 10.1159/000233782; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; WINGREN U, 1983, INT ARCH ALLER A IMM, V70, P193, DOI 10.1159/000233322; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1985, J CELL BIOCHEM, V28, P197, DOI 10.1002/jcb.240280303; ZIEGLER I, 1992, FEBS LETT, V307, P147, DOI 10.1016/0014-5793(92)80755-6; ZIEGLER I, 1990, MED RES REV, V10, P95, DOI 10.1002/med.2610100104; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUO DM, 1991, J CHROMATOGR-BIOMED, V567, P381, DOI 10.1016/0378-4347(91)80144-2	54	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12544	12551						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685343				2022-12-25	WOS:A1993LG65800049
J	PADH, H; HA, JH; LAVASA, M; STECK, TL				PADH, H; HA, JH; LAVASA, M; STECK, TL			A POST-LYSOSOMAL COMPARTMENT IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; PINOCYTOSED FLUID; KINETIC EVIDENCE; TEMPORAL CHANGES; ENDOCYTOSIS; CELLS; VACUOLES; PROBE; MACROPHAGES; FIBROBLASTS	Fluorescein isothiocyanate (FITC)-dextran and pyranine were fed to the social amoeba, Dictyostelium discoideum. These membrane-impermeable, pH-sensitive fluorophores initially entered a congruent-to neutral endocytic compartment. They encountered maximal acidity (pH congruent-to 5) about 15 min after ingestion, in what appeared to be digestive vacuoles (lysosomes). The environment of the probes returned to near neutrality by 30 min. At that time, the probes accumulated in a decreasing number of vacuoles of increasing size; ultimately, there were only a small number of vacuoles per cell with diameters of up to 3 mum. The late vacuoles sedimented more rapidly than did proton pumps, acid hydrolases, and recently ingested cargo. Unlike the vacuoles harvested immediately after the cells were fed FITC-dextran, the late vacuoles were not acidified by MgATP in vitro. Egestion of ingested FITC-dextran commenced after a lag of congruent-to 45 min. A similar lag was observed for the resurfacing of two endocytosed bilayer-intercalated fluorophores. These results suggest that, in Dictyostelium, undigested endocytic cargo accumulates in and is returned to the cell surface through a distinctive compartment of large and nearly neutral post-lysosomal vacuoles. It will be important to determine the degree to which internalized plasma membrane components follow this post-lysosomal pathway.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA	University of Chicago				Padh, Harish/0000-0003-2305-6229				ADAMS CJ, 1982, J CELL BIOL, V93, P632, DOI 10.1083/jcb.93.3.632; ALEY SB, 1984, J EXP MED, V160, P724, DOI 10.1084/jem.160.3.724; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOWERS B, 1983, J CELL BIOL, V97, P317, DOI 10.1083/jcb.97.2.317; BRENOT F, 1992, BIOCHIMIE, V74, P883, DOI 10.1016/0300-9084(92)90072-M; BRONNER C, 1986, BIOCHEMISTRY-US, V25, P2149, DOI 10.1021/bi00356a045; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; BUSH JM, 1989, J BIOL CHEM, V264, P7630; Cardelli J.A., 1988, P363; CASCIOLAROSEN LAF, 1991, J BIOL CHEM, V266, P4341; Chapman-Andresen C., 1973, P319; DAEMS WT, 1969, LYSOSOM BIOL PATHOL, P64; DAUKAS G, 1983, J CELL BIOL, V96, P1642, DOI 10.1083/jcb.96.6.1642; DECHASTELLIER C, 1983, EUR J CELL BIOL, V30, P233; Fok A.K., 1990, International Review of Cytology, V123, P61, DOI 10.1016/S0074-7696(08)60671-3; FOK AK, 1985, J PROTOZOOL, V32, P6, DOI 10.1111/j.1550-7408.1985.tb03004.x; GEISOW MJ, 1981, J CELL BIOL, V89, P645, DOI 10.1083/jcb.89.3.645; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Holtzman E, 1989, LYSOSOMES; IDRISS JM, 1991, J BIOL CHEM, V266, P9438; ILLINGER D, 1990, BIOCHIM BIOPHYS ACTA, V1030, P73, DOI 10.1016/0005-2736(90)90240-O; JENSEN MS, 1973, J CELL BIOL, V56, P379, DOI 10.1083/jcb.56.2.379; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; KITCHING JA, 1956, PROTOPLASMATOLOGIA, P1; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; LAGUNOFF DAVID, 1964, COMPT REND TRAV LAB CARLSBERG, V34, P433; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; NILSSON JR, 1979, BIOCH PHYSL PROTOZOA, V2, P502; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OHKUMA S, 1987, LYSOSOMES THEIR ROLE, P115; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; ROEDERER M, 1989, EUR J CELL BIOL, V48, P37; RYTER A, 1976, J ULTRA MOL STRUCT R, V57, P309, DOI 10.1016/S0022-5320(76)80119-0; RYTER A, 1977, J CELL BIOL, V75, P200, DOI 10.1083/jcb.75.1.200; SIPE DM, 1991, J BIOL CHEM, V266, P3469; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; Stockem W, 1977, MAMMALIAN CELL MEMBR, V5, P151; STRAUBINGER RM, 1990, BIOCHEMISTRY-US, V29, P4929, DOI 10.1021/bi00472a025; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; Vickerman K, 1976, BIOL KINETOPLASTIDA, P35; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295	50	79	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6742	6747						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681066				2022-12-25	WOS:A1993KT36800095
J	INOUE, G; KUZUYA, H; HAYASHI, T; OKAMOTO, M; YOSHIMASA, Y; KOSAKI, A; KONO, S; OKAMOTO, M; MAEDA, I; KUBOTA, M; IMURA, H				INOUE, G; KUZUYA, H; HAYASHI, T; OKAMOTO, M; YOSHIMASA, Y; KOSAKI, A; KONO, S; OKAMOTO, M; MAEDA, I; KUBOTA, M; IMURA, H			EFFECTS OF ML-9 ON INSULIN STIMULATION OF GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; HEXOSE-TRANSPORT; PHORBOL ESTER; S6 KINASE; CATECHOLAMINE SECRETION; PLASMA-MEMBRANE; SWISS 3T3-CELLS; PROTEIN-KINASES; GROWTH-FACTORS; MAP KINASE	Treatment of 3T3-L1 adipocytes with insulin resulted in activation of 2-deoxyglucose transport activity and translocation of glucose transporters (GLUT4 and GLUT1) from the cytoplasmic space to the plasma membrane. ML-9 (a myosin light chain kinase inhibitor) inhibited insulin stimulation of 2-deoxyglucose transport activity by 80% at 100 muM (IC50 = 27 muM) without affecting 2-deoxyglucose transport activity in the basal state. The inhibition was independent of extracellular Ca2+ concentration and almost fully reversible at 40 muM ML-9. ML-9 did not inhibit insulin-stimulated tyrosine phosphorylation of 95-kDa protein in the wheat germ agglutinin-purified preparation and of 95- and 160-kDa proteins in intact cells. However, ML-9 inhibited insulin-induced translocation of both GLUT4 and GLUT1 in a dose-dependent manner. The dose-response curves were similar to those observed for the inhibition of insulin stimulation of 2-deoxyglucose transport activity. Neither insulin nor ML-9 affected the phosphorylation state of both heavy and light chains of myosin. Therefore, it seems likely that ML-9 inhibits the insulin-induced translocation of glucose transporters at a step beyond the insulin receptor kinase activity by a mechanism different from that affecting phosphorylation of the myosin light chain. Phosphorylating activity of microtubule-associated protein 2 and myelin basic protein was stimulated by insulin, and this stimulation was not affected by ML-9. ML-9, however, inhibited the phosphorylating activity in vitro and insulin stimulation of the phosphorylating activity of ribosomal protein S6 in intact cells in a dose-dependent manner similar to that observed for the inhibition of insulin stimulation of glucose transport. These results suggest that mitogen-activated protein kinase may be one of the constituents in intracellular insulin signaling to the glucose transport system.			INOUE, G (corresponding author), KYOTO UNIV,SCH MED,DIV INTERNAL MED 2,54 KAWAHARACHO,SAKYO KU,KYOTO 606,JAPAN.			hayashi, Tatsuya/0000-0001-7600-4735				AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BAINES AJ, 1987, NATURE, V326, P646, DOI 10.1038/326646a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIBBS EM, 1991, BIOCHEM J, V275, P145, DOI 10.1042/bj2750145; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOSAKI A, 1991, MOL CELL ENDOCRINOL, V75, P189, DOI 10.1016/0303-7207(91)90160-T; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MAJERCIK MH, 1988, BIOCHEM J, V252, P815, DOI 10.1042/bj2520815; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAGATSU T, 1987, BIOCHEM BIOPH RES CO, V143, P1045, DOI 10.1016/0006-291X(87)90357-3; NAKANISHI A, 1989, BIOCHEM PHARMACOL, V38, P2615, DOI 10.1016/0006-2952(89)90546-7; OKAMOTO M, 1992, J NUTR BIOCHEM, V3, P241, DOI 10.1016/0955-2863(92)90046-L; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; SAITOH M, 1986, BIOCHEM BIOPH RES CO, V140, P280, DOI 10.1016/0006-291X(86)91087-9; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sherton C C, 1974, Methods Enzymol, V30, P506; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369	44	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5272	5278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680348				2022-12-25	WOS:A1993KP88400101
J	CORVI, R; SAVELYEVA, L; BREIT, S; WENZEL, A; HANDGRETINGER, R; BARAK, J; OREN, M; AMLER, L; SCHWAB, M				CORVI, R; SAVELYEVA, L; BREIT, S; WENZEL, A; HANDGRETINGER, R; BARAK, J; OREN, M; AMLER, L; SCHWAB, M			NON-SYNTENIC AMPLIFICATION OF MDM2 AND MYCN IN HUMAN NEUROBLASTOMA	ONCOGENE			English	Article						ONCOGENES; REVERSE GENOMIC HYBRIDIZATION; TUMORIGENESIS; P53; PEDIATRIC CANCER	AMPLIFIED DNA-SEQUENCES; N-MYC; CELL-LINES; HUMAN SARCOMAS; P53 MUTATIONS; HUMAN CANCER; CDNA CLONES; C-MYC; GENE; TUMOR	Amplification of the MYCN gene is a well documented genetic alteration of aggressively growing human neuroblastomas. Through cytogenetic studies we have identified neuroblastoma cell lines which, in addition to amplified MYCN, carry amplified DNA not harbouring MYCN. In situ hybridization of biotinylated total genomic DNA to metaphase chromosomes of normal human lymphocytes by reverse genomic hybridization revealed the amplified DNA to be derived from chromosome 12 band q13-14, Subsequent filter analyses showed a 20- to 40-fold amplification of the MDM2 gene, located at 12q13-14, both in three cell lines and in an original tumor, in addition to amplified MYCN, As the apparent consequence of amplification abundant MDM2 protein was present, a part of which was complexed with p53.	GERMAN CANC RES CTR, DIV CYTOGENET, D-69120 HEIDELBERG, GERMANY; UNIV TUBINGEN, CHILDRENS CLIN, D-72070 TUBINGEN, GERMANY; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Weizmann Institute of Science								ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAM I, 1992, GENE CHROMOSOME CANC, V4, P314, DOI 10.1002/gcc.2870040407; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; Bertheir F., 1990, Computational Intelligence, II. Proceedings of the International Symposium `Computational Intelligence 89', P1; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; COWELL JK, 1983, CANCER GENET CYTOGEN, V9, P273, DOI 10.1016/0165-4608(83)90011-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1981, J VIROL, V34, P752; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KHATIB ZA, 1993, CANCER RES, V53, P5535; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOMURO H, 1993, CANCER RES, V53, P5284; LADANYI M, 1993, CANCER RES, V53, P16; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIBERT LM, 1994, GENE CHROMOSOME CANC, V9, P261; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RUDOLPH G, 1991, HUM GENET, V86, P562; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; VOGAN K, 1993, CANCER RES, V53, P5269; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	53	98	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1081	1086						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700632				2022-12-25	WOS:A1995QN35300007
J	BUDDE, RJA				BUDDE, RJA			EVIDENCE FOR KINETICALLY DISTINCT FORMS OF PP60(C-SRC) WITH DIFFERENT K(M) VALUES FOR THEIR PROTEIN SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PP60C-SRC; PHOSPHORYLATION; SRC; CELLS; PHOSPHOTYROSINE; IDENTIFICATION; PURIFICATION	The biphasic kinetics for phosphorylation of poly(E4Y) by the protein tyrosine kinase pp60c-src were examined. At pH 6.5 substrate inhibition was observed, whereas at pH 8.0 the kinetics were still biphasic, but the enzyme was no longer inhibited. The reaction rate increased in a nonlinear fashion with increasing concentration of substrate. The kinetics were examined from the view that the biphasic kinetics at pH 8.0 were due to two enzymes acting simultaneously on the same substrate. A 55-fold difference in K(m) values (0.029 versus 1.6 mg/ml) was calculated. The low K(m) form of the enzyme (0.043 mg/ml) was physically separated from the mixture of kinetic variants by immunoaffinity chromatography, and phosphorylation by protein kinase A resulted in the formation of an enzyme with an intermediate K(m) (0.3-0. 4 mg/ml). The presence of multiple kinetic forms of this tyrosine kinase has important implications in our efforts to understand the role of pp60c-src in human oncology.			BUDDE, RJA (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEROONCOL, BOX 316, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U01CA053617, U19CA053617, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA16672, CA53617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BURNELL JN, 1984, ARCH BIOCHEM BIOPHYS, V231, P175, DOI 10.1016/0003-9861(84)90375-8; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CASSIDY R, 1992, LC GC-MAG SEP SCI, V10, P692; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; DIXON M, 1979, ENZYMES, P75; GARCIA R, 1991, ONCOGENE, V6, P1983; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATO G, 1991, BIOCHEM BIOPH RES CO, V178, P764, DOI 10.1016/0006-291X(91)90174-6; KITAS EA, 1990, BIOCHEM BIOPH RES CO, V170, P635, DOI 10.1016/0006-291X(90)92139-Q; LILLEY ER, 1991, CANCER RES, V51, P3906; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; NIMAN HL, 1990, IMMUNODIAGNOSIS CANC, P189; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSMUNDSEN H, 1975, BIOCHEM BIOPH RES CO, V67, P324, DOI 10.1016/0006-291X(75)90319-8; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; WHITEHOUSEHILLS S, 1990, BIOCHIM BIOPHYS ACTA, V1037, P380, DOI 10.1016/0167-4838(90)90040-M; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YU G, 1987, J BIOL CHEM, V262, P17543	31	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24868	24872						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693707				2022-12-25	WOS:A1993MG67300054
J	PAJUSOLA, K; APRELIKOVA, O; ARMSTRONG, E; MORRIS, S; ALITALO, K				PAJUSOLA, K; APRELIKOVA, O; ARMSTRONG, E; MORRIS, S; ALITALO, K			2 HUMAN FLT4 RECEPTOR TYROSINE KINASE ISOFORMS WITH DISTINCT CARBOXY-TERMINAL TAILS ARE PRODUCED BY ALTERNATIVE PROCESSING OF PRIMARY TRANSCRIPTS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; C-KIT; GENE; SPECIFICITY; ORGANIZATION; EXPRESSION; REGION	FLT4 is a recently cloned gene encoding a transmembrane tyrosine kinase related to the FLT1 and KDR/FLK1 vascular endothelial growth factor receptors. We have previously shown that FLT4 is expressed as transcripts of 4.5 and 5.8 kb in several human fetal and adult tissues. Here we show that these transcripts encode two polypeptides, FLT4s (short) and FLT41 (long), which are proteolytically processed in transfected cells and leukemia cells and which have different carboxy terminal tails. The 3' coding region of the 5.8 kb mRNA was found to be 65 codons longer than that of the the 4.5 kb mRNA. Analysis of the genomic structure of the region encoding the two carboxy termini revealed that the two transcripts are generated by alternative polyadenylation and subsequent alternative splicing during RNA processing. Our findings thus show regulation of FLT4 structure in the carboxy terminal tail considered important for receptor function. The significance of the two forms may relate to the role of additional potential autophosphorylation sites in the FLT4 long form.	ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	PAJUSOLA, K (corresponding author), UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, PL 21, SF-00014 HELSINKI, FINLAND.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ANDRE C, 1992, ONCOGENE, V7, P685; APRELIKOVA O, 1992, CANCER RES, V52, P746; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1993, ONCOGENE, V8, P1233; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HAMPE A, 1989, ONCOGENE RES, V4, P9; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PAJUSOLA K, 1992, CANCER RES, V52, P5738; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIBUYA M, 1990, ONCOGENE, V5, P519; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P1829; TAHIRA T, 1990, ONCOGENE, V5, P97; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	23	81	104	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2931	2937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692369				2022-12-25	WOS:A1993MC09300006
J	LAMMERS, R; BOSSENMAIER, B; COOL, DE; TONKS, NK; SCHLESSINGER, J; FISCHER, EH; ULLRICH, A				LAMMERS, R; BOSSENMAIER, B; COOL, DE; TONKS, NK; SCHLESSINGER, J; FISCHER, EH; ULLRICH, A			DIFFERENTIAL ACTIVITIES OF PROTEIN-TYROSINE PHOSPHATASES IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR CHARACTERIZATION; ENDOPLASMIC-RETICULUM; INSULIN-RECEPTOR; GENE-TRANSFER; NEU ONCOGENE; CDNA CLONING; EGF RECEPTOR; SH2 DOMAINS; EXPRESSION	We have employed transient co-overexpression of protein tyrosine phosphatases (PTPs) with a panel of receptor tyrosine kinases (RTKs) to investigate molecular parameters that regulate dephosphorylation activity and specificity in intact cells. Our results demonstrate clear differences in susceptibility of various forms of different RTKs to the action of PTP 1B, T-cell phosphatase (TC-PTP), and CD45, which suggests cellular compartmentalization as a major factor defining activity and overall function. TC-M PTP, a nonlocalized cytosolic mutant, is deregulated and is therefore able to efficiently suppress v-erbB- and v-fms-induced cell transformation, which is not observed with the intact TC-PTP or PTP 1B. The transmembrane PTP CD45 displays more selectivity but appears to be already active during transport to the cell surface. Dephosphorylation activity is also dependent on relative RTK/PTP expression levels and can be modulated by the SH2 domain-containing noncatalytic subunit of phosphatidylinositol 3'-kinase, p85. Overexpression of high affinity binding proteins could therefore contribute to RTK-induced cell transformation and cancer.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	Max Planck Society; University of Washington; University of Washington Seattle; Cold Spring Harbor Laboratory; New York University			Bossenmaier, Birgit/AAN-7075-2020		NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWNSHIMER S, 1992, CANCER RES, V52, P478; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HERBST R, 1991, J BIOL CHEM, V266, P19908; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SCHLESSINGER J, 1992, NEURON, V9, P1; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	48	151	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22456	22462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693671				2022-12-25	WOS:A1993MD34800043
J	SANTINI, F; BEAVEN, MA				SANTINI, F; BEAVEN, MA			TYROSINE PHOSPHORYLATION OF A MITOGEN-ACTIVATED PROTEIN KINASE-LIKE PROTEIN OCCURS AT A LATE STEP IN EXOCYTOSIS - STUDIES WITH TYROSINE PHOSPHATASE INHIBITORS AND VARIOUS SECRETAGOGUES IN RAT RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MAST-CELLS; GROWTH-FACTOR; SIGNAL TRANSDUCTION; MAP KINASE; PHOSPHOLIPASE C-GAMMA-1; HISTAMINE-RELEASE; 2H3 CELLS; RECEPTOR; SECRETION	Several inhibitors of tyrosine phosphatases, which included vanadate/H2O2, phenylarsine oxide, and diamide, blocked exocytosis in basophilic RBL-2H3 cells that had been transfected with the gene for the muscarinic m1 receptor. Because this block was observed whether the secretagogue acted through receptors (i.e. antigen and the muscarinic agonist, carbachol) or by direct activation of intracellular mechanisms (i.e. A23187, A23187 in combination with phorbol 12-myristate 13-acetate, and thapsigargin), the inhibitors appeared to act at a step distal to the mobilization of Ca2+ and activation of protein kinase C. All secretagogues caused the tyrosine phosphorylation of a 40-kDa protein, whereas the inhibitors caused a hyperphosphorylation of this protein. Therefore, both tyrosine kinase and phosphatase activities appear to regulate this phosphorylation which may, in turn, regulate secretion. The 40-kDa protein was identified as a mitogen-activated protein kinase-like protein on the basis of its reactivity to anti-mitogen-activated protein kinase antibodies. In addition, when cells were stimulated the tyrosine phosphorylated and the immunoreactive protein comigrated as a doublet on one-dimensional and as multiple phosphorylated forms on two-dimensional gel-electrophoretic systems.	NHLBI,CHEM PHARMACOL LAB,RM 8N114,BLDG 10,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ALBER G, 1991, J BIOL CHEM, V266, P22613; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P3449; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEMAN E, 1992, NATURE, V355, P78; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HARLOW E, 1988, ATNIBODIES LABORATOR; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JENA BP, 1991, J BIOL CHEM, V266, P1744; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LILLIE THW, 1992, PHILOS T ROY SOC B, V336, P25, DOI 10.1098/rstb.1992.0040; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; METZGER H, 1992, J IMMUNOL, V149, P1477; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TATHAM PER, 1989, BIOSCIENCE REP, V9, P99, DOI 10.1007/BF01117516; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WAGNER PD, 1990, J BIOL CHEM, V265, P10352; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMADA K, 1992, J IMMUNOL, V149, P1031; YU KT, 1991, J BIOL CHEM, V266, P22564; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22716	22722						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693676				2022-12-25	WOS:A1993MD34800078
J	WANG, JL; STUEHR, DJ; IKEDASAITO, M; ROUSSEAU, DL				WANG, JL; STUEHR, DJ; IKEDASAITO, M; ROUSSEAU, DL			HEME COORDINATION AND STRUCTURE OF THE CATALYTIC SITE IN NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOW-SPIN EQUILIBRIUM; RESONANCE RAMAN; CYTOCHROME-P-450; BRAIN; HEMOPROTEIN; ARGININE; ENZYME; LIGAND; FORMS	Nitric oxide (NO), recently found to play many physiological roles, is generated by the catalysis Of L-arginine and O2 to L-citrulline and NO by nitric oxide synthases (NOSs). Resonance Raman spectra from the heme of resting, reduced, and CO-bound forms of rat brain NOS firmly establish that the enzyme belongs to the P-450 class of enzymes. The electron density marker line (nu4) in the Raman spectrum of ligand-free ferrous NOS has a low frequency (1347 cm-1), indicating a thiolate axial ligand on the heme. The assignment of a thiolate axial ligand is confirmed in the CO-bound form of the enzyme by the frequency of the Fe-C-O bending mode at 562 cm-1. The heme in resting NOS is five-coordinate high spin and thereby differs from the resting state of most substrate-free P-450s, which are predominantly six-coordinate low spin. The frequency of the Fe-CO stretching mode in the CO-bound enzyme at 491 cm-1, identified by isotope substitution, is higher than that in substrate-free P-450s. Thus, in the ferric and the CO-bound forms of the enzyme, the sixth-ligand binding site on the heme is restricted by steric or hydrophobic interactions. In addition, the Fe-CO stretching mode is broad (30 cm-1) and may be resolved into two overlapping lines of equal intensity, indicating that the heme domains can adopt two distinct conformations.	AT&T BELL LABS, MURRAY HILL, NJ 07974 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM & BIOPHYS, CLEVELAND, OH 44106 USA; CLEVELAND CLIN FDN, DEPT IMMUNOL, CLEVELAND, OH 44195 USA	AT&T; Nokia Corporation; Nokia Bell Labs; Case Western Reserve University; Cleveland Clinic Foundation			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008					ANZENBACHER P, 1984, 9TH P INT C RAM SPEC, P474; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HAN S, 1990, P NATL ACAD SCI USA, V87, P205, DOI 10.1073/pnas.87.1.205; HILDEBRANDT P, 1989, EUR J BIOCHEM, V186, P291, DOI 10.1111/j.1432-1033.1989.tb15208.x; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JUNG C, 1991, BIOCHIM BIOPHYS ACTA, V1076, P130, DOI 10.1016/0167-4838(91)90229-S; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LANCASTER JR, 1992, AM SCI, V80, P248; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; OZAKI Y, 1978, BIOCHEMISTRY-US, V17, P5826, DOI 10.1021/bi00619a033; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; ROUSSEAU DL, 1984, OPTICAL TECHNIQUES B, P66; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SPIRO TG, 1987, BIOL APPLICATIONS RA, V3, P1; SPIRO TG, 1988, BIOL APPLICATIONS RA, V3; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; TSUBAKI M, 1990, BIOCHEMISTRY-US, V29, P8805, DOI 10.1021/bi00489a043; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Yu N.-T., 1988, RESONANCE RAMAN SPEC, V3, P39	32	101	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22255	22258						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693663				2022-12-25	WOS:A1993MD34800011
J	RUDNICK, CM; DOWTON, SB				RUDNICK, CM; DOWTON, SB			SERUM AMYLOID-P (FEMALE PROTEIN) OF THE SYRIAN-HAMSTER - GENE STRUCTURE AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; ACUTE-PHASE RESPONSE; MESSENGER-RNA; COMPONENT; MOUSE; TESTOSTERONE; CDNA; INTERLEUKIN-6; INFLAMMATION; SEQUENCES	The structure and expression of the gene encoding serum amyloid P (SAP) component of the Syrian hamster have been studied by isolation of cosmid clones, nucleotide sequence analyses, and quantitation of nuclear run-on transcripts, nuclear RNA, mRNA, and protein levels. Hamster SAP, originally identified as female protein (FP), is a unique pentraxin because pretranslational expression of this gene is modulated by mediators of inflammation and sex steroids. SAP(FP) levels are high in sera from female hamsters and low in males. The response to inflammation is divergent; SAP(FP) levels decrease in females and increase in males during an acute phase response. The SAP(FP) gene encodes a 211 amino acid residue mature polypeptide as well as a 22-residue signal peptide. The intron/exon organization is similar to that of other pentraxins, but additional transcripts are generated from alternate polyadenylation sites in the 3' region. Circulating levels of SAP(FP) and the corresponding hepatic transcript levels are augmented by estrogen, while testosterone, dexamethasone, and progesterone cause a decrease in these levels. In addition the cytokines interleukin-1, -6, and tumor necrosis factor mediate a decrease in hepatic SAP(FP) transcript levels in female hamsters but did not cause a significant elevation of SAP(FP) mRNA in livers of male hamsters. The differences in expression of the SAP(FP) gene between male and female hamsters and between unstimulated male hamsters and male hamsters stimulated with an injection of lipopolysaccharide are due, at least in part, to alterations in transcription.	WASHINGTON UNIV,EDWARD MALLINKRODT DEPT PEDIAT,DIV MED GENET,1 CHILDRENS PL,ST LOUIS,MO 63130; WASHINGTON UNIV,JAMES S MCDONNELL DEPT GENET,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)				Dowton, Stephen/0000-0003-0828-1073	NIAID NIH HHS [AI24835-07] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024835] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COE JE, 1977, P NATL ACAD SCI USA, V74, P730, DOI 10.1073/pnas.74.2.730; COE JE, 1983, J EXP MED, V157, P1421, DOI 10.1084/jem.157.5.1421; COE JE, 1981, J EXP MED, V153, P977, DOI 10.1084/jem.153.4.977; DOWTON SB, 1985, SCIENCE, V228, P1206, DOI 10.1126/science.2408337; DOWTON SB, 1990, BIOCHEM J, V270, P553, DOI 10.1042/bj2700553; DOWTON SB, 1991, INFLAMMATION, V15, P391, DOI 10.1007/BF00917355; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G; FIEDEL BA, 1986, THROMB HAEMOSTASIS, V55, P406; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; HU SI, 1986, BIOCHEMISTRY-US, V25, P7834, DOI 10.1021/bi00372a008; HUSBY G, 1986, AMYLOIDOSIS, P23; KALARIA RN, 1992, BIOCHEM BIOPH RES CO, V186, P461, DOI 10.1016/S0006-291X(05)80830-7; Kushin'ska-Sitsin'ska Ia, 1989, Akush Ginekol (Mosk), P69; KYLE RA, 1990, AMYLOID AMYLOIDOSIS, P147; LE PT, 1984, J LEUKOCYTE BIOL, V35, P587; MACINTYRE SS, 1985, J BIOL CHEM, V260, P4169; MAGNUS JH, 1992, SCAND J RHEUMATOL, V21, P155; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MARZLUFF WF, 1984, TRANSCRIPTION TRANSL; MCADAM KPWJ, 1982, ANN NY ACAD SCI, V389, P126, DOI 10.1111/j.1749-6632.1982.tb22131.x; MORTENSEN RF, 1983, J IMMUNOL, V130, P885; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; NISHIGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1366, DOI 10.1016/S0006-291X(88)81292-0; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PEPYS MB, 1982, ANN NY ACAD SCI, V389, P286, DOI 10.1111/j.1749-6632.1982.tb22144.x; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PRELLI F, 1985, J BIOL CHEM, V260, P2895; QUERAT B, 1991, J MOL ENDOCRINOL, V7, P81, DOI 10.1677/jme.0.0070081; RAY A, 1992, J AM SOC NEPHROL, V2, P214; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sambrook J, 1989, MOL CLONING LABORATO; SAMOLS D, 1985, BIOCHEM J, V227, P759, DOI 10.1042/bj2270759; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P5883, DOI 10.1021/bi00566a034; SORIMACHI K, 1990, BIOCHEM INT, V22, P447; SQUIRES EJ, 1990, CAN J PHYSIOL PHARM, V68, P769, DOI 10.1139/y90-118; TONIATTI C, 1990, MOL BIOL MED, V7, P199; VOLIVA CF, 1991, J MOL ENDOCRINOL, V7, P155, DOI 10.1677/jme.0.0070155; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; WHITEHEAD AS, 1989, BIOCHEM J, V263, P25, DOI 10.1042/bj2630025; WOO P, 1985, J BIOL CHEM, V260, P3384	54	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21760	21769						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691816				2022-12-25	WOS:A1993MC80900053
J	BILIR, BM; GONG, TWL; KWASIBORSKI, V; SHEN, CS; FILLMORE, CS; BERKOWITZ, CM; GUMUCIO, JJ				BILIR, BM; GONG, TWL; KWASIBORSKI, V; SHEN, CS; FILLMORE, CS; BERKOWITZ, CM; GUMUCIO, JJ			NOVEL CONTROL OF THE POSITION-DEPENDENT EXPRESSION OF GENES IN HEPATOCYTES - THE GLUT-1 TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; RAT-LIVER; PERIVENOUS HEPATOCYTES; INSITU HYBRIDIZATION; GLUTAMINE-SYNTHETASE; ALBUMIN GENE; CELLS; TRANSCRIPTION; MODULATION; METABOLISM	The basal hepatocyte phenotype is conferred by the expression of liver-specific genes. In the adult liver, the basal hepatocyte phenotype is further modified by transcriptional and post-transcriptional regulation of genes which result in the appearance of specific proteins in selected hepatocytes. One of these proteins is the erythroid/brain or GLUT-1 glucose transporter. The GLUT-1 protein is detected in the plasma membrane of only one or two hepatocytes located at the end of the liver cell plate, contiguous to the hepatic venule. The objective of this study was to define the molecular mechanisms responsible for the restricted expression of the GLUT-1 protein in rat liver. Hepatocytes were isolated from either the proximal (''periportal'') or the distal (''perivenular'') half of the liver cell plate. The GLUT-1 mRNA as well as the GLUT-1 protein content and intracellular distribution were defined after subcellular fractionation of each hepatocyte population. In addition, the location of the GLUT-1 protein in liver tissue was determined by confocal microscopy. We propose that the GLUT-1 gene is transcribed and the mRNA is translated by both ''periportal'' and ''perivenular'' hepatocytes. However, insertion of the GLUT-1 protein into the plasma membrane occurs only in the last two hepatocytes contiguous to the hepatic venule. In other hepatocytes, the protein remains in a different cellular compartment characterized here as a ''low density microsomal'' fraction.	VET AFFAIRS MED CTR,DEPT MED 111D,2215 FULLER RD,ANN ARBOR,MI 48105; VET AFFAIRS MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,ANN ARBOR,MI 48105	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan				Berkowitz, Caryn/0000-0002-4087-6037	NIDDK NIH HHS [F32DK08572, DK32842] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032842, F32DK008572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPINI G, 1989, GASTROENTEROLOGY, V97, P1248, DOI 10.1016/0016-5085(89)91696-X; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BILIR B, 1991, HEPATOLOGY, V13, P804, DOI 10.1016/0270-9139(91)92586-W; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOYER JL, 1975, BIOCHIM BIOPHYS ACTA, V401, P59, DOI 10.1016/0005-2736(75)90341-7; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHARY SC, 1987, P NATL ACAD SCI USA, V84, P680; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRYSDALE JW, 1966, J BIOL CHEM, V241, P3630; FLIER JJ, 1987, P NATL ACAD SCI USA, V83, P5784; GEBHARDT R, 1988, FEBS LETT, V241, P89, DOI 10.1016/0014-5793(88)81037-8; GUMUCIO JJ, 1989, HEPATOLOGY, V9, P154, DOI 10.1002/hep.1840090124; GUMUCIO JJ, 1986, HEPATOLOGY, V6, P932, DOI 10.1002/hep.1840060521; HACKER HJ, 1991, HISTOCHEMISTRY, V96, P435, DOI 10.1007/BF00316001; HAUSSINGER D, 1986, ADV ENZYME REGUL, V25, P159, DOI 10.1016/0065-2571(86)90013-0; INGELMANSUNDBERG M, 1988, BIOCHEM BIOPH RES CO, V157, P55, DOI 10.1016/S0006-291X(88)80010-X; ISHII M, 1989, GASTROENTEROLOGY, V97, P1238; KRUMLAUF R, 1985, MOL CELL BIOL, V5, P1939; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; LINDROS KO, 1985, BIOCHEM J, V228, P757, DOI 10.1042/bj2280757; LOWRY OH, 1951, J BIOL CHEM, V193, P265; POLIARD AM, 1986, J CELL BIOL, V103, P777, DOI 10.1083/jcb.103.3.777; REICH E, 1961, SCIENCE, V134, P556, DOI 10.1126/science.134.3478.556; RHOADS DB, 1986, P NATL ACAD SCI USA, V83, P5784; SCHURMANN A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P245, DOI 10.1016/0167-4781(92)90022-R; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SLOTT PA, 1990, GASTROENTEROLOGY, V99, P466, DOI 10.1016/0016-5085(90)91030-A; SMITH DD, 1983, J BIOL CHEM, V258, P2265; SONG CS, 1969, J CELL BIOL, V41, P124, DOI 10.1083/jcb.41.1.124; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TAL M, 1990, J CLIN INVEST, V86, P986, DOI 10.1172/JCI114801; TAL M, 1991, ENDOCRINOLOGY, V129, P1933, DOI 10.1210/endo-129-4-1933; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; WOJCIK E, 1988, J CLIN INVEST, V82, P658, DOI 10.1172/JCI113645; YAMAUCHI M, 1988, HEPATOLOGY, V8, P243, DOI 10.1002/hep.1840080209; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	37	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19776	19784						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690040				2022-12-25	WOS:A1993LW81900093
J	OTTLINGER, ME; PUKAC, LA; KARNOVSKY, MJ				OTTLINGER, ME; PUKAC, LA; KARNOVSKY, MJ			HEPARIN INHIBITS MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IN INTACT RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MYC MESSENGER-RNA; C-MYC; PHOSPHORYLATION; FOS; PROLIFERATION; TRANSCRIPTION; PROGRESSION; SUPPRESSES; EXPRESSION; MECHANISM	Heparin is potently antiproliferative for vascular smooth muscle cells in vivo and in vitro, inhibiting early proto-oncogene expression and blocking proliferation in the G1 phase of the cell cycle. The mitogen-activated protein kinase (MAPK) family of serine- and threonine-specific kinases is activated in response to a wide range of mitogenic and other factors and is a key intermediate in cell signaling. We found that heparin inhibits activation of MAPK in response to fetal calf serum and phorbol 12-myristate 13-acetate, but not epidermal growth factor, revealing heparin-sensitive and -insensitive pathways of MAPK activation. This report tentatively links suppression of early proto-oncogene expression and inhibition of cellular proliferation by heparin with inhibition of a mitogenically relevant kinase in living cells.			OTTLINGER, ME (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008322, S15HL047718] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08322-02, HL47718] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1990, J BIOL CHEM, V265, P11487; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AU YPT, 1992, J BIOL CHEM, V267, P3438; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DAMON DH, 1992, EXP CELL RES, V201, P154, DOI 10.1016/0014-4827(92)90359-G; DICCIANNI MB, 1991, BIOCHEMISTRY-US, V30, P9090, DOI 10.1021/bi00101a026; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOUELI SA, 1991, FEBS LETT, V282, P445, DOI 10.1016/0014-5793(91)80533-9; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HERBERT JM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P432; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LIPPMAN M, 1968, EPITHELIAL MESENCHYM, P208; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; REILLY CF, 1989, J BIOL CHEM, V264, P6990; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199	28	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19173	19176						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690027				2022-12-25	WOS:A1993LW81900004
J	WONG, NCW; RAYMOND, J; CARR, FE				WONG, NCW; RAYMOND, J; CARR, FE			A LIVER-SPECIFIC NUCLEAR-PROTEIN REPRESSES TRANSCRIPTION OF THE S14 GENE IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RESPONSIVE GENE; THYROID-HORMONE; RAT-LIVER; MESSENGER-RNA; EXPRESSION; HYPOTHYROIDISM; PROMOTER; BINDING; REGION; LEVEL	P1 is a nuclear protein found exclusively in rat liver and binds to a motif that spans nucleotides -310 to -288 of the thyroid hormone responsive gene, S14. We expect P1 to play an important role in regulating gene expression because the binding motif for this factor is contained within a DNase I-hypersensitive site of S14 chromatin. In this report, we have attempted to define the function of P1 by correlating its DNA binding activity with levels of mRNA-S 14 in response to aging and obesity. Results of all studies revealed inverse relationships between the activity of P1 and levels of mRNA-S14, thus suggesting that P1 may function as a repressor of S14 gene expression. Accordingly, we tested the repressor hypothesis using cell-free transcription and transient transfection assays to measure the activity of reporter constructs with and without the P1 binding motif. In the presence of the P1 motif, S14 promoter activity was repressed and the negative effect on gene transcription was further enhanced by thyroid hormone. These observations are consistent with P1 being a repressor of S14 gene transcription.	UNIV CALGARY,DEPT MED,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA; WALTER REED ARMY MED CTR,KYLE METAB UNIT,WASHINGTON,DC 20307	University of Calgary; University of Calgary; United States Department of Defense; United States Army; Walter Reed National Military Medical Center								CARR FE, 1983, J CLIN INVEST, V72, P154, DOI 10.1172/JCI110953; DESCHAMPS BJ, 1992, J BIOL CHEM, V267, P25167; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1986, ENDOCRINOLOGY, V118, P1892, DOI 10.1210/endo-118-5-1892; JUMP DB, 1987, J BIOL CHEM, V262, P778; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KINLAW WB, 1989, J BIOL CHEM, V264, P19779; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; KNOWLES BB, 1984, ADV HEPATITIS RES; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LIAW CW, 1984, J BIOL CHEM, V259, P7253; Maniatis T., 1982, MOL CLONING; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; NARAYAN P, 1985, MOL CELL BIOL, V5, P2642, DOI 10.1128/MCB.5.10.2642; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PEREZCASTILLO A, 1987, AM J PHYSIOL, V253, pE530; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P869, DOI 10.1161/01.ATV.9.6.869; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; WATANABE K, 1987, J BIOL CHEM, V262, P4812; WONG NCW, 1990, J BIOL CHEM, V265, P8775; WONG NCW, 1989, J BIOL CHEM, V264, P4466	28	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19431	19435						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690031				2022-12-25	WOS:A1993LW81900045
J	TAKADA, Y; PUZON, W				TAKADA, Y; PUZON, W			IDENTIFICATION OF A REGULATORY REGION OF INTEGRIN-BETA-1 SUBUNIT USING ACTIVATING AND INHIBITING ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GP-IIB-IIIA; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; BETA-1 SUBUNIT; T-CELLS; 3-DIMENSIONAL STRUCTURE; SIGNAL TRANSDUCTION; LIGAND-BINDING; LYMPHOCYTES-T; CROSS-LINKING	Members of the beta1 integrin subfamily recognize multiple ligands such as fibronectin, laminin, and collagen and mediate cell-cell and cell-extracellular matrix interactions. Beta1 subunit may play a central role in regulating beta1 integrin avidity. Here we have identified a small region of beta1 subunit (residues 207-218) that is critical for the binding of both activating (8A2, A1A5, and TS2/16) and inhibiting (4B4, 4B5, 13, AIIB2, and P4C10) monoclonal antibodies against human beta1 using interspecies chimeric beta1 and site-directed mutagenesis. Chicken beta1 that has human sequence within residues 207-218 (CH mutant) is recognized by all the human specific antibodies listed above. The region 207-218 is located between the two putative ligand binding sites (residues 120-182 and 220-231), and the amino acid sequence of the region involves a predicted bend structure. The other anti-beta1 antibodies that do not affect cell attachment to ligands (K20, 102DF5, LM442, and LM534) recognized the carboxyl-terminal regions of extracellular domain of beta1 (residues 426-587 for K20 and 588-708 for 102DF5, LM442, and LM534, respectively). Our data suggest a potential mechanism for the avidity regulation of beta1 integrin through conformational changes of beta1 subunit.			TAKADA, Y (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, CVB-2, LA JOLLA, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BRACIALE TJ, 1986, J IMMUNOL, V137, P995; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHARO IF, 1991, J BIOL CHEM, V266, P1415; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; PHILLIPS DR, 1988, BLOOD, V71, P831; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SMITH JW, 1988, J BIOL CHEM, V263, P18726; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YAMADA A, 1991, J IMMUNOL, V146, P53; YAMADA A, 1991, EUR J IMMUNOL, V21, P319, DOI 10.1002/eji.1830210212; YAMADA KM, 1990, CANCER RES, V50, P4485; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628	53	207	212	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17597	17601						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688727				2022-12-25	WOS:A1993LQ98800102
J	GREENHALGH, DA; ROTHNAGEL, JA; WANG, XJ; QUINTANILLA, MI; ORENGO, CC; GAGNE, TA; BUNDMAN, DS; LONGLEY, MA; FISHER, C; ROOP, DR				GREENHALGH, DA; ROTHNAGEL, JA; WANG, XJ; QUINTANILLA, MI; ORENGO, CC; GAGNE, TA; BUNDMAN, DS; LONGLEY, MA; FISHER, C; ROOP, DR			HYPERPLASIA, HYPERKERATOSIS AND BENIGN-TUMOR PRODUCTION IN TRANSGENIC MICE BY A TARGETED V-FOS ONCOGENE SUGGEST A ROLE FOR FOS IN EPIDERMAL DIFFERENTIATION AND NEOPLASIA	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; MOUSE SKIN CARCINOGENESIS; TRANSCRIPTION FACTOR AP-1; KERATIN GENE-EXPRESSION; C-FOS; CHEMICAL CARCINOGENESIS; CELL-LINES; PROTEIN; JUN; ACTIVATION	A vector, derived from the human K1 keratin gene, has been employed to target v-fos expression exclusively in the epidermis of transgenic mice. Adult transgenic mice expressors (3-4 months) displayed hyperplasia and hyperkeratosis, initially in wounded (tagged) ears, which later became bilateral. This phenotype appeared at other epidermal sites, most notably in the axilla and inguinal areas. This indicates that a second promoting event, such as wounding or friction, is required to elicit these pathological changes. Highly keratotic benign ear lesions and benign squamous papillomas appeared after long latency at sites of phenotypic epidermis. These data suggest that v-fos may be interfering with c-fos function in normal keratinocyte differentiation, but by itself is insufficient to elicit overt benign lesions.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; UPJOHN CO,KALAMAZOO,MI 49001	Baylor College of Medicine; Pfizer			Rothnagel, Joe/A-4874-2010	Rothnagel, Joe/0000-0002-6710-3165	NCI NIH HHS [CA52607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALDAZ CM, 1988, CANCER RES, V48, P3253; ARGYRIS TS, 1982, CARCINOGENESIS COCAR, P43; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER PA, 1983, METHOD ENZYMOL, V96, P589; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; GREENHALGH DA, 1989, MOL CARCINOG, V3, P154; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOGAN B, 1986, MANIPULATING MOUSE E; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; Klein-Szanto A J, 1989, Carcinog Compr Surv, V11, P19; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS RJ, 1986, CANCER RES, V46, P3061; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V95, pS59, DOI 10.1111/1523-1747.ep12505805; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYNECK RP, 1991, ONCOGENE, V6, P533; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STRICKLAND JE, 1988, CANCER RES, V48, P165; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	63	59	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2145	2157						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687760				2022-12-25	WOS:A1993LP17100015
J	HJERMSTAD, SJ; PETERS, KL; BRIGGS, SD; GLAZER, RI; SMITHGALL, TE				HJERMSTAD, SJ; PETERS, KL; BRIGGS, SD; GLAZER, RI; SMITHGALL, TE			REGULATION OF THE HUMAN C-FES PROTEIN-TYROSINE KINASE (P93C-FES) BY ITS SRC HOMOLOGY-2 DOMAIN AND MAJOR AUTOPHOSPHORYLATION SITE (TYR-713)	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; FUJINAMI SARCOMA-VIRUS; CYTOPLASMIC SIGNALING PROTEINS; SH2 DOMAINS; V-FES; TRANSFORMING ACTIVITY; CATALYTIC DOMAINS; LEUKEMIA-CELLS; MYELOID CELLS; EXPRESSION	The c-fes proto-oncogene product is expressed predominantly in hematopoietic cells of the myeloid lineage and has been implicated in the regulation of myeloid differentiation. The c-fes locus encodes a 93-kDa protein tyrosine kinase (p93c-fes) that possesses several structural features characteristic of the cytoplasmic class of protein tyrosine kinases, including a consensus sequence for autophosphorylation surrounding Tyr-713 and a src homology 2 (SH2) domain. To assess the effect of each of these potential regulatory sites on p93c-fes protein tyrosine kinase activity, we specifically deleted the c-fes SH2 domain using the polymerase chain reaction and replaced Tyr-713 with phenylalanine by oligonucleotide-directed mutagenesis (Y713F mutant). The resulting mutants were expressed in Escherichia coli and assayed for changes in protein tyrosine kinase activity using an immune complex kinase assay. Both mutations produced a marked decrease in the rate and extent of autophosphorylation and phosphorylation of the model substrate, enolase. To test whether the c-fes SH2 domain could interact with the autophosphorylated kinase domain, the SH2 domain was expressed as a fusion protein with glutathione S-transferase and immobilized on glutathione-agarose. The recombinant c-fes SH2 domain precipitated p93c-fes as readily as a monoclonal antibody. Binding of the SH2 domain to p93c-fes was completely dependent upon autophosphorylation, as a kinase-defective mutant of p93c-fes was not precipitated by the SH2 domain. High-affinity binding was also observed with recombinant SH2 domains from v-src and v-fps, raising the possibility of protein-protein interactions between various members of the cytoplasmic PTK family. These results indicate that the c-fes SH2 domain and consensus autophosphorylation site (Tyr-713) play major roles in the positive regulation of p93c-fes tyrosine kinase activity, possibly through intramolecular interaction.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, 600 S 42ND ST, OMAHA, NE 68198 USA; UNIV NEBRASKA, DEPT BIOCHEM & MOLEC BIOL, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, CANC PHARMACOL SECT, WASHINGTON, DC 20007 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska System; University of Nebraska Medical Center; Georgetown University				Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [NCI P30 CA36727-08, NCI CA 58667, NCI CA 54231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA054231, R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOULET I, 1992, ONCOGENE, V7, P703; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOEFFLER HP, 1981, CANCER RES, V41, P919; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VEILLETTE A, 1992, ONCOGENE, V7, P971; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WOOD ER, 1992, J BIOL CHEM, V267, P14138; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	46	52	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2283	2292						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687763				2022-12-25	WOS:A1993LP17100031
J	DIAMOND, RH; DU, K; LEE, VM; MOHN, KL; HABER, BA; TEWARI, DS; TAUB, R				DIAMOND, RH; DU, K; LEE, VM; MOHN, KL; HABER, BA; TEWARI, DS; TAUB, R			NOVEL DELAYED-EARLY AND HIGHLY INSULIN-INDUCED GROWTH-RESPONSE GENES - IDENTIFICATION OF HRS, A POTENTIAL REGULATOR OF ALTERNATIVE PREMESSENGER RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE EXPRESSION; STIMULATED H-35 CELLS; IMMEDIATE-EARLY GENES; CULTURED MOUSE CELLS; REGENERATING LIVER; 3T3 CELLS; MOLECULAR-CLONING; PHOSPHOENOLPYRUVATE CARBOXYKINASE; LYMPHOCYTE MITOGENS; BINDING PROTEINS	We have identified 41 novel and many previously known growth response genes induced in regenerating liver and insulin-treated Reuber H35 cells, a rat hepatoma cell line that grows in response to physiologic concentrations of insulin and retains some properties of regenerating liver. Although many genes are expressed similarly in the two systems, there are important differences in the kinetics of induction of some genes. These differences allowed us to identify and characterize novel genes that are highly insulin-induced and expressed as delayed-early genes in regenerating liver. Sequence analysis of CL-6, the most abundant insulin-induced gene, resulted in the identification of a highly hydrophobic hepatic protein. Sequence analysis of HRS, a highly insulin-induced delayed-early gene, demonstrated that it is a member of the family of regulators of alternative pre-mRNA splicing. Different forms of HRS mRNA are temporally regulated during the growth response, suggesting that HRS could autoregulate processing of its pre-mRNA. Given the dramatic increase in RNA production during late G1, proteins induced by mitogens like insulin that control RNA processing are likely to have important roles in cell cycle regulation.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT MED,DIV GASTROENTEROL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NIDDK NIH HHS [K11 DK02096, K11 DK01905] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002096, K11DK001905] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARRA R, 1977, J EXP ZOOL, V201, P93, DOI 10.1002/jez.1402010111; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUCHER NLR, 1975, P NATL ACAD SCI USA, V72, P1157, DOI 10.1073/pnas.72.3.1157; BUCHER NLR, 1978, CELL REPRODUCTION HO, P661; BUCHER NLR, 1976, METABOLISM, V25, P14231; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHAMPLIN DT, 1991, GENE DEV, V5, P1611, DOI 10.1101/gad.5.9.1611; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; FAUSTO N, 1989, LAB INVEST, V60, P4; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JEFFERSON LS, 1980, DIABETES, V29, P487, DOI 10.2337/diab.29.6.487; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOONTZ JW, 1984, MOL CELL BIOCHEM, V58, P139, DOI 10.1007/BF00240613; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LIM RW, 1987, ONCOGENE, V1, P263; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LLOYD CE, 1987, J CELL PHYSL, V21, pC205; LU XP, 1992, J BIOL CHEM, V267, P2841; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PEAVY DE, 1985, ENDOCRIN METAB CLIN, V248, pE656; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAUB R, 1987, J BIOL CHEM, V262, P10893; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUMSTEIN P, 1987, J BIOL CHEM, V262, P11252	51	103	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15185	15192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686911				2022-12-25	WOS:A1993LL75900093
J	SCOTT, PG; DODD, CM; PRINGLE, GA				SCOTT, PG; DODD, CM; PRINGLE, GA			MAPPING THE LOCATIONS OF THE EPITOPES OF 5 MONOCLONAL-ANTIBODIES TO THE CORE PROTEIN OF DERMATAN SULFATE PROTEOGLYCAN-II (DECORIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN PROTEODERMATAN SULFATE; SMALL INTERSTITIAL PROTEOGLYCANS; BOVINE TEMPOROMANDIBULAR-JOINT; N-LINKED OLIGOSACCHARIDES; AMINO-ACID-SEQUENCES; CONNECTIVE TISSUES; ARTICULAR DISK; COLLAGEN; PREDICTION; MATRIX	Antibodies to dermatan sulfate proteoglycan II (decorin) have been used to study various aspects of the structure, function, and occurrence of this proteoglycan. The epitopes of five monoclonal antibodies (7B1, 5D1, 3B3, 6D6, and 1XA) were localized to specific cyanogen bromide fragments of the protein core separated by gel filtration. One large (159 residue) cyanogen bromide peptide was further digested with endoproteinase Lys-C and the peptides separated by reversed phase high performance liquid chromatography. In this way sequences of a suitable length (21-52 residues) for epitope mapping by synthesis of overlapping hexa- and octapeptides were identified. For each of the five monoclonal antibodies a short linear sequence with antigenic activity, from 4 to 8 amino acids long, depending on the particular antibody, was identified. The locations of the epitopes were correlated with various properties of the protein core predicted from the known amino acid sequence. It was observed that, at most, only one was localized in a region predicted to involve a beta-turn. Although four epitopes were in regions predicted to be moderately hydrophilic, accessible, and flexible, one was located in a hydrophobic sequence predicted to be highly inflexible and inaccessible. The implications of this observation in relation to the function of this proteoglycan are discussed.	UNIV WESTERN ONTARIO,DEPT PATHOL,LONDON N6A 5C1,ONTARIO,CANADA	Western University (University of Western Ontario)	SCOTT, PG (corresponding author), UNIV ALBERTA,DEPT ORAL BIOL,EDMONTON T6G 2N8,ALBERTA,CANADA.							BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DAMLE SP, 1982, J BIOL CHEM, V257, P5523; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRANZEN A, 1984, BIOCHEM J, V224, P59, DOI 10.1042/bj2240059; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAININ J, 1979, NATURE, V277, P491; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KRYSTEK SR, 1985, ENDOCRINOLOGY, V117, P1110, DOI 10.1210/endo-117-3-1110; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENNON DP, 1991, MATRIX, V11, P412, DOI 10.1016/S0934-8832(11)80196-4; MECHANIC G, 1979, SKELETAL RES EXPT AP, P227; NAKANO T, 1989, ARCH ORAL BIOL, V34, P749, DOI 10.1016/0003-9969(89)90082-4; NAKANO T, 1988, BIOMED RES-TOKYO, V9, P269, DOI 10.2220/biomedres.9.269; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PEARSON CH, 1986, ARCH ORAL BIOL, V31, P541, DOI 10.1016/0003-9969(86)90148-2; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PRINGLE GA, 1985, COLLAGEN REL RES, V5, P23; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCOTT JE, 1981, BIOCHEM J, V195, P573, DOI 10.1042/bj1950573; SCOTT JE, 1985, BIOCHEM SOC T, V13, P933, DOI 10.1042/bst0130933; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT PG, 1989, BIOCHEM SOC T, V17, P1031, DOI 10.1042/bst0171031; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; SCOTT PG, 1989, MATRIX, V9, P284, DOI 10.1016/S0934-8832(89)80004-6; SOBUE M, 1988, J HISTOCHEM CYTOCHEM, V36, P479, DOI 10.1177/36.5.3356894; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WINTERBOTTOM N, 1987, THESIS U ALBERTA; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	45	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11558	11564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685016				2022-12-25	WOS:A1993LF28400019
J	CSERMELY, P; SCHNAIDER, T; CHEATHAM, B; OLSON, MOJ; KAHN, CR				CSERMELY, P; SCHNAIDER, T; CHEATHAM, B; OLSON, MOJ; KAHN, CR			INSULIN INDUCES THE PHOSPHORYLATION OF NUCLEOLIN - A POSSIBLE MECHANISM OF INSULIN-INDUCED RNA EFFLUX FROM NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; MESSENGER-RNA; RAT-LIVER; NUCLEOSIDE TRIPHOSPHATASE; 3T3-L1 ADIPOCYTES; RIBOSOMAL-RNA; CELLS; TRANSPORT	Insulin induces the serine phosphorylation of the nucleolar protein nucleolin at subnanomolar concentrations in differentiated 3T3-442A cells. The stimulation is biphasic with phosphorylation reaching a maximum at 10 pM insulin and then declining to only 40% of basal levels at insulin concentrations of 1 muM. These changes are rapid, reaching half-maximal after 4 min and maximal after 15 min of incubation. The cell-permeable casein kinase II inhibitor 5,6-dichlorobenzimidazole-riboside prevents the insulin-stimulated phosphorylation of nucleolin suggesting that casein kinase II may mediate this effect of the hormone. Insulin-like growth factor 1 mimics the action of insulin on dephosphorylation of nucleolin at nanomolar concentrations suggesting that the latter effect may be mediated by insulin-like growth factor 1 receptors. Insulin treatment of 3T3-442A cells also results in a stimulation of RNA efflux from isolated, intact cell nuclei. The dose dependence of insulin-induced nucleolin phosphorylation and insulin-stimulated RNA efflux from intact cell nuclei are almost identical. Insulin induces an increase in the RNA efflux at subnanomolar concentrations in 3T3-442A adipocytes, while high (micromolar) concentrations of insulin inhibited the efflux of RNA. These data indicate that insulin regulates the phosphorylation/dephosphorylation of nucleolin, possibly via stimulation of casein kinase II, and this may play a role in regulation of the RNA efflux from nuclei.	JOSLIN DIABET CTR,DIV RES,ONE JOSLIN PL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MISSISSIPPI,MED CTR,JACKSON,MS 39216	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Mississippi; University of Mississippi Medical Center			Kahn, Ronald/AAY-2435-2021; Csermely, Peter/J-2067-2017	Kahn, Ronald/0000-0002-7583-9228; Csermely, Peter/0000-0001-9234-0659	FOGARTY INTERNATIONAL CENTER [F05TW004319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK033201] Funding Source: NIH RePORTER; FIC NIH HHS [1F05 TW04319-01 B1-5] Funding Source: Medline; NIDDK NIH HHS [DK 36836, DK 33201] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUTTER PS, 1979, BIOCHEM J, V182, P811, DOI 10.1042/bj1820811; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON H, 1983, FEBS LETT, V155, P218, DOI 10.1016/0014-5793(82)80606-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHEN CM, 1991, J BIOL CHEM, V266, P7754; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CZECH MP, 1988, J BIOL CHEM, V263, P11017; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FRIEDMAN DL, 1988, J BIOL CHEM, V263, P1103; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KLARLUND JK, 1991, J BIOL CHEM, V266, P4052; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MARMACK MD, 1979, BIOCHEMISTRY-US, V18, P3381; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; OLSON MOJ, 1974, J BIOL CHEM, V249, P2823; OLSON MOJ, 1981, EXP CELL RES, V135, P259, DOI 10.1016/0014-4827(81)90161-0; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PURRELLO F, 1983, P NATL ACAD SCI-BIOL, V80, P1189, DOI 10.1073/pnas.80.5.1189; PURRELLO F, 1982, SCIENCE, V216, P1005, DOI 10.1126/science.6281885; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHINDLER M, 1987, J CELL BIOL, V104, P849, DOI 10.1083/jcb.104.4.849; SCHNEIDER HR, 1989, EUR J BIOCHEM, V180, P449, DOI 10.1111/j.1432-1033.1989.tb14667.x; SCHNEIDER HR, 1989, BIOCHIM BIOPHYS ACTA, V1014, P98, DOI 10.1016/0167-4889(89)90246-2; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; SCHRODER HC, 1990, BIOCHEMISTRY-US, V29, P2368, DOI 10.1021/bi00461a022; SCHUMM DE, 1981, ARCH BIOCHEM BIOPHYS, V210, P275, DOI 10.1016/0003-9861(81)90190-9; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUZUKI N, 1991, BIOCHIM BIOPHYS ACTA, V1092, P367, DOI 10.1016/S0167-4889(97)90014-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804	51	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9747	9752						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683660				2022-12-25	WOS:A1993LA68900087
J	BREUKINK, E; NOUWEN, N; VANRAALTE, A; MIZUSHIMA, S; TOMMASSEN, J; DEKRUIJFF, B				BREUKINK, E; NOUWEN, N; VANRAALTE, A; MIZUSHIMA, S; TOMMASSEN, J; DEKRUIJFF, B			THE C-TERMINUS OF SECA IS INVOLVED IN BOTH LIPID-BINDING AND SECB BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION ATPASE; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; ACIDIC PHOSPHOLIPIDS; ESSENTIAL COMPONENT; INNER MEMBRANES; SIGNAL SEQUENCE; PHOSPHATIDYLGLYCEROL; SECRETION; PEPTIDE	Using C-terminal deletion mutations in secA, we localized the previously proposed (Breukink, E., Keller, R. C. A., and de Kruijff, B. (1993), FEBS Lett. 331, 19-24) second lipid binding site on Seek Since removal of these residues completely abolished the property of SecA to cause aggregation of negatively charged phosphatidylglycerol vesicles, we conclude that the C-terminal 70 amino acid residues of SecA are involved in lipid-binding. The C-terminal 70 amino acid residues of SecA are important for efficient in vitro translocation of the SecB dependent precursor of PhoE across inverted inner membrane vesicles, Moreover, in vivo studies showed that this region is essential for growth. SecB and a SecB-precursor complex were shown to inhibit the SecA-mediated lipid vesicle aggregation, suggesting that the overall acidic SecB protein binds at or near the second lipid binding site on Seek This together with the observation that the SecA mutant protein lacking the C-terminal 70 residues had a strongly reduced ability to mediate binding of SecB-precursor complexes to inverted inner membrane vesicles demonstrates that the C terminus of SecA is also involved in SecB binding.	UNIV UTRECHT, INST BIOMEMBRANES, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT BIOCHEM MEMBRANES, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT MOLEC CELL BIOL, 3584 CH UTRECHT, NETHERLANDS; TOKYO COLL PHARM & LIFE SCI, SCH LIFE SCI, HACHIOJI, TOKYO 19203, JAPAN	Utrecht University; Utrecht University; Utrecht University; Tokyo University of Pharmacy & Life Sciences			Breukink, Eefjan/I-3039-2016; Tommassen, Jan/I-1690-2016	Breukink, Eefjan/0000-0002-7311-0660; Tommassen, Jan/0000-0001-7633-4945				AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; Bolivar F, 1979, Methods Enzymol, V68, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1993, FEBS LETT, V331, P19, DOI 10.1016/0014-5793(93)80289-7; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; JACQ A, 1993, CURR OPIN STRUC BIOL, V3, P541, DOI 10.1016/0959-440X(93)90080-5; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; KUSTERS R, 1994, J BIOL CHEM, V269, P1560; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Maniatis T., 1982, MOL CLONING; MATSUYAMA S, 1989, J BIOL CHEM, V264, P3583; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PHOENIX DA, 1993, FEBS LETT, V324, P113, DOI 10.1016/0014-5793(93)81543-9; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SCHMIDT MG, 1991, J BACTERIOL, V173, P6605, DOI 10.1128/jb.173.20.6605-6611.1991; SHIBUYA I, 1985, J BACTERIOL, V161, P1086, DOI 10.1128/JB.161.3.1086-1092.1985; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMANE K, 1987, J BIOL CHEM, V262, P2358	41	136	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7902	7907		10.1074/jbc.270.14.7902	http://dx.doi.org/10.1074/jbc.270.14.7902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713885	hybrid			2022-12-25	WOS:A1995QR52600021
J	JEOHN, GH; TAKAHASHI, K				JEOHN, GH; TAKAHASHI, K			PURIFICATION AND CHARACTERIZATION OF A VASOACTIVE INTESTINAL POLYPEPTIDE-DEGRADING ENDOPROTEASE FROM PORCINE ANTRAL MUCOSAL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC-MUCOSA; PROCESSING ENDOPROTEASES; SYNAPTIC-MEMBRANES; SUBSTANCE-P; ENDOPEPTIDASE; SECRETION; CLEAVAGE; STOMACH; ACID; NEUROTENSIN	A neutral endoprotease was isolated from porcine antral mucosa and purified to homogeneity as examined by SDS-polyacrylamide gel electrophoresis (PAGE). Throughout the purification, t-butyloxycarbonyl-Arg-Val-Arg-Arg-4-methylcoumaryl-7-amide (MCA) was used as a substrate, which was found to be hydrolyzed specifically by the enzyme at the Arg-Arg bond. Unexpectedly, however, the enzyme was also found to hydrolyze vasoactive intestinal polypeptide (VIP) fairly specifically and more efficiently when various neuropeptides and related peptides were examined as substrates. It could degrade VIP by cleaving three peptides bonds not containing an arginine residues(s) with K-m = 7.7 x 10(-6) M and k(cat)/K-m = 7.4 x 10(6) M(-1) s(-1) (at pH 7.6 in the presence of 0.1% Lubrol PX), whereas only secretin, substance P, and a few others were hydrolyzed at much slower rates among the various peptides examined. Both activities toward the MCA substrate and VIP behaved in parallel throughout the purification procedures and showed essentially the same pH optimum and susceptibility toward various inhibitors and detergents. Therefore, both activities are thought to be due to the same enzyme. This endoprotease required 0.001% or a higher concentration of a detergent such as Lubrol PX or Triton X-100 for its maximal activity. Its optimum pH was about 7.5 and the molecular weight was estimated to be approximately 37,000 by SDS-PAGE. This enzyme was strongly inhibited by serine protease inhibitors such as diisopropylfluorophosphate and phenylmethanesulfonyl fluoride. It was also inhibited by p-chloromercuribenzoic acid, but not by some other cysteine protease inhibitors. Therefore, the enzyme appears to be most likely a kind of serine protease although its possibility as a cysteine protease cannot be completely excluded. Analysis of its cleavage specific amino acid sequences(s) and/or conformation in the vicinity of the cleavage site of the target peptide. Various characteristics of the endoprotease suggest that it is a novel membrane-bound neuropeptide-degrading endoprotease fairly specific for VIP.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BUNNETT NW, 1990, AM J PHYSIOL, V258, pG143, DOI 10.1152/ajpgi.1990.258.1.G143; BUNNETT NW, 1992, GASTROENTEROLOGY, V102, P76, DOI 10.1016/0016-5085(92)91786-4; CARVALHO KD, 1992, P NATL ACAD SCI USA, V89, P84, DOI 10.1073/pnas.89.1.84; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CHECLER F, 1985, J NEUROCHEM, V45, P1509, DOI 10.1111/j.1471-4159.1985.tb07220.x; FELLEY CP, 1992, AM J PHYSIOL, V263, pG901, DOI 10.1152/ajpgi.1992.263.6.G901; Fruton J. S., 1971, ENZYMES, V3, P119; GOETZL EJ, 1989, BIOCHEM BIOPH RES CO, V158, P850, DOI 10.1016/0006-291X(89)92800-3; HIRAO T, 1984, J BIOCHEM-TOKYO, V95, P871, DOI 10.1093/oxfordjournals.jbchem.a134680; HOSOI K, 1978, BIOCHEM BIOPH RES CO, V85, P558, DOI 10.1016/0006-291X(78)91199-3; JOUDIOU C, 1993, BICOHEMISTRY, V32, P5969; KAGEYAMA T, 1980, J BIOCHEM, V87, P725, DOI 10.1093/oxfordjournals.jbchem.a132801; KEAST JR, 1985, J COMP NEUROL, V236, P403, DOI 10.1002/cne.902360308; KOBAYASHI R, 1994, PEPTIDES, V15, P323, DOI 10.1016/0196-9781(94)90020-5; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1957, METHOD ENZYMOL, V4, P371; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MILLICAN PE, 1991, BIOCHEM J, V276, P583, DOI 10.1042/bj2760583; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OZAKI H, 1992, J PHYSIOL-LONDON, V447, P351, DOI 10.1113/jphysiol.1992.sp019006; Perrin D.D, 1974, BUFFERS PH METAL ION, P48; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SCHUBERT ML, 1993, GASTROENTEROLOGY, V104, P834, DOI 10.1016/0016-5085(93)91020-I; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAYLOR IL, 1991, TXB GASTROENTEROLOGY, V1, P24; TAZISAAD K, 1992, PEPTIDES, V13, P233, DOI 10.1016/0196-9781(92)90102-9; TERASHIMA H, 1992, PEPTIDES, V13, P71; TSURU D, 1978, J BIOCHEM, V84, P467, DOI 10.1093/oxfordjournals.jbchem.a132148; UCHINO T, 1993, J BIOL CHEM, V268, P527; USUI Y, 1982, BIOCHIM BIOPHYS ACTA, V719, P539, DOI 10.1016/0304-4165(82)90244-6; WANG YX, 1993, PEPTIDES, V14, P573, DOI 10.1016/0196-9781(93)90147-9; WOOLLEY DE, 1976, BIOCHEM J, V153, P119, DOI 10.1042/bj1530119	36	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7809	7815		10.1074/jbc.270.14.7809	http://dx.doi.org/10.1074/jbc.270.14.7809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713870	hybrid			2022-12-25	WOS:A1995QR52600006
J	TIPPLES, G; MCCLARTY, G				TIPPLES, G; MCCLARTY, G			CLONING AND EXPRESSION OF THE CHLAMYDIA-TRACHOMATIS GENE FOR CTP SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; RELA GENE; SEQUENCE; REGION	A HindIII partial digest Chlamydia trachomatis L2 Library in pUC19 was screened for the CTP synthetase gene by functional complementation in CTP synthetase-deficient Escherichia coli JF646. A complementing clone was isolated and contained a recombinant plasmid (pH-1) with a 2.7-kilobase C. trachomatis DNA insert. The entire insert was sequenced and found to encode two complete open reading frames (ORFs) that overlapped by 25 bases and the start of a third ORF that overlapped with ORF2 by 14 bases. The derived amino acid sequence of ORFs 1 and 2 shows 37% identity to kdsB, an E. coli gene that codes for CMP-2-keto-3-deoxyoctulosonic acid synthetase and 48% identity to pyrG, an E. coli gene that codes for CTP synthetase, respectively. To obtain downstream sequence data for ORF3, colony hybridization screening of the HindIII. chlamydial DNA library was used to isolate a second recombinant plasmid (pH-11) that contained a 1.7-kilobase chlamydial DNA insert. The deduced amino acid sequence of ORF3 is not significantly homologous to any protein in the translated GenBank data base. Recombinant chlamydial CTP synthetase appears to be similar to the E. coli enzyme in that it is sensitive to inhibition by CTP, requires UTP, ATP, Mg2+, GTP, and glutamine for activity, and can also utilize ammonia as an amido-group donor.	UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA	University of Manitoba								ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BIRKELUND S, 1992, J BACTERIOL, V174, P2742, DOI 10.1128/JB.174.9.2742-2747.1992; FAN HZ, 1991, J BACTERIOL, V173, P6670, DOI 10.1128/jb.173.21.6670-6677.1991; FRAIZ J, 1988, ANNU REV MED, V39, P357, DOI 10.1146/annurev.me.39.020188.002041; FRIESEN JD, 1976, J BACTERIOL, V127, P917, DOI 10.1128/JB.127.2.917-922.1976; FRIESEN JD, 1978, CELL, V15, P1187, DOI 10.1016/0092-8674(78)90045-4; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; KOSHLAND DE, 1994, ENZYMES, V10, P539; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Long C, 1978, Methods Enzymol, V51, P79; MAMT U, 1993, MOL MICROBIOL, V10, P935; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; MCCLARTY G, 1993, J BACTERIOL, V175, P4652, DOI 10.1128/JB.175.15.4652-4661.1993; McClarty Grant, 1994, Trends in Microbiology, V2, P157, DOI 10.1016/0966-842X(94)90665-3; MCPARTLAND RP, 1979, J BIOL CHEM, V254, P1394; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; OZIERKALOGEROPO.O, 1991, MOL GEN GENET, V0231; OZIERKALOGEROPO.O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PAZZANI C, 1993, J BACTERIOL, V175, P5978, DOI 10.1128/JB.175.18.5978-5983.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Sambrook J, 1989, MOL CLONING LABORATO; Stephens RS., 1993, INFECT AGENT DIS, V1, P279; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; UNGER FM, 1981, ADV CARBOHYD CHEM BI, V38, P23; WANG LL, 1994, MOL MICROBIOL, V14, P271, DOI 10.1111/j.1365-2958.1994.tb01288.x; WENG M, 1986, J BIOL CHEM, V261, P5568; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; ZALKIN H, 1988, J BIOL CHEM, V263, P1595	30	29	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7908	7914		10.1074/jbc.270.14.7908	http://dx.doi.org/10.1074/jbc.270.14.7908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713886	hybrid			2022-12-25	WOS:A1995QR52600022
J	BERNARDS, MA; LOPEZ, ML; ZAJICEK, J; LEWIS, NG				BERNARDS, MA; LOPEZ, ML; ZAJICEK, J; LEWIS, NG			HYDROXYCINNAMIC ACID-DERIVED POLYMERS CONSTITUTE THE POLYAROMATIC DOMAIN OF SUBERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED POTATO PERIDERM; SOLID-STATE; ANIONIC PEROXIDASE; SOLANUM-TUBEROSUM; CELL-WALL; LIGNIN; C-13; TYRAMINE; TISSUE; CUTINS	Suberin is an abundant, complex, intractable, plant cell wall polymeric network that forms both protective and wound-healing layers. Its function is, therefore, critical to the survival of all vascular plants. Its chemical structure and biosynthesis are poorly defined, although it is known to consist of both aromatic and aliphatic domains, While the composition of the aliphatic component has been fairly well characterized, that of the phenolic component has not. Using a combination of specific carbon-13 labeling techniques, and in situ solid state C-13 NMR spectroscopic analysis, we now provide the first direct evidence for the nature of the phenolic domain of suberin and report here that it is almost exclusively comprised of a covalently linked, hydroxycinnamic acid-derived polymeric matrix.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, CTR NMR SPECT, PULLMAN, WA 99164 USA	Washington State University; Washington State University				Lewis, Norman/0000-0001-5742-032X				ADAMOVICS JA, 1977, PHYTOCHEMISTRY, V16, P1089, DOI 10.1016/S0031-9422(00)86746-1; BERNARDS MA, 1992, PHYTOCHEMISTRY, V31, P3409, DOI 10.1016/0031-9422(92)83695-U; BORGOLIVIER O, 1989, CR ACAD SCI III-VIE, V308, P141; BORGOLIVIER O, 1993, PHYTOCHEMISTRY, V32, P601, DOI 10.1016/S0031-9422(00)95143-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTLE W, 1982, PLANT PHYSIOL, V69, P393, DOI 10.1104/pp.69.2.393; EBERHARDT TL, 1993, J BIOL CHEM, V268, P21088; Esau K., 1977, ANATOMY SEED PLANTS, P183; ESPELIE KE, 1986, PLANT PHYSIOL, V81, P487, DOI 10.1104/pp.81.2.487; GARBOW JR, 1989, PLANT PHYSIOL, V90, P783, DOI 10.1104/pp.90.3.783; HAYASHI S, 1991, B CHEM SOC JPN, V64, P685, DOI 10.1246/bcsj.64.685; KATAYAMA T, 1987, TECH B FAC AGR KAGAW, V39, P47; KOLATTUKUDY PE, 1984, CAN J BOT, V62, P2918, DOI 10.1139/b84-391; KOLATTUKUDY PE, 1974, PLANT PHYSIOL, V54, P116, DOI 10.1104/pp.54.1.116; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P47, DOI 10.1515/hfsg.1986.40.1.47; LEWIS NG, 1987, SCIENCE, V237, P1344, DOI 10.1126/science.237.4820.1344; LEWIS NG, 1987, MACROMOLECULES, V20, P1752, DOI 10.1021/ma00174a006; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; LEWIS NG, 1994, ACS SYM SER, V562, P202; LOFTY S, 1994, PHYTOCHEMISTRY, V35, P1419, DOI 10.1016/S0031-9422(00)86867-3; MATZKE K, 1991, PLANTA, V185, P233, DOI 10.1007/BF00194066; NEGREL J, 1993, J PLANT PHYSIOL, V142, P518, DOI 10.1016/S0176-1617(11)80392-5; RALPH J, 1992, J CHEM SOC PERK T 1, P2971, DOI 10.1039/p19920002971; RILEY RG, 1975, PLANT PHYSIOL, V56, P650, DOI 10.1104/pp.56.5.650; ROBERTS E, 1988, PLANT MOL BIOL, V11, P15, DOI 10.1007/BF00016010; SCHMUTZ A, 1993, PLANTA, V189, P453, DOI 10.1007/BF00194445; STARK RE, 1994, PLANT PHYSIOL, V104, P527, DOI 10.1104/pp.104.2.527; STARK RE, 1989, ACS SYM SER, V399, P214; WUTHRICH K, 1976, NMR BIOL RES PEPTIDE, P178; YOUNG MR, 1966, CAN J BOTANY, V44, P341, DOI 10.1139/b66-040; ZIMMERMANN W, 1985, HOLZFORSCHUNG, V39, P45, DOI 10.1515/hfsg.1985.39.1.45	31	141	147	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7382	7386		10.1074/jbc.270.13.7382	http://dx.doi.org/10.1074/jbc.270.13.7382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706282	hybrid			2022-12-25	WOS:A1995QQ43100055
J	DUFF, JL; MONIA, BP; BERK, BC				DUFF, JL; MONIA, BP; BERK, BC			MITOGEN-ACTIVATED PROTEIN (MAP) KINASE IS REGULATED BY THE MAP KINASE PHOSPHATASE (MKP-1) IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; 3CH134; PROLIFERATION; STIMULATION	Angiotensin II stimulates hypertrophic growth of vascular smooth muscle cells (VSMC) and activates many growth-promoting kinases such as mitogen activated protein (MAP) kinase, A novel transcriptionally regulated phosphatase, MAP kinase phosphatase-l (MKP-1), is induced by angiotensin II in VSMC and selectively dephosphorylates MAP kinase in vitro. Using actinomycin D and antisense oligonucleotides targeted to MKP-1, we demonstrate that MKP-1 regulates MAP kinase in VSMC. Both actinomycin D and MKP-1 antisense oligo nucleotides inhibited MKP-1 mRNA expression and caused prolonged activation of the p42 and p44 MAP kinases as measured by in-gel kinase assays and Western blot, For example, MAP kinase activity 120 min after angiotensin II treatment was 30% (range 25-35%), 79%, and 74% of maximum in control, actinomycin D-treated (3 mu g/ml, 30 min), and antisense oligonucleotide-treated (300 nM, 6 h) cells, respectively. A sense oligonucleotide was without effect (34%). MKP-1 antisense oligonucleotides did not affect the activity of MEK indicating that sustained activation of MAP kinase was due to inhibition of MKP-1 expression. These findings demonstrate that inactivation of MAP kinase by angiotensin II is mediated predominantly by MKP-1, suggesting an important role for MKP-1 and other related phosphatases in the regulation of MAP kinases in VSMC.	UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195; EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322; ISIS PHARMACEUT,DEPT MOLEC PHARMACOL,CARLSBAD,CA 92008	University of Washington; University of Washington Seattle; Emory University; Isis Pharmaceuticals Inc				Berk, Bradford/0000-0002-2767-4115				ALESSI DR, 1993, ONCOGENE, V8, P2015; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAN JH, 1993, J BIOL CHEM, V268, P25009; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KING A, 1994, J CELL BIOCH B, V18, pI438; KOZMA LM, 1992, METHOD ENZYMOL, V201, P28; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MONIA BP, 1992, J BIOL CHEM, V267, P19954; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; PANG L, 1994, J BIOL CHEM, V269, P10604; PELECH SL, 1993, SCIENCE, V257, P1355; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	41	173	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7161	7166		10.1074/jbc.270.13.7161	http://dx.doi.org/10.1074/jbc.270.13.7161			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706254	hybrid			2022-12-25	WOS:A1995QQ43100025
J	HOUSTEK, J; ANDERSSON, U; TVRDIK, P; NEDERGAARD, J; CANNON, B				HOUSTEK, J; ANDERSSON, U; TVRDIK, P; NEDERGAARD, J; CANNON, B			THE EXPRESSION OF SUBUNIT-C CORRELATES WITH AND THUS MAY LIMIT THE BIOSYNTHESIS OF THE MITOCHONDRIAL F0F1-ATPASE IN BROWN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN COMPONENTS; SYNTHASE BETA-SUBUNIT; ATP SYNTHASE; UNCOUPLING PROTEIN; BINDING-SITES; MESSENGER-RNA; RAT-LIVER; TRANSLATIONAL EFFICIENCY; THERMOGENIC MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE	A low content of mitochondrial ATPase in brown adipose tissue (BAT) has previously been found to contrast with high levels of the transcripts of the beta-subunit of the F-1 part of the ATPase and of the transcripts of the mitochondrial encoded subunits (Houstek, J., Tvrdik, P., Pavelka, S., and Baudysova, M. (1991) FEES Lett. 294, 191-194). To delineate which subunit limits the synthesis of the ATPase complex, we have studied the expression of the nuclear genes encoding subunits alpha, beta, and gamma of the catalytic F-1 part and the b, c, d, and OSCP subunits of the F-0 part of the ATPase. In comparison with other tissues of mice, high levels of transcripts of alpha-F-1, beta-F-1, gamma-F-1, b-F-0, d-F-0, and OSCP were found in BAT. The only genes expressed at a low level in BAT were those of the c-F-0 subunit. The levels of c-F, transcripts were 4-70-fold lower in BAT than in other tissues. An analogous expression pattern of the ATPase genes was found in BAT of adult rat and hamster, In BAT of newborn lamb, which, in contrast to other mammals, has a high content of mitochondrial ATPase, correspondingly high levels of c-F-0 mRNA were found, Expression of the c-F-0 genes also correlated well with the ontogenic development of EAT in the hamster, being high during the first postnatal week when mitochondria are nonthermogenic and contain a relatively high amount of ATPase, but low on subsequent days when ATPase content decreases, as the thermogenic function develops. It is suggested that expression of the c-P-0 genes and subsequent synthesis of the hydrophobic subunit c of the membrane-intrinsic F-0 part of the enzyme may control the biosynthesis of the ATPase complex in BAT. An analogous regulatory role of the c-F-0 subunit could be postulated in other tissues.	UNIV STOCKHOLM,WENNER GREN INST,ARRHENIUS LABS F3,S-10691 STOCKHOLM,SWEDEN	Stockholm University	HOUSTEK, J (corresponding author), ACAD SCI CZECH REPUBL,INST PHYSIOL,VIDENSKA 1083,CR-14220 PRAGUE,CZECH REPUBLIC.		Nedergaard, Jan/A-1706-2010; Tvrdik, Petr/AAK-4398-2021; Nedergaard, Jan/Q-8286-2019; Houstek, Josef/C-5019-2012; Andersson, Ulf/ABD-5162-2021; Cannon, Barbara/B-3089-2016	Houstek, Josef/0000-0002-8413-4772; Andersson, Ulf/0000-0003-0316-3860; Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587; Tvrdik, Petr/0000-0002-8750-9672				ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON B, 1977, COMP BIOCHEM PHYS B, V56, P87, DOI 10.1016/0305-0491(77)90227-9; CANNON B, 1977, FEBS LETT, V76, P284, DOI 10.1016/0014-5793(77)80169-5; CASTEILLA L, 1987, AM J PHYSIOL, V252, pE627, DOI 10.1152/ajpendo.1987.252.5.E627; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FARRELL LB, 1987, BIOCHEM BIOPH RES CO, V144, P1257, DOI 10.1016/0006-291X(87)91446-X; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HOUSTEK J, 1988, EUR J BIOCHEM, V173, P1, DOI 10.1111/j.1432-1033.1988.tb13959.x; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P441, DOI 10.1016/0005-2728(90)90077-H; HOUSTEK J, 1978, COMP BIOCHEM PHYS B, V60, P209, DOI 10.1016/0305-0491(78)90088-3; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; HOUSTEK J, 1991, FEBS LETT, V294, P191, DOI 10.1016/0014-5793(91)80666-Q; HOUSTEK J, 1977, BIOCHIM BIOPHYS ACTA, V484, P127, DOI 10.1016/0005-2744(77)90119-X; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; LUIS AM, 1993, J BIOL CHEM, V268, P1868; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NEDERGAARD J, 1979, METHOD ENZYMOL, V55, P1; Nicholls D. G., 1986, BROWN ADIPOSE TISSUE; RICQUIER D, 1986, BROWN ADIPOSE TISSUE; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; SVOBODA P, 1981, BIOCHIM BIOPHYS ACTA, V634, P321, DOI 10.1016/0005-2728(81)90150-X; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TVRDIK P, 1992, FEBS LETT, V313, P23, DOI 10.1016/0014-5793(92)81175-L; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764	46	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7689	7694		10.1074/jbc.270.13.7689	http://dx.doi.org/10.1074/jbc.270.13.7689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706317	hybrid			2022-12-25	WOS:A1995QQ43100095
J	PEEBLES, RS; MALISZEWSKI, CR; SATO, TA; HANLEYHYDE, J; MAROULAKOU, IG; HUNZIKER, R; SCHNECK, JP; GREEN, JE				PEEBLES, RS; MALISZEWSKI, CR; SATO, TA; HANLEYHYDE, J; MAROULAKOU, IG; HUNZIKER, R; SCHNECK, JP; GREEN, JE			ABNORMAL B-CELL FUNCTION IN HTLV-I-TAX TRANSGENIC MICE	ONCOGENE			English	Article						HTLV-I; GROWTH FACTORS; B-CELLS; TRANSGENIC MICE; LYMPHOPROLIFERATION; AUTOIMMUNE DISEASE	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; COLONY-STIMULATING FACTOR; PRIMARY SJOGRENS-SYNDROME; EPSTEIN-BARR-VIRUS; HEPATITIS-C VIRUS; INTERLEUKIN-2 RECEPTOR; MOUSE MODEL; ACTIVATION; GENE	Transgenic mice that carry the HTLV-I Tax gene develop an exocrinopathy with some similarities to Sjoegren's syndrome. Our experiments reveal that these mice have lymphadenopathy and splenomegaly composed primarily of B lymphocytes, as well as abnormal levels of secreted immunoglobulins. To gain insight into whether the lymphadenopathy manifested by these transgenic mice was the result of induction of cytokines by Tax, we utilized cell lines from these mice to study in vitro B-cell responses. Conditioned media (CM) derived from the cell lines caused B-cells to proliferate when a second signal, surface Ig cross-linking, was provided. The CM also caused a marked enhancement of IgM secretion by spleen cells or by purified B-cells treated with supplemental cytokines. The B-cell proliferative response and enhanced IgM secretion have not been attributed to a known cytokine. These results suggest that the CM from the cell lines contain a factor(s) involved in novel pathways of B-cell growth and differentiation that may participate in the pathologic development of autoimmune disease.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224; NCI,GENET LAB,BETHESDA,MD 20892; IMMUNEX CORP,DEPT CELLULAR IMMUNOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Immunex Corporation								ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P186; BABOONIAN C, 1990, ARTHRITIS RHEUM, V33, P1749, DOI 10.1002/art.1780331122; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FLESCHER E, 1992, ARTHRITIS RHEUM, V35, P1068, DOI 10.1002/art.1780350912; FOX RI, 1993, J RHEUMATOL, V20, P764; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GESSAIN A, 1985, LANCET, V2, P407; GREEN JE, 1992, AM J PATHOL, V140, P1401; GREEN JE, 1991, MOL CELL BIOL, V11, P4635, DOI 10.1128/MCB.11.9.4635; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITESCU S, 1991, RHEUM DIS CLIN N AM, V17, P99; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KARAMERIS A, 1992, CLIN EXP RHEUMATOL, V10, P327; LAVOIE TB, 1992, J IMMUNOL, V1148, P503; LILENBAUM A, 1990, J VIROL, V64, P256; LINDAHL G, 1985, CLIN EXP IMMUNOL, V61, P475; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARIETTE X, 1993, ARTHRITIS RHEUM, V36, P280, DOI 10.1002/art.1780360225; MARKUSSE HM, 1993, CLIN IMMUNOL IMMUNOP, V66, P26, DOI 10.1006/clin.1993.1004; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OUTSCHOORN I, 1993, CLIN IMMUNOL IMMUNOP, V66, P59, DOI 10.1006/clin.1993.1008; PFLUGFELDER SC, 1993, AM J PATHOL, V143, P49; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROUSSEAU PG, 1989, MOL IMMUNOL, V26, P993, DOI 10.1016/0161-5890(89)90118-1; SHATTLES WG, 1991, CLIN EXP IMMUNOL, V89, P46; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TALAL N, 1990, CLIN EXP RHEUMATOL, V8, P23; TALAL N, 1991, B RHEUM DIS, V40, P6; TATEISHI M, 1993, ARTHRITIS RHEUM, V36, P827, DOI 10.1002/art.1780360614; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980; YUAN D, 1992, INT IMMUNOL, V4, P1373, DOI 10.1093/intimm/4.12.1373	40	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1045	1051						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700628				2022-12-25	WOS:A1995QN35300003
J	OTEY, CA; VASQUEZ, GB; BURRIDGE, K; ERICKSON, BW				OTEY, CA; VASQUEZ, GB; BURRIDGE, K; ERICKSON, BW			MAPPING OF THE ALPHA-ACTININ BINDING-SITE WITHIN THE BETA-1 INTEGRIN CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; OVERLAY TECHNIQUE; VINCULIN; PROTEINS; TALIN; ADHESION; MUSCLE	The actin cross-linking protein alpha-actinin binds to the cytoplasmic domain of the beta1 subunit of integrin, suggesting that alpha-actinin may form a direct link between the actin cytoskeleton and the transmembrane fibronectin receptor. In this study, we have used short synthetic peptides to localize the binding site for alpha-actinin within the cytoplasmic domain of beta1 integrin. Four 13-residue peptides were tested in both an affinity chromatographic assay and a solid-phase binding assay. The results indicated that two regions of sequence contribute to the binding of alpha-actinin: one near where the beta1 cytoplasmic tail emerges from the membrane and a second segment located near the C terminus of the cytoplasmic tail. This binding pattern was investigated in more detail using an adaptation of the mimotope assay, in which each of the 32 overlapping sequential decapeptide segments from the beta1 cytoplasmic domain was assembled on the head of a different plastic pin. The peptide-pin constructs were used to detect the binding of I-125-alpha-actinin. As predicted from our initial results, alpha-actinin was found to bind to two distinct clusters of peptide segments. This represents a novel use of the mimotope pin assay to map interactive sites on structural proteins.	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042031, R01GM029860] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29860, GM-42031] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOLDMANN WH, 1991, BIOCHEM BIOPH RES CO, V178, P718, DOI 10.1016/0006-291X(91)90167-6; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SIMON KO, 1991, CURR TOP MEMBR, V38, P57; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WILKINS JA, 1983, BIOCHEM BIOPH RES CO, V116, P1026, DOI 10.1016/S0006-291X(83)80245-9	22	242	248	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21193	21197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691808				2022-12-25	WOS:A1993MA28800081
J	KIM, JS; RAINES, RT				KIM, JS; RAINES, RT			BOVINE SEMINAL RIBONUCLEASE PRODUCED FROM A SYNTHETIC GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; TRANSLATION INITIATION; QUATERNARY STRUCTURE; SECONDARY STRUCTURE; EXPRESSION; DEGRADATION; SEQUENCE	Bovine seminal ribonuclease (BS-RNase), a homolog of bovine pancreatic ribonuclease (RNase A), is isolated as a dimer in which the subunits are cross-linked by two disulfide bonds. In addition to this anomalous quaternary structure, the enzyme has extraordinary biological properties, such as antispermatogenic, antitumor, and immunosuppressive activities. The molecular bases for these properties are well-suited for exploration with the techniques of recombinant DNA. Accordingly, a gene encoding BS-RNase was designed based on criteria expected to maximize the translational efficiency of its mRNA in Escherichia coli. This gene was constructed from 12 synthetic oligonucleotides and expressed with the phage T7 system. The protein thus produced was insoluble and accumulated under optimal conditions to 15% of total cellular protein or 200 mg/liter of culture. Ribonuclease activity was generated by air oxidation of the reduced and denatured protein. Three forms of active BS-RNase were isolated by gel filtration chromatography: the well-characterized dimer and monomer and a previously uncharacterized form that migrated as a trimer. The ribonuclease activities of all three forms were equivalent to or higher than that of dimeric BS-RNase isolated from bull seminal plasma.	UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Raines, Ronald T./A-5009-2013; KIM, Jin-Soo/M-6918-2013	Raines, Ronald T./0000-0001-7164-1719; KIM, Jin-Soo/0000-0003-4847-1306	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44783] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEINTEMA JJ, 1987, LIFE CHEM REPORTS, V4, P333; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; CANNISTRARO VJ, 1991, J BACTERIOL, V173, P4653, DOI 10.1128/jb.173.15.4653-4659.1991; CAPASSO S, 1983, BIOPOLYMERS, V22, P327, DOI 10.1002/bip.360220142; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DOSTAL J, 1973, J REPROD FERTIL, V33, P263, DOI 10.1530/jrf.0.0330263; GHEYSEN D, 1982, GENE, V17, P55, DOI 10.1016/0378-1119(82)90100-7; GOLD L, 1990, METHOD ENZYMOL, V185, P11; GUILLEMETTE JG, 1991, PROTEIN ENG, V4, P585, DOI 10.1093/protein/4.5.585; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HERMES JD, 1987, P RA WELCH F, V31, P207; HORN T, 1986, TETRAHEDRON LETT, V27, P4705, DOI 10.1016/S0040-4039(00)85043-1; ISERENTANT D, 1980, GENE, V9, P1, DOI 10.1016/0378-1119(80)90163-8; KIM JS, 1993, PROTEIN SCI, V2, P348; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LACCETTI P, 1992, CANCER RES, V52, P4582; LI XM, 1991, PROTEIN ENG, V4, P995, DOI 10.1093/protein/4.8.995; MAZZARELLA L, 1987, GAZZ CHIM ITAL, V117, P91; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; PARENTE A, 1985, EUR J BIOCHEM, V149, P381, DOI 10.1111/j.1432-1033.1985.tb08936.x; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; PICCOLI R, 1990, 2ND P INT M STRUCT M, P131; PREUSS KD, 1990, NUCLEIC ACIDS RES, V18, P1057, DOI 10.1093/nar/18.4.1057; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SMITH GK, 1978, BIOCHEMISTRY-US, V17, P2633, DOI 10.1021/bi00606a027; SORRENTINO S, 1980, BIOCHIM BIOPHYS ACTA, V609, P40, DOI 10.1016/0005-2787(80)90199-9; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI H, 1987, BIOL CHEM H-S, V368, P1305, DOI 10.1515/bchm3.1987.368.2.1305; TAMBURRINI M, 1989, J PROTEIN CHEM, V8, P719, DOI 10.1007/BF01024897; TAMBURRINI M, 1986, ITAL J BIOCHEM, V35, P22; TAMBURRINI M, 1990, EUR J BIOCHEM, V190, P145, DOI 10.1111/j.1432-1033.1990.tb15557.x; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	42	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17392	17396						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688724				2022-12-25	WOS:A1993LQ98800075
J	BERTRAN, J; WERNER, A; CHILLARON, J; NUNES, V; BIBER, J; TESTAR, X; ZORZANO, A; ESTIVILL, X; MURER, H; PALACIN, M				BERTRAN, J; WERNER, A; CHILLARON, J; NUNES, V; BIBER, J; TESTAR, X; ZORZANO, A; ESTIVILL, X; MURER, H; PALACIN, M			EXPRESSION CLONING OF A HUMAN RENAL CDNA THAT INDUCES HIGH-AFFINITY TRANSPORT OF L-CYSTINE SHARED WITH DIBASIC AMINO-ACIDS IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER VESICLES; ECOTROPIC RETROVIRUS RECEPTOR; MONOCLONAL-ANTIBODY 4F2; MEMBRANE-VESICLES; PROTEIN; FIBROBLASTS; PATHWAYS; TUBULES; CULTURE; SYSTEM	A renal cDNA clone (rBAT) that induces system b(o,+)-like amino acid transport activity in Xenopus oocytes has recently been isolated (Bertran, J., Werner, A., Moore, M. L., Stange, G., Markovich, D., Biber, J., Testar, X., Zorzano, A., Palacin, and Murer, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5601-5605). Here we show the isolation of a cDNA clone by screening a human kidney cortex cDNA library for expression of sodium-independent transport of L-[H-3]arginine in Xenopus oocytes. The cRNA of this clone induces in oocytes, in addition to the uptake Of L-arginine, that of L-[S-35]cystine and L-[H-3]leucine. Expressed uptake of these amino acids is mutually cis-inhibitable by the other 2 amino acids. Expressed uptake of L-cystine is saturable and shows an apparent K(m) in the micromolar range. All these characteristics resemble induction of system b(o,+) related to rBAT in the oocytes. Human rBAT mRNA (approximately 2.5 kilobases) is found in kidney, small intestine (i.e., jejunum), pancreas, and liver. Human kidney poly(A)+ RNA (mRNA) induces sodium-independent uptake Of L-cystine, L-arginine, and L-leucine in Xenopus oocytes. Hybrid depletion with an antisense oligonucleotide of the isolated clone greatly prevents (80-97%) human kidney mRNA-dependent induction of the uptake of these amino acids (i.e. L-cystine, L-arginine, and L-leucine). The isolated-clone (2304 base pairs in length) contains a poly(A) tail and encodes a predicted 78.8-kDa protein which is 85 and 80% identical to the rabbit and rat rBAT, respectively. This predicted protein corresponds to a membrane glycoprotein, and contains six potential N-glycosylation sites which might be functional in the oocyte: [S-35] methionine labeling of oocytes shows a specific band of 94 kDa in crude membranes of these human cRNA-injected oocytes; treatment of these oocytes with tunicamycin shifts the cRNA-specific translation product to approximately 72 kDa. We conclude that we have isolated a functional cDNA corresponding to human rBAT. The isolation of this human cDNA would lead to the study of the possible involvement of rBAT in human hyperaminoacidurias.	UNIV BARCELONA,DEPT BIOQUIM & FISIOL,AVDA DIAGONAL 645,E-08028 BARCELONA,SPAIN; UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; INST RECERCA ONCOL,DEPT GENET MOLEC,E-08907 BARCELONA,SPAIN	University of Barcelona; University of Zurich			Zorzano, Antonio/R-5479-2018; Chillaron, Josep/ABF-7663-2021; Palacín, Manuel/G-9786-2015; Estivill, Xavier/A-3125-2013; Wilson, Matthew H/K-3193-2013; Nunes, Virginia/AAD-1014-2019	Chillaron, Josep/0000-0003-3068-7598; Estivill, Xavier/0000-0002-0723-2256; Nunes, Virginia/0000-0002-5747-9310; Bertran, Joan/0000-0002-4276-336X; Palacin, Manuel/0000-0002-8670-293X				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BANNAI S, 1980, J BIOL CHEM, V255, P2372; Bergeron M, 1985, KIDNEY PHYSL PATHOPH, P1725; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COICADAN L, 1980, PEDIATR RES, V14, P109, DOI 10.1203/00006450-198002000-00008; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; GROTH U, 1972, J CLIN INVEST, V51, P2130, DOI 10.1172/JCI107020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P9608; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEMLER ME, 1982, J IMMUNOL, V129, P623; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KWON HM, 1992, J BIOL CHEM, V267, P6297; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1985, J IMMUNOL, V153, P3951; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MCNAMARA PD, 1991, J BIOL CHEM, V266, P986; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MIRCHEFF AK, 1982, J MEMBRANE BIOL, V64, P113, DOI 10.1007/BF01870773; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; ROSENBERG LE, 1967, J CLIN INVEST, V46, P30, DOI 10.1172/JCI105508; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; TAKADA A, 1984, J BIOL CHEM, V259, P2441; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; THIER SO, 1965, J CLIN INVEST, V44, P442, DOI 10.1172/JCI105157; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VOLKL H, 1982, PFLUG ARCH EUR J PHY, V395, P196, DOI 10.1007/BF00584809; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982	51	130	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14842	14849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686906				2022-12-25	WOS:A1993LL75900049
J	HILBERT, DM; PUMPHREY, JG; TROPPMAIR, J; RAPP, UR; RUDIKOFF, S				HILBERT, DM; PUMPHREY, JG; TROPPMAIR, J; RAPP, UR; RUDIKOFF, S			SUSCEPTIBILITY AND RESISTANCE TO J3V1 RETROVIRUS-INDUCED MURINE PLASMACYTOMAGENESIS IN RECONSTITUTED SEVERE COMBINED IMMUNODEFICIENT MICE	ONCOGENE			English	Article							MOUSE PLASMACYTOMAS; BALB/C MICE; B-CELLS; V-MYC; INDUCTION; GENETICS; LOCALIZATION; EXPRESSION; MACROPHAGE; MUTATION	To date much is known about the genetics of susceptibility and resistance to plasmacytoma induction in mice, however little is known about the cellular aspects of these phenotypes. The complexity of plasmacytomagenesis allows for susceptibility and resistance to reflect differences in B cells, T cells, accessory cells and/or stromal elements contributing to the disease process. Alternatively, these phenotypes may result from differential abilities to affect events critical to plasmacytomagenesis, such as myc deregulation. To address these possibilities, the v-myc-raf-containing retrovirus, J3V1, was used to induce plasmacytomas (PCTs) in severe combined immunodeficient (SCID) mice reconstituted with susceptible (Balb/c) and/or resistant (DBA/2) cells. The results demonstrate that Balb/c bone marrow (BM)-reconstituted SCID mice yielded PCTs of donor origin, while DBA/2 BM-reconstituted mice did not. Mice reconstituted with both DBA/2 BM and Balb/c peripheral lymphocytes, as well as those reconstituted with Balb/c peripheral lymphocytes alone, also yielded only Balb/c PCTs. These results indicate that: (1) a microenvironment supportive of plasmacytomagenesis is insufficient to allow PCT development among resistant cells; (2) DBA/ 2 BM-derived cells do not suppress plasmacytomagenesis by target cell elimination or microenvironment destruction; (3) resistance is not solely attributable to the inability of DBA/2 B cells to deregulate myc; and (4) potential PCT targets reside in a number of lymphoid tissues. Taken together, these results demonstrate that a major aspect of resistance/susceptibility to plasmacytomagenesis is dictated by the genotype of the target B cell.	NCI,FREDERICK CANC RES CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HILBERT, DM (corresponding author), NCI,GENET LAB,BETHESDA,MD 20892, USA.							ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; AUSTYN JM, 1981, EUR J IMMUNOL, V1, P801; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANCRO M, 1976, J EXP MED, V144, P1554, DOI 10.1084/jem.144.6.1554; CLYNES R, 1989, P NATL ACAD SCI USA, V85, P6067; Coffman R L, 1982, Immunol Rev, V69, P5; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; DORSHKIND K, 1984, J IMMUNOL, V132, P1804; ECKHARDT L, 1989, IMMUNOGENETICS, V11, P275; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; HO MK, 1982, J IMMUNOL, V128, P2281; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KURIE JM, 1990, ONCOGENE, V5, P577; LARGAESPADA D, 1990, CURR TOP MICROBIOL, V166, P91; MERWIN RM, 1959, P SOC EXP BIOL MED, V101, P437; MERWIN RM, 1963, J NAT CANC, V31, P998; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; POTTER M, 1988, Genomics, V2, P257, DOI 10.1016/0888-7543(88)90010-9; POTTER M, 1983, J NATL CANCER I, V71, P391; POTTER M, 1975, J NATL CANCER I, V54, P1413, DOI 10.1093/jnci/54.6.1413; POTTER M, 1984, J EXP MED, V160, P435, DOI 10.1084/jem.160.2.435; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1984, CANCER SURV, V3, P247; POTTER M, 1981, J IMMUNOL, V127, P1591; POTTER M, 1960, J NATL CANCER I, V25, P847, DOI 10.1093/jnci/25.4.847; POTTER M, 1967, METHOD CANCER RES, V2, P105; POTTER M, 1982, CANCER COMPREHENSIVE, P139; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REEVES RH, 1987, CYTOGENET CELL GENET, V44, P76, DOI 10.1159/000132347; SCHEID MP, 1979, IMMUNOGENETICS, V9, P423, DOI 10.1007/BF01570435; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SILVA S, 1991, INT J CANCER, V49, P224, DOI 10.1002/ijc.2910490214; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRINGER TA, 1979, EUR J IMMUNOL, V9, P311; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENNSTROM B, 1981, J VIROL, V39, P625	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1993	2000						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	7685514				2022-12-25	WOS:A1993LG68200032
J	PALLA, E; BENSI, G; SOLITO, E; BUONAMASSA, DT; FASSINA, G; RAUGEI, G; SPANO, F; GALEOTTI, C; MORA, M; DOMENIGHINI, M; ROSSINI, M; GALLO, E; CARINCI, V; BUGNOLI, M; BERTINI, F; PARENTE, L; MELLI, M				PALLA, E; BENSI, G; SOLITO, E; BUONAMASSA, DT; FASSINA, G; RAUGEI, G; SPANO, F; GALEOTTI, C; MORA, M; DOMENIGHINI, M; ROSSINI, M; GALLO, E; CARINCI, V; BUGNOLI, M; BERTINI, F; PARENTE, L; MELLI, M			LOOP SUBSTITUTION AS A TOOL TO IDENTIFY ACTIVE-SITES OF INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; IL-1 RECEPTOR; B-CELLS; BINDING; PROTEIN; EXPRESSION; IL-1-BETA; FRAGMENT; PURIFICATION; PEPTIDE	By computer analysis of the amino acid sequence of human interleukin-1beta (IL-1beta) and of the human type I IL-1 receptor (IL-1RI), we have identified two hydropathically complementary peptides (Fassina, G., Roller, P. P., Olson, A. D., Thorgeirsson, S. S., and Omichinski, J. G. (1989) J. Biol. Chem. 264, 11252-11257) capable of binding to each other. The sequence of the IL-1beta peptide corresponds to that of residues 88-99 (loop 7 of the crystal structure of mature IL-1beta) of mature IL-1beta, one of the exposed and highly charged regions of the molecule. The substitution of this loop with an amino acid sequence of the same length but different hydropathic profile generates a mutant with drastically reduced binding activity to IL-1RI. In contrast, the binding affinity to the type II IL-1R (IL-1RII) is the same as that of wild type IL-1beta. The results show that 1) loop 7 is part of the binding site of IL-1beta to IL-1RI, but not to IL-1RII. 2) The structure of the mutant protein is not grossly altered except locally at the position of the substituted loop. 3) The substitution of amino acids by site-directed mutagenesis of the loop 7 region generates mutants with binding affinity constants slightly lower than that of wild type IL-1beta and not comparable to that of the loop substitution analogue. 4. All mutants analyzed, including the loop substitutions, are biologically active, confirming the structural integrity of the proteins. We propose a binding site in which the cooperation of several low energy bonds extended over a wide area results in a high affinity complex between IL-1 and the type I receptor.	IMMUNOBIOL RES INST SIENA, DEPT MOLEC BIOL, VIA FIORENTINA 1, I-53100 SIENA, ITALY; IMMUNOBIOL RES INST SIENA, DEPT PHARMACOL, I-53100 SIENA, ITALY; TECHNOGEN, I-20131 MILAN, ITALY				Fassina, Giorgio/I-7127-2012; SPANO, FURIO/O-2294-2015; Parente, Luca/G-8997-2012	Fassina, Giorgio/0000-0003-1845-2657; Solito, Egle/0000-0001-5279-0049; Spano, Furio/0000-0002-7324-0895; raugei, giovanni/0000-0003-1294-786X				ANTONI G, 1986, J IMMUNOL, V137, P3201; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; BERTOGLIO JH, 1988, J IMMUNOL, V141, P1191; BIGIO M, 1989, J IMMUNOL METHODS, V123, P1, DOI 10.1016/0022-1759(89)90023-9; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BORASCHI D, 1989, Biotherapy (Dordrecht), V1, P377, DOI 10.1007/BF02171014; BORASCHI D, 1988, J EXP MED, V168, P675, DOI 10.1084/jem.168.2.675; BORASCHI D, 1987, Annales de l'Institut Pasteur Immunology, V138, P492; CASAGLI MC, 1989, PREP BIOCHEM, V19, P23, DOI 10.1080/10826068908544894; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P4668, DOI 10.1021/bi00471a023; FASSINA G, 1992, INT J PEPT PROT RES, V39, P540; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FASSINA G, 1992, INT J PEPT PROT RES, V39, P549; FASSINA G, 1991, Patent No. 411503; GRONENBORN AM, 1986, EUR J BIOCHEM, V161, P37, DOI 10.1111/j.1432-1033.1986.tb10121.x; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HORLICK RA, 1992, PROTEIN ENG, V5, P427, DOI 10.1093/protein/5.5.427; HORUK R, 1987, J BIOL CHEM, V262, P16275; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAYE J, 1984, J IMMUNOL, V133, P1339; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; Maniatis T., 1982, MOL CLONING; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; Rothstein R., 1985, DNA CLONING, VII, P45; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SOLITO E, 1989, BRIT J PHARMACOL, V96, P656, DOI 10.1111/j.1476-5381.1989.tb11865.x; STOPPACCIARO A, 1991, J IMMUNOL, V147, P1561; TATE S, 1992, BIOCHEMISTRY-US, V31, P2435, DOI 10.1021/bi00123a032; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WIEBEL F, 1969, J CELL PHYSIOL, V74, P191, DOI 10.1002/jcp.1040740211; WOLFSON AJ, 1991, PROTEIN ENG, V4, P313, DOI 10.1093/protein/4.3.313	41	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13486	13492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685764				2022-12-25	WOS:A1993LH55300067
J	LUCIBELLO, FC; BRUSSELBACH, S; SEWING, A; MULLER, R				LUCIBELLO, FC; BRUSSELBACH, S; SEWING, A; MULLER, R			SUPPRESSION OF THE GROWTH FACTOR-MEDIATED INDUCTION OF C-FOS AND DOWN-MODULATION OF AP-1-BINDING ACTIVITY ARE NOT REQUIRED FOR CELLULAR SENESCENCE	ONCOGENE			English	Note							HUMAN-FIBROBLASTS; PROTO-ONCOGENE; GENE; JUN; CELLS; PHOSPHORYLATE; FAILURE; PRODUCT; RNA	It has been suggested that the impaired response of the c-fos gene to serum growth factors and the concomitant loss of AP-1 activity may be a crucial step in the process of cellular senescence. In the present study, we provide evidence arguing against such a conclusion. Data obtained in five independent experiments showed that both c-fos RNA and protein expression were similar in 'young' and in senescent serum-stimulated WI-38 cells, suggesting that the previously reported suppression of c-fos induction is not an obligatory event in the process of cellular senescence. Likewise, expression of fra-1, c-jun and junB continued to be high in serum-stimulated senescent cells, while induction of fosB was reduced approximately fivefold. Among all genes tested fosB thus seems to be the most suitable marker for the detection of senescent cells. Stimulated senescent cells showed only a approximately twofold reduction of AP-1-binding activity, and senescent cells continuously exposed to serum exhibited normal AP-1-binding activity. These observations support the conclusion that a down-modulation of AP-1 is not crucial for human fibroblasts to enter the senescent state.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4784; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PAULSSON Y, 1986, EMBO J, V5, P2157, DOI 10.1002/j.1460-2075.1986.tb04479.x; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	24	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684831				2022-12-25	WOS:A1993LE06400031
J	WALDBESER, LS; TOLMASKY, ME; ACTIS, LA; CROSA, JH				WALDBESER, LS; TOLMASKY, ME; ACTIS, LA; CROSA, JH			MECHANISMS FOR NEGATIVE REGULATION BY IRON OF THE FATA OUTER-MEMBRANE PROTEIN GENE-EXPRESSION IN VIBRIO-ANGUILLARUM 775	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHINE-DALGARNO REGION; ESCHERICHIA-COLI; MESSENGER-RNA; PLASMID PJM1; UPTAKE SYSTEM; MOLECULAR CHARACTERIZATION; TRANSPORT-SYSTEM; LAC MESSENGER; CLONING; DECAY	Synthesis of the 86-kDa FatA outer membrane protein is repressed under iron-rich conditions. Complementation of transposition mutants derived from clones containing the pJM1 iron uptake region revealed the existence of an antisense RNA, RNAalpha. This RNA is only expressed under iron-rich conditions and acts as a negative regulator of FatA synthesis, with slight but discernible decrease in the steady-state level of fatA mRNA determined by RNase protection and by Northern blot analysis. Primer extension experiments revealed that the level of several possible fatA transcripts was reduced in the presence of RNAalpha. In addition, we found that fatA mRNA expression is slightly reduced in the presence of Escherichia coli Fur. We have identified and cloned a chromosomally encoded fur-like gene in Vibrio anguillarum.	OREGON HLTH SCI UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL L220, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA	Oregon Health & Science University			Tolmasky, Marcelo/AAC-5316-2020	Tolmasky, Marcelo/0000-0002-6298-7811	NIAID NIH HHS [AI19010] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACTIS LA, 1988, J BIOL CHEM, V263, P2853; ACTIS LA, 1985, J BACTERIOL, V161, P736, DOI 10.1128/JB.161.2.736-742.1985; ACTIS LA, 1986, J BACTERIOL, V167, P57, DOI 10.1128/jb.167.1.57-65.1986; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAGG A, 1985, J BACTERIOL, V161, P450, DOI 10.1128/JB.161.1.450-453.1985; BARCLAY R, 1985, MED LAB SCI, V42, P166; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CALDERWOOD SB, 1988, J BACTERIOL, V170, P1015, DOI 10.1128/jb.170.2.1015-1017.1988; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHO KO, 1988, J MOL BIOL, V204, P51, DOI 10.1016/0022-2836(88)90598-0; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; CROSA JH, 1980, NATURE, V284, P566, DOI 10.1038/284566a0; CROSA JH, 1981, INFECT IMMUN, V31, P223, DOI 10.1128/IAI.31.1.223-227.1981; CROSA JH, 1984, ANNU REV MICROBIOL, V38, P69, DOI 10.1146/annurev.mi.38.100184.000441; CROSA JH, 1989, MICROBIOL REV, V53, P517, DOI 10.1128/MMBR.53.4.517-530.1989; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; ERNST JF, 1978, J BACTERIOL, V135, P928, DOI 10.1128/JB.135.3.928-934.1978; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GHOSH PK, 1978, J MOL BIOL, V126, P813, DOI 10.1016/0022-2836(78)90022-0; GOLDBERG MB, 1990, J BACTERIOL, V172, P6863, DOI 10.1128/jb.172.12.6863-6870.1990; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; HANTKE K, 1984, MOL GEN GENET, V197, P337, DOI 10.1007/BF00330982; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; JALAL MAF, 1989, J AM CHEM SOC, V111, P292, DOI 10.1021/ja00183a044; KOSTER WL, 1991, J BIOL CHEM, V266, P23829; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIM LW, 1979, J MOL BIOL, V135, P369, DOI 10.1016/0022-2836(79)90442-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURAKAWA GJ, 1991, J BACTERIOL, V173, P28, DOI 10.1128/jb.173.1.28-36.1991; NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PAYNE SM, 1978, J CLIN INVEST, V61, P1428, DOI 10.1172/JCI109062; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; QUEEN C, 1981, CELL, V25, P241, DOI 10.1016/0092-8674(81)90249-X; SALINAS PC, 1989, P NATL ACAD SCI USA, V86, P3529, DOI 10.1073/pnas.86.10.3529; SALINAS PC, 1993, IN PRESS GENE AMST; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1989, GENE, V78, P59, DOI 10.1016/0378-1119(89)90314-4; STAGGS TM, 1991, J BACTERIOL, V173, P417, DOI 10.1128/jb.173.2.417-425.1991; TAI SPS, 1988, INFECT IMMUN, V56, P2430, DOI 10.1128/IAI.56.9.2430-2436.1988; TAYLOR RK, 1985, J BACTERIOL, V162, P1054, DOI 10.1128/JB.162.3.1054-1060.1985; TOLMASKY ME, 1991, BIOL MET, V4, P33, DOI 10.1007/BF01135554; TOLMASKY ME, 1992, GENE, V110, P41, DOI 10.1016/0378-1119(92)90442-R; TOLMASKY ME, 1984, J BACTERIOL, V160, P860, DOI 10.1128/JB.160.3.860-866.1984; TOLMASKY ME, 1988, J BACTERIOL, V170, P1913, DOI 10.1128/jb.170.4.1913-1919.1988; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WALTER MA, 1983, J BACTERIOL, V156, P880, DOI 10.1128/JB.156.2.880-887.1983; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WOLOJ M, 1986, ANTIMICROB AGENTS CH, V29, P315, DOI 10.1128/AAC.29.2.315	54	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10433	10439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683679				2022-12-25	WOS:A1993LB80000067
J	ENGHILD, JJ; SALVESEN, G; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; HEFTA, SA				ENGHILD, JJ; SALVESEN, G; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; HEFTA, SA			PRESENCE OF THE PROTEIN-GLYCOSAMINOGLYCAN-PROTEIN COVALENT CROSS-LINK IN THE INTER-ALPHA-INHIBITOR-RELATED PROTEINASE-INHIBITOR HEAVY CHAIN-2 BIKUNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; TRYPSIN-INHIBITOR; HUMAN-PLASMA; QUANTITIES; COMPLEX	HC2/bikunin is a human plasma proteinase inhibitor composed of two polypeptide chains that resist dissociation under reducing conditions in SDS-polyacrylamide gel electrophoresis. This observation suggests that a nondisulfide cross-link is responsible for the association of these two polypeptide chains. In this study, we have utilized a variety of techniques to investigate the structural basis for this observation. We show that the cross-link between the two protein chains is sensitive to chondroitin sulfate-degrading enzymes and to 50 mM NaOH, properties shared by the protein-glycosaminoglycan-protein cross-link found in the related pre-alpha-inhibitor (Enghild, J. J., Salvesen, G., Hefta, S., Thogersen, I. B., Rutherfurd, S., and Pizzo, S. V. (1991) J. Biol. Chem. 266, 747-751). Biochemical and mass spectrometric analysis of the peptides containing the cross-link indicate that it is mediated by a chondroitin-4-sulfate chain that originates from a typical O-glycosidic link to Ser10 of bikunin. The COOH-terminal Asp648 residue of heavy chain 2 is esterified via the alpha-carbon to C-6 of an internal N-acetylgalactosamine of the chondroitin-4-sulfate chain. This suggests that the protein-glycosaminoglycan-protein cross-link that assembles the chains of pre-alpha-inhibitor is identical to that which assembles HC2/bikunin, and is probably a characteristic of the bikunin proteins.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope	ENGHILD, JJ (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,POB 3712,DURHAM,NC 27710, USA.			Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R01HL049542, R37HL024066] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NHLBI NIH HHS [HL-24066, HL-49542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDUYCK M, 1986, EUR J BIOCHEM, V158, P417, DOI 10.1111/j.1432-1033.1986.tb09769.x; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GEBHARD W, 1990, BIOL CHEM H-S, V371, P13; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; KAUMEYER JK, 1989, NUCLEIC ACIDS RES, V14, P7839; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEANS GE, 1971, CHEM MODIFICATION PR, P139; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; SALIER JP, 1983, BIOCHIM BIOPHYS ACTA, V742, P206; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P240; SHULMAN R, 1955, J BIOL CHEM, V213, P655; SUNDQVIST B, 1984, BIOMED MASS SPECTROM, V11, P242, DOI 10.1002/bms.1200110509	22	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8711	8716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682553				2022-12-25	WOS:A1993KX81100052
J	CAPUANO, V; THOMAS, JC; DEMARSAC, NT; HOUMARD, J				CAPUANO, V; THOMAS, JC; DEMARSAC, NT; HOUMARD, J			AN INVIVO APPROACH TO DEFINE THE ROLE OF THE LCM, THE KEY POLYPEPTIDE OF CYANOBACTERIAL PHYCOBILISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING ANTENNA; ANACYSTIS-NIDULANS R2; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; ENERGY-TRANSFER; FOREIGN DNA; WILD-TYPE; GENE; CLONING; CORE	In cyanobacteria, phycobilisomes are regularly arrayed on the surface of the photosynthetic membranes, and their role is to funnel light energy to the underlying photosystem II reaction center. A model has recently been proposed that ascribes to the so-called L(CM), a central role in the building up of the phycobilisome, in addition to its role of terminal energy acceptor (Capuano, V., Braux, A.-S., Tandeau de Marsac, N., and Houmard, J. (1991) J. Biol. Chem. 266, 7239-7247). The phycobilisomes of Calothrix sp. PCC 7601 are typically of the type found in most cyanobacteria. Those of Synechococcus PCC 7942 (or PCC 6301) differ in having central cores made up of two instead of three cylinders. We have integrated the Calothrix PCC 7601 apcE gene that encodes the L(CM) into the chromosome of a Synechococcus PCC 7942 strain. We have observed that the heterologous gene is expressed and that the corresponding product carries a bilin-type chromophore and can be detected in the phycobilisome fraction of the Synechococcus strain. Moreover, it is shown that, in agreement with our model, this L(CM) can direct the formation of phycobilisomes that have three-cylinder cores.	INST PASTEUR, UNITE PHYSIOL MICROBIENNE,CNRS,URA 1129, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE; ECOLE NORMALE SUPER, BIOMEMBRANES LAB, CNRS, URA 311, F-75230 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)				Capuano, Veronique/0000-0001-8738-0947				ANDERSON LK, 1986, J MOL BIOL, V191, P441, DOI 10.1016/0022-2836(86)90139-7; Bryant D. A., 1991, CELL CULTURE SOMATIC, P257; BRYANT DA, 1979, ARCH MICROBIOL, V123, P113, DOI 10.1007/BF00446810; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; DAMERVAL T, 1991, PLANT CELL, V3, P191; DEMARSAC NT, 1982, GENE, V20, P111, DOI 10.1016/0378-1119(82)90092-0; DEMARSAC NT, 1985, NUCLEIC ACIDS RES, V13, P7223, DOI 10.1093/nar/13.20.7223; DEMARSAC NT, 1988, PHOTOSYNTH RES, V18, P99, DOI 10.1007/BF00042981; ELMORJANI K, 1986, ARCH MICROBIOL, V146, P186, DOI 10.1007/BF00402349; GANTT E, 1979, PLANT PHYSIOL, V63, P615, DOI 10.1104/pp.63.4.615; GINGRICH JC, 1983, J CELL BIOCHEM, V22, P1, DOI 10.1002/jcb.240220102; GLAUSER M, 1992, EUR J BIOCHEM, V205, P907, DOI 10.1111/j.1432-1033.1992.tb16857.x; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1983, ANNU REV BIOCHEM, V52, P125, DOI 10.1146/annurev.bi.52.070183.001013; GLAZER AN, 1979, P NATL ACAD SCI USA, V76, P6162, DOI 10.1073/pnas.76.12.6162; GLAZER AN, 1983, ANN INST PASTEUR MIC, VB134, P159, DOI 10.1016/S0769-2609(83)80103-3; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; GOLDEN SS, 1989, J BACTERIOL, V171, P24, DOI 10.1128/jb.171.1.24-29.1989; HANKER JS, 1977, HISTOCHEM J, V9, P789, DOI 10.1007/BF01003075; HOUMARD J, 1990, P NATL ACAD SCI USA, V87, P2152, DOI 10.1073/pnas.87.6.2152; HOUMARD J, 1986, MOL GEN GENET, V205, P404, DOI 10.1007/BF00338074; KOLOWSKY KS, 1984, GENE, V27, P289, DOI 10.1016/0378-1119(84)90073-8; KUHLEMEIER CJ, 1983, PLASMID, V10, P156, DOI 10.1016/0147-619X(83)90068-9; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; MIMURO M, 1986, BIOCHIM BIOPHYS ACTA, V852, P126, DOI 10.1016/0005-2728(86)90065-4; RAPS S, 1990, PLANT PHYSIOL, V92, P358, DOI 10.1104/pp.92.2.358; REDLINGER T, 1982, P NATL ACAD SCI-BIOL, V79, P5542, DOI 10.1073/pnas.79.18.5542; STANIER RY, 1977, ANNU REV MICROBIOL, V31, P225, DOI 10.1146/annurev.mi.31.100177.001301; TANDEAUDEMARSAC N, 1977, P NATL ACAD SCI USA, V74, P1635; VANDENHONDEL CAMJJ, 1980, P NATL ACAD SCI-BIOL, V77, P1570; VANDENHONDEL CAMJJ, 1980, A VAN LEEUW J MICROB, V46, P228, DOI 10.1007/BF00444081; VANDERPLAS J, 1990, GENE, V95, P39, DOI 10.1016/0378-1119(90)90411-J; VANDERPLAS J, 1988, PHOTOSYNTH RES, V18, P179, DOI 10.1007/BF00042984; WILLIAMS JGK, 1983, GENE, V24, P37, DOI 10.1016/0378-1119(83)90129-4; YAMANAKA G, 1982, J BIOL CHEM, V257, P4077; YAMANAKA G, 1980, J BIOL CHEM, V255, P1004	38	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8277	8283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681841				2022-12-25	WOS:A1993KW97900100
J	VANDERVOORN, L; TOL, O; HENGEVELD, TM; PLOEGH, HL				VANDERVOORN, L; TOL, O; HENGEVELD, TM; PLOEGH, HL			STRUCTURAL AND FUNCTIONAL-STUDIES ON THE G(0)-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; BOVINE BRAIN MEMBRANES; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; ADENYLATE-CYCLASE; MOLECULAR-CLONING; SEQUENCE DETERMINATION; BETA-SUBUNITS; GO-ALPHA	Monoclonal antibodies were raised against purified bovine and human brain G-proteins. The epitopes recognized by three monoclonal antibodies (MONO, 3C2, and 3E7) were mapped by expressing defined parts of the bovine G(o)alpha-cDNA in bacteria, followed by immunoblotting. All three antibodies recognize the recombinant bovine alpha(o)-protein, but at distinct sites. The epitopes of MONO and 3C2 were mapped between alpha(o) amino acids 80 and 145, and both antibodies recognize alpha(o) exclusively. Heterotrimeric G(o)-proteins as well as guanosine 5'-3-O-(thio)triphosphate-liganded free alpha(o)-subunits are readily immunoprecipitated by these monoclonal antibodies. Binding of MONO or 3C2 does not affect ADP-ribosylation of the alpha(o)-subunit by pertussis toxin. Apparently, the antibodies do not bind to or induce large conformational changes in regions of the alpha(o)-subunit that are involved in association with betagamma-subunits or ADP-ribosylation. 3E7 behaves as an anti common alpha-subunit antibody when used in immunoblots. However, under nondenaturing conditions, 3E7 recognizes alpha(o) exclusively. After binding of 3E7, the pertussis toxin-dependent ADP-ribosylation of alpha(o) is effectively blocked, while the ADP-ribosylation of the various alpha(i)-subunits is not affected. The epitope of 3E7 was mapped between alpha(o) amino acids 13-88, a region which has been implicated in the interaction between alpha- and betagamma-subunits. Possibly, the inhibitory effect of 3E7 on ADP-ribosylation of G(o) is secondary to the loss of betagamma-subunits that is observed upon binding of 3E7.			VANDERVOORN, L (corresponding author), NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BERTRAND P, 1990, J BIOL CHEM, V265, P18576; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CERIONE RA, 1988, J BIOL CHEM, V263, P345; CORREZE C, 1987, J BIOL CHEM, V262, P15182; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1989, J BIOL CHEM, V264, P11475; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM SH, 1988, COLD SPRING HARB SYM, V53, P273, DOI 10.1101/SQB.1988.053.01.034; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVU S, 1988, BIOCHEM BIOPH RES CO, V150, P811, DOI 10.1016/0006-291X(88)90463-9; LINGHAM RB, 1986, BIOCHEM J, V236, P267, DOI 10.1042/bj2360267; Maniatis T., 1982, MOL CLONING; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILLIGAN G, 1988, BIOCHEM J, V255, P1; Milligan G., 1990, G PROTEINS MEDIATORS, P31; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; PARHAM P, 1979, J IMMUNOL, V123, P342; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVOORN L, 1992, FEBS LETT, V308, P75, DOI 10.1016/0014-5793(92)81054-P; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252	59	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5131	5138						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680347				2022-12-25	WOS:A1993KP88400083
J	FRODIN, M; SEKINE, N; ROCHE, E; FILLOUX, C; PRENTKI, M; WOLLHEIM, CB; VANOBBERGHEN, E				FRODIN, M; SEKINE, N; ROCHE, E; FILLOUX, C; PRENTKI, M; WOLLHEIM, CB; VANOBBERGHEN, E			GLUCOSE, OTHER SECRETAGOGUES, AND NERVE GROWTH-FACTOR STIMULATE MITOGEN-ACTIVATED PROTEIN-KINASE IN THE INSULIN-SECRETING BETA-CELL LINE, INS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CYTOSOLIC CA2+; CAMP; PHOSPHORYLATION; PATHWAY; ISLETS; RAF-1; NUCLEOTIDES	The signaling pathways whereby glucose and hormonal secretagogues regulate insulin-secretory function, gene transcription, and proliferation of pancreatic beta-cells are not well defined. We show that in the glucose-responsive beta-cell line INS-1, major secretagogue-stimulated signaling pathways converge to activate 44-kDa mitogen-activated protein (MAP) kinase. Thus, glucose-induced insulin secretion was found to be associated with a small stimulatory effect on 44-kDa MAP kinase, which was synergistically enhanced by increased levels of intracellular cAMP and by the hormonal secretagogues glucagon-like peptide-1 and pituitary adenylate cyclase-activating polypeptide. Activation of 44-kDa MAP kinase by glucose was dependent on Ca2+ influx and may in part be mediated by MEK-1, a MAP kinase kinase. Stimulation of Ca2+ influx by KCl was in itself sufficient to activate 44-kDa MAP kinase and MEK-1. Phorbol ester, an activator of protein kinase C, stimulated 44-kDa MAP kinase by both Ca2+-dependent and -independent pathways. Nerve growth factor, independently of changes in cytosolic Ca2+, efficiently stimulated 44-kDa MAP kinase without-causing insulin release, indicating that activation of this kinase is not sufficient for secretion. In the presence of glucose, however, nerve growth factor potentiated insulin secretion. In INS-1 cells, activation of 44-kDa MAP kinase was partially correlated with the induction of early response genes junB, nur77, and zif268 but not with stimulation of DNA synthesis, Our findings suggest a role of 44-kDa MAP kinase in mediating some of the pleiotropic actions of secretagogues on the pancreatic beta-cell.	FAC MED NICE, INSERM, U145, F-06107 NICE 2, FRANCE; UNIV GENEVA, DEPT MED, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Geneva			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672; Frodin, Morten/0000-0003-3691-9820				AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUN T, 1993, J BIOL CHEM, V268, P18905; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SA, 1990, ENDOCRINOLOGY, V126, P1895, DOI 10.1210/endo-126-4-1895; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; FEHMANN HC, 1992, MOL CELL ENDOCRINOL, V85, pC39, DOI 10.1016/0303-7207(92)90118-P; FRODIN M, 1993, J BIOL CHEM, V42, P1829; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARIE S, 1993, J BIOL CHEM, V268, P23881; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SCHARFMANN R, 1993, DIABETES, V42, P1829, DOI 10.2337/diabetes.42.12.1829; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; THELER JM, 1992, J BIOL CHEM, V267, P18110; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YADA T, 1994, J BIOL CHEM, V269, P1290	54	193	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7882	7889		10.1074/jbc.270.14.7882	http://dx.doi.org/10.1074/jbc.270.14.7882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713882	hybrid			2022-12-25	WOS:A1995QR52600018
J	HARAYOKOYAMA, M; HIRABAYASHI, Y; IRIE, F; SYUTO, B; MORIISHI, K; SUGIYA, H; FURUYAMA, S				HARAYOKOYAMA, M; HIRABAYASHI, Y; IRIE, F; SYUTO, B; MORIISHI, K; SUGIYA, H; FURUYAMA, S			IDENTIFICATION OF GANGLIOSIDES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASES OF PERTUSSIS TOXIN AND EXOENZYME C3 FROM CLOSTRIDIUM-BOTULINUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; ISLET-ACTIVATING PROTEIN; BORDETELLA-PERTUSSIS; BOVINE BRAIN; MEDIATED MODULATION; NAD GLYCOHYDROLASE; POLY(ADP-RIBOSE) SYNTHETASE; MOLECULAR CHARACTERIZATION; INTERMEDIATE FILAMENTS; RIBOSYLATION REACTION	We have previously reported the presence of an endogenous inhibitory activity in bovine brain for the ADP-ribosylation of GTP-binding proteins catalyzed by pertussis toxin (PT) (Hara-Yokoyama, M., and Furuyama, S, (1989) Biochem. Biophys. Res. Commun. 160, 67-71). In the present study, we identified the inhibitor as a ganglioside, The screening of various gangliosides revealed that G(Q1b alpha) most effectively inhibited the ADP-ribosyltransferase activities of both the holoenzyme and the catalytic subunit of PT. G(Q1b alpha) is a ganglioside newly identified as one of the antigens recognized by the cholinergic neuron-specific antibody, anti-Chol-1 alpha (Hirabayashi, Y,, Nakao, T,, Irie, F,, Whittaker, V,P., Ken, R,, and Ando, S. (1992) J. Biol. Chem. 267, 12973-12978), G(Q1b alpha) also inhibited the PT-catalyzed NAD(+) glycohydrolysis. Unlike PT activity, the ADP-ribosylation and the NAD(+) glycohydrolysis catalyzed by the C3 exoenzyme from Clostridium botulinum type C were inhibited by G(T1b) and G(Q1b). The ADP-ribosylation catalyzed by either PT or the C3 exoenzyme was not inhibited by ceramide, galactocerebroside, or sialic acid. In addition to the inhibitory action of gangliosides on ADP-ribosylation, the importance of gangliosides as regulators of NAD(+) metabolism is discussed.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,GLYCO CELL BIOL LAB,WAKO,SAITAMA 35101,JAPAN; HOKKAIDO UNIV,FAC VET MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	RIKEN; Hokkaido University	HARAYOKOYAMA, M (corresponding author), NIHON UNIV,SCH DENT,DEPT PHYSIOL,NISHI KU,2-870-1 SAKAE CHO,MATSUDO,CHIBA 271,JAPAN.		Moriishi, Kohji/I-4173-2019	Moriishi, Kohji/0000-0002-9542-5188; Hirabayashi, Yoshio/0000-0002-5774-7354				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BANASIK M, 1990, FEBS LETT, V263, P222, DOI 10.1016/0014-5793(90)81378-2; BOHM M, 1991, BIOCHEM J, V277, P223; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; BROWN EB, 1975, BIOCHIM BIOPHYS ACTA, V399, P124, DOI 10.1016/0304-4165(75)90218-4; BRUNE B, 1990, P NATL ACAD SCI USA, V87, P3304, DOI 10.1073/pnas.87.9.3304; BURNS DL, 1986, J BIOL CHEM, V261, P4324; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DIGIROLAMO M, 1992, J BIOL CHEM, V267, P17397; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUNAGA K, 1990, J NEUROCHEM, V54, P102, DOI 10.1111/j.1471-4159.1990.tb13288.x; GILLARD BK, 1992, CELL MOTIL CYTOSKEL, V21, P255, DOI 10.1002/cm.970210402; GILLARD BK, 1993, GLYCOBIOLOGY, V3, P57, DOI 10.1093/glycob/3.1.57; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARAYOKOYAMA M, 1988, FEBS LETT, V234, P27, DOI 10.1016/0014-5793(88)81295-X; HARAYOKOYAMA M, 1989, BIOCHEM BIOPH RES CO, V160, P67, DOI 10.1016/0006-291X(89)91621-5; HARDY DL, 1992, BIOCHEM J, V283, P849, DOI 10.1042/bj2830849; HAUSMAN SZ, 1993, INFECT IMMUN, V61, P335, DOI 10.1128/IAI.61.1.335-337.1993; HEMMI H, 1982, BIOCHEM BIOPH RES CO, V109, P669, DOI 10.1016/0006-291X(82)91992-1; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HIGASHI H, 1992, J BIOL CHEM, V267, P9839; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HOKOMORI S, 1990, J BIOL CHEM, V265, P18713; HOSHINO S, 1990, FEBS LETT, V276, P227, DOI 10.1016/0014-5793(90)80548-W; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; IRIE F, 1994, FEBS LETT, V351, P291, DOI 10.1016/0014-5793(94)00883-3; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KOTANI M, 1994, CELL STRUCT FUNCT, V19, P81, DOI 10.1247/csf.19.81; KRUEGER KM, 1993, J BIOL CHEM, V268, P12570; Ledeen R W, 1976, Adv Exp Med Biol, V71, P83; MACHIDA M, 1985, J BIOL CHEM, V260, P6143; MAEHAMA T, 1991, J BIOL CHEM, V266, P10062; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MATSUYAMA S, 1991, J NEUROCHEM, V57, P1380, DOI 10.1111/j.1471-4159.1991.tb08304.x; MILLERPODRAZA H, 1983, J NEUROCHEM, V41, P860, DOI 10.1111/j.1471-4159.1983.tb04819.x; MORIISHI K, 1990, J BIOL CHEM, V265, P16614; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; MURCIA G, 1988, BIOCH CELL BIOL, V66, P626; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAUKKONEN K, 1992, P NATL ACAD SCI USA, V89, P118, DOI 10.1073/pnas.89.1.118; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SHIMA T, 1969, J BIOL CHEM, V244, P6632; SONNINO S, 1979, J NEUROCHEM, V33, P117, DOI 10.1111/j.1471-4159.1979.tb11713.x; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESAWA S, 1993, J BIOL CHEM, V268, P26052; TAKI T, 1986, J BIOL CHEM, V261, P3075; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TANUMA S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P246, DOI 10.1016/0167-4889(89)90168-7; TANUMA S, 1988, J BIOL CHEM, V263, P5485; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VEDIA LMY, 1989, BIOCHEM J, V261, P841, DOI 10.1042/bj2610841; WEST RE, 1985, J BIOL CHEM, V260, P4428; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989; YAJIMA M, 1978, J BIOCHEM-TOKYO, V83, P295, DOI 10.1093/oxfordjournals.jbchem.a131904; YAJIMA M, 1978, J BIOCHEM-TOKYO, V83, P305, DOI 10.1093/oxfordjournals.jbchem.a131905; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	81	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8115	8121		10.1074/jbc.270.14.8115	http://dx.doi.org/10.1074/jbc.270.14.8115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713915	hybrid			2022-12-25	WOS:A1995QR52600053
J	WARD, NE; GRAVITT, KR; OBRIAN, CA				WARD, NE; GRAVITT, KR; OBRIAN, CA			IRREVERSIBLE INACTIVATION OF PROTEIN-KINASE-C BY A PEPTIDE-SUBSTRATE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; AFFINITY LABELS; DOMAIN; ACTIVATION; INHIBITOR; BINDING	Protein kinase C (PKC) is a phospholipid-dependent isozyme family that plays a pivotal role in mammalian signal-transduction pathways that mediate cell growth and differentiation and pathological developments, such as the acquisition of drug resistance by cancer cells, Several peptide-substrate analogs have been shown to reversibly inhibit PKC with high potency and selectivity, but peptide-substrate analogs that antagonize PKC by forming a covalent complex with the enzyme have not been reported, The development of active site-directed irreversible inactivators of PKC could provide new insights into the catalytic mechanism and might ultimately lead to the design of novel therapeutics targeted at PKC. In this report, we show that the peptide substrate analog Arg-Lys-Arg-Cys-Leu-Arg-Arg-Leu (RKRCLRRL) irreversibly inactivates PKC in a dithiothreitol-sensitive manner, The inactivation mechanism most consistent with our results is the formation of a covalent Linkage between the inhibitor-peptide and the enzyme at its active-site, Limited proteolysis of PKC produces a catalytic domain fragment that is independent of the phospholipid cofactor, RKRCLRRL antagonized the histone kinase activity of PKC and its catalytic-domain fragment with similar efficacies, achieving >50% inactivation at an RKRCLRRL concentration of 10 mu M. In contrast, RKRCLRRL analogs with single amino acid substitutions at Cys were non-inhibitory, The inactivated complex of the catalytic domain fragment and RKRCLRRL was stable upon dilution, and the inactivation of PKC and the catalytic-domain fragment by RKRCLRRL was quenched by dithiothreitol, providing evidence that the enzyme and the synthetic peptide may be covalently linked in an inactivated complex by a disulfide bond, Substrates and substrate analogs protected the catalytic-domain fragment against inactivation by RKRCLRRL, providing evidence that inactivation entailed binding of RKRCLRRL at the active-site of the enzyme. S-Thiolation is the formation of mixed disulfides between proteins and low molecular weight thiols, PRC is thought to have a highly reactive Cys residue in its active-site, and Cys residues that are flanked by basic residues, as is the case in RKRCLRRL, display enhanced reactivity, Our results support an inactivation mechanism that entails S-thiolation of the active-site of PKC by RKRCLRRL. This is the first report of irreversible inactivation of PKC by an active site-directed peptide.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R29CA052460] Funding Source: NIH RePORTER; NCI NIH HHS [CA52460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAMSON HN, 1982, J BIOL CHEM, V257, P575; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; DEBONT HBA, 1989, INT J PEPT PROT RES, V33, P115; DEKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V47, P425, DOI 10.1016/0006-2952(94)90037-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KUO JF, 1994, PROTEIN KINASE C; LESTER DS, 1992, PROTEIN KINASE C CUR; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; OBRIAN CA, 1990, BIOCHEM PHARMACOL, V39, P49, DOI 10.1016/0006-2952(90)90647-4; OBRIAN CA, 1989, MOL PHARMACOL, V36, P355; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; OBRIAN CA, 1993, ADV MOL CEL, V7, P61; OBRIAN CA, 1995, IN PRESS ATYPICAL MU; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SALERNO A, 1993, J BIOL CHEM, V268, P13043; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; SU HD, 1986, BIOCHEM BIOPH RES CO, V134, P78, DOI 10.1016/0006-291X(86)90529-2; TURNER RS, 1985, J BIOL CHEM, V260, P1503; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020	31	33	35	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8056	8060		10.1074/jbc.270.14.8056	http://dx.doi.org/10.1074/jbc.270.14.8056			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713907	hybrid			2022-12-25	WOS:A1995QR52600044
J	DREWES, G; TRINCZEK, B; ILLENBERGER, S; BIERNAT, J; SCHMITTULMS, G; MEYER, HE; MANDELKOW, EM; MANDELKOW, E				DREWES, G; TRINCZEK, B; ILLENBERGER, S; BIERNAT, J; SCHMITTULMS, G; MEYER, HE; MANDELKOW, EM; MANDELKOW, E			MICROTUBULE-ASSOCIATED PROTEIN MICROTUBULE AFFINITY-REGULATING KINASE (P110(MARK)) - A NOVEL PROTEIN-KINASE THAT REGULATES TAU-MICROTUBULE INTERACTIONS AND DYNAMIC INSTABILITY BY PHOSPHORYLATION AT THE ALZHEIMER-SPECIFIC SITE SERINE-262	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; ABNORMAL PHOSPHORYLATION; BINDING DOMAINS; DISEASE; TUBULIN; SEQUENCE; STATE; IDENTIFICATION; LOCALIZATION	Aberrant phosphorylation of the microtubule-associated protein tau is one of the pathological features of neuronal degeneration in Alzheimer's disease. The phosphorylation of Ser-262 within the microtubule binding region of tau is of particular interest because so far it is observed only in Alzheimer's disease (Hasegawa, M., Morishima-Kawashima, M., Takio, K,, Suzuki, M., Titani, K., and Ihara, Y. (1992) J. Biol. Chem. 26, 17047-17054) and because phosphorylation of this site alone dramatically reduces the affinity for microtubules in vitro (Biernat, J., Gustke, N., Drewes, G., Mandelkow, E. M., and Mandelkow, E. (1993) Neuron 11, 153-163). Here we describe the purification and characterization of a protein-serine kinase from brain tissue with an apparent molecular mass of 110 kDa on SDS gels. This kinase specifically phosphorylates tau on its KIGS or KCGS motifs in the repeat domain, whereas no significant phosphorylation outside this region was detected. Phosphorylation occurs mainly on Ser-262 located in the first repeat. This largely abolishes tau's binding to microtubules and makes them dynamically unstable, in contrast to other protein kinases that phosphorylate tau at or near the repeat domain. The data suggest a role for this novel kinase in cellular events involving rearrangement of the microtubule associated proteins/microtubule arrays and their pathological degeneration in Alzheimer's disease.	MAX PLANCK UNIT STRUCT MOLEC BIOL, D-22603 HAMBURG, GERMANY; RUHR UNIV BOCHUM, INST PHYSIOL CHEM, D-44780 BOCHUM, GERMANY	Max Planck Society; Ruhr University Bochum				Drewes, Gerard/0000-0003-0575-6766				ANDERTON BH, 1993, HIPPOCAMPUS, V3, P227; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GONG CX, 1994, J NEUROCHEM, V62, P803; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GROSS U, 1994, MOL BIOL CELL, V5, P289; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1994, CELL MOTIL CYTOSKEL, V28, P195, DOI 10.1002/cm.970280302; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE G, 1992, J CELL SCI, V102, P227; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STEINER B, 1993, THESIS U HAMBURG; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506	70	321	330	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7679	7688		10.1074/jbc.270.13.7679	http://dx.doi.org/10.1074/jbc.270.13.7679			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706316	hybrid			2022-12-25	WOS:A1995QQ43100094
J	LEE, BS; UNDERHILL, DM; CRANE, MK; GLUCK, SL				LEE, BS; UNDERHILL, DM; CRANE, MK; GLUCK, SL			TRANSCRIPTIONAL REGULATION OF THE VACUOLAR H+-ATPASE B2 SUBUNIT GENE IN DIFFERENTIATING THP-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PROMOTER REGION; BOVINE KIDNEY; RECEPTOR GENE; FACTOR AP-2; ENDOCYTIC VESICLES; CYTOPLASMIC PH; EXPRESSION; PUMP; SEQUENCE	Monocyte-macrophage differentiation was used as a model system for studying gene regulation of the human vacuolar H+-ATPase (V-ATPase). We examined mRNA levels of various V-ATPase subunits during differentiation of both native monocytes and the cell line THP-1, and found that transcriptional and post-transcriptional mechanisms could account for increases in cell V-ATPase content. From nuclear runoff experiments, we found that one subunit in particular, the B2 isoform (M(r) = 56,000), was amplified primarily by transcriptional means. We have begun to examine the structure of the B2 subunit promoter region. Isolation and sequencing of the first exon and 5'-flanking region of this gene reveal a TATA-less promoter with a high G+C content. Primer extension and ribonuclease protection analyses indicate a single major transcriptional start site. We transfected promoter-luciferase reporter plasmids into THP-1 cells to define sequences that mediate transcriptional control during monocyte differentiation. We found that sequences downstream from the transcriptional start site were sufficient to confer increased expression during THP-1 differentiation. DNase I footprinting and sequence analysis revealed the existence of multiple AP2 and Spl binding sites in the 5'-untranslated and proximal coding regions.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	LEE, BS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, DIV RENAL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Lee, Beth S/E-9578-2010; UNDERHILL, DAVID/ABE-2185-2021	Lee, Beth S/0000-0002-1468-6387; Underhill, David/0000-0002-2989-658X	NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK09976, DK38848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAKI E, 1987, J BIOL CHEM, V262, P16186; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARON R, 1989, CONNECT TISSUE RES, V20, P109, DOI 10.3109/03008208909023879; BAUER J, 1988, J IMMUNOL METHODS, V112, P213, DOI 10.1016/0022-1759(88)90360-2; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brown T, 1987, CURRENT PROTOCOLS MO; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GABIG TG, 1981, ANNU REV MED, V32, P313, DOI 10.1146/annurev.me.32.020181.001525; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GILLESPIE GAJ, 1991, P NATL ACAD SCI USA, V88, P4289, DOI 10.1073/pnas.88.10.4289; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P221; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MARUSHACK MM, 1992, AM J PHYSIOL, V263, pF171, DOI 10.1152/ajprenal.1992.263.1.F171; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAN YX, 1991, FEBS LETT, V247, P147; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Sambrook J, 1989, MOL CLONING LABORATO; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STARKE T, 1991, Z NATURFORSCH C, V46, P613; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SWALLOW CJ, 1989, J SURG RES, V46, P588, DOI 10.1016/0022-4804(89)90025-5; TSUCHIYA S, 1982, CANCER RES, V42, P1530; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590	58	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7320	7329		10.1074/jbc.270.13.7320	http://dx.doi.org/10.1074/jbc.270.13.7320			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706273	hybrid			2022-12-25	WOS:A1995QQ43100046
J	RAY, A; HANNINK, M; RAY, BK				RAY, A; HANNINK, M; RAY, BK			CONCERTED PARTICIPATION OF NF-KB AND C/EBP HETEROMER IN LIPOPOLYSACCHARIDE INDUCTION OF SERUM AMYLOID A GENE-EXPRESSION IN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; ACUTE-PHASE RESPONSE; LEUCINE ZIPPER PROTEINS; KAPPA-B; A GENE; TRANSCRIPTION FACTOR; NUCLEAR FACTORS; FAMILY; NF-IL6; INTERLEUKIN-6	The promoter region of the rabbit serum amyloid A (SAA) gene contains two adjacent C/EBP and one NF-kappa B binding element. Involvement of these elements in SAA gene induction, following lipopolysaccharide (LPS) stimulation of the liver, has been studied by investigating LPS-activated transcription factors and their interaction with the promoter elements of the SAA gene. Appearance of complexes in the electrophoretic mobility shift assay has indicated that DNA-binding proteins that interact with the NF-KB element of the SAA promoter are induced in the LPS-treated rabbit liver. Presence of RelA (p65 subunit of NF-kappa B) in these complexes was demonstrated by the ability of RelA-specific antisera to supershift the DNA-protein complexes. LPS also induced several members of the C/EBP family of transcription factors, which interacted with the C/EBP motifs of the SAA promoter. Activated C/EBP and RelA form a RelA . C/EBP heteromeric complex that associates with varying affinity to NF-kappa B and C/EBP elements of the SAA gene. Transfection assays using both transcription factor genes have demonstrated that the hetero complex of NF-kappa B and C/EBP is a much more potent transactivator of SAA expression than each transcription factor alone. The heteromeric complex efficiently promotes transcription from both NF-kappa B and C/EBP sites.	UNIV MISSOURI,DEPT VET MICROBIOL,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NIDDK NIH HHS [DK 45144-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK045144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANDERS RF, 1977, J IMMUNOL, V118, P229; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRILLI M, 1993, INT REV CYTOL, V148, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1994, J IMMUNOL, V153, P153; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1991, J BIOL CHEM, V266, P15192; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray Alpana, 1993, Gene Expression, V3, P151; RAY BK, 1991, BIOCHEM BIOPH RES CO, V180, P1258, DOI 10.1016/S0006-291X(05)81331-2; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; RAY BK, 1993, BIOCHEM BIOPH RES CO, V193, P1159, DOI 10.1006/bbrc.1993.1747; RAY BK, 1993, EUR J BIOCHEM, V216, P127, DOI 10.1111/j.1432-1033.1993.tb18124.x; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	46	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7365	7374		10.1074/jbc.270.13.7365	http://dx.doi.org/10.1074/jbc.270.13.7365			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706280	hybrid			2022-12-25	WOS:A1995QQ43100053
J	SMITH, ML; CHEN, IT; ZHAN, QM; OCONNOR, PM; FORNACE, AJ				SMITH, ML; CHEN, IT; ZHAN, QM; OCONNOR, PM; FORNACE, AJ			INVOLVEMENT OF THE P53 TUMOR-SUPPRESSOR IN REPAIR OF UV-TYPE DNA-DAMAGE	ONCOGENE			English	Article						P53; UV; DNA REPAIR; GADD45; HPV E6; CHECKPOINTS	EXCISION REPAIR; IONIZING-RADIATION; CELLULAR-RESPONSE; ESCHERICHIA-COLI; PROTEIN; GENE; ACTIVATION; CHECKPOINT; APOPTOSIS; AGENTS	The tumor suppressor p53 plays a central role in the cellular responses to genotoxic stress. Besides its well known role in activation of the G(1) checkpoint after exposure to agents like ionizing radiation and its role in apoptosis, the possibility exists that p53 may have additional roles, such as in DNA repair. For example, p53, is known to bind to single strand DNA such as would occur during repair events, and the proteins encoded by two p53-regulated genes have previously been found to bind to at least one protein involved in DNA damage processing including nucleotide excision repair (NER). NER is an important and versatile DNA repair mechanism, which is the major pathway for repair of u.v.-type lesions and damage by a variety of important carcinogens and mutagens. If components of the p53 pathway are involved in NER, then disruption of p53 function by mutations or expression of certain viral proteins could have important implications in carcinogenesis and cancer treatment. In the present study we show that disruption of normal p53 function in human colon carcinoma RKO cells with either the human papillomavirus E6 oncoprotein or a dominant-negative mutant p53 transgene results in reduced repair of u.v.-induced DNA damage. The E6 and mutant p53-containing cell lines demonstrated reduced repair of u.v.-induced DNA lesions in host cell reactivation experiments with reporter plasmids, and reduced repair in in vitro DNA repair assays. With this in vitro assay, extracts from the E6- and mutant p53-containing lines also showed loss of induced repair following cellular u.v.-irradiation. The reduced DNA repair activity of the transfected cell lines also correlated with reduced clonogenic survival following u.v.-irradiation. These results indicate that p53 and/or p53-regulated gene products function in the NER pathway and that this process is inducible by DNA damage.			SMITH, ML (corresponding author), NCI,DIV CANC TREATMENT,MOLEC PHARMACOL LAB,DEV THERAPEUT PROGRAM,BLDG 37,ROOM 5C09,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				BOHR VA, 1989, LAB INVEST, V61, P143; BRISTOW RG, 1994, ONCOGENE, V9, P1527; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CROOK T, 1994, ONCOGENE, V9, P1225; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRIEDBERG EC, 1991, BIOESSAYS, V13, P295, DOI 10.1002/bies.950130607; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOY CA, 1984, MUTAT RES, V140, P199, DOI 10.1016/0165-7992(84)90077-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOVAL TM, 1988, RADIAT RES, V115, P413, DOI 10.2307/3577291; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRICE BD, 1994, CANCER RES, V54, P896; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; SMITH ML, 1995, IN PRESS CURR OPINIO; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WANG XW, 1994, P NATL ACAD SCI USA, V91, P230; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	64	379	381	1	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1053	1059						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700629				2022-12-25	WOS:A1995QN35300004
J	WUNDERLICH, M; GLOCKSHUBER, R				WUNDERLICH, M; GLOCKSHUBER, R			IN-VIVO CONTROL OF REDOX POTENTIAL DURING PROTEIN-FOLDING CATALYZED BY BACTERIAL PROTEIN DISULFIDE-ISOMERASE (DSBA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMYLASE-TRYPSIN-INHIBITOR; CIS-TRANS-ISOMERASE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; BONDS; SEQUENCE; STRAINS; BUFFER; CELL	The formation of disulfide bonds in Escherichia coli is catalyzed by periplasmic protein disulfide-isomerase (DsbA). When the alpha-amylase/trypsin inhibitor from Ragi, a protein containing five intramolecular disulfide bridges, is secreted into the periplasm of E. coli, large amounts of misfolded inhibitor with incomplete or incorrect disulfides are accumulated. Folding of the inhibitor in the periplasm is not improved when DsbA is coexpressed and cosecreted. However, an up to 14-fold increase in correctly folded inhibitor is observed by coexpression of DsbA in conjugation with the addition of reduced glutathione to the growth medium. This peptide acts as a disulfide-shuffling reagent and can pass the outer membrane of E. coli. Since the influence of DsbA on the folding yield of the inhibitor is reduced in the presence of oxidized glutathione, the in vivo function of DsbA appears to be dependent on the ratio between oxidizing and reducing thiol equivalents in the periplasm. The high stability of thiol reagents against air oxidation during growth of E. coli allows the investigation of oxidative protein folding in vivo under controlled, thiol-dependent redox conditions.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93040 REGENSBURG,GERMANY	University of Regensburg								BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bieth J., 1974, BAYER S, P463; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CAMPOS FAP, 1983, FEBS LETT, V152, P300, DOI 10.1016/0014-5793(83)80400-1; DECAD GM, 1976, J BACTERIOL, V128, P325, DOI 10.1128/JB.128.1.325-336.1976; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Freedman Robert B., 1992, P455; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Goldenberg David P., 1992, P353; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HEPPEL LA, 1962, J BIOL CHEM, V237, P841; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUYE H, 1982, J BACTERIOL, V149, P434, DOI 10.1128/JB.149.2.434-439.1982; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; LASKOWSKI M, 1986, NUTRITIONAL TOXICOLO, P1; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PAYNE JW, 1968, J BIOL CHEM, V243, P6291; POERIO E, 1991, EUR J BIOCHEM, V199, P595, DOI 10.1111/j.1432-1033.1991.tb16159.x; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHONBRUNNER ER, 1992, P NATL ACAD SCI USA, V89, P4510, DOI 10.1073/pnas.89.10.4510; SHIVARAJ B, 1981, BIOCHEM J, V193, P29, DOI 10.1042/bj1930029; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, IN PRESS J MOL BIOL; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	39	90	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24547	24550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693702				2022-12-25	WOS:A1993MG67300009
J	CULOUSCOU, JM; PLOWMAN, GD; CARLTON, GW; GREEN, JM; SHOYAB, M				CULOUSCOU, JM; PLOWMAN, GD; CARLTON, GW; GREEN, JM; SHOYAB, M			CHARACTERIZATION OF A BREAST-CANCER CELL-DIFFERENTIATION FACTOR THAT SPECIFICALLY ACTIVATES THE HER4/P180(ERBB4) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR-RECEPTOR; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; C-ERBB-2 ONCOGENE; PROTO-ONCOGENE; LIGAND; IDENTIFICATION; AMPLIFICATION; GLYCOPROTEIN; GENE	We recently reported the molecular cloning of HER4/p180erbB4, a new member of the epidermal growth factor receptor family, as well as its activation by a partially purified ligand (Plowman, G. D., Culouscou, J.-M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., and Shoyab, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1746-1750). In this report we describe the purification to homogeneity of a 45-kDa protein (p45) that induces the differentiation of MDA-MB-453 human breast cancer cells and stimulates the tyrosine phosphorylation of p180erbB4, the HER4-encoded protein. Hydrophobic interaction, ion-exchange, heparin, and size exclusion chromatographies were used to purify this p180erbB4 activator to homogeneity. N-terminal amino acid sequencing suggests that p45 is related to heregulin, a recently reported ligand for p185erBB2. Binding and cross-linking experiments demonstrated that p45 specifically binds to cells expressing recombinant p180erbB4 and not cells expressing recombinant p185erbB2.			CULOUSCOU, JM (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		PLOWMAN, Greg D/E-2012-2011	Plowman, Gregory D/0000-0002-6465-309X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1992, CANCER RES, V52, P2580; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOKOTA J, 1986, LANCET, V1, P765; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHAU HE, 1990, MOL CARCINOG, V3, P354; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	34	66	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18407	18410						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689552				2022-12-25	WOS:A1993LV65900003
J	SCHWARTZ, CFW				SCHWARTZ, CFW			INSULIN REGULATION OF PROTEIN-PHOSPHORYLATION IN H4 HEPATOMA-CELLS - EXAMINATION OF RAPID EFFECTS USING 2-DIMENSIONAL ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERINE THREONINE KINASES; TWO-DIMENSIONAL GEL; TYROSINE PHOSPHORYLATION; 3T3-L1 CELLS; STIMULATES PHOSPHORYLATION; MESSENGER-RNA; INTACT-CELLS; SRC GENE; INVITRO	Activation of the insulin receptor tyrosine kinase is thought to initiate a chain of phosphorylation changes which regulate various metabolic and growth processes. Insulin has been shown to regulate some kinases by affecting their phosphorylation states; however, direct connections between activation of the receptor tyrosine kinase and subsequent altered phosphorylations of these kinases have yet to be established. To define the constituents of these regulated phosphorylation cascade systems, the time course of insulin-induced phosphorylation changes has been examined. P-32-Labeled H4IIE hepatoma cells were treated with insulin for 5-300 s, and then cell extracts were subjected to two-dimensional gel electrophoresis. Computer analysis of autoradiograms was employed to quantify insulin-induced phosphorylation changes. Phosphotyrosine was assessed by KOH digestion, by anti-phosphotyrosine immunoprecipitation, and by phenylarsine oxide treatment. Insulin induced a hierarchy of phosphorylation changes over the 300-s time course, with most increases being detectable within 10 s. Of these, only four did not undergo enhanced tyrosine phosphorylation. Eight proteins were found to undergo transient phosphorylation changes. Phenylarsine oxide elicited the appearance of novel low molecular weight phosphoproteins. These results support the concept of insulin-directed phosphorylation cascades, but indicate the magnitude of potential targets of the insulin receptor has been underestimated.	UNIV VIRGINIA,HLTH SCI CTR,DEPT SURG,CHARLOTTESVILLE,VA 22908	University of Virginia								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; AVRUCH J, 1978, J BIOL CHEM, V253, P4754; AVRUCH J, 1985, MOL BASIS INSULIN AC, P263; AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P2487; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; COBB MH, 1986, J BIOL CHEM, V261, P2994; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HOFMANN C, 1980, DIABETES, V29, P865, DOI 10.2337/diabetes.29.11.865; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON G, 1977, J IMMUNOL METHODS, V15, P20; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LAWRENCE JC, 1983, J BIOL CHEM, V288, P10710; LECAM A, 1982, J BIOL CHEM, V257, P8376; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHWARTZ CFW, 1989, ADV PROTEIN PHOSPHAT, V5, P645; SEGER R, 1992, J BIOL CHEM, V267, P14373; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TOTH B, 1988, J BIOL CHEM, V263, P14061; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	53	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14450	14460						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686156				2022-12-25	WOS:A1993LJ82500095
J	CLAY, CM; KERI, RA; FINICLE, AB; HECKERT, LL; HAMERNIK, DL; MARSCHKE, KM; WILSON, EM; FRENCH, FS; NILSON, JH				CLAY, CM; KERI, RA; FINICLE, AB; HECKERT, LL; HAMERNIK, DL; MARSCHKE, KM; WILSON, EM; FRENCH, FS; NILSON, JH			TRANSCRIPTIONAL REPRESSION OF THE GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE BY ANDROGEN MAY INVOLVE DIRECT BINDING OF ANDROGEN RECEPTOR TO THE PROXIMAL PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; MESSENGER-RNA LEVELS; MAMMARY-TUMOR VIRUS; LUTEINIZING-HORMONE; NEGATIVE REGULATION; RESPONSE ELEMENT; MAMMALIAN-CELLS; PITUITARY; RAT; EXPRESSION	Testicular androgens suppress the synthesis and secretion of the pituitary gonadotropins, in particular, luteinizing hormone. This suppressive effect includes transcription of both the common alpha subunit gene and the unique beta subunit genes. Herein, we demonstrate that 1500 base pairs (bp) of proximal 5'-flanking region derived from the human alpha subunit gene and a shorter 315-bp segment of the bovine alpha subunit gene confer negative regulation by androgen to the gene encoding bacterial chloramphenicol acetyltransferase in transgenic mice. Cotransfection assays with human androgen receptor indicated that the 1500-bp promoter region of the human alpha subunit gene also confers androgen regulation (transcriptional suppression) to reporter genes in both pituitary and placental cell lines. This raises the possibility of a role for DNA binding in suppression of alpha subunit transcription by activated androgen receptor. Consistent with this possibility, we have used a gel-mobility shift assay to detect several high affinity binding sites for androgen receptor located in the proximal promoter of the human alpha subunit gene. The strongest androgen receptor binding site is located at approximately -101 in the proximal 5'-flanking region. This steroid receptor binding site overlaps another binding site that defines one of several contiguous cis-acting regulatory elements required for basal transcriptional activity. Thus, binding of activated androgen receptor to this region may block the binding of a requisite transacting factor and lead to an attenuation in transcription. We conclude that this interaction, which occurs directly at the level of the pituitary, represents one of several physiological avenues through which androgens regulate gonadotropin gene expression.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA	Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559, F32DK008612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007382] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28559, DK08612] Funding Source: Medline; NIGMS NIH HHS [GM 07382] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST JAO, 1990, J MOL ENDOCRINOL, V5, P1, DOI 10.1677/jme.0.0050001; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BONSALL RW, 1985, J STEROID BIOCHEM, V23, P389, DOI 10.1016/0022-4731(85)90184-0; BRINKLEY HJ, 1981, BIOL REPROD, V24, P22, DOI 10.1095/biolreprod24.1.22; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHUBB C, 1983, AM J PHYSIOL, V244, pE575, DOI 10.1152/ajpendo.1983.244.6.E575; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DESJARDINS C, 1981, BIOL REPROD, V24, P1, DOI 10.1095/biolreprod24.1.1; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; FINKELSTEIN JS, 1991, J CLIN ENDOCR METAB, V73, P609, DOI 10.1210/jcem-73-3-609; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMERNIK DL, 1992, MOL ENDOCRINOL, V6, P1745, DOI 10.1210/me.6.10.1745; HOJVAT S, 1982, NEUROENDOCRINOLOGY, V34, P327, DOI 10.1159/000123322; HOSTETTER G, 1987, NEUROENDOCRINOLOGY, V46, P185, DOI 10.1159/000124818; KENDALL SK, 1991, MOL ENDOCRINOL, V5, P2025, DOI 10.1210/mend-5-12-2025; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KERI RA, 1991, MOL ENDOCRINOL, V5, P725, DOI 10.1210/mend-5-5-725; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; NAESS O, 1975, ENDOCRINOLOGY, V96, P1; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PAUL SJ, 1990, MOL ENDOCRINOL, V4, P1943, DOI 10.1210/mend-4-12-1943; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; SCHANBACHER BD, 1984, J STEROID BIOCHEM, V20, P1227, DOI 10.1016/0022-4731(84)90149-3; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; TAN JA, 1992, J BIOL CHEM, V267, P4456; THIEULANT ML, 1979, J STEROID BIOCHEM, V10, P677, DOI 10.1016/0022-4731(79)90521-1; TILBROOK AJ, 1991, ENDOCRINOLOGY, V129, P3080, DOI 10.1210/endo-129-6-3080; WIERMAN ME, 1990, BIOL REPROD, V42, P563, DOI 10.1095/biolreprod42.3.563; WIERMAN ME, 1988, MOL ENDOCRINOL, V2, P492, DOI 10.1210/mend-2-6-492; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	38	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13556	13564						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685765				2022-12-25	WOS:A1993LH55300077
J	GROBMYER, SR; KUO, A; ORISHIMO, M; OKADA, SS; CINES, DB; BARNATHAN, ES				GROBMYER, SR; KUO, A; ORISHIMO, M; OKADA, SS; CINES, DB; BARNATHAN, ES			DETERMINANTS OF BINDING AND INTERNALIZATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY HUMAN VASCULAR SMOOTH-MUSCLE AND ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; EXTRACELLULAR-MATRIX; INHIBITOR PAI-1; UROKINASE; MEMBRANE; GROWTH; IDENTIFICATION; LOCALIZATION; COLLAGENASE; MIGRATION	Vascular injury induced by angioplasty is often followed by smooth muscle cell (SMC) proliferation, migration, and accumulation of extracellular matrix. Since plasminogen activators and their receptors may be important both in cell migration and the clearance of plasminogen activators, we studied the binding, internalization, and degradation of radiolabeled tissue-type plasminogen activator (t-PA) by explant cultures of human vascular SMC. Binding of t-PA to SMC at 4-degrees-C was rapid, specific, saturable, and inhibitable by antibodies to plasminogen activator inhibitor type 1 (PAI-1). At 37-degrees-C, labeled t-PA was internalized and degraded by SMC but not by human umbilical vein endothelial cells. Internalization and degradation was mediated by the low density lipoprotein receptor related protein/alpha2-macroglobulin receptor (LRP) in that these processes were inhibited by an anti-LRP antibody, recombinant LRP-associated protein, urokinase-type plasminogen activator-PAI-1 complexes, and lactoferrin. The portion of t-PA most important for internalization after complexing with PAI-1 is likely to be in the finger and/or epidermal growth factor domains or in the carbohydrate at amino acid 117, in that the internalization of preformed t-PA.PAI-1 complexes or complexes formed on the cell surface was inhibited by an excess of active site-blocked wild type t-PA, but not by an active site blocked t-PA variant missing these domains. These studies are consistent with a model in which t-PA binds initially to SMC-associated PAI-1 with subsequent t-PA.PAI-1 internalization via LRP. SMC may play an important role in clearing t-PA.PAI-1 complexes from within the vessel wall.	UNIV PENN, SCH MED,DEPT MED,DIV CARDIOVASC, 503 JOHNSON PAVIL 6060,36TH & HAMILTON WALK, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [R01HL47839, F32HL08621-01, P01HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL047839, F32HL008621] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AU YPT, 1992, J BIOL CHEM, V267, P3438; BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEEBE DP, 1987, THROMB RES, V46, P241, DOI 10.1016/0049-3848(87)90286-6; BEEBE DP, 1989, BLOOD, V74, P2034; BOOYSE FM, 1981, BLOOD, V58, P788; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; DUVE CD, 1974, BIOCHEM PHARMACOL, V23, P2495; FUKAO H, 1992, BIOCHEM BIOPH RES CO, V187, P956, DOI 10.1016/0006-291X(92)91290-7; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1992, CIRCULATION, V86, P148; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; INYANG AL, 1990, BIOCHEM BIOPH RES CO, V171, P1326, DOI 10.1016/0006-291X(90)90831-7; KAMPS JAAM, 1992, EUR J BIOCHEM, V206, P973, DOI 10.1111/j.1432-1033.1992.tb17008.x; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LAUG WE, 1985, THROMB HAEMOSTASIS, V54, P498; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LIOTTA LA, 1981, CANCER RES, V41, P4629; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SAKATA Y, 1988, J BIOL CHEM, V263, P1960; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SKRIVER L, 1984, J CELL BIOL, V99, P753, DOI 10.1083/jcb.99.2.753; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; SPERTI G, 1992, CIRC RES, V71, P385, DOI 10.1161/01.RES.71.2.385; SPRENGERS ED, 1987, BLOOD, V69, P381; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; YEN FT, 1992, CIRCULATION, V86, P611	48	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13291	13300						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685759				2022-12-25	WOS:A1993LH55300043
J	GALLI, J; WIESLANDER, L				GALLI, J; WIESLANDER, L			A REPETITIVE SECRETORY PROTEIN GENE OF A NOVEL TYPE IN CHIRONOMUS-TENTANS IS SPECIFICALLY EXPRESSED IN THE SALIVARY-GLANDS AND EXHIBITS EXTENSIVE LENGTH POLYMORPHISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BALBIANI RING GENES; INVOLUCRIN GENE; SEQUENCE; DNA; EVOLUTION; POLYPEPTIDE; DROSOPHILA; HOMINOIDS; CONTAIN; REPEATS	The secretion from the salivary glands in the dipteran Chironomus tentans has previously been shown to contain secretory proteins encoded by a set of related genes belonging to the Balbiani ring multigene family. Here we describe the characterization of a gene for an additional secretory protein of a novel type. This sp240/420 gene is built from virtually identical 477-base pair repeats organized in tandem. The gene exhibits extensive length polymorphism since allelic length variants with from 12 to 22 repeats were recorded. Antibodies have been raised against the gene product, and it is shown also that the protein varies in size between 240 and 420 kDa. The protein is rich in serine and threonine residues (30%) and has N-linked carbohydrate chains, presumably on each repeat. Despite careful preparation of the gland lumen proteins, the sp240/420 protein was found to form protein ladders of regularly degraded protein, suggesting that this degradation occurs naturally in the salivary glands. Although all previously characterized salivary gland secretory protein genes in C. tentans belong to the same multigene family, the sp240/420 gene appears to represent a novel, unrelated type of repetitive gene. The chromosomal location of the gene was mapped and was found to reside in region 17 on chromosome I.	KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Wieslander, Lars/B-4670-2016	Wieslander, Lars/0000-0003-3271-6946				Armour JAL, 1992, CURR OPIN GENET DEV, V2, P850, DOI 10.1016/S0959-437X(05)80106-6; BEERMANN W, 1973, CHROMOSOMA, V41, P297, DOI 10.1007/BF00344024; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Case S.T., 1992, Results and Problems in Cell Differentiation, V19, P187; COSTA R, 1991, J MOL EVOL, V32, P238, DOI 10.1007/BF02342746; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM SS, 1989, J BIOL CHEM, V264, P9444; DJIAN P, 1989, P NATL ACAD SCI USA, V86, P8447, DOI 10.1073/pnas.86.21.8447; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DOVER GA, 1986, TRENDS GENET, V2, P159, DOI 10.1016/0168-9525(86)90211-8; DREESEN TD, 1988, J CELL BIOL, V106, P21, DOI 10.1083/jcb.106.1.21; DREESEN TD, 1985, J BIOL CHEM, V260, P1824; DWORKINRASTL E, 1984, CELL, V39, P321, DOI 10.1016/0092-8674(84)90010-2; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDSTROM JE, 1982, DEV BIOL, V91, P131, DOI 10.1016/0012-1606(82)90016-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GALLI J, 1990, J MOL EVOL, V31, P40, DOI 10.1007/BF02101791; GALLI J, 1993, IN PRESS J MOL BIOL; Grond C., 1987, Results and Problems in Cell Differentiation, V14, P69; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Grossbach U., 1977, Results Probl Cell Differ, V8, P147; HOOG C, 1988, J MOL BIOL, V200, P655, DOI 10.1016/0022-2836(88)90478-0; ICHIMURA S, 1992, J MOL EVOL, V35, P123, DOI 10.1007/BF00183223; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; KAO WY, 1985, J CELL BIOL, V101, P1044, DOI 10.1083/jcb.101.3.1044; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LOPEZ JA, 1992, J BIOL CHEM, V267, P10055; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEYER B, 1983, DEV BIOL, V98, P265, DOI 10.1016/0012-1606(83)90357-3; PAULSSON G, 1992, J MOL BIOL, V225, P349, DOI 10.1016/0022-2836(92)90926-B; PAULSSON G, 1990, J MOL BIOL, V211, P331, DOI 10.1016/0022-2836(90)90355-P; PAULSSON G, 1992, J MOL EVOL, V35, P205; POOLE CB, 1992, P NATL ACAD SCI USA, V89, P5986, DOI 10.1073/pnas.89.13.5986; PUSTELL J, 1984, J MOL EVOL, V20, P281, DOI 10.1007/BF02104734; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; Sambrook J, 1989, MOL CLONING LABORATO; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SORIMACHI H, 1990, J MOL BIOL, V211, P35, DOI 10.1016/0022-2836(90)90009-B; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TEUMER J, 1989, P NATL ACAD SCI USA, V86, P1283, DOI 10.1073/pnas.86.4.1283; WELLMAN SE, 1989, J BIOL CHEM, V264, P10878; WIESLANDER L, 1984, J MOL EVOL, V20, P304, DOI 10.1007/BF02104736; WIESLANDER L, 1992, P NATL ACAD SCI USA, V89, P4578, DOI 10.1073/pnas.89.10.4578; WYSS C, 1982, EXP CELL RES, V319, P297	50	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11888	11893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685024				2022-12-25	WOS:A1993LF28400065
J	PRASAD, L; SHARMA, S; VANDONSELAAR, M; QUAIL, JW; LEE, JS; WAYGOOD, EB; WILSON, KS; DAUTER, Z; DELBAERE, LTJ				PRASAD, L; SHARMA, S; VANDONSELAAR, M; QUAIL, JW; LEE, JS; WAYGOOD, EB; WILSON, KS; DAUTER, Z; DELBAERE, LTJ			EVALUATION OF MUTAGENESIS FOR EPITOPE MAPPING - STRUCTURE OF AN ANTIBODY-PROTEIN ANTIGEN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HISTIDINE-CONTAINING PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; MONOCLONAL FAB FRAGMENT; ESCHERICHIA-COLI; CRYSTALLOGRAPHIC REFINEMENT; PHOSPHOENOLPYRUVATE; RESOLUTION; BINDING; SITES	The location and description of epitopes on proteins describe the basis of immunological specificity. The 2.8-angstrom structure of the phosphocarrier protein, HPr from Escherichia coli, complexed to the Fab fragment of the monoclonal antibody, Jel42, has been determined. This allows the first comparison of epitope predictions from extensive site-directed mutagenesis experiments, coupled with biological activity studies (Sharma, S., Georges, F., Klevit, R. E., Delbaere, L. T. J., Lee, J. S., and Waygood, E. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4877-4881), with those from x-ray analysis. There are 14 amino acid residues of E. coli HPr that interact with the Jel42 antigen-binding site. Nine of these were correctly assigned by the mutagenesis studies. Of the 5 remaining residues, Met-1 could not be altered; two others appear to have critical roles in determining protein conformation; the other 2 residues have a minimal effect on antibody binding since they are located on the periphery of the epitope with one face of their side chains in van der Waals contact with the antibody and the other face in contact with solvent. Four residues were incorrectly assigned to the epitope. These residues were located adjacent to epitope residues that were likely perturbed by these mutations. This study demonstrates that mutations which caused greater than 10-fold changes in antibody binding affinity were correctly assigned to the epitope by the mutagenesis experiments. Guidelines are also presented in order to minimize incorrect assignments.	UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT CHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; EUROPEAN MOLEC BIOL LAB,HAMBURG OUTSTN,W-2000 HAMBURG,GERMANY	University of Saskatchewan; University of Saskatchewan; European Molecular Biology Laboratory (EMBL)				Wilson, Keith/0000-0002-3581-2194				BACON D, 1991, PRERAS3D RASTER3D GR; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DELBAERE LTJ, 1989, J BIOL CHEM, V264, P18645; DELUCAS LJ, 1992, ADV SPACE RES-SERIES, V12, P393, DOI 10.1016/0273-1177(92)90310-T; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; JEFFREY P, 1989, THESIS U OXFORD; JIA Z, 1992, THESIS U SASKATCHEWA; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; KABAT EA, 1991, NIH913242 PUBL, P664; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PRASAD L, 1988, J BIOL CHEM, V263, P2571; ROSSMANN MG, 1972, MOL REPLACEMENT METH, P1; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; STEEVES T, 1991, BIOCHEM CELL BIOL, V69, P297, DOI 10.1139/o91-045; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; 1979, SERC UK4 DAR LAB COL	28	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10705	10708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684366				2022-12-25	WOS:A1993LD46600002
J	GAUDRY, M; CAON, AC; NACCACHE, PH				GAUDRY, M; CAON, AC; NACCACHE, PH			MODULATION OF THE ACTIVITY AND SUBCELLULAR-DISTRIBUTION OF PROTEIN-TYROSINE KINASES IN HUMAN NEUTROPHILS BY PHORBOL ESTERS	FASEB JOURNAL			English	Note						PROTEIN KINASE-C; SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; PHORBOL 12,13-DIBUTYRATE; PP60(SRC); PP93(FCS)	COLONY-STIMULATING FACTOR; HL-60 LEUKEMIA-CELLS; RABBIT PERITONEAL NEUTROPHILS; POTENT SELECTIVE INHIBITORS; SIGNAL TRANSDUCTION; MONOCYTIC DIFFERENTIATION; 12-MYRISTATE 13-ACETATE; MYRISTATE ACETATE; RESPIRATORY BURST; OXIDATIVE BURST	Although several tyrosine kinases are present in human neutrophils, little is known regarding the biochemical basis for their activation. We have identified two tyrosine kinase activities in 0.1 and 1% Triton cell extracts of human neutrophils using a non-denaturing gel assay. The first protein tyrosine kinase activity of a faster mobility was associated exclusively with the 0.1% Triton cell extract. The second activity, of slower mobility, was mainly associated with the 0.1% Triton cell extract and to a lesser extent with the 1% Triton cell extract. A modulation of the activities and the distribution of these two tyrosine kinase activities was observed upon stimulation of neutrophils with PDBu (phorbol 12,13-dibutyrate), a direct PKC (protein kinase C) activator. The addition of 1 muM PDBu induced a time-dependent decrease of both tyrosine kinases in the 0.1% Triton cell extract. Although the fast mobility tyrosine kinase activity disappeared completely, the slow mobility tyrosine activity decreased only partially. Concomitantly, an increase in the latter activity was detected in the 1% Triton cell extract. The pattern of tyrosine phosphorylation upon PDBu stimulation was also examined and the results showed that the phorbol ester induced time-dependent increases in the level of phosphotyrosine-containing proteins in at least 10 distinct bands. Two lines of evidence indicated that the effects of PDBu were mediated by PKC: 1) The stereo-isomer of PDBu, 4alpha-PDBu, did not affect the activities and distribution of the tyrosine kinases, and 2) The PKC inhibitor, RO 318220, prevented the redistribution of the tyrosine kinase activities and inhibited the stimulation of tyrosine phosphorylation induced by PDBu. These results show that the activity and distribution of at least two human neutrophil tyrosine kinases are modulated after the activation of PKC and that the low mobility tyrosine kinase activity is the most sensitive to PDBu. Based on previous studies, the fast mobility tyrosine kinase activity was likely to be a member of the pp60src tyrosine kinase family and the slower one may be related to the pp93fes. Furthermore, these results begin to define the nature of the relationships among the PKC- and the tyrosine kinase-signaling pathways.	UNIV LAVAL,FAC MED,DEPT MED,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University	GAUDRY, M (corresponding author), CHUL,CTR RECH INFLAMMAT & IMMUNOL RHUMATOL,LOCAL 9800,2705 BLVD LAURIER,ST FOY G1V 4G2,PQ,CANADA.		Gaudry, Murielle/N-5934-2018	Gaudry, Murielle/0000-0002-9281-2334				BERKOW RL, 1990, BLOOD, V75, P2445; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BERKOW RL, 1987, J LEUKOCYTE BIOL, V41, P441, DOI 10.1002/jlb.41.5.441; BERKOW RL, 1991, J LEUKOCYTE BIOL, V49, P599, DOI 10.1002/jlb.49.6.599; BERRIDGE MJ, 1988, COLD SPRING HARB SYM, V53, P927, DOI 10.1101/SQB.1988.053.01.107; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; GAUDRY M, 1990, IMMUNOPHARMACOLOGY, V20, P45, DOI 10.1016/0162-3109(90)90006-Z; GAUDRY M, 1990, IMMUNOPHARMACOLOGY, V19, P23, DOI 10.1016/0162-3109(90)90023-8; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V140, P908, DOI 10.1016/0006-291X(86)90721-7; GLAZER RI, 1987, ANAL BIOCHEM, V164, P214, DOI 10.1016/0003-2697(87)90388-5; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MCCOLL SR, 1991, BLOOD, V78, P1842; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NACCACHE PH, 1990, BLOOD, V76, P2098; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; TAUBER AI, 1987, BLOOD, V69, P711; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WHITE JR, 1984, J BIOL CHEM, V259, P8605; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YU G, 1988, MOL PHARMACOL, V33, P384; YU G, 1987, J BIOL CHEM, V262, P17543	47	25	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					687	693		10.1096/fasebj.7.8.7684713	http://dx.doi.org/10.1096/fasebj.7.8.7684713			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	7684713				2022-12-25	WOS:A1993LE29000011
J	SOKER, S; SVAHN, CM; NEUFELD, G				SOKER, S; SVAHN, CM; NEUFELD, G			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS INACTIVATED BY BINDING TO ALPHA-2-MACROGLOBULIN AND THE BINDING IS INHIBITED BY HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; COVALENT BINDING; FACTOR-BETA; MITOGEN; CELLS; RECEPTOR; PROTEINS; SERUM; GENE; MACROGLOBULIN	Vascular endothelial growth factor (VEGF) is a mitogen for cultured endothelial cells, and a potent angiogenic factor in vivo. Incubation of I-125-VEGF with human or bovine serum led to the formation of I-125-VEGF containing complexes that had a molecular mass greater than 300 kDa. These complexes were specifically immunoprecipitated with anti-human alpha2-macroglobulin (alpha2M) antibodies. Similar high molecular weight complexes were formed when I-125-VEGF was incubated with commercially available alpha2M. The I-125-VEGF.alpha2M complexes were resistant to boiling in the presence of SDS. The formation of I-125-VEGF.alpha2M complexes was inhibited by iodoacetic acid, indicating that free sulfhydryl groups are required for complex assembly. Tryptic digestion of alpha2M did not affect its VEGF binding ability. Tryptic digestion of I-125-VEGF.alpha2M complexes on the other hand, resulted in the degradation of bound I-125-VEGF, indicating that alpha2M does not protect bound I-125-VEGF from proteolytic digestion. The binding of I-125-VEGF to alpha2M was partially inhibited by an excess of basic fibroblast growth factor. Other growth factors which bind to alpha2M, such as platelet-derived growth factor and insulin, did not inhibit the binding of I-125-VEGF. The binding of VEGF to alpha2M inhibited its receptor binding ability, indicating that alpha2M may function as a VEGF removal and inactivation factor. Heparin and heparan sulfate, but not other glycosaminoglycans such as chondroitin sulfate, efficiently inhibited the binding of I-125-VEGF to alpha2M. It is possible that heparin-like molecules released from extracellular matrixes could prevent the inactivation of VEGF by alpha2M resulting in the potentiation of processes such as tumor angiogenesis.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL TECH,IL-32000 HAIFA,ISRAEL; KABI PHARM THERAPEUT,DIV RES & DEV,S-11287 STOCKHOLM,SWEDEN	Technion Israel Institute of Technology			Neufeld, Gera/F-1524-2019					BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HARDOUIN S, 1987, EUR J BIOCHEM, V170, P121, DOI 10.1111/j.1432-1033.1987.tb13676.x; Harpel P C, 1976, Methods Enzymol, V45, P639; HOFFMANN R, 1973, EXP CELL RES, V80, P275, DOI 10.1016/0014-4827(73)90297-8; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SALVESEN GS, 1980, BIOCHEM J, V187, P695, DOI 10.1042/bj1870695; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361	40	103	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7685	7691						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681826				2022-12-25	WOS:A1993KW97900018
J	HUI, Y; CZAPLA, TH				HUI, Y; CZAPLA, TH			ISOLATION AND CHARACTERIZATION OF CDNA CLONES ENCODING JACALIN ISOLECTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; RICINUS-COMMUNIS AGGLUTININ; ARTOCARPUS-INTEGRIFOLIA; CARBOXYPEPTIDASE-Y; ENDOPLASMIC-RETICULUM; MACLURA-POMIFERA; BARLEY LECTIN; PLANT-LECTINS; PRO-REGION; PEP4 GENE	Four jacalin cDNA clones (pSKcJA1, pSKcJA3, pSKcJA15, and pSKcJA17) have been obtained from an Artocarpus integrifolia (jackfruit) seed cDNA library. These clones share over 94% sequence homology, and their deduced polypeptide sequences confirm the existence of multiple jacalin isolectins in jackfruit seeds. The deduced amino acid sequences show that jacalin appears to be initially synthesized as a prepropeptide with the following structure: N-signal (21 residues) --> propeptide (39 residues) --> beta-peptide (20 residues) --> linker region (4 residues) --> alpha-peptide (133 residues). These observations are supported by Western blot analysis of jackfruit seed extract and by immunoprecipitation of in vitro translated products of both pSKcJA3 transcript and jackfruit seed poly(A)+ RNA. Sequence analysis of the 39-residue propeptide reveals that it has the potential to facilitate proper folding of jacalin protein. The unusual primary structure of jacalin prepropeptide suggests a quite interesting processing of this lectin precursor into mature alpha- and beta-subunits.			HUI, Y (corresponding author), PIONEER HI BRED INT INC,DIV PLANT BREEDING,DEPT BIOTECHNOL,7250 NW 62ND AVE,JOHNSTON,IA 50131, USA.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; AUCOUTURIER P, 1987, MOL IMMUNOL, V24, P503, DOI 10.1016/0161-5890(87)90025-3; BANERJEE R, 1991, J MOL BIOL, V221, P773, DOI 10.1016/0022-2836(91)80174-S; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BUNNMORENO MM, 1981, J IMMUNOL, V127, P427; BUTTERWORTH AG, 1983, EUR J BIOCHEM, V137, P57, DOI 10.1111/j.1432-1033.1983.tb07795.x; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CZAPLA TH, 1990, J ECON ENTOMOL, V83, P2480, DOI 10.1093/jee/83.6.2480; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; ETZLER ME, 1985, CHEM BIOL LECTINS; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Firestone G.L., 1990, METHOD ENZYMOL, V182, P688, DOI 10.1016/0076-6879(90)82054-6; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAGIWARA K, 1988, MOL IMMUNOL, V25, P69, DOI 10.1016/0161-5890(88)90092-2; HANKINS CN, 1980, PLANT PHYSIOL, V65, P618, DOI 10.1104/pp.65.4.618; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HATTORI T, 1985, PLANT MOL BIOL, V5, P313, DOI 10.1007/BF00020629; HEMPERLY JJ, 1982, J BIOL CHEM, V257, P7903; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KNOX RB, 1976, P NATL ACAD SCI USA, V73, P2788, DOI 10.1073/pnas.73.8.2788; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LIU YC, 1990, BIOTECHNIQUES, V9, P558; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; NAMJUNTRA P, 1985, BIOCHEM BIOPH RES CO, V128, P833, DOI 10.1016/0006-291X(85)90122-6; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDAMME E, 1991, THESIS KATHOLIEKE U, P87; VASANTHA N, 1984, J BACTERIOL, V159, P811, DOI 10.1128/JB.159.3.811-819.1984; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VIJAYAKUMAR T, 1986, BIOL PLANTARUM, V28, P370, DOI 10.1007/BF02902249; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKINS TA, 1989, PLANT CELL, V1, P541, DOI 10.1105/tpc.1.5.541; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; YOUNG NM, 1989, ARCH BIOCHEM BIOPHYS, V270, P596, DOI 10.1016/0003-9861(89)90542-0; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	54	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5905	5910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680651				2022-12-25	WOS:A1993KR82200083
J	SAIKAWA, Y; KNIGHT, CB; SAIKAWA, T; PAGE, ST; CHABNER, BA; ELWOOD, PC				SAIKAWA, Y; KNIGHT, CB; SAIKAWA, T; PAGE, ST; CHABNER, BA; ELWOOD, PC			DECREASED EXPRESSION OF THE HUMAN FOLATE RECEPTOR MEDIATES TRANSPORT-DEFECTIVE METHOTREXATE RESISTANCE IN KB CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BINDING-PROTEIN; L1210 CELLS; DIHYDROFOLATE-REDUCTASE; MEMBRANE-TRANSPORT; LEUKEMIA-CELLS; FLUORESCEINATED METHOTREXATE; SYNTHETASE-ACTIVITY; HEPATOMA-CELLS; AFFINITY	The human membrane-associated folate binding protein, or folate receptor (hFR), is a necessary component of folate and methotrexate (MTX) transport in some cell lines. To investigate the role of hFR in acquired MTX resistance in human cells, we characterized nine MTX-resistant clones selected from human nasopharyngeal epidermoid carcinoma (KB) cells (cells which transport folates/anti-folates via the hFR) cultured in media containing low folate concentrations. Compared with wild type KB cells, the level of resistance of the clones ranges from 2- to 80-fold higher and the resistant phenotypes of the clones are characterized as follows. 1) DHFR levels are increased (3-13-fold) in four of nine clones; 2) MTX polyglutamation is not detectably different; 3) the extents of MTX efflux are similar; 4) initial rates of MTX efflux are similar except for two clones which exhibit slightly faster efflux rates (approximately 2-fold); and 5) the V(max) for specific MTX and 5-methyltetrahydrofolate transport are decreased (2-18-fold) in all mutants. The K(t) values for MTX transport of each mutant are similar to the K(t) of KB cells. These results indicate that all nine MTX-resistant clones exhibit defective MTX transport and that four clones also have increased DHFR levels. Based on folic acid binding assays, the hFR is reduced by 1.8-24-fold in these clones relative to KB cell hFR expression. Western, Northern, and Southern analyses are consistent with decreased hFR expression in these clones rather than mutations, resulting in alterations in the size or ligand binding affinities of the hFR. The decrement in hFR expression correlates closely with the degree of reduction in MTX transport V(max) for each clone. Since folate and MTX influx proceed via hFR in KB cells and in these mutants, the correlation (R2 = 0.90) between hFR expression and the MTX transport V(max) of each clone indicates that hFR expression is an important determinant of acquired MTX resistance in this human tumor cell line. These studies demonstrate that defective transport (manifested by decreased V(max)) resulting from decreased expression of the hFR is frequent in KB cells cultured under these conditions and suggest that modulation of hFR may be relevant to MTX cytotoxicity or resistance in tissues or cells expressing functionally significant levels of hFR.	NCI, MED BRANCH,BLDG 10,RM 12N226,9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLEGRA CJ, 1990, CANCER CHEMOTHERAPY, P110; ALT FW, 1978, J BIOL CHEM, V253, P1357; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; AYUSAWA D, 1981, CANCER RES, V41, P1497; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CALABRESI P, 1985, PHARMACOL BASIS THER, P1240; CHABNER BA, 1982, PHARM PRINCIPLES CAN, P229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN KH, 1984, J BIOL CHEM, V259, P793; CURT GA, 1985, J CLIN INVEST, V76, P1323, DOI 10.1172/JCI112106; DAVIS LG, 1986, BASIC METHODS MOL BI, P44; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DOLNICK BJ, 1985, J BIOL CHEM, V260, P3006; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; FAN JG, 1991, J BIOL CHEM, V266, P14862; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FLINTOFF WF, 1980, BIOCHEMISTRY-US, V19, P4321, DOI 10.1021/bi00559a027; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1983, CANCER RES, V43, P1087; GALIVAN J, 1979, CANCER RES, V39, P735; GALIVAN J, 1981, CANCER RES, V41, P1757; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1986, CANCER RES, V46, P1639; HENDERSON GB, 1986, CANCER RES, V46, P1633; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON JF, 1984, ANTITUMOR DRUG RESIS, P23; HOFFMEISTER RT, 1983, AM J MED, V75, P69, DOI 10.1016/0002-9343(83)90477-1; JACKSON RC, 1977, EUR J CANCER, V13, P567, DOI 10.1016/0014-2964(77)90118-9; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1989, CANCER RES, V49, P2455; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KNIGHT CB, 1989, ADV ENZYME REGUL, V29, P3, DOI 10.1016/0065-2571(89)90090-3; KOIZUMI S, 1988, JPN J CANCER RES, V79, P1230, DOI 10.1111/j.1349-7006.1988.tb01549.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHERLY LH, 1991, CANCER RES, V51, P3420; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCCORMICK JI, 1981, ARCH BIOCHEM BIOPHYS, V212, P311, DOI 10.1016/0003-9861(81)90371-4; MYERS CE, 1975, P NATL ACAD SCI USA, V72, P3683, DOI 10.1073/pnas.72.9.3683; NORRIS MD, 1991, CANCER, V68, P981, DOI 10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILSKY RL, 1981, BIOCHEM PHARMACOL, V30, P1537, DOI 10.1016/0006-2952(81)90378-6; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SHERWOOD SW, 1990, CANCER RES, V50, P4946; SIROTNAK FM, 1985, CANCER RES, V45, P3992; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; WEITMAN SD, 1992, CANCER RES, V52, P3396; WHITE JC, 1981, J BIOL CHEM, V256, P5722; YANG CH, 1988, J BIOL CHEM, V263, P9703	65	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5293	5301						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680349				2022-12-25	WOS:A1993KP88400104
J	IKEDA, K; CLARK, JC; SHAWWHITE, JR; STAHLMAN, MT; BOUTELL, CJ; WHITSETT, JA				IKEDA, K; CLARK, JC; SHAWWHITE, JR; STAHLMAN, MT; BOUTELL, CJ; WHITSETT, JA			GENE STRUCTURE AND EXPRESSION OF HUMAN THYROID TRANSCRIPTION FACTOR-I IN RESPIRATORY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; TRANSGENIC MICE; REGIONS; IDENTIFICATION; ELEMENTS; PROTEIN	The human gene encoding thyroid transcription factor-1 (TTF-1), a homeodomain-containing nuclear transcription protein of the Nkx2 gene family, was isolated and characterized, Human TTF-1 was encoded by a single gene locus spanning approximately 3.3 kilobases and consisted of two exons and a single intron, The TTF-1 cDNA and polypeptide of 371 amino acids have been highly conserved, sharing 98% identity with the rat TTF-1 polypeptide, Human TTF-1 mRNA and polypeptide were selectively expressed in human and mouse pulmonary adenocarcinoma cell lines, In addition to its presence in thyroid gland epithelium, the human TTF-1 protein was detected by immunohistochemistry in human fetal lung as early as 11 weeks of gestation, being localized in the nuclei of epithelial cells of the developing airways, After birth, TIE-I was selectively expressed in Type II epithelial cells in the alveoli and in subsets of bronchiolar epithelial cells in the conducting regions of the lung, The 5'-flanking region of the human TTF-1 gene directed transcription of luciferase cDNA in a lung epithelial cell-selective manner, The conservation and distribution of TTF-1 in the human respiratory tract support its role in the regulation of lung development and surfactant homeostasis.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229; VANDERBILT UNIV,SCH MED,DIV NEONATOL,NASHVILLE,TN 37232	Cincinnati Children's Hospital Medical Center; Vanderbilt University				Boutell, Chris/0000-0002-2970-7785	NHLBI NIH HHS [HL14214, HL51832, HL41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P01HL051832, P50HL014214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVITAREALE D, 1989, EMBO J, V8, P2533; DAMANTE G, 1991, P NATL ACAD SCI USA, V88, P5388, DOI 10.1073/pnas.88.12.5388; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; MACGREGOR GR, 1989, METHOD MOL BIOL, V7, P1; PRICE M, 1992, NEURON, V8, P1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; Sternberger LA, 1979, IMMUNOCYTOCHEMISTRY, P104; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029	18	165	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8108	8114		10.1074/jbc.270.14.8108	http://dx.doi.org/10.1074/jbc.270.14.8108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713914	hybrid			2022-12-25	WOS:A1995QR52600052
J	KIRSHENBAUM, LA; SCHNEIDER, MD				KIRSHENBAUM, LA; SCHNEIDER, MD			ADENOVIRUS E1A REPRESSES CARDIAC GENE-TRANSCRIPTION AND REACTIVATES DNA-SYNTHESIS IN VENTRICULAR MYOCYTES, VIA ALTERNATIVE POCKET PROTEIN-BINDING AND P300-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-ANTIGEN TRANSGENES; MYOSIN HEAVY-CHAIN; GROWTH-FACTORS; EXPRESSION; MUSCLE; CELL; DIFFERENTIATION; INHIBITION; BINDING; MICE	To examine the potential impact of disrupting ''pocket'' protein function on cardiac differentiation and growth, we introduced 12 S E1A genes into neonatal ventricular myocytes, by adenoviral gene transfer. In the absence of E1B, E1A was cytotoxic, with features typical of apoptosis. In the presence of E1B, E1A preferentially inhibited transcription of cardiac-restricted alpha-actin promoters, and reactivated DNA synthesis in cardiac myocytes, without cell death. Mutations that abrogate known activities of the amino terminus of E1A, versus conserved region 2, demonstrate that the ''pocket'' protein- and p300-binding domains each suffice, in the absence of the other, for transcriptional repression and re-entry into S phase.	BAYLOR COLL MED, DEPT MED, MOLEC CARDIOL UNIT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PHYSIOL & MOLEC BIOPHYS, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Kirshenbaum, Lorrie A./F-5742-2014	Ryplanski, Kairee/0000-0002-3737-7181	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, R01HL047567, T32HL007706] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47567, P01 HL49953, T32 HL07706] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARBEAU D, 1994, ONCOGENE, V9, P359; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARRIER L, 1992, CIRC RES, V70, P999, DOI 10.1161/01.RES.70.5.999; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CLARK WA, 1981, J BIOL CHEM, V256, P4863; DELEON JR, 1994, P NATL ACAD SCI USA, V91, P519, DOI 10.1073/pnas.91.2.519; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KIM KK, 1994, J BIOL CHEM, V269, P22607; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MARTIN AF, 1977, J BIOL CHEM, V252, P3422; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MYMRYK JS, 1992, BIOCHEM CELL BIOL, V70, P1268, DOI 10.1139/o92-173; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCHETTE EC, 1990, GENE DEV, V4, P151; SANDS AT, 1993, MOL REPROD DEV, V34, P117, DOI 10.1002/mrd.1080340202; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SEN A, 1988, J BIOL CHEM, V263, P19132; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; UENO H, 1988, J CELL BIOL, V107, P1911, DOI 10.1083/jcb.107.5.1911; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	39	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7791	7794		10.1074/jbc.270.14.7791	http://dx.doi.org/10.1074/jbc.270.14.7791			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713869	hybrid			2022-12-25	WOS:A1995QR52600003
J	PANNEERSELVAM, K; REITZ, H; KHAN, SA; BISHAYEE, S				PANNEERSELVAM, K; REITZ, H; KHAN, SA; BISHAYEE, S			A CONFORMATION-SPECIFIC ANTIPEPTIDE ANTIBODY TO THE BETA-TYPE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR ALSO RECOGNIZES THE ACTIVATED EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVATION; PDGF RECEPTORS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; IDENTIFICATION; DIMERIZATION; EXPRESSION; BINDING; DOMAINS; PROTEIN	Earlier we reported the generation of a conformation-specific antibody (Ab P2) to the beta-type platelet-derived growth factor receptor (Bishayee, S., Majumdar, S., Scher, C.D., and Khan, S. (1988) Mol. Cell. Biol. 8, 3696-3702). Ab P2 is directed to a 16-amino acid peptide (Glu-Gly-Tyr-Lys-Lys-Lys-Tyr-Gln-Gln-Val-Asp-Glu-Glu-Phe-Leu-Arg) of the cytoplasmic domain of the receptor, and it recognized the phosphorylated platelet-derived growth factor receptor but not the unphosphorylated receptor. We now report that Ab P2 also interacts with the epidermal growth factor receptor and that the recognition is specific for a conformation induced by phosphorylation of the receptor; however, Ab P2 is not directed to phosphotyrosine. Studies conducted with P2-derived peptides suggest that the conformation-specific antibody is directed to an acidic tripeptide, Asp-Glu-Glu, and this sequence is also present in the cytoplasmic domain of the epidermal growth factor receptor. With respect to the C terminus amino acid or ATP-binding site, Asp-Glu-Glu is located in different regions in these receptors; nevertheless, this tripeptide along with the surrounding amino acids is cryptic in the unphosphorylated receptor, and tyrosine phosphorylation uncovers this site. This suggests that the Asp-Glu-Glu sequence may be important in receptor functions.	CORIELL INST MED RES, CAMDEN, NJ 08103 USA; INFIN BIOTECH RES & RESOURCE, UPLAND, PA 19015 USA	Coriell Institute for Medical Research								BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1986, P NATL ACAD SCI USA, V83, P6756, DOI 10.1073/pnas.83.18.6756; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DAS M, 1977, P NATL ACAD SCI USA, V74, P2790, DOI 10.1073/pnas.74.7.2790; DAS M, 1984, EUR J BIOCHEM, V141, P429, DOI 10.1111/j.1432-1033.1984.tb08209.x; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAJ S, 1992, BIOCHEMISTRY-US, V31, P1774, DOI 10.1021/bi00121a027; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	25	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7975	7979		10.1074/jbc.270.14.7975	http://dx.doi.org/10.1074/jbc.270.14.7975			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713896	hybrid			2022-12-25	WOS:A1995QR52600032
J	BIRKENBIHL, RP; SUBRAMANI, S				BIRKENBIHL, RP; SUBRAMANI, S			THE RAD21 GENE-PRODUCT OF SCHIZOSACCHAROMYCES-POMBE IS A NUCLEAR, CELL-CYCLE-REGULATED PHOSPHOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; FISSION YEAST; DNA-REPAIR; PROTEINS; EXPRESSION; SEQUENCES; THIAMINE; CLEAVAGE; CLONING; MUTANTS	The rad21 gene of Schizosaccharomyces pombe is involved in the repair of double-strand breaks in DNA and is essential for mitotic growth (Birkenbihl, R. P., and Subramani, S. (1992) Nucleic Acids Res. 20, 6605-6611), We show that the Rad21 protein migrates with an aberrantly slow mobility, has a thrombin cleavage site, and is multiply phosphorylated mainly at serine residues. The expression of the rad21 mRNA and the Rad21 protein is cell cycle-regulated, with the peak of mRNA and protein expression occurring near the G(1) to S transition. Following translation of the protein, hypophosphorylated forms of the protein appear. However, the most phosphorylated form of Rad21 appears only later in the cell cycle (in S to G(2)). Analysis of the radiosensitive mutant rad21-45 revealed that the mutant protein is permanently hypophosphorylated. The Rad21 protein is nuclear during the cell cycle. The nuclear localization signal was identified in the C-terminal third of the protein. Upon repression of the Rad21 protein expressed from the repressible nmt1 promoter, the unphosphorylated and hypophosphorylated forms of Rad21 disappeared first. When the concentration of the most highly phosphorylated form of Rad21 sank under a critical level, the cells underwent aberrant mitoses, They exhibited loss of proper nuclear organization and abnormal septation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NIGMS NIH HHS [GM31253] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031253] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BACH ML, 1987, CURR GENET, V121, P527; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGAN IM, 1988, J CELL SCI, V89, P343; HOOD MT, 1990, NUCLEIC ACIDS RES, V18, P688, DOI 10.1093/nar/18.3.688; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN AR, 1991, MUTAT RES, V250, P205, DOI 10.1016/0027-5107(91)90177-P; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; NASIM A, 1975, GENETICS, V79, P573; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Sambrook J, 1989, MOL CLONING LABORATO; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANI S, 1991, MOL MICROBIOL, V5, P2311, DOI 10.1111/j.1365-2958.1991.tb02075.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WENCHING L, 1991, J CELL BIOL, V113, P1	29	86	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7703	7711		10.1074/jbc.270.13.7703	http://dx.doi.org/10.1074/jbc.270.13.7703			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706319	hybrid			2022-12-25	WOS:A1995QQ43100097
J	CARRASCO, D; BRAVO, R				CARRASCO, D; BRAVO, R			TISSUE-SPECIFIC EXPRESSION OF THE FOS-RELATED TRANSCRIPTION FACTOR FRA-2 DURING MOUSE DEVELOPMENT	ONCOGENE			English	Article						FRA-2 EXPRESSION; DEVELOPMENT; JUN AND FOS EXPRESSION	C-JUN; DNA-BINDING; NEGATIVE REGULATOR; GENE-EXPRESSION; CARCINOMA-CELLS; GROWTH-FACTORS; NULL MUTATION; FACTOR AP-1; PROTEINS; COMPLEXES	The fra-2 gene is related to the proto-oncogene c-fos and encodes a member of the AP-1 transcription factor gene family. We have studied the expression of fra-2 during mouse embryonic development and compared it to the pattern of expression of other fos and jun family members. By in situ hybridization and immunohistochemical analysis we have shown fra-2 expression during late organogenesis. fra-2 transcripts are detected in several differentiating epithelia, developing cartilage and central nervous system. The pattern of fra-2 expression is distinct from that observed for other fos related genes, suggesting that fra-2 has a unique role in cellular differentiation during fetal development.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFDERHEIDE E, 1987, J CELL BIOL, V15, P599; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CARRASCO D, 1994, CELL BIOL LABORATORY, P466; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1988, TRENDS GENET, V4, P272; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PARAKKAL PF, 1967, AM J ANAT, V121, P175, DOI 10.1002/aja.1001210202; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1988, NATURE, V334, P532; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SUZUKI T, 1992, NUCLEIC ACIDS RES, V19, P5537; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1069	1079						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700631				2022-12-25	WOS:A1995QN35300006
J	JONES, TL; KARAVANOVA, I; MAENO, M; ONG, RC; KUNG, HF; DAAR, IO				JONES, TL; KARAVANOVA, I; MAENO, M; ONG, RC; KUNG, HF; DAAR, IO			EXPRESSION OF AN AMPHIBIAN HOMOLOG OF THE EPH FAMILY OF RECEPTOR TYROSINE KINASES IS DEVELOPMENTALLY-REGULATED	ONCOGENE			English	Article						EPH; TYROSINE KINASE; XENOPUS LAEVIS	XENOPUS-EMBRYOS; PROTEIN-KINASES; CDNA CLONING; W-LOCUS; GENE; MOUSE; DROSOPHILA; IDENTIFICATION; ENCODES; CHICKEN	In order to study the function of tyrosine kinase receptors during Xenopus development, we have isolated Xek (Xenopus Elk-like kinase), a tyrosine kinase receptor, which shows significant homology to rat Elk and chicken cek5, members of the Eph family. Xek exists as a maternally expressed mRNA which decreases in expression at the mid blastula transition and reappears at late neurulation in Xenopus, Xek mRNA is expressed at higher levels in the anterior and dorsal regions of embryonic stages 16, 24 and 37. In adult Xenopus tissues, Xek appears to be ubiquitously expressed with higher expression observed in brain and ovary, In situ hybridization analysis demonstrates localized mRNA expression in the brain, brachial arches, trigeminal facial ganglion, and the retina of the swimming tadpole stage of development. The similarities in sequence and expression pattern suggest that Xek is an amphibian member of the Eph family and may play a role in the development or function of the central nervous system.	NCI,FREDERICK CANC RES & DEV CTR,LEUKOCYTE BIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Daar, Ira/0000-0003-2657-526X				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BECKMANN M, 1994, ONCOGENE, V9, P3757; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FLETCHER FA, 1994, ONCOGENE, V9, P3241; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GANJU P, 1994, ONCOGENE, V9, P1613; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAMPS MP, 1988, ONCOGENE, V2, P305; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEWTIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP PD, 1967, DAUDIN; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; XU QL, 1994, DEVELOPMENT, V120, P287; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	48	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1111	1117						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700636				2022-12-25	WOS:A1995QN35300011
J	KONDO, M; SUZUKI, H; UEDA, R; OSADA, H; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T				KONDO, M; SUZUKI, H; UEDA, R; OSADA, H; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T			FREQUENT LOSS OF IMPRINTING OF THE H19 GENE IS OFTEN ASSOCIATED WITH ITS OVEREXPRESSION IN HUMAN LUNG CANCERS	ONCOGENE			English	Article						GENOMIC IMPRINTING; H19; IGF2; SNRPN; LUNG CANCER	SPORADIC WILMS-TUMOR; GROWTH FACTOR-II; DNA METHYLATION; EXPRESSION; RELAXATION; H19-GENE; ALLELES; RNA	Accumulating evidence suggests that deregulation of the insulin-like growth factor II (IGF2) and H19 genes at 11p15, due to loss of imprinting (LOI), plays a role in the oncogenesis of Wilms' tumors, We previously reported LOI of IGF2 in carcinomas of the lung, a common cancer of adults, We show here that LOI of H19 is also a frequent event in lung cancer development, and correlated with hypomethylation of the promoter region, Furthermore, the present study also revealed that overexpression of H19 is often associated with LOI of H19 in lung cancers retaining both parental alleles, showing a contrast to LOI in Wilms' tumors, Interestingly, in contrast to frequent LOI of the imprinted genes at 11p15, LOI was not observed for the remaining gene known to be imprinted in man, SNRPN at 15q12.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; 				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; JONES PA, 1986, CANCER RES, V46, P461; KONDO M, 1994, ONCOGENE, V9, P3063; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OWEN RD, 1993, CELL GROWTH DIFFER, V4, P1013; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAL N, 1990, ONCOGENE, V5, P1665; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TYCKO B, 1994, AM J PATHOL, V144, P431; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	32	207	211	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1193	1198						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700644				2022-12-25	WOS:A1995QN35300021
J	LIU, Q; NEUHAUSEN, S; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; GRUIS, NA; EDDINGTON, K; ALLALUNISTURNER, MJ; SKOLNICK, MH; FUJIMURA, FK; KAMB, A				LIU, Q; NEUHAUSEN, S; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; GRUIS, NA; EDDINGTON, K; ALLALUNISTURNER, MJ; SKOLNICK, MH; FUJIMURA, FK; KAMB, A			CDKN2 (MTS1) TUMOR-SUPPRESSOR GENE-MUTATIONS IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article						P16; TUMOR SUPPRESSOR; MELANOMA; LOH; MUTATION	ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYPOSIS-COLI GENE; P53 GENE; HOMOZYGOUS DELETIONS; BLADDER-CANCER; LUNG-CANCER; COLORECTAL CARCINOMAS; INTERFERON GENES; CRITICAL REGION; CHROMOSOME-9	Tumor suppressor gene CDKN2 (also called MTS1, CDK4I and p16(INK4)) is located in 9p21 and deleted homozygously in a high percentage of tumor cell lines. We have examined the sequence of CDKN2 in 154 tumor cell lines that are not homozygously deleted for CDKN2. Overall, 18% (27/154) of the cell lines carried mutations in CDKN2. These mutations were found in cell lines derived from melanoma, bladder, lung and prostate cancers, as well as sarcomas of various origin. The spectrum of the CDKN2 mutations found in melanoma cell lines indicated a major role for ultraviolet light in generating the mutations, suggesting the mutations occurred in vivo. The frequency of loss of heterozygosity in 9p21 in this set of lines is only slightly higher than the background rate of aneuploidy, suggesting that a second 9p21 tumor suppressor gene, if it exists, must lie near CDKN2.	MYRIAD DIAGNOST SERV INC,SALT LAKE CITY,UT 84108; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84132; LEIDEN UNIV,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT DERMATOL,2333 AA LEIDEN,NETHERLANDS; CROSS CANC INST,DEPT RADIAT ONCOL,EDMONTON,AB T6G 1Z2,CANADA	Utah System of Higher Education; University of Utah; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); University of Alberta	LIU, Q (corresponding author), MYRIAD GENET INC,421 WAKARA WAY,SALT LAKE CITY,UT 84108, USA.			Gruis, Nelleke/0000-0002-5210-9150	NCI NIH HHS [CA-48711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODNER SM, 1992, ONCOGENE, V7, P743; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1993, CANCER RES, V53, P4761; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P680; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUIS NA, 1994, IN PRESS J PATHOLOGY; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERLO A, 1994, CANCER RES, V54, P640; MIDDLETON PG, 1991, LEUKEMIA, V5, P680; MORI T, 1994, CANCER RES, V54, P3396; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563	43	132	139	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1061	1067						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700630				2022-12-25	WOS:A1995QN35300005
J	KADEREIT, S; GEWERT, DR; GALABRU, J; HOVANESSIAN, AG; MEURS, EF				KADEREIT, S; GEWERT, DR; GALABRU, J; HOVANESSIAN, AG; MEURS, EF			MOLECULAR-CLONING OF 2 NEW INTERFERON-INDUCED, HIGHLY RELATED NUCLEAR PHOSPHOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; NF-KAPPA-B; PROTEIN-KINASE; MESSENGER-RNA; HUMAN-CELLS; CONSTITUTIVE EXPRESSION; GAMMA-INTERFERON; HUMAN-FIBROBLASTS; BINDING DOMAINS; 2-5A SYNTHETASE	During the molecular cloning of the human dsRNA activated-p68 kinase (PKR), polyclonal antibodies against PKR selected, in addition to cDNAs corresponding to PKR, another cDNA presenting only slight homology with PKR cDNA. This cDNA recognized an mRNA species of 2 kilobases induced by both alpha- and gamma-interferons. Its transcription did not require protein synthesis. On further library screening, it selected two highly related cDNAs, referred to as 75 and 41, displaying perfect homology over 612 base pairs and divergent at both ends. In addition, cDNA 75 presents an insertion of 150 base pairs highly homologous to a region common to both sequences. The 75 and 41 peptidic sequences are very hydrophilic, rich in basic amino acid residues, and contain several potential phosphorylation sites for different serine/threonine kinases. Furthermore, they present two protamine- and histone-like nuclear targeting sequences as well as some homology with helix-loop-helix motifs of some DNA-binding proteins. The 75-encoded product, which resolved as a 52-kDa protein after in vitro expression in rabbit reticulocyte lysates, was found to migrate as a 65-67-kDa protein after in vivo expression in insect cells. In accord with sequence data, this 65-67-kDa protein was found to be phosphorylated in vivo in the insect cells and was recovered from the membrane/nuclear pellet. In contrast, the 41-encoded product (30-kDa protein in reticulocyte lysates) could not be expressed in vivo, as it provoked a rapid and severe shut-off of protein synthesis in insect cells. The function of the 75 and 41 proteins and their relation to PKR remains to be determined. However, the presence of nuclear targeting sequences, phosphorylation sites, and helix-loop-helix motif is consistent with a role of these proteins in the mechanism of transduction of the interferon action.	INST PASTEUR, VIROL & CELLULAR IMMUNOL UNIT, F-75724 PARIS 15, FRANCE; WELLCOME FDN LTD, DEPT CELL BIOL, BECKENHAM BR3 3BS, KENT, ENGLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AMALDI I, 1989, J IMMUNOL, V142, P999; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHEBATH J, 1983, NUCLEIC ACIDS RES, V11, P1213, DOI 10.1093/nar/11.5.1213; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KORANT BD, 1984, J BIOL CHEM, V259, P4835; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MARIE I, 1992, J BIOL CHEM, V267, P9933; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MERLIN G, 1983, P NATL ACAD SCI-BIOL, V80, P4904, DOI 10.1073/pnas.80.16.4904; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBIN BY, 1988, J VIROL, V62, P1875, DOI 10.1128/JVI.62.6.1875-1880.1988; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	59	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24432	24441						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693701				2022-12-25	WOS:A1993MF29400106
J	COOK, SP; BABCOCK, DF				COOK, SP; BABCOCK, DF			ACTIVATION OF CA2+ PERMEABILITY BY CAMP IS COORDINATED THROUGH THE PH(I) INCREASE INDUCED BY SPERACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; EGG PEPTIDE SPERACT; DEPENDENT PROTEIN-KINASE; PLASMA-MEMBRANE; GUANYLATE-CYCLASE; HEMICENTROTUS-PULCHERRIMUS; ADENYLATE-CYCLASE; HUMAN-NEUTROPHILS; ACROSOME REACTION; INTRACELLULAR PH	The egg peptide speract activates sperm K channels by transient stimulation of guanylyl cyclase (see the accompanying paper, Cook, S. P., and Babcock, D. F. (1993) J. Biol. Chem. 268, 22402-22407). Behavioral responses to speract are thought to require the brief elevations of cAMP and cytosolic [Ca2+] (Ca(i)) also evoked by speract through yet unknown mechanisms. Here we present evidence that cAMP mediates activation of a putative, Mn2+-permeable Ca channel that is responsible for increased Ca(i). We find that: 1) prolonged elevation of Ca(i) was produced by treatments previously shown to selectively enhance accumulation of cAMP; 2) elevation of Ca(i) and entry of Mn2+ are prevented by those manipulations of external [Na+] and [K+] previously shown to prevent accumulation of cAMP; 3) the blockade to Ca2+ entry imposed by increased external K+ is bypassed by elevation of cytosolic pH (pH(i)) with NH4Cl; 4) in the absence of speract, NH4Cl allows Mn2+ entry that is enhanced by papaverine, an inhibitor of sperm cAMP phosphodiesterase. These results thus also suggest that elevation of pH(i) is both necessary and sufficient to activate adenylylcyclase. This study provides tentative identification of sperm Ca channels as downstream targets of cAMP action and indicates that pH(i) may determine whether cGMP- or cAMP-mediated second messenger pathways predominate in speract signal transduction.	UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Babcock, Donner/0000-0002-4461-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABCOCK DF, 1992, P NATL ACAD SCI USA, V89, P6001, DOI 10.1073/pnas.89.13.6001; BENTLEY JK, 1986, BIOL REPROD, V35, P1249, DOI 10.1095/biolreprod35.5.1249; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; BOOKBINDER LH, 1990, J CELL BIOL, V111, P1859, DOI 10.1083/jcb.111.5.1859; BOOKBINDER LH, 1991, MOL REPROD DEV, V28, P150, DOI 10.1002/mrd.1080280208; BRACHO GE, 1992, J CELL BIOL, V119, pA170; CARLYLE WC, 1991, THESIS U MINNESOTA; CLAPPER DL, 1985, J CELL BIOL, V100, P1817, DOI 10.1083/jcb.100.6.1817; COOK SP, 1993, J BIOL CHEM, V268; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DANGOTT LJ, 1984, J BIOL CHEM, V259, P3712; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GARBERS DL, 1982, J BIOL CHEM, V257, P2734; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; GARCIASOTO J, 1985, FEBS LETT, V190, P33, DOI 10.1016/0014-5793(85)80421-X; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P2235; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P163; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P151; KACZOROWSKI GJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P287, DOI 10.1016/0304-4157(89)90022-1; LEE HC, 1986, J BIOL CHEM, V261, P6026; LEE MYW, 1976, BIOCHIM BIOPHYS ACTA, V429, P123, DOI 10.1016/0005-2744(76)90035-8; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIEVANO A, 1990, J GEN PHYSIOL, V95, P273, DOI 10.1085/jgp.95.2.273; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MILLER RL, 1982, AM ZOOL, V22, P827; MINTA A, 1989, J BIOL CHEM, V264, P19449; NEGULESCU PA, 1990, CELL REGUL, V1, P259, DOI 10.1091/mbc.1.3.259; POTTER LR, 1992, J BIOL CHEM, V267, P14531; SCHACKMANN RW, 1986, J BIOL CHEM, V261, P8719; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SHIMOMURA H, 1986, J BIOL CHEM, V261, P5778; SIMCHOWITZ L, 1990, J BIOL CHEM, V265, P13449; SUZUKI N, 1992, COMP BIOCHEM PHYS B, V102, P679, DOI 10.1016/0305-0491(92)90064-X; SUZUKI N, 1981, BIOCHEM BIOPH RES CO, V99, P1238, DOI 10.1016/0006-291X(81)90752-X; SUZUKI N, 1984, J BIOL CHEM, V259, P4874; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TOOWICHARANONT P, 1988, J BIOL CHEM, V263, P6877; WARD GE, 1985, J CELL BIOL, V101, P2324, DOI 10.1083/jcb.101.6.2324; WELLS JN, 1976, BIOL REPROD, V15, P46, DOI 10.1095/biolreprod15.1.46; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YOSHINO K, 1992, EUR J BIOCHEM, V206, P887, DOI 10.1111/j.1432-1033.1992.tb16997.x; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	47	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22408	22413						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693668				2022-12-25	WOS:A1993MD34800036
J	MCGUIRE, TF; COREY, SJ; SEBTI, SM				MCGUIRE, TF; COREY, SJ; SEBTI, SM			LOVASTATIN INHIBITS PLATELET-DERIVED GROWTH-FACTOR (PDGF) STIMULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY AS WELL AS ASSOCIATION OF P85 SUBUNIT TO TYROSINE-PHOSPHORYLATED PDGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPETITIVE INHIBITOR; SIGNAL TRANSDUCTION; BETA-RECEPTOR; BOVINE BRAIN; RAT-LIVER; KINASE; CELLS; CHOLESTEROL; BINDING; POLYPHOSPHOINOSITIDES	Lovastatin inhibits mitogenesis in cultured cells and growth of tumors in vivo by unknown mechanism(s). Phosphatidylinositol 3-kinase (PI-3-kinase) is a putative second messenger-generating enzyme whose physical association with the platelet-derived growth factor receptor (PDGFR) has been demonstrated to be required for the mitogenic activity of PDGF in cultured fibroblasts. Here we examine the effect of lovastatin on PDGF- and insulin-stimulated PI-3-kinase activity. In quiescent NIH-3T3 cells, PDGF (25 ng/ml) and insulin (200 nM) stimulate PI-3-kinase activity 10- and 6-fold, respectively. However, overnight pretreatment of cells with 10 muM lovastatin inhibits this stimulation of PI-3-kinase activity by PDGF and insulin. Immunoprecipitation of the PI-3-kinase p85 subunit demonstrates a PDGF-dependent association of PI-3-kinase with the tyrosine-autophosphorylated PDGFR. However, upon exposure of cells to 10 muM lovastatin for 40 h, the level of autophosphorylated PDGFR associating with PI-3-kinase after PDGF stimulation decreases significantly (75% reduction). No change in the expression of the PI-3-kinase p85 subunit was observed after treatment of cells with lovastatin. These results demonstrate that lovastatin disrupts a major growth factor signaling pathway and that inhibition of PDGF-induced association of PI-3-kinase with PDGFR and subsequent inhibition of PI-3-kinase activity is one potential mechanism by which lovastatin inhibits cell growth.	UNIV PITTSBURGH,SCH MED,DEPT OBSTET & GYNECOL,PITTSBURGH,PA 15261; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAIRBANKS KP, 1984, J BIOL CHEM, V259, P1546; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HELDIN CH, 1990, J CELL SCI, V96, P193; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, pI121; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMIJAN DA, 1989, P NATL ACAD SCI USA, V86, P8232; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; Rodwell V W, 1976, Adv Lipid Res, V14, P1; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUSA M, 1992, J BIOL CHEM, V267, P22951; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	27	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22227	22230						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693661				2022-12-25	WOS:A1993MD34800004
J	CONRAD, KP; VILL, M; MCGUIRE, PG; DAIL, WG; DAVIS, AK				CONRAD, KP; VILL, M; MCGUIRE, PG; DAIL, WG; DAVIS, AK			EXPRESSION OF NITRIC-OXIDE SYNTHASE BY SYNCYTIOTROPHOBLAST IN HUMAN PLACENTAL VILLI	FASEB JOURNAL			English	Article						NADPH DIAPHORASE; IN-SITU HYBRIDIZATION; MICHAELIS-MENTEN KINETICS; PLACENTAL CIRCULATION	URINARY-EXCRETION; ENDOTHELIUM; CALMODULIN; ADHESION; PREGNANCY; INVITRO; CELLS; CGMP	The endogenous biosynthesis of nitric oxide (NO) is increased during gestation. To begin our investigation of a possible tissue source (or sources), we examined the placenta. We postulated that analogous to the endothelium of blood vessels, the syncytiotrophoblast (STr) cell layer that lines the intervillous blood space of the human placenta would express NO synthase. Our results show that human placental villi express a calcium- and calmodulin-sensitive form of NO synthase, located mainly in the microsomal cell fraction. By in situ hybridization using a riboprobe generated from human endothelial NO synthase cDNA, we observe NO synthase mRNA expression in STr. The STr also shows NADPH-diaphorase staining, indicating the presence of NO synthase, and most likely other flavin-containing enzymes involved in sex steroid metabolism. NO synthase activity was also detected in the villi of a complete mole placenta (which lacks fetal vessels), further supporting a trophoblastic origin. Our findings suggest a previously unrecognized role for STr-derived NO in placental function.	UNIV NEW MEXICO, SCH MED, DEPT OBSTET & GYNECOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, DEPT ANAT, ALBUQUERQUE, NM 87131 USA	University of New Mexico; University of New Mexico	CONRAD, KP (corresponding author), UNIV NEW MEXICO, SCH MED, DEPT PHYSIOL, 915 STANFORD NE, ALBUQUERQUE, NM 87131 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046865] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46865] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; Benirschke K, 1990, PATHOLOGY HUMAN PLAC; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1987, N-S ARCH PHARMACOL, V336, P566; Casey ML, 1992, WILLIAMS TXB ENDOCRI, P977; CONRAD KP, 1989, AM J PHYSIOL, V257, pR847, DOI 10.1152/ajpregu.1989.257.4.R847; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; HOWARD RB, 1987, MED HYPOTHESES, V23, P51, DOI 10.1016/0306-9877(87)90180-0; KIM N, 1993, J CLIN INVEST, V91, P437, DOI 10.1172/JCI116220; KOPP L, 1977, J CLIN ENDOCR METAB, V44, P590, DOI 10.1210/jcem-44-3-590; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MYATT L, 1992, AM J OBSTET GYNECOL, V166, P224, DOI 10.1016/0002-9378(92)91863-6; MYATT L, 1992, PORTL PR P, V1, P347; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; Reid E, 1974, Methods Enzymol, V31, P713; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169	24	144	147	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1269	1276		10.1096/fasebj.7.13.7691671	http://dx.doi.org/10.1096/fasebj.7.13.7691671			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	7691671				2022-12-25	WOS:A1993MB37600011
J	RICH, DP; BERGER, HA; CHENG, SH; TRAVIS, SM; SAXENA, M; SMITH, AE; WELSH, MJ				RICH, DP; BERGER, HA; CHENG, SH; TRAVIS, SM; SAXENA, M; SMITH, AE; WELSH, MJ			REGULATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CHANNEL BY NEGATIVE CHARGE IN THE R-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; K+ CHANNELS; PHOSPHORYLATION; INACTIVATION; EXPRESSION; EFFICIENT; CELLS; GENE; IDENTIFICATION; MUTAGENESIS	Phosphorylation by cAMP-dependent protein kinase (PKA) regulates the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. We previously showed that in vivo PKA phosphorylated 4 serines (Ser-660, Ser-737, Ser-795, and Ser-813) within the R domain. Here we show that a mutant CFTR lacking all 4 serines can still be phosphorylated by PKA to yield an activated Cl- channel, but channel open-state probability was substantially reduced. We also observed phosphorylation and Cl- channel activity in another mutant lacking all 8 consensus PKA serines in the R domain. We were unable to identify the residual phosphorylation sites by tryptic phosphopeptide mapping. These data suggest two possible interpretations: (a) additional, as yet unidentified, phosphorylation sites within CFTR may also open the channel, or (b) the 4 serines, previously identified as in vivo PKA phosphorylation sites, are the primary regulatory sites within CFTR, but in their absence, other sites can be phosphorylated to open the channel. The additional sites are likely located within the R domain: CFTRDELTAR-S660A, which lacks much of the R domain (residues 708-835) and replaces Ser-660 with an alanine, was no longer regulated by PKA. Substitution of aspartate for consensus PKA phosphorylation sites in the R domain mimicked the effect of phosphorylation. Mutants containing six or more serine-to-aspartate substitutions generated Cl- channels that opened without PKA phosphorylation. These results suggest that the R domain keeps the channel closed and that phosphorylation of the R domain or insertion of the negatively charged aspartate opens the channel, perhaps by electrostatic interactions.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	University of Iowa; Sanofi-Aventis; Genzyme Corporation	RICH, DP (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Berger, Herbert/0000-0003-4383-2643	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHENG SH, 1988, MOL CELL BIOL, V6, P1562; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FONG YL, 1989, J BIOL CHEM, V264, P16759; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURRELL-LAGNADO R D, 1992, Biophysical Journal, V61, pA290; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIODAN JR, 1993, ANNU REV PHYSIOL, V55, P609; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WANG YH, 1992, J BIOL CHEM, V267, P16759; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	45	134	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20259	20267						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690753				2022-12-25	WOS:A1993LY01900053
J	WANG, H; LAMBOWITZ, AM				WANG, H; LAMBOWITZ, AM			REVERSE TRANSCRIPTION OF THE MAURICEVILLE PLASMID OF NEUROSPORA - LACK OF RIBONUCLEASE-H ACTIVITY ASSOCIATED WITH THE REVERSE-TRANSCRIPTASE AND POSSIBLE USE OF MITOCHONDRIAL RIBONUCLEASE-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA LINKED MSDNA; MYXOCOCCUS-XANTHUS; CRYSTAL-STRUCTURE; DNA-SYNTHESIS; VIRUS; INTRONS; EVOLUTION; SEQUENCE; CRASSA; IDENTIFICATION	The Mauriceville mitochondrial plasmid of Neurospora encodes a reverse transcriptase that synthesizes a full-length cDNA copy of the major plasmid transcript beginning directly opposite the 3' end of the template RNA (Kuiper, M. T. R., and Lambowitz, A. M. (1988) Cell 55, 693-704). Here, we show that the Mauriceville plasmid reverse transcriptase has no detectable RNase H activity and that cDNAs synthesized either by the column-purified reverse transcriptase or by the endogenous reverse transcriptase in purified ribonucleoprotein particles remain in a full-length duplex with the template RNA. The column-purified Mauriceville plasmid reverse transcriptase initiates cDNA synthesis by using short DNA primers, which remain attached to the 5' end of the (-) strand DNA (Wang, H., Kennell, J. C., Kuiper, M. T. R., Sabourin, J. R., Saldanha, R., and Lambowitz, A. M. (1992) Mol. Cell. Biol. 12, 5131-5144). We rind that these primer DNAs can be precisely removed by S1 nuclease digestion of the initial cDNA.RNA duplex, suggesting a mechanism whereby this structure may contribute to primer removal in vivo. Finally, we show that Neurospora mitochondria contain an endogenous RNase H activity, which is present in mitochondrial ribonucleoprotein particle preparations prior to their purification. This mitochondrial RNase H can degrade the endogenous plasmid transcript in ribonucleoprotein particles in vitro and could play a similar role in vivo. The finding that the Mauriceville plasmid reverse transcriptase, which is believed to be a primitive enzyme, has no detectable RNase H activity is consistent with the hypothesis that retroviral reverse transcriptases acquired their RNase H domains from a gene encoding a cellular RNase H.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1988, J MOL BIOL, V204, P1, DOI 10.1016/0022-2836(88)90594-3; AKINS RA, 1989, MOL CELL BIOL, V9, P678, DOI 10.1128/MCB.9.2.678; COLLINS RA, 1981, CELL, V24, P443, DOI 10.1016/0092-8674(81)90335-4; CROUCH R J, 1990, New Biologist, V2, P771; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GILBOA E, 1979, CELL, V16, P863, DOI 10.1016/0092-8674(79)90101-6; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; KUIPER MTR, 1990, J BIOL CHEM, V265, P6936; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NARGANG FE, 1986, MOL BIOL EVOL, V3, P19; NARGANG FE, 1984, CELL, V38, P441, DOI 10.1016/0092-8674(84)90499-9; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; STARNES MC, 1989, J BIOL CHEM, V264, P7073; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	43	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18951	18959						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689563				2022-12-25	WOS:A1993LV65900086
J	TRAVIS, SM; CARSON, MR; RIES, DR; WELSH, MJ				TRAVIS, SM; CARSON, MR; RIES, DR; WELSH, MJ			INTERACTION OF NUCLEOTIDES WITH MEMBRANE-ASSOCIATED CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CFTR CHLORIDE CHANNEL; SYNTHETIC PEPTIDE; BINDING-SITES; TRANSPORT; CELLS; GENE; ATP; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION	Cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that is regulated by cytosolic nucleotides and by cAMP-dependent phosphorylation. In excised membrane patches, CFTR Cl- channel activity requires hydrolyzable nucleotides and Mg2+, and is inhibited by ADP. We examined the interactions between CFTR and nucleotides using 8-azidoadenosine 5'-triphosphate (8-N3ATP), a photoactivatable ATP analog. Because CFTR functions as a membrane ion channel, we studied CFTR in membranes of Sf9 insect cells. We found that [alpha-P-32]8-N3ATP specifically photolabeled CFTR, with half-maximal labeling at 10 muM 8-N3ATP in the presence of Mg2+ and 100 muM in the absence of Mg2+. The 8-N3ATP also substituted for ATP in activating CFTR Cl- channels, indicating that it interacts with the active site(s). Both ATP and GTP prevented photolabeling with half-maximal inhibition at 1 mM. ADP and adenyl-5'-yl imidodiphosphate (AMP-PNP) prevented photolabeling but at much higher concentrations, whereas AMP did not inhibit photolabeling at concentrations of up to 100 mM. Phosphorylation of CFTR was not a prerequisite for nucleotide binding. These results demonstrate that CFTR interacts directly with nucleotides at concentrations that regulate CFTR Cl- channel activity.	UNIV IOWA, COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED, 500 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660	25	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15336	15339						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687995				2022-12-25	WOS:A1993LN30500004
J	OBLATTMONTAL, M; BUHLER, LK; IWAMOTO, T; TOMICH, JM; MONTAL, M				OBLATTMONTAL, M; BUHLER, LK; IWAMOTO, T; TOMICH, JM; MONTAL, M			SYNTHETIC PEPTIDES AND 4-HELIX BUNDLE PROTEINS AS MODEL SYSTEMS FOR THE PORE-FORMING STRUCTURE OF CHANNEL PROTEINS .1. TRANSMEMBRANE SEGMENT M2 OF THE NICOTINIC CHOLINERGIC RECEPTOR-CHANNEL IS A KEY PORE-LINING STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; TORPEDO-CALIFORNICA; XENOPUS OOCYTES; IONIC CHANNELS; AMINO-ACIDS; PERMEABILITY; SUBUNITS; BILAYERS; CATIONS; HELICES	Monomeric peptides and four-helix bundle proteins with amino acid sequences of the predicted transmembrane segment M2 of nicotinic acetylcholine receptors (AChR) were designed, synthesized, and used as probes to elucidate the pore-forming structure of the authentic AChR channel. Peptides M2delta and M2alpha4 with sequences of M2 from muscle-like Torpedo californica AChR delta subunit and from rat neuronal AChR alpha4 subunit form cation-selective channels in lipid bilayers with predominant single-channel conductances in 0.5 M KCl of 20 pS and 27 pS, respectively. Corresponding analogs with presumed pore-lining residues serine 8 or phenylalanine 16 specifically substituted by alanine retain the ability to self-assemble into conductive oligomers and form channels with primary conductances of 16 pS and 22 pS for M2delta analogs and of 14 pS and 26 pS for M2alpha4 analogs. In contrast, peptides with randomized sequences and the same amino acid composition as M2delta do not form channels. Four-helix bundle proteins T4M2delta and T4M2alpha4 exhibit conductances in 0.5 M KCl of 20 pS and 26 pS. Analogs of T4M2delta with selective replacement of serine 8 for alanine exhibit lower conductances, whereas substitution of phenylalanine 16 for alanine increases the single-channel conductance. T4M2delta channels are blocked by open channel blockers such as the quaternary derivative of lidocaine QX-222 and by chlorpromazine. Channel open probability is reduced, and open time is abbreviated. Conduction properties of T4M2delta and analogs are in accord with several properties of authentic AChRs. These comprehensive studies provide insights into the components of the pore-forming structure of nicotinic AChRs.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, CHILDRENS HOSP, LOS ANGELES, CA 90027 USA	University of California System; University of California San Diego; University of Southern California; University of Southern California; Children's Hospital Los Angeles; University of Southern California				TOMICH, JOHN/0000-0001-7848-8307	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042340, R29GM043617, R01GM043617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43617, GM-42340] Funding Source: Medline; NIMH NIH HHS [MH-44638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BECHINGER B, 1991, Journal of Biomolecular NMR, V1, P167, DOI 10.1007/BF01877228; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; EISENMAN G, 1990, PROG CELL R, V1, P195; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GROVE A, 1992, METHOD ENZYMOL, V207, P510; GROVE A, 1991, SER SYMP AD, V4, P89; GROVE A, 1991, P NATL ACAD SCI USA, V88, P6418, DOI 10.1073/pnas.88.15.6418; Hille B., 1992, IONIC CHANNELS EXCIT; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KARLIN A, 1991, HARVEY LECT, V85, P71; LABARCA P, 1984, J NEUROSCI, V4, P502; LABARCA P, 1984, J GEN PHYSIOL, V83, P473, DOI 10.1085/jgp.83.4.473; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MERRIFIELD RB, 1965, SCIENCE, V150, P178, DOI 10.1126/science.150.3693.178; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; MONTAL M, 1986, ION CHANNEL RECONSTI, P157; NUMA S, 1989, HARVEY LECT, V83, P121; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OIKI S, 1990, PROTEINS, V8, P226, DOI 10.1002/prot.340080305; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; REDDY GL, 1993, J BIOL CHEM, V268, P14608; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SAKMANN B, 1985, NATURE, V318, P538, DOI 10.1038/318538a0; STRICHARTZ GR, 1987, HDB EXPT PHARM, V81, P1; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; [No title captured]	41	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14601	14607						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686900				2022-12-25	WOS:A1993LL75900014
J	NASKI, MC; LAWRENCE, DA; MOSHER, DF; PODOR, TJ; GINSBURG, D				NASKI, MC; LAWRENCE, DA; MOSHER, DF; PODOR, TJ; GINSBURG, D			KINETICS OF INACTIVATION OF ALPHA-THROMBIN BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 - COMPARISON OF THE EFFECTS OF NATIVE AND UREA-TREATED FORMS OF VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; ANTITHROMBIN-III; S-PROTEIN; TRANSIENT KINETICS; ENDOTHELIAL-CELLS; BINDING-PROTEIN; HUMAN-PLASMA; HEPARIN; PURIFICATION; PAI-1	Kinetic studies are presented which show that native human vitronectin, but not urea-treated vitronectin, accelerates the inactivation of human alpha-thrombin by human plasminogen activator inhibitor-1 (PAI-1). We demonstrate that although urea-treated vitronectin binds PAI-1 with an affinity greater than that of native vitronectin, it does not accelerate the rate of inactivation of alpha-thrombin by PAI-1. We present evidence to suggest that the inability of urea-treated vitronectin to accelerate the reaction between alpha-thrombin and PAI-1 results at least in part from the inability of urea-treated vitronectin to bind to alpha-thrombin. The accelerated reaction between PAI-1 and alpha-thrombin can be accounted for by the formation of a tight complex between native vitronectin and PAI-1 that reacts in a saturable manner (K(d) = 75 nM) with alpha-thrombin. The second-order rate constant (k(I)/K(d)) for the reaction of the native vitronectin-PAI-1 complex with alpha-thrombin (1.64 x 10(5) M--1 s-1) is 270-fold greater than the second-order rate constant for the reaction in the absence of vitronectin (610 M-1 s-1). The increase in the second-order rate constant is largely due to an increase in the affinity of alpha-thrombin for the native vitronectin-PAI-1 complex, as reflected by a greater than 25-fold reduction in the dissociation constant (K(d)) observed for the vitronectin-PAI-1 complex relative to that of uncomplexed PAI-1.	HOWARD HUGHES MED INST,4520 MSRB I,1150 W MED CTR DR,ANN ARBOR,MI 48109; MCMASTER UNIV,HAMILTON CIV HOSP,RES CTR,DEPT PATHOL,HAMILTON L8S 4L8,ONTARIO,CANADA; UNIV MICHIGAN,SCH MED,DEPT MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	Howard Hughes Medical Institute; McMaster University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029586, R01HL039137] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-PO1-HL29586, 1-RO1-HL39137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EDELBERG JM, 1991, J BIOL CHEM, V266, P7488; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GREENGARD JS, 1991, THROMB HAEMOSTASIS, V65, P1277; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KEIJER J, 1991, BLOOD, V78, P1254; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LEWIS SD, 1984, THROMB RES, V35, P111, DOI 10.1016/0049-3848(84)90206-8; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NASKI MC, 1990, J BIOL CHEM, V265, P1401; NASKI MC, 1992, J BIOL CHEM, V265, P1344; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1982, J BIOL CHEM, V257, P1491; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PODOR TJ, 1992, ANN NY ACAD SCI, V667, P46, DOI 10.1111/j.1749-6632.1992.tb51595.x; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SPRENGERS ED, 1987, BLOOD, V69, P381; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WUN TC, 1989, J BIOL CHEM, V264, P7862; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHOU JM, 1989, BIOCHEMISTRY-US, V28, P1070, DOI 10.1021/bi00429a022	41	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12367	12372						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685341				2022-12-25	WOS:A1993LG65800025
J	BEDOWS, E; HUTH, JR; SUGANUMA, N; BARTELS, CF; BOIME, I; RUDDON, RW				BEDOWS, E; HUTH, JR; SUGANUMA, N; BARTELS, CF; BOIME, I; RUDDON, RW			DISULFIDE BOND MUTATIONS AFFECT THE FOLDING OF THE HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; FORM; SALT; DNA	Previous kinetic studies have characterized the intracellular folding pathway of the human chorionic gonadotropin (hCG)-beta subunit in which each of the folding intermediates can be biochemically identified based on the formation of disulfide (S-S) bonds: pbeta1-early --> pbeta1-late --> pbeta2-free --> pbeta2-combined --> native hCG-alphabeta. Based on these data, we postulated that hCG-beta folding coincides with the formation of specific S-S bonds. We have now tested this hypothesis employing Chinese hamster ovary cells transfected with mutated hCG-beta genes in which the Cys residues required for the formation of the final four (of six total) S-S bonds were replaced by Ala. When the Cys residues required for the third hCG-beta S-S linkage to form (bond 9-90) were substituted, folding did not proceed beyond the earliest detectable folding intermediate (pbeta1-early). In the absence of the subsequently formed S-S bond (bond 23-72), pbeta1-early was converted into a second folding intermediate (pbeta1-late), but conversion to the next intermediate (pbeta2-free) was inhibited. When either of the final two S-S bonds (the carboxyl-terminal 93-100 or 26-110 bonds) were removed, conversion of pbeta1-late to pbeta2-free was detected, but conversion of pbeta2-free to the last folding intermediate (pbeta2-combined) was not observed. These data support the hypothesis that individual S-S bonds are involved in discrete steps in the hCG-beta folding pathway.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan; Washington University (WUSTL); Washington University (WUSTL); University of Nebraska System; University of Nebraska Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [F05TW004124] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; FIC NIH HHS [1F05TW04124] Funding Source: Medline; NCI NIH HHS [CA32949] Funding Source: Medline; NICHD NIH HHS [HD23398] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BREMS DN, 1989, PROTEINS, V5, P93, DOI 10.1002/prot.340050110; CHEN F, 1991, J BIOL CHEM, V266, P6904; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; MCGUIRE MC, 1989, P NATL ACAD SCI USA, V86, P953, DOI 10.1073/pnas.86.3.953; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TANIYAMA Y, 1992, J BIOL CHEM, V267, P4619; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	26	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11655	11662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685018				2022-12-25	WOS:A1993LF28400032
J	WOLFF, DJ; DATTO, GA; SAMATOVICZ, RA				WOLFF, DJ; DATTO, GA; SAMATOVICZ, RA			THE DUAL-MODE OF INHIBITION OF CALMODULIN-DEPENDENT NITRIC-OXIDE SYNTHASE BY ANTIFUNGAL IMIDAZOLE AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; BOVINE BRAIN; BINDING; KETOCONAZOLE; REDUCTASE; SEQUENCE; AGONIST; PROTEIN; DOMAINS	The antifungal imidazoles miconazole, ketoconazole, and clotrimazole inhibit citrulline formation by nitric-oxide synthase. These agents both increase the concentration of calmodulin required to activate the enzyme half-maximally and reduce the maximal velocity of citrulline formation. This inhibition was not reversed by increased concentrations of either the arginine substrate or (6R)-5,6,7,8-tetrahydro-L-biopterin. Miconazole, ketoconazole, and clotrimazole also inhibited the cytochrome-c reductase activity of nitric-oxide synthase competitively versus calmodulin concentration, with apparent K(i) (IC50) values of 8, 20, and 0.8 muM, respectively. Miconazole, ketoconazole, and clotrimazole inhibited the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase competitively versus calmodulin concentration, with apparent K(i) values of 6, 18, and 25 muM, respectively. These observations are consistent with the proposal that the antifungal imidazoles inhibit citrulline formation by interaction with the nitric-oxide synthase at two sites. Interaction at site 1 reduces the responsiveness of the enzyme to activation by calmodulin, whereas interaction at site 2 (involving putative binding of the imidazole to the heme iron) reduces the maximal velocity of citrulline formation. The interactions of calmodulin antagonists at site 1 occur at substantially lower concentrations of drug than those at site 2 and are the principal determinant of enzyme inhibition.			WOLFF, DJ (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011252] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11252] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; AMBRE JJ, 1991, AM MED ASS DRUG EVAL, P1479; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P1; Beavo J A, 1974, Methods Enzymol, V38, P299; BENSON JM, 1988, CLIN PHARMACY, V7, P424; BODEY GP, 1988, MED CLIN N AM, V72, P637, DOI 10.1016/S0025-7125(16)30763-5; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROOKER G, 1968, BIOCHEMISTRY-US, V7, P4177, DOI 10.1021/bi00852a006; BROSTROM CO, 1974, ARCH BIOCHEM BIOPHYS, V165, P715, DOI 10.1016/0003-9861(74)90300-2; BROWN MW, 1985, CLIN PHARMACOL THER, V37, P290, DOI 10.1038/clpt.1985.42; DAMANHOURI Z, 1988, J ANTIMICROB CHEMOTH, V21, P187, DOI 10.1093/jac/21.2.187; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; HUANG YC, 1986, ANTIMICROB AGENTS CH, V30, P206, DOI 10.1128/AAC.30.2.206; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MASON JI, 1985, BIOCHEM PHARMACOL, V34, P1087, DOI 10.1016/0006-2952(85)90613-6; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NEWTON DL, 1984, FEBS LETT, V165, P269, DOI 10.1016/0014-5793(84)80183-0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OSHIRO Y, 1970, ARCH BIOCHEM BIOPHYS, V138, P392, DOI 10.1016/0003-9861(70)90361-9; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; ROLAN PE, 1983, BRIT MED J, V287, P1760, DOI 10.1136/bmj.287.6407.1760; Segel I.H., 1975, ENZYME KINETICS; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; VANDENBOSSCHE H, 1978, CHEM-BIOL INTERACT, V21, P59, DOI 10.1016/0009-2797(78)90068-6; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WOLFF DJ, 1981, J BIOL CHEM, V256, P1846; WOLFF DJ, 1985, J BIOL CHEM, V260, P4195; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	35	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9430	9436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683652				2022-12-25	WOS:A1993LA68900045
J	ALTHAUS, IW; CHOU, JJ; GONZALES, AJ; DEIBEL, MR; CHOU, KC; KEZDY, FJ; ROMERO, DL; ARISTOFF, PA; TARPLEY, WG; REUSSER, F				ALTHAUS, IW; CHOU, JJ; GONZALES, AJ; DEIBEL, MR; CHOU, KC; KEZDY, FJ; ROMERO, DL; ARISTOFF, PA; TARPLEY, WG; REUSSER, F			STEADY-STATE KINETIC-STUDIES WITH THE NONNUCLEOSIDE HIV-1 REVERSE-TRANSCRIPTASE INHIBITOR U-87201E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SULFATED POLYSACCHARIDES; SELECTIVE-INHIBITION; PENTOSAN POLYSULFATE; ANTIVIRAL ACTIVITY; ENZYME-KINETICS; RNASE-H; TYPE-1; DERIVATIVES; POTENT	The multifunctional HIV-1 RT (human immunodeficiency virus type 1-reverse transcriptase) enzyme possesses three main functions including the RNA- and DNA-directed DNA polymerases and the RNase H. The bisheteroarylpiperazine U-87201E inhibits the two polymerase functions but not the RNase H. Enzymatic kinetic studies of the HIV-1 RT-cataLyzed RNA- and DNA-directed DNA polymerase activities were carried out in order to determine if the inhibitor interferes with either the template:primer or the deoxyribonucleotide triphosphate (dNTP)-binding sites of the enzyme. The data were analyzed using steady-state kinetics, considering that the polymerase reaction is ordered in that the template:primer is added first, followed by the dNTP and that the enzyme funCtions processively. The data were consistent with the model. The steady-state rate constants for the forward and backward reactions were of similar magnitude for both the RNA- and DNA-catalyzed DNA polymerases and suggest that both functions share the same substrate-binding sites. The dissociation constants for the enzyme-inhibitor and enzyme-substrate-inhibitor compleXes were somewhat higher for the DNA-directed DNA polymerase function as compared to the RNA directed one. This indicates that U-87201E is a more potent inhibitor for the RNA-directed DNA polymerase than the DNA-directed DNA polymerase. The pattern of inhibition exerted by U-87201E was noncompetitive with respect to both the nucleic acid and nucleotide-binding sites of the RT enzyme for both the RNA- and DNA-directed DNA polymerases. Hence, U-87201E inhibits these functions by interacting with a Site distinct from the template: primer and dNTP-binding sites. HIV-2 RT was insensitive to U-87201E, demonstrating the unique sensitivity of HIV-1 RT to this inhibitor.	UPJOHN CO,KALAMAZOO,MI 49001; UNIV MICHIGAN,DEPT PHYS,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan			Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Chou, Kuo-Chen/A-8340-2009	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; 				ALTHAUS IW, 1992, EXPERIENTIA, V48, P1127, DOI 10.1007/BF01948005; ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679; BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BUSSO M, 1988, AIDS RES HUM RETROV, V4, P449, DOI 10.1089/aid.1988.4.449; CHA S, 1968, J BIOL CHEM, V243, P820; CHATTOPADHYAY D, 1992, PROTEIN EXPRES PURIF, V3, P151, DOI 10.1016/S1046-5928(05)80032-4; CHOU KC, 1976, SCI SINICA, V19, P505; CHOU KC, 1989, J BIOL CHEM, V264, P12074; CHOU KC, 1990, BIOPHYS CHEM, V35, P1, DOI 10.1016/0301-4622(90)80056-D; CHOU KC, 1982, J AM CHEM SOC, V104, P1409, DOI 10.1021/ja00369a043; Coffin JM, 1990, VIROLOGY, V2, P1437; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; GERARD M, 1990, ANTIVIRAL THERAPY HU, P176; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HUBER HE, 1989, J BIOL CHEM, V264, P4669; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SOSA MAG, 1991, BIOCHEM BIOPH RES CO, V174, P489, DOI 10.1016/0006-291X(91)91443-G; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	34	174	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6119	6124						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681060				2022-12-25	WOS:A1993KT36800010
J	RON, D; REICH, R; CHEDID, M; LENGEL, C; COHEN, OE; CHAN, AML; NEUFELD, G; MIKI, T; TRONICK, SR				RON, D; REICH, R; CHEDID, M; LENGEL, C; COHEN, OE; CHAN, AML; NEUFELD, G; MIKI, T; TRONICK, SR			FIBROBLAST GROWTH-FACTOR RECEPTOR-4 IS A HIGH-AFFINITY RECEPTOR FOR BOTH ACIDIC AND BASIC FIBROBLAST GROWTH-FACTOR BUT NOT FOR KERATINOCYTE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC AMPLIFICATION; MESSENGER-RNA; CELL-GROWTH; DNA; IDENTIFICATION; TRANSFORMATION; FAMILY; EXPRESSION; INDUCTION; MEMBER	A cDNA predicted to encode a transmembrane tyrosine kinase receptor with sequence features characteristic of known fibroblast growth factor (FGF) receptors was isolated from an expression library constructed from the human mammary epithelial cell line B5/589. This cDNA, designated cl44, encodes a product of 803 amino acid residues and was readily distinguishable from known FGF receptors. During the course of our studies, Partanen et al. (Partanen, J., Makela, T. P., Eerola, E., Korhonen, J., Hirvonen, H., Claesson, W. L., and Alitalo, K. (1991) EMBO J. 10, 1347-1354) isolated a new FGF receptor, designated FGFR4, from the human leukemia cell line, K562. Its amino acid sequence is identical to that of cl44 with the exception of 1 residue. The 5'-untranslated sequences of the two cDNAs diverged far upstream of the initiation codon. A myoblast line, L6E9, which lacks FGF receptors, was utilized to express high levels of FGFR4. We found, in contrast to Partenen et al., who reported only binding of acidic FGF, that FGFR4 bound both acidic and basic FGF with dissociation constants of 10-15 and 120 pM, respectively. No detectable binding of keratinocyte growth factor was observed. In studies aimed to determine whether FGF receptors contribute to the development of human tumors, we screened RNAs prepared from cell lines derived from a variety of solid tumors. High levels of the cl44 transcript were detected in 8 of 14 and 6 of 9 human mammary and kidney carcinomas, respectively, but only infrequently in other types of tumors. In contrast, FGFR1 was found to be frequently expressed in kidney, but not in breast tumor cells, suggesting a possible role for FGFR4 in human mammary cancer.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	RON, D (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.		Neufeld, Gera/F-1524-2019; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew Man-Lok/0000-0001-9923-5464				ARMSTRONG E, 1992, CANCER RES, V52, P2004; AVIVI A, 1991, ONCOGENE, V6, P1089; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRUMELY G, 1992, ONCOGENE, V6, P2255; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN M, 1991, METHOD ENZYMOL, V198, P158; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T, 1989, MOL CLONING; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P125; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUNSON PJ, 1980, BIOCHEMISTRY-US, V25, P3487; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RON D, 1993, J BIOL CHEM, V268, P2984; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; TORU M, 1991, SCIENCE, V252, P72; TORU M, 1992, P NATL ACAD SCI USA, V89, P246; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360; YUEN S, 1991, METHOD ENZYMOL, V198, P91; ZHAN Z, 1988, MOL CELL BIOL, V8, P4387	56	93	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5388	5394						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680645				2022-12-25	WOS:A1993KR82200011
J	WONG, P; PINEAULT, J; LAKINS, J; TAILLEFER, D; LEGER, J; WANG, CY; TENNISWOOD, M				WONG, P; PINEAULT, J; LAKINS, J; TAILLEFER, D; LEGER, J; WANG, CY; TENNISWOOD, M			GENOMIC ORGANIZATION AND EXPRESSION OF THE RAT TRPM-2 (CLUSTERIN) GENE, A GENE IMPLICATED IN APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROSTATIC DUCTAL SYSTEM; SULFATED GLYCOPROTEIN-2; VENTRAL PROSTATE; MOLECULAR-CLONING; MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; ANDROGEN WITHDRAWAL; REGIONAL VARIATION	We describe the genomic structure of the rat TRPM-2 gene. This gene is induced de novo during the regression of the prostate and other hormone-dependent tissues after hormone ablation and plays an important role in apoptosis, or active cell death. TRPM-2 is a single copy gene, organized into nine exons, ranging in size from 47 base pairs (exon I) to 412 base pairs (exon IV), spanning a region of 13,750 base pairs. Comparison with sequences registered in the data bases shows that it has extensive homology to SGP-2, a gene that is expressed constitutively in the testis, although the sequences diverge dramatically in the 5'-untranslated region of the mRNA (coded for by exon I in TRPM-2), raising the possibility of alternative exon I usage in SGP-2. Primer extension, S1 nuclease protection, and extensive polymerase chain reaction analysis suggest that the TRPM-2 transcript from the prostate and the SGP-2 transcript from the testis are in fact identical and only contain the exon I sequence identified in the TRPM-2 genomic clone. Analysis of the promoter region of the TRPM-2 gene demonstrates that the putative control region contains several potential regulatory elements that may regulate the complex tissue-specific control of a gene which must be constitutively expressed in some tissues but repressed in others until induced during active cell death.	UNIV OTTAWA, DEPT BIOCHEM, 451 SMYTH RD, OTTAWA K1H 8M5, ONTARIO, CANADA	University of Ottawa				Tenniswood, Martin/0000-0001-7896-4019				ALLDAY MJ, 1987, NUCLEIC ACIDS RES, V15, P10592, DOI 10.1093/nar/15.24.10592; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURSCH W, 1991, CARCINOGENESIS, V12, P855, DOI 10.1093/carcin/12.5.855; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHENG CY, 1988, BIOCHEM BIOPH RES CO, V155, P398; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; CYR DG, 1992, ENDOCRINOLOGY, V130, P2160, DOI 10.1210/en.130.4.2160; DAY JR, 1990, MOL ENDOCRINOL, V4, P1995, DOI 10.1210/mend-4-12-1995; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; GRIMA J, 1990, ENDOCRINOLOGY, V126, P2989, DOI 10.1210/endo-126-6-2989; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JOH K, 1986, J MOL BIOL, V190, P401, DOI 10.1016/0022-2836(86)90011-2; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYPRIANOU N, 1989, BIOCHEM BIOPH RES CO, V165, P73, DOI 10.1016/0006-291X(89)91035-8; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; KYPRIANOU N, 1990, CANCER RES, V50, P3748; KYPRIANOU N, 1991, CANCER RES, V51, P162; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; LAPING NJ, 1991, BRAIN RES, P291; LEE C, 1987, J UROLOGY, V138, P903, DOI 10.1016/S0022-5347(17)43413-6; LEE C, 1990, BIOL REPROD, V43, P1079, DOI 10.1095/biolreprod43.6.1079; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MCNEILL TH, 1991, EXP NEUROL, V111, P140, DOI 10.1016/0014-4886(91)90062-H; MICHEL D, 1989, ONCOGENE RES, V4, P127; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3066, DOI 10.1210/en.130.5.3066; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURRELLO M, 1991, GENOMICS, V10, P151, DOI 10.1016/0888-7543(91)90495-Z; RENNIE PS, 1988, CANCER RES, V48, P6309; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; ROULEAU M, 1990, MOL ENDOCRINOL, V4, P2003, DOI 10.1210/mend-4-12-2003; SAMBOROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENSIBAR JA, 1991, ENDOCRINOLOGY, V128, P2091, DOI 10.1210/endo-128-4-2091; SLAWIN K, 1990, BIOCHEM BIOPH RES CO, V172, P160, DOI 10.1016/S0006-291X(05)80187-1; SMITH FF, 1992, MOL REPROD DEV, V33, P363, DOI 10.1002/mrd.1080330402; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TRUSS M, 1992, J STEROID BIOCHEM, V41, P241, DOI 10.1016/0960-0760(92)90350-R; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WONG P, 1989, GENE, V85, P59, DOI 10.1016/0378-1119(89)90464-2; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; ZAKERI Z, 1992, MOL REPROD DEV, V33, P373, DOI 10.1002/mrd.1080330403	73	193	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5021	5031						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680346				2022-12-25	WOS:A1993KP88400069
J	CHANG, YY; CRONAN, JE				CHANG, YY; CRONAN, JE			DETECTION BY SITE-SPECIFIC DISULFIDE DISULFIDE CROSS-LINKING OF A CONFORMATIONAL CHANGE IN BINDING OF ESCHERICHIA-COLI PYRUVATE OXIDASE TO LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; ALPHA-PEPTIDE; ACTIVATION; ENZYME; RECONSTITUTION; PROTEINS; CLONING; CHAIN	Escherichia coli pyruvate oxidase, a peripheral membrane homotetrameric flavoprotein, exposes its C-terminal lipid binding site in the presence of substrate pyruvate and co-factor thiamine pyrophosphate Mg2+ and binds tightly to phospholipid bilayers during catalysis. Using site-specific disulfide cross-linking, we demonstrate that disulfide cross-links are formed between C termini of D560C pyruvate oxidase and that the degree of cross-linking is greatly increased by the presence of substrate and co-factors indicating a conformational change that results in juxtaposition of two subunit C termini. The cross-linked oxidase is enzymatically active and remains able to associate with lipid micelles. These results argue strongly that lipid bilayer binding of pyruvate oxidase involves pairing of the C termini of two subunits.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	CHANG, YY (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,407 S GOODWIN,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NIGMS NIH HHS [GM 26156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDO S, 1991, J MOL BIOL, V217, P721; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHANG YY, 1983, J BACTERIOL, V154, P756, DOI 10.1128/JB.154.2.756-762.1983; CHANG YY, 1986, J BACTERIOL, V167, P312, DOI 10.1128/jb.167.1.312-318.1986; CHANG YY, 1984, P NATL ACAD SCI-BIOL, V81, P4348, DOI 10.1073/pnas.81.14.4348; CHANG YY, 1982, J BACTERIOL, V151, P1279, DOI 10.1128/JB.151.3.1279-1289.1982; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIEHL P, 1993, J BACTERIOL, V175, P2263, DOI 10.1128/JB.175.8.2263-2270.1993; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GRABAU C, 1989, J BIOL CHEM, V264, P12510; GRABAU C, 1986, BIOCHEMISTRY-US, V25, P3748, DOI 10.1021/bi00361a003; GRABAU C, 1986, NUCLEIC ACIDS RES, V14, P5449, DOI 10.1093/nar/14.13.5449; KOLAND JG, 1982, BIOCHEMISTRY-US, V21, P4438, DOI 10.1021/bi00261a038; KOLAND JG, 1982, J BIOL CHEM, V257, P6023; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P445, DOI 10.1021/bi00298a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHER M, 1982, J BIOL CHEM, V257, P2887; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; OBRIEN TA, 1982, BIOCHIM BIOPHYS ACTA, V705, P321, DOI 10.1016/0167-4838(82)90254-0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RECNY MA, 1985, J BIOL CHEM, V260, P4287; RECNY MA, 1982, J BIOL CHEM, V257, P2878; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1992, P NATL ACAD SCI USA, V89, P4144; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; WANG AY, 1991, J BIOL CHEM, V266, P10959; ZHANG TF, 1987, ARCH BIOCHEM BIOPHYS, V255, P201, DOI 10.1016/0003-9861(87)90311-0	28	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7896	7901		10.1074/jbc.270.14.7896	http://dx.doi.org/10.1074/jbc.270.14.7896			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713884	hybrid			2022-12-25	WOS:A1995QR52600020
J	RIDGWAY, ND; LAGACE, TA				RIDGWAY, ND; LAGACE, TA			BREFELDIN-A RENDERS CHINESE-HAMSTER OVARY CELLS INSENSITIVE TO TRANSCRIPTIONAL SUPPRESSION BY 25-HYDROXYCHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; COENZYME-A REDUCTASE; STEROL REGULATORY REGION; LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; GOLGI-APPARATUS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; OXYGENATED STEROLS; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM	The effect of disruption of the Golgi apparatus on 25-hydroxycholesterol-mediated transcriptional suppression and activation of acyl-CoA:cholesterol acyltransferase was examined. In Chinese hamster ovary (CHO) cells, brefeldin A (BFA) caused dose-dependent inhibition of 25-hydroxycholesterol-mediated suppression of mRNAs for four sterol-regulated genes: 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase, HMG-CoA synthase, farnesyl-diphosphate synthase, and the low density lipoprotein receptor, BFA prevented suppression whether added prior to or following a 4-h pretreatment with 25-hydroxycholesterol. In the presence of BFA (1 mu g/ml), 25-hydroxycholesterol-mediated suppression of mRNAs for HMG-CoA reductase, the low density lipoprotein receptor, and farnesyl-diphosphate synthase was almost completely blocked, HMG-CoA synthase mRNA was 80-90% suppressed by 25-hydroxycholesterol compared with 50-60% suppression in the presence of BFA. These effects of BFA were not due to alterations in mRNA stability. Disruption of the Golgi apparatus, as assessed by staining with a fluorescent lectin, correlated with concentrations of BFA that reversed mRNA suppression. Monensin was also found to block the effects of 25-hydroxycholesterol on suppression of HMG-CoA reductase. However, this ionophore decreased the other three sterol-regulated mRNAs to a similar degree as 25-hydroxycholesterol. In contrast to CHO cells, BFA-resistant PtK1 cells displayed normal down-regulation of HMG-CoA reductase and an intact Gels apparatus in the presence of BFA and 25-hydroxycholesterol. Cholesterol esterification in CHO cells was stimulated to a similar extent by BFA (1 mu g/ml) and 25-hydroxycholesterol, and simultaneous treatment of CHO cells with both compounds was 60-70% additive. These results suggest that an intact Golgi apparatus is required for 25-hydroxycholesterol-mediated suppression of mRNA.	DALHOUSIE UNIV, ATLANTIC RES CTR, HALIFAX, NS B3H 4H7, CANADA	Dalhousie University	RIDGWAY, ND (corresponding author), DALHOUSIE UNIV, DEPT PEDIAT & BIOCHEM, 5849 UNIV AVE, HALIFAX, NS B3H 4H7, CANADA.			Ridgway, Neale/0000-0002-0441-6228				BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNING A, 1992, J BIOL CHEM, V267, P7726; BRUNING A, 1992, J BIOL CHEM, V267, P5052; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; COXEY RA, 1993, J LIPID RES, V34, P1165; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KANDUTSCH AA, 1980, J BIOL CHEM, V255, P813; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LANGE Y, 1991, J LIPID RES, V32, P329; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1125, P28, DOI 10.1016/0005-2760(92)90151-K; SUCKLING KE, 1985, J LIPID RES, V26, P647; TAYLOR FR, 1985, METHOD ENZYMOL, V110, P9; TAYLOR FR, 1984, J BIOL CHEM, V259, P12384; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; URBANI L, 1990, J BIOL CHEM, V265, P1919; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	50	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8023	8031		10.1074/jbc.270.14.8023	http://dx.doi.org/10.1074/jbc.270.14.8023			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713903	hybrid			2022-12-25	WOS:A1995QR52600039
J	OHBO, K; TAKASAWA, N; ISHII, N; TANAKA, N; NAKAMURA, M; SUGAMURA, K				OHBO, K; TAKASAWA, N; ISHII, N; TANAKA, N; NAKAMURA, M; SUGAMURA, K			FUNCTIONAL-ANALYSIS OF THE HUMAN INTERLEUKIN-2 RECEPTOR-GAMMA CHAIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; BOX-BINDING-PROTEINS; VIRUS TYPE-I; IL-2 RECEPTOR; TRANSCRIPTION FACTORS; TRANSACTIVATOR GENE; PHORBOL DIESTER; TAX GENE; EXPRESSION; CLONING	The third component of the interleukin (IL) 2 receptor, gamma chain, is essential not only for IL-2- but also for IL-4-, IL-7-, IL-9-, and IL-15-induced proliferation of lymphocytes. To elucidate the mechanisms by which the gamma chain is expressed, we have analyzed the promoter region of the gamma chain gene. The 633-base pair fragment upstream of the initiation codon showed the promoter activity in human hematopoietic cell lines, Jurkat and THP-1, when linked to the luciferase gene. With a series of 5'-deletion mutants, the basal promoter activity was found in a fragment from nucleotide 80 to 58 upstream from the RNA start site, including an Ets binding sequence, Treatment of cells with either 12-O-tetradecanoylphorbol-13-acetate or phytohemagglutinin but not forskolin induced transcription from the gamma chain gene promoter. A viral trans acting transcriptional activator, Tax, of human T-cell leukemia virus type I elevated expression of the gamma chain gene. In contrast, IL-2 decreased transcription from the IL-2 receptor gamma chain promoter. These results suggest that expression of the gamma chain is regulated at the transcription level by extracellular stimuli and may be implicated in immune response.			OHBO, K (corresponding author), TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 98077,JAPAN.			Ishii, Naoto/0000-0002-0549-8245				ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P3054; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Nakamura M, 1993, Semin Immunol, V5, P309, DOI 10.1006/smim.1993.1037; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TSUCHIYA S, 1982, CANCER RES, V42, P1530; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7479	7486		10.1074/jbc.270.13.7479	http://dx.doi.org/10.1074/jbc.270.13.7479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706294	hybrid			2022-12-25	WOS:A1995QQ43100069
J	YU, JC; LI, WQ; WANG, LM; UREN, A; PIERCE, JH; HEIDARAN, MA				YU, JC; LI, WQ; WANG, LM; UREN, A; PIERCE, JH; HEIDARAN, MA			DIFFERENTIAL REQUIREMENT OF A MOTIF WITHIN THE CARBOXYLTERMINAL DOMAIN OF ALPHA-PLATELET-DERIVED GROWTH-FACTOR (ALPHA-PDGF) RECEPTOR FOR PDGF FOCUS-FORMING ACTIVITY CHEMOTAXIS, OR GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE INSERT DOMAIN; SIGNALING PATHWAYS; PHOSPHOLIPASE-C; EXPRESSION; SEQUENCE; PROTEIN	To determine the molecular basis for the transforming function of platelet derived growth factor (PDGF)-A in NIH/3T3 cells, we have constructed chimerae consisting of the extracellular domain of the human CSF-1R (fms) linked to the cytoplasmic domain of the alpha PDGF receptor (alpha R) containing a series of deletion or point mutations. The ability of fms/alpha R chimerae to mediate CSF-l-dependent anchorage-independent growth, focus formation, and chemotaxis of NIH/3T3 cells was then examined. Our results provide evidence that a domain encompassing amino acid residues 977-1024 of the alpha PDGFR is required for ligand-dependent focus formation, but not chemotaxis or anchorage-independent growth, and that tyrosine residues within this domain constitute the major binding site for phospholipase C gamma. Therefore, our findings suggest that: (i) the focus forming function of alpha PDGFR correlates well with the ability of the receptor to bind phospholipase C gamma, and (ii) the mechanism of focus formation mediated by (alpha PDGFR may be distinguished from that required for chemotaxis or anchorage-independent growth.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; KUNDRA V, 1994, NATURE, V367, P476; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RAPESH LA, 1989, INVAS METAST, V9, P192; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	23	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7033	7036		10.1074/jbc.270.13.7033	http://dx.doi.org/10.1074/jbc.270.13.7033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706238	hybrid			2022-12-25	WOS:A1995QQ43100006
J	AMARATUNGA, A; MORIN, PJ; KOSIK, KS; FINE, RE				AMARATUNGA, A; MORIN, PJ; KOSIK, KS; FINE, RE			INHIBITION OF KINESIN SYNTHESIS AND RAPID ANTEROGRADE AXONAL-TRANSPORT IN-VIVO BY AN ANTISENSE OLIGONUCLEOTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MONOCLONAL-ANTIBODIES; HEAVY-CHAIN; PROTEINS; IDENTIFICATION; MICROTUBULES; MOTILITY; CELLS; EXPRESSION; INVITRO	Synthetic antisense oligonucleotides have been used to inhibit specific protein synthesis in vivo. Antisense oligonucleotides directed to kinesin heavy chain were injected into the vitreous of anesthetized rabbits in order to assess the effects on transport in the retinal ganglion cells whose axons form the optic nerve. The antisense oligonucleotide specifically inhibited retinal kinesin synthesis by 82 +/- 7% (n = 4). The rapid axonal transport of the membrane proteins into the optic nerve was concomitantly inhibited by 70 +/- 10% (n = 4). These results provide direct evidence for the specific role of kinesin in rapid anterograde transport in vivo and indicate the utility of antisense oligonucleotides to explore neuronal dynamics in a specific neuronal cell type in a living animal.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,CTR NEUROL DIS,BOSTON,MA 02115; EDITH NOURSE ROGERS MEM VET ADM HOSP,BEDFORD,MA 01730	Boston University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL EYE INSTITUTE [R01EY008535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029031] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY 08535] Funding Source: Medline; NINDS NIH HHS [R01NS 29031] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, 1992, J CELL BIOL, V119, P1069; BAITINGER C, 1987, J NEUROSCI, V7, P3723; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GIOLLI RA, 1969, J COMP NEUROL, V136, P99, DOI 10.1002/cne.901360107; GUILLERY RW, 1986, TRENDS NEUROSCI, V9, P364, DOI 10.1016/0166-2236(86)90115-3; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; MORIN PJ, 1991, J NEUROCHEM, V56, P415, DOI 10.1111/j.1471-4159.1991.tb08167.x; MORIN PJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P275, DOI 10.1016/0005-2736(93)90366-8; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PENNINGROTH SM, 1987, FEBS LETT, V222, P204, DOI 10.1016/0014-5793(87)80220-X; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WAGNER JA, 1979, BRAIN RES, V168, P97, DOI 10.1016/0006-8993(79)90130-6; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	25	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17427	17430						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688725				2022-12-25	WOS:A1993LQ98800080
J	KOH, J; SFERRA, TJ; COLLINS, FS				KOH, J; SFERRA, TJ; COLLINS, FS			CHARACTERIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROMOTER REGION - CHROMATIN CONTEXT AND TISSUE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSCRIPTS; LOCUS ACTIVATION REGION; HYPERSENSITIVE SITES; MAMMALIAN-CELLS; DNASE-I; INITIATOR CODON; DOWN-REGULATION; GENE; EXPRESSION; SEQUENCE	Expression of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) is tightly regulated. Using a panel of cell lines expressing different levels of CFTR mRNA, we investigated the mechanisms mediating control of CFTR transcription. In highly expressing cells, multiple sites of transcription initiation can be identified between positions -95 and +50 of the CFTR gene, and an alternatively initiated splice variant transcript is also present. Non-epithelial cell lines expressing very low levels of CFTR utilize a start site at -32. Promoter sequence elements from -83 to +111 are at least partially responsible for dictating CFTR transcriptional tissue-specificity, while multiple elements located farther 5' augment promoter strength. Analysis of the chromatin structure and methylation status of the CFTR promoter region reveals cell line differences which correlate with expression levels, suggesting that the physical context of the CFTR gene in vivo may contribute significantly to appropriate regulation of CFTR transcription. Taken together, these findings indicate that cellular control of CFTR gene expression is likely to be a complex function of several overlapping regulatory pathways.	UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PEDIAT & COMMUN DIS, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NICHD NIH HHS [HD-22297] Funding Source: Medline; NIDDK NIH HHS [DK 42718, DK 39690] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042718, R01DK039690] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; BREUER W, 1992, J BIOL CHEM, V267, P10465; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARRIS A, 1991, DEVELOPMENT, V113, P305; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTROSERAFIZADEH C, 1992, J BIOL CHEM, V267, P19299; MORANDI C, 1982, J MOL BIOL, V156, P583, DOI 10.1016/0022-2836(82)90268-6; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NIENHUIS AW, 1987, MOL BASIS BLOOD DISE, P28; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PINTO M, 1983, BIOL CELL, V47, P323; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; STRONG TV, 1990, PEDIATR PULMON S, V5, P195; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Tsui L C, 1991, Adv Hum Genet, V20, P153; Tsui LC, 1991, ADV HUM GENET, V20, P311; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	53	85	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15912	15921						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7688000				2022-12-25	WOS:A1993LN30500084
J	OH, YM; MULLER, HL; LAMSON, G; ROSENFELD, RG				OH, YM; MULLER, HL; LAMSON, G; ROSENFELD, RG			INSULIN-LIKE GROWTH-FACTOR (IGF)-INDEPENDENT ACTION OF IGF-BINDING PROTEIN-3 IN HS578T HUMAN BREAST-CANCER CELLS - CELL-SURFACE BINDING AND GROWTH-INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; CHRONIC-RENAL-FAILURE; FACTOR-I; MOLECULAR-CLONING; CARRIER PROTEINS; HUMAN-SERUM; FACTOR-BETA; RECEPTOR; IDENTIFICATION; EXPRESSION	Estrogen receptor-negative Hs578T human breast cancer cells secrete insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-4 as major binding protein (BP) species. Our previous immunohistochemical studies (Oh, Y., Muller, H. L., Pham, H., Lamson, G., and Rosenfeld, R. G. (1992) Endocrinology 131, 3123-3125) have demonstrated the existence of cell surface-associated IGFBP-3 and release of cell surface-associated IGFBP-3 into conditioned media by addition of IGF peptide in Hs578T cells. In this study, we have demonstrated that IGFBP-3 binding on the cell surface is specific and receptor-mediated, by showing: 1) a dose-dependent increase of IGFBP-3 binding by addition of divalent cations (CaCl2 and MnCl2); 2) dose-dependent competition of I-125-IGFBP-3E. coli by unlabeled IGFBP-3E.coli (>80% competition at 100 nM), but not by IGFBP-1 or fibronectin. In addition, exogenous IGFBP-3 treatment resulted in a significant inhibitory effect on monolayer growth of Hs578T cells. This inhibitory effect of IGFBP-3 was shown to be specific and IGF-independent by demonstrating: 1) dose-dependent inhibition on cell growth (60% inhibition at 20 nM) and inhibition on DNA synthesis (10 nM; p < 0.05, 20 nM; p < 0.005) by exogenous IGFBP-3E.coli, but not by IGFBP- 1; 2) absence of stimulatory effects on monolayer cell growth by either native IGFs or IGF analogs which have significantly decreased affinity for IGFBPs, but retain full affinity for type 1 and 2 IGF receptors; 3) significant diminution of the IGFBP-3 inhibitory effects on monolayer growth by coincubation with native IGFs, but not by coincubation with IGF analogs with decreased affinity for IGFBP-3. In conclusion, exogenous IGFBP-3 shows specific binding on the cell surface and can inhibit Hs578T cell monolayer growth by itself, suggesting the existence of specific membrane-associated proteins or receptors for IGFBP-3. Furthermore, IGF-I and -II can attenuate inhibitory effect of IGFBP-3 by forming IGF.IGFBP-3 complexes, thereby preventing cell surface binding of IGFBP-3.			OH, YM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,ROOM S306,STANFORD,CA 94305, USA.		müller, Hermann l/AAC-1637-2020	Muller, Hermann L./0000-0003-4929-9966	NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHRACH LK, 1989, ENDOCRINOLOGY, V125, P2831, DOI 10.1210/endo-125-6-2831; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CARA JF, 1990, J BIOL CHEM, V265, P17820; CEDA GP, 1992, ENDOCRINOLOGY, V130, P1483, DOI 10.1210/en.130.3.1483; CEDA GP, 1991, ENDOCRINOLOGY, V128, P249; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, ENDOCRINOLOGY, V126, P3139, DOI 10.1210/endo-126-6-3139; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DELBE J, 1990, J CELL PHYSIOL, V142, P359, DOI 10.1002/jcp.1041420219; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; DELEON DD, 1989, MOL ENDOCRINOL, V3, P567, DOI 10.1210/mend-3-3-567; DELEON DD, 1990, J CLIN ENDOCR METAB, V71, P530, DOI 10.1210/jcem-71-2-530; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DEVROEDE MA, 1986, J CLIN INVEST, V77, P602, DOI 10.1172/JCI112343; EDWARDS JG, 1988, J CELL SCI, V89, P507; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; FURLANETTO RW, 1984, CANCER RES, V44, P2122; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3041; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMSON G, 1989, J CLIN ENDOCR METAB, V69, P852, DOI 10.1210/jcem-69-4-852; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; LIU L, 1992, J CELL PHYSIOL, V153, P15, DOI 10.1002/jcp.1041530104; LOTAN R, 1979, CANCER RES, V39, P1014; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; MARTIN JL, 1988, ENDOCRINOLOGY, V123, P1907, DOI 10.1210/endo-123-4-1907; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; MONDSCHEIN JS, 1990, ENDOCRINOLOGY, V127, P2298, DOI 10.1210/endo-127-5-2298; MORIWAKE T, 1992, ENDOCRINOLOGY, V130, P1071, DOI 10.1210/en.130.2.1071; NEELY EK, 1992, ENDOCRINOLOGY, V130, P985, DOI 10.1210/en.130.2.985; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V142, P275, DOI 10.1016/0006-291X(87)90481-5; OH Y, 1991, BIOCHEM J, V278, P249, DOI 10.1042/bj2780249; OH Y, 1992, ENDOCRINOLOGY, V131, P3123, DOI 10.1210/en.131.6.3123; OH Y, 1993, GROWTH REGULAT, V3, P84; POWELL DR, 1986, J CLIN ENDOCR METAB, V63, P1186; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENFELD RG, 1986, BIOCHEM BIOPH RES CO, V138, P304, DOI 10.1016/0006-291X(86)90280-9; ROSENFELD RG, 1989, J CLIN ENDOCR METAB, V68, P638, DOI 10.1210/jcem-68-3-638; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; RUTANEN EM, 1988, J CLIN ENDOCR METAB, V66, P173, DOI 10.1210/jcem-66-1-173; SCHMID C, 1989, FEBS LETT, V244, P328, DOI 10.1016/0014-5793(89)80556-3; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SMITH EP, 1990, ENDOCRINOLOGY, V127, P2744, DOI 10.1210/endo-127-6-2744; SMITH EP, 1992, ENDOCRINOLOGY, V131, P2733, DOI 10.1210/en.131.6.2733; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	76	469	478	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14964	14971						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686909				2022-12-25	WOS:A1993LL75900065
J	HAYAKAWA, M; ISHIDA, N; TAKEUCHI, K; SHIBAMOTO, S; HORI, T; OKU, N; ITO, F; TSUJIMOTO, M				HAYAKAWA, M; ISHIDA, N; TAKEUCHI, K; SHIBAMOTO, S; HORI, T; OKU, N; ITO, F; TSUJIMOTO, M			ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PHOSPHOLIPASE-A(2) IS CRUCIAL IN THE CYTOTOXIC ACTION OF TUMOR-NECROSIS-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; CELL-LINE; EXTRACELLULAR PHOSPHOLIPASE-A2; SYNOVIAL-FLUID; CYTO-TOXICITY; RAT PLATELETS; PURIFICATION; EXPRESSION; INVITRO; INVOLVEMENT	The role of phospholipase A2 (PLA2) in the cytotoxic action of tumor necrosis factor (TNF) was examined. Recently, we described the characterization of TNF-resistant sublines isolated from TNF-sensitive cell line L929 (Hayakawa, M., Oku, N., Takagi, T., Hori, T., Shibamoto, S., Yamanaka, Y., Takeuchi, K., Tsujimoto, M., and Ito, F. (1991) Cell Struct. Funct. 16, 333-340). The most remarkable features of these TNF-resistant sublines were the defects in TNF-stimulated arachidonate metabolism. In this study, we characterized the PLA2 activities of these sublines and found a significant decrease in the activity in one of the TNF-resistant sublines, C12 cells. The enzymological features, such as Ca2+ requirement and substrate specificity, suggested that the high molecular weight arachidonoyl-selective cytosolic PLA2 (cPLA2) was involved in the TNF action. Northern hybridization analysis demonstrated the reduced expression of high molecular weight cPLA2 in C12 cells. Furthermore, expression of a cloned cPLA2 cDNA in C12 cells increased the sensitivity of cells to the TNF cytotoxicity. These results indicate the crucial role of the high molecular weight cPLA2 in the TNF-induced cytolysis.	SUNTORY INST BIOMED RES, MISHIMA, OSAKA 618, JAPAN; UNIV SHIZUOKA, SCH PHARMACEUT SCI, DEPT RADIOBIOCHEM, OYA, SHIZUOKA 422, JAPAN	Suntory Holdings Ltd; University of Shizuoka	HAYAKAWA, M (corresponding author), SETSUNAN UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, HIRAKATA, OSAKA 57301, JAPAN.			Ito, Fumiaki/0000-0002-4129-4899				BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; HAYAKAWA M, 1991, CELL STRUCT FUNCT, V16, P333, DOI 10.1247/csf.16.333; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; ISHIDA N, 1992, J CLIN INVEST, V89, P1431, DOI 10.1172/JCI115732; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LE JM, 1987, LAB INVEST, V56, P234; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; MALIK STA, 1992, TUMOR NECROSIS FACTO, P239; MARAGANORE JM, 1986, J BIOL CHEM, V261, P4797; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; MUTCH DG, 1992, CANCER RES, V52, P866; NAKANO T, 1990, J BIOL CHEM, V265, P12745; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; REID T, 1991, J BIOL CHEM, V266, P16580; REID TR, 1989, J BIOL CHEM, V264, P4583; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	38	257	261	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11290	11295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684376				2022-12-25	WOS:A1993LD46600084
J	DE, BP; BURDSALL, AL; BANERJEE, AK				DE, BP; BURDSALL, AL; BANERJEE, AK			ROLE OF CELLULAR ACTIN IN HUMAN PARAINFLUENZA VIRUS TYPE-3 GENOME TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-INFLUENZA VIRUS-3; NEWCASTLE-DISEASE VIRUS; VESICULAR STOMATITIS-VIRUS; MESSENGER-RNA SYNTHESIS; SENDAI VIRUS; P-PROTEIN; SEQUENCE-ANALYSIS; MEASLES-VIRUS; MUMPS-VIRUS; INFECTED-CELLS	The transcribing ribonucleoprotein (RNP) complex of human parainfluenza virus type 3 (HPIV-3) requires cellular actin for transcription of viral genome in vitro (De, B. P., Lesoon, A., and Banerjee, A. K. (1991) J. Virol. 65, 3268-3275). In this communication, we have studied the interactions between different molecular forms of actin and the RNP of HPIV-3 to understand the role of actin in mRNA synthesis. We demonstrate that both polymeric and monomeric forms of actin (obtained by DNase I treatment) bind strongly to the RNP at 100 mm KCl concentration (polymerizing buffer). The binding was virtually abolished at zero KCl concentration (depolymerizing buffer). Isolation of the RNP-actin complex and subsequent use in a transcription reaction showed that the bound actin alone was sufficient for mRNA synthesis in vitro. Interestingly, the DNase I-arrested monomeric form of actin failed to activate mRNA synthesis, indicating a requirement of polymerization of the bound actin during HPIV-3 transcription. Electron microscopic analyses revealed that a drastic structural modification of the RNP occurred because of the polymerization of actin from a loosely coiled and irregular structure to a condensed and flexible structure. Activation of transcription was observed also with poly-L-glutamic acid, a highly acidic polypeptide. However, unlike cellular actin, poly-L glutamic acid was able to activate only 10% of the input RNP. These results suggest that cellular actin activates HPIV-3 transcription by polymerizing specifically on the RNP complex. This event results in an alteration of the RNP structure that enhances its suitability for efficient transcription. The acidic domain of actin may play an important role in this process.			DE, BP (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.				NIAID NIH HHS [AI 32027] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SC, 1988, J VIROL, V62, P834, DOI 10.1128/JVI.62.3.834-838.1988; BOHN W, 1986, VIROLOGY, V149, P91, DOI 10.1016/0042-6822(86)90090-5; CATTANEO R, 1989, CELL, V56, P759, DOI 10.1016/0092-8674(89)90679-X; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARLTON CA, 1991, J VIROL, V65, P1219, DOI 10.1128/JVI.65.3.1219-1227.1991; CHINCHAR VG, 1981, VIROLOGY, V115, P192, DOI 10.1016/0042-6822(81)90101-X; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CURRAN J, 1992, VIROLOGY, V189, P647, DOI 10.1016/0042-6822(92)90588-G; DE BP, 1990, J VIROL, V64, P1135, DOI 10.1128/JVI.64.3.1135-1142.1990; DE BP, 1991, J VIROL, V65, P3268, DOI 10.1128/JVI.65.6.3268-3275.1991; DESHPANDE KL, 1985, VIROLOGY, V140, P125, DOI 10.1016/0042-6822(85)90451-9; EATON BT, 1987, VIROLOGY, V157, P107, DOI 10.1016/0042-6822(87)90319-9; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; ELLIOTT GD, 1990, J GEN VIROL, V71, P1555, DOI 10.1099/0022-1317-71-7-1555; FRANKEL S, 1990, J BIOL CHEM, V265, P17980; GALINSKI MS, 1986, VIROLOGY, V155, P46, DOI 10.1016/0042-6822(86)90167-4; GALINSKI MS, 1992, VIROLOGY, V186, P543, DOI 10.1016/0042-6822(92)90020-P; GALINSKI MS, 1990, PARAMYXOVIRUSES, P41; GIUFFRE RM, 1982, J VIROL, V42, P963, DOI 10.1128/JVI.42.3.963-968.1982; GORDON DJ, 1977, J BIOL CHEM, V252, P8300; GRIGERA PR, 1988, VIROLOGY, V165, P584, DOI 10.1016/0042-6822(88)90602-2; HAMAGUCHI M, 1985, VIROLOGY, V147, P295, DOI 10.1016/0042-6822(85)90132-1; HAMAGUCHI M, 1983, VIROLOGY, V128, P105, DOI 10.1016/0042-6822(83)90322-7; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HEGGENESS MH, 1980, P NATL ACAD SCI-BIOL, V77, P2631, DOI 10.1073/pnas.77.5.2631; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; JAMBOU RC, 1985, J VIROL, V56, P298, DOI 10.1128/JVI.56.1.298-302.1985; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KONDO K, 1990, VIROLOGY, V178, P321, DOI 10.1016/0042-6822(90)90413-L; KORN ED, 1978, P NATL ACAD SCI USA, V75, P588, DOI 10.1073/pnas.75.2.588; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RA, 1976, VIROLOGY, V69, P116, DOI 10.1016/0042-6822(76)90199-9; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LUFTIG RB, 1982, J THEOR BIOL, V99, P173, DOI 10.1016/0022-5193(82)90397-6; LUK D, 1986, VIROLOGY, V153, P318, DOI 10.1016/0042-6822(86)90036-X; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MARUYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V626, P494; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOYER SA, 1986, P NATL ACAD SCI USA, V83, P5405, DOI 10.1073/pnas.83.15.5405; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; OHGIMOTO S, 1990, VIROLOGY, V177, P116, DOI 10.1016/0042-6822(90)90465-4; ORVELL C, 1978, J GEN VIROL, V41, P527, DOI 10.1099/0022-1317-41-3-527; PATERSON RG, 1990, J VIROL, V64, P4137, DOI 10.1128/JVI.64.9.4137-4145.1990; PELUSO RW, 1977, J VIROL, V23, P177, DOI 10.1128/JVI.23.1.177-187.1977; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SANCHEZ A, 1985, VIROLOGY, V143, P45, DOI 10.1016/0042-6822(85)90095-9; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SOUTHERN JA, 1990, VIROLOGY, V177, P388, DOI 10.1016/0042-6822(90)90497-F; SPRIGGS MK, 1986, J GEN VIROL, V67, P2705, DOI 10.1099/0022-1317-67-12-2705; STALLCUP KC, 1983, VIROLOGY, V124, P59, DOI 10.1016/0042-6822(83)90290-8; STOREY DG, 1984, J VIROL, V52, P761, DOI 10.1128/JVI.52.3.761-766.1984; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P1942, DOI 10.1021/bi00304a009; TAKEUCHI K, 1990, VIROLOGY, V178, P247, DOI 10.1016/0042-6822(90)90400-L; THOMAS SM, 1988, CELL, V54, P891, DOI 10.1016/S0092-8674(88)91285-8; TYRRELL DLJ, 1978, J GEN VIROL, V39, P219, DOI 10.1099/0022-1317-39-2-219; VIDAL S, 1990, J VIROL, V64, P239, DOI 10.1128/JVI.64.1.239-246.1990; VOLKMAN LE, 1987, VIROLOGY, V156, P32, DOI 10.1016/0042-6822(87)90433-8; Wang E., 1976, CELL MOTILITY, P589; WECHSLER SL, 1985, VIRUS RES, V3, P339, DOI 10.1016/0168-1702(85)90434-4	61	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5703	5710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680647				2022-12-25	WOS:A1993KR82200052
J	KISTNER, U; WENZEL, BM; VEH, RW; CASESLANGHOFF, C; GARNER, AM; APPELTAUER, U; VOSS, B; GUNDELFINGER, ED; GARNER, CC				KISTNER, U; WENZEL, BM; VEH, RW; CASESLANGHOFF, C; GARNER, AM; APPELTAUER, U; VOSS, B; GUNDELFINGER, ED; GARNER, CC			SAP90, A RAT PRESYNAPTIC PROTEIN RELATED TO THE PRODUCT OF THE DROSOPHILA TUMOR SUPPRESSOR GENE DLG-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANYLATE KINASE; SYNAPTIC VESICLES; NERVOUS-SYSTEM; BINDING; PURIFICATION; COMPONENT; JUNCTIONS; MEMBRANE; ONCOGENE; ELEMENTS	A novel synapse-associated protein, SAP90, accumulates around the axon hillock of Purkinje cells in rat cerebellum. By immuno-electron microscopy, SAP90 has been localized to the presynaptic termini of basket cells forming inhibitory, gamma-aminobutyric acid (GABA)ergic synapses onto Purkinje cell axon hillocks. The amino acid sequence for SAP90 has been deduced from the nucleotide sequence of a series of overlapping cDNA clones. SAP90 is related to the gene product encoded by the Drosophila tumor suppressor gene dlg-A. SAP90 and the dlg-A product share an overall sequence identity of 54%. Three distinct domains can be identified: (i) a potential cytoskeletal region consisting of three repeats of 90 amino acids in length, (ii) a domain with similarity to SH3, a putative regulatory motif found in the src family of non-receptor protein tyrosine kinases and several proteins associated with the cortical cytoskeleton, and (iii) a carboxyl-terminal domain homologous to yeast guanylate kinase. These features suggest a possible role for SAP90 in a guanine nucleotide-mediated signal transduction pathway at a subset of GABAergic synapses in the rat cerebellum.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; RUHR UNIV BOCHUM,INST ANAT,W-4630 BOCHUM 1,GERMANY	University of Hamburg; Ruhr University Bochum				Garner, Craig/0000-0003-1970-5417				BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DASILVA PP, 1982, CELL, V28, P441, DOI 10.1016/0092-8674(82)90198-2; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FAZELI MS, 1992, TRENDS NEUROSCI, V15, P115, DOI 10.1016/0166-2236(92)90350-H; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; GARNER CC, 1988, GENE, V71, P483, DOI 10.1016/0378-1119(88)90065-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT, P1; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HAYES NVL, 1991, J NEUROCHEM, V57, P397, DOI 10.1111/j.1471-4159.1991.tb03766.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDIS DMD, 1988, INTRINSIC DETERMINAN, V37, P201; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LYNCH G, 1988, INTRINSIC DETERMINAN, V37, P217; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Noirot-Timothee C., 1980, International Review of Cytology, V63, P97, DOI 10.1016/S0074-7696(08)61758-1; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PAWSON T, 1988, ONCOGENE, V3, P491; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; SOMOGYI P, 1985, J HISTOCHEM CYTOCHEM, V33, P240, DOI 10.1177/33.3.2579123; SOUSA R, 1992, J NEUROSCI, V12, P2130; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SU B, 1991, J NEUROSCI RES, V29, P461, DOI 10.1002/jnr.490290406; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WESTEL WC, 1992, J CELL BIOL, V117, P121; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WU K, 1986, MOL BRAIN RES, V1, P167, DOI 10.1016/0169-328X(86)90008-2	36	374	382	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4580	4583						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680343				2022-12-25	WOS:A1993KP88400004
J	PFEFFERKORN, LC; VANDEWINKEL, JGJ; SWINK, SL				PFEFFERKORN, LC; VANDEWINKEL, JGJ; SWINK, SL			A NOVEL ROLE FOR IGG-FC - TRANSDUCTIONAL POTENTIATION FOR HUMAN HIGH-AFFINITY FC-GAMMA RECEPTOR (FC-GAMMA-RI) SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HUMAN MONONUCLEAR PHAGOCYTES; MOUSE MONOCLONAL-ANTIBODIES; NADPH OXIDASE ACTIVITY; HUMAN IMMUNOGLOBULIN-G; CROSS-LINKING; TRANSIENT ACTIVATION; IFN-GAMMA; CELL-LINE; BINDING	Human type 1 FC gamma receptors (Fc gamma RI) bind with high affinity (K-d = similar to 10(-9) M) Fc regions of monomeric IgG1 and IgG3. As demonstrated in this report, interaction of IgG-Fc with the ligand binding site on Fc gamma RI alters its capacity for aggregation-dependent signaling. This Fc-dependence was demonstrated in normal monocytes and U937-10.6 cells exposed to monomeric IgG and then to anti-Fc gamma RI F(ab')(2) that cross-link the receptor. Using O-2(-) production to measure cell signaling, we found that binding by high affinity IgGs of various species, as well as by murine hybrid IgGs containing only one high affinity heavy chain, resulted in a marked increase in Fc gamma RI-mediated signaling. Preaggregated Fc gamma RI/IgG had a ratio of one. IgG binding after aggregation of unligated Fc gamma RI did not restore signaling. Dose responses indicated that concentrations of IgG that saturated Fc gamma RI optimized transductional activity. The inclusion of unligated with ligated Fc gamma RI in aggregates depressed activity, indicating a lack of trans-activation of unligated Fc gamma RI. Significantly, IgG-binding markedly increased aggregation-dependent tyrosine phosphorylation of Fc gamma RI gamma-chains and the association of tyrosine phosphorylated Syk. Thus, the consequences of IgG-Fc binding were increases in aggregation-dependent phosphorylation of Fc gamma RI gamma-chains, recruitment of pp72Syk to Fc gamma RI, and signaling of the NADPH oxidase pathway.	UNIV UTRECHT HOSP, DEPT EXPTL IMMUNOL, UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center	PFEFFERKORN, LC (corresponding author), DARTMOUTH COLL, SCH MED, DEPT MICROBIOL, LEBANON, NH 03756 USA.				NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029455] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108] Funding Source: Medline; NIAID NIH HHS [AI29455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1986, IMMUNOL TODAY, V7, P264, DOI 10.1016/0167-5699(86)90007-1; BASS DA, 1988, J BIOL CHEM, V263, P19610; BENDER JG, 1983, J IMMUNOL, V130, P2316; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BROWN JC, 1977, P NATL ACAD SCI USA, V74, P5682, DOI 10.1073/pnas.74.12.5682; BROWN JC, 1975, P NATL ACAD SCI USA, V72, P5111, DOI 10.1073/pnas.72.12.5111; DUCHEMIN AM, 1994, J BIOL CHEM, V269; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GERGELY J, 1989, IMMUNOL LETT, V20, P1, DOI 10.1016/0165-2478(89)90059-X; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HALLETT MB, 1983, BIOCHEM J, V216, P459, DOI 10.1042/bj2160459; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KANE PM, 1988, J CELL BIOL, V107, P969, DOI 10.1083/jcb.107.3.969; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOOLWIJK P, 1989, J IMMUNOL, V143, P1656; KOOLWIJK P, 1991, J IMMUNOL, V147, P595; LAW CL, 1994, J BIOL CHEM, V269, P12310; LI S, 1986, J IMMUNOL, V137, P3378; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; METZGER H, 1992, J IMMUNOL, V149, P1477; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; ORTEGA E, 1991, BIOCHEMISTRY-US, V30, P3473, DOI 10.1021/bi00228a018; PAN L, 1990, J IMMUNOL, V145, P267; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; PFEFFERKORN LC, 1990, MOL IMMUNOL, V27, P263, DOI 10.1016/0161-5890(90)90139-Q; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; PFEFFERKORN LC, 1994, FASEB J, V8, pA749; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROZSNYAY Z, 1989, IMMUNOLOGY, V66, P491; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SHEN L, 1989, J IMMUNOL, V143, P4117; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8164	8171		10.1074/jbc.270.14.8164	http://dx.doi.org/10.1074/jbc.270.14.8164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713921	hybrid			2022-12-25	WOS:A1995QR52600060
J	ROBBGASPERS, LD; THOMAS, AP				ROBBGASPERS, LD; THOMAS, AP			COORDINATION OF CA2+ SIGNALING BY INTERCELLULAR PROPAGATION OF CA2+ WAVES IN THE INTACT LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE COUPLETS; CALCIUM WAVES; INOSITOL 1,4,5-TRISPHOSPHATE; CONFOCAL MICROSCOPY; OSCILLATIONS; TRISPHOSPHATE; VASOPRESSIN; STIMULATION; MESSENGER; GLUTAMATE	Activation of the inositol lipid signaling system results in cytosolic Ca2+ oscillations and intra- and intercellular Ca2+ waves in many isolated cell preparations. However, this form of temporal and spatial organization of signaling has not been demonstrated in intact tissues. Digital imaging fluorescence microscopy was used to monitor Ca2+ at the cellular and subcellular level in intact perfused rat liver loaded with fluorescent Ca2+ indicators, Perfusion with low doses of vasopressin induced oscillations of hepatocyte Ca2+ that were coordinated across entire lobules of the Liver by propagation of Ca2+ waves along the hepatic plates. At the subcellular level these periodic Ca2+ waves initiated from the sinusoidal domain of cells within the periportal region and propagated radially across cell-cell contacts into the pericentral region, or until terminated by annihilation collision with other Ca2+ wave fronts. With increasing agonist dose, the frequency but not the amplitude of the Ca2+ waves increased. Intracellular Ca2+ wave rates were constant, but transcellular signal propagation was determined by agonist dose, giving rise to a dose-dependent increase in the rate at which Ca2+ waves spread through the liver. At high vasopressin doses, a single Ca2+ wave was observed and the direction of Ca2+ wave propagation was reversed, initiating in the pericentral region and spreading to the periportal region. It is concluded that intercellular Ca2+ waves may provide a mechanism to coordinate responses across the functional units of the liver.	THOMAS JEFFERSON UNIV,DEPT ANAT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University			Gaspers, Lawrence/W-8766-2019; Thomas, Andrew/C-6755-2013	Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [T32-AA07463, AA07215] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; GRAF P, 1987, BIOCHEM J, V241, P933, DOI 10.1042/bj2410933; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1992, CELL CALCIUM, V13, P89, DOI 10.1016/0143-4160(92)90002-A; OSTROWSKI NL, 1993, ENDOCRINOLOGY, V133, P1849, DOI 10.1210/en.133.4.1849; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SNEYD J, 1994, AM J PHYSIOL, V266, pC293, DOI 10.1152/ajpcell.1994.266.1.C293; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; THOMAS AP, 1991, CELL CALCIUM, V12, P8111; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	23	183	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8102	8107		10.1074/jbc.270.14.8102	http://dx.doi.org/10.1074/jbc.270.14.8102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713913	hybrid			2022-12-25	WOS:A1995QR52600051
J	SWARTS, HGP; KLAASSEN, CHW; STEKHOVEN, FMAHS; DEPONT, JJHHM				SWARTS, HGP; KLAASSEN, CHW; STEKHOVEN, FMAHS; DEPONT, JJHHM			SODIUM ACTS AS A POTASSIUM ANALOG ON GASTRIC H,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(H+ + K+)-ATPASE; (NA++K+)-ACTIVATED ATPASE; BETA-SUBUNIT; PHOSPHORYLATION; IONS; (NA++K+)-ATPASE; PROTONS; K+; DEPHOSPHORYLATION; MECHANISM	The effects of Na+ on gastric H,K-ATPase were investigated using leaky and ion-tight H,K-ATPase vesicles. Na+ activated the total ATPase activity in the absence of K+, reaching levels of 15% relative to those in the presence of K+. The Na+ activation, which takes place at the luminal side of the membrane, depended on the ATP concentration and the type of buffer used. The steady-state ATP phosphorylation level, studied with leaky vesicles, was reduced by Na+ due to both activation of the dephosphorylation reaction and a shift to E(2) in the E(1)<->E(2) equilibrium. By studying this equilibrium in ion-tight H,K-ATPase vesicles, it was found that Na+ drives the enzyme via a cytosolic site to the nonphosphorylating E(2) conformation. No H+-like properties of cytosolic Na+ could be detected. We therefore conclude that Na+ behaves like K+ rather than like H+ in the H,K-ATPase reaction.	UNIV NIJMEGEN, DEPT BIOCHEM, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEJONG ML, 1986, THESIS NIJMEGEN NETH, P112; FU YF, 1985, BIOCHIM BIOPHYS ACTA, V817, P7, DOI 10.1016/0005-2736(85)90062-8; HARA Y, 1986, J BIOCHEM, V99, P531, DOI 10.1093/oxfordjournals.jbchem.a135509; HELMICHDEJONGML, 1986, BIOCHIM BIOPHYS ACTA, V860, P841; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; LEWIS SA, 1989, METHOD ENZYMOL, V171, P715; LJUNGSTROM M, 1984, BIOCHIM BIOPHYS ACTA, V769, P220, DOI 10.1016/0005-2736(84)90026-9; LJUNGSTROM M, 1979, ACTA CHEM SCAND B, V33, P618, DOI 10.3891/acta.chem.scand.33b-0618; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; POLVANI C, 1989, J BIOL CHEM, V264, P17854; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; RAY TK, 1985, FEBS LETT, V185, P24, DOI 10.1016/0014-5793(85)80733-X; REENSTRA WW, 1988, J BIOL CHEM, V263, P19618; SCHWARZ W, 1994, CELL PHYSIOL BIOCHEM, V4, P77, DOI 10.1159/000154713; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P391; STEKHOVEN FMAHS, 1986, BIOCHIM BIOPHYS ACTA, V854, P21; STEKHOVEN FMAHS, 1986, BIOCHIM BIOPHYS ACTA, V855, P375; STEWART B, 1981, J BIOL CHEM, V256, P2682; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; SWARTS HGP, 1994, BBA-BIOMEMBRANES, V1189, P143, DOI 10.1016/0005-2736(94)90059-0; VANUEM TJF, 1992, MOL ASPECTS TRANSPOR, P27; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899	28	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7890	7895		10.1074/jbc.270.14.7890	http://dx.doi.org/10.1074/jbc.270.14.7890			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713883	Green Published, hybrid			2022-12-25	WOS:A1995QR52600019
J	SCHMITZ, ML; STELZER, G; ALTMANN, H; MEISTERERNST, M; BAEUERLE, PA				SCHMITZ, ML; STELZER, G; ALTMANN, H; MEISTERERNST, M; BAEUERLE, PA			INTERACTION OF THE COOH-TERMINAL TRANSACTIVATION DOMAIN OF P65 NF-KAPPA-B WITH TATA-BINDING PROTEIN, TRANSCRIPTION FACTOR IIB, AND AND COACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DNA TOPOISOMERASE-I; RNA POLYMERASE-II; ACTIVATION DOMAIN; FACTOR-TFIIB; V-REL; C-REL; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE PRODUCT; 65-KD SUBUNIT	We show that the transactivating COOH terminus of the p65 subunit of human transcription factor NF-kappa B directly binds the general transcription factors TFIIB and TATA-binding protein (TBP) in vitro. Interaction of p65 with TFIIB required the most COOH-terminal se quence repeat within TFIIB. A functional interaction of TFIIB with p65 was evident from assays in yeast cells. Cotransfection experiments in COS cells revealed that only overexpression of TBP was able to further stimulate p65-dependent transactivation of a reporter gene. The coexpression of neither TBP nor TFIIB was able to relieve squelching, indicating the involvement of additional factors in transactivation by p65. A cell-free assay using highly purified factors revealed a specific transcriptional stimulation through the COOH terminal activation domain of NF-kappa B by at least one cofactor, PC1, isolated from HeLa cells. These data show that the potent acidic transactivation domains in the COOH terminus of p65 are able to functionally recruit various components of the basic transcription machinery as well as coactivators.	GENE CTR, MOLEC BIOL LAB, D-81675 MUNICH, GERMANY; LUDWIGS MAXIMILIANS UNIV, INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Munich; University of Munich	SCHMITZ, ML (corresponding author), UNIV FREIBURG, INST BIOCHEM, HERMANN HERDER STR 7, D-79104 FREIBURG, GERMANY.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROKER M, 1991, APPL MICROBIOL BIOT, V34, P756; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CASWELL R, 1993, J GEN VIROL, V74, P2691, DOI 10.1099/0022-1317-74-12-2691; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GRILLI M, 1993, INT REV CYTOL, V143, P1; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Manet Evelyne, 1993, Gene Expression, V3, P49; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Ransone Lynn J., 1993, Gene Expression, V3, P37; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHMITZ ML, 1994, BIOTECHNIQUES, V17, P714; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	85	142	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7219	7226		10.1074/jbc.270.13.7219	http://dx.doi.org/10.1074/jbc.270.13.7219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706261	hybrid			2022-12-25	WOS:A1995QQ43100033
J	GOODYER, P; DEHBI, M; TORBAN, E; BRUENING, W; PELLETIER, J				GOODYER, P; DEHBI, M; TORBAN, E; BRUENING, W; PELLETIER, J			REPRESSION OF THE RETINOIC ACID RECEPTOR-ALPHA GENE BY THE WILMS-TUMOR SUPPRESSOR GENE-PRODUCT, WT1	ONCOGENE			English	Article						WILMS TUMOR; RETINOIC ACID RECEPTOR; WT1; CANCER GENETICS	ACUTE PROMYELOCYTIC LEUKEMIA; FACTOR-A-CHAIN; PROMOTER ACTIVITY; GROWTH; LOCUS; TRANSCRIPTION; EXPRESSION; BINDING; INDUCTION; DELETION	The Wilms' tumor (WT) suppressor gene, WT1, encodes a zinc finger DNA binding protein (wt1) which functions as a transcriptional regulator. Germline WT1 mutations predispose to WTs and in many cases are associated with urogenital anomalies. Identification of wt1 downstream targets is essential to understanding regulatory processes involved in development of this system. In this study, we demonstrate that wt1 can repress transcription of the retinoic acid receptor-alpha 1 (RAR-alpha 1) promoter. Transient transfection, deletion mutagenesis, and mobility shift assays suggest that wt1 mediates repression of the human RAR-alpha 1 promoter through a GC-rich DNA binding motif (5'-GCGGGGGCG-3'), at positions -111 to -120 bp (relative to the transcription initiation site). In contrast, the murine RAR-alpha 1 promoter contains a cryptic binding motif and is not responsive to wt1. These results indicate that some wt1-regulatory pathways are not conserved across species, suggesting a molecular basis for differences in phenotypes between humans and mice harboring WT1 lesions.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL CHILDRENS HOSP,DEPT EXPTL MED,MONTREAL,PQ H3H 1P3,CANADA	McGill University; McGill University; McGill University								BORROW J, 1990, SCIENCE, V249, P1557; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HONG WK, 1994, RETINOIDS BIOL CHEM; KRIEDBERG JA, 1993, CELL, V74, P679; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MORIYA N, 1993, DEV GROWTH DIFFER, V35, P123; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SHENEFELT RE, 1972, TERATOLOGY, V5, P5103; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANGWUU S, 1990, CANCER RES, V50, P2786; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	34	102	110	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1125	1129						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700638				2022-12-25	WOS:A1995QN35300013
J	KRAUTWALD, S; BUSCHER, D; DENT, P; RUTHENBERG, K; BACCARINI, M				KRAUTWALD, S; BUSCHER, D; DENT, P; RUTHENBERG, K; BACCARINI, M			SUPPRESSION OF GROWTH FACTOR-MEDIATED MAP KINASE ACTIVATION BY V-RAF IN MACROPHAGES - A PUTATIVE ROLE FOR THE MKP-1 PHOSPHATASE	ONCOGENE			English	Article						V-RAF; MAP KINASES; PHOSPHATASES; MKP-1	IMMEDIATE-EARLY GENE; SIGNAL-REGULATED KINASE; MAMMALIAN SOMATIC-CELLS; PROTEIN-KINASE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; XENOPUS-OOCYTES; FACTOR P62TCF; C-MYC	Many tyrosine kinase growth factor receptors activate the MAP Kinase (MAPK) pathway by stimulating the activity of the RAF kinase. In some, but not all cell types, the expression of activated RAF is sufficient to induce constitutive MAPK activation. In BAC-1.2F5 macrophages the expression of virally activated RAF does not correlate with constitutive MAPK activation; on the contrary, growth factor-mediated stimulation of MAPK activity is suppressed in these cells. Suppression correlates with v-RAF expression, as MAPK activation is normal in a revertant cell Line that stopped expressing v-RAF. Inhibition of MAPK activation is associated,vith lack of ERK-2 tyrosine phosphorylation, and is not due to the suppression of CSF-l-mediated MEK activation. Pretreatment with vanadate restores growth factor-stimulated activation and tyrosine phosphorylation of MAPK in v-RAF-expressing macrophages, indicating the involvement of a tyrosine phosphatase. Interestingly, v-RAF-expressing macrophages contain low constitutive levels of MKP-1 mRNA, an immediate early gene that encodes a MAPK-specific phosphatase and is induced in the parental cell line by CSF-1 treatment. The restoration of MAPK activation by vanadate pretreatment and the presence of MKP-1 mRNA in V-RAF-expressing macrophages raise the intriguing possibility that in macrophages RAF may be feeding back on the MAPK pathway by participating in the control of MKP-1 expression.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,DEPT IMMUNOBIOL,D-30625 HANNOVER,GERMANY; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Fraunhofer Gesellschaft; University of Virginia; University of Virginia			Baccarini, Manuela/B-6481-2014; Krautwald, Stefan/J-9984-2016	Baccarini, Manuela/0000-0002-3033-391X; Krautwald, Stefan/0000-0001-7768-2132				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Baccarini M, 1991, Receptor, V1, P243; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUSCHER D, 1993, ONCOGENE, V8, P3323; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KEYSE SM, 1992, NATURE, V59, P644; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P56; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1187	1192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700643				2022-12-25	WOS:A1995QN35300020
J	SMITH, DF; ALBERS, MW; SCHREIBER, SL; LEACH, KL; DEIBEL, MR				SMITH, DF; ALBERS, MW; SCHREIBER, SL; LEACH, KL; DEIBEL, MR			FKBP54, A NOVEL FK506-BINDING PROTEIN IN AVIAN PROGESTERONE-RECEPTOR COMPLEXES AND HELA EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; POLYCLONAL ANTIBODY; IMMUNOPHILINS; HSP56; COMPONENT; FK506; FORM	Avian progesterone receptor complexes contain five major co-purifying proteins, including hsp90, hsp70, and a 23-kDa protein. The other receptor-associated proteins, p50 and p54, share amino acid sequence similarities with a 52-59-kDa component (p59, hsp56, or FKBP52) of mammalian steroid receptor complexes that is also a member of the FK506-binding proteins (FKBP) family of immunophilins. We show here that p50, but not p54, cross-reacts with a rabbit antiserum prepared against human FKBP52. Both p50 and p54 bind an FK506 affinity resin at 0.5 M KCl, but only p50 binds efficiently in low salt conditions. Glycerol density gradient analyses show that both p50 and p54 exist predominantly in oligomeric complexes at low ionic strength. The poor retention of p54 on FK506 resin at low ionic strength compared with the high retention of p50 suggests that these proteins may largely exist in separate complexes and may interact with other proteins, such as progesterone receptor, in distinctive manners. In HeLa cell extracts, a 55-kDa FK506-binding protein, distinct from FKBP52, cross-reacts with anti-p54 antibody FF1. We conclude that p50 is avian FKBP52, whereas p54 and the 55-kDa human FF1 antigen are FKBP54, a novel immunophilin.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UPJOHN CO,DEPT CELL BIOL & BIOCHEM,KALAMAZOO,MI 49001	Harvard University; Pfizer	SMITH, DF (corresponding author), UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44923] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; TAI PKK, 1985, CAN J BIOCHEM CELL B, V63, P41, DOI 10.1139/o85-006; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VISHWANATHA JK, 1986, J BIOL CHEM, V261, P6619; YEM AW, 1992, J BIOL CHEM, V267, P2868	22	66	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24270	24273						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693698				2022-12-25	WOS:A1993MF29400082
J	ANAND, R; WILKINSON, JM; KELLIE, S				ANAND, R; WILKINSON, JM; KELLIE, S			LOCALIZATION OF PP60(C-SRC) TO THE SURFACE-MEMBRANE OF HUMAN PLATELETS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; EXPRESS HIGH-LEVELS; INTRACELLULAR MEMBRANES; GLYCOPROTEIN-IIB; ARACHIDONIC-ACID; PHORBOL ESTERS; SRC PROTEIN; PP60C-SRC; PHOSPHORYLATION; LOCALIZATION	In platelets, pp60c-src has been variously localised to cytosol, dense bodies, or plasma membrane and surface-connected canalicular membranes. We have investigated the localisation of pp60c-src in highly purified human platelet subcellular fractions isolated using density gradient centrifugation and continuous flow electrophoresis followed by quantitative immunoblotting. We have obtained fractions enriched in surface membranes and alpha granule membranes as assessed by the presence of the marker proteins gpIb, gpIIb, thrombospondin, fibrinogen and fibronectin. Quantitative immunoblotting demonstrated that most of the cellular pp60c-src co-purified with markers for surface membrane components and that unlike the situation in fibroblasts, platelet pp60c-src did not associate with non-granule intracellular membranes such as Golgi, endoplasmic reticulum and endosomes. A small subpopulation of the total cellular pp60c-src co-purified with granule components or dense body markers, however this occurred in proportion to the presence of surface membrane markers. Our results demonstrate that the majority of platelet pp60c-src is located on the cytoplasmic face of the plasma membrane in human platelets.	LITTLEMORE HOSP,YAMANOUCHI RES INST,OXFORD OX4 4XN,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,DEPT BIOCHEM PHARMACOL,LONDON EC1,ENGLAND				Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474				AAKHUS AM, 1992, THROMB HAEMOSTASIS, V67, P252; AUTHI KS, 1985, BIOCHEM J, V230, P274; Brass L F, 1991, Prog Hemost Thromb, V10, P127; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DHAR A, 1991, J BIOL CHEM, V266, P18797; ELMORE MA, 1990, FEBS LETT, V269, P283, DOI 10.1016/0014-5793(90)81177-P; FEDER D, 1991, J BIOL CHEM, V266, P19040; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOGSTAD GO, 1981, BIOCHIM BIOPHYS ACTA, V670, P150, DOI 10.1016/0005-2795(81)90003-9; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HACK N, 1984, BIOCHEM J, V222, P235, DOI 10.1042/bj2220235; HACK N, 1986, BIOCHEM J, V233, P661, DOI 10.1042/bj2330661; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HORAK ID, 1990, ONCOGENE, V5, P597; HORNBY EJ, 1991, BRIT J HAEMATOL, V79, P277, DOI 10.1111/j.1365-2141.1991.tb04533.x; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KELLIE S, 1987, FEBS LETT, V213, P428, DOI 10.1016/0014-5793(87)81536-3; KNIGHT DE, 1980, THROMB RES, V20, P437, DOI 10.1016/0049-3848(80)90282-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENASHI S, 1981, J BIOL CHEM, V256, P4095; MURPHY CT, 1991, BIOCHIM BIOPHYS ACTA, V1133, P46, DOI 10.1016/0167-4889(91)90240-X; MURPHY CT, 1991, BIOCHEM J, V278, P255, DOI 10.1042/bj2780255; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; POLL C, 1986, BIOCHIM BIOPHYS ACTA, V886, P434, DOI 10.1016/0167-4889(86)90179-5; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RENDU F, 1989, BLOOD, V73, P1545; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	39	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3013	3020						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692371				2022-12-25	WOS:A1993MC09300015
J	COBB, BS; PARSONS, JT				COBB, BS; PARSONS, JT			REGULATION OF THE CELLULAR SRC PROTEIN-TYROSINE KINASE - INTERACTIONS OF THE CARBOXYL-TERMINAL SEQUENCES RESIDING BETWEEN THE KINASE DOMAIN AND TYROSINE-527	ONCOGENE			English	Article							SH3 DOMAINS; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEIN; STABLE ASSOCIATION; PP60C-SRC; PHOSPHORYLATION; PP60SRC; BINDING; SITES; GENE	Negative regulation of the cellular Src tyrosine kinase (pp60c-src) is mediated through the phosphorylation of a C-terminal tyrosine residue, Tyr-527. Current models predict that inhibition of c-Src kinase activity results from an interaction of phosphorylated Tyr-527 with the amino terminal SH2 domain. Tyr-527 is located 11 residues C-terminal from the end of the kinase domain. Insertion or deletion of residues within these 11 residues of pp60c-src activates kinase activity and induces morphological transformation. The resultant variant Src proteins also exhibit a reduced level of phosphorylation of Tyr-527. We have used antibodies to phosphotyrosine, susceptibility to tyrosine phosphatases and binding of mutant Src proteins to peptides mimicking the tyrosine phosphorylated C-terminus of pp60c-src to investigate the tyrosine phosphorylated and unphosphorylated forms of such insertion/deletion variants. The reactivity of variant proteins with phosphotyrosine antibodies and the susceptibility of phosphorylated Tyr-527 to tyrosine phosphatases were similar to that of wild type pp60c-src. In addition, the results of binding experiments performed with a C-terminal peptide containing phosphorylated Tyr-527 indicated that only dephosphorylated forms of variant Src proteins bound phospho-peptide. These data suggest that insertion or deletion mutations within the C-terminal region of pp60c-src do not substantially alter the interaction of phosphorylated Tyr-527 with the SH2 domain. Rather, the data are consistent with the hypothesis that the reduction of phosphorylation of Tyr-527 and the accompanying activation of these variants may be due to the action of a tyrosine phosphatase and the ineffecient phosphorylation of Tyr-527 by a regulatory kinase.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 29243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R37CA029243, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MACAULEY A, 1990, New Biologist, V2, P828; MACAULEY A, 1993, ONCOGENE, V8, P117; MCCARLEY DJ, 1987, J VIROL, V61, P1927, DOI 10.1128/JVI.61.6.1927-1937.1987; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH JL, 1983, J CLIN NEURO-OPHTHAL, V3, P3; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2897	2903						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692368				2022-12-25	WOS:A1993MC09300002
J	SCHILDBACH, JF; NEAR, RI; BRUCCOLERI, RE; HABER, E; JEFFREY, PD; NG, SC; NOVOTNY, J; SHERIFF, S; MARGOLIES, MN				SCHILDBACH, JF; NEAR, RI; BRUCCOLERI, RE; HABER, E; JEFFREY, PD; NG, SC; NOVOTNY, J; SHERIFF, S; MARGOLIES, MN			HEAVY-CHAIN POSITION-50 IS A DETERMINANT OF AFFINITY AND SPECIFICITY FOR THE ANTIDIGOXIN ANTIBODY-26-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SOMATIC MUTATION; BINDING; ENERGY; ANTIBODIES; PROTEINS; DIVERSITY; COMPLEXES	Antibody produced by a variant of the murine anti-digoxin hybridoma 26-10 has reduced afrinity for digoxin but enhanced recognition of the digoxin 12-hydroxyl due to a Tyr to His substitution at heavy chain position 50 (Schildbach, J. F., Panka, D. J., Parks, D. R., Jager, G. C., Novotny, J., Herzenberg, L. A., Mudgett-Hunter, M., Bruccoleri, R. E., Haber, E., and Margolies, M. N. (1991) J. Biol. Chem. 266, 4640-4647). Consistent with these data, the 26-10 Fab-digoxin x-ray crystal structure (Jeffrey, P. D., Strong, R. K., Sieker, L. C., Chang, C. Y., Campbell, R. L., Petsko, G. A., Haber, E., Margolies, M. N., and Sheriff, S. (1993) Proc. Natl. Acad. Sci. U. S. A., in press) reveals that Tyr-50 contacts a region of digoxin that includes the hapten- 12 carbon. To determine the effects of other heavy chain position 50 substitutions, mutant antibodies were engineered, and their affinities for digoxin and digoxin analogues were measured. The affinity of the mutant antibodies for digoxin roughly correlates with the size of the position 50 side chain. Substitutions of Trp or Phe have no effect on affinity, whereas substitutions of Asn, His, Leu, Ala, Gly, and Asp confer progressively lower affinities. Although Trp and Phe mutants exhibit wild-type specificity, Asn and Asp mutants have improved affinity for digoxin relative to digitoxin (12-deshydroxydigoxin). Leu, Ala, and Gly mutants have improved affinity for 12-acetyldigoxin relative to digoxin as compared with 26-10. These results indicate that position 50 is a determinant of both antibody affinity and fine specificity for antibody 26-10 and that single-amino acid substitutions can alter antibody fine specificity. Models of the mutants were computationally constructed, and haptens were docked into the modeled binding sites. The results suggest that 12-acetyldigoxigenin occupies different orientations in the 26-10 and in the Ala mutant binding sites, resulting in altered binding.	MASSACHUSETTS GEN HOSP,DEPT MED,JACKSON 1402,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114; HARVARD UNIV,GRAD SCH ARTS & SCI,PROGRAM IMMUNOL,CAMBRIDGE,MA 02138; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,PRINCETON,NJ 08543; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOL SCI,CARDIOVASC BIOL LAB,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Bristol-Myers Squibb; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health				Schildbach, Joel/0000-0002-3038-9745; Jeffrey, Philip/0000-0002-4351-5341; Near, Richard/0000-0003-3307-9619	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415, P01HL019259] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL47415, P01-HL19259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; FULLERTON DS, 1980, MOL PHARMACOL, V17, P43; GILARDI RD, 1973, ACTA CRYSTALLOGR B, V29, P1842, DOI 10.1107/S0567740873005625; GILARDI RD, 1970, ACTA CRYSTALL B-STRU, VB 26, P207, DOI 10.1107/S0567740870002169; GLOCKSHUBER R, 1991, BIOCHEMISTRY-US, V30, P3049, DOI 10.1021/bi00226a010; GO K, 1981, CRYST STRUCT COMMUN, V10, P1329; GO K, 1980, ACTA CRYSTALLOGR B, V36, P1811, DOI 10.1107/S0567740880007297; GO K, 1989, ACTA CRYSTALLOGR B, V45, P306, DOI 10.1107/S0108768189001734; GO K, 1982, CRYST STRUCT COMMUN, V11, P279; GO K, 1982, CRYST STRUCT COMMUN, V11, P285; GO K, 1984, ACTA CRYSTALLOGR C, V40, P1866, DOI 10.1107/S0108270184009860; GO K, 1980, ACTA CRYSTALLOGR B, V36, P3034, DOI 10.1107/S0567740880010746; HORTON N, 1992, PROTEIN SCI, V1, P169; JEFFREY PD, 1993, IN PRESS P NATL ACAD; Kabat EA, 1991, SEQUENCES PROTEINS I; KARLE IL, 1969, ACTA CRYSTALLOGR C, V40, P1866; KARTHA G, 1981, CRYST STRUCT COMMUN, V10, P1323; Landsteiner K, 1929, J EXP MED, V50, P407, DOI 10.1084/jem.50.4.407; Landsteiner K, 1928, J EXP MED, V48, P315, DOI 10.1084/jem.48.3.315; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MESSERSCHMIDT A, 1980, CRYST STRUCT COMMUN, V9, P1185; MOSTAD A, 1982, ACTA CHEM SCAND B, V36, P635, DOI 10.3891/acta.chem.scand.36b-0635; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NEAR RI, 1990, MOL IMMUNOL, V27, P901, DOI 10.1016/0161-5890(90)90157-U; NEAR RI, 1991, J IMMUNOL, V146, P627; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PRASAD L, 1983, ACTA CRYSTALLOGR C, V39, P273, DOI 10.1107/S0108270183004370; PRZYBYLSKA M, 1979, ACTA CRYSTALLOGR B, V35, P2436, DOI 10.1107/S0567740879009572; RIECHMANN L, 1992, J MOL BIOL, V224, P913, DOI 10.1016/0022-2836(92)90459-W; ROBERTS S, 1987, NATURE, V328, P731, DOI 10.1038/328731a0; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; WILLIAMS DE, 1988, J COMPUT CHEM, V9, P745, DOI 10.1002/jcc.540090705	50	34	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21739	21747						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691815				2022-12-25	WOS:A1993MC80900050
J	VUORI, K; RUOSLAHTI, E				VUORI, K; RUOSLAHTI, E			ACTIVATION OF PROTEIN-KINASE-C PRECEDES ALPHA(5)BETA(1) INTEGRIN-MEDIATED CELL SPREADING ON FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE; EXTRACELLULAR-MATRIX; EMBRYO FIBROBLASTS; FOCAL ADHESIONS; CALPHOSTIN-C; PHOSPHORYLATION; MODULATION; PP125(FAK); RECEPTOR	Increasing evidence indicates that the integrin family of cell adhesion receptors can transduce biochemical signals from the extracellular matrix to the cell interior to modulate cell behavior. We have investigated the role of protein kinase C in alpha5beta1 integrin-mediated signal transduction in Chinese hamster ovary cells. Up-regulation of protein kinase C activity by phorbol esters was found to enhance cell adhesion, spreading, and migration on a fibronectin substrate, without affecting the cell surface expression or fibronectin binding of the alpha5beta1 integrin, whereas inhibition of protein kinase C activity by calphostin C inhibited these functions as well in unstimulated cells. In addition, we observed that protein kinase C activity in the cell membrane fraction transiently increases preceding cell spreading on fibronectin, but not on polylysine, additionally implying a specific role of protein kinase C in alpha5beta1 integrin-mediated spreading on fibronectin. Experiments with phorbol esters and calphostin C also suggested that protein kinase C activity is required for enhanced phosphorylation of the focal adhesion kinase, pp125fak, in cells plated on fibronectin. Protein kinase C-alpha was not, however, found to directly act on pp125fak, suggesting that other mechanisms are involved in this phenomenon.	LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA 28896, CA 42507, CA 30199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R35CA042507, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHUN JS, 1993, MOL BIOL CELL, V4, P271; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P660; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hay E. D., 1981, CELL BIOL EXTRACELLU; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SINGER II, 1988, J CELL BIOL, V106, P2171, DOI 10.1083/jcb.106.6.2171; TAPLEY P, 1989, ONCOGENE, V4, P325; WOODS A, 1992, J CELL SCI, V101, P277; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	34	347	348	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21459	21462						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691809				2022-12-25	WOS:A1993MC80900002
J	UCKUN, FM; BURKHARDT, AL; JARVIS, L; JUN, X; STEALEY, B; DIBIRDIK, I; MYERS, DE; TUELAHLGREN, L; BOLEN, JB				UCKUN, FM; BURKHARDT, AL; JARVIS, L; JUN, X; STEALEY, B; DIBIRDIK, I; MYERS, DE; TUELAHLGREN, L; BOLEN, JB			SIGNAL-TRANSDUCTION THROUGH THE CD19 RECEPTOR DURING DISCRETE DEVELOPMENTAL STAGES OF HUMAN B-CELL ONTOGENY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN-TYROSINE KINASES; POKEWEED ANTIVIRAL PROTEIN; MOUSE LYMPHOCYTES-B; ANTIGEN RECEPTOR; SRC FAMILY; MEMBRANE IMMUNOGLOBULIN; DIFFERENTIATION ANTIGEN; MONOCLONAL-ANTIBODY; DEPENDENT PATHWAY	We present evidence that the CD19 receptor is functionally operative and transmits pleiotropic signals throughout the pro-B, pre-pre-B, pre-B, early B, and mature B cell stages of human B-cell ontogeny. The signaling ability of CD19 does not depend on the existence of a functional B-cell antigen receptor complex (ARC). In B-cell precursors (BCP) lacking a functional ARC, CD19 is physically and functionally associated with Src family protein tyrosine kinases (PTK). The engagement of the CD19 receptor on BCP with a high affinity anti-CD19 monoclonal antibody (mAb) or its homoconjugate rapidly activates the associated PTK and results in tyrosine phosphorylation of CD19. Moreover, this proximal PTK activation step triggers downstream stimulation of several different intracellular messenger systems. Remarkably, CD19 becomes rapidly phosphorylated on tyrosine residues upon engagement of several other surface receptors as well, suggesting that it may function as a common response element linked via tyrosine phosphorylation to multiple BCP/B-cell receptors and signaling pathways. Furthermore, in all B-lineage lymphoid cell populations, co-approximation of the receptors CD19 and CD72 (ligand for the CD5 T-cell receptor) generates a stronger signal than the engagement of either individual receptor. These convergent observations constitute a strong argument for an important regulatory function of CD19 in human BCP and prompt the hypothesis that the CD19 receptor may play an important role in cognate interactions between B- and T-lineage lymphoid compartments as well as the coordinate production of BCP at multiple stages of human B-cell ontogeny.	UNIV MINNESOTA,HLTH SCI CTR,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,HLTH SCI CTR,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,HLTH SCI CTR,BONE MARROW TRANSPLANT PROGRAM,MINNEAPOLIS,MN 55455; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MOLEC BIOL,SIGNAL TRANSDUCT LAB,PRINCETON,NJ 08543	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb	UCKUN, FM (corresponding author), UNIV MINNESOTA,HLTH SCI CTR,DEPT THERAPEUT RADIOL RADIAT ONCOL,TUMOR IMMUNOL LAB,MINNEAPOLIS,MN 55455, USA.			Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [R01-CA-51425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON PM, 1992, BLOOD, V80, P2826; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADBURY L, 1991, FASEB J, V5, P611; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GROSSMAN Z, 1992, P NATL ACAD SCI USA, V89, P10365, DOI 10.1073/pnas.89.21.10365; KAMAL M, 1991, EUR J IMMUNOL, V21, P1419, DOI 10.1002/eji.1830210614; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; LIN JJ, 1992, J IMMUNOL, V149, P1548; LUO W, 1992, J IMMUNOL, V148, P1630; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MYERS DE, 1991, J IMMUNOL METHODS, V136, P221, DOI 10.1016/0022-1759(91)90009-5; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; RIJKERS GT, 1990, P NATL ACAD SCI USA, V87, P8766, DOI 10.1073/pnas.87.22.8766; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TEDDER TF, 1989, J IMMUNOL, V143, P712; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1989, BLOOD, V73, P1000; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1992, BLOOD, V79, P3369; UCKUN FM, 1990, BLOOD, V76, P2449; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VAN DE VELDE H, 1991, NATURE, V351, P662; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519	42	104	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21172	21184						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691807				2022-12-25	WOS:A1993MA28800079
J	OLAH, TV; PERRAULT, AR; COOPERMAN, BS; MONTESANORODITIS, L; MCWILLIAMS, R; GLITZ, DG				OLAH, TV; PERRAULT, AR; COOPERMAN, BS; MONTESANORODITIS, L; MCWILLIAMS, R; GLITZ, DG			INCORPORATION OF DINITROPHENYL DERIVATIVES OF PROTEIN-S6, PROTEIN-S13, PROTEIN-S16, AND PROTEIN-S18 INTO THE 30-S SUBUNIT OF ESCHERICHIA-COLI RIBOSOMES BY TOTAL RECONSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION; ANTIBODY; LOCATION; BINDING; MICROSCOPY; OMISSION	This is the third paper in a series (Olah, T. V., Olson, H. M., Glitz, D. G., and Cooperman, B. S. (1988) J. Biol. Chem. 263, 4795-4800; Olson, H. M., Olah, T., Cooperman, B. S., and Glitz, D. G. (1988) J. Biol. Chem. 263, 4801-4806) describing the use of 2,4-dinitrophenyl (DNP) derivatives of Escherichia coli 30 S ribosomal proteins to locate the positions of these proteins within the 30 S subunit by immune electron microscopy. In it we describe the derivatization of proteins S6, S13, S16, and S18 with [H-3]2,4-dinitrofluorobenzene, identify the nature of the derivatized amino acids within each protein, and demonstrate that each DNP protein, denoted DNP-Sx, can be taken up into a reconstituted 30 S subunit when added to a reconstitution mixture containing 16 S rRNA and total 30 S protein depleted in Sx. We further demonstrate that each DNP-Sx binds within the 30 S subunit in a position identical or similar to that of the unmodified Sx protein, as judged by its meeting one or more of the following three criteria: (i) unmodified Sx competes with the uptake of DNP-Sx into 30 S subunits; (ii) DNP-Sx restores functional activity to those single protein omission reconstitution particles lacking full activity; (iii) DNP-Sx induces the uptake of proteins into 30 S subunits that depend on the presence of Sx. The fourth paper in this series (Montesano-Roditis, L., McWilliams, R., Glitz, D. G., Olah, T. V., Perrault, A. R., and Cooperman, B. S. (1993) J. Biol. Chem. 268, 18701-18709), which follows this one, describes the localization of the DNP-Sx proteins within the 30 S subunit by immune electron microscopy.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Pennsylvania; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032769] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32769] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMANN U, 1990, BIOCHEM INT, V21, P741; BUCK MA, 1990, BIOCHEMISTRY-US, V29, P5374, DOI 10.1021/bi00474a024; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; BUCK MA, 1991, BIOCHIMIE, V73, P769, DOI 10.1016/0300-9084(91)90056-7; CAPEL MS, 1988, J MOL BIOL, V200, P65, DOI 10.1016/0022-2836(88)90334-8; GHRIST BFD, 1990, HPLC BIOL MACROMOLEC, P403; GINZBURG I, 1973, J MOL BIOL, V79, P481, DOI 10.1016/0022-2836(73)90400-2; GOLDMAN RA, 1980, FEBS LETT, V118, P113, DOI 10.1016/0014-5793(80)81230-0; GRANT PG, 1983, J BIOL CHEM, V258, P1305; HELD WA, 1974, J BIOL CHEM, V249, P3103; KERLAVAGE AR, 1986, BIOCHEMISTRY-US, V25, P8002, DOI 10.1021/bi00372a032; KOJOUHAROVA MS, 1988, DOKL BOLG AKAD NAUK, V41, P109; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MONTESANORODITIS L, 1993, J BIOL CHEM, V268, P18701; NAG B, 1991, J BIOL CHEM, V266, P11116; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OLAH TV, 1988, J BIOL CHEM, V263, P4795; OLSON HM, 1988, J BIOL CHEM, V263, P4801; PORTER RR, 1948, BIOCHEM J, V63, P282; SANGER F, 1945, BIOCHEM J, V39, P507, DOI 10.1042/bj0390507; SHALTIEL S, 1967, BIOCHEM BIOPH RES CO, V29, P178, DOI 10.1016/0006-291X(67)90583-9; STOFFLERMEILICKE M, 1984, MOL GEN GENET, V197, P8, DOI 10.1007/BF00327916; STOFFLERMEILICKE M, 1983, FEBS LETT, V163, P94, DOI 10.1016/0014-5793(83)81171-5; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; SUBRAMANIAN AR, 1980, J BIOL CHEM, V255, P6941; Traub P, 1971, METHOD ENZYMOL, V20, P391; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; YAGUCHI M, 1976, FEBS LETT, V59, P217	29	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18696	18700						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689558				2022-12-25	WOS:A1993LV65900053
J	ARNI, S; SENALDI, G; POINCELET, M; HOESSLI, DC				ARNI, S; SENALDI, G; POINCELET, M; HOESSLI, DC			SELECTIVE ASSOCIATION OF THE P59(FYN) TYROSINE KINASE WITH MURINE T-LYMPHOMA MEMBRANE PHOSPHOPROTEINS	ONCOGENE			English	Article							CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; PROTEIN-KINASE; SRC-FAMILY; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; HUMAN-LYMPHOCYTES; MICE LACKING; PHOSPHORYLATION; PHOSPHOTYROSINE	The p59fyn oncogene product, a tyrosine kinase of the src family, is a key enzyme in T-lymphocyte transmembrane signalling that is not known to bind with high stoichiometry to any surface receptor protein. By contrast, the p56lck, another important T-cell tyrosine kinase, is directly linked to CD4 or CD8 surface glycoproteins with high stoichiometry. To document the mode of p59fyn interaction with proteins of the plasma membrane, proteins co-precipitating with the kinase in extracts of purified membranes were phosphorylated in vitro. resolved by two-dimensional electrophoresis and compared with those co-precipitating with the p56lck kinase. The p59fyn, but not the p56lck kinase, associates with three phosphotvrosyl-proteins among which a 95- to 100-kDa component also binds to the src-homology 2 (SH2) domain of the v-crk oncoprotein. This p95-100 phosphoprotein is not the p95Vav product of the Vav proto-oncogene; it is recovered much more effectively from P-32i-metabolically labelled cells after treatment with the tyrosine phosphatase inhibitor phenylarsenoxide, suggesting that its phosphorylation state is controlled by tyrosine phosphatases. The p59fyn may be integrated into the plasma membrane by specific phosphotyrosylproteins and so differ from the p56lck tyrosine kinase, which binds preferentially to the CD4 and CD8 transmembrane adhesion glycoproteins.	CTR MED UNIV GENEVA,FAC MED,DEPT PATHOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva				Arni, Stephan/0000-0001-5497-8256				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HOESSLI DC, 1990, EUR J IMMUNOL, V20, P1497, DOI 10.1002/eji.1830200714; HOESSLI DC, 1983, P NATL ACAD SCI USA, V83, P439; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	44	11	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2485	2491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689723				2022-12-25	WOS:A1993LT36800020
J	ITOH, N; JOBO, K; TSUJIMOTO, K; OHTA, M; KAWASAKI, T				ITOH, N; JOBO, K; TSUJIMOTO, K; OHTA, M; KAWASAKI, T			2 TRUNCATED FORMS OF RAT INSULIN RECEPTOR-RELATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTORS; SECRETED FORM; EXPRESSION; BINDING; CLONING; TISSUE; PROTEINS; LIGAND; FAMILY	The insulin receptor-related receptor (IRR) (1271 amino acids) is expected to have unique functions as a novel member of the insulin receptor family. In this paper, we report two alternatively spliced variants of rat IRR mRNA, which are predicted to encode two truncated forms of IRR, sIRR-1 (410 amino acids) and sIRR-2 (469 amino acids). The amino acid sequence of sIRR-1 is identical to the N-terminal 410-amino acid sequence of IRR. sIRR-2 has an additional 59-amino acid insertion in the C-terminal region. Both truncated forms retain the N-terminal and cysteine-rich domains but lack the transmembrane and intracellular tyrosine kinase domains, indicating that the truncated forms are the secreted forms. The translation products of the truncated form mRNAs were detected in the stomach and kidney by Western analysis. However, the physiological significance of the secreted forms remains to be elucidated.	UTANO NATL HOSP,CLIN RES CTR,KYOTO 616,JAPAN		ITOH, N (corresponding author), KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,KYOTO 60601,JAPAN.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS LG, 1986, METHOD MOL BIOL, P47; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KURACHI H, 1992, BIOCHEM BIOPH RES CO, V187, P934, DOI 10.1016/0006-291X(92)91287-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PEZZINO V, 1992, J CLIN ENDOCR METAB, V74, P1116, DOI 10.1210/jc.74.5.1116; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1989, J BIOL CHEM, V264, P14605; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5408; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG B, 1992, J BIOL CHEM, V267, P18320	22	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17983	17986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688734				2022-12-25	WOS:A1993LT74300053
J	ISBERG, RR; YANG, YX; VOORHIS, DL				ISBERG, RR; YANG, YX; VOORHIS, DL			RESIDUES ADDED TO THE CARBOXYL-TERMINUS OF THE YERSINIA-PSEUDOTUBERCULOSIS INVASIN PROTEIN INTERFERE WITH RECOGNITION BY INTEGRIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MAMMALIAN-CELLS; ALKALINE-PHOSPHATASE; POLYACRYLAMIDE GELS; BINDING DOMAIN; IDENTIFICATION; ADHESION; PATHOGENICITY; SEQUENCE; FUSIONS; FAMILY	Escherichia coli strains encoding the Yersinia pseudotuberculosis invasin protein are efficiently internalized by mammalian cells. Bacterial uptake into cultured cell lines became defective, however, if invasin was altered by fusion of its carboxyl terminus to E. coli alkaline phosphatase or by the addition of two hydrophobic amino acids to its carboxyl-terminal end. Probing with anti-invasin monoclonal antibodies revealed that the amino-terminal end of invasin was properly localized on the bacterial cell surface in strains encoding invasin with 2 additional amino acids, whereas the carboxyl terminus was not accessible to the monoclonal antibody. Therefore, the 2 additional amino acids interfered with the folding or orientation of the carboxyl terminus in the outer membrane. Alkylation experiments in the absence of reduction indicated that this defect was not caused by a gross inability to form a critical disulfide bond. Revertants were selected from a strain encoding this mutant protein by enriching for organisms able to enter cultured mammalian cells. The vast majority of revertants that were isolated following this enrichment contained a stop codon at the usual position found in the wild type inv gene. The most efficient of the remaining revertants resulted in the introduction of a glycine residue at the site of the wild type stop codon, presumably restoring proper conformation of the carboxyl-terminal region.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University	ISBERG, RR (corresponding author), TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI23538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER PB, 1975, INFECT IMMUN, V11, P164, DOI 10.1128/IAI.11.1.164-170.1975; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FALKOW S, 1987, REV INFECT DIS, V9, pS450; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GUAN C, 1988, GENE, V67, P21; HAYMAN EG, 1982, J CELL BIOL, V95, P20, DOI 10.1083/jcb.95.1.20; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; ROSS L, 1992, J BIOL CHEM, V267, P8537; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1991, CELL, V88, P2815; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TAKEUCHI A, 1965, AM J PATHOL, V47, P1011; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOORHIS DL, 1991, MOL MICROBIOL, V5, P317, DOI 10.1111/j.1365-2958.1991.tb02112.x	41	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15840	15846						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687999				2022-12-25	WOS:A1993LN30500075
J	KAKU, H; MORI, Y; GOLDSTEIN, IJ; SHIBUYA, N				KAKU, H; MORI, Y; GOLDSTEIN, IJ; SHIBUYA, N			MONOMERIC, MONOVALENT DERIVATIVE OF MAACKIA-AMURENSIS LEUKOAGGLUTININ - PREPARATION AND APPLICATION TO THE STUDY OF CELL-SURFACE GLYCOCONJUGATES BY FLOW-CYTOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING-SPECIFICITY; TERMINAL SIALIC-ACID; L BARK LECTIN; CONCANAVALIN-A; MONO-VALENT; LINKED OLIGOSACCHARIDES; EXPRESSION; ALPHA-2,3; RESIDUES; SEQUENCE	A stable subunit of Maackia amurensis leukoagglutinin (MMAL) was prepared by the selective reduction of disulfide bridges between the subunits followed by alkylation with 4-vinylpyridine. MMAL failed to precipitate fetuin, whereas it retained its ability to bind to the same glycoprotein coated on a plastic plate, indicating the monovalency of this derivative. This binding to immobilized fetuin was inhibited by a haptenic sugar, Neu5Acalpha2-3lactose, with the same inhibitory potency as against the native M. amurensis leukoagglutinin. Microscopic observation as well as flow cytometric analyses showed that Chinese hamster ovary cells were clearly stained with fluorescein isothiocyanate-labeled MMAL without any detectable agglutination. This staining was inhibited by the addition of fetuin or by the sugar chains of fetuin. Differences in the types of sialylated glycoconjugates on the cell surface of several cell lines were detected by the combined use of fluorescein isothiocyanate-labeled MMAL and the monomeric derivative of elderberry bark lectin (specific for the Neu5Acalpha2-6Gal/GalNAc sequence) by flow cytometry. These results demonstrate the usefulness of these monovalent derivatives of sialylated oligosaccharide-specific lectins as probes for the analysis of cell surface glycoconjugates containing sialic acid by the technique of flow cytometry.	NATL INST ANIM HLTH, DEPT BIOL PROD, TSUKUBA 305, JAPAN; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; University of Michigan System; University of Michigan	KAKU, H (corresponding author), NATL INST AGROBIOL RESOURCES, DEPT CELL BIOL, TSUKUBA 305, JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEPPU M, 1979, J BIOCHEM-TOKYO, V85, P1275; CHAVIN SI, 1984, J BIOL CHEM, V259, P3387; FRASER AR, 1976, P NATL ACAD SCI USA, V73, P790, DOI 10.1073/pnas.73.3.790; ISHII S, 1984, J PROTEIN CHEM, V3, P63, DOI 10.1007/BF01024837; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; KAKU H, 1992, FEBS LETT, V306, P176, DOI 10.1016/0014-5793(92)80994-R; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; KAWAGUCHI T, 1974, J BIOL CHEM, V249, P2786; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KUROKAWA T, 1976, J BIOL CHEM, V251, P5686; LEE EU, 1989, J BIOL CHEM, V264, P13848; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCOY JP, 1986, CYTOMETRY, V7, P142, DOI 10.1002/cyto.990070204; ROLLINGHOFF M, 1973, P SOC EXP BIOL MED, V144, P813; SATA T, 1989, J HISTOCHEM CYTOCHEM, V37, P1577, DOI 10.1177/37.11.2478613; SATA T, 1991, AM J PATHOL, V139, P1435; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUYA H, 1982, J BIOCHEM-TOKYO, V92, P1251, DOI 10.1093/oxfordjournals.jbchem.a134043; TANAKA I, 1981, J BIOCHEM-TOKYO, V89, P1643, DOI 10.1093/oxfordjournals.jbchem.a133360; TARR J, 1986, METHODS PROTEIN MICR, P155; WANG JL, 1978, J BIOL CHEM, V253, P3000; WANG WC, 1988, J BIOL CHEM, V263, P4576	26	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13237	13241						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685757				2022-12-25	WOS:A1993LH55300034
J	LEE, CG; ZAMORE, PD; GREEN, MR; HURWITZ, J				LEE, CG; ZAMORE, PD; GREEN, MR; HURWITZ, J			RNA ANNEALING ACTIVITY IS INTRINSICALLY ASSOCIATED WITH U2AF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; SPLICING FACTOR; BIOCHEMICAL-CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; BINDING PROTEINS; NUCLEAR EXTRACTS; AUXILIARY FACTOR; HELA-CELLS; GENE	U2AF is a protein that is essential for the formation of the prespliceosome complex during pre-mRNA splicing. It contains two subunits, 65 and 35 kDa, although only the 65-kDa subunit has been shown to be essential for its splicing activity. Here, we show that the 65-kDa subunit mediates the annealing of complementary single-stranded RNAs or single-stranded DNAs. This activity was shown to reverse the action of RNA helicase A, an enzyme that catalyzes the displacement of duplex RNAs. The NH2-terminal region of the 65-kDa subunit of U2AF, containing arginine-serine (RS) dipeptides and basic amino acid sequences, was shown to be essential for the annealing of complementary sequences, RNA binding, and the inhibition of RNA helicase A activity. Thus, through the combined action of U2AF and RNA helicases, duplex RNA regions can be reversibly formed and displaced. Such reactions appear to be critical for pre-mRNA splicing, translation, and transcription.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	LEE, CG (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LEE CG, 1992, J BIOL CHEM, V267, P4398; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERIC C, 1986, J VIROL, V60, P450; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	31	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13472	13478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685763				2022-12-25	WOS:A1993LH55300065
J	WOHRL, BM; EHRESMANN, B; KEITH, G; LEGRICE, SFJ				WOHRL, BM; EHRESMANN, B; KEITH, G; LEGRICE, SFJ			NUCLEASE FOOTPRINTING OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE TRANSFER RNA(LYS-3) COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; PHENYLALANINE TRANSFER-RNA; METAL CHELATE ADSORBENT; AVIAN-SARCOMA VIRUS; PRIMER TRANSFER-RNA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENOMIC RNA; INITIATION; SYNTHETASE	Nuclease footprinting has been used to probe features of binary complexes of type 1 human immunodeficiency virus reverse transcriptase (HIV-1 RT) with both natural and synthetic preparations of its cognate replication primer, tRNA(Lys-3). In addition to heterodimeric RT (p66/p51), ribonucleoprotein complexes containing either the p66 or p51 subunit were analyzed. Footprinting experiments employed both structure- and sequence-specific nucleases. Our results indicate a similar mode of interaction for the three RT preparations tested, suggesting contact with each loop of the tRNA primer (D, anticodon, and TPSIC), as well as minor perturbation of the anticodon stem. Although there is little evidence for extensive disruption of the 3'-acceptor stem, RNase A footprinting data with natural and synthetic tRNA suggests that potential base pairing between the TPSIC and D loops is disrupted in the presence of RT.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9002, F-67084 STRASBOURG, FRANCE	Case Western Reserve University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg					NIAID NIH HHS [AI 31147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; BURTON AS, 1982, EUR J BIOCHEM, V121, P587; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; GERWIN BI, 1977, J VIROL, V24, P478, DOI 10.1128/JVI.24.2.478-488.1977; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HARADA F, 1975, J BIOL CHEM, V250, P3487; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; KHAN R, 1992, J BIOL CHEM, V267, P6689; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LEVIN JG, 1979, J VIROL, V29, P328, DOI 10.1128/JVI.29.1.328-335.1979; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER WEG, 1991, BIOCHEMISTRY-US, V30, P2027, DOI 10.1021/bi00222a004; PARK SJ, 1988, J BIOL CHEM, V263, P16527; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PETERS G, 1979, J VIROL, V31, P398, DOI 10.1128/JVI.31.2.398-407.1979; PETERS GG, 1980, J VIROL, V36, P692, DOI 10.1128/JVI.36.3.692-700.1980; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SAMPSON JR, 1989, SCIENCE, V243, P1363; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; TAYLOR JM, 1975, J VIROL, V16, P553, DOI 10.1128/JVI.16.3.553-558.1975; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VASSILENKO SK, 1975, BIOKHIMIYA, V40, P796; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEISS S, 1992, GENE, V111, P183, DOI 10.1016/0378-1119(92)90686-J; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0	44	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13617	13624						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685766				2022-12-25	WOS:A1993LH55300085
J	SHEN, QC; CHU, FF; NEWBURGER, PE				SHEN, QC; CHU, FF; NEWBURGER, PE			SEQUENCES IN THE 3'-UNTRANSLATED REGION OF THE HUMAN CELLULAR GLUTATHIONE-PEROXIDASE GENE ARE NECESSARY AND SUFFICIENT FOR SELENOCYSTEINE INCORPORATION AT THE UGA CODON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; ESCHERICHIA-COLI; ACTIVE-SITE; EXPRESSION; SELENIUM; CDNA; CELLS; IDENTIFICATION; DEIODINASE	Glutathione peroxidase (EC 1.11.1.9) is one of a unique group of prokaryotic and eukaryotic enzymes that contain the unusual amino acid selenocysteine. The genes for these selenoproteins encode for the atypical amino acid at a TGA codon (UGA in the mRNA transcripts), which normally functions as a termination signal. The present studies analyzed the functional importance of sequences in the coding and 3'-untranslated regions of transcripts of the primary human cellular glutathione peroxidase gene (GPX1) to the insertion of selenocysteine at this UGA codon. Deletions in potential stem-loop or hairpin structures in the coding region did not substantially diminish incorporation of selenocysteine into glutathione peroxidase transiently expressed by the pCMV4 vector in COS-1 cells. However, selenocysteine insertion was completely abolished by deletion of four-nucleotide sequences in the 3'-untranslated region from within a conserved ''selenocysteine insertion sequence'' motif also found in the 3'-untranslated region of mammalian genes for other selenoproteins. Moreover, in constructs fusing the glutathione peroxidase 3'-untranslated region to the coding region of rab5b (an unrelated protein normally without any selenium moiety), the glutathione peroxidase 3'-untranslated region was sufficient to direct the translation of an opal (UGA) mutation as selenocysteine. Thus, our data directly demonstrate the importance of the selenocysteine insertion motif in the glutathione peroxidase gene and specifically show that sequence elements in the 3'-untranslated region are both necessary and sufficient for translational insertion of selenocysteine at a UGA codon in eukaryotic mRNA.	UNIV MASSACHUSETTS,SCH MED,DEPT PEDIAT,S5-859,WORCESTER,MA 01655; CITY HOPE NATL MED CTR,DEPT MED ONCOL & THERAPEUT RES,DUARTE,CA 91010	University of Massachusetts System; University of Massachusetts Worcester; City of Hope				Newburger, Peter/0000-0002-8615-673X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041625] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASHI M, 1991, BLOOD, V78, P2005; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHADA S, 1989, BLOOD, V74, P2535; CHADA S, 1988, OXYRADICALS MOL BIOL, P273; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HATFIELD D, 1985, TRENDS BIOCHEM SCI, V10, P201, DOI 10.1016/0968-0004(85)90192-6; HAWKES WC, 1982, BIOCHIM BIOPHYS ACTA, V699, P183, DOI 10.1016/0167-4781(82)90106-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; LEE BJ, 1989, J BIOL CHEM, V264, P9724; MANIATIS T, 1990, MOL CLONING; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; READ R, 1990, J BIOL CHEM, V265, P17899; ROCHER C, 1991, GENE, V98, P193, DOI 10.1016/0378-1119(91)90173-9; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; TAKAHASHI K, 1986, BLOOD, V68, P640; WILSON DB, 1992, J CLIN INVEST, V89, P996, DOI 10.1172/JCI115683; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	29	109	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11463	11469						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684384				2022-12-25	WOS:A1993LD46600107
J	JIANG, WP; SADLER, PM; JENKINS, NA; GILBERT, DJ; COPELAND, NG; BOND, JS				JIANG, WP; SADLER, PM; JENKINS, NA; GILBERT, DJ; COPELAND, NG; BOND, JS			TISSUE-SPECIFIC EXPRESSION AND CHROMOSOMAL LOCALIZATION OF THE ALPHA-SUBUNIT OF MOUSE MEPRIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOHISTOCHEMICAL LOCALIZATION; KIDNEY; GENE; METALLOENDOPEPTIDASES; EXTRACTION; MEMBRANE; MEP-1; MICE; RAT; DNA	Meprins, membrane-bound oligomeric metalloendopeptidases, contain alpha and/or beta subunits. Their activities have been found in the mouse and rat kidney. The cloned cDNA for the mouse alpha subunit of meprin A (EC 3.4.24.18) was used here to survey mRNA expression in kidney of different mouse strains and in various tissues of mice and rats. A single message of 3.6 kilobases was found in kidney of random bred (ICR) and inbred mice (C57BL/6, DBA/2) that contain high meprin A activity and in Sprague-Dawley rat kidney. The alpha subunit message was undetectable in the kidney of C3H/He and CBA mice, inbred strains that do not express meprin A activity. Therefore, meprin A activity in the kidney of mouse strains correlates with the amount of alpha subunit mRNA present. The 3.6-kilobase mRNA meprin alpha subunit message was also detected in the small intestine of the rat but not in mice. No message was detected in brain, heart, skeletal muscle, liver, lung, or spleen of mice or rats. Polymerase chain reaction amplification or Southern blot analysis of genomic DNA revealed that the gene for the alpha subunit is present in all mouse strains as well as in human, monkey, rat, mouse, dog, cow, rabbit, and chicken, but it was not detected in yeast. There is one gene copy present in the mouse genome. The gene was localized to mouse chromosome 17 centromeric to the major histocompatibility complex (H-2) by the interspecific backcrossing method. The localization of this allele to Mep-1, the gene previously found to regulate the expression of meprin A activity in mice, supports the proposal that Mep-1 is the structural gene for the alpha subunit.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LABS INC,MAMALIAN GENET LAB,FREDERICK,MD 21702	Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019691, R37DK019691, R56DK019691] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BEYNON RJ, 1983, SCIENCE, V219, P1351, DOI 10.1126/science.6338590; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BEYNON RJ, 1985, INTRACELLULAR PROTEI, P185; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOND JS, 1988, MAMMALIAN BRUSH BORD, P139; BOND JS, 1984, P NATL ACAD SCI USA, V81, P5541; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; CRAIG SS, 1991, J HISTOCHEM CYTOCHEM, V39, P123, DOI 10.1177/39.1.1701182; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; Green EL, 1981, GENETICS PROBABILITY, P77; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P525; LEPAGE T, 1992, DEVELOPMENT, V114, P147; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; RECKELHOFF JF, 1988, IMMUNOGENETICS, V27, P298, DOI 10.1007/BF00376127; RECKELHOFF JF, 1985, IMMUNOGENETICS, V22, P617, DOI 10.1007/BF00430310; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; Sambrook J, 1989, MOL CLONING LABORATO; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SIRACUSA LD, 1991, GENETICS, V127, P169; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	32	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10380	10385						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683677				2022-12-25	WOS:A1993LB80000061
J	LEE, KM; TOSCAS, K; VILLEREAL, ML				LEE, KM; TOSCAS, K; VILLEREAL, ML			INHIBITION OF BRADYKININ-INDUCED AND THAPSIGARGIN-INDUCED CA(2+) ENTRY BY TYROSINE KINASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-FIBROBLASTS; SIGNAL TRANSDUCTION; CALCIUM ENTRY; DNA-SYNTHESIS; SELECTIVE INHIBITOR; PROTEIN-KINASE; ACINAR-CELLS; RECEPTOR; ACTIVATION; PHOSPHORYLATION	We examined the involvement of tyrosine kinase activity in the bradykinin (BK)-mediated signal transduction process. Immunoblots with anti-phosphotyrosine antibodies following BK stimulation of human fibroblasts showed tyrosine phosphorylation of specific proteins that could be inhibited by the tyrosine kinase inhibitors genistein and tyrphostin. Image analysis data from individual cells stimulated by BK in the presence of genistein and tyrphostin showed that these inhibitors block the plateau phase but not the rapid transient phase of the BK-induced calcium response. That the loss of the plateau phase was due to blockage of calcium entry rather than stimulation of calcium pump activity was confirmed by examining the influx of Ba2+ following BK stimulation. The Ca2+ imaging results were confirmed by Ca-45(2+) uptake measurements and extended to another tyrosine kinase inhibitor (methyl 2,5-dihydroxycinnamate), which was found to interfere with the fura-2 signal and therefore could not be used in imaging experiments. The fact that three structurally distinct inhibitors of tyrosine kinase activity inhibited BK-stimulated calcium influx, while an inactive analogue of genistein (daidzein) did not, strongly suggests the involvement of tyrosine kinases in the regulation of a BK-induced calcium entry pathway. To our knowledge, this is the first report of tyrosine kinase involvement in the regulation of calcium entry following activation of a receptor that lacks endogenous tyrosine kinase activity and is known to be coupled to phosphatidylinositol turnover. We found that calcium entry in HSWP (human foreskin fibroblast) cells can also be stimulated by emptying the intracellular calcium stores with thapsigargin. Genistein also inhibits the plateau phase of the thapsigargin-induced calcium response while leaving the transient phase intact. This suggests that the Ca2+ influx pathway induced by depletion of intracellular calcium stores with thapsigargin also may be regulated via a tyrosine kinase pathway.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAUMGARTEN LB, 1992, J BIOL CHEM, V267, P10524; BYRON KL, 1989, J BIOL CHEM, V264, P18234; BYRON KL, 1992, J BIOL CHEM, V267, P108; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; FAHEY JV, 1977, AGENTS ACTIONS, V7, P255, DOI 10.1007/BF01969984; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONG SL, 1981, J BIOL CHEM, V256, P5215; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JAMIESON GA, 1987, ARCH BIOCHEM BIOPHYS, V252, P478, DOI 10.1016/0003-9861(87)90054-3; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MULDOON LL, 1985, AM J PHYSIOL, V249, pC140, DOI 10.1152/ajpcell.1985.249.1.C140; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROBERTS RA, 1989, J CELL SCI, V94, P527; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SNIDER RM, 1984, J NEUROCHEM, V43, P1749, DOI 10.1111/j.1471-4159.1984.tb06104.x; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	33	218	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9945	9948						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683685				2022-12-25	WOS:A1993LB80000003
J	LIN, HH; LI, WY; ANN, DK				LIN, HH; LI, WY; ANN, DK			THE HELIX-LOOP-HELIX PROTEINS (SALIVARY-SPECIFIC CAMP RESPONSE ELEMENT-BINDING PROTEINS) CAN MODULATE CAMP-INDUCIBLE RP4 GENE-EXPRESSION IN SALIVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEIN; DNA-BINDING; TRANSCRIPTION FACTORS; CATALYTIC SUBUNIT; CYCLIC-AMP; ENHANCER; SEQUENCE; KINASE; RAT; ISOPROTERENOL	Salivary-specific and cAMP-inducible expression of the rat proline-rich protein gene RP4 is dependent on a 28-base pair sequence of a salivary-specific cAMP response element (SCRE) (Lin, H. H., and Ann, D. K. (1992) Gene Expression 2, 365-377). To unravel its trans-acting factor(s), we used double-stranded oligoprobes corresponding to the SCRE to screen a randomly primed lambdagt11 cDNA expression library made from RNA of rat salivary cells. In this report, we describe the cDNA cloning of these helix-loop-helix SCRE-binding proteins (SCBPs) and demonstrate that there are at least three isoforms in salivary cells, namely SCBPalpha, SCBPbeta, and SCBPgamma. RNA polymerase chain reaction and sequence analyses further confirmed the existence of these three different SCBP isoforms, which code for putative proteins of 707, 706, and 682 amino acids, respectively. Expression of the cloned SCBP cDNAs in salivary cells stimulates the expression of a cotransfected reporter construct containing multicopies of the SCRE cloned upstream of the thymidine kinase promoter and the chloramphenicol acetyltransferase structural gene. This stimulation is much more pronounced in transfections in which SCBPalpha and SCBPbeta are cotransfected than when they are transfected individually. Furthermore, when low concentrations of SCBPalpha and SCBPbeta are cotransfected with the SCRE reporter gene, coexpression of the catalytic subunit of protein kinase A is required to efficiently activate the expression of the reporter gene. These results strongly suggest that the observed stimulation of the SCRE is achieved through the coordinated expression of the SCBPalpha, SCBPbeta, and protein kinase A activities, perhaps via a direct association of the two SCBPs and their phosphorylation by protein kinase A. We conclude that the isolated SCBPalpha and SCBPbeta cDNAs encode transcription activators that participate in the control of the inducible RP4 gene expression in salivary cells.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,3-249 MILLARD HALL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K04DE000292, R29DE009175] Funding Source: NIH RePORTER; NIDCR NIH HHS [K04-DE00292, R29-DE09175] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J CELL SCI, V100, P641; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GONALEZ GA, 1989, NATURE, V337, P748; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HE XJ, 1989, J CELL PHYSIOL, V138, P527, DOI 10.1002/jcp.1041380312; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; Lin H. Helen, 1992, Gene Expression, V2, P365; LIN HH, 1991, GENE, V104, P219, DOI 10.1016/0378-1119(91)90253-8; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NURMBERGER M, 1991, EMBO J, V10, P2957; PARK CW, 1992, J BIOL CHEM, V267, P15642; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	39	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10214	10220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683670				2022-12-25	WOS:A1993LB80000041
J	WU, J; AMANDORON, E; LI, XG; WAINBERG, MA; PARNIAK, MA				WU, J; AMANDORON, E; LI, XG; WAINBERG, MA; PARNIAK, MA			MONOCLONAL ANTIBODY-MEDIATED INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE POLYMERASE-ACTIVITY - INTERACTION WITH A POSSIBLE DEOXYNUCLEOSIDE TRIPHOSPHATE BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIDOVUDINE AZT; TYPE-1; PROTEINS; ENZYME; IDENTIFICATION; CHROMATOGRAPHY; SENSITIVITY; PREDICTION; SUBSTRATE; MECHANISM	A series of monoclonal antibodies against p51/p66 human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT) were prepared by immunizing mice with the native enzyme immobilized on nitrocellulose. One of these antibodies, designated 1E8, was found to inhibit both RNA-dependent and DNA-dependent polymerase activities of RT but had no effect on the RNase H activity of the enzyme. This inhibition was noncompetitive with respect to primer/template and competitive with respect to deoxynucleoside triphosphate (dNTP). The extent of 1E8 inhibition of RT polymerase activity decreased with increasing concentrations of dNTP in the incubation but was not affected by changes in primer/template concentration. 1E8 bound equally well in solution to both free RT and to the RT-primer/template complex. However, binding to the latter was significantly reduced by the addition of increasing concentrations of dNTP. The ability of dNTP to inhibit the interaction of 1E8 with the RT-primer/template complex was dependent on the identity of the homopolymeric primer/template used; only that dNTP complementary to the template was effective in this respect. 1E8 bound to the p51/p66 reverse transcriptase heterodimer in solution and reacted with both p51 and p66 subunits of reverse transcriptase on Western blots. The antibody is therefore presumed to recognize a linear surface epitope on the enzyme. 1E8 was found to specifically recognize a peptide with the sequence KKDSTKWRK. This sequence corresponds to residues 65-73 of HIV-1 reverse transcriptase, a region identified as highly antigenic by several computer algorithms. Two mutations within this sequence have been identified with resistance to 3'-azido,3'-deoxythymidine. We conclude that residues 65-73 of HIV-1 reverse transcriptase may be at or near the polymerase active site of the enzyme, and may form part of the deoxynucleoside triphosphate binding domain of the enzyme.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,3755 COTE STE CATHERINE RD,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,MCGILL AIDS CTR,MONTREAL H3T 1E2,QUEBEC,CANADA	Lady Davis Institute; McGill University; McGill University								BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BASU A, 1989, J BIOL CHEM, V264, P8746; BRUCK C, 1986, METHOD ENZYMOL, V121, P587; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; COTTON RGH, 1985, MED RES REV, V5, P77, DOI 10.1002/med.2610050104; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; FERNS RB, 1991, AIDS RES HUM RETROV, V7, P307, DOI 10.1089/aid.1991.7.307; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HIZI A, 1991, J BIOL CHEM, V266, P6230; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LI XG, 1993, J MED VIROL, V39, P251, DOI 10.1002/jmv.1890390314; LINDBORG B, 1992, ANTIVIR CHEM CHEMOTH, V3, P223, DOI 10.1177/095632029200300405; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MITCHELL LLW, 1992, BIOCHEMISTRY-US, V31, P7707, DOI 10.1021/bi00148a035; NARASIMHAN LS, 1992, PROTEIN ENG, V5, P139, DOI 10.1093/protein/5.2.139; ORVELL C, 1991, J GEN VIROL, V72, P1913, DOI 10.1099/0022-1317-72-8-1913; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RESTLE T, 1992, J BIOL CHEM, V267, P14654; SZILVAY AM, 1992, J ACQ IMMUN DEF SYND, V5, P647; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	37	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9980	9985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683687				2022-12-25	WOS:A1993LB80000010
J	REARDON, JE				REARDON, JE			HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE - A KINETIC-ANALYSIS OF RNA-DEPENDENT AND DNA-DEPENDENT DNA POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I KLENOW; ENZYME FUNCTION; MECHANISM; RETROVIRUS; EXONUCLEASE; INITIATION; FIDELITY; GENOME	A minimal kinetic mechanism for HIV reverse transcriptase (RT)-catalyzed RNA-dependent and DNA-dependent DNA polymerization was determined by pre-steady-state kinetic methods to be: [GRAPHICS] where E, TP, dNTP, and PP(i) are RT, template-primer, 2'-deoxynucleoside 5'-triphosphate, and inorganic pyrophosphate, respectively. Defined sequence template-primers that encode for incorporation of dTTP were prepared by annealing either a 44-mer RNA template or a 44-mer DNA template (of the same sequence) to a 21-mer DNA primer (r44:d21-mer and d44:d21-mer, respectively). The values of the above kinetic constants were determined for dTMP and 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP) incorporation into both template primers. The k(cat) and K(m) values calculated from these kinetic constants were similar to the values directly determined from steady-state experiments. Further, the net rate constants for processive incorporation of three successive nucleotides into the r44:d21-mer were similar indicating that a rate-determining step did not follow catalysis. A 20-fold difference in the rate constants (k(p)) for incorporation of dTMP into the r44:d21-mer versus the d44:d21-mer was largely responsible for the difference in the calculated processivity numbers of 340 and 5, respectively. Finally, the rate constant for pyrophosphorolysis of the 3'-AZTMP-terminated r44:d21-mer (k(pyro)) was similar to the rate constant for dissociation of the chain-terminated template primer from the enzyme (k(off)) indicating that millimolar concentrations of intracellular inorganic pyrophosphate would be required for pyrophosphorolysis of AZTMP-terminated retroviral genomes.			REARDON, JE (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BENKOVIC SJ, 1971, ENZYMES, V8, P20; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; Cleland W W, 1979, Methods Enzymol, V63, P103; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FREEMAN GA, 1992, J MED CHEM, V35, P3192, DOI 10.1021/jm00095a014; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HASSETT A, 1982, BIOCHEMISTRY-US, V21, P6335, DOI 10.1021/bi00268a002; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOPKINS S, 1989, BIOCHEM BIOPH RES CO, V163, P106, DOI 10.1016/0006-291X(89)92105-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; SMITH JK, 1984, J VIROL, V49, P200, DOI 10.1128/JVI.49.1.200-204.1984; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; VANDRAANEN NA, 1992, J BIOL CHEM, V267, P25019; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	32	103	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8743	8751						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682554				2022-12-25	WOS:A1993KX81100056
J	GUSOVSKY, F; LUEDERS, JE; KOHN, EC; FELDER, CC				GUSOVSKY, F; LUEDERS, JE; KOHN, EC; FELDER, CC			MUSCARINIC RECEPTOR-MEDIATED TYROSINE PHOSPHORYLATION OF PHOSPHOLIPASE C-GAMMA - AN ALTERNATIVE MECHANISM FOR CHOLINERGIC-INDUCED PHOSPHOINOSITIDE BREAKDOWN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; CALCIUM ENTRY; G-PROTEINS; VASOPRESSIN; ACTIVATION; HYDROLYSIS; ENDOTHELIN; INHIBITOR; BOMBESIN; INFLUX	In Chinese hamster ovary cells transfected with m5 muscarinic receptors, carbachol stimulates both calcium influx and calcium release from intracellular stores. The marine toxin maitotoxin (MTX) elicits a similar response on calcium influx. Carbachol- and MTX-induced calcium influx can be inhibited by the proposed blockers of receptor-operated calcium channels (ROCC), CAI and SK&F 96365. Both carbachol and MTX induce a significant increase in total protein tyrosine phosphorylation, which is dependent on extracellular calcium and can be inhibited by CAI and SK&F 96365. Phospholipase C-gamma was identified as one of the substrates subject to calcium-dependent tyrosine phosphorylation following carbachol or MTX stimulation. Carbachol-induced [H-3]inositol trisphosphate formation was partially inhibited by an inhibitor of tyrosine kinases, by removal of extracellular calcium, and by the inhibitor of receptor-operated calcium channels CAI suggesting that phosphorylation of phospholipase C-gamma plays a role in the muscarinic activation of phosphoinositide breakdown. Such an effect of carbachol is reminiscent of effects observed with peptide growth factors and represents a novel alternative signaling pathway for a muscarinic G protein-coupled receptor.	NIMH,CELL BIOL LAB,BLDG 36,RM 3A-15,BETHESDA,MD 20892; NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD; NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Felder, Christian/0000-0003-1134-8881				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRAUTIGAN DL, 1981, J BIOL CHEM, V256, P6519; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FORCE T, 1991, J BIOL CHEM, V266, P6650; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HUPE DJ, 1989, Patent No. 4847257; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	29	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7768	7772						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681827				2022-12-25	WOS:A1993KW97900031
J	PINOT, F; GRANT, DF; BEETHAM, JK; PARKER, AG; BORHAN, B; LANDT, S; JONES, AD; HAMMOCK, BD				PINOT, F; GRANT, DF; BEETHAM, JK; PARKER, AG; BORHAN, B; LANDT, S; JONES, AD; HAMMOCK, BD			MOLECULAR AND BIOCHEMICAL-EVIDENCE FOR THE INVOLVEMENT OF THE ASP-333-HIS-523 PAIR IN CATALYTIC MECHANISM OF SOLUBLE EPOXIDE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY ESTERS; HUMAN-LIVER; EXPRESSION; PROTEINS; CLONING; CDNA; PRODUCTS; ANTIBODY; ENZYMES; GENE	In order to investigate the involvement of amino acids in the catalytic mechanism of the soluble epoxide hydrolase, different mutants of the murine enzyme were produced using the baculovirus expression system. Our results are consistent with the involvement of Asp-333 and His-523 in a catalytic mechanism similar to that of other alpha/beta hydrolase fold enzymes. Mutation of His-263 to asparagine led to the loss of approximately half the specific activity compared to wild-type enzyme. When His-332 was replaced by asparagine, 96.7% of the specific activity was lost and mutation of the conserved His-523 to glutamine led to a more dramatic loss of 99.9% of the specific activity. No activity was detectable after the replacement of Asp-333 by serine. However, more than 20% of the wild-type activity was retained in an Asp-333 --> Asn mutant produce din Spodoptera frugiperda cells. We purified, by affinity chromatography, the wild-type and the Asp-333 --> Asn mutant enzymes produced in Trichoplusia ni cells. We labeled these enzymes by incubating them with the epoxide containing radiolabeled substrate juvenile hormone III (JH III). The purified Asp-333 --> Asn mutant bound 6% of the substrate compared to the wild-type soluble epoxide hydrolase. The mutant also showed 8% of the specific activity of the wild-type. Preincubation of the purified Asp-333 --> Asn mutant at 37 degrees C (pH 8), however, led to a complete recovery of activity and to a change of isoelectric point (pI), both of which are consistent with hydrolysis of Asn-333 to aspartic acid. This intramolecular hydrolysis of asparagine to aspartic acid may explain the activity observed in this mutant. Wild-type enzyme that had been radiolabeled with the substrate was digested with trypsin. Using reverse phase-high pressure liquid chromatography, we isolated four radiolabeled peptides of similar polarity. These peptides were not radiolabeled if the enzyme was preincubated with a selective competitive inhibitor of soluble epoxide hydrolase 4-fluorochalcone oxide. This strongly suggested that these peptides contained a catalytic amino acid. Each peptide was characterized with N-terminal amino acid sequencing and electrospray mass spectrometry. All four radiolabeled peptides contained overlapping sequences. The only aspartic acid present in all four peptides and conserved in all epoxide hydrolases was Asp-333. These peptides resulted from cleavage at different trypsin sites and the mass of each was consistent with the covalent linkage of Asp-333 to the substrate.	LAWRENCE LIVERMORE NATL LAB,DEPT ENTOMOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002710, P30ES005707] Funding Source: NIH RePORTER; NIEHS NIH HHS [2 RO1 ES02710, C1 P30 ES05707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; FALANY CN, 1987, J BIOL CHEM, V262, P5924; GRANT DF, 1993, J BIOL CHEM, V268, P17628; GUENGERICH FP, 1982, REV BIOCHEM TOXICOL, V4, P5; GUENTHNER TM, 1981, POLYCYCLIC HYDROCARB, P183; HALARNKAR PP, 1989, ARCH BIOCHEM BIOPHYS, V272, P226, DOI 10.1016/0003-9861(89)90214-2; HALARNKAR PP, 1992, ARCH BIOCHEM BIOPHYS, V294, P586, DOI 10.1016/0003-9861(92)90729-G; HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121; HASSETT C, 1989, ARCH BIOCHEM BIOPHYS, V271, P380, DOI 10.1016/0003-9861(89)90287-7; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE BG, 1987, TOXICOLOGY, V44, P213, DOI 10.1016/0300-483X(87)90151-X; MEIJER J, 1987, CHEM-BIOL INTERACT, V62, P249, DOI 10.1016/0009-2797(87)90026-3; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; MULLIN CA, 1982, ARCH BIOCHEM BIOPHYS, V216, P423, DOI 10.1016/0003-9861(82)90231-4; MUMBY SM, 1979, PESTIC BIOCHEM PHYS, V11, P275, DOI 10.1016/0048-3575(79)90067-1; NOUROOZZADEH J, 1992, ARCH BIOCHEM BIOPHYS, V294, P675, DOI 10.1016/0003-9861(92)90741-E; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; SALTO R, 1994, J BIOL CHEM, V269, P10691; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; SKODA RC, 1988, J BIOL CHEM, V263, P1549; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WIXTROM RN, 1988, ANAL BIOCHEM, V169, P71, DOI 10.1016/0003-2697(88)90256-4; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	35	78	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7968	7974		10.1074/jbc.270.14.7968	http://dx.doi.org/10.1074/jbc.270.14.7968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713895	hybrid			2022-12-25	WOS:A1995QR52600031
J	SCARIA, PV; WILL, S; LEVENSON, C; SHAFER, RH				SCARIA, PV; WILL, S; LEVENSON, C; SHAFER, RH			PHYSICOCHEMICAL STUDIES OF THE D(G(3)T(4)G(3))ASTERISK-D(G(3)A(4)G(3))CENTER-DOT-D(C3T4C3) TRIPLE-HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONATED POLYNUCLEOTIDES STRUCTURES; RESONANCE ENERGY-TRANSFER; SITE-SPECIFIC CLEAVAGE; FORMING-OLIGONUCLEOTIDES; POLY(DG) POLY(DC); DNA; TRANSCRIPTION; RECOGNITION; INHIBITION; GENE	We have targeted the d(G(3)A(4)G(3)). d(C3T4C3) duplex for tripler formation with d(G(3)T(4)G(3)) in the presence of MgCl2. The resulting triple helix, d(G(3)T(4)G(3))*d(G(3)-A(4)G(3)) . d(C3T4C3), is considerably weaker than the related tripler, d(G(3)A(4)G(3))*d(G(3)A(4)G(3)). d(C3T4C3), and melts in a biphasic manner, with the third strand dissociating at temperatures about 20-30 degrees C below that of the remaining duplex. This is in distinct contrast to the d(G(3)A(4)G(3))*d(G(3)A(4)G(3)). d(C3T4C3) tripler, which melts in essentially a single transition, Gel electrophoresis under non-denaturing conditions shows the presence of the d(G(3)T(4)G(3))*d(G(3)A(4)G(3)). d(C3T4C3) tripler as a band of low mobility compared to the duplex or the single strand bands. Binding of the d(G(3)T(4)G(3)) third strand and the purine strand of the duplex can be monitored by imino proton NMR spectra, While these spectra are typically very broad for intermolecular triplexes, the line widths can be dramatically narrowed by the addition of two thymines to both ends of the pyrimidine strand, Ther modynamic analysis of UV melting curves shows that this tripler is considerably less stable than related triplexes formed with the same duplex, The orientation of the third strand was addressed by a combination of fluorescence energy transfer and UV melting experiments, Results from these experiments suggest that, in the unlabeled tripler, the preferred orientation of the third strand is parallel to the purine strand of the duplex.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; ROCHE MOLEC SYST, ALAMEDA, CA 94501 USA	University of California System; University of California San Francisco; Roche Holding								BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CHAN SS, 1993, BIOCHEMISTRY-US, V32, P11776, DOI 10.1021/bi00095a005; CHEN FM, 1991, BIOCHEMISTRY-US, V30, P4472, DOI 10.1021/bi00232a014; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COOPER JP, 1990, BIOCHEMISTRY-US, V29, P9261, DOI 10.1021/bi00491a022; DAGNEAU C, 1994, 8TH P CONV STAT U NE, P103; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GRISWOLD BL, 1951, ANAL CHEM, V23, P192, DOI 10.1021/ac60049a041; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HU S, 1992, EUR J BIOCHEM, V204, P31, DOI 10.1111/j.1432-1033.1992.tb16602.x; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; JAYASENA SD, 1993, BIOCHEMISTRY-US, V32, P2800, DOI 10.1021/bi00062a010; JAYASENA SD, 1992, BIOCHEMISTRY-US, V31, P320, DOI 10.1021/bi00117a002; LEVENSON C, 1990, PCR PROTOCOLS GUIDE, P99; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1979, DOI 10.1093/nar/5.6.1979; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; ROY C, 1993, NUCLEIC ACIDS RES, V21, P2845, DOI 10.1093/nar/21.12.2845; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1991, CR ACAD SCI III-VIE, V313, P585; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; THIELE D, 1978, NUCLEIC ACIDS RES, V5, P1997, DOI 10.1093/nar/5.6.1997; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063	39	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7295	7303		10.1074/jbc.270.13.7295	http://dx.doi.org/10.1074/jbc.270.13.7295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706270	hybrid			2022-12-25	WOS:A1995QQ43100043
J	VIVIEN, D; ATTISANO, L; WRANA, JL; MASSAGUE, J				VIVIEN, D; ATTISANO, L; WRANA, JL; MASSAGUE, J			SIGNALING ACTIVITY OF HOMOLOGOUS AND HETEROLOGOUS TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR KINASE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; II RECEPTOR; EXPRESSION CLONING; RESPONSIVENESS; IDENTIFICATION; TRANSDUCTION; BINDING; MUTANTS; FORMS	Transforming growth factor-beta (TGF-beta) signaling in Mv1Lu lung epithelial cells requires coexpression of TGF-beta receptors I (T beta R-I) and II (T beta R-II), two distantly related transmembrane serine/threonine kinases that form a heteromeric complex upon ligand binding, Here, we examine the formation of TGF-beta receptor homooligomers and their possible contribution to signaling. T beta R-I can contact ligand bound to T beta R-II, but not ligand free in the medium, and thus cannot form ligand-induced homo-oligomers, T beta R-II, which binds ligand on its own, formed oligomeric complexes when overexpressed in transfected COS cells. However, these complexes were largely ligand independent and involved immature receptor protein, Since ligand-induced homooligomers could not be obtained with the wild type TGF-beta receptors, we studied receptor cytoplasmic domain homo oligomerization by using receptor chimeras, The extracellular domain of T beta R-II was fused to the transmembrane and cytoplasmic domains of T beta R-I, yielding T beta R-II/I, and the extracellular domain of T beta R-I was fused to the transmembrane and cytoplasmic domains of T beta R-II, yielding T beta R-I/II. When cotransfected with wild-type receptors and exposed to ligand, T beta R-II/I formed a complex with T beta R-I, and T beta R-I/II formed a complex with T beta R-II, thus yielding complexes with homologous cytoplasmic domains, TPR-II/I transfected alone or with T beta R-I did not restore TGF-beta responsiveness in T beta R-II-defective cell mutants. Furthermore, T beta R-II/I acted in a dominant negative fashion, inhibiting restoration of TGF-beta responsiveness by a cotransfected T beta R-II in T beta R-II-defective cells and by a cotransfected T beta R-I in T beta R-I-defective cells, Similarly, T beta R-I/II transfected alone or with T beta R-II did not restore TGF-beta responsiveness and acted in a dominant negative fashion against T beta R-I, Together with previous genetic and biochemical evidence, these results suggest that TGF-beta mediates transcriptional and antiproliferative responses through the heteromeric T beta R-I T beta R-II complex and not through homo-oligomeric T beta R-I . T beta R-II complexes.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	VIVIEN, D (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,BOX 116,NEW YORK,NY 10021, USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408; VIVIEN, DENIS/0000-0002-7636-2185	NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA08748, CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WIESER R, 1995, IN PRESS EMBO J; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	36	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7134	7141		10.1074/jbc.270.13.7134	http://dx.doi.org/10.1074/jbc.270.13.7134			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706250	hybrid			2022-12-25	WOS:A1995QQ43100021
J	SUZUKI, T; HIRAI, H; MURAKAMI, T; YOSHIDA, M				SUZUKI, T; HIRAI, H; MURAKAMI, T; YOSHIDA, M			TAX PROTEIN OF HTLV-1 DESTABILIZES THE COMPLEXES OF NF-KAPPA-B AND I-KAPPA-B-ALPHA AND INDUCES NUCLEAR TRANSLOCATION OF NF-KAPPA-B FOR TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article						HTLV-1; I-KAPPA-B; TRANSCRIPTIONAL-ACTIVATION; NF-KAPPA-B	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEATS; TUMOR-NECROSIS-FACTOR; TRANSACTIVATOR TAX; TRANS-ACTIVATION; GENE-EXPRESSION; PRECURSOR P105; DNA-BINDING; ENHANCER	Tax protein of HTLV-1 stimulates transcription of specific cellular genes through the NF-kappa B binding site. We previously showed that Tax binds to the ankyrin motifs of I kappa B-gamma, and dissociates the I kappa B-gamma/NF-kappa B complexes, resulting in nuclear translocation of NF-kappa B proteins. We herein report the effects of Tax on I kappa B-alpha, another member of I kappa B family proteins expressed in human T cells. Tax binds to I kappa B-alpha and partially dissociates the NF-kappa B/I kappa B-alpha complex in vitro. In Tax-expressing cells, Tax/I kappa B-alpha complex was detected only at low level, but NF-kappa B/I kappa B-alpha complex was mostly dissociated and NF-kappa B was translocated into the nucleus. Furthermore, Tax induced reduction of I kappa B-alpha protein. I kappa B-alpha a protein was stabilized by NF-kappa B protein through forming NF-kappa B/I kappa B-alpha complex, but Tax expression cancelled this stabilization effect on I kappa B-alpha. These findings suggest that Tax induces dissociation of and/or inhibits the formation of NF-kappa B/I kappa B-alpha complexes, resulting in release of NF-kappa B and destabilization of I kappa B-alpha. Consistently, transcription of NF-kappa B directed gene was activated. These Tax effects counteract the negative feedback control of NF-kappa B by I kappa B-alpha and contribute to constitutive activation of NF-kappa B in Tax-transfected and HTLV-1-infected cells.	UNIV TOKYO,INST MED SCI,DEPT CELLULAR & MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEURLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P68; BAIL OL, 1993, EMBO J, V12, P5043; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARUYAMA M, 1987, CELL, V48, P493; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1987, BIOCHIM BIOPHYS ACTA, V907, P145, DOI 10.1016/0304-419X(87)90003-5; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	54	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1199	1207						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700645				2022-12-25	WOS:A1995QN35300022
J	YATES, KE; LYNCH, MR; WONG, SG; SLAMON, DJ; GASSON, JC				YATES, KE; LYNCH, MR; WONG, SG; SLAMON, DJ; GASSON, JC			HUMAN C-FES IS A NUCLEAR TYROSINE KINASE	ONCOGENE			English	Note						C-FES; TYROSINE KINASE; NUCLEAR LOCALIZATION; HEMATOPOIESIS	SIGNAL-TRANSDUCTION; GROWTH-HORMONE; GENE-PRODUCT; FPS-GENE; PROTEIN; PHOSPHORYLATION; JAK2; DNA; ERYTHROPOIETIN; LOCALIZATION	FES is a non-receptor protein tyrosine kinase expressed in hematopoietic progenitors and differentiated myeloid cells. It has recently been implicated in granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) and erythropoietin signal transduction. To better understand the role played by FES in normal and neoplastic hematopoiesis, we used cell fractionation techniques to examine the subcellular localization of FES in myeloid cells and cell lines. FES was observed in the nuclear, granular and plasma membrane fractions of primary human neutrophils and the myeloid leukemia cell line, HL-60. The nuclear localization was confirmed by immunocytochemistry of neutrophils.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA040163] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40163, CA09056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CARE A, 1994, ONCOGENE, V9, P739; DHUT S, 1991, ONCOGENE, V6, P1459; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LANFRANCONE L, 1989, INT J CANCER, P35; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Warren L, 1974, Methods Enzymol, V31, P156; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	37	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1239	1242						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700650				2022-12-25	WOS:A1995QN35300027
J	SCHWANINGER, M; BLUME, R; OETJEN, E; LUX, G; KNEPEL, W				SCHWANINGER, M; BLUME, R; OETJEN, E; LUX, G; KNEPEL, W			INHIBITION OF CAMP-RESPONSIVE ELEMENT-MEDIATED GENE-TRANSCRIPTION BY CYCLOSPORINE-A AND FK506 AFTER MEMBRANE DEPOLARIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PANCREATIC-ISLET CELLS; SOMATOSTATIN GENE; RAT SOMATOSTATIN; GLUCAGON GENE; BETA-CELLS; ACTIVATION; CREB; IDENTIFICATION; CALCINEURIN	The cAMP-responsive element (CRE) and its cognate transcription factor CREB can mediate induction of gene transcription in response to membrane depolarization and calcium influx. In this study, the effect of cyclosporin A (CsA) and FK506 on depolarization-induced glucagon gene transcription was investigated in a pancreatic islet cell line by transfection of reporter fusion genes. CsA and FK506 inhibited depolarization-induced glucagon gene transcription, FK506 being more potent than CsA. CsA/FK506 responsiveness was mediated by the glucagon CRE and also by well characterized CREs of the choriogonadotropin and somatostatin genes. Rapamycin antagonized the inhibitory effect of FK506 but not CsA, suggesting that FK506 and CsA may act through complex formation with distinct intracellular immunophilins. Overexpression of calcineurin, which is known to be inhibited by drug-immunophilin complexes, rendered pancreatic islet cells more resistant to the inhibitory effects of CsA and FK506. These results demonstrate an inhibition by CsA and FK506 of CRE-mediated, calcium-induced transcription and suggest that membrane depolarization relies on calcineurin phosphatase activity for activation of CREB/CRE-mediated gene transcription. The interference with CRE-mediated gene transcription represents a novel mechanism of CsA/FK506 action, which may underlie pharmacological effects and toxic manifestations of these potent immunosuppressive drugs.	UNIV GOTTINGEN,CTR PHARMACOL & TOXICOL,DEPT BIOCHEM PHARMACOL,ROBERT KOCH STR 40,D-37070 GOTTINGEN,GERMANY	University of Gottingen				Schwaninger, Markus/0000-0002-4510-9718				ANDERSSON A, 1984, DIABETOLOGIA, V27, P66, DOI 10.1007/BF00275649; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ERLANGER BF, 1992, IMMUNOL TODAY, V13, P487, DOI 10.1016/0167-5699(92)90023-Z; EUN HM, 1987, DIABETES, V36, P952, DOI 10.2337/diabetes.36.8.952; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOTO S, 1992, NEUROSCI LETT, V143, P51, DOI 10.1016/0304-3940(92)90231-U; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MASON J, 1989, PHARMACOL REV, V41, P423; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORRIS SM, 1992, J BIOL CHEM, V267, P13768; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POWERS AC, 1989, J BIOL CHEM, V264, P10048; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V	28	70	74	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23111	23115						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693684				2022-12-25	WOS:A1993MF51500026
J	KOUNNAS, MZ; HENKIN, J; ARGRAVES, WS; STRICKLAND, DK				KOUNNAS, MZ; HENKIN, J; ARGRAVES, WS; STRICKLAND, DK			LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR MEDIATES CELLULAR UPTAKE OF PROUROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; DEGRADATION; CELLS; TISSUE; BINDS; COMPLEXES; PURIFICATION; INTERNALIZES	The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP) is a large cell surface receptor consisting of a 515-kDa heavy chain and an 85-kDa light chain proteolytically derived from a 600-kDa precursor. Previous work has shown that LRP is responsible for mediating the internalization of urinary-type plasminogen activator (uPA) complexed to plasminogen activator inhibitor type I (PAI-1) (Nykjaer et al, 1992; Herz et al., 1992). The current study indicates that pro-urokinase (pro-uPA) and two chain urokinase (tc-uPA) bind directly to purified LRP, and that LRP mediates their internalization and degradation in Hep G2 cells. In vitro binding assays demonstrated that pro-uPA and tc-uPA bind to purified LRP with affinities (K(d) = 45 and 60 nM, respectively) that are approximately 15 to 20-fold weaker than the affinity of uPA.PAI-1 complex for LRP (K(d) = 3 nM). Competitive binding experiments revealed that pro-uPA and tc-uPA completely inhibit binding of uPA.PAI-1 complexes to purified LRP. The binding of I-125-pro-uPA to LRP is blocked by the 39-kDa receptor-associated protein, but not by an amino-terminal fragment of uPA, which is known to block binding of uPA to the urokinase receptor. I-125-Pro-uPA can be internalized and degraded by Hep G2 cells independent of PAI-1. Both the internalization and degradation are completely blocked by receptor-associated protein or affinity-purified LRP antibodies, indicating that LRP is mediating this process. These processes are also blocked by the amino-terminal fragment, which suggests that the favored pathway for uPA metabolism is initial binding to the urokinase receptor, followed by ligand transfer to LRP, then internalization leading to degradation.	AMER RED CROSS,BIOCHEM LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855; ABBOTT LABS,N CHICAGO,IL 60064	American Red Cross; Abbott Laboratories					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30200] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BROMMER EJP, 1992, THROMB HAEMOSTASIS, V68, P180; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; COLLEN D, 1984, THROMB HAEMOSTASIS, V52, P24; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; HEARING VJ, 1988, CANCER RES, V48, P1270; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIRAMATSU R, 1989, FIBRINOLYSIS, P147; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUIPER J, 1992, J BIOL CHEM, V267, P1589; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LIJNEN HR, 1992, EUR J BIOCHEM, V205, P701, DOI 10.1111/j.1432-1033.1992.tb16832.x; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; UENO T, 1979, THROMB HAEMOSTASIS, V42, P885; VASSALLI J, 1976, CELL, V18, P271; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	41	161	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21862	21867						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691818				2022-12-25	WOS:A1993MC80900065
J	LOGANZO, F; DOSIK, JS; ZHAO, Y; VIDAL, MJ; NANUS, DM; SUDOL, M; ALBINO, AP				LOGANZO, F; DOSIK, JS; ZHAO, Y; VIDAL, MJ; NANUS, DM; SUDOL, M; ALBINO, AP			ELEVATED EXPRESSION OF PROTEIN-TYROSINE KINASE C-YES, BUT NOT C-SRC, IN HUMAN-MALIGNANT MELANOMA	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; HUMAN MELANOCYTES; POINT MUTATIONS; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; CUTANEOUS MELANOMA; SURFACE-ANTIGENS; CELLULAR-YES; HUMAN DNA; DIFFERENTIATION	The c-yes proto-oncogene encodes a protein tyrosine kinase, p62c-yes (c-Yes) that belongs to the Src family of non-receptor type protein tyrosine kinases. We compared the levels of c-Yes kinase activity and protein by immune complex kinase assays and immune blot analysis in 20 human melanoma and 10 human melanocyte cell tines. Results show that the average kinase activity of c-Yes in most melanoma cell lines is 5-10-fold higher than that in melanocyte cell lines. The protein level of c-Yes in these melanoma cell lines is correspondingly higher than that in melanocytes. The increase in c-Yes kinase activity is most likely attributable to the elevated protein level because single-strand conformational polymorphism of all structural and functional domains detected no mutations in any of the c-yes coding regions. Subcellular fractionation analysis indicated that c-Yes localizes to the plasma membrane, perinuclear and cytosolic compartments while c-Src predominantly associates with plasma membranes. In melanoma cells in which an elevated level of c-Yes is observed, a protein of 39 kD is heavily phosphorylated on tyrosine. This protein is only observed in melanoma cells and not in melanocytes, suggesting a perturbed signaling pathway in melanoma cells that results in abnormal tyrosine phosphorylation of cellular proteins. These data suggest that derangement of expression of the c-Yes tyrosine kinase may have a role in the malignant progression of the human melanocyte.	MEM SLOAN KETTERING CANC CTR,MAMMALIAN CELL TRANSFORMAT LAB,1275 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Rockefeller University					NATIONAL CANCER INSTITUTE [R01CA037907] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37907, CA-01605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ALBINO AP, 1991, CANCER RES, V51, P4815; ALBINO AP, 1993, IN PRESS CANCER TREA; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P5847, DOI 10.1073/pnas.78.9.5847; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOLDEN A, 1988, ONCOGENE HDB, P149; GRANDORI C, 1991, ONCOGENE, V6, P1063; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; Houghton A N, 1988, Prog Clin Biol Res, V256, P333; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KOPF AW, 1984, J AM ACAD DERMATOL, V11, P674, DOI 10.1016/S0190-9622(84)70225-8; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRUEGER J, 1991, ONCOGENE, V6, P933; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LASSAM N, 1992, ONCOGENE, V7, P51; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LONGSTRETH J, 1988, CANCER METAST REV, V7, P321, DOI 10.1007/BF00051373; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MCCLAY EF, 1991, CRIT REV ONCOL HEMAT, V11, P299, DOI 10.1016/1040-8428(91)90030-G; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PESCE A, 1964, J BIOL CHEM, V239, P1753; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROWLEY JD, 1990, CANCER RES, V50, P3816; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEMBA K, 1992, GENES CANCER, P74; SOBER AJ, 1991, DERMATOL CLIN, V9, P617; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1992, MOL BASIS HUMAN CANC; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; VEILLETTE A, 1989, ONCOGENES, P121; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	65	55	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2637	2644						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690926				2022-12-25	WOS:A1993LX34300004
J	PARK, JS; MEISLER, AI; CARTWRIGHT, CA				PARK, JS; MEISLER, AI; CARTWRIGHT, CA			C-YES TYROSINE KINASE-ACTIVITY IN HUMAN COLON-CARCINOMA	ONCOGENE			English	Article								To examine the role of Src-related proteins in human colon carcinoma we measured the tyrosine kinase activity of pp60c-src (Src), p62c-yes (Yes), p56lck (Lck), p59fyn (Fyn), p59hck (Hck), p56lyn (Lyn) and p55c-fgr (Fgr) from colonic cells. Yes activity, similar to that of Src, was 10-20 fold higher in three of five colon carcinoma cell lines and fivefold higher in 10 of 21 primary colon cancers than that in normal colonic cells. Lck activity was present in COLO 205 cells, otherwise Lck, Fyn, Hck, Lyn and Fgr activities were not detected in any of the carcinoma cell lines or cancers tested. Increased Yes activity, like that of Src, was due mostly to increased protein levels and not to an apparent decrease in phosphorylation of Tyr 537, the major mechanisms known to deregulate enzymatic activity. Only those colon carcinoma cell lines with elevated Src and/or Yes tyrosine kinase activity as measured in vitro had elevated levels of three tyrosine-phosphorylated proteins as measured in vivo. Thus, colon carcinoma cells contain active tyrosine kinases and/or inactive tyrosine phosphatases not present in normal colonic cells, and Src and Yes appear to be active kinases in the carcinoma cells. These data, together with those demonstrating decreased Src activity in fully differentiated enterocytes, suggest that down regulation of Src-related tyrosine kinases is important for differentiation, and/or deregulation of the kinases is important for growth and transformation of intestinal epithelial cells.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,MED SCH LAB SURGE BLDG, P304, STANFORD, CA 94305 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15240 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIDDK NIH HHS [R29 DK43743, P30-DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043743, P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BUCKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOSS FM, 1989, ONCOGENE RES, V5, P13; GARCIA R, 1991, ONCOGENE, V6, P1983; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAY R, 1992, CATALOGUE CELL LINES, P119; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLEY TR, 1989, ONCOGENE, V4, P265; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629	69	116	117	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2627	2635						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690925				2022-12-25	WOS:A1993LX34300003
J	JOSHIBARVE, SS; RANGNEKAR, VV; SELLS, SF; RANGNEKAR, VM				JOSHIBARVE, SS; RANGNEKAR, VV; SELLS, SF; RANGNEKAR, VM			INTERLEUKIN-1-INDUCIBLE EXPRESSION OF GRO-BETA VIA NF-KAPPA-B ACTIVATION IS DEPENDENT UPON TYROSINE KINASE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN IMMUNODEFICIENCY VIRUS; T-CELLS; GENE-EXPRESSION; HUMAN-FIBROBLASTS; TRANSCRIPTION FACTOR; PROTEIN-KINASE; IL-1 RECEPTORS; FACTOR BINDING; INDUCTION	Interleukin-1 (IL-1) induces programmed growth arrest in human melanoma cells, A375-C6. IL-1 action in these cells is associated with induction of a cell type-specific immediate-early (IE) gene expression program characterized by strong, rapid, and sustained induction of gro-alpha and gro-beta, but transient induction of c-jun, IRG-9, and NAK-1, and lack of induction of c-myc. With the exception of gro-alpha and gro-beta, these IE genes are also associated with growth-stimulatory responses in the melanoma cells, suggesting that the gro-genes may play key roles in the growth arrest action of the cytokine. To elucidate the early intracellular signals associated with IL-1 action, we are studying the second messenger signals and transcription factors required for induction of gro-genes. Here, we present evidence that IL-1-inducible gro-gene expression is dependent on tyrosine kinase signaling. Using gel retardation and transient expression assays, we show that IL-1 causes protein tyrosine phosphorylation-dependent activation of NF-kappaB enhancer binding protein, which then induces transcription of the gro-genes via an NF-kappaB site located 76 base pairs upstream from the cap site. IL-1-activated protein tyrosine phosphorylation is also required for gro-gene induction in human cervical carcinoma cells, HeLa; human fibroblast cells, WI-38; and mouse fibroblast cells, L929. Thus, in diverse cell types, IL-1 induces gro-genes via tyrosine kinase-dependent signals.	UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky					NCI NIH HHS [PTHB1 R29CA52839] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BIRD TA, 1990, J BIOL CHEM, V265, P235; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANFORTH DN, 1991, CANCER RES, V51, P1488; DINARELLO CA, 1991, BLOOD, V77, P1627; DONATI D, 1990, J IMMUNOL, V145, P4115; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; ENDO Y, 1988, J IMMUNOL, V141, P2342; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; FRYLING C, 1989, CANCER RES, V49, P3333; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORUK R, 1987, J BIOL CHEM, V262, P16275; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KILIAN PL, 1991, CANCER RES, V51, P1823; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUNOZ E, 1991, J IMMUNOL, V146, P136; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAMURA S, 1986, JPN J CANCER RES, V77, P767; ONOZAKI K, 1985, J IMMUNOL, V135, P314; ONOZAKI K, 1988, J IMMUNOL, V140, P112; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAGER R, 1991, ADV EXPT BIOL MED CH; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V12, P3454; TWEARDY DJ, 1990, J IMMUNOL, V144, P2233; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; USAI N, 1991, CANCER RES, V51, P769; VILCEK J, 1987, J BIOL CHEM, V262, P11908; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	81	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18018	18029						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688736				2022-12-25	WOS:A1993LT74300058
J	SARGEANT, P; FARNDALE, RW; SAGE, SO				SARGEANT, P; FARNDALE, RW; SAGE, SO			ADP-EVOKED AND THAPSIGARGIN-EVOKED CA2+ ENTRY AND PROTEIN-TYROSINE PHOSPHORYLATION ARE INHIBITED BY THE TYROSINE KINASE INHIBITORS GENISTEIN AND METHYL-2,5-DIHYDROXYCINNAMATE IN FURA-2-LOADED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PLASMA-MEMBRANE; CALCIUM ENTRY; CA-2+ ENTRY; SIGNAL TRANSDUCTION; INOSITOL PHOSPHATES; ADENYLATE-CYCLASE; RABBIT PLATELETS; TUMOR PROMOTER; PHORBOL ESTERS	We have investigated the mechanism of Ca2+ entry in fura-2-loaded human platelets using the inhibitors of tyrosine kinases, genistein, and methyl-2,5-dihydroxycinnamate. Genistein (100 muM; 30 min) or methyl-2,5-dihydroxycinnamate (1 mug/ml; 30 min) reduced ADP-evoked protein-tyrosine phosphorylation at specific bands as assessed by gel electrophoresis and Western blotting with a specific antiphosphotyrosine antibody. Both compounds also reduced ADP-evoked [Ca2+]i rises in the presence, but not the absence, of external Ca2+, suggesting a relatively selective inhibition of Ca2+ entry over internal release. The inactive analogue of genistein, daidzein, was without effect on protein-tyrosine phosphorylation or ADP-evoked Ca2+ elevation in the presence or absence of external Ca2+. Methyl-2,5-dihydroxycinnamate (1 mug/ml; 5 min) significantly reduced the Ca2+ influx evoked by depletion of the intracellular Ca2+ stores using the inhibitor of the endomembranous Ca2+-ATPase, thapsigargin. These results with tyrosine kinase inhibitors are unlikely to be the result of the inhibition of other protein kinases since kinases A, C, and G all inhibit agonist-evoked rises in [Ca2+]i in platelets. These data support a role for tyrosine kinases in the control of Ca2+ entry in human platelets.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge	SARGEANT, P (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.			Sage, Stewart/0000-0001-8578-3558				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BACHELOT C, 1992, BIOCHEM J, V284, P923, DOI 10.1042/bj2840923; CROUCH MF, 1989, J BIOL CHEM, V264, P584; DHAR A, 1990, MOL PHARMACOL, V37, P519; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; ISSHIKI K, 1987, J ANTIBIOT, V40, P1209, DOI 10.7164/antibiotics.40.1209; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KASSIS S, 1985, J BIOL CHEM, V260, P8911; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MACINTYRE DE, 1982, THROMB HAEMOSTASIS, V47, P22; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1101; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1992, AM J PHYSIOL, V262, pC701, DOI 10.1152/ajpcell.1992.262.3.C701; OGAWARA H, 1986, J ANTIBIOT, V39, P606, DOI 10.7164/antibiotics.39.606; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; PRESEK P, 1988, BIOCHIM BIOPHYS ACTA, V969, P271, DOI 10.1016/0167-4889(88)90062-6; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RENDU F, 1989, BLOOD, V73, P1545; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAGE SO, 1992, BIOCHEM J, V285, P341, DOI 10.1042/bj2850341; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1992, CELL CALCIUM, V13, P553, DOI 10.1016/0143-4160(92)90035-Q; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	47	204	205	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18151	18156						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688740				2022-12-25	WOS:A1993LT74300075
J	STOUFFER, GA; LAMARRE, J; GONIAS, SL; OWENS, GK				STOUFFER, GA; LAMARRE, J; GONIAS, SL; OWENS, GK			ACTIVATED ALPHA-2-MACROGLOBULIN AND TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCE A SYNERGISTIC SMOOTH-MUSCLE CELL PROLIFERATIVE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; FACTOR-BETA; EXPRESSION CLONING; BINDING PROTEINS; DENSITY; INHIBITION; CLEARANCE; COMPLEX; HYPERTROPHY; METHYLAMINE	The role that soluble binding proteins might play in regulating transforming growth factor-beta1 (TGF-beta1)-induced growth of smooth muscle cells (SMC) is unknown. Alpha2-macroglobulin (alpha2M) is the major plasma binding protein for TGF-beta. Reaction of alpha2M with methylamine (alpha2M-MA) forms ''activated'' alpha2M which binds TGF-beta and specific cell surface receptors. The objectives of these studies were to determine whether native alpha2M or alpha2M-MA influences growth responses of cultured rat aortic SMC to TGF-beta1. Results demonstrated that native alpha2M was not mitogenic. Treatment with alpha2M-MA or TGF-beta1 stimulated a 3- or 3.5-fold increase in [H-3]thymidine incorporation, respectively. Cotreatment with TGF-beta1 and alpha2M-MA resulted in a 70-fold increase in [H-3]thymidine incorporation. SMC bound alpha2M-MA in a specific and saturable manner and expressed alpha2M receptor/low density lipoprotein receptor-related protein (LRP). A modified form of alpha2M-MA (alpha2M-MA-cis-dichlorodiammine platinum), which bound TGF-beta1 but did not bind alpha2M receptors, failed to enhance TGF-beta1-induced growth. In summary, results demonstrated that alpha2M-MA enhanced TGF-beta1-induced growth responses and that this effect was dependent on alpha2M-MA binding to alpha2M receptor/LRP.	UNIV VIRGINIA,SCH MED,DEPT MOLEC PHYSIOL & CELLULAR BIOPHYS,BOX 449,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PATHOL & BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia			Stouffer, George/AAK-4763-2021		NCI NIH HHS [R01-CA-53462] Funding Source: Medline; NHLBI NIH HHS [P01-HL-19242, R01-HL-38854] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854, P01HL019242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GONIAS SL, 1992, EXP HEMATOL, V20, P302; GOODMAN LV, 1989, J BIOL CHEM, V264, P5241; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JANAT MF, 1992, J CELL PHYSIOL, V150, P232, DOI 10.1002/jcp.1041500203; KERAMIDAS M, 1992, MOL CELL ENDOCRINOL, V84, P243, DOI 10.1016/0303-7207(92)90035-5; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIBBY P, 1985, J CELL PHYSIOL, V125, P357, DOI 10.1002/jcp.1041250302; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MORISAKI N, 1991, ATHEROSCLEROSIS, V88, P227, DOI 10.1016/0021-9150(91)90085-H; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P301, DOI 10.1016/S0006-291X(88)80047-0; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STOUFFER GA, 1993, AM J PHYSIOL, V264, pC390, DOI 10.1152/ajpcell.1993.264.2.C390; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9	40	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18340	18344						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688745				2022-12-25	WOS:A1993LT74300102
J	OURY, TD; PIANTADOSI, CA; CRAPO, JD				OURY, TD; PIANTADOSI, CA; CRAPO, JD			COLD-INDUCED BRAIN EDEMA IN MICE - INVOLVEMENT OF EXTRACELLULAR-SUPEROXIDE DISMUTASE AND NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; AQUEOUS-SOLUTION; NERVOUS-SYSTEM; FREE-RADICALS; ENDOTHELIUM; INJURY; ACID; PEROXYNITRITE; FERRIOXAMINE; INFARCTION	The role of extracellular superoxide in the pathogenesis of vasogenic edema was studied using transgenic mice expressing a 5-fold increase in extracellular superoxide dismutase (EC-SOD) activity in their brains. Increased EC-SOD expression offered significant protection against edema development after cold-induced injury (44% less edema than nontransgenic littermates, p < 0.05). Since iron may contribute to vasogenic edema by catalyzing the production of hydroxyl radical from superoxide and hydrogen peroxide, the effects of the chelator deferoxamine were studied. Deferoxamine reduced edema formation after cold-induced injury (43% less edema than controls, p < 0.05); however, treatment with iron-saturated deferoxamine also reduced edema development in mice (32-48% less edema, p < 0.05). This suggested that the protection offered by deferoxamine was independent of its ability to chelate iron. An iron-independent mechanism by which superoxide can contribute to vasogenic edema is via reaction with nitric oxide to produce the potentially toxic peroxynitrite anion, which is also scavenged by deferoxamine. Mice treated with an inhibitor of nitric oxide synthase were protected against cold-induced edema (37% less edema, p < 0.05). EC-SOD transgenic mice received no additional protection by inhibition of nitric oxide synthesis, supporting this novel alternative mechanism of edema formation.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	OURY, TD (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044571, P01HL031992] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44571, P01 HL31992] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1991, BIOCHEM J, V279, P263, DOI 10.1042/bj2790263; ADACHI T, 1989, J BIOL CHEM, V264, P8537; BARAT F, 1970, J CHEM SOC A, P1982, DOI 10.1039/j19700001982; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BLOUGH NV, 1985, INORG CHEM, V24, P3502, DOI 10.1021/ic00216a003; BULT H, 1988, BRIT J PHARMACOL, V95, P1308, DOI 10.1111/j.1476-5381.1988.tb11769.x; Chan P H, 1990, Adv Neurol, V52, P177; CHAN PH, 1984, FED PROC, V43, P210; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; ERLANSSON M, 1990, FREE RADICAL BIO MED, V9, P59, DOI 10.1016/0891-5849(90)90050-S; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1989, FREE RADICAL RES COM, V5, P315, DOI 10.3109/10715768909073413; HEIJMAN MGJ, 1985, RADIAT PHYS CHEM, V26, P83, DOI 10.1016/0146-5724(85)90037-8; HENDRICKSON DJ, 1990, GENOMICS, V8, P736, DOI 10.1016/0888-7543(90)90264-U; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HOE S, 1982, CHEM-BIOL INTERACT, V41, P75, DOI 10.1016/0009-2797(82)90018-7; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; Ikeda Y, 1990, Adv Neurol, V52, P203; INOUE M, 1990, FEBS LETT, V269, P89, DOI 10.1016/0014-5793(90)81126-9; KARLSSON K, 1988, BIOCHEM J, V255, P223; KEITH WG, 1969, J CHEM SOC A, P90, DOI 10.1039/j19690000090; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MONZYK B, 1982, J AM CHEM SOC, V104, P4921, DOI 10.1021/ja00382a031; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; NUCCI GD, 1988, P NATL ACAD SCI USA, V85, P2334; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; OURY TD, 1992, UNDERSEA BIOMED RE S, V19, P158; PATT A, 1990, J PEDIATR SURG, V25, P224, DOI 10.1016/0022-3468(90)90407-Z; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; Sambrook J, 1989, MOL CLONING LABORATO; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; WILLMORE LJ, 1982, BRAIN RES, V246, P113, DOI 10.1016/0006-8993(82)90147-0; YAMAMOTO S, 1992, J CEREBR BLOOD F MET, V12, P717, DOI 10.1038/jcbfm.1992.102	45	127	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15394	15398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687996				2022-12-25	WOS:A1993LN30500015
J	HOMA, FL; HOLLANDER, T; LEHMAN, DJ; THOMSEN, DR; ELHAMMER, AP				HOMA, FL; HOLLANDER, T; LEHMAN, DJ; THOMSEN, DR; ELHAMMER, AP			ISOLATION AND EXPRESSION OF A CDNA CLONE ENCODING A BOVINE UDP-GALNAC-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; CELL-LINE SF9; O-GLYCOSYLATION; HUMAN FIBRONECTIN; MESSENGER-RNA; PROTEIN; SEQUENCE; OLIGOSACCHARIDES; PURIFICATION; TRANSFERASE	NH2-terminal amino acid sequence obtained from a UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase) isolated from bovine colostrum was used for the construction of synthetic oligonucleotide primers. Subsequent polymerase chain reaction and library screenings of a bovine intestine cDNA library produced seven positive clones. The largest clone had a 2294-base pair insert that contained an open reading frame coding for a protein composed of 559 amino acids with a predicted polypeptide molecular mass of 64,173 Da. The cloned molecule has no significant sequence homology to previously reported cloned glycosyltransferases, but appears to have a similar domain structure. It is a type II membrane protein with a 23-amino acid putative transmembrane region starting 8 amino acids from the NH2 terminus. The transmembrane segment of the molecule is immediately followed by a sequence rich in proline residues. The molecule contains three consensus sequences for N-linked glycosylation and five predicted sites for O-glycosylation. Northern blot analysis of poly(A+) mRNA isolated from Madin-Darby bovine kidney cells, bovine mammary tissue, and eight human tissues demonstrated the expression of two transcripts differing in size by approximately 1 kilobase. The cloned DNA was expressed in insect cells using a baculovirus vector. This resulted in an almost 100=fold increase in GalNAc-transferase activity in lysates prepared from cells infected with virus containing the GalNAc-transferase gene compared to cells infected with virus containing DNA coding for an unrelated molecule or uninfected cells. Immunoprecipitation from lysates prepared from infected cells labeled in vivo with [S-35] methionine showed a large increase in the recovery of an approximately 67-kDa protein.	UPJOHN CO,BIOCHEM RES UNIT,7240-209-622,301 HENRIETTA ST,KALAMAZOO,MI 49001; UPJOHN CO,BIOCHEM RES UNIT,KALAMAZOO,MI 49001	Pfizer; Pfizer								BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BUSHWAY AA, 1979, BIOCHIM BIOPHYS ACTA, V572, P146, DOI 10.1016/0005-2760(79)90209-1; CHEN WY, 1991, J BIOL CHEM, V266, P6246; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; HAGOPIAN A, 1971, J BIOL CHEM, V246, P2519; HILL HD, 1977, J BIOL CHEM, V252, P3799; HOMA FL, 1986, MOL CELL BIOL, V6, P3652, DOI 10.1128/MCB.6.11.3652; HSIEH P, 1984, J BIOL CHEM, V259, P2375; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; PARODI AJ, 1984, MOL CELL BIOCHEM, V58, P157, DOI 10.1007/BF00240615; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRIEELS JP, 1975, EUR J BIOCHEM, V60, P525, DOI 10.1111/j.1432-1033.1975.tb21031.x; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SUMMERS MD, 1986, MANUAL METHODS BACUL; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; THOMSEN DR, 1990, J CELL BIOCHEM, V43, P67, DOI 10.1002/jcb.240430107; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG Y, 1992, J BIOL CHEM, V267, P12706; WATHEN MW, 1991, BIOCHEMISTRY-US, V30, P2863, DOI 10.1021/bi00225a019; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P2512; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	48	151	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12609	12616						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685345				2022-12-25	WOS:A1993LG65800058
J	PANETTI, TS; MCKEOWNLONGO, PJ				PANETTI, TS; MCKEOWNLONGO, PJ			THE ALPHA(V)BETA(5) INTEGRIN RECEPTOR REGULATES RECEPTOR-MEDIATED ENDOCYTOSIS OF VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR INHIBITOR-1; THROMBIN-ANTITHROMBIN-III; EXTRACELLULAR-MATRIX; CELL-SURFACE; HUMAN-PLASMA; VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; ADHESION RECEPTOR; S-PROTEIN; FIBRONECTIN	Vitronectin is an adhesive glycoprotein that binds to the extracellular matrix and interacts with integrin receptors on the surface of adherent cells. Previous studies have demonstrated that the conformationally altered, heparin binding form of vitronectin is removed from the matrix by receptor-mediated endocytosis and degraded through a lysosomal pathway (Panetti, T. S., and McKeown-Longo, P. J. (1993) J. Biol. Chem. 268, 11988-11993). The present studies were undertaken to determine the role of cell surface integrins in the endocytosis and degradation of vitronectin. RGDS peptides, used to disrupt the binding of vitronectin to cell surface integrins, inhibited degradation of vitronectin but had no effect on the binding of vitronectin to the cell layer. Localization of vitronectin in the cell layer by indirect immunofluorescence indicated that the RGDS peptides inhibited degradation by preventing the internalization of vitronectin by the cells. To determine which vitronectin receptor was involved in mediating the endocytosis, vitronectin degradation was measured in the presence of monoclonal antibodies. Antibodies against the alpha(v)beta5 but not the alpha(v)beta3 integrin inhibited degradation of vitronectin by 80%. This study demonstrates a new role for integrins in regulating internalization and degradation of molecules from the extracellular matrix.	ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,NEIL HELLMAN MED RES BLDG,ALBANY,NY 12208	Albany Medical College					NATIONAL CANCER INSTITUTE [R01CA037785, R01CA058626, R56CA058626] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37785, CA-58626] Funding Source: Medline; NHLBI NIH HHS [HL-01794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLYSTONE SD, 1991, BLOOD, V78, P2900; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; HANDAGAMA P, 1993, J CLIN INVEST, V91, P193, DOI 10.1172/JCI116170; HARRISON P, 1989, J CLIN INVEST, V84, P1320, DOI 10.1172/JCI114300; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; ILL CR, 1985, J BIOL CHEM, V260, P5610; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KRUITHOF EKO, 1984, BLOOD, V64, P907; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PODACK ER, 1978, J IMMUNOL, V120, P1841; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; SMITH JW, 1990, J BIOL CHEM, V265, P11008; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7671; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WOODS A, 1992, ADV EXP MED BIOL, V313, P87; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	38	98	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11492	11495						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685013				2022-12-25	WOS:A1993LF28400006
J	DIAZ, A; MUNOZ, E; JOHNSTON, R; KORN, JH; JIMENEZ, SA				DIAZ, A; MUNOZ, E; JOHNSTON, R; KORN, JH; JIMENEZ, SA			REGULATION OF HUMAN LUNG FIBROBLAST-ALPHA-1(I) PROCOLLAGEN GENE-EXPRESSION BY TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-1-BETA, AND PROSTAGLANDIN-E(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA LEVELS; GROWTH-FACTOR-BETA; COLLAGEN-SYNTHESIS; INTERFERON-GAMMA; RECOMBINANT INTERLEUKIN-1; INHIBITS COLLAGEN; DEOXYRIBONUCLEIC-ACID; SYNOVIAL-CELLS; III COLLAGENS	We investigated the participation of prostaglandin (PG) E2 in the regulation of the alpha1(I) procollagen gene expression by tumor necrosis factor alpha (TNFalpha), and interleukin-1beta (IL-1beta) in normal adult human lung fibroblasts. TNFalpha (100 units/ml) and IL-1beta (100 units/ml) stimulated the production of PGE2 and caused a dose-dependent inhibition of up to 54 and 66%, respectively, of the production of type I procollagen. Preincubation of cultures with indomethacin partially reversed the inhibition of procollagen production induced by the cytokines. Cytokine-stimulated endogenous fibroblast PG accounted for 35 and 68% of the inhibition induced by TNFalpha and IL-1beta, respectively. Steady-state mRNA levels for alpha1(I) procollagen paralleled the changes in collagen production. The transcription rate of the alpha1(I) procollagen gene was reduced by 58% by TNFalpha and by 43% by IL-1beta. Cytokine-stimulated endogenous PG production accounted for half of these effects. These results indicate that TNFalpha and IL-1beta inhibit the expression of the alpha1(I) procollagen gene in human lung fibroblasts at the transcriptional level by a PGE2-independent effect as well as through the effect of endogenous fibroblast PGE2 released under the stimulus of the cytokines.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL,ROOM 509 BLUEMLE LIFE SCI BLDG,PHILADELPHIA,PA 19107; UNIV CONNECTICUT,SCH MED,VET ADM MED CTR,DIV RHEUMAT DIS,NEWINGTON,CT 06111	Jefferson University; University of Connecticut; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System				Jimenez, Sergio/0000-0001-5213-1203	NHLBI NIH HHS [HL 41214] Funding Source: Medline; NIAMS NIH HHS [AR 32343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SL, 1989, AM J RESP CELL MOL, V1, P161, DOI 10.1165/ajrcmb/1.3.161; ARENZANASEISDEDOS F, 1988, P NATL ACAD SCI USA, V85, P6087, DOI 10.1073/pnas.85.16.6087; BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8; BARILE FA, 1988, ARCH BIOCHEM BIOPHYS, V265, P441, DOI 10.1016/0003-9861(88)90147-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BHATNAGAR R, 1986, BIOCHEM INT, V13, P709; BISSONNETTE E, 1989, INFLAMMATION, V13, P329, DOI 10.1007/BF00914399; BREUL SD, 1980, J BIOL CHEM, V255, P5250; CANALIS E, 1986, ENDOCRINOLOGY, V118, P74, DOI 10.1210/endo-118-1-74; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DIAZ A, 1992, J BIOL CHEM, V267, P10816; DUBOIS CM, 1989, AM REV RESPIR DIS, V139, P1257, DOI 10.1164/ajrccm/139.5.1257; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; ELIAS JA, 1990, ANN NY ACAD SCI, V580, P233, DOI 10.1111/j.1749-6632.1990.tb17932.x; ELIAS JA, 1988, J CLIN INVEST, V81, P325, DOI 10.1172/JCI113324; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; GOLDSTEIN RH, 1986, J BIOL CHEM, V261, P8734; HAMPSON F, 1989, AM J PHYSIOL, V256, pC336, DOI 10.1152/ajpcell.1989.256.2.C336; HARRISON JR, 1990, MOL ENDOCRINOL, V4, P184, DOI 10.1210/mend-4-2-184; KAHALEH MB, 1988, CLIN IMMUNOL IMMUNOP, V49, P261, DOI 10.1016/0090-1229(88)90116-X; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KORN JH, 1985, ARTHRITIS RHEUM, V28, P315, DOI 10.1002/art.1780280312; KORN JH, 1983, J CLIN INVEST, V71, P1240, DOI 10.1172/JCI110873; LAURENT GJ, 1986, THORAX, V41, P418, DOI 10.1136/thx.41.6.418; LE JM, 1987, LAB INVEST, V56, P234; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; MARTINET Y, 1988, AM REV RESPIR DIS, V138, P659, DOI 10.1164/ajrccm/138.3.659; MARUSIC A, 1991, ENDOCRINOLOGY, V129, P2699, DOI 10.1210/endo-129-5-2699; MAUVIEL A, 1988, FEBS LETT, V236, P47, DOI 10.1016/0014-5793(88)80283-7; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1988, BIOCHEM J, V252, P247, DOI 10.1042/bj2520247; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; RAISZ LG, 1974, PROSTAGLANDINS, V8, P377, DOI 10.1016/0090-6980(74)90113-0; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHARFFETTER K, 1989, EXP CELL RES, V181, P409, DOI 10.1016/0014-4827(89)90098-0; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; TYLER JA, 1988, COLLAGEN REL RES, V8, P393; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7	53	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10364	10371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683676				2022-12-25	WOS:A1993LB80000059
J	END, P; GOUT, I; FRY, MJ; PANAYOTOU, G; DHAND, R; YONEZAWA, K; KASUGA, M; WATERFIELD, MD				END, P; GOUT, I; FRY, MJ; PANAYOTOU, G; DHAND, R; YONEZAWA, K; KASUGA, M; WATERFIELD, MD			A BIOSENSOR APPROACH TO PROBE THE STRUCTURE AND FUNCTION OF THE P85-ALPHA-SUBUNIT OF THE PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; PDGF RECEPTOR; SIGNAL TRANSDUCTION; BOVINE BRAIN; SH2 DOMAINS; RAT-LIVER; MIDDLE-T; PROTEINS; PHOSPHORYLATION	Phosphatidylinositol 3-kinase, which generates putative novel second messenger phospholipids, is a heterodimer composed of regulatory adaptor 85-kDa and catalytic 110-kDa subunits. The p85alpha subunit contains a NH2-terminal src homology (SH) 3 domain, a region with homology to the product of the breakpoint cluster region (bcr) gene, and a COOH-terminal portion of the molecule which contains two SH2 domains, separated by a spacer region. In this study a panel of monoclonal antibodies (mAb) was raised against recombinant bovine p85alpha to probe its multidomain structure in relation to function. These mAbs were characterized using a BIAcore biosensor instrument. Epitopes for nine mAbs were mapped in relation to the domain structure of p85alpha using recombinant protein fragments expressed in bacteria. These mAbs were then used to map the sites on p85alpha which are involved in growth factor receptor binding. Two interesting classes of functional mAbs were identified. First, mAb U14, whose epitope lies within the NH2-terminal SH2 domain of p85alpha, blocked the interaction of p85alpha with activated protein-tyrosine kinase receptors. Second, real-time binding experiments using phospholipid-containing vesicles showed that p85alpha by itself could specifically bind certain phospholipids. Two mAbs (U9 and U15) with epitopes located in the inter-SH2 spacer region blocked the binding of lipids to this site. The relevance of these observations to understanding the relationship of structure to function of p85 and the phosphatidylinositol 3-kinase are discussed.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; KOBE UNIV,SCH MED,CHUO KU,KOBE 650,JAPAN; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Ludwig Institute for Cancer Research; Kobe University; University of London; University College London				Fry, Michael/0000-0001-8518-1370				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARDELLI A, 1992, ONCOGENE, V7, P1973; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HALL A, 1992, CELL, V69, P398; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; JONSSON U, 1992, ADV BIOSENSORS, V2; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PELES E, 1992, J BIOL CHEM, V267, P12266; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHANG J, 1992, J BIOL CHEM, V267, P4686	58	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10066	10075						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683666				2022-12-25	WOS:A1993LB80000022
J	GETHER, U; JOHANSEN, TE; SCHWARTZ, TW				GETHER, U; JOHANSEN, TE; SCHWARTZ, TW			CHIMERIC NK1 (SUBSTANCE-P)NK3 (NEUROKININ-B) RECEPTORS - IDENTIFICATION OF DOMAINS DETERMINING THE BINDING-SPECIFICITY OF TACHYKININ AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SUBSTANCE-P RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; EXTRACELLULAR DOMAIN; SELECTIVE AGONISTS; LIGAND-BINDING; K RECEPTOR; EXPRESSION; CDNA; INHIBITORS	The NK1 (substance P) and NK3 (neurokinin B) receptors are G protein-coupled receptors sharing approximately 70% identity within the membrane-spanning domains. However, they each have a distinct pharmacological profile in respect of peptide binding. To identify epitopes that determine their selectivity for natural and synthetic tachykinin peptides, we constructed a series of chimeric NK1/NK3 receptors in which carboxyl-terminal segments of increasing length in the NK1 receptor were exchanged with the corresponding segments from the NK3 receptor. The general, structural integrity of the chimeric constructs was confirmed by the amphibian tachykinin peptide, eledoisin, which was recognized equally well by both of the wild-type receptors and bound with a similar or even higher affinity to all the chimeric receptors. Competition binding studies showed that the affinity of the two natural ligands, substance P and neurokinin B, changed gradually through the series of chimeric receptors indicating that several binding epitopes throughout the receptor structure are involved in the selective recognition of these peptides. However, whereas the single, largest change in binding affinity for substance P occurred when segments in the amino-terminal end of the receptor were exchanged, this occurred for neurokinin B in the carboxyl-terminal end of the receptor. The affinity of the NK1-selective ligand, [Sar9,Met(O2)11]SP, changed even more gradually through the series of chimeric receptors than that of substance P. In contrast, the NK3-selective hexapeptide, senktide, was recognized only when transmembrane segment III and IV from the NK3 receptor were incorporated into the chimeric constructs. These data suggest that several receptor domains contribute to the binding specificity of tachykinin agonists but in varying degrees for each peptide. It is concluded that the tachykinin peptides, in partially different ways, interact with multiple epitopes scattered throughout the receptor structure, but conceivably these epitopes are closely located in space around a hypothetical receptor center.			GETHER, U (corresponding author), UNIV COPENHAGEN, RIGSHOSP 6321, DEPT CLIN BIOCHEM, MOLEC ENDOCRINOL LAB, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807				BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; CASCIERI MA, 1985, J BIOL CHEM, V260, P1501; CHANG MM, 1970, J BIOL CHEM, V245, P4784; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOPHYS J, V62, P59, DOI 10.1016/S0006-3495(92)81778-2; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; INGI T, 1991, J PHARMACOL EXP THER, V259, P968; IVERSEN LL, 1990, ALFRED BENZON SYMP S, V29, P363; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PERNOW B, 1983, PHARMACOL REV, V35, P85; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WATLING KJ, 1992, TRENDS PHARMACOL SCI, V13, P266, DOI 10.1016/0165-6147(92)90082-H; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	36	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7893	7898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681831				2022-12-25	WOS:A1993KW97900048
J	HAEFNER, B; BAXTER, R; FINCHAM, VJ; DOWNES, CP; FRAME, MC				HAEFNER, B; BAXTER, R; FINCHAM, VJ; DOWNES, CP; FRAME, MC			COOPERATION OF SRC HOMOLOGY DOMAINS IN THE REGULATED BINDING OF PHOSPHATIDYLINOSITOL-3-KINASE - A ROLE FOR THE SRC HOMOLOGY-2 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; EPIDERMAL GROWTH-FACTOR; KINASE-ACTIVITY; SH3 DOMAIN; V-SRC; PI 3-KINASE; PP60V-SRC; PROTEIN; TRANSFORMATION; ASSOCIATION	Fibroblasts transformed by the v-Src oncoprotein exhibit elevated activity of the enzyme phosphatidylinositol 3'-kinase (PI 3-kinase), which binds to, and is activated by, a wide range of receptor tyrosine kinases as well as v-Src and transforming polyoma middle T/c-Src complexes. Here we consider the role of the v-Src homology (SH) domains, SH3 and SH2, and the tyrosine kinase catalytic domain, in the stimulation of v-Src-associated PI 3-kinase activity in response to rapid activation of the oncoprotein. As shown by others, we find that the v-Src SH3 domain tightly binds the PI 3-kinase p85 regulatory subunit in normal growing chicken embryo fibroblasts. However, we also find that in transformed cells there is additional efficient binding of PI 3-kinase to the v-Src SH2 domain in a catalytically active form. Furthermore, the binding of p85 to the SH2 domain, which is almost undetectable in quiescent cells, is rapidly stimulated upon activation of temperature-sensitive v-Src and consequent cell cycle entry, demonstrating that binding is a target for regulation. We also show that v-Src-associated PI 3-kinase differs considerably hom PDGF receptor-associated enzyme by a different mode of binding, a lack of substantial allosteric activation, and a dependence on the tyrosine kinase activity of v-Src. The rapidly induced binding and activation of PI 3-kinase thus provides sensitive regulation of recruitment of PI 3-kinase to its substrates and into other signaling complexes at the cell membrane, which involves all the Src homology domains.	BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Beatson Institute; University of Dundee								BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CATLING AD, 1993, ONCOGENE, V8, P1875; CATLING AD, 1994, J VIROL, V7, P4392; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1991, CELL SIGNAL, V3, P747; FINCHAM V, 1994, CELL BIOL INT, V18, P337, DOI 10.1006/cbir.1994.1083; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1994, J BIOL CHEM, V269, P5403; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLEIMAN CM, 1994, SCIENCE, V163, P1609; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	36	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7937	7943		10.1074/jbc.270.14.7937	http://dx.doi.org/10.1074/jbc.270.14.7937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713890	hybrid			2022-12-25	WOS:A1995QR52600026
J	HIGUCHI, Y; LINN, S				HIGUCHI, Y; LINN, S			PURIFICATION OF ALL FORMS OF HELA-CELL MITOCHONDRIAL-DNA AND ASSESSMENT OF DAMAGE TO IT CAUSED BY HYDROGEN-PEROXIDE TREATMENT OF MITOCHONDRIA OR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; MOUSE L; OXYGEN; SEQUENCE; GENOME; REPAIR; ACID	A purification scheme for mitochondrial DNA (mtDNA) ws designed which maximized the yield of all forms of the DNA while minimizing damage to the DNA during its isolation. Treatment of intact mitochondria with DNase I removed nuclear DNA and the avoidance of phenol and the isolation by CsCl density gradients in the absence of ethidium bromide and subsequent detection by southern hybridization of dot-blots minimized DNA damage. Four different mtDNA forms free of apparent nuclear DNA were obtained: closed circular (I), open circular (II), linear (III), and a large multimer complex (C) which were characterized by agarose gel electrophoresis and electron microscopy. Using this procedure, mtDNA was obtained from both whole cells or intact mitochondria treated with H2O2. Significant fragmentation was observed after treatment at 37 degrees C, but not at 0 degrees C, and more damage was observed when treating whole cells than isolated mitochondria. Very low levels of 8-hydroxydeoxyguanosine were observed in all cases. However, at doses of H2O2 which were just lethal, neither increased DNA damage nor inactivation of cytochrome c oxidase was observed.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R43ES011896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM019020] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES011896] Funding Source: Medline; NIGMS NIH HHS [R29GM19020] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AUDIC A, 1993, PHOTOCHEM PHOTOBIOL, V57, P508, DOI 10.1111/j.1751-1097.1993.tb02327.x; BEAUFAY H, 1959, BIOCHEM J, V73, P623, DOI 10.1042/bj0730623; Becker R, 1974, METHODS ENZYMATIC AN, V3, P286; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLAYCAMP HG, 1992, CARCINOGENESIS, V13, P1289, DOI 10.1093/carcin/13.7.1289; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CURTIS PJ, 1966, BIOCHEM J, V98, P818, DOI 10.1042/bj0980818; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P113; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FISCHERNIELSEN A, 1992, FREE RADICAL BIO MED, V13, P121, DOI 10.1016/0891-5849(92)90073-P; Halliwell B., 1990, METHOD ENZYMOL, V186, P1; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; LIN JH, 1991, BIOCHEM BIOPH RES CO, V176, P690, DOI 10.1016/S0006-291X(05)80239-6; LINN S, 1994, MOL ASPECTS AGING; LOW RL, 1987, J BIOL CHEM, V262, P16164; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; MYERS KA, 1988, CARCINOGENESIS, V9, P285, DOI 10.1093/carcin/9.2.285; PALVA TK, 1985, FEBS LETT, V192, P267, DOI 10.1016/0014-5793(85)80122-8; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; WALLACE DC, 1992, SCIENCE, V265, P628; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	31	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7950	7956		10.1074/jbc.270.14.7950	http://dx.doi.org/10.1074/jbc.270.14.7950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713892	hybrid			2022-12-25	WOS:A1995QR52600028
J	CHOU, MM; HANAFUSA, H				CHOU, MM; HANAFUSA, H			A NOVEL LIGAND FOR SH3 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING; GROWTH-FACTOR; RAS; NCK; BINDS; PHOSPHORYLATION	We have previously shown that overexpression of the SH2- and SH3-containing Nck adaptor protein causes transformation of mammalian fibroblasts. To elucidate the mechanism by which it deregulates growth, we have sought to identify potential effecters for Nck. We report that a serine/threonine kinase, which we term NAK (for Nck-associated kinase), associates with Nck in vivo and in vitro. Using glutathione S-transferase fusion proteins generated with isolated domains of Nck, we demonstrate that NAK binds specifically to the second of Nck's three SH3 domains. NAK is complexed with Nck in a wide variety of cell types, including NIH3T3, A431, PC12, and HeLa cells.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356, T32CA009673] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09673, R35CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIBE S, 1990, SCIENCE, V248, P1253; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1993, J BIOL CHEM, V268, P14956	28	46	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7359	7364		10.1074/jbc.270.13.7359	http://dx.doi.org/10.1074/jbc.270.13.7359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706279	hybrid			2022-12-25	WOS:A1995QQ43100052
J	TAMAI, K; SILOS, SA; LI, KH; KORKEELA, E; ISHIKAWA, H; UITTO, J				TAMAI, K; SILOS, SA; LI, KH; KORKEELA, E; ISHIKAWA, H; UITTO, J			TISSUE-SPECIFIC EXPRESSION OF THE 230-KDA BULLOUS PEMPHIGOID ANTIGEN GENE (BPAG1) - IDENTIFICATION OF A NOVEL KERATINOCYTE REGULATORY CIS-ELEMENT KRE3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE ZONE; DNA-SEQUENCES; CDNA CLONING; I COLLAGEN; POU DOMAIN; TRANSCRIPTION; PROTEIN; BINDING; DIFFERENTIATION; ACTIVATION	The 230-kDa bullous pemphigoid antigen gene (BPAG1) is expressed exclusively in basal keratinocytes of epidermis. In this study, we have identified a novel cis element, keratinocyte responsive element 3 (KRE3), at position -216 to -197 of the human BPAG1 gene. A promoter-CAT construct containing this element had similar to 50-fold higher expression than a similar construct devoid of this sequence when tested in transient transfections of cultured human keratinocytes. However, there was no effect on the low base-line level of expression in cultured skin fibroblasts. KRE3 contains a palindromic sequence 5'-CAAATATTTG-3', and mutations in this sequence significantly reduced the promoter activity. Gel mobility shift assays with an oligomer containing KRE3 sequence demonstrated binding activity with nuclear proteins isolated from keratinocytes. One of the DNA/protein complexes was clearly specific, since competition with >12.5-fold excess of the unlabeled oligomer resulted in disappearance of this band. No specific binding activity was noted with nuclear proteins extracted from fibroblasts, Thus, KRE3 appears to serve as the binding site for keratinocyte-specific trans-activating factor(s), and KRE3 may thus confer the tissue-specific expression to the BPAG1 gene.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923, T32AR007561] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARNEMANN J, 1993, J CELL SCI, V104, P741; BOAST S, 1990, J BIOL CHEM, V265, P13351; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HUFF CA, 1993, J BIOL CHEM, V268, P377; JORDAN RE, 1967, JAMA-J AM MED ASSOC, V200, P91; JORDON RE, 1971, ARCH DERMATOL, V103, P486, DOI 10.1001/archderm.103.5.486; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LI KH, 1993, J BIOL CHEM, V268, P8825; LI KH, 1992, J INVEST DERMATOL, V99, P258, DOI 10.1111/1523-1747.ep12616611; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TAMAKA M, 1994, GENE DEV, V269, P493; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANAKA T, 1991, J BIOL CHEM, V266, P12555; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; UITTO J, 1988, COLLAGEN, V4, P109; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	46	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7609	7614		10.1074/jbc.270.13.7609	http://dx.doi.org/10.1074/jbc.270.13.7609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706309	hybrid			2022-12-25	WOS:A1995QQ43100086
J	JEON, IS; DAVIS, JN; BRAUN, BS; SUBLETT, JE; ROUSSEL, MF; DENNY, CT; SHAPIRO, DN				JEON, IS; DAVIS, JN; BRAUN, BS; SUBLETT, JE; ROUSSEL, MF; DENNY, CT; SHAPIRO, DN			A VARIANT EWINGS-SARCOMA TRANSLOCATION (7-22) FUSES THE EWS GENE TO THE ETS GENE ETV1	ONCOGENE			English	Article							NEUROECTODERMAL TUMOR; TRANSCRIPTION FACTORS; BINDING-PROTEIN; ONCOGENE FAMILY; FUSION; CHROMOSOME; DOMAIN; MEMBER; SPECIFICITIES; LIPOSARCOMA	Most Ewing's sarcomas or related primitive neuroectodermal tumors have the (11;22)(q24;q12) or less frequently the (21;22)(q22;q12) translocation. These rearrangements fuse the EWS gene on chromosome 22q12 to either the FLI1 or ERG genes, both members of the ETS family of transcription factors. Simple variant chromosomal translocations have been occasionally described in these tumors. We have identified a third Ewing's sarcoma translocation, the t(7;22)(q22;q12), that fuses EWS to the human homologue of the murine ETS gene ER81, This gene, designated ETV1 (for ETS Translocation Variant), is located on chromosome band 7p22. Identical EWS nucleotide sequences found in the majority of EWS-FLI1 and EWS-ERG chimeric transcripts are fused to a portion of ETV1 encoding an ETS domain with sequence specific DNA-binding activity. These findings confirm that the fusion of EWS to different ETS family members can result in a similar tumor phenotype.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Tennessee System; University of Tennessee Health Science Center			Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA056819, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56819, CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOUGLASS EC, 1986, J NATL CANCER I, V77, P1211; DOWNING JR, 1993, AM J PATHOL, V143, P1294; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KAWAMOTO EH, 1987, CANCER, V59, P1791, DOI 10.1002/1097-0142(19870515)59:10<1791::AID-CNCR2820591018>3.0.CO;2-#; LADANYI M, 1994, CANCER RES, V54, P2837; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTE D, 1994, ONCOGENE, V9, P1397; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SOUKUP S, 1986, American Journal of Human Genetics, V39, pA43; SQUIRE J, 1993, GENE CHROMOSOME CANC, V8, P190, DOI 10.1002/gcc.2870080309; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; TURCCUREL C, 1983, NEW ENGL J MED, V309, P492; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	422	445	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1229	1234						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700648				2022-12-25	WOS:A1995QN35300025
J	OKAZAKI, K; SAGATA, N				OKAZAKI, K; SAGATA, N			MAP KINASE ACTIVATION IS ESSENTIAL FOR ONCOGENIC TRANSFORMATION OF NIH3T3 CELLS BY MOS	ONCOGENE			English	Article						MAP KINASE; MOS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFORMATION	SIGNAL-REGULATED KINASE; MAMMALIAN SOMATIC-CELLS; NERVE GROWTH-FACTOR; PROTEIN-KINASE; XENOPUS-OOCYTES; IN-VITRO; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; SARCOMA-VIRUS; FROG OOCYTES	The c-mos proto-oncogene product, Mos, is a serine/threonine protein kinase that controls the meiotic cell cycle in vertebrate oocytes. Both;in vivo and in vitro, Mos can activate mitogen-activated protein kinase (MAPK) most probably by direct phosphorylation of MAPK kinase (MAPKK). In many cell types transformed by diverse oncogene products such as Raf, MAPK is constitutively activated, suggesting that the MAPK pathway may mediate oncogenic signalling by many oncogene products. Using mouse NIH3T3 cells, we examined whether oncogenic transformation by Mos is mediated by MAPK activation. Coexpression of a kinase-defective (dominant-negative) mutant of Mek1, one of the MAPKK isoforms, completely suppressed transformation by Mos. By contrast, coexpression of wild-type Mek1 markedly enhanced the transforming efficiency of Mos. Moreover, overexpression of the dominant-negative Mek1 reverted the transformation phenotype of Mos-transformed cells. These results indicate that in NIH3T3,cells the Mek1/MAPK pathway is necessary and sufficient for transformation (and its maintenance) by Mos. Transformation of NIH3T3 cells by Raf or Ras was also suppressed by the dominant-negative Mek1, but significantly less efficiently than that by Mos, suggesting the existence of multiple signalling pathways for Raf and Ras oncoproteins.			OKAZAKI, K (corresponding author), KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN.		Okazaki, Kenji/H-4393-2012					ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sambrook J., 1989, MOL CLONING; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	74	67	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700641				2022-12-25	WOS:A1995QN35300016
J	KIRKLAND, TN; FINLEY, F; LETURCQ, D; MORIARTY, A; LEE, JD; ULEVITCH, RJ; TOBIAS, PS				KIRKLAND, TN; FINLEY, F; LETURCQ, D; MORIARTY, A; LEE, JD; ULEVITCH, RJ; TOBIAS, PS			ANALYSIS OF LIPOPOLYSACCHARIDE-BINDING BY CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING; BACTERIAL LIPOPOLYSACCHARIDE; 70Z/3 CELLS; PROTEIN; RECEPTOR; SITES; IDENTIFICATION; ENDOTOXINS; PHAGOCYTES; COMPLEXES	The cell surface protein CD14 binds bacterial lipopolysaccharide (LPS) in the presence of the serum protein, LPS-binding protein (LBP). This interaction is important for LPS-induced activation of mammalian myeloid cells. We performed quantitative studies of H-3-labeled LPS binding to human CD14 expressed on Chinese hamster ovary cells and on a human macrophage cell line (THP-1). At the concentrations studied (20-100 nM) LPS binding required the expression of CD14 and could be inhibited by a subset of anti-CD14 monoclonal antibodies. LBP was required for LPS binding to CD14. The binding occurred within 10 min and was relatively unaffected by temperature over the range of 4-37-degrees-C. Quantitative binding assays were performed at 10-degrees-C, or at 37-degrees-C, using Chinese hamster ovary cells depleted of ATP. In both cases, 75-90% of the LPS could be released by treatment with phosphatidylinositol-specific phospholipase C, suggesting that it remains associated with the glycosyl phosphatidylinostol-anchored CD14. The apparent dissociation constant of recombinant human CD14 expressed on Chinese hamster ovary cells for LPS at 10-degrees-C was 2.74 (+/- 0.99) x 10(-8) M; the apparent dissociation constant of CD14 expressed on THP-1 cells at 10-degrees-C was 4.89 (+/- 1.42) x 10(-8) M. In both cell lines, at saturating LPS concentrations, the molar ratio of LPS bound per surface CD14 was approximately 20:1. At 37-degrees-C the apparent dissociation constant of recombinant human CD14 for LPS at 37-degrees-C was 2.7 (+/- 1.2) x 10(-8) M, and the molar ratio of LPS bound per surface CD14 was approximately 8:1. Although the difference in molar ratio of LPS bound per surface CD14 at the two temperatures is difficult to interpret, it is clear that at both temperatures the molar ratio is not 1:1. The basis of this phenomenon is unclear, but may involve the repeated leucine-rich motifs, which are found within CD14.	UNIV CALIF SAN DIEGO, DEPT PATHOL, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	KIRKLAND, TN (corresponding author), VET ADM MED CTR, 111F, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.		Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, P01GM037696, R37GM028485] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696, GM28485] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHMUN RA, 1987, BLOOD, V69, P886; BRANDENBURG K, 1992, J STRUCT BIOL, V108, P93, DOI 10.1016/1047-8477(92)90010-8; COUTURIER C, 1991, J IMMUNOL, V147, P1899; FERRERO E, 1990, J IMMUNOL, V145, P331; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GOLENBOCK DT, 1990, INFECT IMMUN, V58, P4069, DOI 10.1128/IAI.58.12.4069-4075.1990; HEUMANN D, 1992, J IMMUNOL, V148, P3505; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEI MG, 1988, J IMMUNOL, V141, P996; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TAKAYAMA K, 1990, J BIOL CHEM, V265, P14023; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; ULEVITCH RJ, 1981, J CLIN INVEST, V67, P827, DOI 10.1172/JCI110100; WOLFF SM, 1974, NEW ENGL J MED, V291, P733, DOI 10.1056/NEJM197410032911411; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	23	140	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24818	24823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693705				2022-12-25	WOS:A1993MG67300047
J	KO, YH; THOMAS, PJ; DELANNOY, MR; PEDERSEN, PL				KO, YH; THOMAS, PJ; DELANNOY, MR; PEDERSEN, PL			THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF WILD-TYPE AND DELTA-F508 MUTANT FORMS OF THE 1ST NUCLEOTIDE-BINDING FOLD IN FUSION WITH THE MALTOSE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; SYNTHETIC PEPTIDE; SEQUENCE ANALYSIS; DNA-POLYMERASE; R-DOMAIN; GENE; IDENTIFICATION; PHOSPHORYLATION; NUCLEOSIDE; MUTATIONS	The first nucleotide binding fold (NBF1) of the cystic fibrosis transmembrane conductance regulator (CFTR) and its disease-causing mutant form (DELTAF508,NBF1) were overexpressed in high yield in Escherichia coli in fusion with the maltose-binding protein (MBP). The rationale for producing the chimerae was to aid in domain purification, solubilization, and crystallization and to examine the effect of protein-protein interactions on the properties of the mutant NBF1. Both the purified wild type and DELTAF508 mutant fusion proteins fold into functional nucleotide binding domains as determined by using the fluorescent nucleotide analog TNP-ATP (2'-(3')-O-(2,4,6-trinitrophenyl)adenosine-5'-triphosphate). Moreover, the prominent secondary structural features of the two proteins as assessed by ultraviolet circular dichroism spectropolarimetry are very similar, as is the higher order structure evident in three separate protease digestion patterns. Finally, the stability of the nucleotide binding function of the two proteins is similar as assessed by sensitivity to urea. Gel filtration chromatography and electron and confocal microscopy reveal that both fusion proteins, but not MBP alone, form organized fibers, suggesting that NBF1 self-associates, thus raising the possibility that CFTR may be oligomeric in the plasma membrane. Significantly, in the presence of high salt, these fusion proteins also have a propensity to form microcrystals. Finally, the two separate domains (NBF1 and MBP) constituting the fusion proteins appear to interact quite strongly as both proteins remain associated even after cleavage of their fusion junction. The possible relevance of these novel findings to those approaches that might be taken to elucidate the three-dimensional structural differences between the wild type and DELTAF508 mutant forms of CFTR, as well as to ameliorate the severity of cystic fibrosis, is discussed.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [DK 43962] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043962] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Cheadle Jeremy P., 1992, Human Molecular Genetics, V1, P123, DOI 10.1093/hmg/1.2.123; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GUAN C, 1987, GENE, V67, P21; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KEREM B, 1980, SCIENCE, V245, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Marston F. A. O., 1987, DNA CLONING, P59; MCDONALD TV, 1992, J BIOL CHEM, V267, P3242; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WITHOLT B, 1976, BIOCHIM BIOPHYS ACTA, V443, P534, DOI 10.1016/0005-2736(76)90471-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	69	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24330	24338						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693699				2022-12-25	WOS:A1993MF29400092
J	STOCKMANN, A; HESS, S; DECLERCK, P; TIMPL, R; PREISSNER, KT				STOCKMANN, A; HESS, S; DECLERCK, P; TIMPL, R; PREISSNER, KT			MULTIMERIC VITRONECTIN - IDENTIFICATION AND CHARACTERIZATION OF CONFORMATION-DEPENDENT SELF-ASSOCIATION OF THE ADHESIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; THROMBIN-ANTITHROMBIN-III; SERUM SPREADING FACTOR; HEPARIN-BINDING PROPERTIES; HUMAN-ENDOTHELIAL-CELLS; HUMAN S-PROTEIN; COMPLEMENT COMPLEX; POLYMERIZATION; MEMBRANE; INVITRO	The adhesive glycoprotein vitronectin (VN) shows a high degree of conformational flexibility implicating that different molecular forms of the molecule may exist. Conformation-dependent monoclonal antibodies 13H1 or 16A7 that, per se, did not react with plasma VN bound to VN treated with heparin, chaotropes, detergents, pH below 6, or by heating at 56-degrees-C. Dependent on the stimulus, recognition of VN by these antibodies varied and preceded heparin binding and self-association of VN resulting in the formation of noncovalently linked multimeric species of the protein. Both monoclonal antibodies also reacted with VN in serum or in platelet releasates as well as with VN in extracellular matrices of endothelial cells and inhibited cell adhesion on immobilized VN. Critical VN levels were needed for concentration-dependent multimerization indicating a nonlinear type of polymerization process. The nature of VN multimers was judged by nondenaturing gel electrophoresis, gel filtration, and sucrose gradient ultracentrifugation and revealed the formation of 3- to 16-mer multimeric species within an M(r) range of 200-1200 kDa representing a mean sedimentation coefficient of 9.6 S. In electron microscopy, multimeric VN occurred as globular specimens with an average diameter of 15-28 nm (monomeric plasma VN, 6-8 nm). In contrast to plasma VN, VN multimers were efficiently stabilized by covalent inter-molecular bonds following chemical or transglutaminase-induced cross-linking. A synthetic peptide comprising the central heparin binding region of VN (residues 348-361) not only bound to plasma VN but induced its multimerization also in plasma. During plasmin proteolysis of VN, fragments were generated that lacked the heparin binding region and that lost the ability to multimerize following urea or detergent treatment, implicating that the highly basic region is essential for multimer formation. These data suggest that non-plasma forms of VN, which are abundant in platelets and subendothelium, represent the prototype conformer of the reactive heparin binding form of VN. Our findings implicate that conformationally altered forms of VN enable the adhesive protein to multimerize in a characteristic fashion and thereby endow extracellular matrix sites with unique multivalent properties.	MAX PLANCK INST PHYSIOL & CLIN RES,KERCKHOFF KLIN,HAEMOSTASIS RES UNIT,SPRUDELHOF 11,D-61231 BAD NAUHEIM,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED MUNCH,GERMANY; CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	Kerckhoff Clinic; Max Planck Society; Max Planck Society; KU Leuven			Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				BARNES DW, 1985, J BIOL CHEM, V260, P9117; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L; COMPER WD, 1977, BIOPOLYMERS, V16, P2113, DOI 10.1002/bip.1977.360161004; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAHLBACK K, 1986, ACTA DERM-VENEREOL, V66, P461; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DEGROOT PG, 1990, BRIT J HAEMATOL, V75, P308; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUETTIER C, 1989, VIRCHOWS ARCH A, V414, P309, DOI 10.1007/BF00734084; Hantgan RR, 1987, HEMOSTASIS THROMBOSI, P269; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOST C, 1992, J BIOL CHEM, V267, P12098; KUBOTA K, 1988, CELL STRUCT FUNCT, V13, P123, DOI 10.1247/csf.13.123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERROW JS, 1981, J SUPRAMOL STRUCT, V17, P275; OBRIEN RD, 1978, ANAL BIOCHEM, V86, P602, DOI 10.1016/0003-2697(78)90788-1; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PARKER CJ, 1989, BRIT J HAEMATOL, V71, P245, DOI 10.1111/j.1365-2141.1989.tb04262.x; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1985, J IMMUNOL, V135, P452; PREISSNER KT, 1993, THROMB HAEMOSTASIS, V69, P422; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; ROTKER J, 1986, EUR J BIOCHEM, V155, P583, DOI 10.1111/j.1432-1033.1986.tb09528.x; RUS HG, 1987, IMMUNOL LETT, V16, P15, DOI 10.1016/0165-2478(87)90054-X; SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; TATUNASHVILI LV, 1990, J MOL BIOL, V211, P161, DOI 10.1016/0022-2836(90)90018-H; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER DD, 1985, J CELL BIOL, V101, P112, DOI 10.1083/jcb.101.1.112; YATHOGO T, 1988, CELL STRUCT FUNCT, V13, P281; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	47	151	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22874	22882						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693680				2022-12-25	WOS:A1993MD34800100
J	TRZASKOS, JM; MAGOLDA, RL; FAVATA, MF; FISCHER, RT; JOHNSON, PR; CHEN, HW; KO, SS; LEONARD, DA; GAYLOR, JL				TRZASKOS, JM; MAGOLDA, RL; FAVATA, MF; FISCHER, RT; JOHNSON, PR; CHEN, HW; KO, SS; LEONARD, DA; GAYLOR, JL			MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE BY 15-ALPHA-FLUOROLANOST-7-EN-3-BETA-OL - A MECHANISM-BASED INHIBITOR OF CHOLESTEROL-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG COA REDUCTASE; LANOSTEROL 14-ALPHA-METHYL DEMETHYLASE; MEVALONATE-DERIVED PRODUCT; STEROL REGULATORY REGION; MESSENGER-RNA; OXIDATIVE DEMETHYLATION; CELL-CULTURES; HEP G2; ACCUMULATION	The chemical synthesis and metabolic characteristics of the lanosterol analogue, 15alpha-fluorolanost-7-en-3beta-ol, are described. The 15alpha-fluorosterol is shown to be a competitive inhibitor of the lanosterol 14alpha-methyl demethylase (K(i) = 315 muM), as well as substrate for the demethylase enzyme. Metabolic studies show that the 15alpha-fluorosterol is converted to the corresponding 15alpha-fluoro-3beta-hydroxylanost-7-en-32-aldehyde by hepatic microsomal lanosterol 14alpha-methyl demethylase but that further metabolic conversion to cholesterol biosynthetic intermediates is blocked by virtue of the 15alpha-fluoro substitution. When cultured cells are treated with the fluorinated lanosterol analogue, a decrease in 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity and immunoreactive protein was observed. However, when the lanosterol 14alpha-methyl demethylase-deficient mutant cell line, AR45, is treated with the fluorosterol, no effect upon HMG-CoA reductase is observed. Thus, metabolic conversion of the sterol to its 32-carboxaldehyde analogue by the lanosterol 14alpha-methyl demethylase is required for HMG-CoA reductase suppressor activity. Measurement of HMG-CoA reductase mRNA levels in 15alpha-fluorosterol-treated Chinese hamster ovary (CHO) cells reveals that mRNA levels are not decreased by the sterol as would be expected for a sterol regulator of HMG-CoA reductase activity. The decrease in HMG-CoA reductase protein is due to inhibition of enzyme synthesis, suggesting that the 15alpha-fluorosterol reduces the translational efficiency of the reductase mRNA. Measurements of the half-life of HMG-CoA reductase show that, in contrast to other oxysterols, the 15alpha-fluorolanostenol does not increase the rate of degradation of the enzyme. Collectively, these data support the premise that oxylanosterols regulate HMG-CoA reductase expression through a post-transcriptional process which may be distinct from other previously described sterol regulatory mechanisms.	JOHNSON & JOHNSON,NEW BRUNSWICK,NJ 08933; W VIRGINIA UNIV,DEPT BIOL,MORGANTOWN,WV 26506	Johnson & Johnson; Johnson & Johnson USA; West Virginia University	TRZASKOS, JM (corresponding author), DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880, USA.							Battey, 1986, BASIC METHODS MOL BI; BLOCH K, 1958, J BIOL CHEM, V233, P1343; BROWN MS, 1980, J LIPID RES, V21, P505; CHEN HW, 1988, J BIOL CHEM, V263, P1248; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; COHEN LH, 1988, BIOCHEM J, V255, P61, DOI 10.1042/bj2550061; FAVATA MF, 1987, J BIOL CHEM, V262, P12254; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; FISCHER RT, 1989, J LIPID RES, V20, P1621; GIBBONS GF, 1975, J CHEM SOC CHEM COMM, P213, DOI 10.1039/c39750000213; GIBBONS GF, 1984, J BIOL CHEM, V259, P4399; GIBBONS GF, 1980, J BIOL CHEM, V255, P395; GIBBONS GF, 1968, J CHEM SOC CHEM COMM, V22, P1458; GUNTHER H, 1980, NMR SPECTROSCOPY INT, P351; KATCOFF P, 1980, P NATL ACAD SCI US; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; MANNING RW, 1988, MOL BRAIN RES, V3, P293, DOI 10.1016/0169-328X(88)90052-6; MAYER RJ, 1991, J BIOL CHEM, V266, P20070; MORISAKI M, 1987, J BIOCHEM-TOKYO, V99, P597; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NELSON JA, 1981, J BIOL CHEM, V256, P1067; ORCI L, 1984, CELL, V36, P835, DOI 10.1016/0092-8674(84)90033-3; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PANINI SR, 1984, J BIOL CHEM, V259, P7767; PANINI SR, 1992, J BIOL CHEM, V267, P12647; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PHILLIPS GN, 1976, BIOORG CHEM, V5, P1, DOI 10.1016/0045-2068(76)90011-0; Rodwell V W, 1976, Adv Lipid Res, V14, P1; SAUCIER SE, 1987, J BIOL CHEM, V262, P14056; SAUCIER SE, 1985, J BIOL CHEM, V260, P4571; SEXTON RC, 1983, BIOCHEMISTRY-US, V22, P5687, DOI 10.1021/bi00294a001; SHAFIEE A, 1986, J LIPID RES, V27, P1; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; TRZASKOS JM, 1985, ENZYMES BIOL MEMBR, V2, P177; WOODWARD RB, 1957, J CHEM SOC, P1131, DOI 10.1039/jr9570001131	42	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22591	22599						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693673				2022-12-25	WOS:A1993MD34800062
J	WU, CY; BAUER, JS; JULIANO, RL; MCDONALD, JA				WU, CY; BAUER, JS; JULIANO, RL; MCDONALD, JA			THE ALPHA-5-BETA-1 INTEGRIN FIBRONECTIN RECEPTOR, BUT NOT THE ALPHA-5 CYTOPLASMIC DOMAIN, FUNCTIONS IN AN EARLY AND ESSENTIAL STEP IN FIBRONECTIN MATRIX ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CELL-ADHESION; EXPRESSION; FIBROBLASTS; MODULATION; ANTIBODIES; DEFICIENT; BINDING; MODULES; ROLES	The alpha5beta1 integrin mediates cell adhesion and migration on fibronectin, a glycoprotein critical for normal vertebrate embryonic development. Indirect evidence reported to date suggests that this receptor also functions in the deposition of fibronectin matrices. We used a molecular genetic approach to critically evaluate this role of alpha5beta1 integrins. Mutant Chinese hamster ovary (CHO) cells deficient in alpha5 integrin expression could not assemble a fibronectin matrix. Reconstituting alpha5beta1 integrin expression by transfecting them with a full-length cDNA encoding the human alpha5 chain completely restored fibronectin matrix assembly. CHO cells expressing an alpha5 chain lacking the cytoplasmic domain also assembled a fibronectin matrix. Removing the cytoplasmic domain of alpha5 appears to increase its activity in fibronectin matrix assembly. In addition to alpha5beta1 integrin binding to fibronectin's RGD-containing domain, cells must bind with high affinity to fibronectin's amino-terminal 29-kDa matrix assembly domain to form a fibronectin matrix. Studies with the alpha5-deficient CHO cells show that the expression of alpha5beta1 integrin is also necessary for cells to bind fragments containing this distinct site in fibronectin and that a fibronectin matrix increases binding of the 29-kDa fragment. Thus, alpha5beta1 integrins not only mediate cell adhesion to fibronectin, but also play an essential role in the assembly of a fibronectin matrix. This role includes direct binding to fibronectin and modulating a distinct binding event involving the interaction of fibronectin's amino-terminal matrix assembly domain with the cell surface.	MAYO CLIN SCOTTSDALE, SAMUEL C JOHNSON MED RES CTR, 13400 E SHEA BLVD, SCOTTSDALE, AZ 85259 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27514 USA	Mayo Clinic; Mayo Clinic Phoenix; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM-38276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALLEN HBL, 1987, J BIOL CHEM, V262, P14361; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HOLERS VM, 1989, J EXP MED, V169, P1589, DOI 10.1084/jem.169.5.1589; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167, DOI 10.1111/j.1749-6632.1991.tb43701.x; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHREINER C, 1991, CLIN EXP METASTAS, V9, P163, DOI 10.1007/BF01756387; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SMITH JC, 1990, DEVELOPMENT, V108, P229; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; VARTIO T, 1987, J CELL SCI, V88, P419; VILLIGER B, 1981, J CELL BIOL, V90, P711, DOI 10.1083/jcb.90.3.711; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	37	158	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21883	21888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691819				2022-12-25	WOS:A1993MC80900068
J	BAEK, KJ; THIEL, BA; LUCAS, S; STUEHR, DJ				BAEK, KJ; THIEL, BA; LUCAS, S; STUEHR, DJ			MACROPHAGE NITRIC-OXIDE SYNTHASE SUBUNITS - PURIFICATION, CHARACTERIZATION, AND ROLE OF PROSTHETIC GROUPS AND SUBSTRATE IN REGULATING THEIR ASSOCIATION INTO A DIMERIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CYTOCHROME P-450 REDUCTASE; ESCHERICHIA-COLI HEMOFLAVOPROTEIN; 2 FUNCTIONAL DOMAINS; SULFITE REDUCTASE; FLAVIN MONONUCLEOTIDE; BACILLUS-MEGATERIUM; C REDUCTASE; L-ARGININE; FLAVOPROTEIN	The cytokine-induced nitric oxide synthase (NOS) of macrophages is a homodimeric enzyme that contains iron protoporphorin IX (heme), FAD, FMN, tetrahydrobiopterin, and calmodulin. To investigate how the enzyme's quaternary structure relates to its catalytic activity and binding of prosthetic groups, dimeric NOS and its subunits were purified separately and their composition and catalytic properties compared. In contrast to dimeric NOS, purified subunits did not synthesize NO or contain bound heme or tetrahydrobiopterin. However, the subunits did contain FAD, FMN, and calmodulin in amounts comparable with dimeric NOS, displayed the light absorbance spectrum of an FAD- and FMN-containing flavoprotein, and generated an air-stable flavin semiquinone radical upon reduction of their ferricyanide-oxidized form. Dimeric NOS and NOS subunits were equivalent in catalyzing electron transfer from NADPH to cytochrome c, dichlorophenolindophenol, or ferricyanide at rates that were 8-30-fold faster than the maximal rate of NO synthesis by dimeric NOS. Reconstitution of subunit NO synthesis required their incubation with L-arginine, tetrahydrobiopterin, and stoichiometric amounts of heme and correlated with formation of a proportional amount of dimeric NOS in all cases. The dimeric NOS reconstituted from its subunits contained 0.9 heme and 0.44 tetrahydrobiopterin bound per subunit and had the spectral and catalytic properties of native dimeric NOS. Thus, NOS subunits are NADPH-dependent reductases that acquire the capacity to synthesize NO only through their dimerization and binding of heme and tetrahydrobiopterin. The ability of heme, tetrahydrobiopterin, and L-arginine to promote subunit dimerization is unprecedented and suggests novel roles for these molecules in forming and stabilizing the active dimeric NOS.	CLEVELAND CLIN,DEPT IMMUNOL,NN-1,9500 EUCLID AVE,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunori, 1972, HEMOGLOBIN MYOGLOBIN; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; FAEDER EJ, 1974, J BIOL CHEM, V249, P1599; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Jaenicke R, 1986, Methods Enzymol, V131, P218; JAENICKE R, 1980, P NATL ACAD SCI-BIOL, V77, P1966, DOI 10.1073/pnas.77.4.1966; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1992, J BIOL CHEM, V267, P11374; KREBS H, 1979, EUR J BIOCHEM, V100, P356; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI HY, 1991, J BIOL CHEM, V266, P11909; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; RUDOLPH R, 1978, EUR J BIOCHEM, V87, P601, DOI 10.1111/j.1432-1033.1978.tb12412.x; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SILVER J, 1983, INORG CHIM A-BIOINOR, V78, P219, DOI 10.1016/S0020-1693(00)86516-0; STEUHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAKESHI F, 1980, ANAL BIOCHEM, V102, P176; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	42	381	386	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21120	21129						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691806				2022-12-25	WOS:A1993MA28800073
J	HERWALD, H; JAHNENDECHENT, W; ALLA, SA; HOCK, J; BOUMA, BN; MULLERESTERL, W				HERWALD, H; JAHNENDECHENT, W; ALLA, SA; HOCK, J; BOUMA, BN; MULLERESTERL, W			MAPPING OF THE HIGH-MOLECULAR-WEIGHT KININOGEN BINDING-SITE OF PREKALLIKREIN - EVIDENCE FOR A DISCONTINUOUS EPITOPE FORMED BY DISTINCT SEGMENTS OF THE PREKALLIKREIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA PREKALLIKREIN; BLOOD-COAGULATION FACTOR; 4 TANDEM REPEATS; HUMAN FACTOR-XI; LIGHT CHAIN; ANTIIDIOTYPIC ANTIBODIES; DISULFIDE BONDS; APPLE DOMAINS; PROTEINS; LOCALIZATION	Prekallikrein, a glycoprotein involved in contact phase activation, circulates in plasma in the form of a binary complex with high molecular weight kininogen (H-kininogen). The binding to H-kininogen is mediated by the prekallikrein heavy chain consisting of four repetitive domains, A1-A4. To define more precisely the region(s) involved in kininogen binding, we have employed an affinity cross-linking strategy with a synthetic peptide of 31 residues which mimics the prekallikrein binding site of H-kininogen. Cross-linking of the radiolabeled peptide to (pre)kallikrein revealed a binding segment in the NH2-terminal portion of the prekallikrein heavy chain; another binding segment was located in the COOH-terminal part of the heavy chain. The latter binding segment is harbored by a previously identified fragment of the kallikrein heavy chain involved in H-kininogen binding (Page, J. D., and Colman, R. W. (1991) J. Biol. Chem. 266, 8143-8148). Chemical cleavage of the heavy chain cross-linked with the radiolabeled peptide mapped the NH2-terminal binding segment to 60 residues (positions 53-112) of A1. Synthesis of a peptide (positions 56-86) and development of specific antibodies to this peptide narrowed down the kininogen binding segment to 31 residues of the center portion of A1. This NH2-terminal segment is equivalent to a kininogen binding site previously identified in factor XI (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1992) J. Biol. Chem. 267, 4247-4252). We conclude that prekallikrein exposes at least two segments on its heavy chain portion which form a continuous surface thereby facilitating the intimate binding of the zymogen to its nonenzymatic cofactor, H-kininogen.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, W-6500 MAINZ 1, GERMANY; BEHRINGWERKE AG, W-3550 MARBURG, GERMANY; ACAD HOSP UTRECHT, DEPT HEMATOL, 3584 CX UTRECHT, NETHERLANDS	Johannes Gutenberg University of Mainz; Utrecht University; Utrecht University Medical Center			Jahnen-Dechent, Willi/A-7608-2011; Herwald, Heiko/AAN-3708-2021	Jahnen-Dechent, Willi/0000-0003-1315-4407; Herwald, Heiko/0000-0002-8111-2842				ATASSI MZ, 1984, EUR J BIOCHEM, V145, P1, DOI 10.1111/j.1432-1033.1984.tb08516.x; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BARDEHLE G, 1991, PARASITOLOGY, V103, P387, DOI 10.1017/S0031182000059904; BEAUBIEN G, 1991, BIOCHEMISTRY-US, V30, P1628, DOI 10.1021/bi00220a027; BOCK PE, 1985, J BIOL CHEM, V260, P2434; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HEIMARK RL, 1980, NATURE, V286, P456, DOI 10.1038/286456a0; HOCK J, 1990, J BIOL CHEM, V265, P12005; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KAPLAN AP, 1987, BLOOD, V70, P1; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; SCARSDALE JN, 1990, J PROTEIN CHEM, V9, P647, DOI 10.1007/BF01025019; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VOGEL R, 1990, J BIOL CHEM, V265, P12494; YOU JL, 1991, J PROTEIN CHEM, V10, P301, DOI 10.1007/BF01025629	38	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14527	14535						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686159				2022-12-25	WOS:A1993LJ82500105
J	ZHANG, GH; ICHIMURA, T; MAIER, JAM; MACIAG, T; STEVENS, JL				ZHANG, GH; ICHIMURA, T; MAIER, JAM; MACIAG, T; STEVENS, JL			A ROLE FOR FIBROBLAST GROWTH-FACTOR TYPE-1 IN NEPHROGENIC REPAIR - AUTOCRINE EXPRESSION IN RAT-KIDNEY PROXIMAL TUBULE EPITHELIAL-CELLS INVITRO AND IN THE REGENERATING EPITHELIUM FOLLOWING NEPHROTOXIC DAMAGE BY S-(1,1,2,2-TETRAFLUOROETHYL)-L-CYSTEINE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE CONJUGATE TOXICITY; FACTOR-I; ENDOTHELIAL-CELLS; FACTOR-BETA; DEFINED MEDIUM; MESSENGER-RNA; FACTOR FAMILY; MOUSE KIDNEY; FACTOR-ALPHA; BINDING	The regenerating proximal tubule epithelium in the rat has striking similarity with rat kidney proximal tubule epithelial cells (RPTE) in primary culture (Wallin, A., Zhang, G., Jones, T. W., Jaken, S., and Stevens, J. L. (1992) Lab. Invest. 66, 474-484). We used this in vitro model to investigate mechanisms which may regulate aspects of nephrogenic repair in vivo, and in particular the role of fibroblast (heparin-binding) growth factor type-1 (FGF-1) expression. FGF-1 was present predominantly as a 14.3-kDa polypeptide in rat kidney. Biological activity and mRNA for FGF-1 increased dramatically in primary RPTE in culture along with an increase in a 18.3-kDa FGF-1. Cycloheximide blocked FGF-1 expression in primary culture indicating that the increase represents newly synthesized factor rather than release from the extracellular matrix. The maximal increase in expression occurs after the peak of RPTE proliferation. Activity was not present in the medium but intracellular FGF-1 was released from RPTE by scrape wounding. Immunohistochemical analysis showed that FGF-1 expression increased in regenerating proximal tubule epithelial cells 5 days after nephrotoxic damage. Collectively, the data suggest that autocrine expression of FGF-1 by regenerating proximal tubule epithelial cells plays a role in the regulation of nephrogenic repair.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; AMER RED CROSS,DEPT MOLEC BIOL,HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross			Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221	NHLBI NIH HHS [HL32348] Funding Source: Medline; NIDDK NIH HHS [DK38925] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON G, 1988, ACTA PHYSIOL SCAND, V132, P453, DOI 10.1111/j.1748-1716.1988.tb08352.x; ANDERSSON GL, 1988, ACTA ENDOCRINOL-COP, V119, P555, DOI 10.1530/acta.0.1190555; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BACALLAO R, 1989, AM J PHYSIOL, V257, pF913, DOI 10.1152/ajprenal.1989.257.6.F913; BORTZ JD, 1988, J CELL BIOL, V107, P811, DOI 10.1083/jcb.107.2.811; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG SD, 1982, J CELL BIOL, V95, P118, DOI 10.1083/jcb.95.1.118; COIMBRA TM, 1990, AM J PHYSIOL, V259, pF438, DOI 10.1152/ajprenal.1990.259.3.F438; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; GAJDUSEK CM, 1989, J CELL PHYSIOL, V139, P570, DOI 10.1002/jcp.1041390317; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GRONE HJ, 1987, AM J PATHOL, V129, P1; GROUXMUSCATELLI B, 1990, DEV BIOL, V142, P380, DOI 10.1016/0012-1606(90)90358-P; HAMMERMAN MR, 1992, AM J PHYSIOL, V262, pF523, DOI 10.1152/ajprenal.1992.262.4.F523; HAMMERMAN MR, 1989, AM J PHYSIOL, V257, pF503, DOI 10.1152/ajprenal.1989.257.4.F503; HATZINGER PB, 1989, IN VITRO CELL DEV B, V25, P205; HATZINGER PB, 1988, BIOCHEM BIOPH RES CO, V157, P1316, DOI 10.1016/S0006-291X(88)81018-0; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HUMES HD, 1989, J CLIN INVEST, V84, P1757, DOI 10.1172/JCI114359; HUMES HD, 1991, LAB INVEST, V64, P538; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAN M, 1985, IN VITRO CELL DEV B, V21, P181; KANDA S, 1989, CELL BIOL INT REP, V13, P687; Maciag T, 1990, Important Adv Oncol, P85; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; Mendley S., 1988, ANNU REV PHYSIOL, V51, P33; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NONCLERCQ D, 1991, NEPHRON, V57, P210, DOI 10.1159/000186253; NORMAN J, 1990, CLIN SCI, V78, P445, DOI 10.1042/cs0780445; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; SALIDO EC, 1989, AM J PHYSIOL, V256, pF632, DOI 10.1152/ajprenal.1989.256.4.F632; SALIDO EC, 1986, J HISTOCHEM CYTOCHEM, V34, P1155, DOI 10.1177/34.9.2426343; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SEGAL R, 1989, KIDNEY INT, V36, pS2; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; STEVENS J, 1986, J BIOL CHEM, V261, P3325; SULLIVAN DE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P17, DOI 10.1016/0167-4781(91)90031-G; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOBACK FG, 1992, KIDNEY INT, V41, P226, DOI 10.1038/ki.1992.32; TOUBEAU G, 1991, KIDNEY INT, V40, P691, DOI 10.1038/ki.1991.262; WALKER C, 1991, CANCER RES, V51, P2973; WALLIN A, 1992, LAB INVEST, V66, P474; ZHANG GH, 1991, J CELL PHYSIOL, V148, P295, DOI 10.1002/jcp.1041480216	59	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11542	11547						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685015				2022-12-25	WOS:A1993LF28400016
J	SUWANICHKUL, A; DEPAOLIS, LA; LEE, PDK; POWELL, DR				SUWANICHKUL, A; DEPAOLIS, LA; LEE, PDK; POWELL, DR			IDENTIFICATION OF A PROMOTER ELEMENT WHICH PARTICIPATES IN CAMP-STIMULATED EXPRESSION OF HUMAN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; MULTIPLE SEQUENCE ELEMENTS; SITE-SPECIFIC MUTAGENESIS; HUMAN AMNIOTIC-FLUID; ATF CDNA CLONES; C-FOS PROMOTER; CYCLIC-AMP; GENE-TRANSCRIPTION; HEPATOMA-CELLS; IGF-I	In hepatocytes, insulin-like growth factor-binding protein-1 (IGFBP-1) levels are increased by glucocorticoids and by agents that raise intracellular cAMP levels such as glucagon, theophylline, forskolin, and cAMP analogues. In contrast, insulin lowers IGFBP-1 levels, an effect dominant over the glucocorticoid and cAMP effects. Previous studies showed that dibutyryl cAMP (Bt2cAMP) and theophylline increase IGFBP-1 promoter activity in HEP G2 human hepatoma cells and that insulin abolishes this increase. In studies reported here, HEP G2 cells were used to further evaluate the role of cAMP in stimulating IGFBP-1 expression. Initial studies found that either 0.5 or 5.0 mM Bt2cAMP alone, or the combination of 0.5 mM Bt2cAMP and 2 mM theophylline, increased IGFBP-1 protein levels, mRNA levels, and promoter activity, but that the addition of theophylline to Bt2cAMP was required to give a approximately 5-fold increase in promoter activity. Deletion mutations of the IGFBP-1 promoter were used to show that much of the effect of Bt2cAMP and theophylline was conferred by the region between 269 and 246 base pairs (bp) 5' of the IGFBP-1 mRNA cap site. DNase I protection assays showed that HEP G2 nuclear extract footprinted the region from 273 to 249 bp 5' of the cap site; this region, designated P2, has a central CGTCA motif common to cAMP-responsive elements (CREs). Mutating the CGTCA motif in the 1205-bp IGFBP-1 promoter construct to TAGCA led to a 51% decrease in the ability of Bt2cAMP and theophylline to stimulate IGFBP-1 promoter activity above control levels. In addition, cotransfection of the catalytic subunit of cAMP-dependent protein kinase A (PKA) with the native 1205-bp IGFBP-1 promoter construct stimulated IGFBP-1 promoter activity 3.9-fold, but the TAGCA mutation decreased by 73% the ability of PKA to stimulate IGFBP-1 promoter activity above control levels. Mutating the CGTCA motif to TAGCA also blocked the ability of both crude HEP G2 nuclear extract and recombinant CRE-binding protein to bind to the P2 element. These data suggest that the P2 element is a CRE that confers at least part of the stimulatory effect of cAMP on the human IGFBP-1 promoter.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine				Lee, Phillip/0000-0002-6856-4262	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P432, DOI 10.1210/jcem-65-3-432; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CONOVER CA, 1992, J CLIN ENDOCR METAB, V74, P1355, DOI 10.1210/jc.74.6.1355; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, DIABETES, V39, P1251, DOI 10.2337/diabetes.39.10.1251; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P908, DOI 10.1210/jcem-59-5-908; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FINK JS, 1991, J BIOL CHEM, V266, P3882; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JULKUNEN M, 1988, FEBS LETT, V236, P295, DOI 10.1016/0014-5793(88)80041-3; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE PDK, 1993, IN PRESS METABOLISM; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maxam A M, 1980, Methods Enzymol, V65, P499; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Montminy M R, 1990, Recent Prog Horm Res, V46, P219; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEERS B, 1991, J BIOL CHEM, V266, P18127; POWELL DR, 1989, INT CONGR SER, V881, P3; POWELL DR, 1991, J BIOL CHEM, V266, P18868; POWELL DR, 1993, IN PRESS DNA CELL BI; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161	64	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9730	9736						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683658				2022-12-25	WOS:A1993LA68900085
J	CHANG, DY; MARAIA, RJ				CHANG, DY; MARAIA, RJ			A CELLULAR PROTEIN BINDS B1 AND ALU SMALL CYTOPLASMIC RNAS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ALPHA-FETOPROTEIN GENE; SRP-RNA; REPETITIVE SEQUENCES; SECONDARY STRUCTURE; 7S RNA; DOMAIN; DNA; TRANSLOCATION; COMPLEMENTARY	B1 and Alu are sequence-homologous interspersed elements of unknown function that have expanded in the genomes of mice and humans, respectively. A minority of B1 and Alu sequences are expressed as small cytoplasmic RNAs. These RNAs have conserved a secondary structure motif also present in signal recognition particle (SRP) RNA despite substantial sequence divergence, whereas random B1 and Alu sequences have not. This RNA structure has also been conserved by the source sequences that gave rise to successive transpositions during B1 and Alu evolution. In the present work small cytoplasmic B1 and Alu RNAs synthesized in vitro were found to bind a cellular protein by mobility shift and UV cross-linking analyses. The mouse and human proteins demonstrate the same specificity to a panel of competitor RNAs. Results using mutated B1 RNA indicate that a single strand loop in the conserved Alu motif is essential for binding. Previous work by Strub et al. (Stub, K., Moss, J. B., and Walter, P. (1991) Mol. Cell. Biol. 11, 3949-3959) demonstrated that the Alu-specific protein SRP 9/14 does not footprint to this region of SRP RNA. This observation coupled with the failure of anti-SRP/9 antibodies to identify SRP 9/14 in the B1 RNA-protein complex as well as the apparent mass and other characteristics of the protein described here suggest that it is a novel B1-Alu RNA-binding protein. Conservation of primary and secondary structure by B1 and Alu small cytoplasmic RNAs as well as features of their specific expression and ability to interact with the conserved binding protein indicate that these RNAs are more homologous than previously appreciated.	NICHHD, MOLEC GROWTH REGULAT LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ANDREWS PG, 1987, J BIOL CHEM, V262, P2908; BATZER MA, 1990, NUCLEIC ACIDS RES, V18, P6793, DOI 10.1093/nar/18.23.6793; GEORGIEV GP, 1982, COLD SPRING HARB SYM, V47, P1109, DOI 10.1101/SQB.1983.047.01.125; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GIORDANO T, 1990, NUCLEIC ACIDS RES, V18, P4627, DOI 10.1093/nar/18.15.4627; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; HOWARD B H, 1990, New Biologist, V2, P759; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; LABUDA D, 1991, J MOL EVOL, V32, P405, DOI 10.1007/BF02101280; LABUDA D, 1989, NUCLEIC ACIDS RES, V17, P2477, DOI 10.1093/nar/17.7.2477; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; SINNETT D, 1991, J BIOL CHEM, V266, P8675; STRUB K, 1990, MOL CELL BIOL, V10, P777, DOI 10.1128/MCB.10.2.777; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEINER AM, 1980, CELL, V22, P209, DOI 10.1016/0092-8674(80)90169-5; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	33	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6423	6428						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681065				2022-12-25	WOS:A1993KT36800052
J	PULLEN, KA; RATTRAY, AJ; CHAMPOUX, JJ				PULLEN, KA; RATTRAY, AJ; CHAMPOUX, JJ			THE SEQUENCE FEATURES IMPORTANT FOR PLUS STRAND PRIMING BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; AVIAN-MYELOBLASTOSIS VIRUS; RNASE-H ACTIVITY; SITE-SPECIFIC MUTAGENESIS; RIBONUCLEASE-H; DNA-SYNTHESIS; NUCLEOTIDE-SEQUENCE; INTEGRATION SITE; POLYMERASE; INITIATION	A specific cleavage by the reverse transcriptase-associated RNase H activity generates the RNA primer for plus strand DNA synthesis during reverse transcription. Previously, we used site-directed mutagenesis to define the sequence features of the polypurine tract (PPT) required for correct plus strand priming by the Moloney murine leukemia virus (M-MuLV) reverse transcriptase (Rattray, A. J., and Champoux, J. J. (1989) J. Mol. Biol. 208, 445-456). Although the sequences of human immunodeficiency virus type 1 (HIV-1) and M-MuLV diverge completely outside a 20-base region encompassing the PPT, within this region there are only three differences between the two viruses. Here we show that the HIV-1 reverse transcriptase will utilize the M-MuLV PPT as an origin for plus strand initiation in vitro. This finding enabled us to use the set of PPT mutants previously generated in M-MuLV, in conjunction with a small set of newly derived mutations within the HIV-1 PPT, to study plus strand priming by the HIV-I reverse transcriptase. Despite the similarity between the two PPT regions, the sequence features important for positioning RNase H for the cleavage reaction that generates the plus strand primer are different for the two viruses. For M-MuLV, the -7A residue is a critical specificity determinant in the priming reaction, whereas for HIV-1, the -2G and -4G residues play key roles in determining the specificity of priming.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Rattray, Alison/A-4847-2008		NCI NIH HHS [CA51605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALTIMORE D, 1972, J BIOL CHEM, V247, P7282; BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BLUM HE, 1985, VIROLOGY, V142, P270, DOI 10.1016/0042-6822(85)90335-6; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; MITRA SW, 1982, J BIOL CHEM, V257, P5983; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TOBALYTAPIERO J, 1991, J GEN VIROL, V72, P605, DOI 10.1099/0022-1317-72-3-605; VARMUS H, 1989, MOBILE DNA, P53; VARMUS H, 1982, RNA TUMOR VIRUSES, V1, P369; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2, P75; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	37	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6221	6227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681062				2022-12-25	WOS:A1993KT36800025
J	RECHTIN, TM; BLACK, ME; MAO, F; LEWIS, ML; DRAKE, RR				RECHTIN, TM; BLACK, ME; MAO, F; LEWIS, ML; DRAKE, RR			PURIFICATION AND PHOTOAFFINITY-LABELING OF HERPES-SIMPLEX VIRUS TYPE-1 THYMIDINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE BINDING-SITE; THYMIDYLATE KINASE; ADENYLATE KINASE; IDENTIFICATION; MUTANTS; DNA; CHROMATOGRAPHY; POLYMERASE; SELECTION; DOMAIN	The molecular basis for the treatment of human herpesviruses with nucleoside drugs is the phosphorylation of these drugs by the viral-encoded thymidine kinases. In order to better understand the structural and enzymatic mechanisms by which herpesviral thymidine ki kinases recognize their substrates, photoaffinity labeling with [alpha-P-32]B-azido-2'-deoxyuridine-5'-monophosphate and [gamma-P-92]8-azidoadenosine-5'-triphosphate was used to characterize the thymidine, thymidylate, and ATP active sites of the herpes simplex virus-1 (HSV-1) thymi dine kinase. For this study, HSV-1 thymidine kinase and a site-specific mutant enzyme (C336Y, known to confer acyclovir resistance) were expressed in bacteria and purified by a rapid, two-step protocol, The specificity of photoaffinity labeling of these HSV-1 thymidine kinases was demonstrated by the ability of site directed substrates such as thymidine, thymidylate, acyclovir, 8-bromovinyl-2'-deoxyuridine, and ATP to inhibit photoinsertion, Differences in inhibition patterns of photoaffinity labeling correlated with kinetic differences between the wild-type and C336Y HSV-1 thymidine kinases, Cumulative results suggest that the acyclovir-resistant cysteine 336 mutation primarily affects the ATP binding site; yet it also leads to alteration in the binding affinity of nucleoside drugs in the thymidine site, In this study, azidonucleotide photoaffinity analogs are shown to be effective tools for studying the active-site environment of HSV-1 thymidine kinase and related site-specific mutants.	UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA; UNIV WASHINGTON, DEPT PATHOL, JOSEPH GOTTSTEIN MEM CANC RES LAB, SEATTLE, WA 98195 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Washington; University of Washington Seattle			Mao, Feng/B-8280-2019					BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLACK ME, 1992, J BIOL CHEM, V267, P9743; BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; CHEN MS, 1979, J BIOL CHEM, V254, P747; CHEN MS, 1977, BIOCHEMISTRY-US, V16, P3310, DOI 10.1021/bi00634a005; CHEN MS, 1978, J BIOL CHEM, V253, P1325; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; Czarnecki J, 1979, Methods Enzymol, V56, P642; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DUBE DK, 1991, BIOCHEMISTRY-US, V30, P11760, DOI 10.1021/bi00115a004; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FURLONG N. BURR, 1963, ANALYT BIOCHEM, V5, P515; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOODCHILD J, 1983, J MED CHEM, V26, P1252, DOI 10.1021/jm00363a009; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HARRISON PT, 1991, J GEN VIROL, V72, P2583, DOI 10.1099/0022-1317-72-10-2583; KIT S, 1974, INT J CANCER, V13, P203, DOI 10.1002/ijc.2910130208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARDER BA, 1983, J BIOL CHEM, V258, P2027; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MACHIDA H, 1986, ANTIMICROB AGENTS CH, V29, P524, DOI 10.1128/AAC.29.3.524; MAGA G, 1994, BIOCHEM J, V302, P279, DOI 10.1042/bj3020279; OAKES JE, 1975, J INFECT DIS, V131, P51, DOI 10.1093/infdis/131.1.51; OKAZAKI R, 1964, J BIOL CHEM, V239, P275; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; RAM Z, 1993, CANCER RES, V53, P83; SAFRIN S, 1992, J ACQ IMMUN DEF SYND, V5, pS29; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WHITLEY RJ, 1985, HERPESVIRUSES, V4, P339	35	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7055	7060		10.1074/jbc.270.13.7055	http://dx.doi.org/10.1074/jbc.270.13.7055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706243	hybrid			2022-12-25	WOS:A1995QQ43100011
J	JANKNECHT, R; ERNST, WH; NORDHEIM, A				JANKNECHT, R; ERNST, WH; NORDHEIM, A			SAP1A IS A NUCLEAR TARGET OF SIGNALING CASCADES INVOLVING ERKS	ONCOGENE			English	Article						C-FOS; ETS PROTEIN SAP1A; PHOSPHORYLATION; TRANSCRIPTION	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; MAP KINASES; RAF; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; COMPLEX; ELK-1; TRANSDUCTION	The Ets protein SAP1a has been shown to interact with the c-fos serum response element upon recruitment by the serum response factor. We demonstrate that SAP1a is a nuclear protein stimulating transcription via the c-fos serum response element, and additionally via an Ets binding site independently of the serum response factor. However, transactivation has only been observed under conditions leading to the activation of extracellular signal-regulated protein kinases (ERKs). The transcriptional activation domain of SAP1a resides within the C-terminal region, the function of which may be impeded by the N-terminus. Several potential ERK consensus sites within the C-terminal region of SAP1a can modulate its transactivation efficacy, implicating that SAP1a is a direct target of ERKs. Since ERKs are activated by a broad range of signals, SAP1a may play an important role in the transformation of extracellular stimuli into a nuclear response.			JANKNECHT, R (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEUNG S, 1993, ONCOGENE, V8, P989; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAO VN, 1992, ONCOGENE, V7, P65; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	87	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1209	1216						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700646				2022-12-25	WOS:A1995QN35300023
J	BJORK, P; JONSSON, U; SVEDBERG, H; LARSSON, K; LIND, P; DILLNER, J; HEDLUND, G; DOHLSTEN, M; KALLAND, T				BJORK, P; JONSSON, U; SVEDBERG, H; LARSSON, K; LIND, P; DILLNER, J; HEDLUND, G; DOHLSTEN, M; KALLAND, T			ISOLATION, PARTIAL CHARACTERIZATION, AND MOLECULAR-CLONING OF A HUMAN COLON ADENOCARCINOMA CELL-SURFACE GLYCOPROTEIN RECOGNIZED BY THE C215 MOUSE MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; TUMOR-CELLS; PROTEIN; DNA; IMMUNOTHERAPY; PEPTIDES; THERAPY; FAMILY; CANCER; KS1/4	The monoclonal antibody C215 (IgG2a) was obtained by the immunization of BALB/c mice with the human colon adenocarcinoma cell line COLO 205 and used in the targeting of colorectal carcinomas. The partial characterization and purification of the C215 target molecule from solubilized COLO 205 membranes indicated that it is an integral membrane glycoprotein of the non-mucin type. The denatured antigen appeared as a major 40-kDa form in Western blots after SDS-polyacrylamide gel electrophoresis and migrated as a monomeric 36-kDa species after the reductive cleavage of intramolecular disulfide bridges. Using a five-step procedure, the antigen was purified 4,300-fold from COLO 205 tumors raised in nude mice to a homogeneity of 95% when assessed by capillary electrophoresis. Removal of N-linked carbohydrate by peptide: N-glycosidase treatment did not affect the visualization of the purified antigen in immunoblots but resulted in a faster migration in the SDS gels. The amino acid sequence was partially determined. Seventeen contiguous NH2-terminal amino acids were identified and coincided exactly with residues 82-98 of the GA733-2 protein cloned by Szala et al. (Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewske, Z., Koprowski, H., and Linnenback, A. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3542-3546). Therefore, the predicted amino acid sequence of this protein was used to prepare overlapping synthetic peptides that cover the entire extracellular domain ih order to identify the C215 epitope. A likely epitope, close to the NH2 terminus and corresponding to the first distinct hydrophilic stretch after the putative signal sequence, was identified in a peptide enzyme-linked immunosorbent assay. Moreover, GA733-2 cDNA was used for the cloning of the C215 protein from COLO 205 cells and the subsequent transfection to K36.16 mouse T cell leukemia cells. The transfected cells were C215 reactive in fluorescence-activated cell sorter analysis, and a 42 kDa band was visualized in Western blots under both non-reducing and reducing conditions. Our findings indicate a close relationship between the C215 antigen and other members of the GA-733 family, some of which are currently being used as targets in clinical trials with monoclonal antibodies. The mammalian expression system described here will enable further studies into the biological role of this protein and the construction of animal models in order to develop optimal therapeutic strategies.	DEPT PHARMACOKINET,S-25109 HELSINGBORG,SWEDEN; BIOSCI CTR,S-11287 STOCKHOLM,SWEDEN; KABI PHARM AB,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; LUND UNIV,WALLENBERG LAB,DEPT TUMOR IMMUNOL,S-22007 LUND 7,SWEDEN	Karolinska Institutet; Lund University	BJORK, P (corresponding author), DEPT IMMUNOL,KABI PHARM ONCOL,SCHEELEVAGEN 22,S-22363 LUND,SWEDEN.							BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLSTEN M, 1991, P NATL ACAD SCI USA, V88, P9287, DOI 10.1073/pnas.88.20.9287; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EDWARDS DP, 1986, CANCER RES, V46, P1306; ELIAS DJ, 1990, CANCER RES, V50, P4154; FERNSTEN PD, 1990, CANCER RES, V50, P4656; FESTENSTEIN H, 1981, IMMUNOL REV, V60, P85, DOI 10.1111/j.1600-065X.1981.tb00363.x; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; HERLYN D, 1991, AM J CLIN ONCOL-CANC, V14, P371, DOI 10.1097/00000421-199110000-00002; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P675; JOHANSSON C, 1991, INT J CANCER, V48, P297, DOI 10.1002/ijc.2910480224; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDO PA, 1993, CANCER IMMUNOL IMMUN, V36, P223, DOI 10.1007/BF01740903; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; LUSKY M, 1981, NATURE, V301, P214; MOSS B, 1972, J BIOL CHEM, V247, P5194; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEREZ MS, 1989, J IMMUNOL, V142, P3662; ROSS AH, 1986, BIOCHEM BIOPH RES CO, V135, P297, DOI 10.1016/0006-291X(86)90976-9; ROSS AH, 1986, HYBRYDOMA S1, V5, P21; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHETYE J, 1988, CANCER IMMUNOL IMMUN, V27, P154; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRNAD J, 1989, CANCER RES, V49, P314; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; WETTENDORFF M, 1989, P NATL ACAD SCI USA, V86, P3787, DOI 10.1073/pnas.86.10.3787	35	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24232	24241						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693697				2022-12-25	WOS:A1993MF29400077
J	KASAHARA, K; KARTASOVA, T; REN, XQ; IKUTA, T; CHIDA, K; KUROKI, T				KASAHARA, K; KARTASOVA, T; REN, XQ; IKUTA, T; CHIDA, K; KUROKI, T			HYPERPHOSPHORYLATION OF KERATINS BY TREATMENT WITH OKADAIC ACID OF BALB/MK-2 MOUSE KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CREATINE PHOSPHOKINASE-B; INTERMEDIATE FILAMENTS; TUMOR PROMOTER; PHOSPHORYLATION SITES; VIMENTIN FILAMENTS; POTENT INHIBITOR; NUCLEAR LAMINA; CDC2 KINASE; CELL-CYCLE	Protein hyper- or hypophosphorylation induced by okadaic acid (OA) treatment was examined using quiescent cultures of the BALB/MK-2 mouse epidermal keratinocytes. Treatment with OA enhanced the phosphorylation of five proteins with molecular weights of 65,000, 55,000, 50,000, 28,000 and 15,000 (p65, p55, p50, p28, and p15, respectively) and decreased that of two proteins with molecular weights of 22,000 and 20,000 (p22 and p20, respectively). The two major phosphorylated proteins, p65 and p55, were identified as type II and type I keratins, respectively, by immunoblotting and immunoprecipitation with keratin specific antibodies. Serine was the only phosphoamino acid residue in hydrolysates of the P-32-labeled keratins purified from OA-treated cells. Two-dimensional tryptic peptide maps of the phosphorylated keratins showed that the hyperphosphorylation was largely due to phosphorylation at several additional sites in both keratins. The hyperphosphorylation of keratins induced by OA treatment resulted in a drastic change in their solubility. This change closely correlated with reorganization of the keratin filament network, which finally collapsed into large perinuclear aggregates. Concomitantly the cells changed from a typical epithelial shape to a round shape. Of several protein kinase inhibitors tested, only staurosporine interfered with this OA-induced morphological change and reorganization of the keratin network.	UNIV TOKYO, INST MED SCI,DEPT CANC CELL RES,SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Kasahara, Kohji/0000-0001-7010-8365				BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P346, DOI 10.1016/S0006-291X(05)81063-0; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P351, DOI 10.1016/S0006-291X(05)81064-2; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GEORGATOS SD, 1993, FEBS LETT, V318, P101, DOI 10.1016/0014-5793(93)80001-B; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HIRANO K, 1992, J MUSCLE RES CELL M, V13, P341, DOI 10.1007/BF01766462; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; KASAHARA K, 1991, J BIOL CHEM, V266, P20018; KASAHARA K, 1993, EUR J BIOCHEM, V213, P1101, DOI 10.1111/j.1432-1033.1993.tb17859.x; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TANABE K, 1981, J BIOL CHEM, V256, P3098; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1989, MOL CARCINOGEN, V2, P150, DOI 10.1002/mc.2940020308; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WONG TW, 1983, J BIOL CHEM, V258, P1022; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; YATSUNAMI J, 1991, BIOCHEM BIOPH RES CO, V177, P1165, DOI 10.1016/0006-291X(91)90662-Q; YATSUNAMI J, 1993, CANCER RES, V53, P239; YATSUNAMI J, 1993, CANCER RES, V53, P992	44	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23531	23537						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693689				2022-12-25	WOS:A1993MF51500088
J	IANNELLO, RC; KOLA, I; DAHL, HHM				IANNELLO, RC; KOLA, I; DAHL, HHM			TEMPORAL AND TISSUE-SPECIFIC INTERACTIONS INVOLVING NOVEL TRANSCRIPTION FACTORS AND THE PROXIMAL PROMOTER OF THE MOUSE PDHA-2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC EXPRESSION; PROTAMINE MESSENGER-RNA; E1-ALPHA SUBUNIT GENES; TRANSLATIONAL REGULATION; TRANSGENIC MICE; GERM-CELLS; INVITRO TRANSCRIPTION; GEL-ELECTROPHORESIS; MEIOTIC PROPHASE; TESTICULAR CELLS	We have determined by deletion analysis that the most proximal region of the Pdha-2 promoter between nucleotide position -187 to +22 harbors a transcriptionally active core. This ''core'' promoter directs high levels of CAT (chloramphenicol acetyltransferase) reporter gene transcription in HeLa cells. DNase I foot-printing of the proximal promoter revealed four regions of protection. One of these contains the consensus sequence for the Sp1 binding site and another the ATF/CREB binding site. The cis-sequences of the remaining two protected regions (designated MEP-2 and MEP-3; Mouse E1apha Promoter site) show no apparent consensus homology with cis-elements of other known transcription factors. Results of electrophoretic mobility shift assays confirm that the ATF/CREB and MEP binding sites interact in a characteristic and specific manner with factors present in nuclei of both testis and somatic tissue. The factor which recognizes the MEP-3 motif appears to be ubiquitous, whereas the MEP-2-protein complexes were tissue-specific. Interestingly, formation of a complex involving MEP-2 and a putative testis-specific binding factor (tay-MEP-2BF) is first observed in the testis of 2-week-old mice, this correlates with the expression of Pdha-2. In contrast, the formation of complexes between the MEP-2 binding site and a somatic variant of MEP-2BF (sigma-MEP-2BF) decreases in the testis as spermatogenesis proceeds. Our results suggest that 1) the MEP-2 binding factors are temporally regulated during spermatogenesis, and 2) interactions involving these factors with the MEP-2 cis-element may be important for modulating Pdha-2 expression.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,CTR EARLY HUMAN DEV,CLAYTON,VIC 3168,AUSTRALIA	Monash University	IANNELLO, RC (corresponding author), ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA.		Kola, Ismail/C-5254-2013					BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BROWN RM, 1990, SOMAT CELL MOLEC GEN, V16, P487, DOI 10.1007/BF01233198; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE KD, 1986, J BIOL CHEM, V261, P7178; CUNLIFFE V, 1990, EMBO J, V9, P197, DOI 10.1002/j.1460-2075.1990.tb08096.x; ERICKSON RP, 1980, P NATL ACAD SCI-BIOL, V77, P6086, DOI 10.1073/pnas.77.10.6086; FITZGERALD J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P83, DOI 10.1016/0167-4781(92)90102-6; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GOLDSBOROUGH A, 1990, NUCLEIC ACIDS RES, V18, P1634, DOI 10.1093/nar/18.6.1634; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTO M, 1991, NUCLEIC ACIDS RES, V19, P3959, DOI 10.1093/nar/19.14.3959; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; GRIMES SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P402, DOI 10.1016/0003-9861(92)90590-S; HAKE LE, 1990, DEVELOPMENT, V110, P249; Hecht N B, 1988, Prog Clin Biol Res, V267, P291; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; IANNELLO RC, 1992, BIOL REPROD, V47, P48, DOI 10.1095/biolreprod47.1.48; JEN J, 1990, MOL REPROD DEV, V25, P14, DOI 10.1002/mrd.1080250104; JOHNSON PA, 1991, BIOL REPROD, V44, P127, DOI 10.1095/biolreprod44.1.127; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; LIM K, 1992, J BIOL CHEM, V267, P15271; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; NAYERNIA K, 1992, MOL REPROD DEV, V31, P241, DOI 10.1002/mrd.1080310403; NELKI D, 1990, NUCLEIC ACIDS RES, V18, P3655, DOI 10.1093/nar/18.12.3655; OLIVA R, 1988, DEV BIOL, V125, P332, DOI 10.1016/0012-1606(88)90216-3; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; Sambrook J, 1989, MOL CLONING LABORATO; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKAKUBO F, 1992, EXP CELL RES, V199, P39, DOI 10.1016/0014-4827(92)90459-L; TAMARU M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P331, DOI 10.1016/0167-4781(90)90106-C; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; TANAKA S, 1986, BIOCHEM BIOPH RES CO, V136, P760, DOI 10.1016/0006-291X(86)90504-8; THOMAS K, 1990, DEVELOPMENT, V109, P483; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	54	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22581	22590						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693672				2022-12-25	WOS:A1993MD34800061
J	MAJIMA, E; KOIKE, H; HONG, YM; SHINOHARA, Y; TERADA, H				MAJIMA, E; KOIKE, H; HONG, YM; SHINOHARA, Y; TERADA, H			CHARACTERIZATION OF CYSTEINE RESIDUES OF MITOCHONDRIAL ADP/ATP CARRIER WITH THE SH-REAGENTS EOSIN 5-MALEIMIDE AND N-ETHYLMALEIMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; BEEF-HEART MITOCHONDRIA; ATRACTYLATE BINDING-PROTEIN; ADENINE-NUCLEOTIDE; 5'-TRIPHOSPHATE CARRIER; ROTATIONAL DIFFUSION; PHOSPHATE-TRANSPORT; INNER MEMBRANE; TRANSLOCATOR; TOPOGRAPHY	The effects of the membrane-impermeable fluorescent sulfhydryl reagent eosin 5-maleimide (EMA) and the membrane-permeable sulfhydryl reagent N-ethylmaleimide (NEM) on ADP transport via the ADP/ATP carrier and their labeling sites in the carrier were studied in bovine heart submitochondrial particles. Of the 4 cysteine residues in the carrier, EMA labeled Cys159 very rapidly, Cys56 slowly, and Cys256 very slowly and did not label Cys128. Its labeling of Cys159 was associated with inhibition of the ADP transport, suggesting that the peptide segment containing Cys159 is involved in the transport of adenine nucleotides. In contrast to the very rapid binding of EMA to Cys159, NEM bound to Cys56 more slowly and labeled Cys159 and Cys256 much more slowly. Like EMA, it did not react with Cys128. The labeling of Cys56 with NEM also inhibited ADP transport. From these results, the locations of these cysteine residues in the ADP/ATP carrier are discussed in relation to the transport of adenine nucleotides mediated by the ADP/ATP carrier.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,SHOMACHI 1,TOKUSHIMA 770,JAPAN; APRO,INST LIFE SCI,KUROSAKI,NARUTO 772,JAPAN	Tokushima University								AQUILA H, 1982, EUR J BIOCHEM, V122, P141, DOI 10.1111/j.1432-1033.1982.tb05859.x; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BOULAY F, 1983, BIOCHEMISTRY-US, V22, P477, DOI 10.1021/bi00271a034; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; GUPTE SS, 1991, BIOCHIM BIOPHYS ACTA, V1069, P131, DOI 10.1016/0005-2736(91)90114-N; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; HANSEN M, 1964, BIOCHIM BIOPHYS ACTA, V81, P214, DOI 10.1016/0926-6569(64)90036-7; HOUSTEK J, 1985, J BIOL CHEM, V260, P6288; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KLINGENBERG M, 1992, BIOCHEM SOC T, V20, P547, DOI 10.1042/bst0200547; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC P, 1972, FEBS LETT, V23, P107, DOI 10.1016/0014-5793(72)80296-5; MARTY I, 1992, BIOCHEMISTRY-US, V31, P4058, DOI 10.1021/bi00131a023; MAYINGER P, 1989, FEBS LETT, V244, P421, DOI 10.1016/0014-5793(89)80576-9; MULLER M, 1982, J BIOL CHEM, V257, P1117; MULLER M, 1984, J BIOL CHEM, V259, P3037; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RICCIO P, 1975, FEBS LETT, V56, P129, DOI 10.1016/0014-5793(75)80126-8; RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SHINOHARA Y, 1987, BIOCHEM BIOPH RES CO, V148, P1081, DOI 10.1016/S0006-291X(87)80242-5; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Stubbs M., 1981, INHIBITORS MITOCHOND, P283; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VIGNAIS PV, 1972, FEBS LETT, V26, P27, DOI 10.1016/0014-5793(72)80534-9	29	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22181	22187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691823				2022-12-25	WOS:A1993MC80900110
J	UGAROVA, TP; BUDZYNSKI, AZ; SHATTIL, SJ; RUGGERI, ZM; GINSBERG, MH; PLOW, EF				UGAROVA, TP; BUDZYNSKI, AZ; SHATTIL, SJ; RUGGERI, ZM; GINSBERG, MH; PLOW, EF			CONFORMATIONAL-CHANGES IN FIBRINOGEN ELICITED BY ITS INTERACTION WITH PLATELET MEMBRANE GLYCOPROTEIN-GPIIB-IIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA; MONOCLONAL-ANTIBODIES; ACTIVATED PLATELETS; ELECTRON-MICROSCOPY; ENDOTHELIAL-CELLS; RECEPTOR; RECOGNITION; INTEGRINS; ADHESION; SEQUENCE	The binding of fibrinogen to membrane glycoprotein GPIIb-IIIa on activated platelets leads to platelet aggregation. This interaction results in conformational changes in fibrinogen as evidenced by the expression of receptor-induced binding sites, RIBS, epitopes which are expressed by the bound but not the free ligand. In the present study, two RIBS epitopes have been localized. One sequence resides at gamma112-119 and is recognized by mAb 9F9; the second is the RGDF sequence at Aalpha 95-98 and is recognized by mAb 155B16. These epitopes are also exposed by adsorption of fibrinogen onto a plastic surface and digestion of the molecule by plasmin. Proteolytic exposure of the epitopes coincides with cleavage of the carboxyl-terminal aspects of the Aalpha-chains to form fragment X2. The inaccessibility of the RGDF sequence at Aalpha 95-98 in fibrinogen suggests that this sequence does not participate in the initial binding of the molecule to GPII-bIIIa. The location of these RIBS epitopes suggests a model in which binding of fibrinogen to its receptor alters the conformation of the carboxyl-terminal aspects of the Aalpha-chains, exposing the sequences which reside in the coiled-coil connector segments between the D and E domains of the molecule. These sequences may then serve as epitopes and may mediate unique functions of the receptor-bound molecule.	SCRIPPS RES INST, COMM VASC BIOL CVB-1, LA JOLLA, CA 92037 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania					NHLBI NIH HHS [HL38292, HL36221, HL16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL038292, R01HL036221] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ABRAMS CS, 1990, BLOOD, V75, P128; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DEVINE DV, 1991, THROMB HAEMOSTASIS, V65, P904; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GRAMSE M, 1978, J CLIN INVEST, V61, P1027, DOI 10.1172/JCI109001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOLB WP, 1975, P NATL ACAD SCI USA, V72, P1687, DOI 10.1073/pnas.72.5.1687; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KUNICKI TJ, 1984, THROMB RES, V35, P169, DOI 10.1016/0049-3848(84)90212-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONAHEY P, 1966, INT ARCH ALLER A IMM, V29, P181; MEDVED LV, 1983, FEBS LETT, V160, P291, DOI 10.1016/0014-5793(83)80985-5; MIHALYI E, 1976, BIOCHEMISTRY-US, V15, P5372, DOI 10.1021/bi00669a025; MORAN JB, 1981, BIOCHIM BIOPHYS ACTA, V659, P161, DOI 10.1016/0005-2744(81)90280-1; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; OUYANG C, 1976, BIOCHIM BIOPHYS ACTA, V420, P298, DOI 10.1016/0005-2795(76)90321-4; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PHILLIPS DR, 1988, BLOOD, V71, P831; PIZZO SV, 1972, J BIOL CHEM, V247, P636; PLOW EF, 1973, P NATL ACAD SCI USA, V70, P1169, DOI 10.1073/pnas.70.4.1169; PLOW EF, 1992, J LAB CLIN MED, V18, P324; RUDEE ML, 1981, ULTRAMICROSCOPY, V7, P193, DOI 10.1016/0304-3991(81)90010-3; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHIELEN WJG, 1989, P NATL ACAD SCI USA, V86, P8951, DOI 10.1073/pnas.86.22.8951; SCHIELEN WJG, 1991, BLOOD, V77, P2169; SHATTIL SJ, 1987, BLOOD, V70, P307; SHIBA E, 1991, AM J PHYSIOL, V260, pC965, DOI 10.1152/ajpcell.1991.260.5.C965; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SOKAL PG, 1962, ACTA HAEMATOL-BASEL, V28, P313; SORIA J, 1985, J COLLOID INTERF SCI, V107, P204, DOI 10.1016/0021-9797(85)90163-8; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; WALL J, 1983, ANN NY ACAD SCI, V408, P164, DOI 10.1111/j.1749-6632.1983.tb23243.x; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WINTROUB BU, 1980, P NATL ACAD SCI-BIOL, V77, P5448, DOI 10.1073/pnas.77.9.5448; ZAMARRON C, 1991, J BIOL CHEM, V266, P16193; [No title captured]	51	121	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21080	21087						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691805				2022-12-25	WOS:A1993MA28800068
J	LIDOFSKY, SD; XIE, MH; SOSTMAN, A; SCHARSCHMIDT, BF; FITZ, JG				LIDOFSKY, SD; XIE, MH; SOSTMAN, A; SCHARSCHMIDT, BF; FITZ, JG			VASOPRESSIN INCREASES CYTOSOLIC SODIUM CONCENTRATION IN HEPATOCYTES AND ACTIVATES CALCIUM INFLUX THROUGH CATION-SELECTIVE CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; GROWTH-FACTOR; ANGIOTENSIN-II; ACINAR-CELLS; ION CHANNELS; LIVER-CELLS; FREE NA+; TRANSPORT; CA-2+; PROLIFERATION	A variety of hormonal agonists activate transmembrane Na+ and Ca2+ flux in hepatocytes, but the responsible mechanisms are poorly understood. We employed microfluorimetric and patch clamp recording techniques in hepatocytes to determine the effect of the hormone vasopressin on cytosolic Na+ concentration ([Na+]i) and to identify the transmembrane Na+ transport pathways activated by this agonist. Under basal conditions, [Na+]i, measured using the Na+-sensitive fluorophore sodium-binding benzofuran isophthalate, averaged 12.1 +/- 1.6 mM. Exposure to vasopressin rapidly increased [Na+]i by 8.3 +/- 0.9 mM. This increase was attributable to activation of Na+ influx. It occurred in the absence of solutes co-transported with Na+ and was not associated with activation of Na+/H+ antiport. In cell-attached membrane patches, vasopressin activated ion channels that carried inward positive current at the resting membrane potential. Further characterization in excised membrane patches revealed two classes of ion channels, with conductances of 16.0 +/- 2.8 and 30.9 +/- 3.1 picosiemens, respectively. Single channel currents reversed near 0 mV, and ion substitution studies demonstrated that each channel type was permeable to Na+, Ca2+, and K+ but not Cl-. These observations in hepatocytes indicate that vasopressin increases [Na+]i and activates cation-selective channels, which likely accounts for vasopressin-activated Na+ and Ca2+ influx.	UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; DUKE UNIV,DEPT MED,DURHAM,NC 27710	University of California System; University of California San Francisco; Duke University	LIDOFSKY, SD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,GI UNIT,HSW 1120,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001987, R01DK043278, R01DK026270] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-01987, DK-26270, DK-43278] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1992, HEPATOLOGY, V15, P134, DOI 10.1002/hep.1840150123; BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BERTHON B, 1985, BRIT J PHARMACOL, V86, P151, DOI 10.1111/j.1476-5381.1985.tb09445.x; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BORIN M, 1991, J BIOL CHEM, V266, P13153; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; FITZ JG, 1991, J MEMBRANE BIOL, V122, P1, DOI 10.1007/BF01872734; FITZ JG, 1991, AM J PHYSIOL, V261, pG803, DOI 10.1152/ajpgi.1991.261.5.G803; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARVEY RD, 1991, P NATL ACAD SCI USA, V88, P6946, DOI 10.1073/pnas.88.16.6946; HWANG SB, 1986, J BIOL CHEM, V261, P532; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; KANEKO A, 1992, HEPATOLOGY, V15, P1173, DOI 10.1002/hep.1840150632; KILBERG MS, 1982, J MEMBRANE BIOL, V69, P1, DOI 10.1007/BF01871236; Koch K S, 1980, Ann N Y Acad Sci, V349, P111, DOI 10.1111/j.1749-6632.1980.tb29520.x; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; KOCH KS, 1984, CELL BIOL INT REP, V8, P309, DOI 10.1016/0309-1651(84)90157-7; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LIDOFSKY SD, 1990, AM J PHYSIOL, V259, pG56, DOI 10.1152/ajpgi.1990.259.1.G56; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MOTULSKY HJ, 1983, J BIOL CHEM, V258, P3913; NEGULESCU PA, 1990, CELL REGUL, V1, P259, DOI 10.1091/mbc.1.3.259; NILIUS B, 1990, PFLUG ARCH EUR J PHY, V416, P609, DOI 10.1007/BF00382697; OKADA K, 1991, AM J PHYSIOL, V261, pF1007; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SCHARSCHMIDT BF, 1981, P NATL ACAD SCI-BIOL, V78, P986, DOI 10.1073/pnas.78.2.986; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; VANDYKE RW, 1983, J BIOL CHEM, V258, P2912; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071	38	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14632	14636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686902				2022-12-25	WOS:A1993LL75900019
J	JI, ZS; BRECHT, WJ; MIRANDA, RD; HUSSAIN, MM; INNERARITY, TL; MAHLEY, RW				JI, ZS; BRECHT, WJ; MIRANDA, RD; HUSSAIN, MM; INNERARITY, TL; MAHLEY, RW			ROLE OF HEPARAN-SULFATE PROTEOGLYCANS IN THE BINDING AND UPTAKE OF APOLIPOPROTEIN-E-ENRICHED REMNANT LIPOPROTEINS BY CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; FIBROBLAST GROWTH-FACTOR; CHYLOMICRON REMNANTS; ALPHA-2-MACROGLOBULIN RECEPTOR; LDL RECEPTOR; LIVER; ENDOCYTOSIS; LIPASE; PURIFICATION	Addition of apolipoprotein (apo) E to rabbit beta-very low density lipoproteins (beta-VLDL) has been shown to result in a marked enhancement of their binding and uptake by various cell types. Apolipoprotein E binds to lipoprotein receptors and proteoglycans. To distinguish between apoE binding to these sites, cells were treated with heparinase. Heparinase treatment of receptor-negative familial hypercholesterolemic (FH) fibroblasts and human hepatoma cells (HepG2) released 30-40% of newly synthesized cell surface S-35-labeled proteoglycans and decreased the binding of beta-VLDL+apoE to FH and normal fibroblasts and HepG2 cells by more than 80%. Furthermore, heparinase treatment significantly decreased the uptake of fluorescently labeled beta-VLDL+apoE by HepG2 cells and decreased cholesteryl ester synthesis in FH fibroblasts by 75%. Likewise, canine chylomicron remnants enriched in apoE demonstrated enhanced binding that was 80% inhibited by heparinase treatment of HepG2 cells. Heparinase treatment did not affect beta-VLDL (without added apoE) or low density lipoprotein (LDL) binding to these cells or the binding activity of beta-VLDL+apoE to the LDL receptor-related protein (LRP) or to the LDL receptor on ligand blots. Chinese hamster ovary (CHO) mutant cells lacking the synthesis of either heparan sulfate (pgsD-677) or all proteoglycans (pgsA-745) did not display any enhanced binding of the beta-VLDL+apoE. By comparison, wild-type CHO cells demonstrated enhanced binding of beta-VLDL+apoE that could be abolished by treatment with heparinase. These mutant cells and wild-type CHO cells possessed a similar amount of LRP, as determined by ligand blot analyses and by alpha2-macroglobulin binding, and possessed a similar amount of LDL receptor activity, as determined by LDL binding. Therefore, we would interpret these data as showing that heparan sulfate proteoglycan may be involved in the initial binding of the apoE-enriched remnants with the subsequent involvement of the LRP in the uptake of these lipoproteins. It remains to be determined whether the heparan sulfate proteoglycan can function by itself in both the binding and internalization of the apoE-enriched remnants or whether the proteoglycan is part of a complex with LRP that mediates a two-step process, i.e. binding and subsequent internalization by the receptor.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, POB 419100, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAJEKSHAUL T, 1982, BIOCHIM BIOPHYS ACTA, V712, P200, DOI 10.1016/0005-2760(82)90103-5; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OKA K, 1989, ANN NY ACAD SCI, V556, P173; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; STOW JL, 1985, J CELL BIOL, V100, P975, DOI 10.1083/jcb.100.3.975; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; WERNETTEHAMMOND ME, 1989, ARTERIOSCLEROSIS, V9, P501, DOI 10.1161/01.ATV.9.4.501; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; YANG VC, 1985, J BIOL CHEM, V260, P1849; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	42	277	284	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10160	10167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683668				2022-12-25	WOS:A1993LB80000035
J	TORIBARA, NW; ROBERTON, AM; HO, SB; KUO, WL; GUM, E; HICKS, JW; GUM, JR; BYRD, JC; SIDDIKI, B; KIM, YS				TORIBARA, NW; ROBERTON, AM; HO, SB; KUO, WL; GUM, E; HICKS, JW; GUM, JR; BYRD, JC; SIDDIKI, B; KIM, YS			HUMAN GASTRIC MUCIN - IDENTIFICATION OF A UNIQUE SPECIES BY EXPRESSION CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE LOCUS PUM; MOLECULAR-CLONING; EPITHELIAL MUCINS; CDNA SEQUENCES; CARCINOMA; ANTIGEN; DNA; POLYMORPHISM; CONTAINS; RAT	Gastric mucin is a large glycoprotein which is thought to play a major role in the protection of the gastrointestinal tract from acid, proteases, pathogenic microorganisms, and mechanical trauma. In this paper we describe the isolation by expression cloning and characterization of cDNAs which code for human gastric mucin. The cDNA sequence is characterized by a tandem repeat region whose individual repeat unit is 507 base pairs (169 amino acids) long. The translated sequence is rich in threonine, serine, and proline (31, 18, and 15%, respectively) and contains a relatively large amount of histidine (7.1%) and alanine (5.6%). RNA blot analysis shows a polydisperse pattern which is characteristic of mucins. Expression of this gene is highest in the stomach and gall bladder, with weaker expression in the terminal ileum and right colon. This expression pattern is different from other human mucins and indicates that this gene codes for a unique mucin. Fluorescence in situ hybridization techniques have localized this gene to chromosome 11p15.4-11p15.5. This is the third mucin to be localized to the 11p15 region and suggests a clustering of secretory mucin genes. We propose that this gene for human gastric mucin be called MUC6.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV AUCKLAND,DEPT BIOCHEM,AUCKLAND,NEW ZEALAND; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455; DEPT VET AFFAIRS MED CTR,MINNEAPOLIS,MN	University of California System; University of California San Francisco; University of Auckland; University of Minnesota System; University of Minnesota Twin Cities	TORIBARA, NW (corresponding author), DEPT VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.							AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BYRD JC, 1989, BIOCHEM J, V261, P617, DOI 10.1042/bj2610617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER J, 1991, BIOCHEM J, V277, P423, DOI 10.1042/bj2770423; DEKKER J, 1989, J BIOL CHEM, V264, P10431; FOUAD FM, 1980, H-S Z PHYSIOL CHEM, V361, P703, DOI 10.1515/bchm2.1980.361.1.703; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HASE T, 1992, BIOMED RES-TOKYO, V13, P149, DOI 10.2220/biomedres.13.149; HO SB, 1993, CANCER RES, V53, P641; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI ZR, 1988, J HISTOCHEM CYTOCHEM, V36, P317, DOI 10.1177/36.3.3278057; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SLOMIANY BL, 1992, J CLIN GASTROENTEROL, V14, pS114, DOI 10.1097/00004836-199206001-00020; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1989, CANCER RES, V49, P3321; TRASK BJ, 1991, AM J HUM GENET, V48, P1; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANCONG N, 1990, HUM GENET, V86, P167; WESLEY A, 1985, J BIOL CHEM, V260, P7955; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YOUNAN F, 1982, GASTROENTEROLOGY, V82, P827	37	359	366	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5879	5885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680650				2022-12-25	WOS:A1993KR82200079
